



Janice
Living with cervical dystonia
Tennessee, USA



© Ipsen 2022 / Matthew Bender / CAPA Pictures

2021 UNIVERSAL REGISTRATION DOCUMENT
INCLUDING THE ANNUAL FINANCIAL REPORT



SUMMARY

| | | | |
|--|------------|---|------------|
| INTRODUCTION | 2 | 4.3 ENHANCING INTEGRITY TO MAINTAIN A TRUSTED RELATIONSHIP WITH OUR STAKEHOLDERS | 162 |
| INTRODUCTION: KEY FIGURES | 3 | 4.3.1 Committed to protect personal data | 162 |
| 1.1 PRESENTATION OF IPSEN AND ITS ACTIVITY | 5 | 4.3.2 Fighting corruption | 164 |
| 1.1.1 History and Development of the Company | 6 | 4.3.3 Promoting and defending Human Rights | 167 |
| 1.1.2 Group's Strategy | 9 | 4.4 DRIVING OUR EMPLOYEES' EXCELLENCE AND ENGAGEMENT | 168 |
| 1.2 GROUP'S ACTIVITY AND CORPORATE STRUCTURE | 12 | 4.4.1 Attracting the best talents | 168 |
| 1.2.1 Group's Products | 12 | 4.4.2 Enhancing employees' engagement | 170 |
| 1.2.2 Major Contracts | 19 | 4.4.3 Providing a healthy and safe workplace | 175 |
| 1.2.3 Research and Development | 22 | 4.5 MINIMIZING OUR ENVIRONMENTAL IMPACT | 177 |
| 1.2.4 Intellectual Property | 26 | 4.5.1 Protecting the Environment | 177 |
| 1.2.5 Main Markets | 30 | 4.5.2 Climate Action | 178 |
| 1.2.6 Regulation | 31 | 4.5.3 Responsible Consumption and Production | 180 |
| 1.2.7 Group's Legal Structure | 31 | 4.6 ANNEX I: SCOPE OF RISKS COVERED | 181 |
| 2.1 RISK AND CONTROL | 33 | 4.7 ANNEX II: CORRESPONDENCE TABLE WITH GRI STANDARDS | 182 |
| 2.1.1 Introduction | 34 | 4.8 ANNEX III: SUMMARY OF OUR KEY PERFORMANCE INDICATORS (KPIs) | 184 |
| 2.1.2 Business Risks | 35 | 4.9 ANNEX IV: COMPLYING WITH THE EUROPEAN TAXONOMY | 187 |
| 2.1.3 Industrial and Environmental Risks | 37 | 4.10 ANNEX V: REPORTING METHODOLOGY AND AUDIT REPORT | 188 |
| 2.1.4 Financial Risks | 38 | 5.1 CORPORATE GOVERNANCE AND LEGAL INFORMATION | 197 |
| 2.1.5 Regulatory and Legal Risks | 39 | 5.1 Framework for the implementation of corporate governance principles | 198 |
| 2.2 RISK MANAGEMENT AND INTERNAL CONTROL | 41 | 5.1.1 The AFEP-MEDEF Corporate Governance Code as a reference code | 198 |
| 2.2.1 Organization | 41 | 5.1.2 Summary table of the AFEP-MEDEF Code recommendations which have not been applied | 198 |
| 2.2.2 Information Management | 44 | 5.1.3 Ethics of the Board of Directors and Executive Management | 199 |
| 2.2.3 Risk Management Framework | 45 | 5.2 Governance structure | 201 |
| 2.2.4 Control Activities | 46 | 5.2.1 Guiding principles | 201 |
| 2.2.5 Review and Assessment of Internal Control | 47 | 5.2.2 The Board of Directors | 205 |
| 3.1 FINANCIAL INFORMATION OF THE COMPANY | 49 | 5.3 Executive Management | 234 |
| 3.1.1 MANAGEMENT REPORT FOR THE FINANCIAL YEAR | 50 | 5.3.1 Organization and modus operandi of the Executive Management | 234 |
| 3.1.1.1 Significant events during the year | 50 | 5.3.2 Executive Management | 235 |
| 3.1.1.2 Analysis of results | 52 | 5.4 COMPENSATION OF CORPORATE OFFICERS | 238 |
| 3.1.1.3 Net cash flow and financing | 57 | 5.4.1 Compensation policy of Corporate Officers | 238 |
| 3.1.1.4 Appendices | 59 | 5.4.2 Compensation of Corporate Officers (Articles L.22-10-34 I and L.22-10-9 I of the French Commercial Code) | 244 |
| 3.1.1.5 Subsequent events | 65 | 5.4.3 Comparative table of compensation of the Chairman and Chief Executive Officer with respect to other employees and put into perspective with the Company's performance | 255 |
| 3.1.1.6 Group outlook | 65 | 5.4.4 Compensation paid or awarded in 2021 (Article L.22-10-34 II of the French Commercial Code) | 257 |
| 3.1.1.7 Subsequent events following the Accounts Settlement Date of 31 December 2021 | 66 | 5.5 Auditors' Special Report on regulated agreements | 259 |
| 3.2 CONSOLIDATED FINANCIAL STATEMENTS 2021 | 66 | 5.6 Share capital and shareholding | 260 |
| 3.2.1 Consolidated income statement | 66 | 5.6.1 Share Capital | 260 |
| 3.2.2 Consolidated balance sheet before allocation of net profit | 68 | 5.6.2 Shareholding | 264 |
| 3.2.3 Consolidated statement of cash flow | 69 | 5.6.3 Main provisions of the Articles of Association | 270 |
| 3.2.4 Statement of change in consolidated shareholders' equity | 70 | 6.1 ANNEXES | 273 |
| 3.2.5 Notes | 72 | 6.1 PERSON RESPONSIBLE | 274 |
| 3.2.6 Statutory Auditors' Report on the consolidated financial statements | 116 | 6.1.1 Person responsible for the universal registration document | 274 |
| 3.3 2021 COMPANY FINANCIAL STATEMENTS | 120 | 6.1.2 Attestation by the person responsible for the universal registration document including the Annual Financial Report | 274 |
| 3.3.1 Summary document | 120 | 6.1.3 Persons responsible for financial information | 274 |
| 3.3.2 Notes to the annual financial statements | 123 | 6.1.4 Person responsible for account audit and fees | 274 |
| 3.3.3 Statutory Auditor's Report on the annual financial statements | 136 | 6.2 THIRD PARTY INFORMATION, STATEMENTS BY EXPERTS AND DECLARATIONS OF INTERESTS | 275 |
| 3.3.4 Information related to Ipsen's business activity | 139 | 6.3 CONSULTATION OF LEGAL DOCUMENTS | 275 |
| 4.1 COMPANY SOCIAL RESPONSIBILITY | 143 | 6.4 CROSS-REFERENCE TABLES | 275 |
| 4.1.1 IPSEN'S COMPANY SOCIAL RESPONSIBILITY (CSR) VISION AND STRATEGY | 144 | 6.4.1 Universal registration document concordance table | 275 |
| 4.1.1.1 Presentation and governance of Ipsen's Company Social Responsibility | 144 | 6.4.2 Annual Financial Report cross-reference table | 279 |
| 4.1.1.2 The Group's key CSR risks and opportunities | 149 | 6.4.3 Cross-reference table of the Management Report and of the Board of Directors' Report on Corporate Governance | 279 |
| 4.2 IMPROVING PATIENTS' LIVES BY OFFERING INNOVATIVE AND SAFE MEDICINES | 151 | 6.4.4 Cross-reference table for the filing of the financial statements | 282 |
| 4.2.1 Bringing high quality product to patients | 151 | | |
| 4.2.2 Ensuring product and patient safety | 153 | | |
| 4.2.3 Animal welfare | 155 | | |
| 4.2.4 Committed to ensure supply continuity | 156 | | |
| 4.2.5 Committed to fight against counterfeit products | 156 | | |
| 4.2.6 Promoting products responsibly | 157 | | |
| 4.2.7 Enlarging access to health | 159 | | |



Société anonyme with a share capital of €83,814,526
Registered office: 65 quai Georges Gorse – 92100 Boulogne-Billancourt
419 838 529 R.C.S. Nanterre

2021 UNIVERSAL REGISTRATION DOCUMENT

including the Annual Financial
Report



This Universal Registration Document was filed on 12 April 2022, with the French Financial Markets' Authority (AMF), as the competent authority under (EU) Regulation 2017/1129, without prior approval as allowed by Article 9 of the Regulation.

The Universal Registration Document may be used as a prospectus for a public offer of financial instruments or the admission of financial instruments for trading on a regulated market, provided that it is accompanied by an information memorandum (or listing particulars) and, if necessary, summary and detailed descriptions of all the amendments made to the Universal Registration Document. In this case, the prospectus comprising the Universal Registration Document and the information memorandum or listing particulars is submitted to the AMF for approval in accordance with (EU) Regulation 2017/1129.

This is a translation into English of the (universal) registration document of the Company issued in French and it is available on the website of the Issuer (cf. article 3 of [AMF instruction DOC-2019-21](#)).

Incorporation by reference:

Pursuant to Article 19 of Regulation (EU) 2017/1129 of the European Parliament and of Council of 14 June 2017, the following financial information are included by reference : (i) historical consolidated financial statement for 2020 fiscal year (including the auditors' reports) and management report for the financial year presented in the universal registration document registered by Autorité des marchés financiers on 12 April 2021 under number D.21-0294, and (ii) historical consolidated financial statement for 2019 fiscal year (including the auditors' reports) and management report for the financial year presented in the universal registration document registered by Autorité des marchés financiers on 14 April 2020 under number D.20-0303.

INTRODUCTION

In this universal registration document, unless stated otherwise, the terms “Company” and “Ipsen” refer to Ipsen S.A. and the term “Group” refers to Ipsen and its subsidiaries and shareholdings.

This universal registration document contains forward-looking statements about the Group’s targets and forecasts, especially in Chapter 3.1.6. Such statements may in certain cases be identified by the use of the future or conditional tense or by forward-looking words including but not limited to “believes”, “targets”, “anticipates”, “intends”, “should”, “aims”, “estimates”, “considers”, “wishes” and “may”. These statements are based on data, assumptions and estimates that the Company considers to be reasonable. They are subject to change or adjustment owing to uncertainties arising from the vagaries inherent in all research and development activities, as well as in the economic, financial, competitive, regulatory and climatic environment. In addition, the Group’s business activities and its ability to meet its targets and forecasts may be affected if certain risk factors described in Chapter 2.1 – “Risk Factors” of this universal registration document arise. In addition, attainment of the targets and forecasts implies the success of the strategy presented in section 1.1.2 – “Group Strategy” of this universal registration document.

The Company makes no undertaking and gives no guarantee as to the attainment of the targets and forecasts shown in this universal registration document.


Investors are urged to pay careful attention to the risk factors described in the second chapter of this universal registration document before making their investment decision. One or more of these risks may have an adverse effect on the Group’s activities, condition, results of operations or on its targets and forecasts. Furthermore, other risks not yet identified or considered as significant by the Group could have the same adverse effects.

This universal registration document also contains details of the markets in which the Group operates. This information is notably taken from research produced by external organizations. Given the very rapid pace of change in the pharmaceutical sector in France and the rest of the world, this information may prove to be erroneous or out of date.


Forward-looking statements, targets and forecasts shown in this universal registration document may be affected by risks, either known or unknown, uncertainties or other factors that may lead to the Group’s future results of operations, performance and achievements differing significantly from the stated or implied targets and forecasts. These factors may include changes in economic or trading conditions and regulations, as well as the factors set forth in Chapter 2.1 – “Risk factors” of this universal registration document.

INTRODUCTION: KEY FIGURES


2021 Group Sales by therapeutic area




2021 Group Sales by geographic area




Core Operating Income (in million euros) and core operating margin (as a % of sales)




Core consolidated Net Profit (in million euros)



Dividend per share paid for the financial year (in euros)*



Ownership of the Company's share capital at 31 December 2021



* Proposed by the Ipsen S.A. Board of Directors, for vote at the next Annual Shareholders' Meeting.

* Directly and indirectly through its subsidiary MR BMH.

INTRODUCTION: KEY FIGURES

Share price performance on the stock exchange

Shares in Ipsen S.A. have been traded on the Eurolist by Euronext™ market (Compartment A) since 7 December 2005, when the IPO (Initial Public Offering) price was €22.20 per share.

Ipsen shares joined the Deferred Settlement System on 28 March 2007 and joined the SBF120 index on 24 December 2007.


Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program and trades on the over-the-counter market in the United States under the symbol IPSEY.

| Share information | | 2021 trading data | |
|-----------------------------|--------------|--|------------|
| ISIN Code | FR0010259150 | Average share price | €81.61 |
| Euronext Code | IPN.PA | Highest price (14/12/2021) | €94.56 |
| ADR Code | IPSEY | Lowest price (09/03/2021) | €65.90 |
| SRD / PEA Eligibility | Yes / Yes | Stock market capitalization ⁽¹⁾ | €6,747.07M |
| Total Shares ⁽¹⁾ | 83.8 M | Average daily volume | 111,546 |

(1) As of 31 December 2021.

Comparison between Ipsen's share price performance and the principal stock market indicators between 4 January 2021 and 31 December 2021 (Source: Onvista)

Price (Base 100 on 2 January 2021)



1

PRESENTATION OF IPSEN AND ITS ACTIVITY

| | |
|---|-----------|
| 1.1 GROUP'S OVERVIEW AND STRATEGY | 6 |
| 1.1.1. History and Development of the Company | 6 |
| 1.1.2. Group's Strategy | 9 |
| 1.2 GROUP'S ACTIVITY AND CORPORATE STRUCTURE | 12 |
| 1.2.1. Group's Products | 12 |
| 1.2.2. Major Contracts | 19 |
| 1.2.3. Research and Development | 22 |
| 1.2.4. Intellectual Property | 26 |
| 1.2.5. Main Markets | 30 |
| 1.2.6. Regulation | 31 |
| 1.2.7. Group's Legal Structure | 31 |



1.1 GROUP'S OVERVIEW AND STRATEGY

1.1.1. History and Development of the Company

■ 1.1.1.1 Legal Entity Overview

Registered name

Ipsen

Registered office

65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France

Telephone number

+33 (0)1 58 33 50 00

Legal Form and applicable laws

The Company is a limited liability company incorporated under French law with a Board of Directors governed by the provisions of Book II of the French Commercial Code.

Registration details

The Company is registered in the Trade and Companies Registry in Nanterre under registration number 419 838 529.

Its Legal Entity Identifier number is 549300M6SGDPB4Z94P11.

Date of incorporation and term

The Company was incorporated on 28 July 1998, for a fixed period, except in the case of early dissolution or extension, of ninety-nine years from its registration in the Trade and Companies Registry, or until 18 August 2097.

■ 1.1.1.2 Group Overview

Ipsen is a global biopharmaceutical group focused on innovation and Specialty Care.

The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Rare Disease and Neuroscience. Ipsen also has a well-established Consumer Healthcare business. With total sales of €2,868.9 million in 2021, Ipsen sells more than 25 drugs in 115 countries, with a direct commercial presence in 34 countries.

Specialty Care

Ipsen has built its strength in Specialty Care through a robust portfolio of drugs with leading international research hubs and solid long-term partnerships.

The Specialty Care business generated sales of €2,643.3 million in 2021, or 92.1% of the Group's sales. The Group focuses on:

- Oncology (75.1% of Ipsen's sales) with Somatuline® (*lanreotide*), a best-in-class somatostatin analog with a new delivery system for the treatment of neuroendocrine tumors and acromegaly; Cabometyx® (*cabozantinib*), the first and only monotherapy tyrosine kinase inhibitor demonstrating significant clinical improvements in both first-line and second-line renal cell carcinoma, and also a tyrosine kinase inhibitor with proven, significant overall survival in a second-line advanced hepatocellular carcinoma population;

Onivyde® (*irinotecan liposome injection*), a differentiated product with overall survival benefit addressing a high unmet medical need in second-line pancreatic cancer; and Decapeptyl® (*triptorelin*), an established and growing product in Europe and China notably for the treatment of advanced metastatic prostate cancer;

- Rare Disease (1.7% of Ipsen's sales) with Nutropin® (*somatropin*), a liquid formulation of recombinant human growth hormone and Increlex® (*mecasermin*), a recombinant insulin-like growth factor 1 (IGF-1) of human origin. The Group's recent acquisition of Clementia Pharmaceuticals and the exclusive license agreement with Blueprint Medicines supplement its Rare Disease franchise with treatments for patients living with Fibrodysplasia Ossificans Progressiva, an ultra-rare bone disorder with Sohonos® (*palovarotene*);
- Neuroscience (15.4% of Ipsen's sales) with the key neurotoxin product Dysport® (*botulinum toxin type A*) for the treatment of therapeutic and aesthetic indications.

Consumer Healthcare

The Consumer Healthcare business is the historical business of the Group with several strong regional brands. It generated sales of €225.6 million in 2021, or 7.9% of the Group's sales. China, France and Russia account for 58.8% of Consumer Healthcare sales.

The Consumer Healthcare business is transforming from a prescription-based promotional model to a combination of prescription and over-the-counter (OTx).

Key brands include Smecta® (*diosmectite*), a naturally extracted purified clay for the treatment of acute diarrhea in children above 2 years old in association with oral rehydration solution, the symptomatic treatment of chronic functional diarrhea in adults, and the symptomatic treatment of pain associated with functional bowel diseases in adults; Tanakan® (*Ginkgo biloba* extract), a standardized extract from the leaves of *Ginkgo biloba* for the treatment of various neurological and neuro-sensorial disorders; Forlax® (*macrogol 4000*), an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans®/ Eziclen®, colon cleansing solutions indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery.

■ 1.1.1.3 History and Development of the Company

The Group was founded in 1929 when Doctor Henri Beaufour created Laboratoires Beaufour in Dreux for the launch of Romarène®, a naturally-occurring product derived from rosemary for the treatment of digestive disorders. The 1970s were marked by a period of expansion for the Group's activities in organic products during which Ipsen launched Tanakan and Smecta, which remain within the Group's products portfolio today.



During the 1970s, the Group focused its activities on engineering peptide products and set up Biomeasure (now known as Ipsen Bioscience, Inc.), which became the Group's peptide product research facility based close to universities around Boston. Through Biomeasure, the Group established and fostered strong relationships with several American universities. These partnerships led to the marketing of Decapeptyl, which was launched in 1986 and fueled the Group's international expansion.

In the late 1980s and early 1990s, the Group continued its international expansion by setting up subsidiaries and offices outside of France and acquiring foreign companies.

In 1994, the Group acquired the UK-based company Speywood (known at the time as Porton International), which was responsible for developing Dysport and in 1995, the Group launched its second sustained-release peptide, Somatuline in France.

The Group went public in December 2005 on the Euronext market of Euronext™ in order to accelerate and support its growth in Specialty Care and to enter the world's largest pharmaceutical market in the United States.

From 2010 onwards, the Group increased its focus and investment in its toxin research platform. The Group's active policy of building partnerships to create value through the licensing of products that arise from its research but are not deemed to be part of its core business (see part 1.2.2 "Major Contracts").

More recently, the Group completed important transactions to accelerate its evolution toward becoming a leading global biopharmaceutical company:

In 2016, the Group acquired the exclusive commercialization rights for cabozantinib, including future indications outside of the United States and Japan from Exelixis.

In early 2017, the Group acquired Onivyde, the oncology asset from Merrimack Pharmaceuticals.

In 2019, the Group acquired Clementia Pharmaceuticals including its key late-stage clinical asset palovarotene, an investigational retinoic acid receptor gamma (RAR γ) selective agonist, for the treatment of ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP).

In 2019, Ipsen expanded its Rare Disease portfolio by signing an exclusive global license agreement with Blueprint Medicines to develop and commercialize IPN60130 (formerly known as BLU-782), a highly selective investigational ALK2 inhibitor, for the treatment of fibrodysplasia ossificans progressiva (FOP) and potential other indications.

In 2021, seven transactions were completed across Ipsen three therapeutic areas:

- Oncology: Accent Therapeutics, BAKX Therapeutics, Queen's University
- Rare Disease: Genfit
- Neuroscience: Irlab, Exicure, and BCH/UOS.

Strong Foundation

Ipsen is built on a strong foundation with a 90-year heritage of family ownership, a solid and diversified portfolio with a fast-growing and dynamic Specialty Care business, a solid Consumer Healthcare business, and with significant competitive advantages:

- *proven financial strength* through a significant and recurring cash flow and strong balance sheet;
- *a global footprint in 115 countries*, with nearly 50% of revenues generated outside Europe. The Group entered the U.S. market in 2008 which now represents the fastest-growing region and the top affiliate in terms of sales. The Group also benefits from an important historical presence in markets such as China and Russia;
- *proven expertise in cutting-edge technologies*, such as toxin engineering and advanced drug delivery systems, which can be employed together at an early stage of development;
- *the geographic proximity of its research, development and innovation teams* based in the United States (Cambridge, MA) and in Europe (Oxford, United Kingdom – Paris Saclay, France – Shanghai, China) to highly-regarded university research centers which enable the Group to benefit from available scientific expertise and to hire highly-qualified personnel;
- *a recognized ability to secure and manage large-scale partnerships* with the world's leading and innovative pharmaceutical and biotechnology companies such as Debiopharm, Exelixis, TerSera, Servier, Teijin and Galderma;
- *an effective management team* with significant experience in the pharmaceutical industry.



■ 1.1.1.4 Group's Main Products

The following table presents the main therapeutic indications for the Group's main marketed products.

| Therapeutic area ⁽¹⁾ | Product name | 2021 sales (in million euros) | Principal therapeutic indications ⁽²⁾ |
|---|----------------------|----------------------------------|--|
| Specialty Care: 92.1% of full year sales | | | |
| Oncology | Somatuline® | 1,202.7 | Neuroendocrine tumors; acromegaly |
| Oncology | Decapeptyl® | 459.6 | Advanced metastatic prostate cancer; uterine fibroids; central precocious puberty; endometriosis; female infertility (<i>in vitro</i> fertilization), early stage breast cancer in combination with hormone therapy |
| Oncology | Cabometyx® | 354.6 | Renal cell carcinoma, second-line hepatocellular carcinoma |
| Oncology | Onivyde® | 127.4 | Second-line metastatic pancreatic cancer |
| Neuroscience | Dysport® | 434.6 | Motor muscular disorders (cervical dystonia; adult and children spasticity, blepharospasms and hemifacial spasms) and medical aesthetics (glabellar lines, lateral canthal lines, hyperhidrosis) |
| Rare Disease | NutropinAq® | 32.0 | Growth failure in children due to growth hormone (GH) deficiency, Turner syndrome or chronic renal insufficiency and GH deficiency in adults |
| Rare Disease | Increlex® | 17.1 | Long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGF-D) |
| Consumer Healthcare: 7.9% of full year sales | | | |
| Gastroenterology | Smecta® | 88.8 | Acute diarrhea and chronic diarrhea; symptomatic treatment of pain associated with functional bowel diseases |
| Gastroenterology | Forlax® | 36.0 | Symptomatic treatment of constipation in adults or in children above the age of 6 months |
| Gastroenterology | Fortrans® / Eziclen® | 35.9 | Fortrans: Bowel cleansing prior to endoscopy, X-ray examination or colonic surgery Eziclen: Bowel cleansing in adults for bowel cleansing prior to any procedure requiring a clean bowel (e.g. bowel visualisation including endoscopy and radiology or surgical procedure) |
| Cognitive disorders | Tanakan® | 36.6 | Symptomatic treatment of cognitive disorders in adults Adjunctive treatment of vertigo of vestibular origin in addition to vestibular rehabilitation Symptomatic treatment of tinnitus |

(1) Products are classified into therapeutic areas based on their primary indications.

(2) Therapeutic indications of products vary from country to country.

For more details about the sales geographical breakdown, see the management report (part 3.1.2 "Analysis of results").



1.1.2 Group's Strategy

■ 1.1.2.1 General Context

The pharmaceutical industry is facing several macro-trends transforming societies and economies, bringing opportunities as well as challenges.

On one hand, the underlying drivers of the pharmaceutical industry open up opportunities:

- demographic and health shifts, with a growing and aging population and a more sedentary lifestyle driving a higher prevalence of unmet medical needs;
- growing patient influence, with patients becoming central to healthcare delivery due to increasing knowledge and willingness to actively manage their health;
- growth in Big Data capabilities, with technology advancements applied to science and medical fields having the potential to vastly increase therapeutic options and accelerate personalized care delivery.

At the same time, the pharmaceutical industry is impacted by the transformation of healthcare across the world and increasing innovation hurdles:

- continuous increase of healthcare costs, leading to a focus on costs and productivity across healthcare systems, resulting in the rise of value-based care, and the reconfiguration of healthcare delivery (e.g. through consolidation);
- increasing innovation hurdles, with patent expiries generating an imperative to innovate in an environment of rapid scientific advancements, supportive regulatory frameworks but with high evidence requirements.

These macro-trends, bringing both opportunities and challenges for pharmaceutical companies to continue to save and improve patient lives, are closely monitored and accounted for in the Group's strategy.

■ 1.1.2.2 Group's vision and ambition

Ipsen is a dynamic and growing global specialty-driven biopharmaceutical group with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience. The strong position in Specialty Care, combined with the presence in Consumer Healthcare, provides the Group with the scale, expertise and stability needed to make a sustainable difference for people in a quickly-evolving healthcare environment.

A strengthened leadership position in three therapeutic areas and a sustainable business in Consumer Healthcare

Innovation is driving the business in a rapidly-transforming healthcare environment. The Group's global footprint and recognized leadership across the core focus areas of Oncology, Rare Disease and Neuroscience position it to take on the challenges faced by patients and caregivers.

Specialty Care

In Specialty Care, Ipsen is focused on three key therapeutic areas: Oncology, Rare Disease and Neuroscience, where Ipsen can establish a leadership position and leverage its expertise from drug development to commercialization and deliver sustainable long-term growth.

- In Oncology where the Group currently has differentiated, best-in-class products in niche indications such as neuroendocrine tumors, renal cell carcinoma, pancreatic cancer, prostate cancer and hepatocellular carcinoma. Life Cycle Management programs are being pursued in additional indications to further grow the existing brands and expand positioning on indications with high unmet needs.
- In Rare Disease, where Ipsen expanded its Rare Disease portfolio, with the acquisition in April 2019 of Clementia Pharmaceuticals and its key late-stage drug candidate palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP) and with the worldwide exclusive license agreement with Blueprint Medicines in October 2019 for the development and commercialization of IPN60130 (formerly known as BLU-782), an investigational treatment for FOP.
- In Neuroscience Ipsen has expertise in research, development, manufacturing, commercialization, in both the therapeutic area mainly focused on spasticity currently, and the aesthetics area through the partnership with Galderma.
- Across these three therapeutic areas, Ipsen's ambition is to fully leverage its broad geographic presence (in more than 115 countries) and its global commercial powerhouse to grow and roll out its Specialty Care portfolio in all key geographies.

Consumer Healthcare

In Consumer Healthcare, the Group maintains a sustainable business, in an environment of increasing consolidation, impacted by changes in market dynamics, competitive environment and more stringent regulatory requirements. To sustain growth, Ipsen is completing its OTx model transformation and leveraging its three main market-leading brands by enhancing consumer innovation, capturing the underlying market growth in emerging markets and strengthening the European business.

A Development and Commercial Powerhouse driven by innovation

A Development and Commercial Powerhouse driven by innovation, building an innovative and sustainable pipeline is essential for continued growth and is a key objective for the Group. Ipsen has focused its internal resources and efforts on becoming a Development Powerhouse while increasingly turning toward external sourcing for new assets.



Ipsen is built around a culture of open innovation, which drives research, development and commercialization. The Group identifies, develops and integrates innovative products that are a strategic fit for its portfolio and that deliver value to patients. It brings together the best minds to tackle some of the most difficult diseases and it does so by developing long-lasting, mutually-beneficial partnerships and through open and smart collaborative innovation.

Externally-sourcing innovation (see part 1.2.3.1 “Research and Development Activities”) is a key tenet of Ipsen’s business model. This principle, along with its strong track record and growing U.S. presence has positioned the Group as a partner of choice from early-stage development and academic partnerships to late-stage and product commercialization. With an open innovation model in mind, the Group has placed its four R&D centers at the heart of internationally-reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom and Cambridge in the United States, Shanghai in China.

The Group’s biotech mindset, combined with the scale and advantages of a global pharmaceutical company, has helped establish the Company as a development and commercial powerhouse in its core focus areas, with a proven ability to bring new, life-changing therapies to market.

Business Development

Further building on its outstanding achievements of 2021, Ipsen will continue to invest in business development in its three key therapeutic areas. The Group continues to be active in its business development efforts and is evaluating assets in its key therapeutic areas in all phases of clinical development.

All transactions should enable to achieve long-term sustainable value and growth potential, meet Group’s strategic ambition, be financially viable and generate synergies for the Group.

The ambition for external innovation is to fuel the R&D pipeline across the three therapeutic areas of focus:

- In Oncology, the focus is on solid as well as hematological tumors. The ambition is to focus on areas in which the Group can compete effectively by targeting tumor types where a differentiated medical benefit can be brought to patients. Ipsen targets a large panel of potential areas, including biomarker segments of larger tumor types and will continue to build synergies across prioritized pathways.
- In Rare Disease, Ipsen targets a large panel of conditions with unmet medical needs and defined patient populations, with all stages of development candidates and marketed products and both established and innovative technologies being considered. To further build this franchise, the Group will expand its synergies in endocrinology, bone disease and liver diseases while pursuing additional attractive opportunities with strong biology validation in other areas where a clinical path can be established.
- In Neuroscience, the priority is on rare neurological, neuro-degenerative and neuro-inflammatory disorders, as well as adjacencies including movement disorders, to further build up on expertise and synergies derived from previous deals in these areas.



1.1.2.3 Ipsen Business Model

| | |
|--|---|
| Ipsen's Mission: <i>"Improving patients lives"</i> | Ipsen's Vision: <i>"To be a leading global mid-size biopharmaceutical company with a focus on transformative medicines in oncology, rare disease & neuroscience"</i> |
|--|---|

Our assets and resources...

| | | | |
|--|--|--|---|
| Intellectual capital <ul style="list-style-type: none"> ● Intellectual property focused company ● 14,9% of sales invested in R&D ● 4 global R&D hubs in Cambridge, Oxford, Paris & Shanghai ● 710+ employees in R&D | Human capital <ul style="list-style-type: none"> ● 5,744 employees in 38 countries ● 19 countries with external & independent recognition awards ● Medicalized accident frequency rate of 0.4 | Manufacturing network <ul style="list-style-type: none"> ● 7 internal manufacturing sites ● External CMO partners ● 81,6M units produced ● €50.8M manufacturing investment | Natural resources* <ul style="list-style-type: none"> ● 7% reduction in energy consumption ● 33% reduction in water consumption ● 37% reduction in waste |
| Relationships <ul style="list-style-type: none"> ● Collaborations with healthcare professionals and patient associations to improve impact for patients ● Partnerships with external organization to accelerate innovation and expand access to medicines | Financial resources <ul style="list-style-type: none"> ● €2.9bn net sales ● Net debt 0.1x EBITDA ● A publicly traded business with a family control | Product portfolio <ul style="list-style-type: none"> ● 25+ medicines in our portfolio ● 122 Countries where medicines are registered | |

... contributing to the sustainability of our Business Model based on a strong ethical culture...

We develop **innovative medicines** to address conditions with **high unmet medical needs** to deliver outcomes that genuinely improve patients' lives

We continuously **invest both in our internal R&D platforms as well as in external innovation** to build a sustainable pipeline across all stages of development

We own **global commercial capabilities** and work with healthcare providers to successfully bring our medicines to the right patients

We work with **regulators and payers** to secure a broader access of our medicines across the globe

We leverage our **high-quality manufacturing network and end-to-end supply chain** to deliver our medicines to patients in a safe and reliable manner

We aim at **ensuring product quality excellence**, as well as compliance with regulatory and legal requirements and good manufacturing practices

... for patients, employees and society while protecting the environment



Note: Except if stated differently, all figures at 31/12/2021
 * Compared to 2019.
 ** Scope 1 & 2 without car fleet emissions.



■ 1.1.2.4 2024 Financial Outlook

Ipsen has updated its outlook for 2020-24 to exclude any contribution from the CHC business⁽¹⁾ and based on the strong performance delivered in 2021:

- Total-sales 2020-24 compound annual growth rate between +4% and +6%⁽²⁾ at constant currency and assuming risk-adjusted potential additional indications.
- Continued commitment to invest in R&D supported by SG&A efficiencies:

- Reduced SG&A expenses as a percentage of total sales, driven by further focus and optimization
- Higher R&D expenses as a percentage of total sales, driven by the external-innovation strategy.

To support the external-innovation strategy, Ipsen anticipates cumulative remaining firepower of €3.5bn by 2024, including the divestment of the CHC business. The calculation is based on net debt at 2.0 x EBITDA.

1.2 GROUP'S ACTIVITY AND CORPORATE STRUCTURE

1.2.1 Group's Products

■ 1.2.1.1 Specialty Care Products

Oncology

Somatuline and Somatuline® Autogel® / Depot®

Active substance and indications

Somatuline (*lanreotide*) is a somatostatin analog which inhibits the secretion of growth hormones and certain other hormones by the digestive system.

Somatuline Autogel (marketed as Somatuline Depot in the U.S.) is the first semi-solid formulation for injection without any polymeric excipient since the active substance itself controls the sustained release. Somatuline Autogel releases the active substance over a duration of at least 28 days, thus requiring just one deep subcutaneous injection per month. This unique formulation was launched in 2001 and allows the product to be presented in a pre-filled, ready-to-use syringe for easier administration. A pre-filled ready-to-use device was launched in 2011 with a retractable needle enabling the safe delivery of the full dose with every injection. A new delivery system with a further improved design was approved in 2019 in Europe and in the U.S.

The main indications of Somatuline and Somatuline Autogel / Depot are the following:

- **Neuroendocrine tumors**
 - The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease;
 - The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.

- **Acromegaly**

- The treatment of patients with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. The goal of treatment in acromegaly is to normalize GH and IGF-1 levels and control symptoms.

Marketing

Somatuline was initially launched in France in 1995. The Somatuline Autogel formulation was launched in 2001 for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. In 2015, the EMA approved Somatuline Autogel for the treatment of Gastro-Enteropancreatic Neuroendocrine Tumors in adults with unresectable locally advanced or metastatic disease.

Somatuline Depot was first approved by the U.S. Food and Drug Administration (FDA) in 2007 for the treatment of acromegaly. In 2014, Somatuline Depot was approved for the anti-proliferative treatment of Gastro-Enteropancreatic Neuroendocrine Tumors in adults with unresectable locally advanced or metastatic disease. The label was extended in September 2017 for the treatment of carcinoid syndrome associated with neuroendocrine tumors. Somatuline Depot became the first and only somatostatin analog FDA-approved for these two last indications.

Somatuline Depot received Orphan Drug Designation in the U.S. for the treatment of neuroendocrine tumors with exclusivity ended since the end of 2021.

As of 31 December 2020, Somatuline Autogel / Depot was marketed in more than 60 countries for the treatment of acromegaly and neuroendocrine tumors.

In 2021, Somatuline Autogel / Depot was the first and fastest growing product of the Group with sales of €1,202.7 million, of which 56.6% were generated in North America.

⁽¹⁾ Assuming presentation of the CHC business as discontinued operations starting in 2022 and comparing to the FY 2020 operating performance, excluding the contribution from the CHC business.

⁽²⁾ Prior outlook, outlined in December 2020, included a total-sales 2020-24 compound annual growth rate of 2% to 5% at CER.



Somatuline Autogel / Depot is prescribed mainly by endocrinologists, oncologists, gastroenterologists, and digestive surgeons.

Competition

The main competitor of Somatuline Autogel is Sandostatin® LAR® (*octreotide*), a somatostatin analog called octreotide developed by Novartis for the treatment of acromegaly and neuroendocrine tumors. However, the approved indications are not identical as Sandostatin does not have the anti-proliferative indication for Gastro-Entero-Pancreatic Neuroendocrine Tumors in the U.S. Other competitors in the acromegaly market are: Somavert® (*pegvisomant*), a growth hormone receptor antagonist developed by Pfizer, and Signifor® LAR (*pasireotide*) developed by Novartis.

In April 2019, Teva received European approval under a decentralized procedure for an octreotide generic. The approval included 27 countries, and the first octreotide generic was launched in Germany in July 2019 followed by 9 additional countries since then.

In March 2021, Advanz Pharma received positive outcome of the Decentralized Procedure for a lanreotide generic formulation. Mytolac® (*lanreotide*) has been launched in Germany in July 2021. On June 2021, Advanz Pharma announced the completion of its acquisition by a subsidiary of Nordic Fund X Epsilon, Cidron Aida Bidco Limited.

In June 2020, Chiasma (now part of Amryt Pharma Group) was granted U.S. FDA approval for Mycapssa® (*octreotide*), a somatostatin analog administered orally twice a day, for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa is available to patients since 31 August 2020 in the USA. In June 2021, Chiasma announces submission of marketing authorization application for Mycapssa® to the European Medicines Agency as a maintenance therapy for adults with acromegaly.

In December 2021, Cipla Limited and its subsidiary Cipla USA, Inc. has received final approval of a lanreotide product from the U.S. Food and Drug Administration; the FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.

Cabometyx®

Active substance and indications

Cabometyx is a small molecule administered orally in the form of tablets that acts as a targeted tyrosine kinase inhibitor (TKI).

With a unique mechanism of action targeting MET (hepatocyte growth factor receptor) and AXL (tyrosine kinase receptor) beyond VEGFR (Vascular Endothelial Growth Factor Receptor) and other molecular targets like RET, Cabometyx has the potential to overcome the resistance induced by prior antiangiogenic therapies. The mechanism of action for Cabometyx has been shown to inhibit angiogenesis and the migration and proliferation of tumor cells. Cabometyx has also been found to disrupt tumor vasculature and induce tumor cell death in pre-clinical models.

Cabometyx is indicated for the treatment of advanced renal cell carcinoma in both treatment-naïve adults with intermediate or poor risk as well as in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx is the first and only targeted therapy in second-line renal cell carcinoma to demonstrate clinically and statistically significant improvement across three endpoints (progression free survival, overall survival, overall response rate), with a convenient regimen of one tablet daily as well as the first and only single agent targeted therapy in first-line treatment of a renal cell carcinoma to demonstrate superiority over sunitinib, the former standard of care across progression free survival and disease control.

Cabometyx is also indicated as monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.

Marketing

Cabometyx was first launched in Europe in Germany in 2016 for second-line renal cell carcinoma. As of 31 December 2021, Cabometyx was available in over 60 countries with reimbursement in second-line treatment of renal cell carcinoma and in 20 countries with reimbursement as first-line monotherapy renal cell carcinoma.

In November 2018, the European Commission approved Cabometyx as a monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib. This approval has allowed for the marketing of Cabometyx in this indication in all 28 member states of the European Union, Norway and Iceland, and 30 other countries have a market authorization for the treatment of hepatocellular carcinoma in second line. As of 31 December 2021, Cabometyx was available in 12 countries with reimbursement in second-line treatment of hepatocellular carcinoma.

In February 2021 Ipsen announced the first presentation of new analyses from the pivotal Phase III CheckMate -9ER trial demonstrating clinically meaningful, sustained efficacy benefits as well as quality of life improvements with the combination of Cabometyx® (*cabozantinib*) and Opdivo® (*nivolumab*) compared to sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC).

In August 2021, the EMA validated Ipsen's submission for extension of indication for Cabometyx® (*cabozantinib*) to include use in a rare form of Thyroid Cancer. EU approval for the use of Cabometyx in previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) is expected mid 2022.

In 2021, total sales of Cabometyx amounted to €354.6 million.

Cabometyx is prescribed primarily by oncologists.

Cabometyx stems from a partnership with Exelixis (paragraph 1.2.2 "Major Contracts").

Competition

Many other treatments are approved in Europe for renal cell carcinoma. Some products have been marketed for several years like Sutent® (*sunitinib*) (Pfizer), Nexavar® (*sorafenib*) (Bayer), Afinitor® (*everolimus*) (Novartis), and Inlyta® (*axitinib*) (Pfizer). Two other products received approval in 2016 in second-line treatment of renal cell carcinoma: Opdivo® (*nivolumab*) (Bristol-Myers Squibb), and Kisplyx® (*lenvatinib*) (Eisai) in combination with Afinitor.



In the most recent European Society for Medical Oncology (ESMO) renal cell carcinoma guidelines, only Cabometyx and Opdivo are considered standard of care therapies in second-line post-tyrosine kinase inhibitors use. Nexavar, Afinitor, and Inlyta are only considered as treatment options, while Kisplyx in combination with Afinitor[®] was not included.

In first-line treatment of renal cell carcinoma, five other therapies are currently approved as of 31 December 2021: Sutent[®], Votrient[®] (*pazopanib*), Fotivda[®] (*tivozanib*) (Aveo Pharmaceuticals), Torisel[®] (*temsirolimus*) (Pfizer) and the combination of Avastin[®] (*bevacizumab*) (Roche) and interferon alfa. Only Cabometyx demonstrated superiority over sunitinib, which was considered as the standard of care to date.

In January 2019, the combination of Yervoy[®] (*ipilimumab*) and Opdivo (Bristol-Myers Squibbs) received European approval for the initial treatment of advanced renal cell carcinoma patients with intermediate and poor risk. In September 2019, the combination of Keytruda[®] (*pembrolizumab*) (Merck) and Inlyta (Pfizer) received European approval for the frontline treatment of patients with advanced renal cell carcinoma. In October 2019, the combination of Bavencio[®] (*avelumab*) (Merck KGaA) and Inlyta (Pfizer) received European approval for the first line treatment of patients with advanced renal cell carcinoma.

In Europe, Stivarga[®] (*regorafenib*) (Bayer), is approved for second-line hepatocellular carcinoma after sorafenib treatment as well as Cyramza[®] (*ramucirumab*) (Lilly) indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.

Onivyde[®]

Active substance and indications

Onivyde[®] is a unique encapsulation formulation of irinotecan. Irinotecan sucrose octasulfate is a long-circulating liposomal form, which is designed to increase the length of tumor exposure to irinotecan and its active metabolite SN-38.

Irinotecan, a topoisomerase 1 inhibitor, is a derivative of camptothecin that relieves torsional strain in DNA by inducing single-strand breaks, rotating the cleaved strand around the double-helix axis and re-ligating the cleaved strand to re-establish intact duplex DNA. Both irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase I-DNA complex and prevent re-ligation of these single-strand breaks. The liposome is a unilamellar lipid bilayer vesicle, which encapsulates an aqueous space containing irinotecan sucrose octasulfate.

Onivyde is indicated, in combination with 5-fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Marketing

Onivyde was approved in the U.S. in 2015 for the treatment of metastatic adenocarcinoma of the pancreas after disease progression with gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.

Onivyde was developed by Merrimack Pharmaceuticals and acquired by Ipsen in April 2017. The Group currently markets Onivyde in the U.S. and retains exclusive U.S. commercialization rights to potential future indications for the

drug. Servier has ex-U.S., ex-Taiwan commercialization rights to Onivyde and PharmaEngine has commercialization rights in Taiwan.

Onivyde sales reached €127.4 million in 2021 including mainly direct sales in the U.S. but also sales at supply price to Servier.

Onivyde is prescribed by oncologists in the U.S.

Competition

The main competitors of Onivyde are fluorouracil-based combination regimens of generic chemotherapy agents including: Folfirinox[®] (*fluorouracil, leucovorin, irinotecan and oxaliplatin*), Folfox[®] (*fluorouracil, leucovorin, and oxaliplatin*), and Folfiri[®] (*fluorouracil, leucovorin, and irinotecan*).

Onivyde is indicated following gemcitabine-based therapy. The most common gemcitabine-based therapy is gemcitabine in combination with Abraxane[®] (*paclitaxel*), a microtubule inhibitor, developed and marketed by Celgene, indicated in combination with gemcitabine as first-line treatment for advanced pancreatic cancer.

Decapeptyl[®]

Active substance and indications

Decapeptyl is a synthetic hormone with active ingredient triptorelin, a decapeptide analog of GnRH (Gonadotrophin Releasing Hormone). GnRH is a hormone secreted by the hypothalamus, which initially stimulates the release of pituitary gonadotrophins (hormones produced by the pituitary gland) and in turn controls hormonal secretions by the testicles and ovaries.

Decapeptyl is indicated for:

- **Treatment of locally advanced or metastatic prostate cancer:** Decapeptyl temporarily increases the concentration of testosterone and dihydrotestosterone, but continuous administration paradoxically leads to a reduction in plasmatic testosterone concentration. After two to three weeks of treatment, testosterone is reduced to levels below the castration threshold, thereby depriving prostate tumors of one of the main hormones promoting tumor development;
- **Endometriosis:** Decapeptyl is used as a treatment aimed at suppressing estrogen secretion, which deprives the ectopic endometrial tissue of the critical stimulus it needs to grow;
- **Uterine fibroids:** Decapeptyl is used to reduce the risk of blood loss following ablative surgery to remove uterine fibroids and to relieve symptoms such as abdominal pain, dysmenorrhea (painful menstruation), and menorrhagia (excessive menstrual bleeding) associated with uterine fibroids through the reduction in their hormonal stimulation;
- **In vitro fertilization:** Decapeptyl is used in association with gonadotrophins to induce ovulation for *in vitro* fertilization followed by embryo transfer;
- **Central precocious puberty:** Decapeptyl is used to inhibit over-secretion of hormones by the pituitary gland at a premature age, which improves the height age/bone age ratio;
- **Endocrine-responsive early-stage breast cancer:** Decapeptyl monthly is used in pre-menopausal women at high risk of recurrence following chemotherapy, in combination with tamoxifen or an aromatase inhibitor. Triptorelin leads to ovarian function suppression, which in



combination with tamoxifen (anti-œstrogen) or aromatase inhibitor (inhibitor of œstrogen synthesis) deprives the breast tumor of the main hormones promoting its development;

- Decapeptyl is available in daily, monthly, three-month, and six-month sustained-release formulations.

Marketing

Decapeptyl was the Group's second largest product in terms of sales in 2021 reaching €459.6m with Major Western European countries (G5) accounting for 46% of total sales and China representing a large portion of Decapeptyl sales (21%).

At 31 December 2021, Decapeptyl had marketing authorizations in over 90 countries.

Decapeptyl is prescribed primarily by the following specialists: urologists, oncologists, radiation oncologists, pediatric endocrinologists, gynecologists and *in vitro* fertilization specialists.

Decapeptyl stems from a partnership with Debiopharm (paragraph 1.2.2 "Major Contracts").

Competition

Competitors' products vary depending on therapeutic indications and countries. For prostate cancer, the main competitors are: Enantone® (*leuprorelin*) (Takeda/Wyeth/Abbott), Zoladex® (*goserelin*) (AstraZeneca), Eligard® (*leuprorelin*) (Recordati).

The currently available GnRHa's (triptorelin, leuprorelin and goserelin) are available as intramuscular and/or subcutaneous injectables with daily, 1M, 3M and 6M dosing options.

New competitors in the form of a once, daily, oral antagonist as well as branded generic GnRHa's are anticipated from H1 2022 onwards:

Relugolix (Myovant) a once, daily oral antagonist anticipated EU approval in Q2'2022

Camcevi (Accord/Foresee) - a 6M leuprolide mesylate in a pre-filled syringe, earliest anticipated EU approval in Q4'2021

Camcevi (Accord/Foresee) a 3M leuprolide mesylate in a pre-filled syringe, earliest anticipated EU approval in Q4'2022

Eligard (Tolmar/Recordati) - relaunch with a new injection device, anticipated EU approval by end H1'22.

Xermelo® (*telotristat ethyl*)

Active substance and indications

Xermelo is a novel, orally-administered, inhibitor of the enzyme tryptophan hydroxylase (TPH). Through inhibition of TPH, the rate-limiting step in the synthesis of serotonin, Xermelo is designed to reduce the production of serotonin within neuroendocrine tumors, thus reducing the presence of some of the symptoms associated with carcinoid syndrome, in particular diarrhea and the secretion of 5HIAA (5 hydroxy-indole acetic acid).

Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.

Marketing

Xermelo was approved by EMA in 2017 for the treatment of carcinoid syndrome diarrhea in combination with a somatostatin analog. As of 31 December 2021, Xermelo is available in 23 countries, including 21 European countries.

Xermelo is prescribed by the same physicians that prescribe Somatuline and other somatostatin analogs (endocrinologists, oncologists, gastroenterologists, and digestive surgeons), as the treatment is an add-on to this therapy.

Xermelo stems from a partnership with Lexicon Pharmaceuticals (paragraph 1.2.2 "Major Contracts"). On 8 September 2020, Lexicon Pharmaceuticals completes the sale of Xermelo to TerSera therapeutics. Agreements between Ipsen and Lexicon Pharmaceuticals have been assigned to TerSera therapeutics.

Competition

Xermelo currently has no direct competition as it is a first-in-class drug, with little or no other validated therapies available in this particular patient segment.

Cometriq® (*cabozantinib*)

Active substance and indications

Cometriq is a small molecule administered orally in the form of capsules that acts as a targeted tyrosine kinase inhibitor (TKI).

Cometriq targets three important intracellular pathways in medullary thyroid cancer (MTC): RET, VEGFR, and MET, besides other molecular targets like AXL. The mechanism of action for Cometriq has been shown to inhibit angiogenesis and the migration and proliferation of tumor cells. Cometriq has also been found to disrupt tumor vasculature and induce tumor cell death in pre-clinical models.

Cometriq was approved in Europe based on the Phase 3, international, multicenter, randomized, double-blind study (EXAM).

This study demonstrated a statistically significant and clinically meaningful improvement in progression-free survival with Cometriq as compared to placebo, corresponding to a decrease of 72% of the risk of disease progression in patients with progressive locally advanced (not amenable by surgery) or metastatic medullary thyroid cancer.

Cometriq is indicated for the treatment of adult patients with progressive, unresectable, locally-advanced or metastatic medullary thyroid carcinoma. Cometriq has orphan drug status and fulfils an unmet medical need in medullary thyroid cancer.

Marketing

As of 31 December 2021, Cometriq was approved in 30 countries and available in 13 countries.

Cometriq is prescribed primarily by oncologists and endocrinologists.

Cometriq stems from a partnership with Exelixis (paragraph 1.2.2 "Major Contracts").

Competition

The main competitor for the product is Caprelsa® (*vandetanib*) (Sanofi) which is used to treat patients with medullary thyroid cancer that cannot be removed through surgery or that has spread to other parts of the body.



Rare Disease

NutropinAq®

Active substance and indications

NutropinAq is a liquid formulation of recombinant human growth hormone administered using the "NutropinAq Pen". Growth hormone is involved in several physiological processes.

NutropinAq is a ready-to-use liquid formulation for injection.

NutropinAq is indicated for the following:

Pediatric population:

- Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion;
- Long-term treatment of girls from 2 years old with growth failure associated with Turner syndrome;
- Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.

Adult population:

- Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology.

Marketing

As of 31 December 2021, the Group had obtained marketing authorizations in 37 countries. The product has been launched in 20 countries across Europe since 2004.

Growth hormones are prescribed by pediatric and adult endocrinologists.

NutropinAq stems from a partnership with Genentech (now, a member of the Roche Group) in 2002 (paragraph 1.2.2 "Major Contracts").

Competition

Six other companies have marketed recombinant growth hormones: Pfizer with Genotropin® (*somatropin*), Eli Lilly with Humatrope® (*somatropin*), Novo Nordisk with Norditropin® (*somatropin*), Merck Serono with Saizen® (*somatropin*) and Ferring with Zomacton® (*somatropin*). Sandoz commercialized Omnitrope® (*somatropin*), a biosimilar product of Pfizer's Genotropin.

Increlex®

Active substance and indications

The active substance in Increlex is a recombinant DNA-derived human insulin-like growth factor (IGF-1). IGF-1 is the direct hormonal mediator of stature and bone growth and must be present for normal growth of bones and cartilage in children.

Increlex is approved for the long-term treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (Primary IGFD), an ultra-rare disease.

Marketing

Increlex was granted marketing authorization in 2005 in the United States and under a centralized marketing authorization in 2007 in Europe under exceptional circumstances. Increlex® is currently authorized in a total of 37 countries and marketed in 22 countries worldwide.

Recombinant IGF-1 is prescribed by pediatric endocrinologists.

Competition

Increlex is the only treatment available for patients living with Severe-Primary IGF-1 deficiency in the U.S, European Union and Australia. There are no other competitors in these territories.

Neuroscience

Dysport®

Active substance and indications

Dysport is a botulinum neurotoxin type A product, which is a substance derived from a bacterium (*clostridium botulinum*) that blocks acetylcholine release from nerve endings resulting in the relaxation of hyperactive muscles.

Dysport is approved in the following therapeutic indications in adults:

- Treatment of focal spasticity in adult upper and/or lower limbs. Spasticity is characterized by uncontrollable muscle overactivity, which leads to muscle contraction and soft tissue shortening resulting in impairment of activities of daily living, function, mobility and social isolation. Spasticity generally occurs in the first six months following an acute or progressive disorder of the central nervous system, such as stroke, spinal cord injury, traumatic brain injury, multiple sclerosis or cerebral palsy.
- Treatment of Cervical Dystonia (CD), which is the most common adult-onset form of focal dystonia, an orphan neurological condition characterized by involuntary and sustained muscles spasms. Symptomatic presentation of cervical dystonia can be abnormal neck posture and degree of head rotation, neck and shoulder pain and involuntary twisting or jerking of the head.
- Treatment of blepharospasm. Blepharospasm is an abnormal and involuntary contraction of the eyelid, that can be chronic and persistent.
- Treatment of hemifacial spasm. Hemifacial spasm is a benign neuromuscular disease characterized by irregular, involuntary muscles contraction on one side of the face.
- Treatment of severe primary hyperhidrosis of the axillae. Hyperhidrosis (HH) is characterized by excessive sweating due to the overactivity of the sweat glands and affects about 1%-3% of the population.

Dysport is also approved in children aged 2 years and older for:

- treatment of focal spasticity in upper and/or lower limbs.

Cerebral Palsy (CP) is the most frequent cause of spasticity in children and the leading cause of childhood disability affecting movement and posture, causing limitation of activity.

Dysport is approved in aesthetics for the temporary improvement in the appearance of moderate to severe:

- glabellar lines,
- lateral canthal lines (crow's feet lines),
- in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.



Marketing

Dysport was initially approved in the United Kingdom in 1990 and had marketing authorization in over 90 countries as of 31 December 2020.

In the United States, on 30 April 2009, the Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for Dysport (*abobotulinumtoxinA*) in cervical dystonia and for the temporary improvement in the appearance of moderate to severe glabellar lines in adults aged 65 years and under.

In 2015, the FDA approved the use of Dysport for injection for the treatment of spasticity in adults, based on its supplemental Biologics License Application (sBLA) in upper limb spasticity. In 2017, the FDA expanded the approved use of Dysport for injection for the treatment of spasticity in adults, based on its supplemental Biologics License Application (sBLA) in lower limb spasticity.

Dysport was approved in 2016 to treat pediatric patients with lower limb spasticity aged 2 and older, making it the first botulinum toxin approved by the FDA for this indication. In 2019, Dysport received FDA approval for the treatment of upper limb spasticity in children 2 years of age and older, excluding upper limb spasticity caused by CP, due to Orphan Drug exclusivity granted to another manufacturer. Ipsen has worked with the FDA and this manufacturer to selectively waive their respective exclusivities to better support patient care. As a result, Dysport is now FDA-approved to treat both upper and lower limb spasticity in pediatric patients 2 years of age and older, including spasticity caused by cerebral palsy.

In esthetics, Ipsen and Galderma have been exclusive partners since 2007 for the research, development and distribution of Ipsen's botulinum toxin type A product for esthetic and dermatological indications in some European countries (under the brand name Azzalure®) (*botulinum toxin type A*), in other territories including the United States and Canada since 2014 and Galderma launched Dysport 300U in China in November 2020 (these agreements are presented in detail in section 1.2.2 of this universal registration document).

Dysport is administered by trained physicians e.g. neurologists, physical medicine & rehabilitation specialists, neuropsychiatrists, orthopedic surgeons, ENT specialists, ophthalmologists, dermatologists, plastic surgeons and esthetic medicine physicians.

Competition

Dysport's main competitors are Botox®/Vistabel® (*botulinum toxin type A*) (Allergan, An AbbVie Company) and Xeomin®/Bocouture® (*botulinum toxin type A*) (Merz) for both therapeutic and esthetic indications. Competitive intensity in the botulinum neurotoxin market is increasing as more competitors enter the U.S. and European markets. In 2019, Jeuveau® (*botulinum toxin type A*) (Evolus), which was launched in the U.S. aesthetics-only market and approved in Europe, as brand name Nuceiva® (*botulinum toxin type A*), is expected to launch in Europe in 2022.

■ 1.2.1.2 Consumer Healthcare Products

Smecta®

Active substance and indications

Smecta is an oral formulation of pharmaceutical clay indicated in the treatment of acute diarrhea in both adults and children, and in the symptomatic treatment of digestive pain and

chronic diarrhea in adults. Smecta is a natural clay processed and purified for therapeutic use. Ipsen is actively working on the lifecycle management of its original oral Smecta powder (vanilla and vanilla/orange) with new flavors and new galenic forms including:

- Smectalia® (drug) /SmectaGo® (medical device), a liquid ready-to-use suspension in stick, marketed in 21 countries;
- Smecta strawberry, powder for oral use.

Marketing

As of 31 December 2021, Smecta had market authorizations in about 80 countries. In 2021, Smecta sales represented 3.1% of total Ipsen sales, of which 69% were generated in China, Russia and France, the product's main markets.

Smecta is Ipsen's leading Consumer Healthcare product in terms of sales.

Smecta is prescribed by general practitioners, gastroenterologists, and pediatricians. The product can also be dispensed without prescription under pharmacist advice or as an OTC self-medication for patients.

In 2020, Smecta is turning 45 years, since its launch in 1975, almost 700 million people have used around 15 billion sachets of Smecta, which confirms the confidence that patients and healthcare professionals around the world have in this brand for years.

Competition

Smecta's main competitors are Imodium® (*loperamide*) (Johnson & Johnson), Ercefuryl® (*Nifuroxazide*) (Sanofi), Ultralevure® (*Saccharomyces boulardii*) (Biocodex), and Tiorfar® (*raccadotril*) (Bioproject Pharma). French authorities granted reimbursement to a generic player of Smecta in Q3 2019.

Probiotics

Smebiocla®/SmectaFlora Comfort®

(*Lactobacillus plantarum 299v*)

Active substance and indications

Smebiocla®/SmectaFlora Comfort® is a food supplement composed of a well-documented, with high dosage, probiotic strain *Lactobacillus plantarum 299v*. The probiotic transiently colonizes the gut and can be taken in the case of irritable bowel syndrome.

Marketing

Ipsen signed a license and supply agreement in 2016 with Probi for the commercialization of its probiotic strain LP299V (*Lactobacillus plantarum 299v*). Probi is a Swedish publicly-traded bioengineering company that develops effective and well-documented probiotics. The agreement covers 20 countries, many with high-growth potential, with an option to include additional countries. Since 2017 Smebiocla®/SmectaFlora Comfort is already commercialized in 9 countries.

Competition

The main competitor is Symbiosis Alforex® (BIOCOCODEX) which contains the strain *Bifidobacterium infantis 35624*.

Smebiocla®/SmectaFlora Protect®

(*Saccharomyces boulardii* and *Lactobacillus rhamnosus*)



Active substance and indications

Smebiocta/SmectaFlora Protect® is a new food supplement composed of a new combination of the well-documented, with high dosage, yeast and probiotic strains *Saccharomyces boulardii* and *Lactobacillus rhamnosus* GG manufactured by Lallemand. The product can be taken during antibiotic therapy.

Marketing

The probiotic Smebiocta/SmectaFlora Protect has been launched in 4 countries (France and Czech Republic in 2019, Italy in 2020 and Greece in 2021).

Competition

Smebiocta/SmectaFlora Protect's main competitors are Ultra Levure (Biocodex) and Lactibiane ATB® (Pileje).

Bloating

SmectaGas® (*Simeticone and Chitin-Glucan*)

Active substance and indications

SmectaGas is a medical device, ready to use solution composed of 250 mg *Simeticone* and 500 mg *KiOtransine®* (*Chitin-Glucan*), intended to be used in the symptomatic treatment of gas-related gastrointestinal disorders: relief of gas-related symptoms such as bloated feeling, abdominal distension, flatulence or abdominal pain, regularization of intestinal transit and stool evacuation.

Marketing

Since 2018 and as per the distribution agreement signed with Kitozyme SmectaGas is commercialized in 6 European countries: France, Poland, Latvia, Lithuania, Romania and Czech Republic.

Competition

SmectaGas main competitors are Espumisan® (*Simeticone formula*) in Eastern Europe & Russia and Carbolevure® (*Saccharomyces cerevisiae*) in France.

Forlax®

Active substance and indications

Forlax is an oral osmotic laxative, designed and developed by Ipsen, and indicated for the symptomatic treatment of constipation in both adults and children (from 6 months). Forlax is a linear polymer of ethylene glycol molecules and constitutes a high molecular weight polyethylene glycol (PEG) with no added electrolytes.

Marketing

Forlax was first registered in France in 1995. The marketing authorization was later extended to EU countries through a mutual recognition procedure and is now approved in 17 EU countries.

As of 31 December 2021, Forlax was granted marketing authorizations in more than 60 countries. In 2021, around 43% of Forlax sales were generated in France.

Forlax is also marketed in a ready-to-use stick under the name ForlaxGo®/Forlib®.

Forlax is primarily prescribed by general practitioners, gastroenterologists, gynecologists and pediatricians. The product can also be dispensed without a prescription under pharmacist advice or as an OTC self-medication for patients. To position Forlax as an OTC self-medication product, a liquid form has been launched as a medical device in selected European markets.

Competition

Forlax's main competitors are other osmotic laxatives, including lactulose products such as Duphalac® (Solvay Pharma), other PEGs such as Transipeg® (Roche Nicholas) and Movicol® (Norgine Pharma), and stimulant laxatives (e.g. bisacodyl) such as Dulcolax® (Sanofi).

In France, Forlax generics are marketed by competitors. Today, Ipsen produces two generic products marketed by Biogaran and Sandoz.

Fortrans®

Active substance and indications

Fortrans is aimed before endoscopy procedure (colonoscopy, surgery, or radiology). Fortrans is a linear polymer of ethylene glycol molecules, and constitutes a high molecular weight polyethylene glycol (PEG) of high molecular weight with added electrolytes. Its ingestion exerts a cleansing effect on the colon and the electrolytes present in the formulation prevent hydro- electrolyte disorders.

Marketing

Fortrans is indicated for bowel cleansing preparation before endoscopy, X-ray examination or colonic surgery.

As of 31 December 2021, Fortrans held marketing authorizations in more than 50 countries.

Russia and Poland are the two largest markets for Fortrans.

Eziclen®

Active substance and indications

BLI-800 commercialized under Ipsen trademarks Eziclen or Lzinova® is a new-generation osmotic low volume laxative, indicated in adults, for cleaning the bowel before endoscopy procedure (colonoscopy), surgery or radiology. Since 2019, Eziclen is included in the European Society of Gastrointestinal Endoscopy (ESGE) guidelines.

Marketing

On 31 December 2021, Eziclen was marketed by Ipsen or its local partners in 19 countries.

Ipsen acquired in 2009 from Braintree (now Sebela Pharmaceuticals) the exclusive manufacturing, marketing and distribution rights of BLI-800 for the European Union, the Commonwealth of Independent States (CIS), some Asian countries (including China) and some North African and South American countries. The agreement is presented in detail in section 1.2.2 "Major Contracts" of this universal registration document.

Etiasa® (mesalazine)

Active substance and indications

Etiasa is indicated in inflammatory bowel diseases (ulcerative colitis and Crohn's disease), for the treatment of mildly to moderately-active condition and maintenance of remission.



Marketing

In 2015, Ipsen has renewed its exclusive agreement with Ethypharm for Etiasa in China. The drug is manufactured by Ethypharm in its Shanghai subsidiary and Ipsen has exclusive rights for the distribution activities and promotion of Etiasa.

Competition

The drug's principal competitors in China are other 5-ASA products such as Pentasa® (Ferring Pharmaceuticals), Salofalk® (Vifor Pharma), mesalazine generic, and sulfasalazine.

Tanakan®

Active substance and indications

Tanakan is a drug indicated for the symptomatic treatment of cognitive disorders, of vertigo of vestibular origin in addition to vestibular rehabilitation and of tinnitus. Tanakan contains natural substances with antioxidant and neuro-protective properties.

The active substance in Tanakan – EGb 761® – is a standardized extract from the leaves of *Ginkgo biloba* (dioecious tree in the *Ginkgoaceae* family) cultivated and extracted under controlled conditions.

Marketing

As of 31 December 2021, Tanakan was approved in almost 60 countries, mainly in Europe, Russia, and Asia.

In 2021, 29% of Tanakan sales were generated in Russia, where the product is offered as a self-medication OTC product.

Other Consumer Healthcare Products

Ipsen Consumer Healthcare has other products mainly in the gastro-intestinal area, including those commercialized in Italy following the acquisition of Akkadeas and some selected OTC products acquired from Sanofi in 2017: Buscopan® (*hyoscine butylbromide*), Clin4000®, Prontalgine® (*paracetamol/codein*), Suppositoria Glycerini, and Mucothiol® (*diacetylcysteine*) and Mucodyne® (*carbocysteine*), Floractin(R) (*Lactobacillus rhamnosus GG*).

1.2.2 Major Contracts

The Group markets its products either directly through its sales force or through third parties under licensing or other agreements. Furthermore, the Group has earned the confidence of third parties that have entrusted it with selling their products such as Cabometyx, Decapeptyl, and NutropinAq. In certain cases, the Group has entered into agreements with third party companies to manufacture drugs or raw materials.

The Group complements the implementation of its internal Research and Development program by entering into partnership agreements with university teams and pharmaceutical and biotechnology companies. These partnerships help the Group gain access to cutting-edge technologies in complex areas of expertise.

This partnership strategy helps the Group finance the development of its products while extending its range of existing products. The Group is constantly looking for high-quality, complementary, and long-lasting marketing, research and development partnerships.

■ 1.2.2.1 Agreements in Specialty Care

1.2.2.1.1 Agreements in Oncology

Debiopharm (Lausanne, Switzerland)

The Group has maintained an ongoing relationship with Debiopharm since 1983 when it entered into its first licensing agreement to manufacture and market Decapeptyl in locally-advanced cancer or metastatic prostate cancer. This licensing agreement was renewed in June 2019 to extend the collaboration through 2034 for the treatment of metastatic and non-metastatic patients with locally advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty and endocrine-responsive early-stage breast cancer. The agreement covers Debiopharm's expertise and patents related to the active substance triptorelin and its various salts (particularly the pamoate formulation), which are sold under the Decapeptyl and Pamorelin® (*triptorelin*) trademarks, both of which were assigned to Ipsen in 2010. The daily, one-

month, and three-month acetate and pamoate formulations of Decapeptyl are no longer protected by any patents.

The licensing agreement with Debiopharm grants the Group the right to collaborate with Debiopharm on the development of Decapeptyl as well as the right to manufacture and market Decapeptyl worldwide with the exclusion of North America and certain other countries, principally Israel, Japan, and English-speaking African countries. Pursuant to the agreement, the Group commercializes Decapeptyl under a daily formulation as well as under monthly, 3-month, and 6-month sustained-release formulations. A separate license agreement exists between the Group and Debiopharm for the commercialization by Ipsen of triptorelin under the trade names Salvacyl®, Salvacyl LP®, Moapar®, and Salvapar® for the treatment of paraphilia (sexual perversions).

Exelixis (San Francisco, California, USA)

In 2016, the Group and Exelixis Inc. signed an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis' lead oncology asset. The parties agreed to collaborate on the development of cabozantinib for current and potential future indications, and Ipsen has exclusive commercialization rights worldwide outside the United States and Japan.

This agreement includes the rights to Cometriq currently approved in the United States and the European Union (EU) for the treatment of adult patients with progressive, unresectable, locally-advanced or metastatic medullary thyroid cancer (MTC), and Cabometyx currently approved in a number of countries, among others the U.S., the European Union (EU) and Canada for the second-line treatment of patients with advanced renal cell carcinoma (RCC) who have received first-line antiangiogenic therapy, and for the first-line treatment of adults with intermediate or poor risk advanced RCC, and for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.

Under the agreement Exelixis received a \$200 million upfront payment, several regulatory milestone payments as well as up



to \$545 million of potential commercial milestones and tiered royalties to Exelixis of up to 26% on Ipsen's net sales of cabozantinib in its territories.

Servier (Suresnes, France)

In 2017, the Group acquired from Merrimack Pharmaceuticals, Onivyde® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin as well as the commercial and manufacturing infrastructure for Onivyde®, and MM-434 the generic doxorubicin HCl liposome injection. Through such acquisition, Ipsen has acquired exclusive commercialization rights of Onivyde® in the United States, as well as the licensing agreements that was entered into by Merrimack Pharmaceuticals respectively with PharmaEngine and with Shire (whose biopharmaceutical division was spun off in 2016 as Baxalta, which oncology business including Onivyde was subsequently assigned to Servier). Pursuant to said license agreements, PharmaEngine has exclusive commercialization rights in Taiwan (the "PEI License Agreement"). Servier has development and exclusive commercialization rights outside of the United States and Taiwan (the "Servier License Agreement"). Under the terms of the Servier License Agreements, Servier will pay to Ipsen certain milestone payments and royalties on sales of the products outside United States and Taiwan. Under the PEI License Agreement, PharmaEngine is eligible to receive from Ipsen certain milestone payment upon the achievement of certain regulatory and commercial milestone events and royalties on sales made outside the United States and Taiwan.

1.2.2.1.2 Agreements in Neuroscience Galderma (Lausanne, Switzerland)

In 2007, under the terms of a development and distribution agreement, Ipsen granted Galderma S.A., a Swiss company, exclusive rights to develop, promote, and distribute specific formulations of its botulinum toxin type A product in aesthetic medicine indications in the European Union and certain Eastern European countries and Central Asia. The Group also granted Galderma first rights of negotiation for aesthetic medicine indications outside Galderma territories.

The product is distributed in Europe under the Azzalure trademark owned by Galderma. Azzalure is mainly commercialized in the United Kingdom, France, Germany, Portugal, Denmark, Finland, Sweden, and Poland. Ipsen owns all regulatory approvals and all data arising from development activities.

In 2014, the Dysport distribution rights in the U.S. and Canada, initially held by Valeant, were granted to Galderma. The agreement was further expanded to include new neurotoxins in addition to Azzalure and Dysport, namely their respective liquid formulations. Ipsen gained control of the intellectual property for Galderma's liquid toxin in the U.S., Canada, Brazil, and Europe, while Galderma retained commercialization rights. In addition, the distribution rights were extended until 2036.

In the context of the first rights of negotiations granted to Galderma to further expand the territories, the Group granted to Galderma exclusive rights, to promote and distribute under

the trademark Dysport certain formulations of botulinum toxin in aesthetic indications in Brazil, Argentina, Mexico, Australia, New Zealand, China, India, South Korea, Hong Kong, Macau, Taiwan, Singapore and Thailand. In consideration among others for such expansion granted to Galderma, Ipsen has acquired the title to the intellectual property for Galderma's liquid toxin in the partnership countries.

The Group supplies the finished product to Galderma, and Galderma pays Ipsen royalties based on sales of the product.

Public Health England (PHE) (Porton Down, United Kingdom)

The Group entered a licensing agreement with the PHE in 1994 covering the botulinum toxin type A complex, which is the active substance in Dysport. Until December 2036, the Group holds an exclusive worldwide license to use and sell the botulinum neurotoxin type A produced by the PHE and the co-exclusive right with the PHE to manufacture this toxin using the PHE processes. Further to an amendment in 2001, the Group began producing botulinum toxin type A in 2004. The Group is now discharged from the obligation to purchase botulinum toxin from PHE.

Under this agreement, the Group pays the PHE royalties based on revenues generated from the sale of products containing botulinum toxin type A, particularly those realized under the Dysport brand name, together with minimum royalty clauses.

1.2.2.1.3 Agreements in Rare Disease Allergan GI (Madison, New Jersey, USA)

In 2013, Rhythm was split into two entities to continue the development of separate programs and the Group granted Motus Therapeutics an exclusive worldwide license for the research, development and commercialization of Ipsen's compounds and intellectual property related to its peptide ghrelin agonist. Motus Therapeutics was acquired by Allergan in 2016. Allergan GI (formerly Motus Therapeutics) is developing relamorelin for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. Under the terms of the license agreement, Ipsen will receive progressive payments of up to \$40 million upon the achievement of certain development and commercial milestones and royalties on future sales of the products. In September 2020 Allergan GI (now part of AbbVie) notified the termination of this license agreement to Ipsen. The termination is effective as of March 2021.

Blueprint Medicines (Cambridge, Massachusetts, USA)

In 2019, the Group and Blueprint Medicines entered into an exclusive, worldwide license agreement for the development and commercialization of IPN60130 (formerly known as BLU-782), an oral, highly selective investigational ALK2 inhibitor being developed for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). Blueprint Medicines will be eligible to receive up to \$535 million, including an upfront cash payment of \$25 million and up to \$510 million in potential payments related to development, regulatory and sales-based milestones.

Genentech (San Francisco, California, USA)

The Group entered into a distribution agreement with Genentech in 2002 which covers NutropinAq, a liquid formulation of human growth hormone for daily use produced using recombinant DNA technology. Under this agreement, the Group has the exclusive right to market worldwide (with



the exception of North America, Mexico, Brazil, and Japan) NutropinAq and the NutropinAq Pen Cartridge® (i.e. the configuration used for the daily administration of the liquid formulation of NutropinAq) and any improvement made to these products for a period of 20 years starting from the date on which NutropinAq was launched in the market.

The Group agreed to pay Genentech (now, a member of the Roche Group since 2009) milestone payments when certain net sales figures are reached. The Group also agreed to pay royalties based on the total amount of annual sales of each product in the territory covered by the distribution agreement. The European patent owned by Genentech protecting the product expired on 29 July 2013.

GENFIT (Loos, France)

In December 2021, Ipsen and GENFIT have entered into a long-term strategic partnership for global collaboration between the two companies. The agreement gives Ipsen exclusive worldwide* license to develop, manufacture and commercialize GENFIT's investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC). The partnership also gives Ipsen access to future clinical programs led by GENFIT and combines GENFIT's scientific expertise and proprietary technologies in liver disease with Ipsen's development and commercialization capabilities. To underscore the long-term commitment represented by this partnership, Ipsen will also purchase newly issued GENFIT equity representing 8% post-issuance through a €28m investment in GENFIT, becoming one of the largest shareholders.

Irlab Therapeutics AB (Gothenburg, Sweden)

In July 2021, the Group and Irlab entered into an exclusive licensing agreement pursuant to which Ipsen has obtained the exclusive right to develop and commercialize worldwide an investigational drug mesdopetam, which is an oral dopamine D3-receptor antagonist for the treatment of patients with Parkinson's disease experiencing levodopa-induced dyskinesia. Under this agreement, Irlab has received a \$28 million upfront payment and is eligible to receive certain contingent payments up to \$335 million upon achievement of certain development, regulatory events and commercial sales milestones, as well as tiered low-double digit royalties on worldwide net sales.

TerSera Therapeutics (Deerfield, Illinois, USA)

In 2014, the Group entered into an exclusive licensing agreement with Lexicon Pharmaceuticals for Ipsen to commercialize Xermelo outside North America and Japan, with a focus on the treatment of carcinoid syndrome. Through an amendment in March 2015, Ipsen was granted exclusive rights in Canada. Lexicon retains sole rights to commercialize Xermelo in the U.S. and Japan. In September 2020, Lexicon sold Xermelo and assigned the related license agreement with Ipsen to TerSera Therapeutics.

On March 31st, 2022, Serb Pharmaceuticals has acquired the rights from Ipsen to commercialize Xermelo (telotristat ethyl) in Europe and other countries outside the US and Japan. Xermelo will be commercially available from Serb outside the US and Japan starting in July 2022.

Teijin (Tokyo, Japan)

The Group granted Teijin exclusive rights in Japan to develop and market Somatuline Autogel for the treatments of acromegaly, Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NET) and TSHoma (thyrotropinoma).

In 2012, Teijin received marketing approval in Japan for Somatuline 60/90/120 mg for subcutaneous injection for the treatment of acromegaly and pituitary gigantism.

In 2017, Teijin received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen's subcutaneous drug Somatuline for the treatment of GEP NET.

■ 1.2.2.2 Agreements in Consumer Healthcare

Braintree Laboratories (Braintree, Massachusetts, USA)

In 2009, the Group acquired exclusive license rights to market, manufacture and commercialize Braintree Laboratories proprietary formulation, BLI-800 for colonic cleansing before colonoscopy. This agreement covers countries within the European Union, Russia and certain Commonwealth of Independent States, selected Asian (including China), North African and Latin American countries.

Braintree Laboratories receives royalties on Ipsen's sales as well as payments upon the achievement of certain milestones such as product launches and commercial sales thresholds. The product is marketed under the Eziclen and Izinova trademarks in the European Union and outside the European Union, including France, Germany and Russia. In 2018, Braintree Laboratories was acquired by Sebel.

Ethypharm (Saint-Cloud, France)

The Group has longstanding links with Ethypharm a French pharmaceutical company, for the exclusive distribution and promotion by Ipsen in China of a mesalazine (5ASA) product manufactured by Ethypharm for the treatment of Inflammatory Bowel Disease under Ipsen proprietary trademark Etiasa®.

Schwabe (Karlsruhe, Germany)

The Group and the Schwabe group cooperate since 2005 in the development and supply of *Ginkgo Biloba* extracts used to manufacture pharmaceutical products via a joint venture on companies and limited partnerships in Ireland, France, the United States and Hong Kong. In April 2021, the Group sold its shares and interests in this joint venture. The cooperation continues with Schwabe group supplying the Group with EGB761CP, EGB761SE and other *Ginkgo biloba* extracts and granting right to use the trademarks EGB® and EGB761®.

Teijin (Tokyo, Japan) / Menarini (Italy)

In 2006, the Group and Teijin signed a distribution and promotion agreement which determined the definitive terms of Ipsen's exclusive rights to febusostat in various countries worldwide, excluding Japan and the U.S.

In 2009, the Group sublicensed its exclusive development and commercialization rights for febusostat in Europe, including Russia and certain Commonwealth of Independent States (CIS) countries, to Menarini.

Febuxostat was launched by Menarini in 2010 in Europe and in 2017 in Russia, under the trademark Adenuric®. Generics of the product are marketed in the European Union since April 2019.



1.2.3 Research and Development

The Group is transforming and enhancing its R&D operating model with a focus on accelerating prioritized internal projects, effectively managing the R&D portfolio and actively externally sourcing assets through disciplined business development. The mission of the R&D organization is to deliver at least one new molecular entity or meaningful indication every year.

■ 1.2.3.1 Research and Development Activities

The Group's R&D efforts aim to respond to unmet medical needs to develop innovative therapeutic solutions and utilizing an entrepreneurial, collaborative approach to build a sustainable portfolio.

Research and Development primarily focuses on two areas:

- discovery, development, and regulatory approval of new molecular entities;
- lifecycle management of products marketed by the Group through the:
 - extension and expansion of labelled indications;
 - development of new indications;
 - development of new formulations and delivery systems;
 - registration in new geographical areas.

Additionally, the Group partners on in-licensing development opportunities when appropriate to deliver its strategy.

As of 31 December 2021, more than 713 employees were employed in Research and Development including 174 employees in Pharmaceutical Development.

For the financial year 2021, Research and Development expenses totaled €428.4 million, compared to €405.6 million in 2020.

Novel botulinum toxin-based drug discovery in Neuroscience

The engineering of new botulinum toxins is primarily carried out in Ipsen's R&D facilities in Milton Park (Oxford, UK), in partnership with Les Ulis (Paris-Saclay) and/or in collaboration with academic research centers and biotechnology companies. Botulinum toxins have a unique potential for very broad therapeutic applications in many areas including neurology, urology, oncology, endocrinology, regenerative medicine, etc. The R&D team in Milton Park is very experienced in botulinum toxin biology, and the team's innovations are reflected in an extensive patent portfolio. Additionally, the Group is one of the few to master the manufacturing and testing of botulinum toxins at its plant in Wrexham (United Kingdom) as well as the technologies needed to explore new applications and to develop new toxin-based products. The Group is developing novel recombinant long-acting neurotoxins that have potential advantages of better control, robustness as well as quality and process manufacturing. It also allows the Group to leverage its development, manufacturing and commercialization expertise in the neurotoxin market.

Pharmaceutical development is located at the Dreux, Dublin and Wrexham sites and aims to design and develop formulations and innovative delivery systems for new chemical entities or for marketed products. These novel technologies can optimize the efficacy of active ingredients while improving the quality of life of patients and facilitating the use of these products by health care professionals.

Investment in translational sciences

Research and Development at Ipsen strives to be at the forefront of major advances emerging in science and medical practice such as the progression of molecular medicine and biomarkers which are revolutionizing the diagnosis and prognosis of diseases and the selection of the best treatment leading based on genetic markers to the emergence of personalized medicine. This commitment to translational sciences is reflected in a willingness to invest in biobanking during clinical trials, bioinformatics, predictive biometry based on simulation modelling and requiring large data banks, in-depth knowledge of pathophysiological/molecular mechanisms of diseases and from the outset to identify biomarkers which will accompany the development of candidate drugs with the potential to become companion diagnostics.

Partnership policy and open innovation

Internal Research and Development efforts are also supported through an active partnership policy, from basic research through clinical development. The Group's partnership philosophy stems from the recognition that Ipsen's R&D staff members are highly skilled in their fields but are a tiny fraction of the expertise available worldwide in the scientific community. Thus, it is essential to look for synergies between internal projects and skills and those of other leading-edge players in medical and pharmaceutical R&D in the context of robust open innovation policy.

At the research stage, the Group has established numerous academic collaborations with *Massachusetts General Hospital*, *Dana-Farber Cancer Institute*, *Harvard Medical School*, *Boston Children's Hospital* in Boston, U.S. *Stockholm University* in Stockholm, Sweden, *Université de Montréal* in Montreal, Canada and in France with *InnoBio 2*, *Inserm*, *Institut Gustave Roussy* and *Institut Curie*. Since 2008, Ipsen has been involved in a long-term partnership with the prestigious *Salk Institute* (La Jolla, California) on basic research in areas of Ipsen's interest. The Group has also forged partnerships on specific projects with innovative biotechnology companies, thereby accessing new compounds and promising technologies for the discovery of new drug candidates. In July 2021, the Group entered into a research collaboration with *Excure* to develop SNAs (spherical nucleic acids) as potential therapies for Huntington Disease and Angelman Syndrome.

Ipsen is considering different ways to invest in innovation and in 2018 contributed to a venture capital fund investing in pre-IND (Investigational New Drug) to late clinical phase assets. In 2018, Ipsen also partnered with *Arix Bioscience* and *BioLabs*.



In July 2021, Ipsen has signed a worldwide licensing agreement with BAKX therapeutics which gives us exclusive rights to develop, manufacture and commercialize BAX-001. BAX-001 has shown promise in activating the BCL-2 associated protein that drives programmed cell death in tumor cells, potentially creating an anti-cancer therapy. It is being evaluated for leukemia, lymphoma and solid tumors. Bax is downstream effector of Bcl-2 in the intrinsic apoptosis pathway. Ipsen and BAKX will be jointly responsible for research activities.

In November 2021, Ipsen signed a partnership with Queen's University Belfast (QUB) that will give Ipsen access to their novel first-in-class FLIP inhibitor program to advance our Oncology portfolio. FLIP is a major apoptosis-regulatory protein that is overexpressed in many hematological cancers and solid tumors, including colorectal, lung and pancreatic cancer. It is involved in the disruption of cell death signaling, one of the classical hallmarks of cancer, promoting tumor growth and resistance to currently available therapies. Upregulation of FLIP has been associated with tumor progression in a variety of solid and hematologic malignancies. This agreement gives Ipsen a global, exclusive licence to research, develop, manufacture, and commercialize the FLIP inhibitor. QUB will be responsible for research activities to development candidate selection and Ipsen for subsequent development and commercialization.

■ 1.2.3.2 Research and Development Centers

The Group has strategically established an international network of research and development centers in geographical areas where it has access to world-class expertise in scientific and clinical research. The Group believes its Research and Development programs and the geographical distribution of its Research and Development centers allow it to attract talented scientists, which makes the Group highly competitive in the field of pharmaceutical R&D compared with other groups of similar size.

The Research and Development Center in Paris-Saclay (France)

Ipsen Innovation, the Research and Development Center in Les Ulis, located in the Paris-Saclay hub, was opened in 1969 and a new facility was built in 1996. The scientists focus on novel medicines in the fields of Neuroscience, Rare Disease and Oncology. Notably, the Pharmacology, Non-clinical Safety, Pharmacodynamic and Metabolism groups in Les Ulis have expanded to support Ipsen projects from discovery to commercialization. The Group have also established a pre-clinical and clinical development operations organization together with the Global Regulatory Affairs, Pharmacovigilance and Quality departments to support the design and execution of the worldwide development strategy to bring to market the new compounds developed by Ipsen.

The Research and Development Center in Cambridge (Massachusetts, United States)

Ipsen Bioscience is located in the heart of the Cambridge biotech hub in order to allow broader access to external resources and knowledge in terms of innovative molecules and drug candidates. Cambridge is a "Center of Innovation" combining activities of research and assessment of these new molecules, through our External Innovation team, based on a strategic and operational partnership between the R&D and Business Development teams.

The Group also has Clinical Research, Development and Operations teams whose task is to coordinate and perform global clinical research related to Oncology, Neuroscience and Rare Disease, and a dedicated regulatory group that focuses on the Group's regulatory activities with the FDA.

The Research and Development Centers in Montreal (Quebec, Canada) and Cambridge (Massachusetts, United States)

Clementia Pharmaceuticals, an Ipsen company located in Montreal (Quebec, Canada) and Cambridge (Massachusetts, United States), is focusing on developing palovarotene, an investigational retinoic acid receptor gamma (RAR γ) selective agonist, and IPN60130, an oral ALK2 kinase inhibitor, for the treatment of individuals living with fibrodysplasia ossificans progressiva (FOP).

The Research and Development Center in Milton Park (Oxford, UK)

Ipsen Bioinnovation, located in a leading innovation hub at the Milton Park campus in Oxfordshire, represents Ipsen's technological platform for toxins, with expertise in engineering recombinant and modified toxins for new therapeutic solutions in Neuroscience and co-locates research scientists with the major R&D activities of clinical development, clinical development operations, regulatory affairs, pharmacovigilance, project management, and publication.

The Research and Development Center in Shanghai (China)

Ipsen Innovation hub in Shanghai, located in the Hong Kou district, has opened in 2019. The Group is establishing a Global R&D organization including Clinical Development, Biometry, Regulatory Affairs, Pharmacovigilance and Quality departments. This team will support the design and execution of the appropriate development strategy to register in China new indications and new compounds. The Shanghai Innovation hub will also collaborate closely with Global External Innovation and Partnering to pursue opportunities in China.

■ 1.2.3.3 The Portfolio of Research and Development Projects

1.2.3.3.1 The research and development process

At the end of the research stage that results in the selection of a candidate molecule for development, the process of securing approval for this new molecule or compound by the regulatory authorities may take eight to twelve years and is typically broken down into five stages: the pre-clinical stage, Phase 1 FIH clinical trial (Phase 1 or first-in-human study) to assess safety and pharmacokinetics/pharmacodynamics of the compound; Phase 2 to characterize safety and efficacy across a dose-range of the tested compound in patients; Phase 3 to confirm both safety/efficacy and therapeutic benefit in a large patient population and Phase 4 (post-approval).

During the research stage, which usually lasts three to five years, the Group's researchers synthesize innovative molecules and study their effects on cell systems or isolated organs, *in vitro*, or in animal subjects, to better understand their pharmacological, pharmacokinetic, and toxicological properties. An analysis of the study results makes it possible to select the compound that meets the set treatment goals to move forward in development.



The pre-clinical stage of development aims to gather the pre-clinical safety toxicological and pharmacokinetic data essential for initial administration in humans and for preparing the regulatory dossier to start clinical trials that are subject to approval from regulatory authorities and ethics committees.

The development continues with clinical trials that are principally intended to provide evidence of the safety and efficacy of the drug in humans. When the results support the targeted indication, a registration dossier is then submitted to the regulatory authorities to assess and decide on its marketing authorization.

At Ipsen, once a clinical candidate has been selected, the next stage of project centric and cross-functional development approaches is conducted. The scope of the Exploratory Development phase is up to the clinical proof of concept (PoC). Once both early efficacy and short-term safety have been established from the PoC and meet the Product Target Profile, the drug can proceed to the confirmatory development phase. Exploratory development benefits from innovative question-based development plans, adaptive

design, modeling and simulation, biomarkers, and translational science/medicine.

This approach allows: 1) shortening of the time to decision (Go/No-Go) to proceed to confirmatory trials using a parallel rather than sequential development path, 2) de-risking projects before large investments are made, and 3) more efficient management of the project portfolio.

1.2.3.3.2 The development programs

The table below lists the Group's clinical programs. This table is subject to change depending on numerous factors that can be extremely unpredictable. The Group might experience delayed completion of clinical trials, treatment failures, absence of marketing authorization, and the occurrence of a technical or administrative event beyond the Group's reasonable control. A summary of risks is described in Chapter 2.1 "Risk Factors" of this document and a detailed description of the products development programs is given in part 1.2.1 "The Group's Products".

The molecule portfolio in development is the following:

| Product under development | Indications | Development stage |
|--|---|---|
| Oncology | | |
| Decapeptyl® | 3M Endometriosis – China | Approved |
| Decapeptyl® | 3M (Central Precocious Puberty) CPP – China | Phase III |
| Decapeptyl® | 6M (Central Precocious Puberty) CPP – China | Phase III |
| Cabometyx® in combination with nivolumab ⁽¹⁾ | Advanced Renal Cell Carcinoma (RCC) 1L | Approved in EU |
| Cabometyx® in combination with atezolizumab ⁽²⁾ | Solid tumors | Phase Ib |
| Cabometyx® in combination with atezolizumab ⁽²⁾ | Non-small Cell Lung Cancer (NSCLC) 2L/3L | Phase III |
| Cabometyx® in combination with atezolizumab ⁽²⁾ | Metastatic Castration-resistant Prostate Cancer (mCRPC) 1L/2L | Phase III |
| Onivyde® | Small Cell Lung Cancer (SCLC) 2L | Phase III |
| | Pancreatic ductal adenocarcinoma (PDAC) 1L | Phase III |
| Neuroscience | | |
| Dysport® Solution (liquid) | Pediatric Upper Limb Spasticity (PUL) | Approved U.S. and EU |
| | Glabellar Lines – China | Submitted |
| | Glabellar Lines | Approved |
| Long acting toxin rBoNT/A | Multiple therapeutic and aesthetic indications | Phase I/II |
| Long acting toxin rBoNT/A' | Multiple therapeutic and aesthetic indications | Phase I/II |
| Mesdopetam | Levodopa-induced dyskinesias (LIDs) | Phase II |
| Rare Disease | | |
| Somatuline® Autogel® | Acromegaly – China | Approved |
| | New delivery system | Approved (U.S.) |
| | GEP-NET – China | Phase III |
| IPN60120 (palovarotene) | Fibrodysplasia Ossificans Progressiva (FOP) | Phase II |
| | Fibrodysplasia Ossificans Progressiva (FOP) chronic | Phase III ⁽³⁾ ⁽⁴⁾ |
| IPN60130 (BLU-782) - ALK2 inhibitor | Fibrodysplasia Ossificans Progressiva (FOP) | Phase II |
| Elafibranor | Primary Biliary Cholangitis (PBC) | Phase III |

(1) Study sponsored by Exelixis and Bristol-Myers Squibb. Ipsen opted in to co-fund this study.

(2) Study sponsored by Exelixis and Roche. Ipsen opted in to co-fund this study.

(3) Partial clinical hold from the FDA since 5 December 2019 for patients under the age of 14 years.

(4) Trial paused following prespecified interim futility analysis; Ipsen then amended the protocol for the Phase III MOVE trial and reinitiated palovarotene dosing in patients 14 years of age and older as announced on 26 March 2020.



Oncology

Decapeptyl

The Group continues to develop new indications and formulations of Decapeptyl in China.

Somatuline®

The Group continues to develop new indications and formulations of Somatuline in China.

Cabometyx

The Group opted to participate in the funding of several trials with Exelixis and other partners to explore the combination of cabozantinib with other agents in different solid tumors:

- Cabozantinib in combination with nivolumab (Opdivo®) in first-line advanced renal cell carcinoma. The Phase III CheckMate 9ER study, sponsored by Bristol-Myers Squibb and co-funded by Exelixis and Ipsen, was initiated in July 2017. This trial evaluated Cabometyx in combination with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic renal cell carcinoma (RCC). The new indication has been approved by the EMA in March 2021, and is still waiting for approval in other countries.
- Cabozantinib in combination with nivolumab (Opdivo®) in patients with advanced liver cancer. The Phase I/II Checkmate 040 sponsored by Bristol-Myers Squibb and co-funded by Exelixis and Ipsen is an open label multi-cohort study nivolumab in combination with other agents including Cabometyx in patients with advanced liver cancer.
- Cabozantinib in combination with atezolizumab (Tecentriq®) in previously untreated advanced hepatocellular carcinoma. The Phase III COSMIC-312 study, sponsored by Exelixis and co-funded by Ipsen, was initiated in December 2018. The pivotal trial evaluates Cabometyx in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC).
- Cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) in patients with previously treated Metastatic Non-Small Cell Lung Cancer (NSCLC) with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy. The Phase III CONTACT-01 study sponsored by Roche and co-funded by Ipsen and Exelixis, was initiated in September 2020. The pivotal trial evaluates Cabometyx in combination with atezolizumab versus Docetaxel in previously treated Metastatic Non-Small Cell Lung Cancer (NSCLC) with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- Cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) in patients with previously treated Metastatic Castration-Resistant Prostate Cancer (mCRPC). The Phase III CONTACT-02 study sponsored by Exelixis and co-funded by Ipsen and Roche, was initiated in June 2020. The pivotal trial evaluates Cabometyx in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

- Cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors. The dose-escalation stage of a Phase I trial sponsored by Exelixis and co-funded by Ipsen was initiated in June 2017 to evaluate cabozantinib in combination with atezolizumab (Tecentriq®) in patients with locally advanced or metastatic solid tumors.

In addition, numerous investigator-sponsored studies are ongoing to explore Cabometyx in monotherapy and in combination with other treatments for different types of cancer.

Onivyde

The Group continues to advance the Onivyde clinical development program, including clinical studies in patients with previously untreated, metastatic pancreatic adenocarcinoma and patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy.

In addition, numerous investigator-sponsored studies are ongoing to explore Onivyde in monotherapy and in combination with other treatments for different types of cancer.

Neuroscience

Dysport

The Group has now completed several Phase III trials worldwide including the United States since 2011 to reinforce therapeutic indications, focusing on spasticity. The indication for pediatric upper limb spasticity (PUL) has received an approval in the U.S. following a last spasticity Phase III trial requested by the FDA for all neurotoxin manufacturers.

Ipsen continues to foster the development of alternative formulations (e.g. liquid formulation that is a ready-to-use and convenient alternative to the current dry formulation).

Since first approval in 2018 in the EU and in 2019 by FDA, the cell-based assay is replacing the *in vivo* mouse-based LD50 assay for establishing the stability and the potency of Ipsen's toxin-based product (Dysport and Azzalure).

Ipsen's world class R&D centers are pushing technological boundaries to develop the next generation of recombinant toxins, including fast and long-acting neurotoxins, expected to address a broad range of clinical conditions. As of 31 December 2019, Ipsen is the only company with recombinant toxins in pre-clinical and Phase I trials.

Rare Disease

Somatuline Autogel in acromegaly

The Group continues to expand the potential of this product with the regulatory approval for the acromegaly indication in China in December 2019.

Palovarotene

In April 2019, Ipsen completed the acquisition of Clementia Pharmaceuticals to strengthen its Rare Disease portfolio. Ipsen acquired Clementia Pharmaceuticals' late-stage drug candidate palovarotene, with pediatric disease and breakthrough therapy designations for the treatment of the ultra-rare bone disorder, fibrodysplasia ossificans progressiva (FOP).



On 6 December 2019, following discussions with the U.S. Food and Drug Administration (FDA), a partial clinical hold was issued for patients under the age of 14 for studies evaluating palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO). This was due to events of premature physal closure in growing children in the FOP studies.

On 24 January 2020, the Group announced it was decided to pause dosing in the palovarotene trials based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the pre-specified interim analysis.

The Group have conducted further assessment and showed that encouraging therapeutic activity was observed in *post-hoc* analyses of interim data for the Phase III MOVE trial and shared with, and acknowledged by, the Independent Data Monitoring Committee (IDMC). As such, Ipsen amended the protocol for the Phase III MOVE trial to include updates to the statistical analysis section as recommended by the IDMC to allow for additional analyses to be performed in addition to the primary pre-specified analysis. On 26 March 2020, Ipsen announced it will begin to reinstate palovarotene dosing in patients 14 years of age and older currently participating in its fibrodysplasia ossificans progressiva (FOP) clinical program. The Food and Drug Administration (FDA) in the U.S. confirmed they have no safety concerns with restarting dosing in patients 14 years of age and older. Clearance to reinstate dosing in these patients has also been received to date from all other ex-U.S. regulatory agencies.

In January 2022, Ipsen announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma (RAR γ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formation) in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP). Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide.

IPN60130 (formerly known as BLU-782)

In October 2019, Ipsen finalized an agreement with Blueprint Medicines to in-license the global rights to IPN60130 (formerly known as BLU-782), an highly selective investigational ALK2 inhibitor for the treatment of fibrodysplasia ossificans progressiva (FOP). Now, with the addition of IPN60130 (formerly known as BLU-782), which is in Phase II. Ipsen will have the potential to offer a broader suite of treatment options for patients living with FOP, an ultra-rare bone disorder.

Elafibranor

On 17 December 2021, Ipsen announced a strategic partnership with GENFIT, which grants Ipsen the exclusive worldwide (excluding Greater China region) license to develop, manufacture and commercialize the investigational treatment elafibranor. This is a first-in-class PPAR alpha and delta agonist being developed for people living with primary biliary cholangitis (PBC) who have an inadequate response or intolerance to ursodeoxycholic acid; a rare, progressive, chronic autoimmune disease of the liver.

1.2.4 Intellectual Property

■ 1.2.4.1 Patents

The Group's intellectual property – including patents, trademarks, copyrights, trade secrets, and know-how – is of material importance to the success of the business. In some cases, these intellectual property rights are directly owned by the Group, and in other cases, the Group benefits from protections provided by intellectual property rights licensed to the Group from the owner.

Patent exclusivity

To protect the Group's investments in research and development, Ipsen files patent applications covering significant inventions made throughout the drug discovery and development process. These may include inventions relating to: new active substances (biologics or small molecules); salt forms and polymorphs; pharmaceutical compositions; formulated drug products; therapeutic indications and methods of use, including dosing regimens; manufacturing processes and synthetic intermediates; and general technologies, such as assay methods. Ipsen files patent applications in all countries of importance to the Group's business.

The duration of patent protection generally is 20 years from the filing date, although the United States provides a patent term adjustment (PTA) to compensate for patent office delay. Because the pharmaceutical development and regulatory review process requires many years, and because pharmaceutical patents often are filed early in the process,

the patent term remaining at the time of market authorization typically is significantly less than 20 years.

In some countries, notably including the United States, Europe, and Japan, mechanisms exist to extend pharmaceutical patent protection following product approval to partially compensate for the term lost during clinical development and regulatory review. The law and procedures governing such extensions of patent protection vary considerably from country to country. In the United States, up to five years of patent term extension (PTE) is available, provided the total extended patent term does not exceed 14 years from the NDA approval date. In Europe, a patent protecting a pharmaceutical product may be granted a supplementary protection certificate (SPC) of up to five years, provided that the extended patent term does not exceed 15 years from the first marketing authorization for the product in the EU. In Japan, up to five years of patent term extension is available. Recently, the Canadian patent law was amended to provide up to two years of extended patent protection in the form of a certificate of supplementary protection (CSP).

The protection a patent provides to a product depends on the type of patent and its scope. Protection also may vary from country to country. For a pharmaceutical product, a patent that covers the active substance itself provides the strongest protection, since it is effective to prevent a competitor from marketing another product containing the same active substance in any formulation for any method of use. By contrast, patents that cover formulations or methods of use



(so-called “secondary patents”) do not prevent a competitor from marketing a product containing the same active substance, but in an alternative formulation or for a different method of use.

Regulatory exclusivity

In addition to patent protection, the Group's products also may benefit from regulatory exclusivity protections. During the exclusivity period, a generic manufacturer is not able to rely on the Group's clinical data demonstrating drug safety and efficacy. Regulatory exclusivity is particularly important to incentivize the investment in clinical development of products for which patent protection is limited. Regulatory exclusivity periods run in parallel to any patent protection that may exist for the product.

United States

In the United States, new small molecule products benefit from five years of New Chemical Entity (NCE) exclusivity. For five years after the first marketing authorization of an active substance, FDA will not approve another product containing the same active molecule unless the second applicant has generated its own clinical data demonstrating safety and efficacy. If a New Drug Application (NDA) or supplemental New Drug Application (sNDA) contains reports of new clinical investigations that are conducted or sponsored by the applicant and essential for FDA approval, but the product contains an active substance that has been previously approved, the applicant is awarded three years of data exclusivity. For three years after the NDA or sNDA is approved, FDA may not approve a generic drug application that relies upon the new clinical information.

Different exclusivity periods apply for biological products. The abbreviated pathway for approval of biological products that are shown to be biosimilar to a reference biological product that has been licensed by FDA is governed by the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Under the BPCIA, an application for approval of a biosimilar product may not be submitted until four years after the reference product was first licensed, and the biosimilar product may not be approved until 12 years after the reference product was first licensed.

Small molecule or biological products that receive FDA approval for the treatment of a disease or condition affecting fewer than 200,000 individuals in the U.S. may be protected by Orphan Drug Exclusivity (ODE). For a period of seven years after approval of the product for the orphan indication, FDA may not approve any similar product (containing the same active molecule) for the same orphan indication.

Europe

In Europe, new drugs are eligible for a combination of data and market exclusivity, according to an “8+2+1” formula. The same formula applies to both small molecule and biological products. For a period of eight years after the first marketing authorization of an active molecule, the European Medicines Authority (EMA) will not accept for review another application that references the originator's pre-clinical and clinical data, and the generic product cannot be placed on the market for an additional two years. This means that a product that contains a new active molecule will not face generic competition in Europe for at least 10 years after its first marketing authorization, irrespective of patent protection. If the originator drug receives marketing authorization for a significant new indication during the first eight years after the initial marketing authorization, then the exclusivity period is extended by one additional year.

Small molecule or biological products that receive EMA approval for the treatment of a seriously debilitating or life-threatening condition that affects fewer than 5 in 10,000 individuals in the EU are eligible for orphan drug exclusivity. For a period of 10 years after marketing authorization for the orphan indication in the EU, the EMA will not accept for review an application for marketing authorization of a similar product (not necessarily containing exactly the same active molecule) for the same orphan indication. However, orphan drug exclusivity will not prevent marketing authorization of a second product that is shown to be safer, more effective, or otherwise clinically superior.

Exclusivity Protections for Ipsen Products

Regulatory and patent exclusivity protections for Ipsen's marketed products and products in Phase 2 or Phase 3 clinical development are summarized in the table below. Only patents that cover the active molecule, the formulated drug product, or a method of using the drug are included in table. For some products, patents that cover manufacturing processes or key synthetic intermediates may provide additional protection.



| Product | United States | Europe |
|--|--|--|
| Specialty care | | |
| Oncology | | |
| Somatuline® Depot/ Somatuline® Autogel® (lanréotide) – compound – formulation – Regulatory exclusivities | Expired Expired (with PTE) ODE (acromegaly) expired; ODE (GEP-NET) Dec-2021; ODE (carcinoid syndrome) Sep-2024 | Expired Expired Expired |
| Decapeptyl® (triptorelin) • 1- and 3-month formulations • 6-month formulation – formulation – Regulatory exclusivities | N/A N/A N/A | All exclusivities expired Jun-2028 (Europe) ⁽¹⁾ Expired |
| Cabometyx® (cabozantinib) – compound – polymorphic form – formulation – Regulatory exclusivities | N/A N/A N/A N/A | Sep-2024 (Mar-2029 with SPC) Jan-2030 ⁽²⁾ Jul-2031 NCE Mar-2025 |
| Cometriq® (cabozantinib) – compound – polymorphic form – formulation – Regulatory exclusivities | N/A N/A N/A N/A | Sep-2024 (Mar-2029 with SPC) Jan-2030 ⁽²⁾ Feb-2032 NCE Mar-2025 |
| Onivyde® (irinotecan liposome injection) – compound – Medical use (2L PDAC indication) – Medical use (other indications) – formulation – Regulatory exclusivities | May-2025 (Aug-2028 with PTA) (Jan-2027 with PTE) Jun-2033 2035-2037 (if granted) Oct-2036 ODE (2L PDAC) Oct-2022 | May-2025 (May-2030 with SPC, when and where granted) ⁽³⁾ Jun-2033 ⁽⁴⁾ 2035-2037 (if granted) Oct-2036 (if granted) ODE (PDAC) Oct-2026 |
| Xermelo® (telotristat ethyl) – compound – polymorphic form – formulation – Regulatory exclusivities | N/A N/A N/A N/A | Dec-2027 (Sep-2032 with SPC, when and where granted) ⁽⁵⁾ Sep-2028 ⁽⁶⁾ Oct-2032 NCE Sep-2027 |
| Neuroscience | | |
| Dysport® (abobotulinumtoxinA) – Regulatory exclusivities | ODE (pediatric lower limb spasticity) Jul-2023 | |
| Alluzience® (abobotulinumtoxinA) – formulation | Jul-2025 | Jul-2025 ⁽⁷⁾ |
| Mesdopetam | | |
| – compound – salt – medical use | Apr-2032 (PTE possible after approval) May-2040 (if granted, PTE possible after approval) Nov-2041 (if granted, PTE possible after approval) | Apr-2032 (SPC possible after approval) May-2040 (if granted, SPC possible after approval) Nov 2041 (if granted, SPC possible after approval) |
| Rare Disease | | |
| NutropinAq® (somatropin) | N/A | All exclusivities expired |
| Increlex® (mecasermin) – Medical use – Medical use – Formulation – Regulatory exclusivities | Expired Aug-2025 Expired Expired | Expired Sep-2024 Expired Expired |
| Palovarotene – compound – medical use – medical use | – Oct-2021 – Aug-2031 (PTE possible after approval) – Jun-2037 | – Oct-2021 – Aug-2031 (SPC possible after approval) – Jun-2037 (if granted) |



| Product | United States | Europe |
|--|---|--|
| IPN60130 | | |
| – compound | Apr-2037 (PTE possible after approval) | Apr-2037 (if granted, SPC possible after approval) |
| – salt | Aug-2040 (if granted) | Aug-2040 (if granted) |
| Elafibranor | | |
| – compound | Sep - 2024 | Jul-2023 (FR, DE and UK) |
| – medical use | Nov - 2030 | Nov-2030 |
| – medical use | Mar - 2037 (PTE possible after approval) | Mar-2037 (if granted; SPC possible after approval) |
| Consumer HealthCare | | |
| Smecta® (diosmectite) | | |
| – formulation | N/A | Aug-2028 |
| – formulation | N/A | Apr-2030 |
| – Regulatory exclusivities | N/A | Expired |
| Forlax® (macrogol 4000) | N/A | All exclusivities expired |
| Tanakan® (<i>Ginkgo biloba</i> extract) | N/A | All exclusivities expired |
| Adenuric® (febuxostat) | | |
| – compound | N/A | Expired |
| – polymorphic form | N/A | Jun-2019 (Apr-2023 with SPC) ⁽⁸⁾ |
| – formulation | N/A | Mar-2023 (Apr-2023 with SPC) ⁽⁹⁾ |
| – Regulatory exclusivities | N/A | Expired |
| Eziclen® / Izinova® (Magnesium Sulfate heptahydrate/Sodium sulfate/Potassium Sulfate) | | |
| – composition | N/A | April-2023 (Feb-2028 with SPC) ⁽¹⁰⁾ |
| – Regulatory exclusivities | N/A | Feb-2023 |

- (1) One EP patent has been revoked and an appeal is pending. Opposition filed against another EP patent. Patent maintained under an amended form which still covers the product. After the notification of decision, a 2-month period for Patentee and/or Opponent to appeal the decision. A divisional patent application is still pending.
- (2) Oppositions have been filed against the EP patent. At the end of the opposition procedure, the EP patent has been maintained under an amended form which still covers the product. Opponents appealed the decision but the Appeal Board dismissed the Appeal.
- (3) Patent maintained in original form following Opposition. Opponent appealed the decision but the Appeal Board dismissed the Appeal.. Applications for an extension *via* SPC are pending in Austria, Belgium, Germany, Ireland, the Netherlands, Denmark, Poland, and Portugal, and have been granted in the Czech Republic, France, the United Kingdom, Greece, Italy, Luxembourg, Norway, Sweden, and Slovenia. Ipsen has appealed the SPC application refusal in Spain.
- (4) One EP patent was revoked following Opposition. An appeal is pending. A divisional patent has granted.
- (5) Applications for extension *via* SPC are pending in Austria, Belgium, Finland and Great Britain, and have been granted in Czech Republic, Germany, Denmark, Spain, France, Greece, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Romania, Switzerland and Sweden.
- (6) In Bulgaria, an SPC has been granted which extends the patent term until Sep-2032.
- (7) Patents maintained in amended form following Appeal Proceedings.
- (8) An extension *via* SPC is granted in Austria, Belgium, Czech Republic, Croatia, Cyprus, Denmark, Finland, France, Germany, Great Britain, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and Switzerland. It is still pending in Bulgaria.
- (9) An extension *via* SPC is granted in Estonia.
- (10) An extension *via* SPC is granted in Czech Republic, Estonia, France, Germany, Great Britain, Greece, Italy, the Netherlands, Portugal, Romania and Spain. The SPC application is still pending in Belgium.



■ 1.2.4.2 Brand Names and Trademarks

Trademarks identify and build the notoriety of the Group and its products worldwide. They contribute to the business success of the Group, especially for Consumer Healthcare products and products that have lost their patent and regulatory exclusivity protections. They are also key to patients' safety by helping to differentiate medicines.

Trademark protection varies from country to country. In some countries, this protection is based primarily on the use of the trademark, while in others it results from its registration. In the latter case, trademark rights are obtained through national, international or regional routes (e.g. European Union trademarks). Registrations are generally granted for a period of ten years and are indefinitely renewable, although in some cases, maintenance requires the continued use of the trademark.

To support the timely launch of new products, the Group proceeds to trademark clearance searches and files trademark applications in accordance with commercialization plans. The Group seeks protection for the product names in Latin characters as well as in local characters (Cyrillic, Chinese, etc.) wherever relevant. These trademarks provide

protection notably for "pharmaceutical products" included in Class 5 of the International Classification of Products and Services.

To protect its image and reputation, the Group also holds trademark for Ipsen and the Ipsen logo.

The Group monitors trademark registries and defends its trademark rights by initiating administrative proceedings or taking legal action against any infringement.

The Group's key products are protected by trademarks owned by the Group (e.g. for Consumer Healthcare products - Smecta[®], Smectago[®] and Smebiocta[®], Tanakan[®], Forlax[®], Fortrans[®], Eziclen[®] and Izinova[®]; for Specialty Care products - Somatuline[®] and Somatuline[®] Autogel[®] / Somatuline[®] Depot, Decapeptyl[®]/Diphereline[®], Dysport[®], Onivyde[®], Increlex[®]) or used under license (e.g. Cabometyx[®] and Cometriq[®] are trademarks of Exelixis, Inc., Xermelo[®] is a trademark of TerSera therapeutics, Inc., NutropinAq[®] is a trademark of Genentech, Inc.).

To strengthen the protection of its trademarks and support its digital visibility, the Group also registers domain names in the extensions of interest.

1.2.5 Main Markets

■ 1.2.5.1 Market Data

Sectorial information by therapeutic area and region is detailed in section 3 of this universal registration document for the 2021 and 2020 financial years.

The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Disease. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer and prostate cancer. Ipsen also has a well-established Consumer Healthcare business. The Group's main drug markets and their sizes are detailed in section 1.2.1 of this universal registration document ("The Group's Products").

Additionally, in terms of marketing, this strategy has led the Group to concentrate its efforts on key prescribing physicians, mainly specialists, who are responsible for drug prescriptions or who may induce such a prescription from other practitioners. By developing a strong reputation with these prescribing specialists in highly specific and specialized areas, the Group believes it is able to direct its marketing activities selectively and cost efficiently, thereby reducing the need for a large sales force.

■ 1.2.5.2 Competitive Position

The pharmaceutical industry is highly competitive. In recent years, the pharmaceutical industry has experienced an increasing level of horizontal and vertical concentration. Within this competitive environment, the Group faces competition from other companies to develop and secure marketing authorizations for new pharmaceutical specialties in targeted therapeutic areas, as well as for specific products that generate similar therapeutic results to those generated by medicines marketed by the Group. Numerous companies that compete with the Group to develop and secure marketing authorizations for new medicines are significantly larger than the Group and are accordingly able to invest more resources in Research and Development as well as in marketing, which may provide them with the advantage of offering a larger range of products and having access to larger sales forces.

For example, Dysport faces competition from Botox (Abbvie), a well-established botulinum toxin, while Somatuline faces competition from Sandostatin (Novartis) and the octreotide generic (Teva) in Europe. The Group also competes with other pharmaceutical companies in its search for suitable partners to ensure the growth of its research and development and marketed products portfolio. The Group's competitive position is detailed in section 1.2.1 of this universal registration document.



1.2.6 Regulation

The pharmaceutical industry is highly regulated. Regulation covers nearly all aspects of the Group's activities from Research and Development to manufacturing facilities, processes, and marketing. In each country where Ipsen markets its products or conducts research, the Group has to comply with the standards of local regulatory authorities and by any other national regulatory authority. These authorities namely include the European Medicines Agency (EMA), the French Agency for the Safety of Medicines and Health Products (ANSM), the UK Medicines & Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, and the Food and Drug Administration (FDA) in the United States as well as various other regulatory bodies, depending on the relevant market.

Price-setting and control

Regulation may cover the setting and control of selling prices in certain countries in which the Group markets its products. These controls are implemented pursuant to law or because the government or other healthcare agencies in a given country are the principal purchasers of products or reimburse purchasers for their cost. Price control mechanisms vary in the way they operate from country to country. This may lead to significant differences between markets, which may be amplified by exchange rate fluctuations. These pricing differences may also be exploited by parallel import companies which buy branded products in markets where prices are low and sell them in markets where prices are higher.

In recent years, efforts by government authorities to curb healthcare spending have led to tighter controls on reimbursement policies and price setting in most of the countries in which the Group operates, particularly in Europe. Measures intended to curb direct costs come in various forms, which include mandatory price cuts (or a refusal to accept price increases), a larger share of the cost being covered by the patient (reduction in the amount reimbursed by the third party), the withdrawal of certain products from the lists of reimbursable products, the alignment of reimbursed prices with the lowest product price in a given therapy category, analysis of the cost/benefit ratio of drugs prescribed, and efforts to promote growth in the generic drugs market as the co-pay regulation ("*tiers-payant contre génériques*") introduced in July 2012 in France.

In some European countries, governments also influence the prices of drugs indirectly through control of national health systems that fund a significant portion of costs related to these products. In France, for instance, a government authority sets the price of reimbursable drugs taking into account the product's value. The price set for a drug depends notably on the improvement in medical performance of the new drug with existing treatments. In addition, when fixing the price of a product, the national agency takes into account the price of the same drug in other countries.

The governments of many countries in which the Group operates continue to introduce new measures to reduce public health expenses, some of which have affected the Group sales and profitability over the last years.

1.2.7 Group's Legal Structure

Ipsen S.A. acts as a holding company with regards to its affiliated companies and has no operational activities. Certain senior managers are employed by Ipsen S.A. under certain conditions and invoicing provisions described in paragraph 3.3.4. The Group comprises 53 consolidated affiliates, which are shown as such in note 26 in paragraph 3.2.5.

These companies are categorized as Research and Development, manufacturing, management, or commercialization entities.

A description of Ipsen's share ownership and voting rights is presented in section 5.6.2.1.


■ 1.2.7.1 Organizational Structure

The stated percentages in the following chart indicate the proportion of both non-diluted, share capital and voting rights⁽³⁾ held in each company.

⁽³⁾ The stated percentages for Ipsen S.A. shareholders indicate the proportion of share capital.



Group Organization chart as of 31 December 2021



1.2.7.2 Incorporations

As part of the Group's development, several companies were created in 2021. In August 2021, the Group set up a subsidiary in Japan and, at the end of October 2021, in Colombia. Furthermore, in the context of the continued empowerment of the Consumer Healthcare activities, Ipsen

Consumer Healthcare OOO (Russia) was created in April 2021 and the Group's ownership of the capital of Beaufour Ipsen Tianjin Pharmaceuticals Co. Ltd and Ipsen Tianjin Pharmaceutical Trade Co. Ltd was also changed in December 2021.

2

RISK AND CONTROL

| | |
|---|-----------|
| 2.1 RISK FACTORS | 34 |
| 2.1.1 Introduction | 34 |
| 2.1.2 Business Risks | 35 |
| 2.1.3 Industrial and Environmental Risks | 37 |
| 2.1.4 Financial Risks | 38 |
| 2.1.5 Regulatory and Legal Risks | 39 |
| 2.2 RISK MANAGEMENT AND INTERNAL CONTROL | 41 |
| 2.2.1 Organization | 41 |
| 2.2.2 Information Management | 44 |
| 2.2.3 Risk Management Framework | 45 |
| 2.2.4 Control Activities | 46 |
| 2.2.5 Review and Assessment of Internal Control | 47 |




2.1 RISK FACTORS

2.1.1 Introduction

The Group operates in a rapidly evolving environment which may pose many risks for the Group, some of which are outside of its control. Investors are advised to carefully review each of the risks described below as well as all the information contained in this universal registration document. The risks and uncertainties set out in this section are not the

only ones faced by the Group. Other risks and uncertainties of which the Group is not currently aware or of which it does not consider material or specific may also have an unfavorable impact on its business, financial situation and results. Materiality is a combination of probability and impact after considering measures adopted by the Group to manage it.



| # | Risk name | CSR |
|---------|---|-----|
| 2.1.2.1 | Market competition and dependence on products | |
| 2.1.2.2 | Risks of failure in Research & Development | |
| 2.1.2.3 | Risks of cyberattacks | |
| 2.1.2.4 | Inability to face systemic risks | |
| 2.1.2.5 | Failure of third parties | |
| 2.1.2.6 | Risks related to drug approval, pricing and reimbursement | |
| 2.1.2.7 | Risks associated with international activities | |
| 2.1.2.8 | Risks related to acquisition and integration activities | |
| 2.1.2.9 | Business Ethics risks | X |
| 2.1.3.1 | Supply shortages and other disruptions risks | X |

| # | Risk name | CSR |
|---------|--|-----|
| 2.1.3.2 | Environment and safety risks | X |
| 2.1.4.1 | Exchange rate risks | |
| 2.1.4.2 | Interest rate risks | |
| 2.1.4.3 | Liquidity and counterparty risks | |
| 2.1.4.4 | Share price fluctuation | |
| 2.1.5.1 | Risks related to intellectual property | |
| 2.1.5.2 | Undesired disclosure of critical information | X |
| 2.1.5.3 | Counterfeiting risks | X |
| 2.1.5.4 | Product liability risks | X |
| 2.1.5.5 | Legal and administrative proceedings | |

2.1.2 Business Risks

| # | Risk name | Risk description and mitigation | Materiality |
|---------|--|---|-------------|
| 2.1.2.1 | Market competition and dependence on products | <p>The Group operates in well-established, rapidly-evolving, and very competitive markets, in particular in Oncology:</p> <ul style="list-style-type: none"> the Group's competitors include major international pharmaceutical groups whose size, experience, and capital resources exceed its own; the Group has just entered a challenging phase with the news of the registration of a Somatuline pharmaceutical alternative (which is not a generic and cannot be substituted automatically) in the U.S. end of 2021; however, the Group anticipated that this would happen and, in Europe, has been able to handle the situation very well; in the large majority of countries, Somatuline continued to expand its leadership; the Group may have to adapt quickly to new technologies, scientific changes, digital and advanced analytics introduced by competitors. <p>Since a few products make up the majority of Group sales, with Somatuline, Decapeptyl, Dysport, Cabometyx and Onyvive representing around 90% of sales in 2021, the competitive threat to Ipsen's business model and performance is accrued.</p> <p>The trends are closely monitored and accounted for in the Group strategy.</p> <p>Across all its therapeutic areas in Specialty Care, the Group's ambition is to fully leverage its broad geographic presence and its global commercial powerhouse to grow and roll out its Specialty Care portfolio in all key geographies.</p> <p>The Group has focused its internal resources and efforts on becoming a Development Powerhouse while increasingly turning toward external sourcing of new assets. The ambition for external innovation is to fuel the R&D pipeline across all its therapeutic areas of focus.</p> <p>Details are set out in section 1.2.1 of this universal registration document "The Group's products".</p> | High |
| 2.1.2.2 | Risks of failure in Research and Development | <p>In order to build an innovative and sustainable pipeline the Group invests substantial amounts in Research and Development. In 2021, the Group spent €428.4 million on Research and Development, representing around 15% of consolidated sales. The Group is also investing in intangible assets and companies related to its Research and Development activities.</p> <p>Ipsen will be unable to recover these investments if the Group's clinical trials are not as successful as anticipated or if such products do not receive regulatory approval. The Research and Development process is long and there is a substantial risk that drugs may not be approved.</p> <p>Ipsen continuously invests in its internal R&D platforms as well as in external innovation to build a sustainable pipeline across all stages of development.</p> <p>Its R&D operating model focuses on accelerating internal projects, effectively managing the R&D portfolio and actively externally sourcing assets through disciplined business development.</p> <p>For more details on R&D process, please refer to 1.2.3 "Research and Development".</p> | High |
| 2.1.2.3 | Risk of cyberattacks | <p>The Group's activities are largely dependent on information systems. Despite all the measures in place to secure its processes, the Group may have to deal with incidents, notably connected to malicious acts against such information systems, such as cyberattacks that could lead to activity disruptions, fraud, the loss or alteration of critical data, or theft or corruption of data.</p> <p>The Group has put in place a cyber security plan, with dedicated team and governance, validated at the highest level and implemented across all Group entities.</p> <p>This plan articulates actions around Governance, Risk, Compliance (GRC), OT Mitigation, Technical Controls, People Security, Data Security, Travel, Response and Recovery and Physical Security.</p> | High |
| 2.1.2.4 | Inability to face systemic risks | <p>The Group could face a systemic risk, <i>i.e.</i> the risk that a particular event will have a major impact on the whole system. These systemic risks are likely to affect the Group's operational capacities.</p> <p>The Group defines and constantly updates measures to guarantee business continuity in the event of a systemic event arising. These measures also include the guarantee of employee safety.</p> <p>The Group implements the following measures in particular:</p> <ul style="list-style-type: none"> Crisis management and mobilization of specific teams to enable the Group to adapt to these situations; Adaptation and roll-out of business continuity plans; Strict monitoring by the Group of security stocks, goods and services at suppliers as well as its own production capacities. <p>The Group has thus managed to face two major systemic events over recent years, the COVID-19 pandemic and the conflict between Russia and Ukraine, suffering no supply disruption in 2020, 2021 and early 2022.</p> | High |



| # | Risk name | Risk description and mitigation | Materiality |
|---------|--|--|-------------|
| 2.1.2.5 | Failure of third parties | <p>The Group depends on third parties:</p> <ul style="list-style-type: none"> to optimize the Research and Development portfolio: the Group enters into collaborative agreements with third parties to carry out pre-clinical and clinical trials; to manufacture certain products: the Group subcontracts the production of certain active ingredients to third parties or purchases finished products directly from its partners or their subcontractors; to develop and market certain products; related to intellectual property: (1) the Group's intellectual property: third parties collaborating with Ipsen may claim the benefits from intellectual property rights for the Group's inventions or may not ensure that the Group's unpatented technology remains confidential; (2) third party intellectual property: the Group is dependent on intellectual property rights held by third parties in order to manufacture and market several of its products. <p>All those third parties could behave in ways that are damaging to the Group's business. For key alliances (please see paragraph 1.2.2 "Major Contracts"), a dedicated Alliance Management team is in charge to ensure alignment of strategies and constant optimization of governance process.</p> <p>Relationships with other partners are also managed by dedicated teams, to maximize their value. For instance, a Global Procurement Department is:</p> <ul style="list-style-type: none"> mapping the risks associated with the Group's key suppliers, maintaining close relationships with them, in order to secure the Group's supplies; diversifying its sources of supply when possible, endeavoring to conclude long-term supply contracts, building up; building security stocks from suppliers or its own production. | Moderate |
| 2.1.2.6 | Risks related to drug approval, pricing and reimbursement | <p>The Group is dependent on prices that are set for drugs and is vulnerable to the potential withdrawal of certain drugs from the list of reimbursable products by governments and the relevant regulatory authorities in the countries in which it operates. In general terms, the Group is faced with uncertainty related to the prices set for its products, since pharmaceutical prices have come under severe pressure over the last few years (recommendation to use generic drugs, lower prices or reimbursement, other restrictive measures that limit increases in the cost of medical services, parallel imports). Price pressure is particularly high in the Group's therapeutic areas (Specialty Care).</p> | Moderate |
| 2.1.2.7 | Risks associated with international activities | <p>The Group operates throughout the world (50% in Europe, 32% in North America and 18% in the rest of the world in 2021). As such, the Group faces various risks specific to its international activities, and in particular, and the following:</p> <ul style="list-style-type: none"> risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures; risks arising from limitations on the repatriation of earnings; risk of financial default on the part of certain public and private operators with which the Group conducts business; risks arising from the validity of various intellectual property rights being deferred; risks arising from various labor regulations; risks arising from political or economic changes affecting a given region or country; risks arising from increased difficulties in recruiting staff and managing operating entities abroad; risks arising from the absence of an international agreement on regulatory standards; risk incurred by employees when travelling for their missions; risks arising from the occurrence of natural disasters, wars, epidemics or even pandemics, in the areas at risk in which the Group and/or its major partners do business (e.g. Russia/Ukraine conflict in 2022). <p>The Group has various teams dedicated to the coverage of these risks: Regulatory Department, Finance Division, Legal Division, IP Department, HR Division, Risk Management Department, Global Security Department, etc. All those functions regularly monitor these topics to anticipate evolutions and adapt Group's policies and procedures accordingly.</p> | Moderate |
| 2.1.2.8 | Risks related to acquisition and integration activities | <p>To continue to build a sustainable pipeline of innovative assets, the Group has been transforming the R&D model by accelerating focused internal projects, de-prioritizing selected internal programs and externally sourcing assets. In this respect, the Group has been investing in business development through innovative deal structures in its key therapeutic areas. Despite dedicated processes in place, acquisitions could fail or underperform in case of inappropriate due diligence or unsuccessful integration.</p> <p>Within the Group, an External Innovation & Business Development organization is dedicated to the acquisition and integration of strategic deals, with ability to:</p> <ul style="list-style-type: none"> assess opportunities and conduct quick and effective due-diligence; differentiate Ipsen from other companies; increase its visibility as a partner for innovation. | Moderate |

| # | Risk name | Risk description and mitigation | Materiality |
|---------|---|--|-------------|
| 2.1.2.9 | Business Ethics risks  | <p>Despite its continued commitment to upholding the highest ethical standards, Ipsen could face various Business Ethics risks, such as:</p> <ul style="list-style-type: none"> • risk of off-label promotion: the Group’s employees or third parties involved in the promotion of Ipsen products could fail to observe the ethical principles laid down by the Group, and promote products off-label; • risk of improper influence and conflicts of interests: the employees of the Group or third parties involved in the Group’s activities could put themselves in a situation where there is an actual, apparent or perceived conflicts of interests between their role within the Group and their own financial or personal situation, which could influence their ability to act in the best interest of the Group. These conflicts of interests could involve external stakeholders such as HCPs, HCOs, payers, members of regulatory bodies or government officials; • risk of corruption: Ipsen employees or third parties involved in Ipsen activities could promise, offer, give, receive or solicit any kind of value or advantage to another person to distort someone’s conduct or to obtain an undue favor or advantage; as a matter of fact, Ipsen operates in risky countries with history for corruption and white-collar crime; • risk of non-compliance with pharmaceutical regulations and code: there is a risk for Ipsen employees or third parties involved in Ipsen activities to be non-compliant with requirements of international and country regulations and Pharma Codes (e.g. IFPMA, EFPIA, PhRma, country codes, U.S. price reporting) in interactions with HCPs, HCO and other stakeholders, in all promotional and non-promotional interactions (e.g. meetings, congresses, fee for services, etc.). <p>For details regarding mitigation plan to cover this risk, please refer to the sections 2.2.1 “Organization”, 4.3.2 “Fighting corruption” and 4.3.3 “Promoting and defending Human Rights within Ipsen’s value” in the “Company Social Responsibility” chapter.</p> | Low |

2.1.3 Industrial and Environmental Risks

| # | Risk name | Risk description | Materiality |
|---------|--|---|-------------|
| 2.1.3.1 | Supply shortages and other disruptions risks  | <p>Despite a strong end-to-end supply chain organization, the marketing of certain products by the Group has been and could be affected by supply shortages and other disruptions. Such difficulties may be:</p> <ul style="list-style-type: none"> • regulatory (e.g. the need to correct certain technical problems in order to bring production sites into compliance with applicable regulations); or • technical (e.g. difficulties obtaining supplies of satisfactory quality, equipment failures, difficulties manufacturing active ingredients, or drugs complying with their technical specifications on a sufficiently reliable and uniform basis at the required volume); or • natural (natural disasters...). <p>Supply shortages and other disruption risks may impact patients and may result in a significant reduction in sales for one or more products.</p> <p>Supply risk management is implemented and regularly updated across the whole supply chain. Major actions are:</p> <ul style="list-style-type: none"> • risk identification: supply chain risk mapping exercise conducted every year; • risk response: robustness and continuous improvement of manufacturing processes, critical suppliers risk management, insurance prevention actions, capital investments, security stocks and business continuity plans. <p>For further details please refer to the section 4.2.4 “Committed to ensure supply continuity” in the “Company Social Responsibility” chapter.</p> | Moderate |
| 2.1.3.2 | Environment and safety risks  | <p>Environmental laws in various countries impose real and potential obligations on the Group with regards to repairing environmental damage or refurbishing contaminated sites.</p> <p>Stricter laws relating to the environment, health, and safety as well as more rigorous enforcement measures than those in force currently could generate considerable liabilities and costs for the Group and make the Group’s handling, production, use, reuse, or processing of substances or pollutants subject to more rigorous inspection measures than those currently observed.</p> <p>The Group uses dangerous substances in performing its business, and claim related to the Group’s handling, storage, use or reuse of those substances could generate considerable liabilities and costs for the Group. The Group is exposed not only to environmental risks related to environmental contamination but also to health risks (accidental contamination or occupational disease) linked to the fact that Ipsen’s employees handle active or toxic substances in the course of their research or production activities. These risks also exist for third parties with which the Group works.</p> <p>Environment and safety issues are managed by the Environment Health and Safety (EHS) governance bodies at every level of the organization. Ipsen Environment Health and Safety (EHS) team aims at:</p> <ul style="list-style-type: none"> • protecting Ipsen people and improving their well-being to ensure provision of Ipsen drugs for patients; • reducing Ipsen energy consumption and our impact on climate change. <p>For further details, please refer to the sections 4.4.3 “Providing a healthy and safe workplace” and 4.5 “Minimizing our environmental impact” in the “Company Social Responsibility” chapter.</p> | Low |



2.1.4 Financial Risks

| # | Risk name | Risk description | Materiality |
|---------|---|--|-------------|
| 2.1.4.1 | Exchange rate risks | <p>A significant share of the Group's business is conducted in countries where the euro, the Group's reporting currency, is the functional currency. Nevertheless, owing to its international business scope, the Group is exposed to exchange rate fluctuations that can affect its results.</p> <p>Several types of risks can be identified:</p> <ul style="list-style-type: none"> • transactional foreign exchange risk related to business activities: the Group hedges its main foreign currencies, including the USD, GBP, CNY, RUB, CHF, AUD, and BRL, based on its budget forecasts; • financing foreign exchange risk related to financing contracted in a currency other than the functional currencies of Group entities. <p>Ipsen is implementing a foreign exchange rate hedging policy to reduce the exposure of its net profit to foreign currency fluctuations.</p> <p>For more details, please refer to Note 21 in Chapter 3: section 21.2 "Exchange rate risk hedging".</p> | Low |
| 2.1.4.2 | Interest rate risks | <p>Given its current mix of level of long-term debt as of 31 December 2021 (note 20 to the consolidated financial statements in Chapter 3 of the universal registration document), the Group has limited exposure to interest rate risks.</p> <p>The Group's funding consists in a fixed-rate debt from bond debts (bonds and U.S. Private Placement – USPP), as well as a variable-rate debt from revolving credit facilities and program of emission of commercial papers (NEU CP – Negotiable EUropean Commercial Papers). As of 31 December 2021, there were no derivative financial instruments for hedging interest rate risk. For more details, please see note 21 "Financial Instruments" to the consolidated financial statements as of 31 December 2021 in Chapter 3 of this universal registration document.</p> | Low |
| 2.1.4.3 | Liquidity and counterparty risks | <p>The Group's policy consists of diversifying its business counterparties so as to avoid excessive concentration and in choosing their counterparties wisely.</p> <p>As of 31 December 2021, the Group's cash and cash equivalents amounted to €809.1 million largely invested in term accounts and term deposits. More detailed analysis of the Group's liquidity position is described in section 3.1.3.2 related to the Group's net cash position.</p> <p>For more details please refer to the note 24 of the finance section, in particular the 24.4 part "Liquidity risk and counterparty risk".</p> | Low |
| 2.1.4.4 | Share price fluctuation | <p>The Group's share price could fluctuate significantly, in particular in response to the following types of events:</p> <ul style="list-style-type: none"> • changes in the Group's or its competitors' financial performance from one period to another; • the announcement by the Group or one of its partners of the success or failure of one of the Group's Research and Development programs conducted either on its own or in conjunction with a third party; • the announcement by the Group or one of its partners of the failure of the commercial launch of a new product; • announcements by competitors or announcements concerning the pharmaceutical industry; • announcements regarding changes in the Group's executive team or key personnel. <p>An indication of the share price evolution for fiscal year 2021 is available in the introduction on page 4.</p> | Low |

2.1.5 Regulatory and Legal Risks

| # | Risk name | Risk description | Materiality |
|---------|---|--|-------------|
| 2.1.5.1 | Risks related to intellectual property | <p>The expiration of a patent may result in substantial competition due to the emergence of a generic drug.</p> <p>The Group cannot be certain that:</p> <ul style="list-style-type: none"> • it will be able to develop other patentable inventions; • patents for which it has applied will be granted; • any patents granted to it or that are the subject of licenses granted to it will not be challenged and judged to be invalid or unenforceable; • the protection afforded by a patent will be sufficiently broad so as to exclude competitors; • other persons or entities will not claim rights including ownership rights over patents and other intellectual property rights owned by the Group or which are the subject of licenses granted to it; • the Group's competitors will not infringe its patents or circumvent them through innovations in design. <p>An IP strategy is defined and implemented to fight against risks related to intellectual property. The information related to the patents held by the Group is detailed in section 1.2.4.1 "Patents".</p> | Moderate |
| 2.1.5.2 | Undesired disclosure of critical information | <p>The Group cannot be certain that it will not be faced with undesired or uncontrolled disclosure of critical information including private data or strategic information, which might adversely affect the Company's financial position, competitive situation, or share value.</p> <p>The Group has set up procedures to control the dissemination of this information to protect either the confidentiality of sensitive information, particularly to protect its intellectual property or competitive positions, or to ensure that privileged information is disseminated to investors in a manner that complies with the legislation in force.</p> <p>For further details in particular on policies and action plans regarding personal data protection, please refer to the section 4.3.1 "Committed to protect personal data" in the "Company Social Responsibility" chapter.</p> | Moderate |
| 2.1.5.3 | Counterfeiting risks | <p>As a manufacturer of medication, the Group is exposed to the risk that third parties might attempt to counterfeit its products and sell counterfeit products as if they were the Group's products. Counterfeit products are not approved by the competent regulatory authorities and could prove dangerous for the patients. To the extent that counterfeit products are sold as being those of the Group, its reputation could be affected and the patients' confidence in the Group's products could be undermined. In addition, some of the Group's products could be withdrawn from the market if counterfeit products are sold.</p> <p>Ipsen is committed to taking the necessary proactive steps to always allow the patients to access to the highest health standards. Ipsen collaborates with other national and international stakeholders to protect the patients, partners and business from the risks of falsified and counterfeit medicines.</p> <p>For further details, please refer to the section 4.2.5 "Committed to fight against counterfeit products" in the "Company Social Responsibility" chapter.</p> | Low |
| 2.1.5.4 | Product liability risks | <p>The Group's business exposes it to product liability risk, and its insurance coverage could be insufficient to protect it against such risks should the need arise. Product liability constitutes a substantial risk for the Group and one that increase with the Group's business expanding into new markets and continuing to grow in the United States (where the costs associated with product liability claims can be particularly onerous). Although the Group is not currently involved in any substantial proceedings arising from product liability and including significant damages claims, the Group could be faced with claims related to the safety of its products, and in particular products relating to neurology (marketed under the brand names Dysport® and Azzalure®) which may cause, or appear to cause, serious side effects or potentially dangerous interactions with other drugs if misused or not properly prescribed.</p> <p>Pharmacovigilance, Quality and Technical Operations controls protect the Group from the product liability risks. For further details, please refer to the sections 4.2.1 "Bringing high quality product to patients" and 4.2.2 "Ensuring product safety" in the "Company Social Responsibility" chapter.</p> <p>Insurance also covers this risk.</p> <p>Product liability insurance covers all products manufactured, marketed, and sold by the Group as well as all clinical trials that the Group conducts. For more details, please refer to section 2.2.3 "Risk Management Framework".</p> | Low |



| # | Risk name | Risk description | Materiality |
|---------|---|--|-------------|
| 2.1.5.5 | Legal and administrative proceedings | <p>In the normal course of business, the Group is or may be involved in legal or administrative proceedings. Financial claims are or may be brought against the Group in connection with some of these proceedings.</p> <p>Galderma initiated arbitration proceedings against the Group at the ICC International Court of Arbitration; arbitrators were appointed in the fourth quarter of 2021. This request for arbitration is related to Galderma-developed liquid toxin, QM-1114 for which the Group, in its capacity as marketing-authorization holder and owner of the intellectual property since 2014, has a different view to the regulatory-submission strategy. There is also a difference of opinion on the territorial scope of the partnership under the 2007 agreement. The outcome of the cases cannot be predicted at this preliminary stage of the proceedings. The Group intends to fully defend and vindicate its rights against Galderma's allegations.</p> <p>In addition, the Group is also aware of an anti-competitive practices investigation has been initiated in 2019 against Linnea. As the authorities have provided little information at this stage about the allegations made, Linnea cannot predict with a reasonable level of assurance the potential financial impact this could have on its accounts. For these reasons, no provision has been recorded as of 31 December 2021 in Linnea's accounts.</p> | Low |



2.2 RISK MANAGEMENT AND INTERNAL CONTROL

Ipsen aims to continuously improve its internal control and risk management environment to be compliant with the “*Cadre de Référence*” issued by “*l’Autorité des marchés financiers*” (AMF) and with measures described in the COSO II standard (Committee of Sponsoring Organizations of the Treadway Commission).

Risk management objectives are to:

- secure the general Group objective of improving patient health and quality of life by providing effective therapeutic solutions for unmet medical needs;
- preserve the value, assets, people, environment and reputation of the Group;
- ensure decisions and processes, needed to reach Group objectives, take into account risk factors;
- ensure risk factors are assessed towards Group values;
- mobilize employees around a shared vision of the Group main risks and around the specific risks in their own area of activity.

Internal control and compliance frameworks are implemented by operational management and employees to provide Executive Management and shareholders with reasonable assurance about the achievement of the following objectives:

- compliance with all applicable laws and regulations;
- implementation of the instructions and directives provided by the Executive Leadership Team;

- effectiveness of Group internal processes, notably those aimed at protecting Group assets;
- reliability of financial data and, more generally, of all data included in published statements.

The Group’s internal control rules apply to all Company entities under exclusive control within the meaning of the IFRS standards. The main internal control components that are further explained in this report are as follows:

- an organization that gives a clear definition of responsibilities, with competent and adequate resources using appropriate information systems, procedures, processes, tools and rules;
- reliable and relevant information management that enables every employee, whatever his/her level to fulfil his/her responsibilities;
- a risk management framework;
- control activities aimed at monitoring risks and securing objectives;
- a regular review and assessment of the internal control framework.

The constant collaboration between Global Quality, Business Ethics and Corporate Social Responsibility, Risk, Security and Insurances, Finance and Global Internal Audit departments at various levels and on numerous subjects is an important consistency factor for internal control.

2.2.1 Organization

General framework

If necessary, local management is in charge of applying, adapting and supplementing Group procedures.

Operational Committees

Executive Leadership Team (ELT)

Under the oversight of the Board of Directors, the ELT is leading the strategic direction of Ipsen and its implementation. The ELT is chaired by the Chief Executive Officer and meets on a monthly basis and *ad hoc* as needed.

Scope of responsibility of the ELT is the following:

- Set the Group’s strategy and ambition:
 - set the Group’s mid-term strategy and long-term ambition and vision, and endorse the corresponding strategic plans,
 - approve R&D pipeline priorities,
 - translate the Group’s strategic vision and ambition into annual objectives for the organization,
 - validate annual budget;
- Act as an efficient decision-making body:
 - monitor financial performance and review division/function corrective action plans, endorse recommended financial communication and guidance,

- align the organization, processes, talent and capabilities to deliver on the Group’s annual objectives,
- assess talent and ensure succession planning,
- endorse the launch of key cross-functional projects, fund them adequately and monitor progress made on a regular basis,
- implement Deal Review Board (DRB) decisions on Merger and Acquisitions (M&A) / Business Development and Licensing (BD&L) deals;
- Promote efficient governance and decision-making process:
 - ensure the Group’s policies and procedures are consistent, built on ethical principles, appropriate organizational structures, well-defined responsibilities and demonstrated competencies,
 - coordinate with Global Business Ethics, Company Social Responsibility, Global EHS, Global Quality, Global Internal Audit functions and Enterprise Risk Management, to ensure adequate level of risk mapping and mitigation,
 - monitor deployment of enterprise-wide robust and effective internal control and audit, quality and risk management systems,
 - monitor performance achieved in Business Ethics, Company Social Responsibility, EHS and Global Quality;



- Promote and enhance our Company Social Responsibility.

The composition of the ELT is given in Chapter 5 of this universal registration document.

Deal Review Board (DRB)

The DRB assists Ipsen's management in decision-making for M&A and Corporate Business Development activities.

The permanent members of the DRB include: the Chief Executive Officer, the EVP Chief Business Officer, the EVP Chief Financial Officer, the EVP General Counsel, the EVP Head of R&D, the EVP Chief Medical Officer, the EVP Chief Commercial Officer Specialty Care and the EVP Strategy & Transformation.

Portfolio Committee (PC)

The PC assists Ipsen's management in decision-making on Ipsen's R&D portfolio within budget / 5Y Business Plan envelope as approved by the ELT.

The PC is co-chaired by the EVP R&D, Chief Scientific Officer and the EVP GPPS.

Benefit-Risk Decision Board (BRDB)

The BRDB assists Ipsen's management decision-making for strategic benefit-risk decisions with impact across products, therapeutic areas and the Ipsen product and candidate portfolio.

Quality and Safety

Global Quality Function

The Company has Global Quality Function that reports to the Executive Vice President, Technical Operations, with a dotted reporting to the Chief Executive Officer. This function supports the research, development, manufacturing and distribution activities across the product life cycle and is accountable to ensure compliance of the Group to all applicable standards.

It covers Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), Good Laboratory Practices (GLP), Good Clinical Practices (GCP) and Good Pharmacovigilance Practices (GVP).

Each manufacturing plant and development/business unit has a Quality Group that is responsible for assuring state of compliance. Head of these Quality Group belongs functionally to Quality Organization.

Quality Governance

A Group Quality Council meets at least on an annual basis to discuss quality vision and strategy for the Company. It includes the Chief Executive Officer, ELT members and the Senior Vice President Quality.

Ipsen Quality Management system

The Quality Management System is described in the Group Quality Manual which:

- gives an overview of the Company's Quality Management System;
- defines the GxP policies and procedures used to ensure that the Company's products and services meet GXP regulatory requirements and business objectives in a consistent, compliant and reliable manner;
- defines the Quality governance structure;
- defines the GxP documentation system;
- defines the roles and responsibilities of Quality personnel as well as senior management.

The Group Quality Manual is signed by the Senior Vice President of Quality.

Quality Systems Evaluation Board (QSEB)

The QSEB is chaired by the Senior Vice President of Global Quality or its delegate and include all relevant functions to ensure proper assessment of issues that can impact the quality and/or safety of Company products and require awareness beyond the site level. The QSEB:

- ensures resolution of critical product quality issues;
- ensures reporting of relevant issues to key stakeholders and Health Authorities if applicable;
- ensures proper corrective actions are defined;
- ensures follow up on relevant actions;
- ensures issues are communicated to the ELT and CEO as needed.

Pharmacovigilance

The Global Patient Safety (Pharmacovigilance) Department is part of Chief Medical Officer Organization that reports to the Executive Vice President and Chief Medical Officer, and is led by a Vice President, who is also the European Union Qualified Person for Pharmacovigilance. With patient safety central to Ipsen's work, the Global Patient Safety department ensures the proactive evaluation and communication of evolving safety knowledge of all Company drug products, so that benefit-risk is optimized for patients, both in clinical development and after market launches. To do this Ipsen maintains a sustainable cross-functional Pharmacovigilance System that is compliant with pharmacovigilance legislation worldwide. The Pharmacovigilance System, described in detail in the Pharmacovigilance System Master File, operates throughout the full life cycles of our products and extends across the entire company, including all affiliate staff, specifically, but not limited to, those with direct pharmacovigilance responsibilities.



Business Ethics

The Group Code of Ethical Conduct governs all employees. The Code of Ethical Conduct is one of the key elements of the Business Ethics program which is more precisely defined through Policies, Procedures and Education. The Company's Business Ethics department, under the responsibility of the Chief Business Ethics Officer, reports directly to the Chief Executive Officer. Its mission is to:

- maintain an effective compliance and ethics program that ensures a culture of integrity enabling the Company to conduct its global business with the highest ethical standards, in full compliance with all applicable laws and regulations and the Group Code of Conduct;
- specifically maintain an integrated, robust and efficient anti-corruption/anti-bribery system;
- regularly review and improve our compliance and ethics program to ensure it remains current with respect to significant risks, developments and trends;
- communicate and train employees and relevant third parties to these standards;
- monitor the enforcement of these standards within the Group entities;
- develop and maintain Business Ethics due diligence for third parties;
- develop a continuous improvement approach with the update of these standards;
- act as the point of contact for anyone who would like to address Business Ethics issues, and to address them in a confidential manner.

The Business Ethics team covers all geographies where the Group operates.

The Group's Chief Business Ethics Officer periodically reports on the state of progress of the Business Ethics program to the Board of Directors' Ethics & Governance Committee.

CSR (Corporate Social Responsibility)

The CSR strategy is implemented at the different levels of the Company through a strong governance:

The Company Social Responsibility department coordinates and aligns the deployment of the CSR strategy within the Group, working closely with different departments to align the CSR roadmap and actions with the overall strategy of the Company.

For further details, please refer to 4.1.1.

Risk Management organization

The following organization supports the framework described in section 2.2.3.

Risk Management, Insurance and Global Security department

Reporting to the Executive Vice President General Counsel, the Risk Management, Insurance and Global Security department's role is to guarantee that a relevant process of identification and management of the Group's major risks is in place. Its main objectives are:

- to promote a risk culture and to ensure Group's resiliency through a consistent approach to risk management, in compliance with the Group's policies and risk appetite;

this objective includes the definition of an annual Group Risk Map;

- to provide Ipsen divisions with methodological and technical support (risk identification and quantification, analysis and processing, engineering prevention and protection, business continuity management & risk exposure monitoring);
- to define and manage the Group's insurance programs as described in the paragraph 2.2.3;
- to define and manage the Global Security roadmap and organization;
- to pilot the Group corporate crisis management process.

Risk Committee

The Risk Committee includes individuals representing transversal Group functions with its members reporting to either an ELT member or directly to the Chief Executive Officer. The Risk Committee's mission is to facilitate the implementation of the risk management approach and to control its efficiency. The Risk Committee members meet at least once a quarter.

Security steering Committee

A Security steering Committee includes members reporting to either ELT members or directly to the Chief Executive Officer and meets at least every quarter. Its objectives are to sign off Security strategy, agree on security investments, set risk tolerance and ensure oversight of Security roadmap.

Expenditure and Cash control financial framework

Financial authorization

The financial authorization procedure lays down the financial approval levels for managers who are authorized to enter into commitments.

Financing and Treasury

The Company has a centralized cash management system to optimize its financial assets and liquidity. Exchange rate and interest rate risk exposures are centralized by the Treasury department in order to cover the risks related to commercial and industrial activities, the variations of perimeter and/or financing structure.

A Treasury charter defines the rules and principles for managing financing, treasury, and risks.

Taxes

The Group is committed to observing all applicable laws, rules and regulations in meeting its tax compliance and reporting responsibilities and paying its fair share of taxes in all jurisdictions where it operates.

The Group applies diligent professional care and judgment, including ensuring that all decisions are taken at an appropriate level and are supported by consistent processes and guidelines and thorough documentation. The tax function is localized in France, UK and the U.S. The VP Group Tax department reports to the EVP CFO and the Group tax professionals are committed to the highest compliance standards in tax laws and regulations.



2.2.2 Information Management

Reliable and relevant information, provided to the right people at the right time is a key element in the internal control and risk management.

Information on Risk Management

A Group Risk Map, defining major risks of the Company with their action plans is validated by the ELT and presented once a year for approval to the Board of Directors Audit Committee. The action plans include risk transfer to the insurance market where appropriate.

Information on Audit findings and conclusions

Internal Audit reports are communicated as presented in section 2.2.4.

Information on product Quality and Safety

Information on product Quality and Safety is ensured by the Quality and Safety functions as presented in paragraph 2.2.1.

Financial information

Reporting to the Finance Department, internal control over financial reporting is responsible for:

- preparing consolidated financial statements in accordance with the applicable laws and regulations;
- managing the budgeting and forecasting processes; reviewing Group performance and any variance against forecasts and providing the ELT with the relevant Key Performance Indicators to support the strategy implementation;
- reviewing periodical management reporting for each of the Company's entities;
- managing tax affairs;
- ensuring effective treasury management and financing for all Company entities;
- controlling the integrity of financial reporting.

Preparation of consolidated financial statements

The Group Finance Department centralizes information reported by the Finance Department of each Company entity and produces consolidated financial statements for the Group.

The financial statements reported by each Company entity are analyzed before consolidation.

The financial statements are reconciled with the management indicators monitored by the Group Finance Department.

As part of its responsibility for producing consolidated financial statements, the Group Finance Department draws up accounting manuals, management reporting packages and the chart of accounts to be used for preparing the consolidated financial statements. The Group Finance Department also ensures that all Company entities produce consistent information that complies with the Company accounting policies. A Finance Handbook is made available to all employees to provide them with the reference information they need.

The Group Finance Department also verifies that the financial and accounting information reported externally by the Company is fair and comprehensive.

The Company has implemented an ERP system, which is contributing to the optimization of financial processes and activity management. This ERP system has been implemented across the majority of the Company's research and commercial entities. Further deployment is planned in the coming years to the extend ERP's geographical coverage.

External Communications Committee

The Investor Relations department, which is overseen by the Executive Vice President Finance, and the Corporate Communications department, which is overseen by the Chief Executive Officer, are both responsible for preparing external communications documents for approval by the Chief Executive Officer, ELT and the Chief Medical Officer.

The Corporate Disclosure Committee meets as required to prepare communications and statements related to unforeseen events, which could potentially have a significant impact on the value of Company shares, and to decide, when appropriate, if communications must be postponed.

Financial controlling

Financial controlling is organized on the basis of the Group's business activities. The Group Finance Department issues budgets and forecasts instructions and controls the quality of information related to the Actuals and Planning exercises.

The Group's Finance Department analyzes the Group's actual performance and variances against forecasts and identifies and quantifies the risks and opportunities involved in budget and forecast information. The Finance Department also advises the operational managers on financial matters.

2.2.3 Risk Management Framework

The Risk Management Framework described below has been defined in accordance with measures described in the COSO II standard (Committee of Sponsoring Organizations of the Treadway Commission) and refers to the “*Cadre de Référence de l’AMF*”.

Risk Management Components

The Group’s Risk Management Policy Statement and Framework describes Risk Management objectives and terminology, defines roles & responsibilities, and documents approaches to risk identification, assessment, prioritization, treatment, and monitoring.

The Risk Management organization is described in section 2.2.1.

Risk identification and analysis

Risks are identified and analyzed through an annual risk mapping process that documents the main risks of the Group’s divisions and prioritizes them in terms of impact and level of control.

Risk mapping now covers all entities and critical processes within the Group.

Once a year, a Group Risk Map is validated by the ELT and submitted for approval to the Chief Executive Officer and to the Board of Directors Audit Committee.

Risk factors

The Group’s main risk factors are described in Chapter 2.1 of this universal registration document.

Risk treatment and insurance

For every major risk identified, an owner at ELT level is designated to monitor it and to ensure that the relevant corrective action plan is implemented. The process and all related information are coordinated by the Group’s Risk Management and Insurance Department. Some risks are transferred to the insurance market.

The Group has put in place worldwide insurance coverage with top-ranking insurance companies.

Product liability insurance covers all products manufactured, marketed, and sold by the Group as well as all clinical trials that the Group conducts. The level of coverage for clinical trials generally exceeds that required under applicable local regulations.

In order to mitigate risk volatility of product liability risk in the insurance market, a part of the Group’s liability insurance program is financed through its reinsurance subsidiary. The reinsurance subsidiary is a regulated company ruled by the Luxembourg Control authorities.

The Group also maintains insurance cover relative to its general activities, which mainly industrial and Research and Development sites insurance, business interruptions as well as environmental liability insurance.

Actuarial studies are regularly performed by external consultants to confirm adequation between the limitations of the main insurances of the Group and its insurable risks.

Generally speaking, the Group’s policies carry certain restrictions, exclusions, limitations, and deductibles that are common practice for policies of this type.

The Group considers the limitations of its insurance coverage as reasonable and conservative given the Group’s business activities and the potential risks.

Financial Risk Management

A “Market Committee” managed by the Vice President Treasury and composed also of the Executive Vice President Chief Financial Officer, Executive Vice President General Counsel and Vice President Chief Risk Officer meets every semester, or upon request of any of its members, to review and approve the forex policy, provide guidelines, and validate the hedging strategy.

Financial Risk Management hedges the following risks:

- **Foreign exchange risks:**
Due to its global business, the Group is exposed to fluctuations in exchange rates that may impact its results. The Group hedges the budgeted amount of foreign currency cash flow to mitigate the effect of currency rate changes through standard currency derivatives.
In 2021, the Group hedged the budgeted amount of foreign currency cash flow to mitigate the effect of currency rate changes.
In 2021, the instruments purchased to hedge exposure, mainly forward exchange contracts, are denominated in USD, RUB, GBP, BRL, CNY/CNH, PLN, CZK, HUF, RON, AUD, CHF. The Group’s policy is to hedge for the coming budget period.
- **Interest rate risks:**
The Group’s funding consists in a fixed-rate debt from bond debts (bonds and U.S. Private Placement – USPP), as well as a variable-rate debt from revolving credit facilities and NEU CP program (Negotiable EUropean Commercial Papers).
At 31 December 2021, there were no derivative financial instruments for hedging interest rate risk.
- **Counterpart and liquidity risks:**
Within the scope of its activities, the Finance Department makes forecasts regarding the Group application of funds and resources and implements financial instruments aligned with these forecasts, which are duly submitted to and approved by the Board of Directors. This cash position is mainly centralized and the selection of investment options is carried out by the Treasury Department in pursuance of a formalized charter which defines:
 - the treasury management objectives;
 - the criteria in terms of asset allocation and risk diversification;
 - the methodology for monitoring the performance and position of the Group cash flow.
 In accordance with its treasury charter, the Group Treasury Department is in charge of optimizing liquidity, overseeing the selection of banking establishments with which it subscribes to foreign exchange derivatives, and ensuring financial asset allocation is safe and liquid.
Within the scope of its commercial operations, the Group’s Treasury Department ensures that the credit limits applicable to its international customers are respected (notably distributors and agents), in particular upon the



receipt of new orders. It also monitors the overall status of average payment timescales of customers in its entities.

Within the scope of its partnerships, and with the support of the Group's Legal Department and respective

Development Departments, the Group's Finance Department approves contractual provisions that aim to protect the Group from the potential negative consequences of the possible failure of its partners.

2.2.4 Control Activities

Audits

The pharmaceutical industry is regulated at both the national and international level. A strict framework of laws and standards govern all Company business activities. These laws govern the Group's research and development, manufacture of active substances and drugs, promotion and distribution into the global market, financial reporting, and business ethics and compliance requirements. Global audits within Ipsen are conducted by two functions; Global Internal Audit and Quality Audit. In addition, industrial and research and development sites are responsible for their own site level audit plans.

Global Internal Audit

Global Internal Audit provides the independent assurance that key business risks are being managed appropriately and that the risk management and internal control frameworks are operating effectively. Global Internal Audit reports to the Chief Executive Officer and to the Chief Financial Officer. Global Internal Audit also has direct and regular access to the Audit Committee of the Board (referred to as the Audit Committee).

As part of Global Internal Audit governance, an Audit Charter (approved by the Chief Executive Officer and the Audit Committee) is in effect. This Audit Charter defines the Global Internal Audit's scope of audit services as covering all areas of Ipsen's activities, functions, and processes. These audits may include, but are not limited to, audits of country managed units (e.g., commercial business units, Technical Operations plants, R&D centers), third-party vendors, Group functions, global processes, internal control frameworks, compliance requirements, Information Technology, Environmental, Health and Safety and independent assessments of the effectiveness of Ipsen's Good Quality Systems across the Good Pharmaceutical Practices (GXP) where GXP apply (note: in this case GXP refer to the quality systems related to Good Manufacturing Practices, Good Clinical Practices, Good Laboratory Practices, Good Distribution Practices and Good Pharmacovigilance Practices). The GXP good practices audits (quality audits) are covered under the GXP Quality Audit program as described below.

The Global Internal Audit plan is risk-based and developed using a variety of inputs including a bottom-up approach for quantitative data, the Group Risk Map and inputs from key stakeholders (e.g., the Finance Leadership and Executive teams, Global Business Ethics and Company Social Responsibility and other relevant Company's managers). This audit plan is approved by Ipsen Internal Audit Council and the Audit Committee on an annual basis.

Audit reports containing findings and specific recommendations are generated and distributed to relevant management with a copy to the ELT members responsible for the audited areas. Key findings and main conclusions are communicated within an Executive Summary report to the Audit Committee and to ELT members. Corrective and

preventative action plans are developed and owned by management in response to audit observations and the status of all actions is tracked to completion.

Global Internal Audit works with other internal assurance type functions such as Internal Controls, Risk Management, Business Ethics and Company Social Responsibility and Quality Audit to enable consistency of objectives, alignment on plans and alleviate duplication of efforts. Global Internal Audit liaises with the Company's external Statutory Auditors on a periodic basis to ensure their respective work will be complementary.

GXP Quality Audit

GXP refer to the quality systems related to Good Manufacturing Practices, Good Clinical Practices, Good Laboratory Practices, Good Distribution Practices and Good Pharmacovigilance Practices.

The GXP Quality Audit Group reports into the VP of Quality System, Technical Operations who reports to the SVP Global Quality, Technical Operations. GXP Quality Audit assures audits of all GXP (Good Practices) areas are performed, including on many of the Group sites as well as service providers and suppliers where GXP apply. Audit frequencies are defined using a risk-based approach. Annual audit schedules are determined at the start of the year. Critical audit observations are escalated for prompt attention. Corrective and Preventative Action plans are developed and owned by management in response to audit observations and the status of all quality audit action plans are tracked to completion.

Audit compliance to quality targets is measured routinely and Global Internal Audit is provided with regular status updates from the Quality Audit program.

External Audit

In accordance with the law, Group financial statements are audited by Statutory Auditors. Their responsibility encompasses all Group companies included in the scope of consolidation. Each company, with the exception of certain companies which are not material to the consolidated financial statements, is subject to an audit or limited review as required.

Apart from the legal requirements, the Statutory Auditors produce a report on their work summarizing all key audit points identified and their resolution, as well as recommendations on the Group internal control system. The Statutory Auditors' Report is presented to the Audit Committee and the Board of Directors.

In addition, Group manufacturing plants, clinical research programs and information systems are also frequently inspected by regulatory agencies and periodically by the Company's partners.



2.2.5 Review and Assessment of Internal Control

Global Internal Audit periodically presents a summary of key observations and trend analysis resulting from its internal audit assignments to the Ipsen Internal Audit Council. The SVP Quality is responsible for providing regular updates on quality audit outcomes to the ELT.

Global Internal Audit met with the Audit Committee twice in 2021 and provided summary reports and status updates, including dashboards and trends' data, on the execution of the audit plans along with an assessment as to the overall level of internal control.

Statutory Auditors and Global Internal Audit met periodically throughout 2021 including as part of the Audit Committee updates.

[This page is intentionally left blank]

3

FINANCIAL INFORMATION OF THE COMPANY

| | | |
|------------|--|------------|
| 3.1 | MANAGEMENT REPORT FOR THE FINANCIAL YEAR | 50 |
| 3.1.1 | Significant events during the year | 50 |
| 3.1.2 | Analysis of results | 52 |
| 3.1.3 | Net cash flow and financing | 57 |
| 3.1.4 | Appendices | 59 |
| 3.1.5 | Subsequent events | 65 |
| 3.1.6 | Group outlook | 65 |
| 3.1.7 | Subsequent events following the Accounts Settlement Date of 31 December 2021 | 66 |
| 3.2 | CONSOLIDATED FINANCIAL STATEMENTS 2021 | 66 |
| 3.2.1 | Consolidated income statement | 66 |
| 3.2.2 | Consolidated balance sheet before allocation of net profit | 68 |
| 3.2.3 | Consolidated statement of cash flow | 69 |
| 3.2.4 | Statement of change in consolidated shareholders' equity | 70 |
| 3.2.5 | Notes | 72 |
| Note 1 | Significant events and transactions during the period that had an impact on the consolidated financial statements as of 31 December 2021 | 73 |
| Note 2 | Changes in the scope of consolidation | 74 |
| Note 3 | Accounting principles and methods and compliance statement | 74 |
| Note 4 | Operating Segments | 84 |
| Note 5 | Personnel | 87 |
| Note 6 | Other operating income and expense | 92 |
| Note 7 | Restructuring costs | 92 |
| Note 8 | Net financial income (expense) | 92 |
| Note 9 | Income taxes | 93 |
| Note 10 | Goodwill | 95 |
| Note 11 | Other intangible assets | 96 |
| Note 12 | Property, plant and equipment | 98 |
| Note 13 | Equity investments | 99 |
| Note 14 | Investments in equity-accounted companies | 100 |
| Note 15 | Non-current financial assets and other non-current assets | 100 |
| Note 16 | Current assets and liabilities | 101 |
| Note 17 | Cash and cash equivalents | 102 |
| Note 18 | Consolidated shareholders' equity | 103 |
| Note 19 | Provisions | 104 |
| Note 20 | Bank loans and financial liabilities | 105 |
| Note 21 | Financial instruments | 106 |
| Note 22 | Financial instruments reported in the balance sheet | 108 |
| Note 23 | Information on related parties | 109 |
| Note 24 | Commitments and contingent liabilities | 111 |
| Note 25 | Subsequent events with no impact on the consolidated financial statements as of 31 December 2021 | 113 |
| Note 26 | Consolidation scope | 113 |
| Note 27 | Fees paid to the Statutory Auditors | 115 |
| 3.2.6 | Statutory Auditors' Report on the consolidated financial statements | 116 |
| 3.3 | 2021 COMPANY FINANCIAL STATEMENTS | 120 |
| 3.3.1 | Summary document | 120 |
| 3.3.2 | Notes to the annual financial statements | 123 |
| 3.3.3 | Statutory Auditors' Report on the annual financial statements | 136 |
| 3.3.4 | Information related to Ipsen's business activity | 139 |



3.1 MANAGEMENT REPORT FOR THE FINANCIAL YEAR

3.1.1 Significant events during the year

All press releases are available on the Group's website (www.ipсен.com).

Acquisitions and Agreements

DECEMBER 17, 2021

Ipsen and GENFIT have entered into a long-term strategic partnership for global collaboration between the two companies. The agreement gives Ipsen exclusive worldwide license to develop, manufacture and commercialize GENFIT's investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC). The partnership also gives Ipsen access to future clinical programs led by GENFIT and combines GENFIT's scientific expertise and proprietary technologies in liver disease with Ipsen's development and commercialization capabilities. To underscore the long-term commitment represented by this partnership, Ipsen will also purchase newly issued GENFIT equity representing 8% post-issuance through a €28m investment in GENFIT, becoming one of the largest shareholders.

OCTOBER 18, 2021

Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3.

AUGUST 2, 2021

Ipsen and Exicure Inc. have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington's disease and Angelman syndrome.

JULY 27, 2021

Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway.

JULY 15, 2021

Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson's disease.

Research and Development

SEPTEMBER 18, 2021

ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncommon form of thyroid cancer.

JUNE 28, 2021

Exelixis, Inc. and Ipsen announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC) met one of the primary endpoints, demonstrating significant improvement in progression-free survival (PFS) at the planned primary analysis.

JUNE 11, 2021

Ipsen announced findings from a new U.S. healthcare database analysis to assess the current treatment patterns of adults living with spasticity in a real-life setting. The analysis focused on the proportion of people living with active spasticity who received botulinum neurotoxin type A (BoNT-A) treatment.¹ The abstract, Analysis of U.S. Commercial Claims to Understand Patient Treatment Pathways in Spasticity, is being presented during the International Society of Physical and Rehabilitation Medicine (ISPRM) 2021 Congress, which is taking place virtually between 12-15 June 2021.

JUNE 7, 2021

Exelixis, Inc. and Ipsen announced detailed results from the Phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX®) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC). Results from the trial, which met the co-primary endpoint of significant improvement in progression-free survival (PFS) assessed by blinded independent radiology committee (BIRC), are in press to be published in The Lancet Oncology and have been submitted to the U.S. Food and Drug Administration (FDA). The data are being presented during the Oral Abstract Session: Head and Neck Cancer at 11:45 a.m. PT on Monday, June 7 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract #6001).

FEBRUARY 22, 2021

Ipsen announced a total of 9 abstracts presenting new data with a focus in NETs.1-10. These include data from the Phase II CLARINET FORTE study and data on the use of independent administration of lanreotide autogel to be presented at the ENETS Conference.

FEBRUARY 8, 2021

Ipsen announced the first presentation of new analyses from the pivotal Phase III CheckMate -9ER trial demonstrating clinically meaningful, sustained efficacy benefits as well as quality of life improvements with the combination of Cabometyx® (cabozantinib) and Opdivo® (nivolumab) compared to sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC).¹ These data will be presented in two posters at the virtual American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium (ASCO GU) from 11-13 February 2021.

FEBRUARY 5, 2021

Ipsen announced that new data from its growing oncology portfolio will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place virtually from 11-13 February 2021. A total of 10 abstracts spanning several genitourinary cancers including advanced RCC, and metastatic, castration-resistant prostate cancer (mCRPC), highlight the utility of Ipsen's medicines and its commitment to advancing patient care.

JANUARY 15, 2021

Ipsen announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.

Regulatory

AUGUST 13, 2021

Ipsen announced, following very recent discussions with the U.S. Food and Drug Administration (FDA), withdrawal of the New Drug Application (NDA) for palovarotene. This follows ongoing dialogue with the FDA following the acceptance of the NDA for Priority Review which was announced on 28 May 2021. During the review and ongoing dialogue between Ipsen and the FDA, it was recognized that additional analyses and evaluation of data collected from Ipsen's Phase III MOVE and FOP program would be required to progress and complete the review process. It was agreed between Ipsen and the FDA that it would not be possible to complete this within the current NDA review cycle. As a result, Ipsen has therefore confirmed their withdrawal of the NDA for palovarotene. After recent discussion with FDA, Ipsen plans to resubmit to the FDA upon completion of the additional data analyses.

MAY 28, 2021

Ipsen announced that its New Drug Application (NDA) for palovarotene, an oral, investigational, selective RAR γ agonist for the prevention of heterotopic ossification (new bone formation) as a potential treatment option for people living with the progressive disabling and ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP), has been accepted by the U.S. Food and Drug Administration (FDA). The target regulatory action date assigned by the FDA under a Priority Review status is 30 November 2021.

MARS 31, 2021

Ipsen announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb's Opdivo® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). This decision marks the first approval for Cabometyx in combination with another therapy in Europe and the third indication of Cabometyx in renal cell carcinoma (RCC).

Governance

OCTOBER 11, 2021

Ipsen announced the appointment of Mari Scheiffele as EVP and President, Specialty Care International, effective 1 November 2021. Based in Boulogne, France, she will be reporting directly to David Loew, CEO, Ipsen, and serve on the Executive Leadership Team.

JANUARY 20, 2021

Ipsen announced the appointment of Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021. Based in Boulogne, France, she will be responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen at global level, reporting directly to David Loew, CEO, Ipsen. Gwenan will serve on the Executive Leadership Team.

Other

DECEMBER 20, 2021

Ipsen has learned that Cipla Limited and its subsidiary Cipla USA, Inc. has received final approval of a lanreotide product from the U.S. Food and Drug Administration; the FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway. There is no change to Ipsen's mid-term financial outlook to 2024.

OCTOBER 27, 2021

Ipsen has pledged to play its part in securing global net-zero emissions, ahead of the COP26 conference in Glasgow, UK, next month. Ipsen is proud to have joined the Business Ambition for 1.5°C campaign and is committed to science-based greenhouse-gas (GHG) emissions reductions,

JUNE 2, 2021

Ipsen initiated a share buy-back program to cover its performance and employee share plans.

JUNE 1, 2021

Ipsen announced the launch of an Employee Shareholding Plan.

MARCH 8, 2021

Ipsen has learned that Amdipharm Ltd, which is believed to be a subsidiary of Advanz Pharma, has received a positive outcome by the Reference Member State, Denmark, and closure of the Decentralized Procedure, for a generic formulation of lanreotide in 60mg, 90mg and 120mg dose presentations. This represents a step towards the first national regulatory approval of a lanreotide generic in Europe.



3.1.2 Analysis of results

3.1.2.1 Comparison of Consolidated Sales for the Fourth Quarter and Full Year 2021 and 2020

Sales by therapeutic area and by product

| (in millions of euros) | Fourth Quarter | | | | Full Year | | | |
|----------------------------------|----------------|--------------|---------------|----------------------------------|----------------|----------------|---------------|----------------------------------|
| | 2021 | 2020 | % Variation | % Variation at constant currency | 2021 | 2020 | % Variation | % Variation at constant currency |
| Oncology | 588.1 | 523.2 | 12.4 % | 10.1 % | 2,153.5 | 1,969.8 | 9.3 % | 10.8 % |
| <i>Somatuline</i> ® | 328.3 | 310.1 | 5.9 % | 3.6 % | 1,202.7 | 1,145.2 | 5.0 % | 7.1 % |
| <i>Decapeptyl</i> ® | 127.0 | 102.5 | 23.9 % | 21.9 % | 459.6 | 390.5 | 17.7 % | 17.5 % |
| <i>Cabometyx</i> ® | 96.0 | 75.3 | 27.4 % | 26.3 % | 354.6 | 288.9 | 22.7 % | 22.8 % |
| <i>Onivyde</i> ® | 34.4 | 33.3 | 3.3 % | (0.8) % | 127.4 | 123.3 | 3.3 % | 7.2 % |
| Other Oncology | 2.4 | 2.1 | 15.4 % | 14.2 % | 9.1 | 21.8 | (58.2) % | (58.5) % |
| Neuroscience | 131.1 | 97.6 | 34.3 % | 32.3 % | 440.7 | 356.1 | 23.8 % | 27.1 % |
| <i>Dysport</i> ® | 129.3 | 96.3 | 34.4 % | 32.4 % | 434.6 | 353.2 | 23.1 % | 26.3 % |
| Rare Diseases | 11.8 | 12.6 | (6.2) % | (7.6) % | 49.1 | 55.2 | (11.0) % | (10.4) % |
| <i>NutropinAq</i> ® | 7.5 | 8.4 | (11.3) % | (11.7) % | 32.0 | 36.2 | (11.5) % | (11.8) % |
| <i>Increlex</i> ® | 4.3 | 4.2 | 4.0 % | 0.3 % | 17.1 | 19.0 | (10.1) % | (7.8) % |
| Total Specialty Care | 731.0 | 633.5 | 15.4 % | 13.2 % | 2,643.3 | 2,381.1 | 11.0 % | 12.7 % |
| <i>Smecta</i> ® | 25.2 | 22.9 | 10.0 % | 5.8 % | 88.8 | 80.9 | 9.7 % | 10.1 % |
| <i>Tanakan</i> ® | 8.6 | 8.6 | 0.4 % | (3.1) % | 36.6 | 35.2 | 3.9 % | 5.7 % |
| <i>Forlax</i> ® | 10.1 | 9.0 | 12.1 % | 13.1 % | 36.0 | 39.0 | (7.9) % | (6.8) % |
| <i>Fortrans/Eziclen</i> ® | 9.9 | 9.1 | 9.8 % | 5.8 % | 35.9 | 28.1 | 28.1 % | 29.1 % |
| Other Consumer Healthcare | 6.2 | 7.0 | (10.9) % | (11.0) % | 28.4 | 27.4 | 3.7 % | 5.1 % |
| Total Consumer Healthcare | 60.2 | 56.6 | 6.3 % | 3.5 % | 225.6 | 210.6 | 7.1 % | 8.1 % |
| Total Sales | 791.2 | 690.1 | 14.6 % | 12.4 % | 2,868.9 | 2,591.6 | 10.7 % | 12.3 % |

Specialty Care sales amounted to €2,643.3 million, an increase of 12.7%¹, and comprised 92.1% of total sales (FY 2020: 91.9%).

Oncology

Oncology sales of €2,153.5 million represented a growth of 10.8%¹ and comprised 75.1% of total sales (FY 2020: 76.0%).

Somatuline – sales of €1,202.7 million, an increase of 7.1%¹, with a 7.4%¹ growth in North America reflecting strong volumes, even with the residual impact of COVID-19 on patient diagnoses and treatments. The performance was also a result of continued market-share gains in most other geographies with a limited impact from generic octreotide and lanreotide in Europe.

Decapeptyl – sales of €459.6 million reflected a growth of 17.5%¹, mainly driven by the performance in China, which significantly recovered from the impact of COVID-19, along with market-share gains in other countries including in the rest of Asia, France and Italy.

Cabometyx – sales of €354.6 million, up by 22.8%¹, driven by a strong volume uptake across most geographies in both renal cell carcinoma and hepatocellular carcinoma indications.

Onivyde – sales of €127.4 million, growing by 7.2%¹, driven by higher volumes in the U.S. and to Ipsen's ex-U.S. partner despite negative impact from COVID-19 on patients.

Neuroscience

Neuroscience sales increased by 27.1%¹ to €440.7 million and comprised 15.4% of total sales (FY 2020: 13.7%).

Dysport – sales reached €434.6 million, up by 26.3%¹, driven by a solid recovery from the COVID-19 pandemic in most geographies and a strong performance both in aesthetics markets including in markets operated by Ipsen's partner, Galderma and in therapeutics markets in Europe and North America.

¹ At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.

Rare Disease

Rare Disease sales declined by 10.4%² to €49.1 million, and comprised 1.7% of total sales (FY 2020: 2.1%).

NutropinAq (somatropin) sales of €32.0 million, a decline of 11.8%², reflected a slowdown in the market and competitive pressures across Europe.

Increlex (mecasermin) sales of €17.1 million, a decrease of 7.8%², resulting from lower demand in the U.S., along with COVID-19 impact.

Consumer Healthcare

Sales of €225.6 million, an increase of 8.1%², driven by the growth of **Smecta** (diosmectite) and **Fortrans/Eziclen** (macrogol 4000) by 10.1%² and 29.1%² to €88.8 million and €35.9 million respectively, mainly driven by the COVID-19 recovery as well as performance in Europe and China, as well the growth of **Tanakan** (*ginkgo biloba* extract) by 5.7%² to €36.6 million, driven by the performance in Vietnam.

Consumer Healthcare sales comprised 7.9% of total sales (FY 2020: 8.1%).

Sales by geographical area

| (in millions of euros) | Fourth Quarter | | | | Full Year | | | |
|---|----------------|--------------|--------------|----------------------------------|----------------|----------------|--------------|----------------------------------|
| | 2021 | 2020 | % Variation | % Variation at constant currency | 2021 | 2020 | % Variation | % Variation at constant currency |
| France | 81.2 | 77.2 | 5.1 % | 4.5 % | 314.3 | 297.3 | 5.7 % | 6.0 % |
| Germany | 48.6 | 44.9 | 8.4 % | 8.4 % | 198.9 | 191.0 | 4.1 % | 4.1 % |
| Italy | 33.4 | 26.1 | 27.9 % | 27.9 % | 130.0 | 109.1 | 19.2 % | 19.2 % |
| U.K. | 26.1 | 30.6 | (14.8)% | (20.1)% | 116.1 | 116.2 | (0.1)% | (3.4)% |
| Spain | 35.4 | 29.9 | 18.5 % | 18.5 % | 124.6 | 110.9 | 12.3 % | 12.3 % |
| Major Western European Countries | 224.8 | 208.8 | 7.6% | 6.6% | 883.8 | 824.5 | 7.2% | 6.8% |
| Eastern Europe | 76.0 | 61.5 | 23.6 % | 20.0 % | 261.4 | 219.4 | 19.2 % | 22.5 % |
| Others Europe | 85.9 | 75.1 | 14.4 % | 16.0 % | 294.7 | 281.5 | 4.7 % | 6.4 % |
| Other European Countries | 161.9 | 136.6 | 18.5% | 17.8% | 556.1 | 500.9 | 11.0% | 13.5% |
| North America | 266.5 | 234.2 | 13.8% | 10.0% | 916.3 | 857.6 | 6.8% | 10.5% |
| Asia | 63.2 | 57.3 | 10.5 % | 5.8 % | 252.2 | 192.9 | 30.7 % | 28.9 % |
| Other Rest of the World | 74.7 | 53.2 | 40.6 % | 38.4 % | 260.4 | 215.7 | 20.7 % | 23.4 % |
| Rest of the World | 138.0 | 110.4 | 25.0% | 21.7% | 512.6 | 408.6 | 25.4% | 26.0% |
| Total Sales | 791.2 | 690.1 | 14.6% | 12.4% | 2,868.9 | 2,591.6 | 10.7% | 12.3% |

Major Western European countries

Sales reached €883.8 million, an increase of 6.8%². Major Western European countries comprised 30.8% of total sales (FY 2020: 31.8%).

France – sales of €314.3 million, an increase of 6.0%², reflecting continued market-share gains for Decapeptyl and Somatuline, along with a solid performance and recovery from the pandemic for Dysport.

Germany – sales reached €198.9 million, up by 4.1%², mainly driven by continued market-share gains for Cabometyx and Somatuline with only a limited impact from the launch of generic lanreotide.

Italy – sales of €130.0 million, up by 19.2%², mainly a result of a solid Cabometyx and Decapeptyl performance.

Spain – sales of €124.6 million reflected growth of 12.3%², driven by market-share gains for Somatuline and Decapeptyl.

U.K. – sales reached €116.1 million, a decrease of 3.4%², mainly due lower volumes of Decapeptyl despite positive performance of Somatuline.

Other European countries

Sales reached €556.1 million, an increase of 13.5%², driven by a strong Dysport performance in Russia and Turkey, market-share gains and successful launches of Cabometyx, along with growing Consumer Healthcare sales in Eastern Europe.

Other European countries sales comprised 19.4% of total sales (FY 2020: 19.3%).

North America

Sales of €916.3 million reflected a growth of 10.5%², driven by continued strong Somatuline, Onivyde and Cabometyx demand, despite a residual impact of COVID-19 on patient diagnoses and treatments. Solid Dysport sales reflected good performances in both aesthetics and therapeutics markets.

North America sales comprised 31.9% of total sales (FY 2020: 33.1%).

² At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.



Rest of the World

Sales reached €512.6 million, an increase of 26.0%³, driven by the China recovery that resulted in strong Decapeptyl and Consumer Healthcare sales, a solid Dysport performance in Latin America and the Middle East, continued good

Decapeptyl performance in South Korea and Taiwan, along with strong Cabometyx volume growth in Brazil and Mexico.

Rest of the World sales comprised 17.9% of total sales (FY 2020: 15.8%).

■ 3.1.2.2 Comparison of Core consolidated income statement

Core financial measures are performance indicators. Reconciliation between these indicators and IFRS aggregates is presented in Appendix 4 "Bridges from IFRS consolidated net profit to Core consolidated net profit".

| | 2021 | | 2020 | | % change |
|--|------------------------|----------------|------------------------|----------------|---------------|
| | (in millions of euros) | % of sales | (in millions of euros) | % of sales | |
| Sales | 2,868.9 | 100 % | 2,591.6 | 100 % | 10.7 % |
| Other revenues | 130.2 | 4.5 % | 94.5 | 3.6 % | 37.8 % |
| Revenue | 2,999.1 | 104.5 % | 2,686.2 | 103.6 % | 11.6 % |
| Cost of goods sold | (538.0) | (18.8) % | (490.6) | (18.9) % | 9.6 % |
| Selling expenses | (835.7) | (29.1) % | (784.0) | (30.3) % | 6.6 % |
| Research and development expenses | (428.4) | (14.9) % | (405.6) | (15.6) % | 5.6 % |
| General and administrative expenses | (199.6) | (7.0) % | (187.8) | (7.2) % | 6.3 % |
| Other core operating income | 13.9 | 0.5 % | 11.8 | 0.5 % | N.A. |
| Other core operating expenses | (0.1) | — | (0.6) | — | N.A. |
| Core Operating Income | 1,011.3 | 35.2 % | 829.3 | 32.0 % | 21.9 % |
| Net financing costs | (21.3) | (0.7) % | (24.7) | (1.0) % | (13.8) % |
| Core other financial income and expense | (14.3) | (0.5) % | (19.6) | (0.8) % | (27.2) % |
| Core income taxes | (217.9) | (7.6) % | (172.9) | (6.7) % | 26.0 % |
| Share of net profit/(loss) from equity-accounted companies | 0.4 | — | (1.5) | (0.1) % | (124.5) % |
| Core consolidated net profit | 758.1 | 26.4 % | 610.5 | 23.6 % | 24.2 % |
| - Attributable to shareholders of Ipsen S.A. | 758.0 | 26.4 % | 609.6 | 23.5 % | 24.3 % |
| - Attributable to non-controlling interests | 0.1 | — | 0.9 | — | (86.5) % |
| <i>Core EPS fully diluted - attributable to Ipsen S.A. shareholders (in € per share)</i> | <i>9.09</i> | | <i>7.31</i> | | <i>24.5 %</i> |

Reconciliation from Core consolidated net profit to IFRS consolidated net profit

| (in millions of euros) | 2021 | 2020 |
|--|--------------|--------------|
| Core consolidated net profit | 758.1 | 610.5 |
| Amortization of intangible assets (excluding software) | (61.7) | (62.9) |
| Other operating income and expenses ⁽¹⁾ | (36.5) | (13.4) |
| Restructuring costs | (14.7) | (32.7) |
| Impairment losses | (6.5) | (109.2) |
| Others | 8.1 | 156.6 |
| IFRS consolidated net profit | 646.7 | 548.9 |
| <i>IFRS EPS fully diluted - attributable to Ipsen S.A. shareholders (in € per share)</i> | <i>7.76</i> | <i>6.57</i> |

(1) Proceeds received in 2020 from businesses sold before 2020 were reclassified from "Profit from discontinued operations" to the "Other operating income" line item for €3.8 million.

³ At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.

Total sales

Total sales grew by 10.7% as reported to €2,868.9 million.

Other revenue

Other revenue totaled €130.2 million an increase of 37.8%, reflecting the growth in royalties paid by partners, mainly by Galderma in respect of Dysport.

Cost of goods sold

Cost of goods sold of €538.0 million represented 18.8% of total sales (FY 2020: €490.6 million, 18.9%), reflecting a growth of 9.6% thanks to the favorable mix impact from Specialty Care growth, despite an increase of royalties paid to partners, notably for Cabometyx.

Selling expenses

Selling expenses increased by 6.6% to €835.7 million, compared to lower 2020 baseline impacted by COVID-19 restrictions. The increase is driven by inflation, the commercial efforts deployed to support Specialty Care growth offset by the impact of the Company's efficiency program. Selling expenses represented 29.1% of total sales, an improvement of 1.1 point.

Research and development expenses

Research and development expenses totaled €428.4 million, representing a growth of 5.6% driven by investment in Oncology mainly for Onivyde and Cabometyx, in Rare Disease for palovarotene and in Neuroscience notably for next-generation neurotoxins. R&D expenses represented 14.9% of total sales, a decline of 0.7 point.

General and administrative expenses

General and administrative expenses increased by 6.3% to €199.6 million, to support growth platforms in the organization. General and administrative represented 7.0% of total sales, an improvement of 0.3 point.

Other core operating income and expenses

Other core operating income and expenses amounted to an income of €13.8 million (FY 2020 income of €11.2 million), primarily reflecting the impact of Ipsen's currency-hedging policy.

Core Operating Income

Core Operating Income amounted to €1,011.3 million, representing growth of 21.9% and comprised 35.2% of total sales (FY 2020: 32.0%).

Core net financing costs and other financial income and expenses

The Group incurred net financial expenses of €35.6 million, versus €44.4 million in 2020.

Net financing costs decreased by €3.4 million to €21.3 million, driven by lower costs mainly attributable to the reduction of the Revolving Credit Facility ("RCF").

Other financial income and expense decreased by €5.3 million to €14.3 million, mainly from lower hedging costs.

Core income taxes

Core income tax expense of €217.9 million, an increase of 26.0% resulted from a Core effective tax rate of 22.3% (FY 2020: 22.0%).

Core consolidated net profit

Core consolidated net profit increased by 24.2% to €758.1 million with €758.0 million fully attributable to Ipsen S.A. shareholders. This compares to Core consolidated net profit of €610.5 million in 2020, with €609.6 million fully attributable to Ipsen S.A. shareholders.

Core Earning per share

Core EPS fully diluted came to €9.09, representing growth of 24.5% (FY 2020: €7.31).

■ 3.1.2.3 From Core financial measures to IFRS reported figures

Reconciliations between IFRS results and the Core financial measures are presented in Appendix 4.

The main reconciling items between Core consolidated net profit and IFRS consolidated net profit were:

Amortization of intangible assets (excluding software)

Amortization of intangible assets (excluding software) amounted to €82.3 million before tax, compared to €86.5 million before tax in 2020.

Other operating income and expenses

Other non-core operating income and expenses amounted to an expense of €50.6 million before tax, mainly related to costs arising from the Group's transformation programs.

Other non-core operating income and expenses in 2020 totaled €18.6 million before tax, mainly related to the Group's transformation programs and the discontinuation of deprioritized research programs.

Restructuring costs

Restructuring costs came to €19.8 million before tax, mainly impacted by transformation projects mostly in France and in the U.S.

Restructuring costs in 2020 amounted to €45.6 million before tax including mainly the Consumer Healthcare transformation projects and the cost of the transfer of Onivyde manufacturing site.

Impairment losses

The Group recognized an impairment loss of €9.1 million before tax following an unfavorable result of a clinical study.

In 2020, the Group recognized impairment losses of €153.9 million before tax, including €55.8 million on the intangible assets of palovarotene, €52.1 million on deprioritized R&D programs and €42.0 million on intangible assets related to some commercialized non-core products.

Other (Financial income and expenses, Income taxes and net profit from discontinued operations)

Other items amounted to an income of €8.1 million.

Other items in 2020 amounted to an income of €156.6 million, driven by a tax income of €134.2 million resulting from the recognition of tax losses generated by Group legal restructuring.

As a consequence, IFRS reported indicators are:

Operating income

Operating Profit amounted to €849.5 million compared to a €524.8 million in 2020. This increase mainly resulted from the non-recurring impairment in 2020 of the intangible assets of palovarotene and some commercialized non-core products.

Consolidated net profit

2021 Consolidated net profit was €646.7 million with €646.6 million fully attributable to Ipsen S.A. shareholders, compared to a net profit of €548.9 million in FY 2020.

Sales, Revenue and Core Operating Income are presented by therapeutic area for the 2021 and 2020 financial years in the following table:

| (in millions of euros) | 2021 | 2020 | Change | | |
|----------------------------|--------------|--------------|--------|--------|--|
| | | | | % | |
| Specialty Care | | | | | |
| Sales | 2,643.3 | 2,381.1 | 262.2 | 11.0% | |
| Revenue | 2,748.6 | 2,453.6 | 295.1 | 12.0% | |
| Core Operating Income | 1,186.6 | 1,014.3 | 172.3 | 17.0% | |
| <i>% of sales</i> | <i>44.9%</i> | <i>42.6%</i> | | | |
| Consumer Healthcare | | | | | |
| Sales | 225.6 | 210.6 | 15.0 | 7.1% | |
| Revenue | 250.5 | 232.6 | 17.9 | 7.7% | |
| Core Operating Income | 31.7 | 15.6 | 16.1 | 103.0% | |
| <i>% of sales</i> | <i>14.1%</i> | <i>7.4%</i> | | | |
| Total Unallocated | | | | | |
| Core Operating Income | (207.1) | (200.6) | (6.5) | 3.2% | |
| Group total | | | | | |
| Sales | 2,868.9 | 2,591.6 | 277.2 | 10.7% | |
| Revenue | 2,999.1 | 2,686.2 | 312.9 | 11.6% | |
| Core Operating Income | 1,011.3 | 829.3 | 181.9 | 21.9% | |
| <i>% of sales</i> | <i>35.2%</i> | <i>32.0%</i> | | | |

Specialty Care sales grew to €2,643.3 million, an increase of 11.0% (12.7% at CER⁴), reaching 92.1% of total sales (FY 2020: 91.9%). Core operating income for Specialty Care increased by 17.0% to €1,186.6 million, representing 44.9% of total sales (FY 2020: 42.6%), reflecting the contribution from continued sales growth of all key products and an increase in selling expenses and research & development investment.

Earnings per share

2021 Fully diluted EPS was a net profit per share amounting to €7.76 per share compared to €6.57 net profit per share in 2020.

3.1.2.4 Operating segments: Core Operating Income by therapeutic area

Segment information is presented according to the Group's two operating segments, Specialty Care and Consumer Healthcare.

All costs allocated to these two segments are presented in the key performance indicators. Corporate overhead expenses and the impact of the currency hedging policy are not allocated to the two operating segments.

Core operating income is the indicator used by Ipsen to measure operating performance and to allocate resources.

Consumer Healthcare sales grew to €225.6 million, an increase of 7.1% (8.1% at CER⁴). Core operating income for Consumer Healthcare amounted to €31.7 million, representing 14.1% of total sales (FY 2020: 7.4%), reflecting higher sales driven by the COVID-19 recovery and good cost management.

Unallocated core operating income amounted to a negative €207.1 million (FY 2020: negative €200.6 million) with a limited growth of 3.2%.

⁴ At CER, which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.

3.1.3 Net cash flow and financing

The Group had a net debt decrease of €398.8 million over 2021, bringing closing net debt to €126.4 million.

■ 3.1.3.1 Analysis of the consolidated net cash flow statement

| (in millions of euros) | 2021 | 2020 |
|--|----------------|------------------|
| Opening net cash / (debt) | (525.3) | (1,115.6) |
| Core Operating Income | 1,011.3 | 829.3 |
| Non-cash items | 157.0 | 132.7 |
| Change in operating working capital requirement | 15.7 | 53.8 |
| (Increase) decrease in other working capital requirement | (13.1) | (55.6) |
| Net capital expenditures (excluding milestones paid) | (121.0) | (117.9) |
| Dividends received from entities accounted for using the equity method | — | — |
| Operating Cash Flow | 1,049.8 | 842.3 |
| Other non-core operating income and expenses and restructuring costs | (63.6) | (41.3) |
| Financial income | (28.6) | (43.3) |
| Current income tax | (150.4) | (118.4) |
| Other operating cash flow | 0.1 | 7.2 |
| Free Cash Flow | 807.4 | 646.4 |
| Distributions paid | (83.1) | (83.5) |
| Net investments (business development and milestones) ⁽¹⁾ | (220.5) | (39.0) |
| Share buyback | (36.7) | (36.4) |
| FX on net indebtedness and change in earn-out | (68.3) | 101.2 |
| Other ⁽¹⁾ | — | 1.6 |
| Shareholders return and external growth operations | (408.6) | (56.1) |
| CHANGE IN NET CASH / (DEBT) | 398.8 | 590.4 |
| Closing net cash / (debt) | (126.4) | (525.3) |

(1) Proceeds received in 2020 from businesses sold before 2020 were reclassified from "Profit from discontinued operations" to the "Other operating income" line item for €3.8 million.

Operating Cash Flow

Operating Cash Flow totaled €1 049.8 million, an increase of €207.6 million (+24.6%) versus 2020, mainly driven by higher Core Operating Income (up €182 million) and higher non-cash items (up €24.3 million).

Non-cash items reached €157.0 million versus €132.7 million in 2020, mainly impacted by an increase in amortization of tangible assets and higher provisions.

Operating working capital requirement decreased by €15.7 million mainly from higher trade payables by €83.5 million partially offset by higher trade receivables by €67.3 million.

Other working capital requirement increased by €13.1 million, driven by an increase in tax receivables.

Net capital expenditures amounted to €121.0 million, compared to €117.9 million in 2020 including projects at industrial sites, corporate investments in IT and digital projects, and new lease contracts and extensions.

Free Cash Flow

Free Cash Flow totaled €807.4 million, an increase of €161.0 million versus 2020, mainly driven by higher Operating Cash Flow and lower financial expenses due to lower hedging and financing costs, slightly offset by higher non-core expenses and restructuring costs, and higher current income tax.

Shareholders return and external growth operations

Distribution payout to Ipsen S.A. shareholders amounted to €82.9 million in 2021.

Net investments amounted to €220.5 million, mainly driven by investments in external innovation including upfront payment and purchase of Genfit shares for a total of €148 million. It also includes Onivyde's commercial milestones received for €20.8 million, the proceeds from the divestiture in equity-accounted companies for €24.0 million, partly offset by additional milestones payments for Cabometyx to Exelixis for €51.3 million.

Net investments in 2020 amounted to €39.0 million, including additional milestones of €17.6 million for IPN60130 paid to Blueprint Medicines Corporation, and of €24.1 million for Cabometyx paid to Exelixis.

Foreign Exchange on net indebtedness and change in earn-out included mainly the negative impact of higher U.S. Dollar versus Euro on the indebtedness.

3.1.3.2 Reconciliation of cash and cash equivalents and net cash

| (in millions of euros) | 2021 | 2020 |
|--|----------------|------------------|
| Current financial assets (derivative instruments on financial operations) | 0.6 | 0.2 |
| Closing cash and cash equivalents | 809.1 | 639.6 |
| Non-current loans | (562.8) | (542.7) |
| Other non-current financial liabilities (excluding derivative instruments) (**) | (209.3) | (218.9) |
| Non-current financial liabilities | (772.2) | (761.6) |
| Credit lines and bank loans | — | (199.0) |
| Other current financial liabilities (excluding derivative instruments) (**) | (164.0) | (204.5) |
| Current financial liabilities | (164.0) | (403.5) |
| Debt | (936.2) | (1,165.2) |
| Net cash / (debt) (*) | (126.4) | (525.3) |

(*) Net cash / (debt): derivative instruments booked in financial assets and related to financial operations, cash and cash equivalents, less bank overdrafts, bank loans and other financial liabilities and excluding financial derivative instruments on commercial operations.

(**) Financial liabilities mainly exclude €10.7 million in derivative instruments related to commercial operations in 2021, compared with €4.4 million in 2020.

Analysis of Group cash

Ipsen S.A. issued in June 2016 €300 million in unsecured, seven-year public bonds.

Ipsen S.A. issued also in July 2019 \$300 million through U.S. Private Placement ("USPP") in two tranches of 7 and 10-year maturities.

Ipsen S.A. has signed in May 2019 an initially five-year Revolving Credit Facility (RCF) of €1,500 million, which has been extended in 2020 to May 2025, and in 2021 to May 2026.

The Group has to comply with a Net Debt / EBITDA covenant to remain below 3.5 times at each financial closing in both RCF and USPP and the RCF includes also specific indicators linked to Corporate Social Responsibility ("CSR") to be assessed annually.

The Group was fully complying with its covenant ratio for the RCF and the USPP.

On 31 December 2021, the RCF was fully reimbursed and Ipsen S.A. program of emission of NEU CP – Negotiable European Commercial Paper of €600 million was drawn for €80 million.

3.1.4 Appendices

■ 3.1.4.1 Appendix 1 – Consolidated income statement

| (in millions of euros) | 2021 | 2020 |
|---|----------------|----------------|
| Sales | 2,868.9 | 2,591.6 |
| Other revenues | 130.2 | 94.5 |
| Revenue | 2,999.1 | 2,686.2 |
| Cost of goods sold | (538.0) | (490.6) |
| Selling expenses | (835.7) | (784.0) |
| Research and development expenses | (428.4) | (405.6) |
| General and administrative expenses | (199.6) | (187.8) |
| Other operating income ⁽¹⁾ | 53.1 | 34.0 |
| Other operating expenses | (172.2) | (127.9) |
| Restructuring costs | (19.8) | (45.6) |
| Impairment losses | (9.1) | (153.9) |
| Operating Income | 849.5 | 524.8 |
| <i>Investment income</i> | <i>2.4</i> | <i>2.3</i> |
| <i>Financing costs</i> | <i>(23.7)</i> | <i>(27.1)</i> |
| Net financing costs | (21.3) | (24.7) |
| Other financial income and expenses | (13.6) | 32.5 |
| Income taxes | (168.2) | 17.8 |
| Share of net profit/(loss) from equity-accounted companies | 0.4 | (1.5) |
| Net profit (loss) from continuing operations | 646.7 | 548.9 |
| Net profit (loss) from discontinued operations ⁽¹⁾ | – | – |
| Consolidated net profit (loss) | 646.7 | 548.9 |
| - Attributable to shareholders of Ipsen S.A. | 646.6 | 548.0 |
| - Attributable to non-controlling interests | 0.1 | 0.9 |
| <i>Basic earnings per share, continuing operations (in euros)</i> | <i>7.82</i> | <i>6.61</i> |
| <i>Diluted earnings per share, continuing operations (in euros)</i> | <i>7.76</i> | <i>6.57</i> |
| <i>Basic earnings per share, discontinued operations (in euros)</i> | <i>0.00</i> | <i>0.00</i> |
| <i>Diluted earnings per share, discontinued operations (in euros)</i> | <i>0.00</i> | <i>0.00</i> |
| <i>Basic earnings per share (in euros)</i> | <i>7.82</i> | <i>6.61</i> |
| <i>Diluted earnings per share (in euros)</i> | <i>7.76</i> | <i>6.57</i> |

(1) Proceeds received in 2020 from businesses sold before 2020 were reclassified from "Profit from discontinued operations" to the "Other operating income" line item for €3.8 million.

■ 3.1.4.2 Appendix 2 – Consolidated balance sheet before allocation of net profit

| (in millions of euros) | 31 December 2021 | 31 December 2020 ⁽¹⁾ |
|--|------------------|---------------------------------|
| ASSETS | | |
| Goodwill | 623.2 | 592.8 |
| Other intangible assets | 1,392.0 | 1,121.1 |
| Property, plant & equipment | 647.5 | 646.6 |
| Equity investments | 106.9 | 84.5 |
| Investments in equity-accounted companies | 26.2 | 19.1 |
| Non-current financial assets | 0.1 | 23.1 |
| Deferred tax assets | 253.1 | 243.2 |
| Other non-current assets | 4.3 | 3.8 |
| Total non-current assets | 3,053.0 | 2,734.2 |
| Inventories | 219.4 | 213.9 |
| Trade receivables | 564.3 | 476.2 |
| Current tax assets | 122.8 | 83.6 |
| Current financial assets | 54.1 | 48.9 |
| Other current assets | 178.6 | 113.7 |
| Cash and cash equivalents | 814.7 | 642.5 |
| Total current assets | 1,953.8 | 1,578.8 |
| TOTAL ASSETS | 5,006.8 | 4,313.0 |
| EQUITY AND LIABILITIES | | |
| Share capital | 83.8 | 83.8 |
| Additional paid-in capital and consolidated reserves | 1,983.9 | 1,558.9 |
| Net profit (loss) for the period | 646.6 | 548.0 |
| Foreign exchange differences | 37.2 | (59.6) |
| Equity attributable to Ipsen S.A. shareholders | 2,751.5 | 2,131.2 |
| Equity attributable to non-controlling interests | 2.5 | 2.7 |
| Total shareholders' equity | 2,754.0 | 2,133.8 |
| Retirement benefit obligation | 40.7 | 47.4 |
| Non-current provisions | 64.0 | 32.0 |
| Other non-current financial liabilities | 772.2 | 761.6 |
| Deferred tax liabilities | 101.8 | 79.9 |
| Other non-current liabilities | 45.8 | 45.1 |
| Total non-current liabilities | 1,024.4 | 966.0 |
| Current provisions | 41.6 | 45.7 |
| Current financial liabilities | 174.8 | 408.6 |
| Trade payables | 594.7 | 495.2 |
| Current tax liabilities | 10.0 | 10.8 |
| Other current liabilities | 401.7 | 250.0 |
| Bank overdrafts | 5.5 | 2.8 |
| Total current liabilities | 1,228.4 | 1,213.1 |
| TOTAL EQUITY & LIABILITIES | 5,006.8 | 4,313.0 |

(1) The financial statements as of 31 December 2020 were restated with retroactive application of the IFRIC agenda decision on Employee Benefits starting on 1 January 2020.

■ 3.1.4.3 Appendix 3 – Cash flow statements

Appendix 3.1 – Consolidated statement of cash flow

| (in millions of euros) | 2021 | 2020 |
|--|----------------|----------------|
| Consolidated net profit | 646.7 | 548.9 |
| Share of profit/(loss) from equity-accounted companies | (0.4) | — |
| Net profit/(loss) before share from equity-accounted companies | 646.3 | 548.9 |
| Non-cash and non-operating items: | | |
| - Depreciation, amortization, provisions | 237.0 | 234.7 |
| - Impairment losses included in operating income and net financial income | 9.1 | 153.9 |
| - Change in fair value of financial derivatives | 0.8 | (5.0) |
| - Net gains or losses on disposals of non-current assets | 5.8 | (5.7) |
| - Unrealized foreign exchange differences | 1.1 | 4.6 |
| - Change in deferred taxes | 16.2 | (136.3) |
| - Share-based payment expense | 28.7 | 22.5 |
| - Other non-cash items | (3.6) | (36.3) |
| Cash flow from operating activities before changes in working capital requirement | 941.4 | 781.4 |
| - (Increase)/decrease in inventories | (0.5) | (7.1) |
| - (Increase)/decrease in trade receivables | (67.3) | 56.3 |
| - Increase/(decrease) in trade payables | 83.5 | 4.5 |
| - Net change in income tax liability | (32.8) | (66.9) |
| - Net change in other operating assets and liabilities | (15.1) | 3.0 |
| Change in working capital requirement related to operating activities | (32.2) | (10.1) |
| NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES | 909.2 | 771.3 |
| Acquisition of property, plant & equipment | (96.0) | (81.4) |
| Acquisition of intangible assets | (331.7) | (59.3) |
| Proceeds from disposal of intangible assets and property, plant & equipment | 1.1 | 15.0 |
| Acquisition of shares in non-consolidated companies | (28.4) | (5.9) |
| Payments to post-employment benefit plans | (2.5) | (2.3) |
| Impact of changes in the consolidation scope | 14.7 | — |
| Change in working capital related to investment activities | 96.1 | (29.8) |
| Other cash flow related to investment activities | 2.4 | — |
| NET CASH PROVIDED (USED) BY INVESTMENT ACTIVITIES | (344.2) | (163.7) |
| Additional long-term borrowings | 30.8 | 11.8 |
| Repayment of long-term borrowings | (0.9) | (0.9) |
| Net change in short-term borrowings | (310.6) | (194.9) |
| Capital increase | — | — |
| Treasury shares | (36.7) | (36.4) |
| Distributions paid by Ipsen S.A. | (82.9) | (83.2) |
| Dividends paid by subsidiaries to non-controlling interests | (0.2) | (0.3) |
| Change in working capital related to financing activities | (0.7) | (3.6) |
| NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES | (401.2) | (307.5) |
| CHANGE IN CASH AND CASH EQUIVALENTS | 163.7 | 300.1 |
| OPENING CASH AND CASH EQUIVALENTS | 639.6 | 339.0 |
| Impact of exchange rate fluctuations | 5.8 | 0.5 |
| CLOSING CASH AND CASH EQUIVALENTS | 809.1 | 639.6 |



Appendix 3.2 – Consolidated net cash flow statement

| (in millions of euros) | 2021 | 2020 |
|--|----------------|----------------|
| Opening net cash / (debt) | (525.3) | (1,115.6) |
| CORE OPERATING INCOME | 1,011.3 | 829.3 |
| Non-cash items | 157.0 | 132.7 |
| (Increase) /decrease in inventories | (0.5) | (7.1) |
| (Increase) / decrease in trade receivables | (67.3) | 56.3 |
| Increase / (decrease) in trade payables | 83.5 | 4.5 |
| Change in operating working capital requirement | 15.7 | 53.8 |
| Change in income tax liability | (32.8) | (66.9) |
| Change in other operating assets and liabilities (excluding milestones received) | 19.7 | 11.4 |
| Other changes in working capital requirement | (13.1) | (55.6) |
| Acquisition of property, plant & equipment | (96.0) | (81.4) |
| Acquisition of intangible assets (excluding milestones paid) | (31.5) | (26.6) |
| Disposal of fixed assets | (0.1) | — |
| Change in working capital related to investment activities | 6.5 | (9.9) |
| Net capital expenditures (excluding milestones paid) | (121.0) | (117.9) |
| Operating Cash Flow | 1,049.8 | 842.3 |
| Other non-core operating income and expenses and restructuring costs | (63.6) | (41.3) |
| Financial income | (28.6) | (43.3) |
| Current income tax | (150.4) | (118.4) |
| Other operating cash flow | 0.1 | 7.2 |
| Free Cash Flow | 807.4 | 646.4 |
| Distributions paid (including payout to non-controlling interests) | (83.1) | (83.5) |
| Acquisition of shares in non-consolidated companies ⁽¹⁾ | (10.6) | (6.4) |
| Acquisition of other financial assets | — | — |
| Impact of changes in consolidation scope ⁽²⁾ | 13.7 | — |
| Milestones paid ⁽³⁾ | (260.3) | (52.1) |
| Milestones received ⁽⁴⁾ | 25.2 | 2.7 |
| Other Business Development operations | 11.5 | 16.8 |
| Net investments (Business Development and milestones) | (220.5) | (39.0) |
| Share buyback | (36.7) | (36.4) |
| FX on net indebtedness and change in earn out | (68.3) | 101.2 |
| Other | — | 1.6 |
| Shareholders return and external growth operations | (408.6) | (56.1) |
| CHANGE IN NET CASH / (DEBT) | 398.8 | 590.4 |
| Closing net cash / (debt) | (126.4) | (525.3) |

(1) Acquisition of shares in non-consolidated companies mainly reflected investments in external innovation funds.

(2) In 2021, impact of change in consolidation scope includes the proceeds from the divestiture in equity-accounted companies for €24.0 million and the purchase of an equity investment in Bakx Therapeutics Inc. for €10.3 million.

(3) Milestones paid in 2021 correspond to payments subject to the terms and conditions set out in the Group's partnership agreements including €148 million related to the partnership with GENFIT and €51.3 million milestones paid to Exelixis.
Milestones paid in 2020 correspond to payments subject to the terms and conditions set out in the Group's partnership agreements including €24.1 million milestones paid to Exelixis and €17.6 million milestone paid to Blueprint Medicines Corporation.

(4) Milestones received in 2021 include Onivyde's commercial milestones for €20.8 million.

■ 3.1.4.4 Appendix 4 – Bridges from IFRS consolidated net profit to Core consolidated net profit

| (in millions of euros) | IFRS | | | | | | CORE |
|--|----------------|---|------------------------------------|---------------|-------------------|---------------|----------------|
| | 2021 | Amortization of intangible assets (excl software) | Other operating income or expenses | Restructuring | Impairment losses | Other | 2021 |
| Sales | 2,868.9 | — | — | — | — | — | 2,868.9 |
| Other revenues | 130.2 | — | — | — | — | — | 130.2 |
| Revenue | 2,999.1 | — | — | — | — | — | 2,999.1 |
| Cost of goods sold | (538.0) | — | — | — | — | — | (538.0) |
| Selling expenses | (835.7) | — | — | — | — | — | (835.7) |
| Research and development expenses | (428.4) | — | — | — | — | — | (428.4) |
| General and administrative expenses | (199.6) | — | — | — | — | — | (199.6) |
| Other operating income | 53.1 | — | (39.2) | — | — | — | 13.9 |
| Other operating expenses | (172.2) | 82.3 | 89.8 | — | — | — | (0.1) |
| Restructuring costs | (19.8) | — | — | 19.8 | — | — | — |
| Impairment losses | (9.1) | — | — | — | 9.1 | — | — |
| Operating Income | 849.5 | 82.3 | 50.6 | 19.8 | 9.1 | — | 1,011.3 |
| Net financing costs | (21.3) | — | — | — | — | — | (21.3) |
| Other financial income and expense | (13.6) | — | — | — | — | (0.7) | (14.3) |
| Income taxes | (168.2) | (20.5) | (14.1) | (5.0) | (2.6) | (7.4) | (217.9) |
| Share of profit/(loss) from equity-accounted companies | 0.4 | — | — | — | — | — | 0.4 |
| Net profit/(loss) from continuing operations | 646.7 | 61.7 | 36.5 | 14.7 | 6.5 | (8.1) | 758.1 |
| Net profit/(loss) from discontinued operations | — | — | — | — | — | — | — |
| Consolidated net profit | 646.7 | 61.7 | 36.5 | 14.7 | 6.5 | (8.1) | 758.1 |
| – Attributable to shareholders of Ipsen S.A. | 646.6 | 61.7 | 36.5 | 14.7 | 6.5 | (8.1) | 758.0 |
| – Attributable to non-controlling interests | 0.1 | — | — | — | — | — | 0.1 |
| Earnings per share fully diluted – attributable to Ipsen S.A. shareholders (in € per share) | 7.76 | 0.74 | 0.44 | 0.18 | 0.08 | (0.10) | 9.09 |

The reconciliation items between Core consolidated net profit and IFRS consolidated net profit are described in the paragraph “From Core financial measures to IFRS reported figures”.

| (in millions of euros) | IFRS | | | | | | CORE |
|--|----------------|---|------------------------------------|---------------|-------------------|----------------|----------------|
| | 2020 | Amortization of intangible assets (excl software) | Other operating income or expenses | Restructuring | Impairment losses | Other | 2020 |
| Sales | 2,591.6 | — | — | — | — | — | 2,591.6 |
| Other revenues | 94.5 | — | — | — | — | — | 94.5 |
| Revenue | 2,686.2 | — | — | — | — | — | 2,686.2 |
| Cost of goods sold | (490.6) | — | — | — | — | — | (490.6) |
| Selling expenses | (784.0) | — | — | — | — | — | (784.0) |
| Research and development expenses | (405.6) | — | — | — | — | — | (405.6) |
| General and administrative expenses | (187.8) | — | — | — | — | — | (187.8) |
| Other operating income ⁽¹⁾ | 34.0 | — | (22.2) | — | — | — | 11.8 |
| Other operating expenses | (127.9) | 86.5 | 40.8 | — | — | — | (0.6) |
| Restructuring costs | (45.6) | — | — | 45.6 | — | — | — |
| Impairment losses | (153.9) | — | — | — | 153.9 | — | — |
| Operating Income | 524.8 | 86.5 | 18.6 | 45.6 | 153.9 | — | 829.3 |
| Net financing costs | (24.7) | — | — | — | — | — | (24.7) |
| Other financial income and expense | 32.5 | — | — | — | — | (52.2) | (19.6) |
| Income taxes | 17.8 | (23.6) | (5.2) | (12.9) | (44.7) | (104.4) | (172.9) |
| Share of profit/(loss) from equity-accounted companies | (1.5) | — | — | — | — | — | (1.5) |
| Net profit/(loss) from continuing operations | 548.9 | 62.9 | 13.4 | 32.7 | 109.2 | (156.6) | 610.5 |
| Net profit/(loss) from discontinued operations ⁽¹⁾ | — | — | — | — | — | — | — |
| Consolidated net profit | 548.9 | 62.9 | 13.4 | 32.7 | 109.2 | (156.6) | 610.5 |
| – Attributable to shareholders of Ipsen S.A. | 548.0 | 62.9 | 13.4 | 32.7 | 109.2 | (156.6) | 609.6 |
| – Attributable to non-controlling interests | 0.9 | — | — | — | — | — | 0.9 |
| <i>Earnings per share fully diluted – attributable to Ipsen S.A. shareholders (in € per share)</i> | <i>6.57</i> | <i>0.75</i> | <i>0.16</i> | <i>0.39</i> | <i>1.31</i> | <i>(1.88)</i> | <i>7.31</i> |

(1) Proceeds received in 2020 from businesses sold before 2020 were reclassified from "Profit from discontinued operations" to the "Other operating income" line item for €3.8 million.

3.1.5 Subsequent events

Exclusive negotiations to divest the Consumer Healthcare business

Following the decision of its Board of Directors held on 10 February 2022, Ipsen has entered into exclusive negotiations with Mayoly Spindler for the divestment of its global CHC business. This is a major step forward in the Company's execution of its strategic roadmap presented in December 2020 towards building a more-focused Ipsen, centring on Specialty Care.

The combination of Ipsen's and Mayoly Spindler's respective CHC businesses will create a global consumer-healthcare platform with a critical size and the capacity to support its growth. The consideration for Ipsen's CHC business represents an enterprise value of €350m, including an earnout contingent payment of €50m.

The proposed transaction will be submitted to the relevant employee-representation bodies and is expected to close before the end of Q3 2022, subject to regulatory approvals and customary closing conditions.

Palovarotene

On 24 January 2022, Ipsen announced the Health Canada approval of Sohonos™ (palovarotene capsules) indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP). Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide.

3.1.6 Group outlook

2022 Financial guidance

Ipsen has set its financial guidance for FY 2022, excluding any contribution from the CHC business⁽⁵⁾:

- Total sales growth greater than 2.0%, at constant currency. Based on the level of exchange rates in January 2022, Ipsen anticipates an additional favorable impact of 2% from currencies
- Core Operating margin greater than 35% of total sales, excluding any potential impact of incremental investments from any future external-innovation transactions.

This guidance incorporates expectations for Somatuline of further launches of generic lanreotide in other countries in the EU, as well as increased competition in the U.S.

Ipsen proposes a dividend of €1.20 per share for the 2021 financial year, a 20% increase versus the prior year.

Mid-term 2020-2024 outlook

Ipsen has updated its outlook for 2020-24, to exclude any contribution from the CHC business⁽⁶⁾:

- Total Sales 2020-24 compound annual growth rate between +4% and +6% at constant currency and assuming risk-adjusted potential additional indications;
- Continued commitment to invest in R&D supported by SG&A efficiencies:

- reduced SG&A expenses as a percentage of total sales, driven by further focus and optimization;
- higher R&D expenses as a percentage of total sales, driven by the external-innovation strategy.

To support the external-innovation strategy, Ipsen anticipates cumulative remaining firepower of €3.5bn by 2024, including the divestment of the CHC business. The calculation is based on net debt at 2.0 x EBITDA.

The guidance has been established on historical financial information and scope in accordance with accounting methodology applied to the consolidated financial statements for the exercise 2021.

This guidance is taking into account:

- Local markets growth where Ipsen is present;
- Competition evolution in term of innovating products and Generics entrance;
- Regulatory evolution on pricing and other regulations related to the pharmaceutical sector;
- R&D programs advancement;
- Impact of the costs management policy and its evolution;
- Interest and exchange rates evolution.

This guidance is based on Ipsen management vision and could be evolve or be modified in the future.

⁽⁵⁾ Assuming presentation of the CHC business as discontinued operations starting in 2022 and comparing to the FY 2021 operating performance excluding the contribution from the CHC business.

⁽⁶⁾ Assuming presentation of the CHC business as discontinued operations starting in 2022 and comparing to the FY 2020 operating performance, excluding the contribution from the CHC business



3.1.7 Subsequent events following the Accounts Settlement Date of 31 December 2021

Due to the confirmed lack of statistical significance for the overall survival primary endpoint of the COSMIC-312 Phase III trial, together with the emerging potential of new advanced hepatocellular carcinoma (aHCC) combination treatments, Ipsen anticipates that very few patients would be eligible to receive the combination of Cabometyx and atezolizumab in Ipsen territories. In this scenario, the regulatory and access

environment would be particularly challenging, suggesting that limited benefits would be realized for patients and restricted business opportunities for Ipsen. Consequently, Ipsen took the decision in March 2022 not to proceed with regulatory submission for the combination of Cabometyx and atezolizumab in previously untreated aHCC.

3.2 CONSOLIDATED FINANCIAL STATEMENTS 2021

3.2.1 Consolidated income statement

| (in millions of euros) | Notes | 2021 | 2020 |
|---|----------------------|----------------|----------------|
| Sales | 4.2 & 4.3 | 2,868.9 | 2,591.6 |
| Other revenues | 4.4 | 130.2 | 94.5 |
| Revenue | | 2,999.1 | 2,686.2 |
| Cost of goods sold | | (538.0) | (490.6) |
| Selling expenses | | (835.7) | (784.0) |
| Research and development expenses | | (428.4) | (405.6) |
| General and administrative expenses | | (199.6) | (187.8) |
| Other operating income ⁽¹⁾ | 6 | 53.1 | 34.0 |
| Other operating expenses | 6 | (172.2) | (127.9) |
| Restructuring costs | 7 | (19.8) | (45.6) |
| Impairment losses | | (9.1) | (153.9) |
| Operating Income | | 849.5 | 524.8 |
| Investment income | 8 | 2.4 | 2.3 |
| Financing costs | 8 | (23.7) | (27.1) |
| Net financing costs | 8 | (21.3) | (24.7) |
| Other financial income and expenses | 8 | (13.6) | 32.5 |
| Income taxes | 9.1 | (168.2) | 17.8 |
| Share of net profit/(loss) from equity-accounted companies | 14 | 0.4 | (1.5) |
| Net profit/(loss) from continuing operations | | 646.7 | 548.9 |
| Net profit/(loss) from discontinued operations ⁽¹⁾ | | — | — |
| Consolidated net profit | | 646.7 | 548.9 |
| - Attributable to shareholders of Ipsen S.A. | | 646.6 | 548.0 |
| - Attributable to non-controlling interests | | 0.1 | 0.9 |
| Basic earnings per share, continuing operations (in euros) | 18.2 | 7.82 | 6.61 |
| Diluted earnings per share, continuing operations (in euros) | 18.2 | 7.76 | 6.57 |
| Basic earnings per share, discontinued operations (in euros) ⁽¹⁾ | 18.2 | — | — |
| Diluted earnings per share, discontinued operations (in euros) ⁽¹⁾ | 18.2 | — | — |
| Basic earnings per share (in euros) | 18.2 | 7.82 | 6.61 |
| Diluted earnings per share (in euros) | 18.2 | 7.76 | 6.57 |

(1) Proceeds received in 2020 from businesses sold before 2020 were reclassified from "Profit from discontinued operations" to the "Other operating income" line item for €3.8 million.

Comprehensive income statement

| (in millions of euros) | 2021 | 2020 |
|--|---------------|---------------|
| Consolidated net profit | 646.7 | 548.9 |
| Actuarial gains and (losses) on defined benefit plans, net of taxes | 5.5 | (1.7) |
| Financial assets at fair value through other items of comprehensive income (OCI), net of taxes | (15.8) | 7.3 |
| Other items of comprehensive income that will not be reclassified to the income statement | (10.2) | 5.7 |
| Revaluation of financial derivatives for hedging, net of taxes | (23.1) | 30.0 |
| Foreign exchange differences, net of taxes | 98.8 | (118.4) |
| Other items of comprehensive income likely to be reclassified to the income statement | 75.8 | (88.4) |
| Comprehensive income: consolidated net profit (loss) and gains and (losses) recognized directly in equity | 65.5 | (82.7) |
| Comprehensive income | 712.2 | 466.2 |
| - Attributable to shareholders of Ipsen S.A. | 711.9 | 465.3 |
| - Attributable to non-controlling interests | 0.3 | 1.0 |

3.2.2 Consolidated balance sheet before allocation of net profit

| (in millions of euros) | Notes | 31 December 2021 | 31 December 2020 ⁽¹⁾ |
|---|---------|------------------|---------------------------------|
| ASSETS | | | |
| Goodwill | 10 | 623.2 | 592.8 |
| Other intangible assets | 11 | 1,392.0 | 1,121.1 |
| Property, plant & equipment | 12 | 647.5 | 646.6 |
| Equity investments | 13 | 106.9 | 84.5 |
| Investments in equity-accounted companies | 14 | 26.2 | 19.1 |
| Non-current financial assets | 15 | 0.1 | 23.1 |
| Deferred tax assets | 9.2 | 253.1 | 243.2 |
| Other non-current assets | 15 | 4.3 | 3.8 |
| Total non-current assets | | 3,053.0 | 2,734.2 |
| Inventories | 16.1 | 219.4 | 213.9 |
| Trade receivables | 16.2 | 564.3 | 476.2 |
| Current tax assets | | 122.8 | 83.6 |
| Current financial assets | 16.4 | 54.1 | 48.9 |
| Other current assets | 16.4 | 178.6 | 113.7 |
| Cash and cash equivalents | 17 | 814.7 | 642.5 |
| Total current assets | | 1,953.8 | 1,578.8 |
| TOTAL ASSETS | | 5,006.8 | 4,313.0 |
| EQUITY AND LIABILITIES | | | |
| Share capital | 18.1 | 83.8 | 83.8 |
| Additional paid-in capital and consolidated reserves | | 1,983.9 | 1,558.9 |
| Net profit/(loss) for the period | | 646.6 | 548.0 |
| Foreign exchange differences | | 37.2 | (59.6) |
| Equity attributable to Ipsen S.A. shareholders | | 2,751.5 | 2,131.2 |
| Equity attributable to non-controlling interests | | 2.5 | 2.7 |
| Total shareholders' equity | | 2,754.0 | 2,133.8 |
| Retirement benefit obligation | 5.3.2.2 | 40.7 | 47.4 |
| Non-current provisions | 19 | 64.0 | 32.0 |
| Non-current financial liabilities | 20 | 772.2 | 761.6 |
| Deferred tax liabilities | 9.2 | 101.8 | 79.9 |
| Other non-current liabilities | 16.5 | 45.8 | 45.1 |
| Total non-current liabilities | | 1,024.4 | 966.0 |
| Current provisions | 19 | 41.6 | 45.7 |
| Current financial liabilities | 20 | 174.8 | 408.6 |
| Trade payables | 16.3 | 594.7 | 495.2 |
| Current tax liabilities | | 10.0 | 10.8 |
| Other current liabilities | 16.5 | 401.7 | 250.0 |
| Bank overdrafts | 17 | 5.5 | 2.8 |
| Total current liabilities | | 1,228.4 | 1,213.1 |
| TOTAL EQUITY & LIABILITIES | | 5,006.8 | 4,313.0 |

(1) The financial statements as of 31 December 2020 were restated with retroactive application of the IFRIC agenda decision on *Employee Benefits* starting on 1 January 2020 (see note 5.3.2.5).

3.2.3 Consolidated statement of cash flow

| (in millions of euros) | Notes | 2021 | 2020 |
|--|----------------|----------------|----------------|
| Consolidated net profit | | 646.7 | 548.9 |
| Share of net profit/(loss) from equity-accounted companies | 14 | (0.4) | — |
| Net profit/(loss) before share from equity-accounted companies | | 646.3 | 548.9 |
| Non-cash and non-operating items: | | | |
| - Depreciation, amortization, provisions | 11.1, 12.1, 19 | 237.0 | 234.7 |
| - Impairment losses | 11.2 | 9.1 | 153.9 |
| - Change in fair value of financial derivatives | | 0.8 | (5.0) |
| - Net gains or losses on disposals of non-current assets | | 5.8 | (5.7) |
| - Unrealized foreign exchange differences | | 1.1 | 4.6 |
| - Change in deferred taxes | 9.2 | 16.2 | (136.3) |
| - Share-based payment expense | | 28.7 | 22.5 |
| - Other non-cash items | 8 | (3.6) | (36.3) |
| Cash flow from operating activities before changes in working capital requirement | | 941.4 | 781.4 |
| - (Increase)/decrease in inventories | 16 | (0.5) | (7.1) |
| - (Increase)/decrease in trade receivables | 16 | (67.3) | 56.3 |
| - Increase/(decrease) in trade payables | 16 | 83.5 | 4.5 |
| - Net change in income tax liability | | (32.8) | (66.9) |
| - Net change in other operating assets and liabilities | 16 | (15.1) | 3.0 |
| Change in working capital requirement related to operating activities | | (32.2) | (10.1) |
| NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES | | 909.2 | 771.3 |
| Acquisition of property, plant & equipment | 12.1 | (96.0) | (81.4) |
| Acquisition of intangible assets | 11 | (331.7) | (59.3) |
| Proceeds from disposal of intangible assets and property, plant & equipment | | 1.1 | 15.0 |
| Acquisition of shares in non-consolidated companies | | (28.4) | (5.9) |
| Payments to post-employment benefit plans | | (2.5) | (2.3) |
| Impact of changes in the consolidation scope | | 14.7 | — |
| Change in working capital related to investment activities | 16 | 96.1 | (29.8) |
| Other cash flow related to investment activities | | 2.4 | — |
| NET CASH PROVIDED (USED) BY INVESTMENT ACTIVITIES | | (344.2) | (163.7) |
| Additional long-term borrowings | 20 | 30.8 | 11.8 |
| Repayment of long-term borrowings | 20 | (0.9) | (0.9) |
| Net change in short-term borrowings | 20 | (310.6) | (194.9) |
| Capital increase | | — | — |
| Treasury shares | | (36.7) | (36.4) |
| Distributions | 18.3 | (82.9) | (83.2) |
| Dividends paid by subsidiaries to non-controlling interests | | (0.2) | (0.3) |
| Change in working capital related to financing activities | | (0.7) | (3.6) |
| NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES | | (401.2) | (307.5) |
| CHANGE IN CASH AND CASH EQUIVALENTS | | 163.7 | 300.1 |
| OPENING CASH AND CASH EQUIVALENTS | 17 | 639.6 | 339.0 |
| Impact of exchange rate fluctuations | | 5.8 | 0.5 |
| CLOSING CASH AND CASH EQUIVALENTS | 17 | 809.1 | 639.6 |

3.2.4 Statement of change in consolidated shareholders' equity

| (in millions of euros) | Share capital | Share premiums or contributions | Consolidated reserves ⁽²⁾ | Foreign exchange differences | Reserves related to retirement benefit obligations | Cash flow hedge reserves | Treasury shares | Net profit/(loss) for the period | Total Group equity | Equity attributable to non-controlling interests | Total equity |
|--|---------------|---------------------------------|--------------------------------------|------------------------------|--|--------------------------|-----------------|----------------------------------|--------------------|--|--------------|
| Balance at 01 January 2021 | 83.8 | 122.3 | 1,547.6 | (59.6) | (34.4) | 25.5 | (102.1) | 548.0 | 2,131.2 | 2.7 | 2,133.8 |
| Consolidated net profit/(loss) for the period | — | — | — | — | — | — | — | 646.6 | 646.6 | 0.1 | 646.7 |
| Gains and (losses) recognized directly in equity ⁽¹⁾ | — | — | (15.8) | 98.6 | 5.5 | (23.1) | — | — | 65.3 | 0.2 | 65.5 |
| Consolidated net profit/(loss) and gains and losses recognized directly in equity | — | — | (15.8) | 98.6 | 5.5 | (23.1) | — | 646.6 | 711.9 | 0.3 | 712.2 |
| Allocation of net profit (loss) from the prior period | — | — | 549.0 | (1.0) | — | — | — | (548.0) | — | — | — |
| Capital increases/(decreases) | — | — | — | — | — | — | — | — | — | — | — |
| Share-based payments | — | — | 13.0 | — | — | — | 21.8 | — | 34.8 | — | 34.8 |
| Own share purchases and disposals | — | — | — | — | — | — | (42.8) | — | (42.8) | — | (42.8) |
| Distributions | — | — | (82.9) | — | — | — | — | — | (82.9) | (0.2) | (83.1) |
| Change of consolidation scope | — | — | (5.5) | — | 5.8 | — | — | — | 0.3 | (0.3) | — |
| Other changes | — | — | — | (0.8) | (0.1) | — | — | — | (0.9) | (0.1) | (1.0) |
| Balance at 31 December 2021 | 83.8 | 122.3 | 2,005.4 | 37.2 | (23.2) | 2.4 | (123.1) | 646.6 | 2,751.5 | 2.5 | 2,754.0 |

(1) Detailed items in the note "Comprehensive income statement".

(2) The main sources of consolidated reserves were as follows:

- Reserves on financial assets at fair value through other items of comprehensive income;
- Retained earnings.

| (in millions of euros) | Share capital | Share premiums or contributions | Consolidated reserves ⁽²⁾ | Foreign exchange differences | Reserves related to retirement benefit obligations | Cash flow hedge reserves | Treasury shares | Net profit/(loss) for the period | Total Group equity | Equity attributable to non-controlling interests | Total equity |
|--|---------------|---------------------------------|--------------------------------------|------------------------------|--|--------------------------|-----------------|----------------------------------|--------------------|--|--------------|
| Balance at 31 December 2019 | 83.8 | 741.9 | 1,024.0 | 61.8 | (32.8) | (4.5) | (72.5) | (50.7) | 1,751.0 | 2.0 | 1,753.1 |
| Application of IFRIC's decision related to IAS19 Employee benefits ⁽⁴⁾ | 0.0 | 0.0 | 12.1 | — | 0.0 | 0.0 | 0.0 | 0.0 | 12.1 | 0.0 | 12.1 |
| Balance at 01 January 2020 | 83.8 | 741.9 | 1,036.1 | 61.8 | (32.8) | (4.5) | (72.5) | (50.7) | 1,763.1 | 2.0 | 1,765.2 |
| Consolidated net profit/(loss) for the period | — | — | — | — | — | — | — | 548.0 | 548.0 | 0.9 | 548.9 |
| Gains and (losses) recognized directly in equity ⁽¹⁾ | — | — | 7.3 | (118.4) | (1.7) | 30.0 | — | — | (82.7) | — | (82.7) |
| Consolidated net profit/(loss) and gains and losses recognized directly in equity | — | — | 7.3 | (118.4) | (1.7) | 30.0 | — | 548.0 | 465.3 | 1.0 | 466.2 |
| Allocation of net profit (loss) from the prior period ⁽³⁾ | — | (536.4) | 485.7 | — | — | — | — | 50.7 | — | — | — |
| Capital increases/(decreases) | — | — | — | — | — | — | — | — | — | — | — |
| Share-based payments | — | — | 15.1 | — | — | — | 7.4 | — | 22.5 | — | 22.5 |
| Own share purchases and disposals | — | — | — | — | — | — | (37.0) | — | (37.0) | — | (37.0) |
| Distributions | — | (83.2) | — | — | — | — | — | — | (83.2) | (0.3) | (83.5) |
| Other changes | — | — | 3.5 | (3.0) | — | — | — | — | 0.5 | — | 0.5 |
| Balance at 31 December 2020 | 83.8 | 122.3 | 1,547.6 | (59.6) | (34.4) | 25.5 | (102.1) | 548.0 | 2,131.2 | 2.7 | 2,133.8 |

(1) Detailed in the note "Comprehensive income statement".

(2) The main sources of consolidated reserves were as follows:

- Reserves on financial assets at fair value through other comprehensive income;
- Retained earnings.

(3) On 29 May 2020, Ipsen S.A.'s Shareholders' Meeting voted to allocate 2019 earnings, particularly by allocating share premiums and contributions as follows:

- Allocating the loss to the Share contributions line item for an amount of €29,809,299.76;
- Allocating the loss to the Share premiums line item for an amount of €506,522,631.95.

(4) The financial statements as of 31 December 2021 were prepared with application of the IFRIC agenda decision on IAS 19 – *Employee Benefits* starting on 1 January 2020 (see note 5.3 of the Notes to the Consolidated Financial Statements for the year ended 31 December 2021).



3.2.5 Notes

Introduction

- Ipsen is a global biopharmaceutical group focused on innovation and Specialty Care.
- Its registered office is 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France.
- These notes form an integral part of Ipsen Group's consolidated financial statements (hereafter the "consolidated financial statements").
- All amounts are expressed in millions of euros unless otherwise specified.
- The consolidated financial statements are closed on 31 December every year. Individual statements included in the consolidated financial statements are prepared on the closing date of the consolidated financial statements, 31 December, and cover the same period.
- The Group's Board of Directors approved the consolidated financial statements on 10 February 2022. They will be submitted to the Shareholders' Meeting for approval on 24 May 2022.

| | | |
|----------------|---|------------|
| Note 1 | Significant events and transactions during the period that had an impact on the consolidated financial statements as of 31 December 2021 | 73 |
| Note 2 | Changes in the scope of consolidation | 74 |
| Note 3 | Accounting principles and methods, and compliance statement | 74 |
| Note 4 | Operating segments | 84 |
| Note 5 | Personnel | 87 |
| Note 6 | Other operating income and expenses | 92 |
| Note 7 | Restructuring costs | 92 |
| Note 8 | Net financial income (expense) | 92 |
| Note 9 | Income taxes | 93 |
| Note 10 | Goodwill | 95 |
| Note 11 | Other intangible assets | 96 |
| Note 12 | Property, plant & equipment | 98 |
| Note 13 | Equity investments | 99 |
| Note 14 | Investments in equity-accounted companies | 100 |
| Note 15 | Non-current financial assets and other non-current assets | 100 |
| Note 16 | Current assets and liabilities | 101 |
| Note 17 | Cash and cash equivalents | 102 |
| Note 18 | Consolidated shareholders' equity | 103 |
| Note 19 | Provisions | 104 |
| Note 20 | Bank loans and financial liabilities | 105 |
| Note 21 | Financial instruments | 106 |
| Note 22 | Financial instruments reported in the balance sheet | 108 |
| Note 23 | Information on related parties | 109 |
| Note 24 | Commitments and contingent liabilities | 111 |
| Note 25 | Subsequent events with no impact on the consolidated financial statements as of 31 December 2021 | 113 |
| Note 26 | Consolidation Scope | 113 |
| Note 27 | Fees paid to the Statutory Auditors | 115 |

Note 1 Significant events and transactions during the period that had an impact on the consolidated financial statements as of 31 December 2021

■ 1.1 New collaboration and license agreements signed in 2021

On 11 May 2021, Ipsen opted in to join Exelixis to develop Cabometyx for patients living with a form of thyroid cancer, based on promising results of the pivotal interim Phase III COSMIC-311 clinical trial.

On 15 July 2021, Ipsen and Irlab entered into an exclusive worldwide licensing agreement to improve the everyday lives of people living with Parkinson's disease. Ipsen obtained exclusive worldwide rights to develop and market mesdopetam, an experimental treatment based on a novel mechanism of action. Under the agreement, Ipsen paid an upfront payment of \$28 million—including development, regulatory and commercial milestones payments—the total amount could go up to \$363 million.

On 27 July 2021, Ipsen added to its clinical trial Oncology pipeline through an exclusive worldwide collaboration with BAKX Therapeutics Inc. for BKX-001, a small-molecule targeting the apoptosis pathway. Ipsen paid US \$14.5 million upon closing, comprising an equity investment and an upfront payment, followed by up to U.S. \$837.5 million in milestone payments

On 2 August 2021, Ipsen launched an exclusive collaboration with Exicure targeting rare neurodegenerative disorders by obtaining an exclusive license for Spherical Nucleic Acids (SNAs™) currently under evaluation for Huntington's disease and Angelman syndrome. Exicure received a U.S. \$20 million upfront payment for this option.

On 18 October 2021, Ipsen added another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3. This collaboration with Accent Therapeutics rounds out the partnerships Ipsen recently announced and builds on Ipsen's expansion into hematological malignancies, with a focus on acute myeloid leukemia. Under the agreement, Ipsen paid an upfront payment of U.S. \$12.5 million. Including pre-clinical, clinical, regulatory, and sales-based milestone payments, the total amount could go up to U.S. \$446 million.

On 17 December 2021, Ipsen and GENFIT entered into an exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership. The agreement gives Ipsen global rights to develop and market elafibranor, GENFIT's first-in-class PPAR alpha and delta agonist drug candidate, elafibranor, to treat Primary Biliary Cholangitis (PBC).

Ipsen paid an upfront cash payment of €120 million. Regulatory, commercial, and sales-based milestone payments could go up to €360 million. Ipsen also became a shareholder of GENFIT through the purchase of 8% of GENFIT S.A after issuance, *via* a €28 million investment.

■ 1.2 Palovarotene

On 28 May 2021, Ipsen announced that the U.S. Food and Drug Administration (U.S. FDA) approved its new drug application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP).

On 13 August 2021, Ipsen announced it withdrew its new drug application for palovarotene, and confirmed it intends to re-submit it following additional data analyses. The Group made this decision following discussions with the U.S. FDA as part of their review of the new drug application for palovarotene which began in May 2021.

Upon successful completion of the additional data analyses, Ipsen currently anticipates regulatory resubmission in the U.S. during H1 2022. A 'clock-stop' was also granted by the European Medicines Agency.

■ 1.3 Disposal of some entities co-owned with Schwabe group

On 30 April 2021, the Group signed an agreement to sell the stake it held in several entities it co-owned with Schwabe group. The sale totaled €32.0 million. The gain on disposal had no material impact within the Group.

■ 1.4 Strategic review of the Consumer Healthcare Business

A strategic review of the Consumer Healthcare business (CHC), which was declared as non-core in December 2020, was conducted during the course of 2021 to define the most optimal setup to maximize its value. A process was launched in the second half of 2021 to assess a potential divestiture of the CHC business.

As of December 31, 2021, the management did not consider the sale as highly probable within 12 months. Therefore, the CHC business has not been presented as discontinued operations, in 2021 Financial Statements in accordance with IFRS 5.



Note 2 Changes in the scope of consolidation

■ 2.1 2021

In 2021, the Group created the following subsidiaries: Ipsen Consumer Healthcare LLC (Russia), IPSEN K.K. (Japan), which are wholly-owned and fully consolidated into the scope of consolidation, as well as Sullypharm S.A.S. (France) and Ipsen Colombia S.A.S., which have not been consolidated into the scope of consolidation as of 31 December 2021, considering they are non-material.

On 22 December 2021, Beaufour Ipsen (Tianjin) Pharmaceutical Co. (China) sold its 100% stake in Ipsen (Tianjin) Pharmaceutical Trade Co. (China) to Ipsen Pharma S.A.S., increasing the Group's stake in Ipsen (Tianjin) Pharmaceutical Trade Co. (China) from 96% to 100%, without changing control.

On 27 July 2021, Ipsen purchased an interest in Bakx Therapeutics, Inc., 14.9% of which is consolidated into the scope of consolidation. As of 31 December 2021, 13.7% of the entity is consolidated using the equity method.

On 30 April 2021, Ipsen finalized the sale of its stake in the following entities: Garnay Inc., Cara Partners, Perechin

Company, Portpirie Company, Wallingstown Company, Wallingstown Company Limited and Saint-Jean d'Ilac S.C.A.. Ipsen recognized its stake in these entities using the equity method until 30 April 2021, except for Saint-Jean d'Ilac S.C.A., which was removed from the scope of consolidation on 31 July 2021.

■ 2.2 2020

In 2020, the Group created the wholly-owned subsidiary Ipsen Shanghai Innovation Pharmaceutical Co. Ltd. The Group used the full consolidation method to include it into the scope of consolidation.

The Group also created two new subsidiaries in France: Naripharm S.A.S. and Leripharm S.A.S. As of 31 December 2020, these new entities were not included in the scope of consolidation given their non-material impact.

On 9 September 2020, Ipsen S.A. absorbed company 11188291 Canada Inc. after it was dissolved. Consequently, 11188291 Canada Inc. no longer part of the scope of consolidation as of 31 December 2020.

Note 3 Accounting principles and methods, and compliance statement

■ 3.1 General principles and compliance statement

The main accounting methods used to prepare the consolidated financial statements are described below. Unless otherwise stated, these methods were used consistently for all financial years presented.

In compliance with European regulation n° 1606 / 2002 adopted on 19 July 2002 by the European Parliament and the European Council, the Group's consolidated financial statements for 2021 were prepared in accordance with International Financial Reporting Standards (IFRS) as endorsed by the European Union as of the date the Group prepared these consolidated financial statements. The IFRS as endorsed by the European Union differ in certain aspects from the IFRS published by the IASB. Nevertheless, the Group has verified that the financial information for the periods presented would not have been substantially different if it had applied IFRS as published by the IASB.

International accounting standards include International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), as well as the interpretations issued by the Standing Interpretations Committee (SIC), and the International Financial Reporting Standards Interpretations Committee (IFRS IC).

All the standards adopted by the European Union are available on the European Commission's website: https://ec.europa.eu/info/business-economy-euro/company-reporting-and-auditing/company-reporting/financial-reporting_en#ifrs-endorsement-process.

■ 3.2 Standards and interpretations that entered into force as of 1 January 2021

The mandatory standards, amendments and interpretations published by the IASB and applicable as of the 2021 financial year are listed below:

- Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4, and IFRS 16 – *Phase 2 of Interest Rate Benchmark Reform*
- Amendments to IFRS 4 – *Insurance Contracts: Extension of the Temporary Exemption from Applying IFRS 9 – Financial Instruments*
- Amendments to IFRS 16 – *Leases - COVID-19-Related Rent Concessions beyond 30 June 2021*

A review of legislation that entered into force as of 1 January 2021 or as of 1 April 2021 pertaining to the amendment to IFRS 16 showed that their application had a non-material impact on the Group's financial statements. Details are presented below.

3.2.1 Application of amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 – *Phase 2 of Interest Rate Benchmark Reform*

Ipsen reviewed contracts affected by the change in interest rate benchmarks and concluded that contracts did not suffer a material change in effective interest rate.

3.2.2 Application of amendments to IFRS 4 – *Insurance Contracts: Extension of the Temporary Exemption from Applying IFRS 9 – Financial Instruments*

These amendments did not have an impact on the Group's consolidated financial statements for financial year ended 31 December 2021.

3.2.3 IFRIC decision on attributing retirement benefits based on length of service

The IFRIC's agenda decision in May 2021 led the Group to review how it calculates retirement benefits for certain retirement plans:

- plans where you have to be employed at the company when you retire to receive the benefits (and all benefits are lost if you leave early);
- plans where benefits depend on seniority, but are capped starting at a certain number of years seniority. The ceiling usually applies before the retirement date.

The IFRIC believes that provided that no benefits are granted for employees who leave before retirement age, and benefits are capped after a certain number of years at the company (N), employees will receive the last (N) number of years worth of retirement benefits upon retirement.

This change in method resulted in a €16.3 million reduction in the retirement benefits provision and a €12.1 million net tax effect on the Group's shareholders' equity as of 1 January 2020.

3.2.4 IFRIC decision on Configuration or Customization Costs in a Cloud Computing Arrangement

The IFRIC's agenda decision in April 2021 led the Group to review how it recognizes the Configuration or Customization Costs in a Cloud Computing Arrangement. The Group is still reviewing the potential impact of this decision that will be finalized in the course of the half year.

The potential changes resulting from this decision will be recognized retrospectively, according to IAS 8.

■ 3.3 Standards, amendments and interpretations endorsed by the European Union and not adopted early by the Group

The Group did not opt for early adoption of the standards, amendments and interpretations endorsed by the European Union for which the application was not mandatory on 1 January 2021, namely:

- Amendments to IFRS 16 – *Property, Plant and Equipment – Proceeds before Intended Use*
- Amendments to IAS 37 – *Provisions, Contingent Liabilities, and Contingent Assets – Onerous Contracts – Cost of Fulfilling a Contract*
- Amendments to IFRS 3 – *Business Combinations – Reference to the Conceptual Framework*
- IFRS 17 – *Insurance Contracts and amendments to IFRS 17*
- Annual improvements for the 2018-2020 cycle

The Group was still reviewing these standards, amendments, and interpretations as of the date these consolidated financial statements were approved.

■ 3.4 Standards, amendments and interpretations published but not yet endorsed by the European Union

3.4.1 IASB publications not yet endorsed by the European Union

Standards, amendments and interpretations published but not yet endorsed by the European Union are listed below:

- Amendments to IAS 1 – *Presentation of the Financial Statements – Classification of Liabilities as Current or Non-Current*
- Amendments to IAS 1 – *Presentation of the Financial Statements – Disclosure of Accounting Policies*
- IAS 8 – *Accounting Policies – Definition of Accounting Estimates*
- IAS 12 – *Income Taxes – Deferred tax related to assets and liabilities arising from a single transaction*
- IFRS 17 – *Insurance Contracts – Initial Application of IFRS 17 and IFRS 9 – Comparative Information*

The Group was still reviewing the impacts of these standards and/or amendments as of the date these consolidated financial statements were approved.

3.4.2 IASB Publications following the closing date

No standard or interpretation was published by the IASB since the closing date or up to the date these consolidated financial statements were approved.

■ 3.5 Measurement bases used to prepare the consolidated financial statements

The consolidated financial statements were prepared using the historical cost principle, except for certain asset and liability classes, in accordance with IFRS. The related classes are described in the notes below.

■ 3.6 Use of estimates

Preparing financial statements in accordance with international financial reporting standards requires Group management to make estimates and use certain assumptions that are likely to impact the carrying value of assets and liabilities, shareholders' equity, income and expense items, and information provided in the notes to the financial statements.

Management has regularly made these estimates and assumptions based on its past experience and other factors deemed reasonable. Changing assumptions, in particular as a result of the economic or financial environment, which could weaken some of the Group's partners and make it difficult to estimate future outlook, could ultimately lead to different amounts.

The estimates were made based on information available at the closing date, after taking into account subsequent events.

The main material estimates made by management concern changes to employee benefits (see note 5), any impairment of goodwill (see note 10) or intangible assets (see note 11), deferred tax asset assessments (see note 10), and provisions (see note 19).

■ 3.7 Consolidation methods

Subsidiaries controlled by the Group are fully consolidated.

Companies controlled jointly with one or several outside partners are either consolidated as a joint venture using the equity method, or as a joint operation, whereby Ipsen recognizes its assets and liabilities proportionally to its rights and obligations in the arrangement, in accordance with IFRS 11.

An associated company is an entity in which the Group has significant influence over the entity's financial and operating policy decisions but without control or joint control. A joint venture is an arrangement in which the Group has joint control and rights over the arrangement's net assets but no direct rights on its assets or obligations arising from its liabilities.

Companies over which the Group exercises significant influence are consolidated using the equity method.

If the accounting methods used by subsidiaries, joint operations, joint ventures, and equity-accounted companies do not comply with those used by the Group, all necessary changes are made to ensure that the financial statements of those companies are compatible with the Group's accounting principles. Transactions between consolidated companies and intra-group results are eliminated.

Investments in companies that are not consolidated are recognized as equity investments.

■ 3.8 Business combinations

Business combinations are accounted for using the purchase method. The cost of an acquisition is based on the fair value of the assets acquired, equity instruments issued, and liabilities incurred or assumed from the previous owners on the acquisition date. The costs directly attributable to the combination are accounted for as "Other operating expenses" in the period they are incurred.

When an exclusively controlled company is consolidated for the first time, identifiable assets and liabilities are valued at their fair value, apart from exceptions specifically provided for in IFRS 3 – *Business Combinations*.

Goodwill recorded in the consolidated balance sheet is the difference between:

- the total amount of the following items:
 - the acquisition cost on the date when control is obtained;
 - the total non-controlling interests in the acquired company determined either at fair value on the acquisition date (full goodwill method), or based on their share in the fair value of the identifiable net assets acquired and liabilities assumed (partial goodwill method). The Group reviews this option on a transaction-by-transaction basis;
 - for business combinations achieved in stages, the fair value of the share held by the Group on the acquisition date, but before the date when control is obtained;
 - and the estimated impact of any adjustments in the acquisition cost, such as earnouts. These contingent earnouts are measured by applying the criteria set out in the purchase agreement, such as sales and earnings targets, to forecasts deemed to be highly probable. The contingent earnouts are then re-measured at each closing date, with any changes recognized on the income

statement after the acquisition date (including the one-year period following the acquisition date, as long as they do not result from existing facts and circumstances as of the transaction date). They are discounted over their useful life if the impact is material. Any discounting adjustments to the carrying amount of the liability are recognized in *Other financial income and expenses*;

- and the net amount of identifiable assets acquired and identifiable liabilities assumed, measured at their fair value as of the acquisition date.

If the values of the assets and liabilities are recognized on a provisional basis, adjustments resulting from facts and circumstances existing as of the transaction date and made within one year of the acquisition date, are adjusted and recognized retrospectively, in accordance with IFRS 3 – *Business Combinations*.

After initial recognition, goodwill is tested for impairment once a year and whenever there is an indication that it may be impaired (see note 3.15).

For equity-accounted companies, goodwill is included in the amount invested in the equity-accounted company. The costs directly related to the combination are included in the measurement of the investment acquisition price.

When the acquisition price is below the fair value of the Group's share in the identifiable assets acquired and liabilities assumed from the acquired subsidiary, the difference is recognized directly in revenue on the income statement.

■ 3.9 Operating segments

In accordance with IFRS 8 – *Operating Segments*, reported segment information is built based on management data the "chief operating decision maker", i.e. the Executive Leadership Team, uses to analyze business performance and allocate resources.

The Group's two operating segments are Specialty Care and Consumer Healthcare. Only general and administrative expenses and the impact of cash flow hedges are not allocated to the two operating segments.

The Group uses Core operating income to measure its segment performance. Core operating income is the internally used indicator to measure operating performance and to allocate resources.

Core operating income excludes amortization expenses for intangible assets (excluding software), restructuring costs, impairment losses on intangible assets and property, plant and equipment, as well as other items arising from significant events that could distort the reading of the Group's performance from one year to another. The reconciliation of Core operating income and operating income is presented in note 4.1.

These performance indicators do not replace IFRS indicators and should not be viewed as doing so. The Group uses them in addition to IFRS indicators. Although used by the Executive Leadership Team as important factors for setting targets and measuring the Group's performance, these indicators are not required nor defined by IFRS.

As internal performance measures, these operational indicators have limitations. As a result, the Group uses additional benchmarks to manage performance.

■ 3.10 Translation of financial statements in foreign currencies

The Group's consolidated financial statements are denominated in euros. In accordance with IAS 21, the assets and liabilities of subsidiaries whose functional currency is not the euro are translated at the exchange rates prevailing on the closing date. No Group entity operates in a hyper-inflationary economy. Their income statements and the items in their cash flow statement are translated at the average rate for the year, which comes close to the prevailing exchange rate as of the date of the different transactions, as long as there are no significant fluctuations.

Exchange differences from translating balance sheets and income statements are recorded under the "Cumulative translation reserves" line item, which forms an integral part of shareholders' equity, and under "Non-controlling interests" for the share attributable to third parties. These differences arise from:

- any difference between the exchange rates used for the opening and closing balance sheets found when translating balance sheet items;
- any difference between the year's average rate and closing rate.

Goodwill and fair value adjustments arising when a foreign entity is acquired are treated as the foreign entity's assets and liabilities. As such, they are expressed in the entity's functional currency and translated at the exchange rate prevailing on the closing date.

During consolidation, exchange differences due to the translation of net investments in businesses abroad and of loans and other exchange instruments designated as hedging instruments for these investments are recognized in equity. When a foreign entity is disposed of, these translation differences, initially recognized as equity, are recorded in profits or losses on disposals.

■ 3.11 Translation of receivables, payables, transactions, and flows denominated in foreign currencies

Receivables and payables denominated in foreign currencies are initially translated at the exchange rates prevailing on the transaction date and then revalued at the closing rates prevailing on the reporting date.

Exchange differences on monetary assets denominated in foreign currencies are recognized in the income statement.

Exchange differences arising from eliminating foreign currency transactions between fully consolidated companies are recorded in cumulative translation reserves under shareholders' equity and under non-controlling interests for the share attributable to third parties, to eliminate their impact on consolidated results. Exchange differences arising from foreign currency cash flow movements between fully-consolidated companies are accounted for under a separate line item in the consolidated statement of cash flows.

■ 3.12 Other intangible assets (excluding goodwill)

"Other intangible assets" are accounted for at acquisition price or fair value for business combinations, less cumulative amortization and any impairment losses.

Impairment related to intangible assets is presented with property, plant and equipment impairment and goodwill on a separate line item on the income statement.

The gains and losses on asset disposals are determined by comparing the disposal value with the carrying value of the disposed asset.

3.12.1 Assets with a finite useful life

An asset's useful life is the period of time the Group expects to use that asset. Intangible assets with a defined useful life are amortized over a period corresponding to useful lives estimated by the Group. Amortization periods are determined on a case-by-case basis depending on the type of asset concerned. Rights on products marketed by the Group are amortized on a straight-line basis for the duration of their useful lives. Useful life is determined based on cash flow forecasts that take into account the underlying patent-protection period, among other factors. Acquired patents are recognized as intangible assets at acquisition price, or at fair value for business combinations.

Identified rights regarding intellectual property are amortized on a straight-line basis over their estimated useful lives, which in practice is between 8 and 20 years. These useful life periods vary depending on cash flow forecasts, which are based on the underlying patent-protection period.

The development costs of software developed internally are identified as intangible assets as soon as they comply with the criteria defined in IAS 38 – *Intangible Assets*. Such expenses include mainly the salaries of personnel involved in the project and third party consulting fees. They are amortized on a straight-line basis over the duration of their useful lives.

Software and application licenses acquired under a SaaS distribution model (Software as a Service) are recognized in the Income Statement and are not recognized as an intangible asset or a lease contract. Development costs related to these applications and software are accounted for the same way and are recognized in the Income Statement.

Acquired software licenses are amortized on a straight-line basis over the duration of their useful lives (from 1 to 10 years).

3.12.2 Assets with an indefinite useful life

Intangible assets with an indefinite useful life are not amortized, but are systematically tested for impairment on a yearly basis (see note 3.15).

The accounting treatment of research and development expenses for internally generated intangible assets and for research and development work acquired separately is described in note 3.29.

■ 3.13 Property, plant & equipment

Property, plant and equipment items are accounted for at acquisition price, at fair value for business combinations, or at production cost less cumulative depreciation and any impairment loss.

Subsequent costs are included in the asset's carrying value, or, if applicable, they are recognized as a separate asset if the future economic benefits associated with the asset are likely to go to the Group, and the cost of the asset can be measured reliably.

Depreciation is usually calculated on a straight-line basis over the assets' estimated useful lives. Fixtures and fittings related to lease assets have their lease term is determined in line with the term of the leases themselves. Some industrial assets are depreciated based on production volumes.

Estimated useful lives are as follows:

- buildings, fixtures and fittings 5 to 30 years
- industrial plant & equipment 5 to 10 years
- other property, plant and equipment 3 to 10 years

Land is not depreciated.

Residual values and the duration of the assets' useful lives are revised and, if applicable, adjusted at each closing.

The carrying value of an asset is depreciated immediately to bring it back to its recoverable amount when the asset's carrying value is greater than its estimated recoverable amount (see note 3.15).

Impairment losses on property, plant and equipment are reported together with losses on intangible assets and losses on goodwill in a specific line item in the income statement.

The gains and losses on disposals of assets, included in other operating income and expenses, are determined by comparing proceeds from disposals with the carrying value of the disposed asset.

■ 3.14 Leases

Leases are accounted for using a single recognition model that leads to a right of use being recognized for an asset under property, plant and equipment and lease liabilities recorded in "Current financial liabilities" or "Non-current financial liabilities". The Group recognizes leases in the balance sheet as soon as the lease is created for the discounted value of future cash outflows. They are amortized according to the lease term of the agreement, which corresponds to the economic life of similar tangible assets.

Amortization expenses are accounted for in the income statement under each line of Operating income that involves leases "Cost of goods sold", "Selling expenses", "Research and development expenses", etc.) and interest expenses in "Net financing costs".

The Group has two main types of leases — property leases and vehicle leases. In accordance with options authorized by the standard, lease agreements with a term of less than 12 months or leases with an asset value totaling less than 5 thousand U.S. dollars are not recognized under assets in the balance sheet.

Commercial lease reviews rely on contractual provisions to determine which assumptions to use to estimate rights-of-use assets or lease liabilities.

- The term of the lease used corresponds to the non-cancellable period defined in the agreement, unless the Group is reasonably sure it will renew the lease.

- The Group has assessed the term of the lease used for properties in line with the term used for depreciating fixtures and fittings recognized as an asset for these properties.
- The Group measures lease liabilities from lease agreements at the present value of remaining lease payments and discounts using each lease agreement's incremental borrowing rate and taking into account the remaining term of the lease commitment. The Group applies the marginal incremental interest rate and uses a swap curve adjusted for Ipsen's financing spread depending on the currency zone where the lease operates.
- Pending IFRS IC conclusions, Ipsen considered that the IAS 12 exemption for the initial recognition of deferred taxes applied to the recognition of rights of use and lease liabilities during the transition to IFRS 16. As a result, the Group did not recognize any deferred tax.

The Group uses the same method to conduct impairment tests as the one used in 2019.

- Rights of use and lease liabilities have been respectively included in and excluded from the net carrying amount of the cash generating units.
- The Group has taken into account impacts from the initial application of IFRS 16 on future cash flow projections and in calculating the weighted average cost of capital (WACC).

In accordance with the standard, Ipsen applies IFRS 16 provisions to all lease agreements except low value (less than 5 thousand U.S. dollars) and/or short-term (less than twelve months) agreements. Payments related to lease agreements (rent) receiving the exemption are recognized as operating expenses.

■ 3.15 Impairment of assets

3.15.1 Type of asset tested

Goodwill and intangible assets with an indefinite useful life (such as intangible rights acquired from a third party for drugs not yet marketed) are tested for impairment in accordance with IAS 36 – *Impairment of Assets*, at least once a year and whenever there is an indication that the asset may be impaired.

Indicators of impairment loss can be related particularly to the success of successive phases of clinical trials, to pharmacovigilance, to patent protection, to the arrival of competing products and/or generics and the comparison between actual and forecast sales. These impairment indices are applied to all intangible assets with both finite and indefinite useful lives as soon as required by IAS 36.

3.15.1.1 Goodwill

For impairment testing purposes, starting from the acquisition date, goodwill acquired under a business combination is allocated to one of two of the Group's cash generating units (Specialty Care and Consumer Healthcare).

Goodwill arising from the acquisition of an equity-accounted company is included in the carrying amount of the investment and is not recognized separately, in accordance with IAS 28 – *Investments in Associates and Joint Ventures*. As a result, it is not tested for impairment separately, as described in IAS 36 – *Impairment of Assets*. The full carrying amount of the investment, including goodwill, is tested for impairment. In accordance with paragraph 23 of IAS 28 – *Investments in*

Associates and Joint Ventures, appropriate adjustments to the Group's share of the profits or losses after acquiring equity-accounted companies are made for impairment losses related to goodwill and intangible assets.

3.15.1.2 Intangible assets with an indefinite useful life

Intangible assets with an indefinite useful life *i.e.* mainly intellectual property rights and licenses to use intellectual property rights, are tested annually for impairment and whenever there is an indication that an asset may be impaired.

3.15.1.3 Intangible assets with a finite useful life

Intangible assets with a finite useful life are tested whenever events or circumstances indicate that an asset may be impaired.

3.15.1.4 Tangible fixed assets and long-term financial assets

Other non-current assets, including tangible fixed assets and long-term financial assets, are also tested for impairment when events or changed circumstances indicate that an asset may be impaired, in line with IAS 36 – *Impairment* and IFRS 9 – *Financial Instruments*.

3.15.2 Impairment tests – methods used by the Group

Impairment tests involve comparing an asset's carrying value (asset groups or cash-generating units) with its recoverable amount. The recoverable amount is the higher of fair value less selling costs and value-in-use.

Value-in-use is the net present value of future cash flows expected to be derived from continuing use of the asset, group of assets or cash-generating unit and its ultimate disposal.

Fair value less selling costs is the amount obtainable from the sale of the asset, group of assets or cash-generating unit in an arm's length transaction between knowledgeable, willing parties, less selling costs.

Impairment tests are carried out annually or whenever an event indicates that an asset may be impaired.

An impairment loss is recorded on a separate line in the income statement for the difference when the recoverable amount is less than the asset's, the group of assets, or the cash generating unit's net carrying amount. If the Group identifies impairment on a cash generating unit, it is deducted from goodwill. Goodwill impairment cannot be reversed.

3.15.2.1 Goodwill

Regarding goodwill, the Group calculates recoverable amounts of cash-generating units from their value-in-use. This is determined by discounting their estimated future cash flows to present value. These cash flow estimates are based on five-year or, if warranted, longer estimates and are made for each operating segment (*i.e.* Specialty Care and Consumer Healthcare) by the Group's operating entities. In addition, tests are performed to assess the sensitivity of the recoverable amount of cash-generating units or groups of cash-generating units to changes in certain assumptions, primarily to the discount rate (+/- 1% range), sales growth (-1% to -2% range) and the long-term growth rate (+/- 1% range).

3.15.2.2 Intangible assets with an indefinite useful life

When it is not possible to estimate the recoverable amount of a particular fixed asset, the Group determines the recoverable amount of the cash-generating unit that holds it. More specifically, for an intangible right in the early development phase, the asset is tested for impairment only if an indication of loss of value arises between the date it is acquired and the annual closing date.

3.15.2.3 Intangible assets with a finite useful life

For other intangible assets, the period taken into account for estimating anticipated cash flows is based on the economic life intrinsic to each intangible asset. When the economic life exceeds Group forecasts, the terminal value may be used. Tests are also performed to assess the sensitivity of the recoverable amount to changes in certain assumptions, primarily to the discount rate (+/- 1% range) and to sales growth (-1% to -2% range) and the long-term growth rate (+/- 1% range).

Estimated cash flows are discounted to present value using the weighted average cost of capital of each cash-generating unit (Specialty Care and Consumer Healthcare), except in specific cases when additional risk premiums are taken into account based on the asset tested.

■ 3.16 Government grants

Government grants received by the Group are accounted for as deferred income and recognized in the income statement over the estimated useful lives of the assets financed by the grants.

■ 3.17 Financial assets

A financial asset is an asset that meets the definition IAS 32 – *Financial Instruments* and can be cash (see note 3.20), another entity's equity instrument, a contractual right to receive and exchange cash, or another equity instrument, or a contract that will or may be settled in the entity's own equity.

Financial assets, excluding cash and derivative financial assets used for hedging purposes, are classified in one of the three following categories:

- financial assets at amortized cost;
- financial assets at fair value through other items of comprehensive income;
- financial assets at fair value through profit or loss.

The Group classifies financial assets upon initial recognition based on the characteristics of their contractual cash flows and the Group's management model.

3.17.1 Financial assets at amortized cost

Financial assets at amortized costs primarily comprise Group-issued loans and receivables. The Group measures financial assets at amortized cost:

- if the asset is owned within a business model whose objective is to maintain assets for contractual cash flows;
- if its contractual terms and conditions give rise to cash flows on set dates that are solely payments of principal and interest on the principal amount outstanding.

Interest income from financial assets is calculated according to the effective interest rate method. Upon initial recognition, financial assets at amortized costs are subject to impairment recognized in the income statement for the amount of the expected losses, and are subsequently remeasured each year. Gains and losses are recognized in the income statement whenever the asset is derecognized or modified.

The Group uses the expected loss model, as introduced by IFRS 9 – *Financial Instruments*, for its trade receivables. The impairment allowance for trade receivables is based on a historical loss rate observed over the three previous years on a receivable-by-receivable basis and adjusted for prospective events that take into account individualized credit risks and the economic outlook of the relevant market.

3.17.2 Financial assets at fair value through other comprehensive income

Financial assets representing debt instruments are measured at fair value through other comprehensive income when:

- they are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and sell financial assets;
- the contractual conditions of the financial asset give rise to cash flows on set dates that are solely payments of principal and interest on the principal amount outstanding.

The Group does not hold any financial assets measured at fair value through other comprehensive income with the recycling of cumulative gains and losses.

Further, IFRS 9 provides an option to classify equity instruments irrevocably on an instrument-by-instrument basis as instruments measured at fair value through other comprehensive income, as long as these instruments meet the IAS 32 definition of equity.

The Group opted to irrevocably classify its investments in non-consolidated companies in this category, as they represent equity instruments. They are measured at fair value through equity without later recycling gains or losses to the income statement. These financial assets are presented under “Equity investments”. The associated dividends are recognized in the income statement.

3.17.3 Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss include financial assets held for trading, assets designated as financial assets at fair value through profit or loss upon initial recognition, and other assets belonging to this category in accordance with the provisions of IFRS 9 – *Financial Instruments*.

As of the reporting date, financial assets recognized at fair value through profit or loss consisted primarily of:

- short-term investments. These investments are held for trading and do not meet the definition of cash equivalents (as per IAS 7 – *Statement of Cash Flows*), but which nonetheless show limited volatility;
- interests the Group owns in investment funds. The interests held in these funds do not meet the definition of equity instruments but do meet the definition of debt instruments instead;
- contingent milestone payments already recognized in the financial statements of an acquired entity or resulting from a business combination.

Assets recognized at fair value through profit or loss are accounted for as an asset in the balance sheet for their fair value amount. Changes in fair value are recognized in the income statement.

3.17.4 Fair value of financial instruments

The Group measures their financial instruments at fair value. These instruments include derivative instruments, listed and unlisted financial assets and variable payments recognized as part of business combinations.

For investments in listed equity instruments, fair value is the quoted market price. For investments in unlisted equity instruments, fair value is determined by referring to recent market transactions or using a valuation technique that provides reliable and objective price estimates in line with those used by other players active in the market.

■ 3.18 Non-current assets held for sale and discontinued operations

A non-current asset, or group of assets and liabilities, is classified as held for sale if its carrying value will be recovered mainly through a sale transaction rather than through continuing use. The asset or disposal group must be available for immediate sale and the sale must be highly likely.

For the sale to be highly likely, the appropriate level of management must be committed to a plan to sell the asset (or disposal group), and an active program to locate a buyer and complete the plan must be initiated.

An operation is classified as discontinued if it is a business the Group has sold or is classified as held for sale, and:

- it represents a principal and distinct business line or geographic region;
- it is part of a specific and coordinated plan to dispose of a principal and distinct business line or geographic region;
- it is a subsidiary acquired exclusively for resale.

■ 3.19 Inventories

Inventories are measured at the lower of cost and net realizable value. The internal cost price is determined using the weighted average cost method.

Net realizable value is the estimated selling price in the normal course of business, less the estimated costs necessary to make the sale.

The cost of finished goods includes all purchasing costs, transformation costs and other costs incurred to ship inventories to their present location and in their current condition.

■ 3.20 Cash and cash equivalents

Cash includes cash on hand in demand deposits with banks.

Cash equivalents include term deposits, short-term, highly liquid investments (with a maturity of less than three months), and are subject to an insignificant risk of changes in value in the event of interest rate variations.

Cash equivalents are classified as financial assets at fair value held for transactions. They are measured at fair value and any changes are recognized in the income statement. Given the nature of these assets, their fair value is generally close to their net carrying value.

■ 3.21 Stock option plans

Stock options and bonus share plans are awarded to executive officers and some employees of the Group. As required by IFRS 2 – *Share-based Payments*, these options and shares are measured at their fair value on the date of grant. The fair value is calculated with the most relevant formula regarding the settlement and the conditions of each stock options plan or share award (“Black and Scholes” or “Monte Carlo”). The fair value is recorded in personnel expenses (allocated by function in the income statement) on a straight-line basis over the vesting period (period from the date of grant to maturity of the plan) with a corresponding increase in equity.

At each closing date, the Group re-examines the number of options likely to become exercisable and the number of shares likely to be awarded. If applicable, the impact of the review of the estimates is recognized in the income statement with a corresponding adjustment in equity.

■ 3.22 Retirement benefit obligations

3.22.1 Post-employment benefits

Depending on the laws and practices of the countries where the Group operates, employees may be entitled to compensation when they retire or to a pension following their retirement.

The liability corresponding to the employees’ vested rights is covered by either:

- contributions to independent organizations (insurance companies) responsible for paying the pensions or other benefits; or
- provisions.

For State-managed plans and other defined contribution plans, the Group records them as expenses when they become payable, the Group’s commitment being limited to its contributions.

For defined benefit plans, the Group’s liability is determined by external actuaries using the projected unit credit method. Under this method, each period of service gives rise to an additional unit of benefit entitlement and each unit is valued separately to obtain the final obligation.

The final amount of the liability is then discounted. The main assumptions used to calculate the liability are:

- discount rate;
- inflation rate;
- future salary increases;
- employee turnover.

3.22.2 Other employee benefits

In some countries, employees are entitled to bonuses for years of service. The Group records a provision in the balance sheet to cover its liability in this respect.

■ 3.23 Provisions

Provisions are recognized in accordance with IAS 37 – *Provisions, Contingent Liabilities and Contingent Assets* to cover all liabilities to third parties that are neither financial guarantees nor commitments but are likely or certain to cause an outflow of resources embodying economic benefits, provided the amount of the provision can be reliably estimated. These provisions are estimated based on the most likely assumptions at the closing date.

In the case of restructurings, a liability is recorded as soon as the restructuring has been announced and the Group has drawn up or started to implement a detailed restructuring plan.

Provisions are discounted if the time value is material. The discount rate used to determine the present value reflects current market assessments of the time value of money and the risks inherent to the liability. The provision increase resulting from the restatement at historical value is recorded as a financial expense.

■ 3.24 Financial liabilities

Financial liabilities consist of loans and are initially recognized at their fair value. Then they are measured at amortized cost using the effective interest rate method.

■ 3.25 Derivative financial instruments and hedge accounting

3.25.1 Hedge accounting

As part of its overall strategy for managing foreign exchange risks, the Group completed a number of transactions involving the use of derivative financial instruments. The Group uses derivatives instruments designated as cash flow hedge instruments. The Group has also set-up net investment hedge transactions in foreign countries and have accounted for them in a similar way as cash flow hedges. Exchange rate exposure in foreign subsidiaries has been hedged with debt instruments.

The Group has not designated any derivative instruments as fair value hedge.

The Group buys and sells derivative financial instruments to manage and reduce its exposure to the risk of exchange rate fluctuations. The Group only works with first-class financial institutions. Hedge accounting is applied to instruments formally designated as such and subject to structured documentation from their inception. Under IFRS 9 – *Financial*

Instruments, hedge accounting requires that the following conditions be met:

- there is an economic relationship between the hedged item and the hedging instrument;
- the effect of credit risk does not dominate the value changes that result from that economic relationship;
- the effectiveness of the hedging relationship does not reflect an imbalance that could result in an accounting outcome that would be inconsistent with the purpose of hedge accounting.

Derivative instruments recognized as hedging instruments are recognized in accordance with IFRS 9 hedge accounting criteria.

A cash flow hedge is a hedge of the exposure to cash flow fluctuations, which stem from a particular risk associated with a recognized asset or liability, or a highly probable forecast transaction, and which could affect profit or loss. Changes in the fair value of the hedging instrument are recognized in equity in the consolidated statement of comprehensive income for the effective portion of the hedging relationship. For the ineffective portion, changes in the fair value of hedging instruments are recognized in "Other financial income and expenses" on the income statement.

Aggregate changes in the fair value of the hedging instrument that were previously recognized in equity are recycled into the income statement in the same period(s) in which the hedged transaction affects profit or loss. For hedges related to operating activities, the recycled gains and losses are recognized in "Other core operating income and expenses". This line item also includes foreign exchange translation differences generated by operating receivables and liabilities.

When the hedging instrument expires, the aggregate gains or losses previously recognized in equity remain in equity and are recycled into the income statement only after the forecast transaction has been effectively completed. However, when the Group no longer expects the forecast transaction to be completed, aggregate gains and losses previously recognized in equity are immediately recognized in the income statement.

The Group mainly uses forward currency contracts to hedge its transactional foreign exchange risk. The Group excludes swap points and foreign currency basis spread components of foreign exchange contracts from its hedge designation and recognizes changes in the fair value of these components directly in net financial income/(expenses).

The Group has carried out foreign net investment hedge transactions. Changes in the fair value of the hedging instrument are directly recognized in equity regarding the effective portion. Change in the fair value related to the ineffective portion of the hedge is recognized in the Income Statement.

If an investment that qualifies for foreign net investment hedge is disposed of, amounts previously booked in equity are recycled to the Income Statement.

3.25.2 Other derivative instruments

Derivative instruments that do not qualify as hedge accounting are initially and subsequently measured at fair value. Changes in fair value are recognized in "Other financial income and expenses".

■ 3.26 Sales

The Group's revenues are mainly generated by pharmaceutical product sales. Sales are recognized when control of the goods or services has been transferred to the customer. Sales are recognized for the amounts the Group expects to collect. Revenue from pharmaceutical product sales is recognized when control has been transferred (generally upon delivery), in accordance with the delivery and acceptance clauses provided in the customer contract. Note 4 – *Operating Segments*, includes a breakdown of sales by cash generating unit, by geographic area, and by therapeutic area, showing the portion of sales each product marketed by the Group represents.

Revenue from product sales comprises pharmaceutical product sales net of returns, rebates, and discounts granted to customers, as well as certain payments payable to health authorities and determined based on sales. Rebates and discounts are recognized at the same time as the accompanying sales they belong to. They are identified as being variable price components, in accordance with IFRS 15.

When another party is involved in completing the sales of goods or services, the Group assesses the degree to which the third party acts as an agent or principal. If the products were sold on consignment, or if the third party acted as the agent, the revenues are recognized upon the sale to the end customer. Paid commissions are recognized in the "Selling expenses" line item.

■ 3.27 Other revenues

Other revenues include royalties, revenues received from licensing agreements concluded with partners and revenues generated by various services provided.

Royalties received are recognized as "Other revenues" based on sales achieved by the partners and contractual royalty rates during the period.

Licensing Agreements are recognized in "Other revenues" and can be broken down into two distinct types, as follows:

- Static licenses are contracts where control has been transferred to the customer and under which the Group has an enforceable payment right. Revenue from these licenses is recognized at the date when control of the licensed asset has been transferred;
- Dynamic licenses are licenses in which the royalties received correspond to either the right held by the customer to use an intangible asset without a transfer of control, or to a situation where the licensing agreement cannot be separated from the sale of the goods or services. This type of revenue is spread over the lifespan of the licensing agreement. Upfront payments and milestone payments are spread over the licensing contract period they belong to.

Revenues generated by various services provided are recognized based on the goods or services delivered to the other contracting party.

Off balance-sheet commitments corresponding to milestone payments to be received and arising from the Group's main agreements are presented in note 24.1.2. Payments received for these milestones are recognized on the date when the regulatory triggering event occurs and after both parties give their approval.

■ 3.28 Cost of sales

Cost of sales primarily includes the industrial cost of goods sold and royalties paid under licenses. The industrial cost of goods sold includes the cost of raw materials consumed, including in-bound freight costs, direct and indirect costs for production services personnel, manufacturing-related depreciation, all types of external costs related to manufacturing activities, such as electricity, water, maintenance, and equipment costs, and indirect costs, such as the share of purchasing, human resources and IT costs. Production costs also include quality control, production quality assurance, engineering, and logistics services expenses.

■ 3.29 Research and Development

3.29.1 Internal Research and Development

Internal research costs are expensed. Internal pharmaceutical development costs are expensed in the period during which they are incurred as long as capitalization criteria are not deemed to be met.

In accordance with IAS 38, internal development costs are recognized as intangible assets only if the following six criteria have been met:

- the technical feasibility required to complete the development project;
- the Group's intention to complete the project;
- its ability to use the intangible asset;
- the probable future economic benefit of the asset can be demonstrated;
- the availability of technical, financial and other resources to complete the project; and
- the reliable measurement of development costs.

Due to the risks and uncertainties associated with regulatory approvals and the research and development process, the six criteria for intangible assets are not deemed to be fulfilled until marketing authorization for the drugs has been granted, *i.e.* approval of the Marketing Authorization Application (MAA).

As a result, internal development expenses, primarily consisting of clinical study costs arising before approval of the MAA, are generally recognized in "Research and development expenses" as soon as they are incurred.

Some industrial development costs are generated after the MAA has been approved to improve the process for manufacturing an active ingredient. If the six IAS 38 criteria are deemed to have been met, these costs are included in the measurement of the project's costs and recorded as "Other intangible assets" under assets in the balance sheet, as soon as they are incurred (see note 11.3). Likewise, some clinical study costs, such as those arising from efforts to extend the geographical access of a molecule that has already obtained MAA approval in a major market, may in certain cases meet the six intangible asset recognition criteria under IAS 38 – *Intangible Assets*. In such cases, those costs are recorded as other intangible assets under the asset in the balance sheet as soon as they are incurred.

3.29.2 Research and Development acquired separately

Payments made to acquire research and development work separately are recognized as other intangible assets when they meet the definition of an intangible asset, *i.e.* a controlled resource with probable future economic benefits for the Group that are identifiable, either being separable or arising from contractual or other legal rights. In accordance with IAS 38, the first recognition criterion related to the probability of the intangible asset generating future economic benefits is presumed to be met when research and development work is acquired separately. The second recognition criterion related to the reliable measurement of the asset is satisfied as well when payment amounts are determined.

Accordingly, amounts paid to third parties as an upfront payment or as milestone payments for proprietary drugs are recognized under assets in the balance sheet. These rights are amortized on a straight-line basis over the duration of their useful lives beginning on the date the products are marketed.

3.29.3 Research and Development acquired in a business combination

Other intangible assets related to research and development work in progress and acquired within the scope of a business combination, and which can be reliably measured, are identified separately from goodwill and recognized as other intangible assets, in accordance with IFRS 3 – *Business Combinations* and IAS 38 – *Intangible Assets*. A related deferred tax liability is also recognized, if applicable.

3.29.4 Research tax credits

Research tax credits are classified as operating grants, which is common practice within the pharmaceutical industry. In accordance with IAS 20 – *Accounting for Government Grants and Disclosure of Government Assistance*, operating grants are recognized in operating income, after the R&D expenses to which they are directly linked have been deducted.

■ 3.30 Other operating income and expenses

Other operating income and expenses primarily include amortization expenses for intangible assets (excluding software), the impact of cash flow hedges related to commercial operations, capital gains and losses on asset disposals, and any item not directly related to operations.

■ 3.31 Taxes

Applying the variable carryover method, deferred taxes are recorded on all temporary differences between the carrying value and tax base of assets and liabilities, and on tax loss carryforwards.

The main temporary differences in the Group's consolidated financial statements stem from tax loss carry forwards, restatements to eliminate internal margins on inventory and provisions for retirement benefits.

The Group only recognizes deferred tax assets for deductible temporary differences when it is likely that taxable profits will be available for the temporary differences to be offset.

Deferred tax assets and liabilities are valued using the expected tax rate for the period in which the asset will be realized and the liability will be settled, based on the tax rates enacted or virtually enacted as of the balance sheet date. Deferred tax assets undergo a recoverability analysis based on Group forecasts.

Deferred tax assets and liabilities are not discounted, in accordance with IAS 12 – *Income Taxes*.

The Group calculates the amount of deferred taxes to recognize in the Group's consolidated financial statements per entity included in the scope of consolidation.

The Group elected to recognize the CVAE business tax (*Cotisation sur la Valeur Ajoutée des Entreprises*) as an income tax expense in the income statement. In accordance with IAS 12, the total amount of current and deferred expenses related to the CVAE is presented on the "Income Tax" line item.

■ 3.32 Earnings per share

Basic earnings per share is calculated by dividing consolidated net profit for the year attributable to Ipsen S.A. shareholders by the weighted average number of shares outstanding during the period.

The weighted average number of shares outstanding is calculated according to movements in share capital, less any treasury shares held by the Group.

Diluted earnings per share is calculated by dividing consolidated net profit for the year attributable to equity holders of Ipsen S.A. by the weighted average number of ordinary shares outstanding plus any potentially dilutive ordinary shares not yet issued.

Note 4 Operating segments

The Group's business is organized into two operating segments—Specialty Care and Consumer Healthcare.

All costs are allocated to these two segments except for Corporate overhead costs and the impact of currency hedging.

The Group uses Core operating income to measure its performance and to allocate resources.

Core operating income is operating income that excludes amortization expenses for intangible assets (excluding software), restructuring costs, impairment losses on intangible assets and property, plant and equipment, as well as other items arising from significant events that could distort the reading of the Group's performance from one year to another.

These performance indicators do not replace IFRS indicators and should not be viewed as such. They are used in addition to IFRS indicators.

■ 4.1 Core Operating Income by operating segment

| (in millions of euros) | 2021 | 2020 |
|----------------------------|---------|---------|
| Specialty Care | | |
| Sales | 2,643.3 | 2,381.1 |
| Revenue | 2,748.6 | 2,453.6 |
| Core Operating Income | 1,186.6 | 1,014.3 |
| <i>% of net sales</i> | 44.9% | 42.6% |
| Consumer Healthcare | | |
| Sales | 225.6 | 210.6 |
| Revenue | 250.5 | 232.6 |
| Core Operating Income | 31.7 | 15.6 |
| <i>% of net sales</i> | 14.1% | 7.4% |
| Other (unallocated) | | |
| Core Operating Income | (207.1) | (200.6) |
| Total Group | | |
| Sales | 2,868.9 | 2,591.6 |
| Revenue | 2,999.1 | 2,686.2 |
| Core Operating Income | 1,011.3 | 829.3 |
| <i>% of net sales</i> | 35.2% | 32.0% |

A reconciliation between Core Operating Income and Operating Income is presented in the table below:

| (in millions of euros) | 2021 | 2020 |
|---|----------------|--------------|
| Core Operating Income | 1,011.3 | 829.3 |
| Amortization of intangible assets, excluding software | (82.3) | (86.5) |
| Other operating income and expenses ⁽¹⁾ | (50.6) | (18.6) |
| Restructuring costs | (19.8) | (45.6) |
| Impairment losses | (9.1) | (153.9) |
| Operating Income | 849.5 | 524.8 |

(1) Proceeds received in 2020 from businesses sold before 2020 were reclassified from "Profit from discontinued operations" to the "Other operating income" line item for €3.8 million.

■ 4.2 Sales by geographical region

| (in millions of euros) | 2021 | | 2020 | |
|----------------------------------|----------------|-------------|----------------|-------------|
| | Amounts | % share | Amounts | % share |
| Major Western European countries | 883.8 | 31 % | 824.5 | 32 % |
| Rest of Europe | 556.1 | 19 % | 500.9 | 19 % |
| North America | 916.3 | 32 % | 857.6 | 33 % |
| Rest of the World | 512.6 | 18 % | 408.6 | 16 % |
| Group Sales | 2,868.9 | 100% | 2,591.6 | 100% |

■ 4.3 Sales by therapeutic area and product

| (in millions of euros) | 2021 | 2020 |
|---|----------------|----------------|
| Oncology | 2,153.5 | 1,969.8 |
| <i>Somatuline</i> ® | 1,202.7 | 1,145.2 |
| <i>Decapeptyl</i> ® | 459.6 | 390.5 |
| <i>Cabometyx</i> ® | 354.6 | 288.9 |
| <i>Onivyde</i> ® | 127.4 | 123.3 |
| <i>Other Oncology products</i> | 9.1 | 21.8 |
| Neurosciences | 440.7 | 356.1 |
| <i>Dysport</i> ® | 434.6 | 353.2 |
| Rare diseases | 49.1 | 55.2 |
| <i>NutropinAq</i> ® | 32.0 | 36.2 |
| <i>Increlex</i> ® | 17.1 | 19.0 |
| Specialty Care | 2,643.3 | 2,381.1 |
| <i>Smecta</i> ® | 88.8 | 80.9 |
| <i>Tanakan</i> ® | 36.6 | 35.2 |
| <i>Forlax</i> ® | 36.0 | 39.0 |
| <i>Fortrans/Eziclen</i> ® | 35.9 | 28.1 |
| <i>Other Consumer Healthcare products</i> | 28.4 | 27.4 |
| Consumer Healthcare | 225.6 | 210.6 |
| Group Sales | 2,868.9 | 2,591.6 |

■ 4.4 Other revenues

| (in millions of euros) | 2021 | 2020 |
|--|--------------|-------------|
| Royalties received | 98.5 | 67.2 |
| Milestone payments – Licenses | 8.5 | 7.3 |
| Other (co-promotion revenues, re-billings) | 23.2 | 20.0 |
| Other revenues | 130.2 | 94.5 |

In 2021, other revenues amounted to €130.2 million (€94.5 million reported in 2020). This change was due to an increase in royalties received from Galderma for Dysport®.

■ 4.5 Other information

| (in millions of euros) | 31 December 2021 | | | Total |
|--|------------------|---------------------|---------------------|----------------|
| | Specialty Care | Consumer Healthcare | Other (unallocated) | |
| Acquisition of property, plant & equipment | (88.2) | (7.9) | (1.4) | (96.0) |
| Acquisition of intangible assets | (303.1) | (1.2) | (25.9) | (331.7) |
| Total investments (excluding changes in consolidation scope) | (391.2) | (9.1) | (27.3) | (427.6) |
| Net depreciation, amortization and provisions (excluding financial assets) | (179.0) | (15.3) | (41.9) | (236.2) |

Note 5 Personnel

■ 5.1 Headcount

At the end 2021, the Group totaled 5,744 employees, compared to 5,703 at the end of 2020.

The average headcount in 2021 was 5,671 employees, compared to 5,746 in 2020.

■ 5.2 Employee expenses

Employee expenses, which are included in the cost of goods sold, selling costs, corporate overheads, research and development expenses, and restructuring costs encompass the following items:

| (in millions of euros) | 2021 | 2020 |
|--|----------------|----------------|
| Wages and salaries | (553.3) | (514.5) |
| Employer's Social security contributions and payroll taxes | (173.6) | (160.4) |
| Interest on employee benefits | (3.1) | (1.0) |
| Share-based payment expenses | (29.9) | (24.8) |
| Employee profit-sharing | (13.7) | (13.8) |
| Total - Employee expenses | (773.6) | (714.5) |

In 2021, the average rate of Social security contributions and payroll taxes amounted to 31.4% of gross payroll, compared to 31.2% in 2020.

The Group's French companies have an employee profit-sharing agreement as required by law. Employees may invest their assets in either an interest-bearing savings account within the company or in a company savings plan invested in collective investment funds managed by a financial institution.

■ 5.3 Long-term employee benefits

5.3.1 Benefit plans

5.3.1.1 Retirement benefit obligations

In some countries, the Group's employees are eligible for supplementary pension payments paid annually to retirees, or to lump sum retirement allowances paid upon retirement. The main countries with defined benefit plans are France and the United Kingdom. In France, a limited number of employees also receive a supplementary pension plan.

The Group provides these benefits either through defined contribution plans or through defined benefit plans.

Under defined contribution plans, the Group is only obligated to pay the agreed contributions, with the corresponding expense charged to income for the year.

5.3.1.2 Other long-term benefits

The Group also pays out bonuses intended to reward employees based on years of service. These long service awards mainly relate to the Group's employees in France.

5.3.2 Measurement and recognition of liabilities

The Group's liabilities related to employee benefits are calculated by an external actuary using the applicable assumptions in the relevant countries.

Discount rates are determined by reference to a market rate based on bonds issued by first class issuers. The main benchmark index used is the iBoxx Corporate AA for the Eurozone and the United Kingdom.

Assumptions with regard to staff turnover and mortality rates are specific to each country.

Some liabilities are covered by financial assets held in funds invested with insurance companies (plan assets).

The impact of the return on plan assets for retirement plans on the income statement is measured by applying the discount rate used for the liabilities.

Unfunded liabilities and plan deficits are recognized in the balance sheet under "Retirement benefit obligations".

5.3.2.1 Assumptions used

The main actuarial assumptions applied as of 31 December 2021 are as follows:

| | 31 December 2021 | | |
|--|---------------------------------|----------------|----------------|
| | Europ (excluding UK) | United Kingdom | Asia - Oceania |
| Discount rate | 0.9% | 2.0% | 2.3% |
| Inflation rate | 1.9% | 3.1% | N/A |
| Rate of increase in salaries, net of inflation | Varies by professional category | N/A | 5.6% |
| Rate of increase in pensions | N/A | 3.1% | N/A |

A 1.0% increase in the discount rate would lead to a 9.5% decrease in employee benefit obligations in France, a 17.2% decrease in the UK, and a 13.8% decrease in Asia-Oceania.

5.3.2.2 Reconciliation of balance sheet assets and liabilities

| (in millions of euros) | 31 December 2021 | | | 31 December 2020 |
|--|--------------------------|--------------------------|------------------------------------|------------------------------------|
| | Post-employment benefits | Other long-term benefits | Total long-term personnel benefits | Total long-term personnel benefits |
| Defined benefit plan obligations - Opening balance | 70.8 | 5.7 | 76.5 | 91.9 |
| Application of the IFRIC's agenda decision on IAS19 - Employee Benefits | | | | (16.3) |
| Present value of defined benefit obligations after applying IFRIC | 70.8 | 5.7 | 76.5 | 75.6 |
| Current service costs | 4.7 | 0.7 | 5.4 | 5.4 |
| Past service costs (plan amendments and curtailments) | (1.7) | (0.2) | (1.8) | (4.8) |
| Interest expense on obligations | 0.5 | (0.7) | (0.2) | 0.8 |
| Actuarial gains and (losses) - changes to demographic assumptions | 1.2 | — | 1.2 | 1.5 |
| Actuarial gains and (losses) - changes to discount rate | (6.4) | — | (6.4) | 2.7 |
| Actuarial gains and (losses) - experience adjustments | 1.2 | — | 1.2 | (0.6) |
| Benefits paid | (2.1) | (0.1) | (2.2) | (2.7) |
| Changes in scope | — | — | — | — |
| Exchange differences | 1.7 | — | 1.7 | (1.2) |
| Other | 1.0 | — | 1.0 | (0.1) |
| Defined benefit plan obligations - Closing balance | 71.0 | 5.4 | 76.4 | 76.5 |
| Fair value of assets allocated to plans – Opening balance | 29.1 | — | 29.1 | 31.2 |
| Interest income on plan assets | 0.3 | — | 0.3 | 0.4 |
| Actuarial gains/(losses) on plan assets | 3.4 | — | 3.4 | 0.3 |
| Employee contributions to plan assets | — | — | — | — |
| Employer's contributions to plan assets | 2.5 | — | 2.5 | 0.1 |
| Benefits paid from plan assets | (0.8) | — | (0.8) | (1.9) |
| Changes in scope | — | — | — | — |
| Exchange differences | 1.3 | — | 1.3 | (1.0) |
| Other | — | — | — | — |
| Fair value of assets allocated to plans – Closing balance | 35.7 | — | 35.7 | 29.1 |
| Closing net liability recognized in the balance sheet | 35.3 | 5.4 | 40.7 | 47.4 |
| Impact on comprehensive income | | | | |
| Operating expenses | (3.1) | (0.5) | (3.6) | (0.6) |
| Interest expenses recognized in financial result | (0.2) | 0.7 | 0.5 | (0.4) |
| Other | — | — | — | — |
| Income statement expenses | (3.3) | 0.2 | (3.1) | (1.0) |
| Actuarial gains and (losses) on defined benefit obligations | 4.0 | — | 4.0 | (3.5) |
| Actuarial gains/(losses) on plan assets | 3.4 | — | 3.4 | 0.3 |
| Items recognized in comprehensive income | 7.4 | — | 7.4 | (3.1) |
| | | | | — |
| Impact on comprehensive income | 4.1 | 0.2 | 4.3 | (4.1) |

5.3.2.3 Allocation of plan assets

| (in millions of euros) | 31 December 2021 | | | Total |
|--------------------------------|------------------|-------------|----------------------|-------------|
| | Shares | Bonds | Other ⁽¹⁾ | |
| Europe (excluding UK) | 8.2 | 4.6 | 1.8 | 14.6 |
| United Kingdom | 12.0 | 7.5 | 0.9 | 20.4 |
| Asia-Oceania | 0.6 | 0.1 | — | 0.7 |
| Total | 20.7 | 12.3 | 2.7 | 35.7 |
| Total (as a percentage) | 58% | 34% | 8% | 100% |

(1) Property, cash, and other.

As of 31 December 2021, plan assets primarily broke down between France (40.9%) and the UK (57.0%).

| (in millions of euros) | 31 December 2020 | | | Total |
|--------------------------------|------------------|-------------|----------------------|-------------|
| | Shares | Bonds | Other ⁽¹⁾ | |
| Europe (excluding UK) | 6.9 | 4.7 | 0.4 | 11.9 |
| United Kingdom | 10.1 | 6.2 | 0.2 | 16.5 |
| Asia-Oceania | 0.5 | 0.1 | — | 0.7 |
| Total | 17.5 | 10.9 | 0.7 | 29.1 |
| Total (as a percentage) | 60% | 38% | 2% | 100% |

(1) Property, cash, and other.

5.3.2.4 Future probable plan benefits

| (in millions of euros) | 31 December 2021 | | Total |
|------------------------|--------------------------|--------------------------|-------|
| | Post-employment benefits | Other long-term benefits | |
| 2022 | 6.1 | 0.2 | 6.2 |
| 2023 | 3.6 | 0.9 | 4.4 |
| 2024 | 1.2 | 0.9 | 2.1 |
| 2025 | 2.6 | 0.9 | 3.5 |
| 2026 | 3.8 | 0.8 | 4.6 |
| 2027-2031 | 11.5 | 3.7 | 15.2 |

5.3.2.5 Application of the IFRIC agenda decision on IAS 19 – Employee Benefits

Ipsen Group applied the IFRIC's agenda decision on IAS 19 – *Employee Benefits* retroactively as of 1 January 2020, which led the Group to restate the impact on the opening balance sheet as of 1 January 2020 as follows:

| (in millions of euros) | 31 December 2019 As published | IFRIC related to IAS19 Employee benefits | 1st January 2020 Restated |
|--|----------------------------------|--|------------------------------|
| Deferred tax assets | 149.4 | (4.2) | 145.2 |
| Other non-current assets | 2,811.0 | — | 2,811.0 |
| Total non-current assets | 2,960.4 | (4.2) | 2,956.2 |
| Total current assets | 1,346.5 | — | 1,346.5 |
| TOTAL ASSETS | 4,306.9 | (4.2) | 4,302.7 |
| Additional paid-in capital and consolidated reserves | 1,656.1 | 12.1 | 1,668.2 |
| Other shareholder's equity | 97.0 | — | 97.0 |
| Total shareholders' equity | 1,753.1 | 12.1 | 1,765.2 |
| Retirement benefit obligation | 60.7 | (16.3) | 44.4 |
| Other non-current liabilities | 1,040.7 | — | 1,040.7 |
| Total non-current liabilities | 1,101.4 | (16.3) | 1,085.0 |
| Total current liabilities | 1,452.5 | — | 1,452.5 |
| TOTAL EQUITY & LIABILITIES | 4,306.9 | (4.2) | 4,302.7 |

Impacts on the 2020 results were not restated because they were not material.

■ 5.4 Share-based payments

5.4.1 Bonus share grants

Ipsen granted various bonus share plans within the scope of IFRS 2 – *Share-Based Payments*, that were still vesting as of 31 December 2021.

| (in millions of euros/number of shares) | Number of bonus shares | Vesting period | Performance conditions | Value of shares on date granted, before reduction | Fair value of bonus share | Initial value of the plan | 2021 | 2020 |
|---|------------------------|----------------------------------|------------------------|---|---------------------------|---------------------------|---------------|---------------|
| Plan dated June 1, 2016 | 242,290 | | | | | 10.5 | | 0.1 |
| Chairman, Chief Executive Officer & Executive Committee Members | 64,019 | 2 years | yes | €56.69 | €47.73 | | | |
| Beneficiaries from French subsidiaries | 72,208 | 2 years | yes | €56.69 | €47.73 | | | |
| Beneficiaries from American subsidiaries | 64,727 | 2 years | yes | €56.69 | €47.73 | | | |
| Beneficiaries outside the French & American subsidiaries | 41,336 | 4 years | yes | €56.69 | €49.04 | | | |
| Plan dated March 29, 2017 | 151,890 | | | | | 13.3 | (0.1) | 0.1 |
| Chief Executive Officer & Executive Leadership Team | 41,640 | 2 years | yes | €93.40 | €101.47 | | | |
| Beneficiaries from French subsidiaries | 44,070 | 2 years | yes | €93.40 | €97.01 | | | |
| Beneficiaries from American subsidiaries | 28,200 | 2 years | yes | €93.40 | €97.00 | | | |
| Beneficiaries outside the French & American subsidiaries | 37,980 | 4 years | yes | €93.40 | €99.27 | | | |
| Plan dated May 30, 2018 | 211,140 | | | | | 25.3 | 0.2 | (4.0) |
| Chief Executive Officer & Executive Leadership Team | 39,390 | | yes | €134.40 | €134.90 | | | |
| Beneficiaries from subsidiaries subject to performance conditions | 84,240 | 50% to 2 years 50% to 3 years | yes | €134.40 | €134.90 | | | |
| Beneficiaries from subsidiaries not subject to performance conditions | 87,510 | | no | €134.40 | €131.84 | | | |
| Plan dated February 13, 2019 | 25,880 | | | | | 2.8 | (0.1) | (0.9) |
| Beneficiaries from subsidiaries | 25,880 | 2 years | no | €109.60 | €109.60 | | | |
| Plan dated May 28, 2019 | 288,880 | | | | | 25.5 | (6.0) | (7.7) |
| Chief Executive Officer & Executive Leadership Team | 43,520 | 3 years | yes | €112.10 | €90.25 | | | |
| Beneficiaries from subsidiaries subject to performance conditions | 117,160 | 50% to 2 years 50% to 3 years | yes | €112.10 | €87.83 | | | |
| Beneficiaries from subsidiaries not subject to performance conditions | 128,200 | | no | €112.10 | €109.57 | | | |
| Plan dated February 12, 2020 | 71,650 | | | | | 2.8 | (0.5) | (2.2) |
| Beneficiaries from subsidiaries | 71,650 | 2 years | no | €109.60 | €109.60 | | | |
| Plan dated May 29, 2020 | 520,268 | | | | | 34.8 | (10.7) | (7.6) |
| Executive Leadership Team | 70,610 | 3 years | yes | €72.00 | €62.02 | | | |
| Beneficiaries from subsidiaries subject to performance conditions | 106,261 | 3 years | yes | €72.00 | €62.02 | | | |
| Beneficiaries from subsidiaries not subject to performance conditions | 223,154 | 2 years | no | €72.00 | €69.98 | | | |
| Beneficiaries from subsidiaries not subject to performance conditions | 120,243 | 3 years | no | €72.00 | €68.71 | | | |
| Plan dated July 29, 2020 | 37,829 | | | | | 2.8 | (0.6) | (0.4) |
| Chief Executive Officer | 37,829 | 3 years | yes | €81.75 | €74.83 | | | |
| Plan dated May 27, 2021 | 427,333 | | | | | 39.9 | (8.1) | |
| Executive Leadership Team | 81,473 | 3 years | yes | €85.78 | €84.37 | | | |
| Beneficiaries from subsidiaries subject to performance conditions | 79,840 | 3 years | yes | €85.78 | €84.37 | | | |
| Beneficiaries from subsidiaries not subject to performance conditions | 172,930 | 2 years | no | €85.78 | €83.76 | | | |
| Beneficiaries from subsidiaries not subject to performance conditions | 93,090 | 3 years | no | €85.78 | €82.74 | | | |
| Plan dated May 27, 2021 | 24,400 | | | | | 2.3 | (0.5) | |
| Beneficiaries from subsidiaries | 24,400 | 2 years | no | €85.78 | €83.76 | | | |
| TOTAL | | | | | | | (26.5) | (22.5) |

5.4.2 Bonus share plans

The employee shareholding plan launched in 2021 resulted in the Group delivering 114,442 Ipsen S.A. shares to employees, representing a total of €8.4 million, €6.2 million of which for contributions paid by employees.



Note 6 Other operating income and expenses

In 2021, other operating income and expenses generated a net €119.1 million expense, mainly related to amortizing the Cabometyx and Onivyde intangible assets and costs arising from the Group's transformation programs.

In 2020, other operating income and expenses came to €93.9 million in expenses. The expenses were mainly associated with amortization expenses on the Cabometyx® and Onivyde® intangible assets, with costs from the Group's transformation programs, including the discontinuation of some research programs after redefining the Group's strategic priorities, and with the impact of foreign exchange hedges.

Note 7 Restructuring costs

Restructuring costs amounted to an €19.8 million expense, mainly due to restructuring projects, especially in France and in the United States.

At the end of December 2020, these costs totaled €45.6 million before taxes. They primarily related to transformation projects within the French Consumer Healthcare business as well as to relocating the Onivyde® manufacturing site to France.

Note 8 Net financial income/(expense)

| (in millions of euros) | 2021 | 2020 |
|--|---|----------------|
| Investment income | 2.4 | 2.3 |
| Financing costs | (23.7) | (27.1) |
| Net financing costs | (21.3) | (24.7) |
| Foreign exchange gain / (loss) on non-operating activities | (0.9) | 11.6 |
| Change in fair value of equity investments | 3.1 | 7.6 |
| Net interest on employee benefits | 0.5 | (0.4) |
| Change in fair value of contingent assets and liabilities | (8.4) | 29.0 |
| Other financial liabilities | (8.0) | (15.3) |
| Other financial income and expenses | (13.6) | 32.5 |
| Financial income/(expenses) | (35.0) | 7.8 |
| | <i>of which total financial income</i> | <i>135.7</i> |
| | <i>of which total financial expense</i> | <i>(128.0)</i> |

Other financial items particularly included the cost of the Group's currency hedges.

In 2020, Ipsen recorded €29 million in income from remeasuring contingent payments. After the Group decided to halt the Phase II MO-Ped clinical trial, Ipsen remeasured the Contingent Value Rights (CVR) issued to former Clementia Pharmaceuticals shareholders, as well as conditional regulatory and sales milestone payments related to palovarotene research, which resulted in a positive €43.3 million. The Group also recognized a €24.4 million loss from remeasuring contingent payments associated with the intangible asset Onivyde after revising how successful R&D studies would likely be.

Note 9 Income taxes

■ 9.1 Tax expenses

9.1.1 Effective tax rate

| (in millions of euros) | 2021 | 2020 |
|---|----------------|--------------|
| Net profit/(loss) from continuing operations | 646.7 | 548.9 |
| Share of net profit/(loss) from equity-accounted companies | 0.4 | (1.5) |
| Net profit/(loss) from continuing operations before share of results from equity-accounted companies | 646.3 | 550.4 |
| Current tax | (151.9) | (118.4) |
| Deferred tax | (16.2) | 136.3 |
| Income taxes | (168.2) | 17.8 |
| Pre-tax profit from continuing operations before share of results from equity-accounted companies | 814.5 | 532.6 |
| Effective tax rate | 20.6% | -3.3% |

In 2021, €168.2 million in income tax expenses resulted in an effective tax rate of 20.6% on pre-tax profit from continuing operations, excluding the share of profit/(loss) from equity-accounted companies.

In 2020, the effective tax rate, restated for the impacts related to the Group's legal restructuring, came to 22.0%.

9.1.2 Reconciliation between the effective and nominal tax expense

The following table shows the reconciliation between the effective tax expense and nominal tax expense based on pre-tax profit from continuing operations taxed at the standard French rate of 28.41% for the two years presented:

| (in millions of euros) | 2021 | 2020 |
|---|----------------|----------------|
| Pre-tax profit from continuing operations before share of results from equity-accounted companies | 814.5 | 532.6 |
| Group tax rate | 28.41% | 32.02% |
| Nominal tax expense | (231.4) | (170.5) |
| (Increase)/Decrease in tax expense arising from: | | |
| - Tax credits | 13.4 | 6.6 |
| - Non-recognition of tax impact on certain losses during the year | (31.9) | (77.2) |
| - Utilization of tax losses not recognized as deferred tax assets | — | — |
| - Recognition of deferred tax assets | 38.8 | 5.8 |
| - Other permanent differences | 42.9 | 251.9 |
| Effective tax expense | (168.2) | 17.8 |
| Effective tax rate | 20.6% | -3.3% |

Items impacting tax expenses in 2021 included:

- an expense related to non-recognition of the tax effect on certain tax losses generated during the year in Canada and in Germany;
- the income recorded from recognizing deferred net tax assets were mainly due to losses generated in France in 2020;
- other permanent differences, which included differences in the effective tax rate of 28.41% and the effective tax rates where the Group's subsidiaries are located, as well as tax costs from the Group's legal restructuring.

In 2020, other permanent differences included:

- differences in tax rates between 32.02% and the tax rates where the Group's subsidiaries are located;
- the tax income as a result of recognizing gross deferred tax assets on tax losses from the Group's legal business restructuring transactions;
- a lack of tax effect from adjusting the fair value of contingent assets and liabilities associated with the intangible asset Onivyde and with Clementia Pharmaceuticals.

9.2 Deferred tax assets and liabilities

Changes in deferred tax assets and liabilities in 2021 broke down as follows:

| (in millions of euros) | 31 December 2020 | (Loss) / profit in income statement | Deferred taxes recorded directly to reserves | Foreign Exchange differences | Transfers and other movements | 31 December 2021 |
|--------------------------------|------------------|-------------------------------------|--|------------------------------|-------------------------------|------------------|
| Deferred tax assets | 243.2 | 5.5 | (0.1) | 4.8 | (0.3) | 253.1 |
| Deferred tax liabilities | (79.9) | (21.7) | 7.4 | (7.4) | (0.1) | (101.8) |
| Net deferred tax assets | 163.2 | (16.2) | 7.2 | (2.6) | (0.4) | 151.3 |

Changes in “Income statement income/(expenses)” totaling €16.2 million mainly included:

- €50.9 million in income on deferred tax assets on tax losses carried forward related to losses generated in 2020 that were partially offset by a €25.0 million expense for deferred tax assets related to inventory internal profit margin elimination;
- a €21.7 million net expense for deferred tax liabilities primarily due to updating deferred tax liabilities in the United Kingdom after the tax rose from 19% to 25%.

Changes in deferred tax assets and liabilities in 2020 break down as follows:

| (in millions of euros) | 31 December 2019 published | IFRIC related to IAS19 Employee benefits | 31 December 2020 restated | (Loss) / profit in income statement | Foreign exchange differences | Transfers and other movements | 31 December 2020 |
|--------------------------------|----------------------------|--|---------------------------|-------------------------------------|------------------------------|-------------------------------|------------------|
| Deferred tax assets | 149.4 | (4.2) | 145.2 | 108.8 | (9.6) | (2.7) | 243.2 |
| Deferred tax liabilities | (107.7) | — | (107.7) | 27.5 | 9.3 | 2.4 | (79.9) |
| Net deferred tax assets | 41.7 | (4.2) | 37.5 | 136.3 | (0.3) | (0.3) | 163.2 |

Changes in “Income statement income/(expense)” totaling €136.3 million mainly include:

- €60.3 million in income on deferred tax assets on tax losses carried forward related to Group legal restructuring;
- €36.4 million in income related to inventory internal profit margin elimination;
- €14.9 million in income related to the reversal of deferred tax liabilities due to the impairment of palovarotene intangible assets.

9.3 Type of deferred taxes recognized on the balance sheet and the income statement

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| Deferred tax related to employee benefits | 14.4 | 15.0 |
| Deferred tax related to internal profit margin elimination | 97.0 | 119.2 |
| Deferred tax assets related to tax loss carry-forward | 90.6 | 81.3 |
| Other deferred tax assets | 89.1 | 66.3 |
| Offset of deferred tax assets and liabilities by fiscal entity | (38.1) | (38.7) |
| Deferred tax assets | 253.1 | 243.2 |
| Deferred tax liabilities related to the remeasurement of acquired intangibles assets | (81.6) | (76.3) |
| Other deferred tax liabilities | (58.3) | (42.3) |
| Offset of deferred tax assets and liabilities by fiscal entity | 38.1 | 38.7 |
| Deferred tax liabilities | (101.8) | (79.9) |

The Group recognized €90.6 million in tax loss carryforwards as of 31 December 2021 (compared to €81.3 million in 2020). This increase was primarily due to recognizing deferred taxes from losses generated in 2020, which were partially offset by the use of deferred tax assets in France.

Deferred tax assets are recognized based on results forecasts for each tax consolidation group. These forecasts are in line with Ipsen’s long- and medium-term plans and take into account the time frames in relation to the duration of the tax loss carryforwards and the specific situation of each tax consolidation group.

The “Deferred taxes related to the remeasurement of acquired intangible assets” line item mainly included the amount of deferred tax liabilities recorded for palovarotene intangible assets.

Note 10 Goodwill

10.1 Changes in Goodwill

| (in millions of euros) | Gross goodwill | Impairment losses ⁽¹⁾ | Net goodwill |
|--------------------------------|----------------|----------------------------------|--------------|
| 1 January 2020 | 641.2 | (8.5) | 632.6 |
| Changes in consolidation scope | — | — | — |
| Foreign exchange differences | (40.3) | 0.5 | (39.8) |
| 31 December 2020 | 600.9 | (8.0) | 592.8 |
| Changes in consolidation scope | — | — | — |
| Foreign exchange differences | 31.0 | (0.6) | 30.3 |
| 31 December 2021 | 631.8 | (8.7) | 623.2 |

(1) The impairment previously recorded only concerns goodwill acquired when purchasing Stérix Ltd.

10.2 Impairment of goodwill

Impairment tests are conducted for each of the two Cash Generating Units (CGU): Specialty Care and Consumer Healthcare.

The recoverable value of each Cash Generating Unit corresponds to the value-in-use determined by discounting their estimated future cash flows to present value. The assumptions used for the goodwill impairment tests are reviewed once a year and are based on:

- a five-year estimate made by the Group's operating entities;
- if longer estimates are warranted, cash flows are extrapolated by applying the long-term expected market growth rate.

As of 31 December 2021, the Group did not record any impairment loss related to goodwill.

The carrying amount of respective Cash Generating Units and main assumptions are as follows:

| (in millions of euros) | Specialty Care | Consumer Healthcare | Total |
|---|----------------|---------------------|----------------|
| Net carrying value at 31 December 2020 | | | |
| Goodwill | 495.9 | 96.9 | 592.8 |
| Net underlying assets | 1,676.3 | 177.7 | 1,854.0 |
| Total | 2,172.2 | 274.6 | 2,446.8 |
| <i>Perpetuity growth rate</i> | 1.5% | 1.5% | |
| <i>Discount rate</i> | 8.0% | 8.0% | |
| Net carrying value at 31 December 2021 | | | |
| Goodwill | 526.2 | 96.9 | 623.2 |
| Net underlying assets | 1,924.0 | 148.2 | 2,072.2 |
| Total | 2,450.2 | 245.1 | 2,695.3 |
| <i>Perpetuity growth rate</i> | 1.5% | 1.5% | |
| <i>Discount rate</i> | 8.0% | 8.0% | |

Tests were performed to assess the sensitivity of the recoverable amount to probable changes in certain actuarial assumptions, primarily to the discount rate (range +/- 1%), sales growth (range -1% to -2%) and the long-term growth rate (range +/-1%). Implementing sensitivity tests would not lead to the recognition of significant goodwill impairments.

Note 11 Other intangible assets

| (in millions of euros) | Intellectual property | Software | Other intangible assets and intangible assets in progress | Total other intangible assets |
|--|-----------------------|----------------|---|-------------------------------|
| Gross value at 01 January 2020 | 2,495.2 | 141.2 | 36.0 | 2,672.4 |
| Acquisitions / increases | 32.7 | 11.9 | 14.7 | 59.3 |
| Disposals / decreases | (49.0) | (8.0) | — | (57.0) |
| Foreign exchange differences | (152.9) | (1.1) | (0.3) | (154.3) |
| Transfers and other movements | 3.5 | 22.0 | (23.7) | 1.9 |
| Gross value at 31 December 2020 | 2,329.5 | 166.0 | 26.8 | 2,522.2 |
| Acquisitions / increases | 300.2 | 10.0 | 21.5 | 331.7 |
| Disposals / decreases | (53.8) | (3.8) | — | (57.5) |
| Foreign exchange differences | 127.6 | 1.3 | 0.1 | 129.1 |
| Transfers and other movements | — | 17.8 | (15.0) | 2.8 |
| Gross value at 31 December 2021 | 2,703.5 | 191.3 | 33.4 | 2,928.2 |
| Amortization and impairment at 01 January 2020 | (1,186.7) | (99.4) | (3.2) | (1,289.2) |
| Amortization | (86.1) | (20.1) | (0.4) | (106.6) |
| Impairment losses | (125.9) | — | — | (125.9) |
| Disposals / decreases | 22.7 | 3.7 | — | 26.4 |
| Foreign exchange differences | 93.7 | 0.6 | — | 94.3 |
| Transfers and other movements | — | (0.1) | — | (0.1) |
| Amortization and impairment at 31 December 2020 | (1,282.4) | (115.2) | (3.5) | (1,401.1) |
| Amortization | (81.9) | (20.4) | (0.4) | (102.7) |
| Impairment losses | (9.1) | — | — | (9.1) |
| Disposals / decreases | 53.8 | 1.6 | — | 55.4 |
| Foreign exchange differences | (77.8) | (0.9) | — | (78.7) |
| Transfers and other movements | — | — | — | — |
| Amortization and impairment at 31 December 2021 | (1,397.4) | (134.9) | (3.9) | (1,536.2) |
| Net value at 31 December 2020 | 1,047.1 | 50.8 | 23.2 | 1,121.1 |
| Net value at 31 December 2021 | 1,306.1 | 56.4 | 29.5 | 1,392.0 |

11.1 Gross value of intangible assets

In 2021, the change in gross value of intangible assets was mainly due to the following items:

- Ipsen recognized €138.7 million in intangible assets for additional Exelixis milestone payments;
- Ipsen had intangible assets related to collaboration agreements signed in 2021, particularly with GENFIT for €98.3 million, Irlab for €23.5 million, and Exicure for €16.6 million;
- Ipsen sold intellectual property from research programs pertaining to Systemic Radiation Therapy (SRT) to Fusion Pharmaceuticals Inc. and SatoSea Oncology GmbH.

As of 31 December 2021, the Group's "Licenses" with an indefinite useful life and classified under "intellectual property" had a total carrying value of €483.4 million (€298.7 million in 2020).

These assets concerned rights acquired for specialty pharmaceuticals in Oncology, Neuroscience, and Rare Diseases that were in an advanced phase of development but had not yet been marketed. As a result, the assets have not been amortized yet, in accordance with the Group's accounting principles. For these intangible assets, the recoverable amount corresponds to the value-in-use based on estimated expected future cash flows.

In 2020, changes in the gross value of intangible assets were due to the following items:

- Ipsen recognized €22.2 million in intangible assets for additional Exelixis milestone payments;
- Ipsen had intangible assets related to collaboration agreements signed in 2020;
- Ipsen returned intellectual property to partners as part of Ipsen's strategic review of the Specialty Care business.

11.2 Impairment tests of intangible assets

Impairment tests on intangible assets (excluding software) led Ipsen to record impairment on the following intangible assets for 2020 and 2021:

| (in millions of euros) | 2021 | 2020 |
|--|--------------|----------------|
| Impairment losses on intangible assets (excluding software) (a) | (9.1) | (149.8) |
| Research and development projects - Specialty Care (b) | — | (107.8) |
| <i>Of which palovarotene</i> | — | (55.8) |
| Marketed products - Specialty Care (c) | (9.1) | (25.0) |
| Marketed products - Consumer Healthcare (d) | — | (17.0) |
| Other impairment losses (a) | — | (4.1) |

(a) Impairment on intangible assets (excluding software) and other impairment are shown on the “impairment losses” line of the income statement.

(b) In 2021, as part of the annual review of assets with an indefinite useful life, the Group conducted an impairment test to remeasure the intangible asset palovarotene’s recoverable amount.

The recoverable amount corresponds the discounted value of expected future cash flows from these scenarios over the product’s estimated life cycle, including new clinical data and potential sales developments as well as estimated approval dates for the FOP indication.

A probability of success for the approval of this indication was also applied.

The Group used 9% as the discount rate given the specific level of risk to palovarotene.

These assumptions reflect management's best estimate as well as information management knew at the time the impairment test was conducted.

An increase or decrease in probability of success could significantly impact the value of the asset tested:

- a 5% increase in the probability would increase the recoverable value by €31 million;
- a 5% increase in the probability would reduce the recoverable value by €32 million.

The Group has performed sensitivity analyses based on a change of only one parameter. As a result, these sensitivity analyses correspond to a mechanical calculation method that does not reflect a consistent change in all parameters (regulatory and commercial) nor does it incorporate additional measures the Group could take in such circumstances.

The impairment tests results do not conduct to any change in the net booked value of the palovarotene intangible asset as of December 31, 2021.

In 2020, Ipsen recorded impairments on the IPN60090, IPN01087, and Satoreotide research programs.

(c) In 2020, the intangible asset Xermelo was fully impaired after revising potential geographic developments and future sales outlooks. Ipsen partially impaired the asset Increlex to take into account a downward revision in the asset’s future sales forecast.

(d) In 2020, Ipsen discounted future cash forecasts for the asset Prontalgine to take into account the latest business plan and new strategic priorities for the sales team in France.

11.3 Breakdown of intangible assets by asset type

| (in millions of euros) | 31 December 2021 | | | 31 December 2020 | | |
|-------------------------------|------------------|---------------------------|----------------|------------------|---------------------------|----------------|
| | Gross value | Amortization & impairment | Net value | Gross value | Amortization & impairment | Net value |
| Brands and Trademarks | 67.1 | (57.8) | 9.3 | 67.3 | (57.0) | 10.3 |
| Licenses | 2,594.5 | (1,312.9) | 1,281.6 | 2,220.5 | (1,200.2) | 1,020.3 |
| Patents | 9.5 | (9.5) | — | 9.2 | (9.1) | 0.1 |
| Know-How | 32.3 | (17.2) | 15.2 | 32.6 | (16.1) | 16.5 |
| Software | 191.3 | (134.9) | 56.4 | 166.0 | (115.2) | 50.8 |
| Other intangible assets | 4.3 | (3.9) | 0.3 | 4.3 | (3.5) | 0.7 |
| Intangible assets in progress | 29.1 | — | 29.1 | 22.5 | — | 22.5 |
| TOTAL | 2,928.2 | (1,536.2) | 1,392.0 | 2,522.2 | (1,401.1) | 1,121.1 |
| Of which impairment losses | | (865.8) | | | (864.2) | |

Note 12 Property, plant & equipment

12.1 Movements

| (in millions of euros) | Lands | Buildings | Equipment and tools | Other assets | Tangible assets in progress | Total property, plant and equipment |
|--|--------------|----------------|---------------------|---------------|-----------------------------|-------------------------------------|
| Gross value at 01 January 2020 | 18.3 | 517.2 | 376.6 | 128.6 | 129.8 | 1,170.6 |
| Acquisitions / increases | 1.5 | 9.1 | 9.9 | 14.2 | 46.8 | 81.4 |
| Disposals / decreases | — | (4.4) | (10.1) | (8.4) | — | (22.9) |
| Foreign exchange differences | (0.2) | (15.0) | (8.8) | (5.2) | (1.5) | (30.7) |
| Transfers and other movements | 2.0 | 45.4 | 25.0 | 10.3 | (84.6) | (1.8) |
| Gross value at 31 December 2020 | 21.7 | 552.3 | 392.4 | 139.4 | 90.6 | 1,196.5 |
| Acquisitions / increases | 0.1 | 26.6 | 2.9 | 14.5 | 51.8 | 96.0 |
| Disposals / decreases | — | (11.5) | (10.3) | (11.8) | — | (33.7) |
| Foreign exchange differences | 0.2 | 15.6 | 11.5 | 4.7 | 2.1 | 34.1 |
| Transfers and other movements | 0.1 | 13.9 | 15.7 | 5.1 | (37.7) | (2.9) |
| Gross value at 31 December 2021 | 22.1 | 596.9 | 412.3 | 151.9 | 106.7 | 1,290.0 |
| Amortization and impairment at 01 January 2020 | (2.9) | (217.0) | (213.6) | (56.3) | (1.5) | (491.3) |
| Amortization | (0.5) | (42.6) | (21.3) | (19.7) | — | (84.1) |
| Impairment losses ⁽¹⁾ | — | (1.3) | (2.7) | — | — | (4.0) |
| Disposals / decreases | — | 1.6 | 9.3 | 7.8 | — | 18.8 |
| Foreign exchange differences | — | 4.9 | 3.6 | 2.2 | — | 10.8 |
| Transfers and other movements | — | — | (0.1) | — | — | — |
| Amortization and impairment at 31 December 2020 | (3.3) | (254.3) | (224.7) | (66.0) | (1.5) | (549.9) |
| Amortization | (0.6) | (44.8) | (24.0) | (21.4) | — | (90.7) |
| Impairment losses ⁽¹⁾ | — | (13.4) | 0.5 | (1.8) | — | (14.7) |
| Disposals / decreases | — | 9.3 | 7.4 | 10.2 | — | 26.9 |
| Foreign exchange differences | (0.1) | (6.9) | (5.1) | (2.2) | — | (14.2) |
| Transfers and other movements | — | (0.1) | (0.2) | 0.4 | — | 0.1 |
| Amortization and impairment at 31 December 2021 | (3.9) | (310.2) | (246.1) | (80.8) | (1.5) | (642.5) |
| Net value at 31 December 2020 | 18.4 | 298.0 | 167.7 | 73.5 | 89.1 | 646.6 |
| Net value at 31 December 2021 | 18.2 | 286.7 | 166.1 | 71.2 | 105.2 | 647.5 |

(1) Changes relating to impairment losses on property, plant and equipment are shown on the "Other operating income/(expenses)" line item in the 2021 income statement.

In 2021, acquisitions of property, plant and equipment totaled €96.0 million, compared with €81.4 million in 2020. The increase in acquisitions resulted primarily from project delays and/or cancellations caused by the COVID-19 pandemic in

2020. Acquisitions in 2021 mostly related to investments at Group industrial sites in France, in Ireland, in the United Kingdom, and in the United States to increase production capacity.

12.2 Rights of use of leased assets

| (in millions of euros) | Real estate | Cars | Other | Total assets rights of use |
|--------------------------------------|-------------|-------------|------------|----------------------------|
| Net value at 31 December 2020 | 96.0 | 11.0 | 0.8 | 107.7 |
| Acquisitions / increases | 21.0 | 7.1 | — | 28.2 |
| Disposals / decreases | (1.6) | (0.2) | — | (1.8) |
| Impairment / amortization | (28.6) | (8.0) | (0.3) | (37.0) |
| Foreign exchange differences | 3.6 | 0.3 | — | 3.9 |
| Transfers and other movements | — | — | — | — |
| Net value at 31 December 2021 | 90.5 | 10.2 | 0.4 | 101.1 |

An analysis of lease liabilities is shown in note 20.

As of 31 December 2021, amortization of lease assets amounted to a €31.0 million expense under the "Other operating expenses" line item in the income statement. Depreciation totaled a €6.0 million expense in the income statement.

As of 31 December 2021, interest expense in the income statement amounted to €3.2 million.

For 2021, cash outflows amounted to €33.3 million. It is shown in the Statement of Cash Flows under "Net change in short-term borrowings".

Note 13 Equity investments

| (in millions of euros) | Equity investments at fair value through other comprehensive income | Equity investments at fair value through profit and loss | Equity investments |
|--|---|--|--------------------|
| 31 December 2020 | 44.2 | 40.2 | 84.5 |
| Change in fair value | (17.2) | 3.1 | (14.1) |
| Increase | 25.2 | 12.6 | 37.9 |
| Disposals / decrease | (1.8) | — | (1.8) |
| Other movements including foreign exchange differences | 0.3 | 0.1 | 0.4 |
| 31 December 2021 | 50.8 | 56.0 | 106.9 |

13.1 Equity investments at fair value through other items of comprehensive income

Acquisitions primarily included equity investments in GENFIT S.A. totaling €17.9 million and in SatoSea Oncology GmbH totaling €4.0 million.

As of 31 December 2021, changes in fair value of these equity investments mainly corresponded to a decrease in the fair value of shares in Rhythm Pharmaceuticals Inc. for €17.9 million.

13.2 Equity investments at fair value through profit/(loss)

The acquisitions mainly included equity investments in Fusion Pharmaceuticals Inc. amounting to €5.4 million and payments made to Agent Capital Funds for €7.3 million.

The change in fair value of equity investments through profit/(loss) mainly included Agent Capital for €7.3 million.

Note 14 Investments in equity-accounted companies

As of 31 December 2021, the Group owns a 50% interest in Linnea S.A., and 13.7% interest in Bakx Therapeutics Inc. both companies were consolidated using the equity method.

| (in millions of euros) | 31 December 2020 | Movements during the year | | | | 31 December 2021 |
|---|------------------|---------------------------|-------------|---------------------------------|--|------------------|
| | | Acquisition | Divestiture | Net profit/(loss) of the period | Foreign exchange differences and other movements | |
| Investments accounted for using the equity method | 19.1 | 10.3 | (5.1) | 0.4 | 1.5 | 26.2 |

On 30 April 2021, Ipsen sold its interest in the following companies:

- Garnay Inc.
- Cara Partners
- Perechin Company
- Portpirie Company
- Wallingstown Company
- Wallingstown Company Limited
- Saint-Jean d'Ilac S.C.A.

Ipsen recognized its investment in these entities using the equity accounting method until 30 April 2021, except for Saint-Jean d'Ilac S.C.A., which was removed from the scope of consolidation on 31 July 2021.

On 27 July 2021, Ipsen purchased an equity investment in Bakx Therapeutics Inc. for €10.3 million, or 14.87% of the share capital. Ipsen consolidated this entity using the equity method.

The information below corresponds to financial statement data for equity-accounted companies, prepared using the Group's accounting policies (for amounts up to 100%):

| (in millions of euros) | 31 December 2021 | | | |
|------------------------|------------------|---|-------------|--------------------------------|
| | Assets | Liabilities, excluding shareholders' equity | Sales | Net profit/(loss) for the year |
| Linnea S.A. | 39.8 | 9.5 | 22.4 | 0.1 |
| Bakx Therapeutics Inc. | 19.8 | 0.1 | — | (1.7) |
| Total | 59.6 | 9.6 | 22.4 | (1.6) |

An anti-competitive practices investigation was launched in 2019 against the company Linnea. As the authorities have provided little information at this stage on the allegations made, Linnea cannot predict with a reasonable level of assurance the potential financial impact this could have on its accounts. For these reasons, no provision has been recorded in Linnea's accounts as of 31 December 2021.

Note 15 Non-current financial assets and other non-current assets

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| Contingent assets related to business combinations | — | 23.1 |
| Liquidity agreement | 1.3 | 1.3 |
| Deposits paid | 2.9 | 2.5 |
| Other non-current assets | 0.1 | — |
| Total other non-current assets | 4.3 | 26.9 |

Non-current financial assets related to contingent payments decreased after reclassifying them under "Current financial assets" for €23.9 million.

Note 16 Current assets and liabilities

■ 16.1 Inventories

| (in millions of euros) | 31 December 2021 | | | 31 December 2020 |
|----------------------------|------------------|---------------|--------------|------------------|
| | Gross value | Depreciations | Net value | Net value |
| Raw materials and supplies | 63.2 | (4.3) | 59.0 | 54.4 |
| Work in progress | 56.6 | (5.1) | 51.5 | 47.5 |
| Finished goods | 117.7 | (8.8) | 108.9 | 112.1 |
| Total | 237.5 | (18.2) | 219.4 | 213.9 |

Changes during the period mainly included €4.9 million related to foreign exchange impacts.

■ 16.2 Trade receivables

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|------------------------|------------------|------------------|
| Gross value | 569.6 | 481.3 |
| Depreciation | (5.4) | (5.1) |
| Net value | 564.3 | 476.2 |

The increase in trade receivables was due to improvement in the Group's performance. Changes during the period also included €20.8 million related to foreign exchange impacts.

| (in millions of euros) | Total overdue trade receivables - gross value | Trade receivables < 3 months | Trade receivables from 3 to 6 months | Trade receivables from 6 to 12 months | Trade receivables > 12 months |
|------------------------|---|------------------------------|--------------------------------------|---------------------------------------|-------------------------------|
| 31 December 2021 | 8.8 | (4.3) | 0.8 | 5.8 | 6.6 |
| 31 December 2020 | 13.9 | 1.6 | 1.3 | 4.5 | 6.6 |

■ 16.3 Trade payables

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|------------------------|------------------|------------------|
| Trade payables | 594.7 | 495.2 |

Changes during the period mainly included €15.8 million related to foreign exchange impacts.

■ 16.4 Other current assets

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| Contingent assets related to business combinations | 42.4 | 18.2 |
| Derivative financial instruments | 11.7 | 3.9 |
| Other current financial assets | — | 26.8 |
| Advance payments to suppliers | 9.8 | 12.1 |
| Prepayments | 68.0 | 36.2 |
| Recoverable VAT | 77.4 | 43.0 |
| Other assets | 23.4 | 22.4 |
| Total current financial assets and other current assets | 232.7 | 162.6 |

Contingent assets related to business combinations increased after reclassifying them from "Non current financial assets" to "Current financial assets" for €23.9 million.

The increase in "Prepayments" primarily included a prepayment for GENFIT's R&D activities.

The increase in "Recoverable VAT" mainly included €24 million in VAT related to the initial payment resulting from the partnership with GENFIT S.A.

16.5 Other current and non-current liabilities

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|---|------------------|------------------|
| Non-current deferred income | 45.8 | 45.1 |
| Total other non-current liabilities | 45.8 | 45.1 |
| Amounts due to non-current asset suppliers | 135.7 | 38.6 |
| Employment-related liabilities | 198.2 | 164.7 |
| VAT payable | 37.6 | 20.2 |
| Other current tax liabilities (excluding VAT and Corporate Tax) | 18.4 | 15.6 |
| Current deferred income | 6.0 | 5.4 |
| Other liabilities | 5.8 | 5.5 |
| Total other current liabilities | 401.7 | 250.0 |

The increase in “Amounts due to non-current asset suppliers” as of 31 December 2021 was due to receiving €87.9 million in undisbursed milestone payments as part of Ipsen’s partnership with Exelixis.

Note 17 Cash and cash equivalents

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|---------------------------|------------------|------------------|
| Cash and cash equivalents | 814.7 | 642.5 |
| Bank overdrafts | (5.5) | (2.8) |
| Total cash | 809.1 | 639.6 |

Note 18 Consolidated shareholders' equity

■ 18.1 Share capital

As of 31 December 2021, Ipsen's share capital comprised 83,814,526 ordinary shares each with a par value of €1, including 48,311,316 shares with double voting rights, compared with 83,814,526 ordinary shares each with a par value of €1, including 48,301,470 shares with double voting rights as of 31 December 2020.

■ 18.2 Earnings per share

Basic earnings per share were calculated on the weighted average number of shares outstanding during the year (see note 3.32).

• Bonus share plans

As of 31 December 2021:

- bonus shares granted by the plans dated 28 May 2019 (2nd tranche), 12 February 2020, 29 May 2020, 29 July 2020, and 27 May 2021 are not included in the weighted average number of shares used to calculate basic income;
- bonus shares granted by the plans dated 28 May 2019 and 12 February 2020, as well as the share of bonus shares not subject to performance conditions in the 29 May 2020, 29 July 2020, and 27 May 2021 plans are included in calculating the weighted average number of shares from diluted earnings.

| (in millions of euros/number of shares) | 31 December 2021 | 31 December 2020 |
|--|-------------------|-------------------|
| Net profit from continuing operations - attributable to Ipsen S.A. shareholders | 646.6 | 548.0 |
| Net profit from discontinued operations - attributable to Ipsen S.A. shareholders ⁽¹⁾ | — | — |
| Consolidated net profit - attributable to Ipsen S.A. shareholders | 646.6 | 548.0 |
| Number of ordinary shares at start of year | 83,814,526 | 83,814,526 |
| Treasury shares (weighted average number) | (1,167,170) | (849,687) |
| Impact of options exercised during the year | 0 | 0 |
| Weighted average number of shares outstanding during the year | 82,647,356 | 82,964,839 |
| Basic earnings per share (in euros) | 7.82 | 6.61 |
| Basic earnings per share, continuing operations (in euros) | 7.82 | 6.61 |
| Basic earnings per share, discontinued operations (in euros) ⁽¹⁾ | 0.00 | 0.00 |
| Weighted average number of shares outstanding to calculate basic earnings per share | 82,647,356 | 82,964,839 |
| Dilutive effect of stock options | 0 | 0 |
| Dilutive effect of bonus shares | 711,070 | 483,275 |
| Weighted average number of shares outstanding to calculate diluted earnings per share | 83,358,426 | 83,448,114 |
| Diluted earnings per share (in euros) | 7.76 | 6.57 |
| Diluted earnings per share, continuing operations (in euros) | 7.76 | 6.57 |
| Diluted earnings per share, discontinued operations (in euros) ⁽¹⁾ | 0.00 | 0.00 |

(1) Profit received in 2020 from businesses sold before 2020 were reclassified from "Profit from discontinued operations" to the "Other operating income" line item for €3.8 million.

■ 18.3 Distributions

| | | 31 December 2021 | 31 December 2020 |
|--|----------------|------------------|------------------|
| Distribution payout (in euros) | (a) | 82,891,813 | 83,189,972 |
| Number of shares on the payment date | (b) | 82,891,813 | 83,189,972 |
| Distribution per share (in euros) | (a)/(b) | 1.00 | 1.00 |

Note 19 Provisions

| (in millions of euros) | Provisions for business and operating risks | Provisions for legal risks | Provision for restructuring costs | Other provisions | Total Provisions |
|---|---|----------------------------|-----------------------------------|------------------|------------------|
| 31 December 2019 | 7.5 | 20.7 | 8.4 | 3.0 | 39.6 |
| Charges | 4.9 | 9.6 | 36.7 | 2.3 | 53.4 |
| Applied reversals | (2.5) | (2.1) | (5.4) | (1.7) | (11.6) |
| Released reversals | (0.1) | (0.7) | (0.8) | — | (1.7) |
| Change in consolidation scope | — | — | — | — | — |
| Foreign exchange differences, transfers and other movements | (0.1) | (0.5) | (0.8) | (0.6) | (2.0) |
| 31 December 2020 | 9.7 | 27.0 | 38.1 | 2.9 | 77.7 |
| Charges | 6.1 | 41.3 | 19.0 | 2.7 | 69.1 |
| Applied reversals | (3.9) | (0.5) | (20.4) | (0.8) | (25.6) |
| Released reversals | (1.9) | (7.3) | (6.9) | (0.4) | (16.4) |
| Foreign exchange differences, transfers and other movements | — | 0.1 | 0.6 | — | 0.8 |
| 31 December 2021 | 10.0 | 60.6 | 30.5 | 4.5 | 105.6 |
| <i>of which non-current</i> | <i>5.1</i> | <i>49.2</i> | <i>6.2</i> | <i>3.4</i> | <i>64.0</i> |
| <i>of which current</i> | <i>4.9</i> | <i>11.4</i> | <i>24.3</i> | <i>1.1</i> | <i>41.6</i> |

As of 31 December 2021, provisions broke down as follows:

- **Business and operating risks**

These provisions included certain risks of an economic nature reflecting costs that the Group could be brought to bear to terminate commercial contracts and research studies or resolve various commercial disagreements.

- **Legal risks**

These provisions included, in particular, the risk of tax reassessment by local authorities at certain Group subsidiaries and certain additional taxes that the Group may be required to pay.

- **Restructuring costs**

These provisions mainly correspond to costs incurred by the Group to adapt its structure, transformation costs for French subsidiaries, and costs to relocate the Onivyde manufacturing site from Cambridge (Massachusetts, United States) to Signes, France.

Allowances and reversals during 2021 are recognized in Operating Income.

Note 20 Bank loans and financial liabilities

| (in millions of euros) | 31 December 2020 | New loans / Increases | Repayments / Decreases | Change in fair value | Other movements including foreign exchange differences | 31 December 2021 |
|---|------------------|-----------------------|------------------------|----------------------|--|------------------|
| Bonds and bank loans | 542.7 | — | — | — | 20.1 | 562.8 |
| Lease liabilities | 96.4 | 28.5 | (2.0) | — | (27.9) | 95.0 |
| Other financial liabilities | 4.4 | 2.4 | (0.9) | — | (0.8) | 5.1 |
| Non-current financial liabilities (measured at amortized cost) | 643.5 | 30.8 | (3.0) | — | (8.6) | 662.9 |
| Contingent liabilities related to business combinations | 118.1 | — | (0.1) | 2.1 | (10.8) | 109.3 |
| Non-current financial liabilities (measured at fair value) | 118.1 | — | (0.1) | 2.1 | (10.8) | 109.3 |
| Non-current financial liabilities | 761.6 | 30.8 | (3.0) | 2.1 | (19.4) | 772.2 |
| Credit lines and bank loans | 199.0 | — | (209.8) | — | 10.8 | — |
| Lease liabilities | 29.9 | — | (33.3) | — | 33.1 | 29.8 |
| Other financial liabilities ⁽¹⁾ | 155.7 | 657.0 | (724.7) | — | 0.4 | 88.4 |
| Current financial liabilities (measured at amortized cost) | 384.7 | 657.0 | (967.8) | — | 44.3 | 118.2 |
| Contingent liabilities related to business combinations | 19.1 | — | (20.8) | 25.1 | 21.6 | 45.1 |
| Derivative financial instruments | 4.8 | — | — | 6.7 | — | 11.5 |
| Current financial liabilities (measured at fair value) | 23.9 | — | (20.8) | 31.8 | 21.6 | 56.6 |
| Current financial liabilities | 408.6 | 657.0 | (988.5) | 31.8 | 65.9 | 174.8 |
| Total financial liabilities | 1,170.2 | 687.8 | (991.5) | 33.9 | 46.5 | 947.0 |

(1) Additions and repayments of "Other current financial liabilities measured at amortized cost" are mainly related to commercial paper.

The Group's financing mainly includes:

- a €300 million, unsecured, seven-year public bond taken out on 16 June 2016 with a coupon at an annual interest rate of 1.875%;
- a \$300 million long-term U.S. Private Placement (USPP) taken out on 23 July 2019 in two tranches with 7- and 10-year maturities;
- a €1.5 billion Revolving Credit Facility (RCF) taken out on 24 May 2019. The new Revolving Credit Facility initially matured in five years and had two one-year extension options, exercised in 2020 and 2021, respectively, extending the maturity to May 2026. As of 31 December 2021, the RCF was no longer used;

- a €600 million commercial paper program (NEU CP – Negotiable EUROpean Commercial Paper), €80 million of which has been drawn as of 31 December 2021.

Changes in fair value of "Contingent assets and liabilities related to business combinations" included, particularly, a change in fair value of contingent regulatory and commercial milestone payments related to the intangible asset Onivyde, totaling €25.9 million.

Other movements included €46.3 million in foreign exchange differences and reclassifications between non-current and current liabilities.

Movements in financial liabilities between 31 December 2019 and 31 December 2020 were as follows:

| (in millions of euros) | 31 December 2019 | New loans / Increases | Repayments / Decreases | Change in fair value | Other movements including foreign exchange differences | 31 December 2020 |
|---|------------------|--------------------------|---------------------------|-------------------------|---|------------------|
| Bonds and bank loans | 568.2 | — | — | — | (25.5) | 542.7 |
| Lease liabilities | 128.1 | 9.3 | (0.1) | — | (40.9) | 96.4 |
| Other financial liabilities | 3.5 | 2.5 | (0.9) | — | (0.6) | 4.4 |
| Non-current financial liabilities (measured at amortized cost) | 699.8 | 11.8 | (1.1) | — | (67.0) | 643.5 |
| Contingent liabilities related to business combinations | 155.0 | — | — | (25.7) | (11.2) | 118.1 |
| Non-current financial liabilities (measured at fair value) | 155.0 | — | — | (25.7) | (11.2) | 118.1 |
| Non-current financial liabilities | 854.7 | 11.8 | (1.1) | (25.6) | (78.2) | 761.6 |
| Credit lines and bank loans | 270.8 | — | (47.9) | — | (23.8) | 199.0 |
| Lease liabilities | 31.8 | — | (33.1) | — | 31.1 | 29.9 |
| Other financial liabilities | 271.4 | 1,181.0 | (1,294.8) | — | (2.0) | 155.7 |
| Current financial liabilities (measured at amortized cost) | 574.0 | 1,181.0 | (1,375.8) | — | 5.3 | 384.7 |
| Contingent liabilities related to business combinations | 26.4 | — | — | (8.6) | 1.4 | 19.1 |
| Derivative financial instruments | 9.1 | — | — | (4.1) | (0.2) | 4.8 |
| Current financial liabilities (measured at fair value) | 35.4 | — | — | (12.8) | 1.3 | 23.9 |
| Current financial liabilities | 609.5 | 1,181.0 | (1,375.8) | (12.7) | 6.6 | 408.6 |
| Total financial liabilities | 1,464.2 | 1,192.8 | (1,376.9) | (38.4) | (71.6) | 1,170.2 |

Note 21 Financial instruments

■ 21.1 Interest rate risk hedging

The Group's funding consists of a fixed-rate debt from bond debts (bonds and U.S. Private Placement – USPP), as well as variable-rate debt from revolving credit facilities and a commercial paper program (NEU CP – Negotiable European Commercial Papers).

As of 31 December 2021, there were no derivative financial instruments for hedging interest rate risk.

■ 21.2 Exchange rate risk hedging

21.2.1 Exposure to exchange rate risk

Part of the Group's business is conducted in countries where the euro, the Group's reporting currency, is the functional currency. Nevertheless, owing to its international business scope, the Group is exposed to exchange rate fluctuations that can affect its results.

A 10% increase or decrease in the U.S. dollar, the pound sterling, the Chinese yuan, or the Russian ruble against the euro (the main currencies in which the Group operates) would impact sales by plus 5% or minus 4%, and Group Operating income by plus 5% or minus 4%.

Several types of risks can be identified:

- transactional foreign exchange risk related to business activities: the Group hedges its main foreign currencies, including the USD, GBP, CNY, RUB, CHF, AUD, and BRL, based on its budget forecasts;
- financing foreign exchange risk related to financing contracted in a currency other than the functional currencies of Group entities.

Ipsen implemented a foreign exchange rate hedging policy to reduce the exposure of its net profit to foreign currency fluctuations.

- **Impact of financial instruments used for future cash flow hedges on "Shareholders' equity"**

As of 31 December 2021, the future cash flow hedge reserve for business transactions came to €2.3 million pre-tax, compared to a reserve of €14.3 million pre-tax as of 31 December 2020.

• **Impact of financial instruments used for future cash flow hedges on "Operating Income"**

As of 31 December 2021, financial instruments used for future cash flow hedges on business transactions positively impacted Operating income in the amount of €13.6 million.

• **Impact of financial instruments used for future cash flow hedges on "Net financial income/(expense)"**

As of 31 December 2021, the impact of financial instruments used for future cash flow hedges recognized in Net financial income/(expense) came to (€7.2) million.

• **Impact of financial instruments not qualified for future cash flow hedges on "Net financial income/(expense)"**

As of 31 December 2021, the impact of financial instruments not qualified for future cash flows is included in the "Foreign exchange gain/(loss) on non-operating activities" line item in net financial income/(expense) and came to (€0.9) million as of 31 December 2021. The impact of these financial instruments in "Net financial income/(expense)" came to (€0.5) million over the period.

• **Impact of financial instruments used for net investment hedges on "Shareholders' equity"**

As of 31 December 2021, the net investment hedge reserve accounted for €1.0 million before tax.

As of 31 December 2021 and 31 December 2020, derivative financial instruments held by the Group broke down as follows:

| (in millions of euros) | 31 December 2021 | | | | | | 31 December 2020 | | | |
|---|-------------------------|----------------|-------------|---------------------------|----------------|--------------|------------------|--------------|-------------|--------------|
| | Face value | Fair value | | Nominal value by maturity | | | Face value | Fair value | | |
| | | Assets | Liabilities | Less than 1 year | 1 to 5 years | Over 5 years | | Assets | Liabilities | |
| Exchange rate risk hedging - Business transactions | | | | | | | | | | |
| Put forward contracts | Cash Flow Hedge | 610.1 | 8.4 | (10.1) | 610.1 | — | — | 345.1 | 2.7 | (3.7) |
| Put option contracts | Cash Flow Hedge | — | — | — | — | — | — | — | — | — |
| Seller at maturity foreign exchange swaps | Cash Flow Hedge | 57.9 | 0.2 | (0.4) | 57.9 | — | — | 73.1 | 0.8 | (0.5) |
| Call forward contracts | Cash Flow Hedge | 138.9 | 2.1 | — | 138.9 | — | — | 84.8 | 0.1 | (0.2) |
| Call option contracts | Cash Flow Hedge | — | — | — | — | — | — | — | — | — |
| Buyer at maturity foreign exchange swaps | Cash Flow Hedge | 43.6 | 0.4 | (0.2) | 43.6 | — | — | 13.3 | — | — |
| Total business transactions | | 850.5 | 11.1 | (10.7) | 850.5 | — | — | 516.3 | 3.6 | (4.4) |
| Exchange rate risk hedging - Financial transactions | | | | | | | | | | |
| Put forward contracts | Non-hedging derivatives | — | — | — | — | — | — | — | — | — |
| Seller at maturity foreign exchange swaps | Non-hedging derivatives | 124.2 | 0.1 | (0.5) | 124.2 | — | — | 96.2 | 0.2 | (0.2) |
| Call forward contracts | Non-hedging derivatives | — | — | — | — | — | — | — | — | — |
| Buyer at maturity foreign exchange swaps | Non-hedging derivatives | 266.9 | 0.6 | (0.2) | 266.9 | — | — | 74.8 | — | (0.2) |
| Total financial transactions | | 391.1 | 0.7 | (0.7) | 391.1 | — | — | 171.1 | 0.2 | (0.4) |
| Total hedging of business and financial transactions | | 1,241.6 | 11.8 | (11.4) | 1,241.6 | 0.0 | 0.0 | 687.4 | 3.9 | (4.8) |

21.2.2 Transactional foreign exchange risk

The Group's hedging policy aims to protect Operating income from foreign exchange rate fluctuations compared to its company forecasts. Accordingly, the effective portion of the hedge is recorded in operating income.

The Group hedges its main foreign currencies, including the USD, GBP, CNY, RUB, CHF, AUD, and BRL, based on its budget forecasts and highly probable business transactions.

To reduce its exposure to foreign exchange rate fluctuations, Ipsen mainly uses derivative instruments, primarily put or call forward contracts as well as currency swaps and non deliverable forward (NDF) contracts.

These derivatives hedge primarily significant future cash flows denominated in foreign currencies after the close of the reporting period, *i.e.* the balance sheet date. The Group mainly uses future cash flow hedge accounting.

The Group's policy is not aimed at carrying out derivative financial instrument transactions for speculative gain.

21.2.3 Financing foreign exchange risk

Pooling financing surpluses and needs of foreign subsidiaries outside the euro zone exposes certain entities to foreign exchange risk arising from fluctuations in the value of financial liabilities and receivables denominated in currencies other than the functional currency of the lending or borrowing entity. To pool the risk, intra-group financing is generally denominated in the subsidiary's functional currency.

The Group hedges financial current accounts denominated in the functional currencies of its subsidiaries through financial instruments that match current account balances. These include currency swaps and loans and borrowings contracted from counterparty banks.

21.3 Derivative financial instruments reported in the balance sheet

Derivative financial instruments reported in the balance sheet as of 31 December 2021 and 2020 are as follows:

| (in millions of euros) | 31 December 2021 | | 31 December 2020 | |
|--------------------------------------|------------------|-----------------------|------------------|-----------------------|
| | Financial assets | Financial liabilities | Financial assets | Financial liabilities |
| Market value of currency instruments | 11.7 | (11.5) | 3.9 | (4.8) |
| Total | 11.7 | (11.5) | 3.9 | (4.8) |

Note 22 Financial instruments reported in the balance sheet

In accordance with the amendment to IFRS 13 – *Fair Value Measurement*, financial instruments are presented in three categories based on a hierarchical method used to determine their fair value:

- level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities;
- level 2: fair value calculated using valuation techniques based on observable market data such as prices of similar assets and liabilities or parameters quoted in an active market;
- level 3: fair value calculated using valuation techniques based wholly or partly on unobservable inputs such as prices in an inactive market or a valuation based on multiples for unlisted securities.

Financial instruments reported in the balance sheet as of 31 December 2021 broke down as follows:

| (in millions of euros) | 31 December 2021 | Breakdown by financial instrument class - balance sheet value | | | | | | Level of fair value | | |
|-----------------------------------|------------------|---|---|--|--------------------------|-------------------------------|----------------------------------|---------------------|-------------|--------------|
| | Carrying value | Fair value through income statement | Financial assets at fair value through other comprehensive income | Financial assets at fair value through profit/(loss) | Assets at amortized cost | Liabilities at amortized cost | Derivative financial instruments | Level 1 | Level 2 | Level 3 |
| Equity investments | 106.9 | — | 50.8 | 56.1 | — | — | — | 48.7 | — | 58.2 |
| Non-current financial assets | 0.1 | — | — | — | 0.1 | — | — | — | — | — |
| Other non-current assets | 4.3 | 1.3 | — | — | 2.9 | — | — | 1.3 | — | — |
| Trade and account receivables | 564.3 | — | — | — | 564.3 | — | — | — | — | — |
| Current financial assets | 54.1 | 42.4 | — | — | — | — | 11.7 | — | 11.7 | 42.4 |
| Other current assets | 178.6 | — | — | — | 178.6 | — | — | — | — | — |
| Cash and cash equivalents | 814.7 | 814.7 | — | — | — | — | — | 814.7 | — | — |
| ASSETS | 1,722.9 | 858.4 | 50.8 | 56.1 | 745.9 | — | 11.7 | 864.7 | 11.7 | 100.5 |
| Non-current financial liabilities | 772.2 | 109.3 | — | — | — | 662.8 | — | — | — | 109.3 |
| Other non-current liabilities | 45.8 | — | — | — | — | 45.8 | — | — | — | — |
| Current financial liabilities | 174.8 | 45.1 | — | — | — | 118.2 | 11.5 | — | 11.5 | 45.1 |
| Trade payables | 594.7 | — | — | — | — | 594.7 | — | — | — | — |
| Other current liabilities | 401.7 | — | — | — | — | 401.7 | — | — | — | — |
| Bank overdrafts | 5.5 | 5.5 | — | — | — | — | — | 5.5 | — | — |
| LIABILITIES | 1,994.7 | 160.0 | — | — | — | 1,823.2 | 11.5 | 5.5 | 11.5 | 154.4 |

Derivative financial instruments reported in the balance sheet as of 31 December 2020 broke down as follows:

| (in millions of euros) | 31 December 2020 | Breakdown by financial instrument class - balance sheet value | | | | | | Level of fair value | | |
|-----------------------------------|------------------|---|---|--|--------------------------|-------------------------------|-------------|---------------------|------------|--------------|
| | Carrying value | Fair value through income statement | Financial assets at fair value through other comprehensive income | Financial assets at fair value through profit/(loss) | Assets at amortized cost | Liabilities at amortized cost | Derivatives | Level 1 | Level 2 | Level 3 |
| Equity investments | 84.5 | — | 44.2 | 40.2 | — | — | — | 42.2 | — | 42.3 |
| Non-current financial assets | 23.1 | 23.1 | — | — | — | — | — | — | — | 23.1 |
| Other non-current assets | 3.8 | 1.3 | — | — | 2.5 | — | — | 1.3 | — | — |
| Trade and account receivables | 476.2 | — | — | — | 476.2 | — | — | — | — | — |
| Current financial assets | 48.9 | 18.2 | — | — | 26.8 | — | 3.9 | — | 3.9 | 18.2 |
| Other current assets | 113.7 | — | — | — | 113.7 | — | — | — | — | — |
| Cash and cash equivalents | 642.5 | 642.5 | — | — | — | — | — | 642.5 | — | — |
| ASSETS | 1,392.6 | 685.0 | 44.2 | 40.2 | 619.2 | — | 3.9 | 686.0 | 3.9 | 83.5 |
| Non-current financial liabilities | 761.6 | 118.1 | — | — | — | 643.5 | — | — | — | 118.1 |
| Other non-current liabilities | 45.1 | — | — | — | — | 45.1 | — | — | — | — |
| Current financial liabilities | 408.6 | 19.1 | — | — | — | 384.7 | 4.8 | — | 4.8 | 19.1 |
| Trade payables | 495.2 | — | — | — | — | 495.2 | — | — | — | — |
| Other current liabilities | 250.0 | — | — | — | — | 250.0 | — | — | — | — |
| Bank overdrafts | 2.8 | 2.8 | — | — | — | — | — | 2.8 | — | — |
| LIABILITIES | 1,963.4 | 140.1 | — | — | — | 1,818.5 | 4.8 | 2.8 | 4.8 | 137.2 |

Note 23 Information on related parties

■ 23.1 Director and Executive compensation

In 2021, the total compensation paid to Board and Executive Leadership Team members amounted to €24.3 million, €0.7 million of which was paid to members of the Board of Directors and €23.6 million of which was paid to members of the Executive Leadership Team (see Chapter 5).

Pension and similar benefits for Board members and members of the Executive Leadership Team totaled €4.2 million as of 31 December 2021, with €1.8 million paid to members of the Board of Directors and €2.3 million paid to Executive Leadership Team members.

23.2 Transactions with related parties

Transactions with related parties mainly corresponded to transactions with entities involved in the manufacturing chain of the EGb 761 extract and other plants wholly owned by the Schwabe group since Ipsen sold its equity investment in the

following entities in 2021: Garnay Inc., Cara Partners, Perechin Company, Portpirie Company, Wallingstown Company, Wallingstown Company Limited and Saint-Jean d'Ilac S.C.A.

| (in millions of euros) | 2021 | | 2020 | |
|--|----------|--------------------|----------|--------------------|
| | Income | Operating expenses | Income | Operating expenses |
| Associated companies | — | — | — | (4.8) |
| Companies over which the Group's executive officers exercise significant influence | — | (5.7) | — | — |
| Total | — | (5.7) | — | (4.8) |

23.2.2 In the balance sheet

| (in millions of euros) | 31 December 2021 | | | | 31 December 2020 | | | |
|--|-------------------|-------------------|-------------------|----------------|-----------------------|-------------------|-------------------|----------------|
| | Other receivables | Trade receivables | Bank loans / Debt | Trade payables | Loans and receivables | Trade receivables | Bank loans / Debt | Trade payables |
| Associated companies | — | — | — | — | 26.9 | — | (1.0) | — |
| Companies over which the Group's executive officers exercise significant influence | 3.3 | — | — | (1.3) | — | — | — | — |
| Total gross | 3.3 | — | — | (1.3) | 26.9 | — | (1.0) | — |
| Provisions for doubtful accounts receivable | — | — | — | — | — | — | — | — |
| Total | 3.3 | — | — | (1.3) | 26.9 | — | (1.0) | — |

23.2.3 Off-balance sheet commitments

Off-balance sheet commitments include rent commitments to companies over which executive officers of the Group

exercise significant influence. The total amount of future rent payments due in respect of these rented premises amounted to €0.04 million on 31 December 2021.

Note 24 Commitments and contingent liabilities

24.1 Operating commitments

Within the scope of its business, and in particular with strategic development operations that lead to partnerships, the Group regularly enters into agreements that may result in potential financial commitments, subject to the completion of certain events.

The probability-weighted and discounted value of the commitments represents the amount that the Group actually expected to pay or to receive as of 31 December 2021. The value of these commitments was determined by weighing the future commitments by the following criteria:

- probabilities of occurrence of each milestone payment planned in the contract. The probabilities of occurrence are estimated between 0% and 100% and are reviewed and approved by the Group management team;
- discount rate corresponding to each of the Group's Cash Generating Unit to which the agreement belongs.

The maximum amounts that may be owed (commitments given) or received (commitments received) represent the maximum amounts if all the contractual terms and conditions were met, not probability-weighted, and not discounted.

24.1.1 Operating commitments given

As part of its key agreements, the Group could make the regulatory or marketing milestone payments shown below:

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|---|------------------|------------------|
| Probable and discounted commitments given | 444.0 | 161.8 |

The maximum amount of commitments given as of 31 December 2021 and 31 December 2020 is detailed below:

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|---------------------------------------|------------------|------------------|
| Key agreements in Oncology | 1,832.1 | 512.5 |
| Key agreements in Rare Diseases | 789.2 | 403.8 |
| Key agreements in Neuroscience | 322.0 | 85.4 |
| Key agreements in Consumer Healthcare | 5.3 | 8.9 |
| Total | 2,948.7 | 1,010.6 |

The increase in commitments given mainly corresponded to initial payments for new agreements signed:

- in Oncology with Bakx Therapeutics (€735 million), Accent Therapeutics (€372 million) and Queen's University Belfast (€263 million);

- in Rare Diseases, with GENFIT S.A. (€358 million);
- in Neuroscience, with Irlab Therapeutics (€295 million).

24.1.2 Operating commitments received

As part of its key agreements, the Group could receive regulatory or marketing milestone payments:

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| Probable and discounted commitments received | 16.1 | 16.8 |

The maximum amount of commitments received as of 31 December 2021 and 31 December 2020 broke down as follows:

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|---------------------------------------|------------------|------------------|
| Key agreements in Oncology | 587.0 | 18.3 |
| Key agreements in Neuroscience | 24.7 | 21.9 |
| Key agreements in Rare Diseases | 30.9 | 243.1 |
| Key agreements in Consumer Healthcare | 67.0 | 67.5 |
| Key agreements in Hematology | 140.9 | 130.5 |
| Total | 850.4 | 481.3 |

As of 31 December 2021, the increase in commitments received primarily corresponded to amounts receivable under new agreements in Oncology signed with SatoSea Oncology GmbH and Fusion Pharmaceuticals related to the sale of the Systemic Radiation Therapy (SRT) program.

As of 31 December 2020, commitments received mainly consisted of €243.1 million in amounts receivable for agreements signed in Rare Diseases. Since one of the partner companies dissolved in 2021, these commitments declined €210 million as of 31 December 2021.

24.2 Financial commitments

Ipsen Group has taken out a worldwide liability insurance policy from a third-party insurer. The insurance company itself is underwritten by the captive reinsurance company Ipsen Ré, a wholly-owned subsidiary of the Group, for up to the first €20 million for any potential claim made.

To cover that financial commitment and address any potential default by Ipsen Ré, on 19 May 2021, the Ipsen S.A. parent company issued a letter of guarantee payable upon first demand to the third-party insurer for a total amount of €3 million. This first demand guarantee takes effect on 1 January 2021 and expires on 31 December 2025 if it has not already been used in its entirety. It can be renewed annually.

Furthermore, the previous civil liability insurance policy was reinsured by the captive reinsurance company (Ipsen Ré) and was terminated on 31 December 2018. Under this contract, the previous €9 million first demand guarantee, issued in favor of the previous insurer, has been extended for five years after the reinsurance policy expires on 31 December 2023.

The Group owns a 50% interest in a Swiss company. It is consolidated using the equity method, and it has taken out three credit lines totaling CHF11 million. These credit lines were not drawn on during the year. The company also took out a derivative foreign exchange instrument to hedge its operating cash flow, the fair value of which was €0.01 million as of 31 December 2021.

24.3 General risks

The Group may be involved in litigation, arbitration and other legal proceedings. Such proceedings are generally related to civil litigation concerning product liability, intellectual property rights, competition law, trading practices, trade rules, labor rights, tax issues, waste treatment and environmental issues, and requests for guaranteeing the liabilities of assets sold. Provisions related to litigation and arbitration are recognized in compliance with the principles presented in note 3.23.

Most of the questions raised by these claims are complex and subject to significant uncertainties. As a result, it is sometimes difficult to measure how likely it is that the Group will have to recognize an expense and measure how much to provision for. Contingent liabilities relate to instances where either it is not reasonably possible to provide a reliable estimate of the financial impact that could arise from a case being settled, or where it is not likely that a case will result in payment by the Group.

In general, risks are measured according to a series of complex assumptions about future events. These measurements are based on estimates and assumptions deemed reasonable by management. The Group believes that

the total amount of provisions recognized for the aforementioned general risks is adequate based on information currently available. However, given the uncertainties inherent to such litigation and to contingent liability estimates, the Group cannot rule out the possibility of future rulings that could have an unfavorable material impact on its results.

The Group set up a tax pool in France for all Group companies operating in France that meet legal requirements. The system provides for various penalty provisions when entities leave the tax group, mentioned here for informational purposes.

Arbitration proceedings with Galderma

In 2021, Galderma initiated two arbitration proceedings against Ipsen at the ICC International Court of Arbitration with arbitrators seized in the fourth quarter, related to a dispute over Galderma's filing of the BLA of QM-1114 for which Ipsen, in its capacity as marketing authorization holder and owner of the intellectual property, has objected to such filing as Ipsen is the ultimate responsible entity towards the regulatory agencies and Galderma acting as Ipsen's distributor.

There second dispute involves differences of opinion on the territorial scope of the partnership with Galderma under the 2007 Agreement.

The outcome of the cases and any potential financial impact they could have on the financial statements cannot be reasonably predicted at this preliminary stage of the proceedings. Ipsen intends to fully defend and vindicate its rights against Galderma's allegations.

24.4 Liquidity risk and counterparty risk

The Group's policy includes diversifying its business counterparties to avoid risks by spreading out revenue streams and choosing these counterparties wisely. In addition, the Group monitors the credit risks associated with the financial instruments it invests in and limits its investments according to the credit rating of its business counterparties. The Group manages these funds and mainly invests them as fixed-term investments (term deposits and term accounts). The Group invests its surpluses in short-term money-market financial instruments negotiated with counterparties whose credit ratings are at least investment grade.

24.5 Other commitments

24.5.1 Capital expenditure commitments

Future Group expenditures resulting from existing investment commitments amounted to €8.7 million as of 31 December 2021, and break down as follows:

| (in millions of euros) | Maturity | | | Total |
|---------------------------------|--------------------|------------------------|-----------------|------------|
| | Less than one year | From one to five years | Over five years | |
| Industrial assets | 8.4 | 0.0 | 0.0 | 8.4 |
| Research and Development assets | 0.3 | 0.0 | 0.0 | 0.3 |
| Total | 8.7 | 0.0 | 0.0 | 8.7 |

24.5.2 Risk of acceleration of borrowings

The Group's exposure to this risk is described in note 21.2.

As of 31 December 2021, no commitment or contingent liability had been contracted that could significantly affect the assessment of the consolidated financial statements.

24.5.3 Endorsements, pledges and guarantees given

Total guarantees given amounted to €53.7 million as of 31 December 2021. These commitments primarily correspond to guarantees given to government authorities to participate in calls for tender.

24.5.4 Commitments arising from Research and Development agreements

Within the scope of its business, the Group regularly enters into Research and Development agreements with partners that may result in potential financial commitments. As of 31 December 2021, those commitments totaled €66.9 million.

Note 25 Subsequent events with no impact on the consolidated financial statements as of 31 December 2021

Exclusive negotiations to divest the Consumer Healthcare business

Following the decision of its Board of Directors held on 10 February 2022, Ipsen has entered into exclusive negotiations with Mayoly Spindler for the divestment of its global CHC business. This is a major step forward in the Company's execution of its strategic roadmap presented in December 2020 towards building a more-focused Ipsen, centring on Specialty Care.

The combination of Ipsen's and Mayoly Spindler's respective CHC businesses will create a global consumer-healthcare platform with a critical size and the capacity to support its growth. The consideration for Ipsen's CHC business represents an enterprise value of €350m, including an earnout contingent payment of €50m.

The proposed transaction will be submitted to the relevant employee-representation bodies and is expected to close before the end of Q3 2022, subject to regulatory approvals and customary closing conditions.

Palovarotene

On 24 January 2022, Ipsen announced the Health Canada approval of Sohonos™ (palovarotene capsules) indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP). Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide.

Note 26 Consolidation scope

The table below shows the following information for all companies included in the consolidation scope:

- country of incorporation;
- location of registered office (State of incorporation for U.S. companies);
- the percent of interest held in each company.

26.1 Fully-consolidated companies

| Name and legal form | Country | Registered office | 31 December 2021 | 31 December 2020 |
|---|----------------|-------------------|------------------|------------------|
| | | | % interest | % interest |
| Ipsen S.A. (société consolidante) | France | Boulogne (92) | 100 | 100 |
| BB et Cie S.A.S. | France | Boulogne (92) | 100 | 100 |
| Beaufour Ipsen Industrie S.A.S. | France | Dreux (28) | 100 | 100 |
| Ipsen Consumer Healthcare S.A.S. | France | Boulogne (92) | 100 | 100 |
| Ipsen Innovation S.A.S. | France | Les Ulis (91) | 100 | 100 |
| Ipsen Pharma S.A.S. | France | Boulogne (92) | 100 | 100 |
| Ipsen PharmSciences S.A.S. | France | Dreux (28) | 100 | 100 |
| Ipsen Pharma Biotech S.A.S. | France | Signes (83) | 100 | 100 |
| Ipsen Pharma Algérie S.P.A. | Algeria | Algiers | 49 | 49 |
| Ipsen Pharma GmbH | Germany | Munich | 100 | 100 |
| OctreoPharm Sciences GmbH | Germany | Berlin | 100 | 100 |
| Ipsen Pty Limited | Australia | Glen Waverley | 100 | 100 |
| Ipsen N.V. | Belgium | Merelbeke | 100 | 100 |
| Beaufour Ipsen Farmaceutica LTDA | Brazil | Sao Paulo | 100 | 100 |
| Ipsen Biopharmaceuticals Canada Inc. | Canada | Mississauga | 100 | 100 |
| Clementia Pharmaceuticals, Inc. | Canada | Montreal | 100 | 100 |
| Beaufour Ipsen (Tianjin) Pharmaceutical Co. Ltd | China | Tianjin | 96 | 96 |
| Ipsen (Beijing) Pharmaceutical science and technology development Co. Ltd | China | Beijing | 100 | 100 |
| Ipsen (Tianjin) Pharmaceutical Trade Co. Ltd | China | Tianjin | 100 | 96 |
| Ipsen (Shanghai) innovation pharmaceuticals Co., Ltd | China | Shanghai | 100 | 100 |
| Ipsen Korea | Korea | Seoul | 100 | 100 |
| Ipsen Pharma S.A. | Spain | Barcelona | 100 | 100 |
| Ipsen Biopharmaceuticals, Inc. | United States | New Jersey | 100 | 100 |
| Ipsen Bioscience Inc. | United States | Massachusetts | 100 | 100 |
| Clementia Pharmaceuticals USA, Inc. | United States | Massachusetts | 100 | 100 |
| Ipsen Epe | Greece | Athens | 100 | 100 |
| Ipsen Pharma Hungary Kft | Hungary | Budapest | 100 | 100 |
| Elsegundo Limited | Ireland | Cork | 100 | 100 |
| Ipsen Manufacturing Ireland Limited | Ireland | Dublin | 100 | 100 |
| Ipsen Pharmaceuticals Limited | Ireland | Dublin | 100 | 100 |
| Ipsen S.p.A. | Italy | Milan | 100 | 100 |
| Akkadeas Pharma S.r.l | Italy | Milan | 100 | 100 |
| IPSEN K.K. | Japan | Tokyo | 100 | — |
| Ipsen Pharma Kazakhstan | Kazakhstan | Almaty | 100 | 100 |
| Ipsen Ré S.A. | Luxembourg | Luxembourg | 100 | 100 |
| Ipsen Mexico S. de R.L. de C.V. | Mexico | Mexico | 100 | 100 |
| Ipsen Farmaceutica B.V. | Netherlands | Hoofddorp | 100 | 100 |
| Ipsen Poland LLC | Poland | Warsaw | 100 | 100 |
| Ipsen Portugal - Produtos Farmaceuticos S.A. | Portugal | Alges | 100 | 100 |
| Ipsen Pharma s.r.o. | Czech Republic | Prague | 100 | 100 |
| Ipsen Pharma Romania S.R.L. | Romania | Bucharest | 100 | 100 |
| Ipsen Limited | United Kingdom | Berkshire | 100 | 100 |
| Ipsen Biolnnovation Limited | United Kingdom | Oxford | 100 | 100 |
| Ipsen Biopharm Limited | United Kingdom | Wrexham | 100 | 100 |
| Ipsen Developments Limited | United Kingdom | Berkshire | 100 | 100 |
| Sterix Limited | United Kingdom | Slough | 100 | 100 |

| Name and legal form | Country | Registered office | 31 December 2021 | 31 December 2020 |
|---------------------------------------|-------------|-------------------|------------------|------------------|
| | | | % interest | % interest |
| Ipsen OOO | Russia | Moscow | 100 | 100 |
| Ipsen Consumer Healthcare LLC | Russia | Moscow | 100 | — |
| Ipsen Pharma Singapore PTE Ltd | Singapore | Singapore | 100 | 100 |
| Institut Produits Synthèse (Ipsen) AB | Sweden | Kista | 100 | 100 |
| IPSEN Pharma Schweiz GmbH | Switzerland | Zug | 100 | 100 |
| Ipsen Pharma Tunisie S.A.R.L. | Tunisia | Tunis | 100 | 100 |
| Ipsen Ukraine Services LLC | Ukraine | Kyiv | 100 | 100 |

26.2 Equity-accounted companies

| Name and legal form | Country | Registered office | 31 December 2021 | 31 December 2020 |
|------------------------------|---------------|-------------------|------------------|------------------|
| | | | % interest | % interest |
| Garnay Inc. | United States | South Carolina | — | 50 |
| Bakx Therapeutics Inc. | United States | New York | 14 | — |
| Saint-Jean d'Ilac S.C.A. | France | Boulogne (92) | — | 50 |
| Cara Partners | Ireland | Cork | — | 50 |
| Perechin Company | Ireland | Cork | — | 50 |
| Portpirie Company | Ireland | Cork | — | 50 |
| Wallingstown Company | Ireland | Cork | — | 50 |
| Wallingstown Company Limited | Ireland | Cork | — | 50 |
| Linnea S.A. | Switzerland | Riazzino | 50 | 50 |

Note 27 Fees paid to the Statutory Auditors

The fees paid by the Group to the Statutory Auditors and members of their networks are presented in the following table:

| (in thousands of euros) | Deloitte & Associés | | | | KPMG Audit | | | |
|---|---------------------|------------|-------------|-------------|-------------------|------------|-------------|-------------|
| | Amount net of VAT | | % | | Amount net of VAT | | % | |
| | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 |
| Certification and limited interim review of separate and consolidated financial statements | | | | | | | | |
| Issuer | 216 | 206 | 32% | 24% | 235 | 230 | 19% | 26% |
| Fully consolidated subsidiaries | 400 | 601 | 59% | 71% | 617 | 608 | 49% | 69% |
| Sub-total | 616 | 806 | 91% | 95% | 852 | 837 | 68% | 96% |
| Services other than the certification of the financial statements⁽¹⁾ | | | | | | | | |
| Issuer | 30 | 29 | 4% | 3% | 0 | 0 | 0% | 0% |
| Fully consolidated subsidiaries | 30 | 11 | 4% | 1% | 409 | 37 | 32% | 4% |
| Sub-total | 60 | 40 | 9% | 5% | 409 | 37 | 32% | 4% |
| Total | 676 | 846 | 100% | 100% | 1,261 | 874 | 100% | 100% |

(1) The type of services other than the "certification of financial statements" provided by the Statutory Auditors to the consolidating entity and to its controlled subsidiaries includes the contractual audit, certification of financial, environmental, and corporate social responsibility data, and independent third-party assignments.



3.2.6 Statutory Auditors' Report on the consolidated financial statements

This is a translation into English of the statutory auditors' report on the financial statements of the Company issued in French and it is provided solely for the convenience of English speaking users.

This statutory auditors' report includes information required by European regulation and French law, such as information about the appointment of the statutory auditors or verification of the management report and other documents provided to shareholders.

This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.

Ipsen S.A.

Registered office: 65, Quai Georges Gorse – 92100 Boulogne-Billancourt

Statutory Auditors' Report on the consolidated financial statements

For the year ended 31 December 2021

To the shareholders of Ipsen S.A.,

Opinion

In compliance with the engagement entrusted to us by your annual general meetings, we have audited the accompanying consolidated financial statements of Ipsen S.A. for the year ended 31 December 2021.

In our opinion, the consolidated financial statements give a true and fair view of the assets and liabilities and of the financial position of the Group as at 31 December 2021 and of the results of its operations for the year then ended in accordance with International Financial Reporting Standards as adopted by the European Union.

The audit opinion expressed above is consistent with our report to the Audit Committee.

Basis for Opinion

Audit Framework

We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the Statutory Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report.

Independence

We conducted our audit engagement in compliance with independence requirements of the French Commercial Code (*Code de commerce*) and the French Code of Ethics (*Code de déontologie*) for statutory auditors for the period from 1 January 2021 to the date of our report and specifically we did not provide any prohibited non-audit services referred to in Article 5 of Regulation (EU) No 537/2014.

Justification of the Assessments – Key Audit Matters

Due to the global crisis related to the COVID-19 pandemic, the financial statements of this period have been prepared and audited under specific conditions. Indeed, this crisis and the exceptional measures taken in the context of the state of sanitary emergency have had numerous consequences for companies, particularly on their operations and their financing, and have led to greater uncertainties on their future prospects. Those measures, such as travel restrictions and remote working, have also had an impact on the companies' internal organization and the performance of the audits.

It is in this complex and evolving context that, in accordance with the requirements of Articles L.823-9 and R.823-7 of the French Commercial Code (*Code de commerce*) relating to the justification of our assessments, we inform you of the key audit matters relating to risks of material misstatement that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period, as well as how we addressed those risks.

These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on specific items of the consolidated financial statements.

Assessment of the recoverable amount of licenses

Notes 3.12, 3.15, 3.29 and 11 to the consolidated financial statements

Identified risk

As at 31 December 2021, the net value of the Group's licenses presented in "Other intangible assets" amounted to €1,281.6 million out of a total balance sheet of €5,006.8 million.

These licenses relate to acquired rights for pharmaceutical specialties that can be:

- marketed and amortized on a straight line basis over their useful life. The useful life is determined on the basis of the cash flow forecasts which take into account, among others, the period of protection of the underlying patents;
- during the ongoing development phase and therefore not yet marketed, and thus not yet amortized.

As indicated in note 3.15, these licenses with a defined useful life and indefinite useful life, which mainly are intellectual property rights and licenses, are subject to an impairment test as follow:

- license with a defined useful life: whenever a trigger event is identified;
- license with an indefinite useful life: an annual impairment test and whenever a trigger event is identified.

Impairment tests consist in comparing the net book value of the asset to its recoverable amount, which is the higher of its fair value less costs to transfer and its value in use. The value in use is determined on estimated future cash flows expected of the asset.

The implementation of the impairment test is described in note 3.15. to the consolidated financial statements.

We considered that the value of these licenses is a key audit matter because of its significant importance in the Group accounts and the method of determining their recoverable value, most often based on future cash flow forecasts, which requires the use of assumptions and estimates by management based on the future discounted cash flows used to perform these tests.

Audit procedures implemented with regard to the identified risk

We have reviewed the procedures implemented by the Group in relation with impairment tests and, evaluated the design of the relevant controls.

We have analyzed the implementation of these impairment tests on acquired licenses. Particularly, a specific focus has been made on acquired licenses in the development phase considering the difficulties to assess the ongoing development phase and future expected growth, which is a key factor in the preparation of cash flow forecasts.

We appreciated the reasonableness of the main assumptions, including future cash flows, long term growth rates and related discount rates with our valuation experts. We also analyzed the consistency of the evolution of the research programs, the market perspectives and the forecast data and reviewed the sensitivity tests on the related impairment tests to corroborate those prepared by the finance department.

Finally, we also verified the adequacy of the information provided in the notes 3.12, 3.15, 3.29 and 11 to the consolidated financial statements.

Specific verifications

We have also performed, in accordance with professional standards applicable in France, the specific verifications required by laws and regulations of the Group's information given in the management report of the Board of Directors.

We have no matters to report as to its fair presentation and its consistency with the consolidated financial statements.

We attest that the consolidated non-financial statement required by Article L. 225-102-1 of the French Commercial Code (*Code de commerce*), is included in the Group's information given in the management report, it being specified that, in accordance with the provisions of Article L. 823-10 of this Code, we have verified neither the fair presentation nor the consistency with the consolidated financial statements of the information contained therein and this information must be reported by an independent third party.



Report on Other Legal and Regulatory Requirements

Format of the presentation of the consolidated financial statements intended to be included in the annual financial report

We have also verified, in accordance with the professional standard applicable in France relating to the procedures performed by the statutory auditor relating to the annual and consolidated financial statements presented in the European single electronic format, that the presentation of the consolidated financial statements intended to be included in the annual financial report mentioned in Article L.451-1-2, I of the French Monetary and Financial Code (*Code monétaire et financier*), prepared under the responsibility of Chief Executive Officer, complies with the single electronic format defined in the European Delegated Regulation 2019/815 of December 17, 2018. As it relates to consolidated financial statements, our work includes verifying that the tagging of these consolidated financial statements complies with the format defined in the above delegated regulation.

Based on the work we have performed, we conclude that the presentation of the consolidated financial statements intended to be included in the annual financial report complies, in all material respects, with the European single electronic format.

We have no responsibility to verify that the consolidated financial statements that will ultimately be included by your company in the annual financial report filed with the AMF are in agreement with those on which we have performed our work.

Appointment of the auditors

We were appointed statutory auditors for Ipsen S.A. by the Annual General Meeting held on 18 June 2005 for KPMG S.A. and on 17 December 1998 for Cogercro Flipo which was acquired by Deloitte & Associés in 2001.

As of 31 December 2021, KPMG S.A. was in the 17th consecutive year of its assignment and Deloitte & Associés was in its 24th year, including 17 years for both firms since the shares of the company have been admitted to trading on a regulated market.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards as adopted by the European Union and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless it is expected to liquidate the Company or to cease operations.

The Audit Committee is responsible for monitoring the financial reporting process and the effectiveness of internal control and risks management systems and where applicable, its internal audit, regarding the accounting and financial reporting procedures.

The consolidated financial statements were approved by the Board of Directors.

Statutory Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Objectives and audit approach

Our role is to issue a report on the consolidated financial statements. Our objective is to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As specified in Article L.823-10-1 of the French Commercial Code (*Code de commerce*), our statutory audit does not include assurance on the viability of the Company or the quality of management of the affairs of the Company.

As part of an audit conducted in accordance with professional standards applicable in France, the statutory auditor exercises professional judgment throughout the audit and furthermore:

- Identifies and assesses the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, designs and performs audit procedures responsive to those risks, and obtains audit evidence considered to be sufficient and appropriate to provide a basis for his opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtains an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluates the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management in the consolidated financial statements.
- Assesses the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. This assessment is based on the audit evidence obtained up to the date of his audit report. However, future events or conditions may cause the Company to cease to continue as a going concern. If the statutory auditor concludes that a material uncertainty exists, there is a requirement to draw attention in the audit report to the related disclosures in the consolidated financial statements or, if such disclosures are not provided or inadequate, to modify the opinion expressed therein.

- Evaluates the overall presentation of the consolidated financial statements and assesses whether these statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtains sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. The statutory auditor is responsible for the direction, supervision and performance of the audit of the consolidated financial statements and for the opinion expressed on these consolidated financial statements.

Report to the Audit Committee

We submit to the Audit Committee a report which includes in particular a description of the scope of the audit and the audit program implemented, as well as the results of our audit. We also report, if any, significant deficiencies in internal control regarding the accounting and financial reporting procedures that we have identified.

Our report to the Audit Committee includes the risks of material misstatement that, in our professional judgment, were of most significance in the audit of the consolidated financial statements of the current period and which are therefore the key audit matters, that we are required to describe in this audit report.

We also provide the Audit Committee with the declaration provided for in Article 6 of Regulation (EU) N° 537/2014, confirming our independence within the meaning of the rules applicable in France such as they are set in particular by Articles L.822-10 to L.822-14 of the French Commercial Code (*Code de commerce*) and in the French Code of Ethics (*Code de déontologie*) for statutory auditors. Where appropriate, we discuss with the Audit Committee the risks that may reasonably be thought to bear on our independence, and the related safeguards.

The Statutory Auditors

Paris La Défense, on 16 February 2022

KPMG Audit
Department of KPMG S.A.

Catherine Porta
Partner

Paris La Défense, on 16 February 2022

Deloitte & Associés

Frédéric Souliard
Partner



3.3 2021 COMPANY FINANCIAL STATEMENTS

3.3.1 Summary document

Balance sheet at 31 December 2021

| Assets (in millions of euros) | 31 December 2021 | | | 31 December 2020 |
|--|------------------|--|----------------|------------------|
| | Gross | Depreciation, amortization & write-downs | Net | |
| Intangible assets | | | | |
| – Concessions, patents and similar rights | 0.2 | | 0.2 | 0.2 |
| – Other intangible assets | | | | |
| Financial investments | | | | |
| – Equity investments | 1,167.4 | | 1,167.4 | 1,167.4 |
| – Loans | | | | – |
| – Other financial assets | 14.4 | 2.6 | 11.8 | 13.4 |
| Non-current assets | 1,182.0 | 2.6 | 1,179.4 | 1,181 |
| Receivables | | | | |
| – Advances and down-payments to suppliers | – | | – | 0.2 |
| – Trade and accounts receivables | 16.6 | | 16.6 | 8.5 |
| – Other receivables | 135.3 | | 135.5 | 52.9 |
| Other | | | | |
| – Short-term investments | 120.2 | 0.1 | 120.1 | 96.3 |
| – Cash and cash equivalents | 378.0 | | 378.0 | 262.1 |
| – Prepayments | | | | – |
| Current assets | 650.1 | 0.1 | 650.0 | 419.9 |
| Debt issuance costs to be amortized | 3.7 | | 3.7 | 5.2 |
| Bond redemption premium | 0.4 | | 0.4 | 0.7 |
| Unrealized losses on foreign exchange | – | | – | – |
| Total assets | 1,836.2 | 2.6 | 1,833.5 | 1,606.8 |

| Liabilities (in millions of euros) | 31 December 2021 | 31 December 2020 |
|---|------------------|------------------|
| Share capital | 83.8 | 83.8 |
| Paid-in capital | 122.3 | 122.3 |
| Legal reserve | 8.4 | 8.4 |
| Other reserves | | - |
| Retained earnings | 196.0 | |
| Net profit (loss) for the period | 1.3 | 278.9 |
| Regulated provisions | 0.4 | 0.2 |
| Equity | 412.3 | 493.6 |
| Provisions for contingencies | 49.0 | 29.5 |
| Provisions for losses | 0.2 | 0.1 |
| Provisions for contingencies and losses | 49.1 | 29.7 |
| Other bonds | 307.4 | 307.1 |
| Bank borrowings | 264.5 | 444.1 |
| Sundry borrowings and financial liabilities | 80.0 | 147.0 |
| Trade and accounts payable | 6.3 | 1.4 |
| Taxes payable and payroll on-cost amounts payable | 11.4 | 7.1 |
| Amounts due to non-current asset suppliers | 3.7 | 4.3 |
| Other liabilities | 693.8 | 132.7 |
| Cash instruments | | - |
| Deferred income | | - |
| Debts | 1,367.1 | 1,043.7 |
| Unrealized gains on foreign exchange | 5.1 | 39.7 |
| Total equity & liabilities | 1,833.5 | 1,606.8 |



Income statement at 31 December 2021

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|--|------------------|------------------|
| Sales of merchandise | - | - |
| Production sold – services | 27.9 | 17.4 |
| Net sales | 27.9 | 17.4 |
| Reversal of depreciation, amortization & provisions, expense transfers | 11.8 | 8.0 |
| Other revenues | - | 0.1 |
| Operating income | 39.6 | 25.5 |
| Other purchases and external charges | (10.8) | (10.1) |
| Taxes and duties | (1.0) | (1.0) |
| Wages and salaries | (9.5) | (6.3) |
| Payroll on-costs | (5.9) | (3.3) |
| Depreciation expense on fixed assets | (1.5) | (1.5) |
| Provision expense on fixed assets | - | - |
| Provision expense for contingencies and losses | (33.1) | (22.0) |
| Miscellaneous operating expenses | (0.9) | (0.9) |
| Operating expenses | (62.7) | (45.2) |
| Operating profit (loss) | (23.1) | (19.7) |
| Financial income from participating interests | - | 300.0 |
| Income from other non-current receivables | - | 1.1 |
| Other interest and similar income | 22.9 | 2.3 |
| Reversal of provisions and transfer of extraordinary expense | 3.1 | 596.4 |
| Foreign exchange gains | 7.0 | 2.3 |
| Financial income | 33.1 | 902.1 |
| Depreciation, amortization and provision charges | (2.8) | (0.6) |
| Interest and other financial expenses | (20.2) | (20.7) |
| Foreign exchange losses | (29.2) | (2.2) |
| Financial expense | (52.2) | (23.5) |
| Net financial income (expense) | (19.1) | 878.6 |
| Pre-tax profit (loss) on ordinary activities | (42.1) | 858.9 |
| Extraordinary income from operations | - | - |
| Extraordinary income from capital transactions | 1.5 | 183.2 |
| Reversal of provisions and transfer of extraordinary expense | - | - |
| Extraordinary income | 1.5 | 183.2 |
| Extraordinary expenses from operations | - | - |
| Extraordinary expenses from capital transactions | (13.3) | (848.2) |
| Depreciation, amortization and provision charges | (0.3) | (0.2) |
| Extraordinary expenses | (13.5) | (848.4) |
| Net extraordinary income (expense) | (12.0) | (665.2) |
| Employee profit-sharing | 0.0 | 0.0 |
| Income tax income (expense) | 55.5 | 85.2 |
| Net profit (loss) for the year | 1.3 | 278.9 |

3.3.2 Notes to the annual financial statements

Notes

These are the notes to the balance sheet and the income statement for the year ended 31 December 2021. The total balance sheet amount comes to €1,833.5 million, while the income statement shows a net profit of €1.3 million for the period. Had the Company Ipsen S.A. been taxed separately, its net loss for tax purposes would have totaled €(78.4) million.

The reporting period covers the 12-month period from 1 January to 31 December 2021.

The notes and tables presented below form an integral part of the annual financial statements.

Note 1 Significant events during the year

■ 1.1 Launch of an Employee Shareholding plan

On 1 June 2021, Ipsen announced the launch of an employee Shareholding plan.

This third transaction over the last five years aims to involve Ipsen's employees more closely, both in France and abroad, in the Group's development and performance. It has been launched in 21 countries.

This transaction was carried out through the sale of existing shares reserved to members of a company savings plan.

■ 1.2 Share repurchasing program

The company has been implementing a liquidity contract with ODDO BHF since 2018.

The Combined General Meeting of Shareholders, held on 27 May 2021, granted the Company's Board of Directors an authorization to repurchase shares, for a period of 18 months, and terminated the one previously given at the 29 May 2020 Meeting.

In accordance with this authorization, the Board of Directors decided, on 27 May 2021, to implement the new buyback program for a maximum of 10% of the share capital.

On 2 June 2021, Ipsen announced that it had granted a mandate to purchase 500,000 Ipsen S.A. shares, representing approximately 0.6% of the Company's share capital at that date. The purchase was to take place over a period of six months. The purchased shares were allocated primarily to cover 2021 share awards as part of the Company's long term incentive plans.

The program ended on 25 August 2021. Under the program, the Company repurchased shares for a total €42.9 million in the year ended 31 December 2021.

In addition, 142,071 self-owned shares were used in 2021 as part of the allocation of shares to employees.

Note 2 Accounting principles and valuation methods

■ 2.1 Standards, principles and valuation methods

2.1.1 Accounting principles

The annual financial statements have been prepared in accordance with legal and regulatory provisions applicable in France, as set out in the French Chart of Accounts (ANC Regulation n° 2018-07 of 10 December 2018, which modified ANC Regulation n° 2014-03 approved by the Order of 5 June 2014), in observance of the prudence principle and the independence of financial years and the presumption of a going concern.

The Company did not carry out a revaluation of its balance sheet.

2.1.2 Valuation methods

2.1.2.1 Intangible assets

Intangible assets are accounted for at acquisition cost or contribution value, less cumulative amortization and any impairment losses.

The cost of intangible assets with a defined useful life, less any residual value, is amortized over a period corresponding to the useful life estimated by the Company. Amortization

periods are determined on a case-by-case basis depending on the type of asset concerned.

Intangible assets with an indefinite useful life are not amortized but are systematically tested annually for impairment.

As a general rule, brands and trademarks are not amortized.

2.1.2.2 Financial investments

• Equity investments

Equity investments whose long-term ownership is deemed useful to Ipsen's activity, notably because it allows for the exercise of influence or control over the issuing company, are recognized at acquisition cost. When the value at the closing date is below the carrying value, a provision for impairment is recorded for the difference. The value at the closing date is measured according to such criteria as the value of the share held in the net assets or the earnings prospects of the relevant company. These criteria are weighted by the effects of owning these shares in terms of strategy or synergies, in respect of other investments held.

Acquisition-related expenses are included in the acquisition cost of the shares. These expenses are spread over five years for tax purposes *via* a regulated provision in the accounts.

• Other financial assets

- Liquidity agreement. Under the program to buy back the Company's own shares, Ipsen funds a liquidity account as part of a liquidity agreement. The contributions made are not available and, as a result, are posted to "Other financial assets."

The capital gains and losses from each transaction are recognized on the income statement, without offset.

At the closing date, short-term investment amounts are measured at their net asset liquidation value. Capital gains realized between the closing date value and the starting value are not recognized. Unrealized capital losses are written down.

2.1.2.3 Receivables

Receivables are measured at nominal value.

Receivables are assessed on a case-by-case basis and may be written down depending on the risks identified.

2.1.2.4 Short-term investments

In accordance with opinion 2008-17 of France's National Accounting Board (*Conseil National de Comptabilité* – CNC), Company shares allotted to bonus share plans and purchased outside the framework of a liquidity agreement are recorded at acquisition cost, *i.e.* the purchase price plus transaction fees, in "Short-term investments". Other Company shares held as part of a liquidity agreement are fixed assets classified as other investment securities.

At the closing date, provisions were recorded as follows:

- If Company shares are purchased with a view to allocating them to bonus share plans, a provision is recorded on the liability side of the balance sheet to account for employee share allocation obligations based on services rendered. Because the allotment of Ipsen's bonus share plans are subject to length of service conditions at the Company, the provision is spread over the vesting period, as required under the CNC opinion;
- Otherwise, for Company shares, if the value at the closing date, *i.e.* the average monthly share price during the last month of the financial year, is below carrying value, a provision for impairment is recorded for the difference.

The income and expenses generated from buying and selling the Company's own shares are recognized as extraordinary income or expenses. To determine the net income or expense when selling repurchased shares, the oldest shares are considered to have been sold first in accordance with the FIFO, first-in, first-out method.

2.1.2.5 Provisions for contingencies and losses

Provisions for contingencies and losses are recognized at the period close to cover all Company liabilities to third parties likely or certain to give rise to an outflow of resources to said third-parties without any counterpart. These provisions are estimated on the basis of the most likely assumptions at the closing date.

2.1.2.6 Debts

Debts are measured at nominal value.

2.1.2.7 Forward financial instruments and hedging transactions

As part of its overall strategy for managing foreign exchange risks, the Company uses forward financial instruments, such as forward contracts and swaps as part of its hedging transactions. These forward financial instruments are contracted only with first-class financial institutions. They are documented as hedging instruments to hedge exposure to fluctuations in cash flows denominated in foreign currencies and associated with a recognized asset or liability, or a sufficiently probable future transaction. Forward financial instruments documented as hedges are accounted for in accordance with regulation n° 2015-05 of 2 July 2015 established the ANC, France's accounting standards authority, and relative to forward financial instruments and hedging transactions.

Unrealized or realized gains and losses on a foreign exchange hedging instrument are symmetrically recognized in the income statement with the hedged item. If the hedge's gains or losses are realized before the hedged item is recognized in the income statement, then the gains and losses are recorded in suspense accounts on the balance sheet. Changes in the value of hedging instruments are not recognized in the balance sheet, unless the recognition in full or in part of the changes can be symmetrically recognized with the hedged instrument. However, in the event the Company does not expect to complete the planned transaction, the hedge will be reclassified as an isolated open position (IOP) and recognized as such. Derivative instruments classified as IOPs are recognized at fair value on the balance sheet against corresponding amounts in revaluation reserves. Unrealized losses on IOP transactions were provisioned as contingencies.

Foreign exchange gains and losses are posted in the "Other operating income" or "Other operating expenses" line item under operating income (expenses), or in the "Foreign exchange gains" or "Foreign exchange losses" line item under financial income (expense), depending on the nature of the transaction. In line with the hedge accounting symmetry principle, foreign exchange hedging transactions are recognized in the same income statement line item as the hedged item.

The Company opted to stagger premiums and discounts on foreign exchange hedges over the hedging period in the "Other financial income" / "Other financial expenses" line item on the income statement.

2.1.2.8 Foreign exchange differences

Foreign-currency denominated income and expense items were recorded in euros based on the exchange rate in effect at the transaction date. Debts, receivables, and cash denominated in foreign currencies were translated into euros at the closing exchange rate at year-end.

The resulting translation differences for debts and receivables denominated in foreign currencies were posted to "Foreign exchange differences" on the balance sheet. The Company follows "overall foreign exchange position" principles. For transactions whose due dates are sufficiently close, any foreign exchange gains or losses are considered as part of an overall foreign exchange position and the amount of the provision for foreign exchange losses is limited to the excess of losses over gains. Hedging transactions and the items hedged are excluded from the position.

2.1.2.9 Retirement benefit obligations

Company employees may be entitled to compensation when they retire or to a pension following their retirement. The Company's liabilities arising from such post-employment benefits are calculated by using an actuary model and assumptions applicable in France.

The corresponding liabilities, based on the rights vested to the beneficiaries, are covered by contributions to independent organizations (insurance companies), which are responsible for paying the pensions and other benefits. In accordance with provision of the French Commercial Code, net assets and liabilities arising from these obligations were not recognized, as the Company does not apply the preferential method.

Further, amounts intended to reward employees for their length of service are paid out as bonuses by the Company.

2.1.2.10 Tax consolidation regime

To reflect the tax consolidation that unites the Company with its subsidiaries, Ipsen, in accordance with the other member companies of its tax consolidation group, has adopted the following rules, reflecting the position of French tax authorities.

Each subsidiary within the consolidation scope recognizes its income tax as if it were taxed separately, *i.e.* particularly after carrying forward tax losses incurred earlier by the subsidiary and transferred to the Parent Company.

Ipsen calculates the income tax due by the consolidated group and expenses the charge. Further, the Company recognizes the tax savings arising from the tax consolidation as income.

Note 3 Notes to the balance sheet

■ 3.1 Non-current assets

3.1.1 Intangible assets

• Change in gross amounts

| (in millions of euros) | 31 December 2020 | Increases | Decreases | 31 December 2021 |
|------------------------|------------------|-----------|-----------|------------------|
| Brands and trademarks | 0.2 | – | – | 0.2 |
| Total | 0.2 | – | – | 0.2 |

No amortization or provisions were recognized for these intangible assets, which had a net carrying value of €0.2 million at 31 December 2021.

3.1.2 Financial investments

• Change in gross amounts

| (in millions of euros) | 31 December 2020 | Increases | Decreases | 31 December 2021 |
|--|------------------|------------|-----------|------------------|
| Equity investments – shares Note 3.1.3 | 1,167.4 | – | – | 1,167.4 |
| Company shares / liquidity agreement | 3.0 | – | – | 3.0 |
| Liquidity agreement | 0.8 | 0.6 | – | 1.4 |
| Loans | – | – | – | – |
| FPCI – Private equity professional fund | 10.0 | – | – | 10.0 |
| Total other financial assets - Note 3.1.4 | 13.8 | 0.6 | – | 14.4 |
| Total financial assets | 1,181.2 | 0.6 | – | 1,181.8 |

• Change in write-downs

| (in millions of euros) | 31 December 2020 | Increases | Decreases | 31 December 2021 |
|-----------------------------|------------------|------------|--------------|------------------|
| Equity investments – shares | – | – | – | – |
| Company shares - Note 3.1.4 | 0.4 | 2.4 | (0.3) | 2.5 |
| Total | 0.4 | 2.5 | (0.3) | 2.6 |

3.1.3 Equity investments

Information about subsidiaries and affiliates is disclosed in the subsidiaries and affiliates table.

3.1.4 Other financial assets

At 31 December 2021, this item broke down as follows:

- Shares in the InnoBio FPCI private equity professional fund: In 2009, the Company signed a subscription form for five thousand shares at an initial investment value of

€1,000 each, with the InnoBio FPCI for a total of €5 million. The commitment includes 13 tranches representing 94% of the commitment, or €4.7 million paid from 2009 to 2021, and deferred tranches totaling €0.3 million that will be gradually called by the fund management company. At 31 December 2021, the Company held 2.89% of the fund.

- Shares in the InnoBio 2 FPCI private equity professional fund: in 2018, the Company signed a subscription form for five thousand shares at an initial investment value of €1,000 each, with the InnoBio 2 FPCI for a total of €5 million. The commitment includes the amount initially called and four tranches totaling 14.2% of the commitment, or €0.7 million paid between 2018 and 2021, and deferred tranches totaling €3.5 million that will be gradually called by the fund management company. At 31 December 2021, the Company held 3.54% of the fund.

- Company shares held as part of a liquidity agreement entrusted to Oddo BHF as of 1 July 2018 for a period of one year and renewable by tacit agreement. The liquidity agreement complies with the AMAFI Ethics Charter, approved by the French financial markets authority.

At 31 December 2021, the Company held 34,053 shares with a gross value of €2.9 million and provided €1.4 million in cash under the liquidity agreement. These own shares were depreciated by €2.4 million at 31 December 2021.

■ 3.2 Receivables by maturity

| (in millions of euros) | Gross amount 2020 | Gross amount 2021 | of which | |
|--------------------------------|-------------------|---------------------|--------------------|--------------------|
| | | | Less than one year | More than one year |
| Other financial assets | 3.8 | 4.4 | 4.4 | – |
| Other trade receivables | 8.5 | 16.6 | 16.6 | – |
| – Income tax | 34.8 | 70.8 ^(a) | 70.8 | – |
| – Value added tax | 0.3 | 0.3 | 0.3 | – |
| Group and associated companies | 10.7 | 64.1 ^(b) | 64.1 | – |
| Miscellaneous receivables | 7.1 | 0.2 | 0.2 | – |
| Prepayments | – | – | – | – |
| TOTAL RECEIVABLES | 65.2 | 156.5 | 156.5 | – |

(a) At 31 December 2021, the Company was in a tax loss position. The “Income tax” receivables position consisted of the Research Tax Credit, the income tax installments cashed out in 2021, and carry-back for an amount of €12.1 million.

(b) The variation of “Group and associated companies” was generated by the gain resulting from the tax Group consolidation.

■ 3.3 Short-term investments

The Company holds short-term investments comprised of 1,283,666 of its own shares valued at €120.1 million.

• Change in short-term investments

| In millions of euros) | 31 December 2020 | Increases | Decreases | 31 December 2021 |
|-----------------------|------------------|---------------------|--------------------|------------------|
| Gross value | 99.1 | 21.0 ^(a) | – | 120.2 |
| Write-downs | (2.9) | – | 2.8 ^(b) | (0.1) |
| Net value | 96.3 | 21.0 | 2.8 | 120.1 |

(a) Increase in short-term investments from the repurchase of 500,000 shares authorized by the Combined Shareholders’ Meeting of 27 May 2021.

(b) Provision for impairment induced by the share price evolution.

■ 3.4 Cash and cash equivalents

At 31 December 2021, the “Cash and cash equivalents” item consisted primarily of term deposits.

■ 3.5 Debt issuance costs to be amortized

Debt issuance costs are amortized over the duration of the respective bonds and loans from which they arose. At 31 December 2021, debt issuance costs came to €3.7 million compared with €5.2 million at 31 December 2020 and broke down as follows:

- €0.3 million arising from the bonds issued by the Company on 16 June 2016. The issuance costs of the bond were spread over the duration of the loan, *i.e.* seven years. An amount of €0.2 million was expensed for the 2021 financial year.
- €2.7 million arising from the new credit facility signed in May 2019. The issuance costs of the bond were spread over the duration of the credit facility, *i.e.* five years. An amount of €1.2 million was expensed for the 2021 financial year.

- €0.7 million arising from the U.S. Private Placement signed on 23 June 2019 for an amount of \$300 million in two tranches of seven and ten years maturity. Issuance costs for the tranche A (€0.5 million) are spread over 7 years. Issuance costs for the tranche B (€0.5 million) are spread over 10 years. An amount of €0.1 million was expensed for the 2021 financial year.

■ 3.6 Bond redemption premium

In line with the bonds issued by the Company on 16 June 2016, the Company recognized a redemption premium spread over the duration of the bonds, *i.e.* seven years.

At 31 December 2020, the balance of the redemption premium remaining on the asset side of the balance sheet came to €0.7 million. The Company expensed €0.3 million for the 2021 financial year, with a redemption-premium balance of €0.4 million remaining on the asset side of the balance sheet at 31 December 2021.

■ 3.7 Unrealized losses on foreign exchange

At 31 December 2021, there is no unrealized losses on foreign exchange.

■ 3.8 Equity

• Share capital

At 31 December 2021, Ipsen's share capital was comprised of 83,814,526 ordinary shares each with a nominal value of €1, including 48,311,316 shares with double voting rights, compared with 83,814,526 ordinary shares each with a nominal value of €1, including 48,301,470 shares with double voting rights at 31 December 2020.

• Change in share capital

| (in millions of euros) | Share capital | Share premium | Issue premium | Legal reserve | Other reserves | Retained earnings | Net profit (loss) for the period | Regulated provisions | Total equity |
|---|---------------|---------------|---------------|---------------|----------------|-------------------|----------------------------------|----------------------|--------------|
| Balance at 31 December 2020, before allocation of net profit | 83.8 | – | 122.3 | 8.4 | – | – | 278.9 | 0.2 | 493.6 |
| Distribution | – | – | – | – | – | – | (82.9) | – | (82.9) |
| Net profit (loss) for the period | – | – | – | – | – | – | 1.3 | – | 1.3 |
| Capital increase from exercised warrants | – | – | – | – | – | – | – | – | – |
| Other movements | – | – | – | – | – | 196.0 | (196.0) | 0.3 | 0.3 |
| Balance at 31 December 2021, before allocation of net profit | 83.8 | – | 122.3 | 8.4 | – | 196.0 | 1.3 | 0.4 | 412.3 |

The 2020 net result was distributed to shareholders in the amount of €82.9 million and allocated to Retained Earnings for the remaining amount.

■ 3.9 Provisions for contingencies and losses

The change in provisions for contingencies and losses from the opening to the closing of the financial year breaks down as follows:

| (in millions of euros) | 2020 | Movements during the period | | | | 2021 |
|--------------------------------|------|-----------------------------|-----------|----------|-----------------|------|
| | | Dotations | Reversals | | Other movements | |
| | | | Applied | Released | | |
| – Provisions for contingencies | 29.6 | 33.0 | (9.1) | (4.6) | – | 49.0 |
| – Provisions for losses | 0.1 | 0.0 | 0.0 | 0.0 | – | 0.2 |
| Total | 29.6 | 33.1 | (9.1) | (4.6) | – | 49.2 |

At 31 December 2021, provisions for contingencies and losses included the following items:

- Provisions recorded to account for employee bonus-share and stock-option allocation obligations based on services rendered;
- Provisions to cover expenses related to long service awards.

■ 3.10 Borrowings and debt

3.10.1 Liabilities by maturity

| (in millions of euros) | Gross amount 2020 | Gross amount 2020 | Of which | | |
|--|----------------------|----------------------|---------------|--------------|--------------|
| | | | Within 1 year | 1 to 5 years | Over 5 years |
| Other bonds | 307.1 | 307.4 | 7.4 | 300.0 | – |
| Bank borrowings | | | | | |
| – Initially up to one year | 0.3 | 0.3 | 0.3 | – | – |
| – Initially over one year | 443.8 | 264.2 ^(a) | – | – | 264.2 |
| Sundry borrowings and financial liabilities | 147.0 | 80.0 ^(b) | 80.0 | – | – |
| Trade payables | 1.4 | 6.3 | 6.3 | – | – |
| Taxes payable and payroll on-cost amounts payable | | | | | |
| Personnel and related accounts payable | 2.7 | 4.3 | 4.3 | – | – |
| Social security and other welfare agency payables | 4.0 | 6.8 | 6.8 | – | – |
| State and other public authority payables: | | | | | |
| – Value added tax | – | – | – | – | – |
| – Other taxes and duties | 0.5 | 0.3 | 0.3 | – | – |
| Total taxes payable and payroll on-cost amounts payable | 7.1 | 11.4 | 11.4 | – | – |
| Other liabilities | | | | | |
| Amounts payable to fixed asset suppliers and related accounts | 4.3 | 3.7 | 3.7 | – | – |
| Group and associated companies | 125.1 | 693.4 ^(c) | 693.4 | – | – |
| Other liabilities | 7.5 | 0.4 | 0.4 | – | – |
| Total other liabilities | 137.0 | 697.5 | 697.5 | – | – |
| Deferred income | – | – | – | – | – |
| TOTAL LIABILITIES | 1,043.7 | 1,367.1 | 802.9 | 300.0 | 264.2 |

(a) The decrease consisted mainly of the Revolving Credit Facility reimbursement for €199.0 million and of the foreign exchange difference for €(19.5) million.

(b) Commercial paper issuance.

(c) The increase stemmed primarily from the current account with Ipsen Pharma S.A.S., the Group's centralizing cash pooling company.

3.10.2 Sundry borrowings, financial liabilities and bonds

Ipsen S.A. financing mainly includes:

- a €300 million unsecured, seven-year public bond taken out on 16 June 2016 with a coupon at an annual interest rate of 1.875%;
- a \$300 million long-term U.S. Private Placement (USPP) taken out on 23 July 2019 in two tranches with 7 and 10 year maturities;
- a Revolving Credit Facility (RCF) €1,500 million taken out on 24 May 2019. The new Revolving Credit Facility matures in five years and has two one-year extension options.

As part of the new Revolving Credit Facility, the Group has to comply with a Net Debt / EBITDA covenant to remain below 3.5 times at each financial closing, and the facility includes specific CSR (Corporate Social Responsibility) indicators to be assessed annually.

On 31 December 2021, the Group was complying with its net debt/EBITDA ratio;

- a €600 million commercial paper program (NEU CP – *Negotiable European Commercial Paper*), €80.0 million of which has been drawn as of 31 December 2021.

■ 3.11 Accrued liabilities

| (in millions of euros) | 2021 | 2020 |
|---|-------------|-------------|
| Sundry borrowings and financial liabilities | 7.7 | 7.4 |
| Suppliers – invoices not yet received | 1.6 | 1.2 |
| Fixed asset suppliers – invoices not yet received | 3.7 | 4.3 |
| Personnel | | |
| – Accrued liabilities for paid vacation | 0.5 | 0.4 |
| – Accrued liabilities for bonuses | 3.7 | 2.2 |
| – Accrued liabilities for profit-sharing | 0.1 | 0.1 |
| – Accrued liabilities for retirement indemnities | – | – |
| – Accrued social welfare expenses | 2.0 | 1.2 |
| State – Accrued expenses | 0.1 | 0.2 |
| Other accrued expenses and interest on current accounts | – | – |
| TOTAL | 19.4 | 17.1 |

■ 3.12 Unrealized gains on foreign exchange

At 31 December 2021, unrealized gains on foreign exchange corresponding to the conversion of bank borrowings and assets and liabilities denominated in foreign currencies to the exchange rate at the closing date were non-material.

Note 4 Notes to the income statement

■ 4.1 Operating income

Operating income totaled €39.6 million in the 2021 financial year and broke down as follows:

- €6.0 million in personnel expenses re-invoiced to subsidiaries;
- €21.9 million in miscellaneous costs re-invoiced to subsidiaries;
- €11.8 million in reversals of provisions for contingencies and losses.

■ 4.2 Operating expenses

Operating expenses totaled €62.7 million versus €45.2 million in 2020.

The €17.5 million increase in operating expenses versus the previous financial year stemmed mainly from:

- the increase in salary expenses by €3.2 million plus an increase in social contributions by €2.6 million;
- the allocation to provisions for contingencies related to free share allocation plans (see note 3.9) up €11.1 million.

■ 4.3 Financial income

| (in millions of euros) | 2021 | 2020 |
|--|-------------|--------------|
| Income from equity investments ^(a) | – | 300.0 |
| Income from other non-current receivables ^(b) | – | 1.1 |
| Reversal of provisions and expenses transferred ^(c) | 3.1 | 596.4 |
| Other financial income ^(d) | 22.9 | 2.3 |
| Foreign exchange gains ^(e) | 7.0 | 2.3 |
| Total financial income | 33.1 | 902.1 |

(a) In 2020, income from equity investments consisted of the dividends paid by Ipsen Pharma S.A.S. No dividend was paid in 2021.

(b) At 31 December 2020, this line item consisted mainly of interest on loans granted to subsidiaries.

(c) At 31 December 2021, this line item mainly included the reversal of impairment of the Company own shares for €3.1 million. At 31 December 2020, this line item mainly included the reversal of depreciation on 11188291 Canada Inc. investment for €580.5 million, the reversal of impairment of the Company own shares for €7.0 million and the reversal of foreign exchange losses provision for €8.9 million.

(d) At 31 December 2021, this line item mainly included other financial income (positive carry over/offset) from forward financial instruments, as well as proceeds from commercial paper issuance.

(e) At 31 December 2021, this line item primarily consisted of foreign exchange gains related to financial transactions.

■ 4.4 Financial expense

| (in millions of euros) | 2021 | 2020 |
|---|---------------|---------------|
| Foreign exchange losses ^(a) | (29.2) | (2.2) |
| Interest and other financial expenses ^(b) | (20.2) | (20.7) |
| Depreciation, amortization and provision charges ^(c) | (2.8) | (0.6) |
| Total financial expense | (52.2) | (23.5) |

(a) At 31 December 2021, this line item primarily consisted of unfavorable foreign exchange losses arising from financial transactions.

(b) At 31 December 2021, this line item was mainly constituted of interests on the borrowings and bond.

(c) At 31 December 2021, this line item was related to the bond redemption premium to be amortized for €0.3 million and from the provision for impairment of the InnoBio fund shares for €2.4 million.

■ 4.5 Net extraordinary income (expense)

| (in millions of euros) | 2021 | 2020 |
|---|---------------|----------------|
| Gains from share buybacks | 1.5 | 1.2 |
| Reversal of provision for investment | – | – |
| Extraordinary income from capital transactions | – | 182.0 |
| Extraordinary income | 1.5 | 183.2 |
| (Losses) from share buybacks | (13.3) | (8.8) |
| Extraordinary expense from capital transactions | – | (839.4) |
| Miscellaneous extraordinary expenses | (0.3) | (0.2) |
| Extraordinary expenses | (13.5) | (848.4) |
| Net extraordinary income (expense) | (12.0) | (665.2) |

The net extraordinary expense for the 2021 financial year stemmed primarily from the capital loss realized during the transfer of treasury shares to certain beneficiaries in respect of long term incentive plans and the loss on sales of treasury share within the liquidity contract.

The net extraordinary expense for the 2020 financial year stemmed primarily from the net capital loss of €657 million, arising from the dissolution of 11188291 Canada Inc., by the capital loss realized during the transfer of treasury shares to certain beneficiaries in respect of long term incentive plans and the loss on sales of treasury share within the liquidity contract.

■ 4.6 Income tax breakdown

The income tax line for the 2021 financial year shows a net profit of €55.5 million corresponding to the income tax profit resulting from the tax consolidation for €43.4 million and to the income of €12.1 million recorded as part of the carry-back calculated on part of the tax deficit as at 31 December 2020

| (in millions of euros) | Pre-tax | Net tax amount | After tax |
|--|---------------|----------------|------------|
| Profit on ordinary activities | (42.1) | – | (42.1) |
| Net extraordinary income (expense) and employee profit-sharing | (12.1) | – | (12.1) |
| Income tax income from tax consolidation | – | 55.5 | 55.5 |
| Book profit (loss) | (54.2) | 55.5 | 1.3 |

■ 4.7 Tax consolidation

Ipsen S.A. leads a tax consolidation group. To reflect the tax consolidation that unites the Company with its subsidiaries, the following methods were applied in the annual financial statements:

- Each subsidiary within the tax group recognizes its income tax as if it were taxed separately, *i.e.* particularly after recognizing its tax-loss carryforwards.
- Payments were made by bank transfer to the Company's account at dates scheduled for payment transfer to the Treasury. Ipsen calculated the income tax owed by the tax consolidated group and expensed the amount. In addition, the Company recorded the income tax recognized by its integrated subsidiaries as income.

- If a subsidiary exits the scope of consolidation after a period of five years, it recovers no income tax or tax-loss carryforwards.
- At 31 December 2021, the net operating losses to carry-forward represent an amount of €318.9 million compared with €426.6 million as of 31 December 2020, mainly coming from the losses generated by the rationalization of the ownership of the Group's subsidiary, after compensation with the positive taxable results of its integrated subsidiaries.

■ 4.8 Increases or decreases in future tax liability

The temporary differences generate a future tax savings for an amount of €25.7 million, in basis:

| (in € million) | Basis | Income Tax (28.41%) |
|---|-------------|---------------------|
| Future savings - foreign exchange differences | 5.1 | 1.4 |
| Futures savings - Non tax-deductible provisions | 20.7 | 5.9 |
| Total Future Savings | 25.7 | 7.3 |

To those amounts should be added the future tax savings from the net operating losses to carryforward for an amount of €318.9 million to offset against future taxable results.

Note 5 Other information

5.1 Directors, executives and officers

5.1.1 Remuneration paid to corporate officers

Remuneration paid by the Company to directors, executives and officers for the 2021 financial year totaled €2.7 million.

5.2 Average headcount at period closing

| | 2021 | 2020 |
|--------------------------|----------|----------|
| Top and upper management | 9 | 7 |
| TOTAL | 9 | 7 |

5.3 Financial commitments

5.3.1 Commitments to personnel

Apart from retirement bonuses mandated under a collective bargaining agreement with the French pharmaceutical industry and obligations related to a supplementary pension plan, the Company has no other obligations arising from employee pensions, complementary retirement benefits, retirement bonuses or contributions, or similar post-employment benefits.

At 31 December 2021, obligations arising from retirement bonuses and the supplementary pension plan amounted to €0.8 million and €9.7 million respectively. The amounts were determined *via* actuarial valuation using the “projected unit credit” method.

The main assumptions used in the calculations were as follows:

- Discount rate of 0.88%,
- Inflation rate of 1.9%,
- Voluntary retirement for managers at age 67 for those born after 1963 and 64 for those born before 1963; voluntary retirement for non-managers at age 65 for those born after 1963 and age 63 for those born before 1963,
- Mortality table: TH 16-18 / TF 16-18.

These obligations were outsourced to an insurance company. At 31 December 2021, the fair value of these financial assets came to €0.9 million for the retirement bonuses and the €1.8 million for the supplementary pension plan, assuming a long-term rate of return of 0.88%.

In accordance with provision of the French Commercial Code, net assets and liabilities arising from these obligations were not recognized, as the Company does not apply the preferential method.

The obligation arising from long-service awards was determined *via* actuarial valuation using the “projected unit credit” method and fully provisioned at 31 December 2021. A discount rate of 0.88% was assumed to calculate the €0.2 million long-service award obligation.

Retirement pensions and similar benefit obligations for executives and officers came to €1.8 million at 31 December 2021.

5.1.2 Loans and advances to top management.

No advances or loans were made to the Company’s top management.

5.3.2 Commitments given

The Ipsen Group has subscribed to a worldwide civil liability insurance policy from a third-party insurer. The insurance company itself is underwritten by the captive reinsurance company Ipsen Ré, a wholly owned subsidiary of the Group, up to the first €20.0 million for any potential claim made.

To cover that financial commitment and address any potential default by Ipsen Ré, the Ipsen S.A. parent company issued, on 19 May 2021, a letter of guarantee payable upon first demand in favor of the third-party insurer for a total amount of €3.0 million. This first-demand guarantee is applicable from 1 January 2021, and if it has not been called for its maximum amount, it will expire on 31 December 2025. The first-demand guarantee is renewable annually.

In addition, under the previous civil liability insurance contract also reinsured in the captive reinsurance company Ipsen Ré and terminated on 31 December 2018, the previous guarantee on first demand issued in March 2018 in favor of the previous insurer for an amount of €9 million has been extended for five years after the expiration date of the reinsurance contract, *i.e.* until 31 December 2023.

5.4 Bonus share plans

On 27 May 2021, the Board of Directors granted 427,333 bonus shares:

- 81,473 bonus shares to the Executive Leadership Team, subject to Group-specific length of service conditions as well as performance conditions;
- 79,840 bonus shares to beneficiaries of Group subsidiaries, subject to Group-specific length of service conditions as well as performance conditions;
- 266,020 bonus shares to beneficiaries of Group subsidiaries, subject to Group-specific length of service conditions but not subject to performance conditions.

The Board also granted 24,400 bonus shares to certain Group employees, on an exceptional basis and subject to length of service conditions.

| (in millions of euros/number of shares) | Number of bonus shares | Vesting period | Performance conditions | Value of shares on date granted, before reduction | Fair value of bonus share | Initial value of the plan |
|---|------------------------|----------------------------------|------------------------|---|---------------------------|---------------------------|
| Plan dated June 1, 2016 | 242,290 | | | | | 10.5 |
| Chairman, Chief Executive Officer & Executive Committee Members | 64,019 | 2 years | yes | €56.69 | €47.73 | |
| Beneficiaries from French subsidiaries | 72,208 | 2 years | yes | €56.69 | €47.73 | |
| Beneficiaries from American subsidiaries | 64,727 | 2 years | yes | €56.69 | €47.73 | |
| Beneficiaries outside the French & American subsidiaries | 41,336 | 4 years | yes | €56.69 | €49.04 | |
| Plan dated March 29, 2017 | 151,890 | | | | | 13.3 |
| Chief Executive Officer & Executive Leadership Team | 41,640 | 2 years | yes | €93.40 | €101.47 | |
| Beneficiaries from French subsidiaries | 44,070 | 2 years | yes | €93.40 | €97.01 | |
| Beneficiaries from American subsidiaries | 28,200 | 2 years | yes | €93.40 | €97.00 | |
| Beneficiaries outside the French & American subsidiaries | 37,980 | 4 years | yes | €93.40 | €99.27 | |
| Plan dated May 30, 2018 | 211,140 | | | | | 25.3 |
| Chief Executive Officer & Executive Leadership Team | 39,390 | | yes | €134.40 | €134.90 | |
| Beneficiaries from subsidiaries subject to performance conditions | 84,240 | 50% to 2 years 50% to 3 years | yes | €134.40 | €134.90 | |
| Beneficiaries from subsidiaries not subject to performance conditions | 87,510 | | no | €134.40 | €131.84 | |
| Plan dated February 13, 2019 | 25,880 | | | | | 2.8 |
| Beneficiaries from subsidiaries | 25,880 | 2 years | no | €109.60 | €109.60 | |
| Plan dated May 28, 2019 | 288,880 | | | | | 25.5 |
| Chief Executive Officer & Executive Leadership Team | 43,520 | 3 years | yes | €112.10 | €90.25 | |
| Beneficiaries from subsidiaries subject to performance conditions | 117,160 | 50% to 2 years 50% to 3 years | yes | €112.10 | €87.83 | |
| Beneficiaries from subsidiaries not subject to performance conditions | 128,200 | | no | €112.10 | €109.57 | |
| Plan dated February 12, 2020 | 71,650 | | | | | 2.8 |
| Beneficiaries from subsidiaries | 71,650 | 2 years | no | €109.60 | €109.60 | |
| Plan dated May 29, 2020 | 520,268 | | | | | 34.8 |
| Executive Leadership Team | 70,610 | 3 years | yes | €72.00 | €62.02 | |
| Beneficiaries from subsidiaries subject to performance conditions | 106,261 | 3 years | yes | €72.00 | €62.02 | |
| Beneficiaries from subsidiaries not subject to performance conditions | 223,154 | 2 years | no | €72.00 | €69.98 | |
| Beneficiaries from subsidiaries not subject to performance conditions | 120,243 | 3 years | no | €72.00 | €68.71 | |
| Plan dated July 29, 2020 | 37,829 | | | | | 2.8 |
| Chief Executive Officer | 37,829 | 3 years | yes | €81.75 | €74.83 | |
| Plan dated May 27, 2021 | 427,333 | | | | | 39.9 |
| Executive Leadership Team | 81,473 | 3 years | yes | €85.78 | €84.37 | |
| Beneficiaries from subsidiaries subject to performance conditions | 79,840 | 3 years | yes | €85.78 | €84.37 | |
| Beneficiaries from subsidiaries not subject to performance conditions | 172,930 | 2 years | no | €85.78 | €83.76 | |
| Beneficiaries from subsidiaries not subject to performance conditions | 93,090 | 3 years | no | €85.78 | €82.74 | |
| Plan dated May 27, 2021 | 24,400 | | | | | 2.3 |
| Beneficiaries from subsidiaries | 24,400 | 2 years | no | €85.78 | €83.76 | |
| TOTAL | | | | | | |



Note 6 Subsidiaries and affiliates

(Amounts in thousands of currency units)

| Detailed information for each interest, in which gross value exceeds 1% of the company's share capital | Share capital | Equity other than share capital and excl. net profit | Percentage of share capital held % | Number | | Carrying amount of shares held | | Outstanding loans and advances granted by the Company | Amount of endorsements, guarantees, and letters of intent provided by the Company | Sales, net of VAT, for the last year (avg. exch. rate) | Net profit (loss) for the last year (avg. exch. rate) | Dividends collected by the Company in the last year, net of ESOP |
|--|---------------|--|------------------------------------|----------|---------|--------------------------------|------------|---|---|--|---|--|
| | | | | Interest | Shares | Gross amounts | Provisions | | | | | |
| Dividends collected by the Company in the last year, net of ESOP | | | | | | | | | | | | |
| Ipsen Pharma | €7,755 | €1,477,161 | 100 | | 188,905 | €1,167,432 | – | – | – | €1,635,063 | €96,892 | – |
| General information for other interests, in which gross value exceeds 1% of the Company's share capital | | | | | | | | | | | | |
| 1. Equity interests in foreign companies | | | | | | | | | | | | |
| Ipsen Poland LLC | 1,210 PLN | 12,432 PLN | 1 | | 1 | €15 | – | – | – | 175,685 PLN | 1,038 PLN | – |

Note 7 Cash flow statement

| (in millions of euros) | 31 December 2021 | 31 December 2020 |
|---|------------------|------------------|
| Opening cash and cash equivalents | 262.1 | 130.7 |
| Net profit (loss) | 1.3 | 278.9 |
| Elimination of income and expense with no impact on cash flow or not used in operating activities | | |
| – Net depreciation, amortization and provision charges | 32.6 | 84.7 |
| Cash flow | 33.9 | 363.7 |
| Change in working capital requirement related to operating activities | (123.1) | 23.1 |
| Net cash flow from operating activities - Note 3.3.4.6 | (89.2) | 386.8 |
| Acquisition of equity investments | – | – |
| Disposal of equity investments | – | 182.0 |
| Other cash flows related to financing activities | (0.6) | 355.1 |
| Change in working capital related to investment activities | (0.6) | (0.5) |
| Net cash provided (used) by investment activities - Note 3.3.4.7 | (1.2) | 536.6 |
| Repayment of borrowings | (246.2) | (211.9) |
| Debt issues | – | – |
| Change in share capital | – | – |
| Share repurchasing agreement | (32.8) | (36.4) |
| Dividends paid | (82.9) | (83.2) |
| Change in working capital related to financing activities | 568.26 | (460.6) |
| Net cash provided (used) by financing activities - Note 3.3.4.8 | 206.3 | (792.0) |
| Changes in cash and cash equivalents | 115.9 | 131.4 |
| Closing cash and cash equivalents | 378.0 | 262.1 |

Note 8 Subsequent events

Exclusive negotiations to divest the Consumer Healthcare business

Following the decision of its Board of Directors held on 10 February 2022, Ipsen has entered into exclusive negotiations with Mayoly Spindler for the divestment of its global CHC business. This is a major step forward in the Company's execution of its strategic roadmap presented in December 2020 towards building a more-focused Ipsen, centring on Specialty Care.

The combination of Ipsen's and Mayoly Spindler's respective CHC businesses will create a global consumer-healthcare platform with a critical size and the capacity to support its growth. The consideration for Ipsen's CHC business represents an enterprise value of €350m, including an earnout contingent payment of €50m.

The proposed transaction will be submitted to the relevant employee-representation bodies and is expected to close before the end of Q3 2022, subject to regulatory approvals and customary closing conditions.

No other event occurring between the closing date of the consolidated financial statements and the date of their approval by the Board of Directors, and not taken into consideration, was likely to call into question the annual financial statements themselves or make it necessary to mention such an event in the notes to the annual financial statements.



3.3.3 Statutory Auditors' Report on the annual financial statements

This is a translation into English of the statutory auditors' report on the financial statements of the Company issued in French and it is provided solely for the convenience of English speaking users.

This statutory auditors' report includes information required by European regulation and French law, such as information about the appointment of the statutory auditors or verification of the management report and other documents provided to shareholders.

This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.

Ipsen S.A.

Registered office: 65, Quai Georges Gorse - 92100 Boulogne-Billancourt

Statutory auditors' report on the financial statements

For the year ended 31 December 2021.

Opinion

In compliance with the engagement entrusted to us by your Annual General Meeting, we have audited the accompanying financial statements of Ipsen S.A. for the year ended 31 December 2021.

In our opinion, the financial statements give a true and fair view of the assets and liabilities and of the financial position of the Company as at 31 December 2021 and of the results of its operations for the year then ended in accordance with French accounting principles.

The audit opinion expressed above is consistent with our report to the Audit.

Basis for Opinion

Audit Framework

We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the *Statutory Auditors' Responsibilities for the Audit of the Financial Statements* section of our report.

Independence

We conducted our audit engagement in compliance with independence requirements of the French Commercial Code (*Code de commerce*) and the French Code of Ethics (*Code de déontologie*) for statutory auditors for the period from 1 January 2021 to the date of our report and specifically we did not provide any prohibited non-audit services referred to in Article 5(1) of Regulation (EU) No 537/2014.

Justification of Assessments - Key Audit Matters

Due to the global crisis related to the COVID-19 pandemic, the financial statements of this period have been prepared and audited under specific conditions. Indeed, this crisis and the exceptional measures taken in the context of the state of sanitary emergency have had numerous consequences for companies, particularly on their operations and their financing, and have led to greater uncertainties on their future prospects. Those measures, such as travel restrictions and remote working, have also had an impact on the companies' internal organization and the performance of the audits.

It is in this complex and evolving context that, in accordance with the requirements of Articles L.823-9 and R.823-7 of the French Commercial Code (*Code de commerce*) relating to the justification of our assessments, we inform you of the key audit matters relating to risks of material misstatement that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period, as well as how we addressed those risks.

These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in

forming our opinion thereon, and we do not provide a separate opinion on specific items of the consolidated financial statements.

Investments Valuation

Identified risk

Investments as at 31 December 2021 for a net amount of €1,167.4 million represent one of the most significant items in the balance sheet. They are recognized at their acquisition cost and written down, if necessary based on their fair value, representing what the Company would agree to pay to obtain them if it had to acquire them.

As stated in note 2.1.2.2. to the annual financial statements, the Company estimates, at each year-end, the fair value of each of its investments to determine whether it is less than the net book value.

The analysis is carried out using criteria such as the net equity value of the share, the multiple method, or profitability outlooks such as cash flow forecasts established by the local Management.

In this context, and due to inherent uncertainties in certain components, in particular profitability outlook, we considered that the valuation of investments was a key audit matter.

Audit procedures implemented with regard to the identified risk

To assess the reasonableness of the estimated fair values of the investments, our work consisted mainly in verifying that such fair values determined by Management were based on appropriate valuation methods, quantified data used and:

- Verifying that the value of the share of net assets is consistent with the value determined using a multiple approach;
- Verifying that the retained equity is in line with the accounts of the entities that have been subject to an audit or analytical procedures and that the adjustments made, if any, on such net equity value are based on appropriate documentation;

- Obtaining the profitability outlooks for the activities of the relevant entities established by local Management and assessing their consistency with the forecast data from the latest business plans, established under the control of Management for each of these activities;
- Verifying the consistency of the assumptions adopted with the economic environment at the closing and accounts preparation dates;
- Verifying that the value resulting from the cash flow forecasts has been adjusted by the debt amount of the relevant entity.

Specific Verifications

We have also performed, in accordance with professional standards applicable in France, the specific verifications required by laws and regulations.

Information given in the management report and in the other documents with respect to the financial position and the financial statements provided to the Shareholders

We have no matters to report as to the fair presentation and the consistency with the financial statements of the information given in the management report of the Board of Directors and in the other documents with respect to the financial position and the financial statements provided to the Shareholders.

We attest the fair presentation and the consistency with the financial statements of the information relating to payment deadlines mentioned in Article D.441-6 of the French Commercial Code (*Code de commerce*).

Report on corporate governance

We attest that the Board of Directors' report on corporate governance sets out the information required by Articles L.225-37-3 and L.225-37-4 of the French Commercial Code.

Concerning the information given in accordance with the requirements of Article L.225-37-3 of the French Commercial Code (*Code de commerce*) relating to remunerations and benefits received by or awarded to the directors and any other commitments made in their favor, we have verified the consistency with the financial statements, or with the underlying information used to prepare these financial statements and, where applicable, with the information obtained by your Company from controlled companies included in the scope of consolidation. Based on these procedures, we attest the accuracy and fair presentation of this information.

Other information

In accordance with French law, we have verified that the required information concerning the identity of the shareholders and holders of the voting rights has been properly disclosed in the management report.

Report on Other Legal and Regulatory Requirements

Format of the presentation of the financial statements intended to be included in the annual financial report

We have also verified, in accordance with the professional standard applicable in France relating to the procedures

performed by the statutory auditor relating to the annual and consolidated financial statements presented in the European single electronic format, that the presentation of the consolidated financial statements intended to be included in the annual financial report mentioned in Article L.451-1-2, I of the French Monetary and Financial Code (*Code monétaire et financier*), prepared under the responsibility of Chief Executive Officer, complies with the single electronic format defined in the European Delegated Regulation 2019/815 of 17 December 2018.

Based on the work we have performed, we conclude that the presentation of the consolidated financial statements intended to be included in the annual financial report complies, in all material respects, with the European single electronic format.

We have no responsibility to verify that the consolidated financial statements that will ultimately be included by your company in the annual financial report filed with the AMF are in agreement with those on which we have performed our work.

Appointment of the Statutory Auditors

We were appointed statutory auditors for Ipsen S.A. by the Annual General Meeting held on 18 June 2005 for KPMG S.A. and on 17 December 1998 for Cogenco Flipo which was acquired by Deloitte & Associés in 2001.

As of 31 December 2021, KPMG S.A. was in the 17th consecutive year of its assignment and Deloitte & Associés was in its 24th year, including 17 years for both firms since the shares of the Company have been admitted to trading on a regulated market.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with French accounting principles and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless it is expected to liquidate the Company or to cease operations.

The Audit Committee is responsible for monitoring the financial reporting process and the effectiveness of internal control and risks management systems and where applicable, its internal audit, regarding the accounting and financial reporting procedures.

The financial statements were approved by the Board of Directors.

Statutory Auditors' Responsibilities for the Audit of the Financial Statements

Objectives and audit approach

Our role is to issue a report on the financial statements. Our objective is to obtain reasonable assurance about whether the financial statements as a whole are free from material



misstatement. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As specified in Article L.823-10-1 of the French Commercial Code (*Code de commerce*), our statutory audit does not include assurance on the viability of the Company or the quality of management of the affairs of the Company.

As part of an audit conducted in accordance with professional standards applicable in France, the statutory auditor exercises professional judgment throughout the audit and furthermore:

- Identifies and assesses the risks of material misstatement of the financial statements, whether due to fraud or error, designs and performs audit procedures responsive to those risks, and obtains audit evidence considered to be sufficient and appropriate to provide a basis for his opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtains an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluates the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management in the financial statements.
- Assesses the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going

concern. This assessment is based on the audit evidence obtained up to the date of his audit report. However, future events or conditions may cause the Company to cease to continue as a going concern. If the statutory auditor concludes that a material uncertainty exists, there is a requirement to draw attention in the audit report to the related disclosures in the financial statements or, if such disclosures are not provided or inadequate, to modify the opinion expressed therein.

- Evaluates the overall presentation of the financial statements and assesses whether these statements represent the underlying transactions and events in a manner that achieves fair presentation.

Report to the Audit Committee

We submit to the Audit Committee a report which includes in particular a description of the scope of the audit and the audit program implemented, as well as the results of our audit. We also report, if any, significant deficiencies in internal control regarding the accounting and financial reporting procedures that we have identified.

Our report to the Audit Committee includes the risks of material misstatement that, in our professional judgment, were of most significance in the audit of the financial statements of the current period and which are therefore the key audit matters that we are required to describe in this report.

We also provide the Audit Committee with the declaration provided for in Article 6 of Regulation (EU) N° 537/2014, confirming our independence within the meaning of the rules applicable in France such as they are set in particular by Articles L.822-10 to L.822-14 of the French Commercial Code (*Code de commerce*) and in the French Code of Ethics (*Code de déontologie*) for statutory auditors. Where appropriate, we discuss with the Audit Committee the risks that may reasonably be thought to bear on our independence, and the related safeguards.

Paris La Défense, on the 16 February 2022

The Statutory Auditors

French original signed by

Catherine Porta
Partner

Paris La Défense, on the 16 February 2022

Frédéric Souliard
Partner

3.3.4 Information related to Ipsen's business activity

■ 3.3.4.1 Significant events during the year

Significant events of the year are disclosed in the first part of the notes to the annual financial statements.

■ 3.3.4.2 Analysis of the changes in the business and results

Breakdown of sales and other income:

| (in millions of euros) | 2021 | 2020 |
|-------------------------|-------------|-------------|
| Services | 27.9 | 17.4 |
| Operating income | 27.9 | 17.4 |

Services correspond primarily to personnel-related expenses billed back to the subsidiaries.

The following table provides a summary of the main aggregate items on the income statement:

| (in millions of euros) | 2021 | 2020 |
|--------------------------------------|---------------|--------------|
| Net sales | 27.9 | 17.4 |
| Operating profit (losses) | (23.1) | (19.7) |
| Net financial income (expense) | (19.1) | 878.6 |
| Profit on ordinary activities | (42.1) | 858.9 |
| Net extraordinary income (expense) | (12.0) | (665.2) |
| Pre-tax profit | (54.2) | 193.7 |
| Income tax – Gain | 55.5 | 85.2 |
| Net profit (loss) | 1.3 | 278.9 |

Operating losses decreased by €3.4 million compared to 2021 financial year. The main observations are as follows:

- an increase in Operating Income by €14.2 million related to operating expenses being rebilled;
- compensated by an increase in operating expenses by €17.5 million:
 - increase in salary expenses by €3.2 million plus an increase in social contributions by €2.6 million;
 - allocation to provisions for contingencies related to free share allocation plans up €11.1 million.

Net financial result decreased by €897.7 million vs 2020 financial year:

- the Company did not receive any dividend in 2021 compared with €300.0 million paid in 2020;
- in addition, in 2020, a reversal of the 2019 provision for impairment on 11188291 Canada Inc. shares was recorded for €580.5 million..

Net extraordinary expense increased by €653.1 million compared to 2020 where €657 million capital loss arising from the dissolution of 11188291 Canada Inc was booked.

At 31 December 2021, the Company reported an income tax profit of €55.5 million.

The net result for the 2021 financial year came to a profit of €1.3 million.

■ 3.3.4.3 Cash Flow Statement

The cash flow statement disclosed in the notes shows that cash and cash equivalents at the close of 2021 were increasing by €115.9 million.

The decrease of €476.0 million observed in net cash flow from operating activities in 2021 stemmed notably from the decrease in dividends received from the affiliates (impact of €300.0 million) and the impact of unfavorable change in the operating working capital requirement for €146.2 million.

This deterioration is mainly explained by the income tax installments cashed out in 2021 as well as commercial receivables and payables, with a significant impact of the exchange rate in 2020.

In 2020, the net cash provided (used) by investment activities consists primarily of partial repayments of loans granted to Group subsidiaries for €355.1 million and by the gain related to the dissolution of 11188291 Canada Inc. for €182.0 million.

In 2021, the Company did not carry out any investment transaction with a significant impact on its cash flows.



The €206.3 million net variation in financial debt stemmed from the following items:

- €(179.6) million from the full reimbursement of the Revolving Credit Facility (RCF) of €199.0 million and the foreign exchange differences on USPP,
- €(67.0) million from the net change in commercial paper,
- €(32.8) million from share buyback agreements,
- (82.9) from distribution to shareholders,
- €568.3 million from current account balance with Group companies.

■ 3.3.4.4 Subsequent events

Subsequent events are disclosed in Note 8 to the Company's annual financial statements.

■ 3.3.4.5 Business trends and outlook

In 2022, Ipsen S.A.'s net profit will be derived essentially from the dividends it receives from its subsidiaries, its financial expense and the tax consolidation gain.

■ 3.3.4.6 Subsidiaries and affiliates

The lion's share of sales from Ipsen S.A. subsidiaries are generated by the marketing and sale of proprietary drugs prescribed by the medical profession. Purchases of most of the drugs are reimbursed by national health programs.

| (in millions of euros) | 2021 | | 2020 | |
|------------------------|---------|-------------------|---------|-------------------|
| | Sales | Net profit (loss) | Sales | Net profit (loss) |
| Ipsen Pharma S.A.S. | 1,635.1 | 96.9 | 1,568.4 | 222.0 |

The list of subsidiaries and affiliates is provided in the notes to the Company's annual financial statements.

■ 3.3.4.7 Accounting principles and methods

No changes were made in the accounting principles and methods versus the prior year.

■ 3.3.4.8 Payment due dates

The following information on due dates for Company payables and receivables is provided in accordance with Articles L.441-6-1 and D.441-4 of France's Commercial Code. This information included intra-group payables and receivables information.

Invoices received or issued at the closing date of the financial year:

| Amounts in millions of euros | Invoices received but not paid at the closing date of the period | | | | | | | Invoices issued but not paid at the closing date of the period | | | | | | | |
|---|--|--------------|--------------|---------------|---------------|--------------|----------------------|--|--------------|---------------|---------------|--------------|----------------------|-------|----|
| | Late payment tranches | Not past due | Overdue | | | | | Not past due | Overdue | | | | | | |
| | | | 1 to 30 days | 31 to 60 days | 61 to 90 days | Over 91 days | 1 day and over total | | 1 to 30 days | 31 to 60 days | 61 to 90 days | Over 91 days | 1 day and over total | | |
| Number of invoices | 6 | 6 | | | | | | 23 | 3 | | | | | | 20 |
| Total amount of invoices, incl. VAT | 4.7 | 4.7 | | | | | | 4.1 | 0.1 | 3.1 | - | - | 0.9 | 4.0 | |
| Percentage of invoices, incl. VAT | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% | 75.5% | 0.0% | 0.0% | 22.7% | 98.2% | | |
| Percentage of total amount of purchases for the period, incl. VAT | 11.2 | 42.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | | | | | | |
| Percentage of total amount of sales, incl. VAT | | | | | | | | 23.7 | 0.3% | 13.0% | 1.2% | 0.0% | 3.9% | 16.9% | |
| Due dates used to determine late payment | Contractual due dates | | X | | | | | Contractual due dates | | X | | | | | |
| | Legal due dates | | | | | | | Legal due dates | | | | | | | |

■ 3.3.4.9 Sumptuary spending

An amount of €0.04 million of non-tax-deductible expenses targeted under Article 39-4 of the French Tax Code were added back during the financial year just ended.

■ 3.3.4.10 Dividend payout

In accordance with Article 243 bis of the French Tax Code, the dividends paid out for the last three financial years were as follows:

| (in € per share) | Annual dividend payout Total (*) | Dividend per share |
|------------------|----------------------------------|--------------------|
| 2019 | 83,201,522 | 1,00 |
| 2020 | 83,189,972 | 1,00 |
| 2021 | 82,891,813 | 1,00 |

(*) After cancelling dividends on treasury shares in retained earnings.

■ 3.3.4.11 Company earnings and other financial highlights over the past five years

| | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|----------|--------|---------|---------|--------|
| Share capital at year-end (in millions of euros) | | | | | |
| – Share capital | 83.7 | 83.8 | 83.8 | 83.8 | 83.8 |
| – Number of shares outstanding (in thousands) | 83,732.1 | 83,809 | 83,815 | 83,815 | 83,815 |
| – Number of outstanding preferred shares without voting rights | – | – | – | – | – |
| – Maximum number of shares to be created | – | – | – | – | – |
| Transactions and results for the year (in millions of euros) | | | | | |
| – Net sales | 20.1 | 15.4 | 21.4 | 17.4 | 27.9 |
| – Profits before income tax, employee profit-sharing, amortization, depreciation and provisions | (27.6) | (12.5) | (642.9) | (386.6) | (33.4) |
| – Income tax – Gain (losses) | 12.6 | (0.6) | 18.3 | 85.2 | 55.5 |
| – Employee profit-sharing for the year | – | – | – | – | – |
| – Earnings after income tax, employee profit-sharing, amortization, depreciation and provisions | (17.4) | (15.4) | (626.9) | 278.9 | 1.3 |
| – Dividends paid out(**) | 70.2 | 83.0 | 83.2 | 83.2 | 83.9 |
| Earnings per share (in € per share) | | | | | |
| – Earnings after income tax and employee profit-sharing, but before amortization, depreciation and provisions | 0.0 | 0.0 | (8.0) | (3.6) | 0.3 |
| – Earnings after income tax, employee profit-sharing, amortization, depreciation and provisions | 0.0 | 0.0 | (7.0) | 3.3 | - |
| – Dividend per share | 0.85 | 1.00 | 1.00 | 1.00 | 1.00 |
| Personnel (in millions of euros) | | | | | |
| – Average number of employees during the year(*) | 11 | 6 | 5 | 7 | 9 |
| – Total payroll for the year | 20.7 | 10.9 | 8.5 | 6.3 | 9.5 |
| – Total payroll on-costs for the year (Social security, welfare, etc.) | 7.6 | 2.0 | 5.1 | 3.3 | 5.9 |

(*) Including Management bodies.

(**) Dividends on treasury shares are posted to retained earnings.

[This page is intentionally left blank]

4

COMPANY SOCIAL RESPONSIBILITY

| | | |
|-------------|---|------------|
| 4.1 | IPSEN'S COMPANY SOCIAL RESPONSIBILITY (CSR) VISION AND STRATEGY | 144 |
| 4.1.1 | Presentation and governance of Ipsen's Company Social Responsibility | 144 |
| 4.1.2 | The Group's key CSR risks and opportunities | 149 |
| 4.2 | IMPROVING PATIENTS' LIVES BY OFFERING INNOVATIVE AND SAFE MEDICINES | 151 |
| 4.2.1 | Bringing high quality product to patients | 151 |
| 4.2.2 | Ensuring product and patient safety | 153 |
| 4.2.3 | Animal welfare | 155 |
| 4.2.4 | Committed to ensure supply continuity | 156 |
| 4.2.5 | Committed to fight against counterfeit products | 156 |
| 4.2.6 | Promoting products responsibly | 157 |
| 4.2.7 | Enlarging access to health | 159 |
| 4.3 | ENHANCING INTEGRITY TO MAINTAIN A TRUSTED RELATIONSHIP WITH OUR STAKEHOLDERS | 162 |
| 4.3.1 | Committed to protect personal data | 162 |
| 4.3.2 | Fighting corruption | 164 |
| 4.3.3 | Promoting and defending Human Rights | 167 |
| 4.4 | DRIVING OUR EMPLOYEES' EXCELLENCE AND ENGAGEMENT | 168 |
| 4.4.1 | Attracting the best talents | 168 |
| 4.4.2 | Enhancing employees' engagement | 170 |
| 4.4.3 | Providing a healthy and safe workplace | 175 |
| 4.5 | MINIMIZING OUR ENVIRONMENTAL IMPACT | 177 |
| 4.5.1 | Protecting the Environment | 177 |
| 4.5.2 | Climate Action | 178 |
| 4.5.3 | Responsible Consumption and Production | 180 |
| 4.6 | ANNEX I: SCOPE OF RISKS COVERED | 181 |
| 4.7 | ANNEX II: CORRESPONDENCE TABLE WITH GRI STANDARDS | 182 |
| 4.8 | ANNEX III: SUMMARY OF OUR KEY PERFORMANCE INDICATORS (KPIs) | 184 |
| 4.9 | ANNEX IV: COMPLYING WITH THE EUROPEAN TAXONOMY | 187 |
| 4.10 | ANNEX V: REPORTING METHODOLOGY AND AUDIT REPORT | 188 |



Introduction

The present Chapter reflects Ipsen Company Social Responsibility information according to the requirements of Articles L.225-102-1 and R.225-105 of the French Commercial Code, amended by ordonnance 2017-1180 and Application decree 2017-1265, transposing Directive 2014/95/UE of the European Parliament and 22 October 2014 Council on disclosure of non-financial information.

As per the Non-Financial Statement regulations, for social, societal and environmental risks, this Chapter 4 includes:

- A description of the policies and diligence implemented to identify, prevent and limit the occurrence of the risk.
- The results of such policies through key performance indicators.

The business model is included in section 1.1.2

4.1 IPSEN'S COMPANY SOCIAL RESPONSIBILITY (CSR) VISION AND STRATEGY

4.1.1 Presentation and governance of Ipsen's Company Social Responsibility

Dear stakeholders,

2021 was the first year of implementation of our Group strategy Focus. Together. For patients & society. Our commitment to social responsibility being at the heart of this strategy, it has been a year of exceptional and unprecedented engagement as we worked with all of our stakeholders to enhance and drive a positive impact for patients and society.

Our Company Social Responsibility approach is based on three pillars: employees, communities, and the environment. It is fully embedded in our strategy, contributing to the sustainability of our business model, and built on a strong ethical culture.

During 2021, we progressed key actions and accomplished major achievements.

On the Employee pillar, we strengthened and enhanced our Ipsen Way of Being in order to boost a culture of collaboration and excellence to fully support our new strategy. We set significant diversity targets for our Executive Leadership Team (ELT) and Global Leadership Team (GLT) that we are on track to reach. And as part of our goal to create a world-class work environment, we are very proud that we were recognized as an employer of choice in 19 countries this year.

The Community pillar is bolstered by Ipsen's employees' profound sense of purpose. Not only are we committed to making a difference for people living with difficult-to-treat conditions, we want to make a difference for society as a whole. This year, two of our biggest community-based initiatives, Community Day and Ipsen in Motion reached new levels of engagement as Ipsen teams worldwide contributed time, energy and dedication to their local communities.

Our concern for society extends to the well-being of the environment. We want to do our part to ensure we limit the impact of climate change for future generations. As part of our Environment pillar, we joined the Business Ambition for 1.5°C and have pledged to a science-based 50% reduction in absolute greenhouse gas emissions of our facilities and fleet by 2030 vs 2019. We will also deliver a science based reduction in emissions across the rest of our value chain in the same period.

These commitments and achievements demonstrate the values we share and that we aim to live fully every day. At Ipsen, we are truly driven to make a positive impact: for patients, employees, our communities, our partners and shareholders.

Best regards,
David Loew
Chief Executive Officer



CSR strategy

Our CSR strategy is embedded in the Company's strategy Focus.Together.For patients & society

**FOCUS.TOGETHER.FOR PATIENTS and SOCIETY:
Ipsen social Responsibility strategy**



Employees

Caring for and developing employees, encouraging diversity & inclusion, and supporting an open & respectful culture

- Well-being at work
- Employee development and Talent attraction & retention
- Diversity and Inclusion



Communities

Supporting Communities oriented actions for the benefit of patients and Society

- Support our employees to play a role into healthcare & environmental areas
- Be a recognized health partner for the populations in need
- Value Foundation Ipsen CSR actions on Rare Disease



Environment

Protecting the environment, minimizing the impact on it, by making activities safe and sustainable

- Carbon footprint reduction
- Water use reduction
- Waste management

5,700+ employees committed to society with clear KPIs by 2024

- **Best place to work** certification in >75% of countries
- **Gender balance**¹ in global leadership team
- Fill 65% of leadership roles via internal

- 1/3+ of employees supporting healthcare and environment communities¹
- Continue support for IFPMA Access Accelerated initiative³

- 21% reduction of greenhouse gas emissions^{1,2}
- 24% reduction of water consumption
- 20% reduction of process waste

Deliver our results and achieve our objectives in an ethical and compliant manner

IPSEN WAY OF BEING

We lead with purpose We learn and share every day We drive for success We trust each other We own the outcome

KPI: Key performance indicators;

IFPMA: International federation of pharmaceutical manufacturers & associations.

1. Metrics included in compensation of management & credit facility.

2. Carbon equivalent emissions for all possible types of greenhouse gases emitted by Ipsen including scope 1 & 2 emissions.


3. Through 2021.



CSR governance

The CSR strategy of the Group is implemented at the different levels of the Company through a strong governance:


The Company Social Responsibility department coordinates and aligns the deployment of the CSR strategy within the Group, working closely with different departments to align the CSR roadmap and actions with the overall strategy of the Company.



CSR criteria in the remuneration of the leadership

In 2020, CSR metrics were introduced in the variable compensation of the Global Leadership Team (top 170 of the Company) highlighting the importance of Company Social Responsibility in the strategy of Ipsen.

For the sake of consistency, the CSR metrics for the variable compensation are the same than the ones embedded in 2019 in the Revolving Credit Facility. They are the following:



CSR metrics are also part of the compensation package of the CEO.

Ipsen has decided to establish gender-balance and international experience targets for both Executive Leadership Team and Global Leadership Team (Top 170 of the Company) by 2025:

- Executive Leadership Team: to achieve 35% minimum of both gender and 45% of diverse nationals (i.e. employees having a nationality different from the most represented one).
- Global Leadership Team: to attain and maintain gender-balance 50% and 65% of diverse nationals.

| Targets | | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---------------------------|-----------------------|------|------|------|------|------|------|------|------|
| Global Leadership Team | Women (%) | 33 | 36 | 41,8 | 42,3 | 45 | 48 | 50 | 50 |
| | Diverse nationals (%) | 56 | 57 | 57 | 59 | 61 | 63 | 64 | 65 |
| Executive Leadership Team | Women (%) | 23 | 23 | 14 | 20 | 23 | 28 | 35 | 35 |
| | Diverse nationals (%) | 42 | 50 | 43 | 45 | 45 | 45 | 45 | 45 |



2021 Ipsen's main CSR achievements in a nutshell:

5,700+ employees committed to society in 2021



Employees

- 30 sites engaged in 2021
- 121 initiatives
- From 3 commitments to 3 categories of initiatives



- Taking care of employees
- Stay connected/Reconnect with employees and communities
- Gender equality



Communities

- 34 sites engaged in 2021
- 67 initiatives
- From 3 commitments to 4 categories of initiatives



- Taking care of people/patients
- Supporting Associations
- Financial donation
- COVID 19 Equipment donation



Environment

- 32 sites engaged in 2021
- 87 initiatives
- From 3 commitments to 5 categories of initiatives



- Equipment/Travel/ Fleet management (Carbon footprint)
- Waste/Packaging/ Resource management
- Methodology/Education/ Awareness/ISO certification
- Supporting & partnership with associations
- Nature, Biodiversity

3 PILLARS

1. Well-being at work
2. Employee development and Talent attraction & retention
3. Diversity and Inclusion

1. Support our employees to play a role into healthcare & environment communities
2. Be a recognized health partner for the populations in need
3. Value Foundation Ipsen CSR actions on Rare Disease

1. Carbon footprint reduction
2. Water use reduction
3. Waste management

4.1.2 The Group's key CSR risks and opportunities

The Non-Financial Statement (NFS) is evolving towards a more business-oriented approach.

It should reflect the business model and an approach based on the analysis of the main CSR risks for five categories of information: social, environmental and human rights matters throughout the value chain, the fight against corruption and the fight against tax evasion.

The Statement is an opportunity to highlight the strategy and achievements of the Company. This implies aligning the materiality analysis of CSR issues with the identification of the main risks and opportunities.

The materiality analysis performed by the company helped to shape the current Non-Financial Statement and reflect Ipsen's main stakeholders' expectations in terms of risks and risk management.

Ipsen, as a global specialty-driven pharmaceutical Company, with drugs marketed in more than 100 countries, acts to provide concrete responses to the needs and expectations of a wide variety of stakeholders, particularly those in the healthcare field. Ipsen has a transparent and regular dialogue with its main stakeholders (employees, healthcare professionals and patients, investors and the financial community, suppliers and partners, regulatory authorities and agencies, local communities, and the media) to provide reliable and factual information, to pursue a constructive dialogue, develop partnerships, support patients associations, with the ultimate goal of providing differentiated and innovative solutions for patients.

Ipsen's Stakeholders:




The Non-Financial Statement is based on the United Nations Sustainable Development Goals (UN SDGs) evidencing the importance for the Company of the commitment taken for the first time in 2012.

An analysis performed in 2021 led to the conclusion that the materiality analysis performed in 2019 is still valid.

The table below shows the results of the analysis with 13 main CSR risks selected and classified into four categories.

At Group level, the risks are ranked as medium and low. Within the framework of the analysis of CSR risks and opportunities, they have been identified as main risks.

| Category | SDG's contribution | Name of the risk/opportunity | Description of risk and links to Ipsen's activities | Chapter references |
|--|--|--|---|--------------------|
| Improving people's life by offering innovative and safe medicines |   | Product quality | Protecting patients against the risks inherent to the biologic action of medicinal products and ensuring that benefit/risk for all products is positive. | 2.1.5.4 and 4.2.1 |
| | | Product and Patient Safety | Non compliance with security requirements that could jeopardize patients' health. | 2.1.5.4 and 4.2.2 |
| | | Animal welfare | Ensuring the respect of the highest standards of animal welfare while guaranteeing the safety of Ipsen. | 4.2.3 |
| | | Committed to ensure supply continuity | Risk of Ipsen medicines supply shortage. | 4.2.4 and 2.1.3.1 |
| | | Counterfeit products | Counterfeit products of low quality and not complying with Ipsen's health standards, which may endanger patients' health and generate loss in sales revenues. | 2.1.5.3 and 4.2.5 |
| | | Responsible product promotion | Improper marketing claims resulting in legal proceedings and mistrust of patients and Healthcare professionals, which could damage Ipsen. | 2.1.2.9 and 4.2.6 |
| | | Access to health | The implementation of initiatives and actions to improve healthcare in countries where access to medicines is difficult and diseases are difficult to treat. | 4.2.7 |
| Enhancing integrity to maintain a trusted relationship with our stakeholders |     | Data privacy | Inability to ensure integrity and confidentiality of data, resulting in disclosure or theft of patient's information and breach of data privacy. | 2.1.5.2 and 4.3.1 |
| | | Anti-Corruption | Corruption and conflicts of interest situations which could lead to major fines and penalties and damage to Ipsen's image. | 2.1.2.9 and 4.3.2 |
| | | Human Rights | Respect of human rights in Ipsen's operations and in its supply chain. | 4.3.3 |
| Driving our employees' excellence and engagement |    | Talent attraction | Loss and/or lack of key skills leading to delay of key programs and research projects launch, which could jeopardize Ipsen's ability to improve patients' health. | 4.4.1 |
| | | Employee engagement | Negative impacts on employee motivation or on the quality of social relations that could jeopardize the achievement of some objectives and lead to a corresponding impact on the Group's results or financial position. | 4.4.2 |
| | | Health and safety | Compliance or risk control failure which could result in several incidents causing injury or impacting employees' health. | 2.1.3.2 and 4.4.3 |
| Minimizing our environmental impact |       | Climate and energy | The climate risk related to business and supply chain disruption. Failure to take action on climate change which could have an impact on investor confidence and talent retention. | 2.1.3.2 |
| | | Management of water, waste and air emissions | Failure of compliance or risk control which could result in water, waste and/or air pollution harming the environment and/or human health. | 2.1.3.2 |
| | | | | |

4.2 IMPROVING PATIENTS' LIVES BY OFFERING INNOVATIVE AND SAFE MEDICINES

4.2.1 Bringing high quality product to patients


Definition of the risk

Quality risk management is a systematic process for the assessment, control, communication and review of risks for the quality of the drug (medicinal) product across the product lifecycle.

These aspects include development, manufacturing, distribution, and commercialization of drug (medicinal) products, biological and biotechnological products (including the use of raw materials, solvents, excipients, packaging and labeling materials) in drug (medicinal) products, biological and biotechnological products.

Risk Management is an essential part of a Pharmaceutical Quality Management System. When making decisions on events that have the potential to impact the Safety, Identity, Strength, Purity and Quality (SISPQ) of products, it is important to have relevant Quality Risk Management Process.

Overview of a typical quality risk management process according to the International standards regulating registration of Pharmaceuticals for human use (ICH Q9. ICH stands for International Conference on Harmonization (ICH)):



Purpose







Within Ipsen, Quality is embedded in all the life cycle of our products to ensure we bring to patients high products quality. As a pharmaceutical company we have to comply with all good practices (GxP) expectations applicable to our portfolio in all markets we supply (EU, U.S., Japan & Intercontinental).

To ensure our readiness, at any time, we have established a strong Quality Management System that relies on keys principles:

- Extended audit program of our operations and external partners
- Risk Based approach in design of all our processes (See below)
- Risk based approach in our decision making process based on SISQP (Safety, Integrity, Strength, Purity and Quality) principles
- Escalation to Management through the Quality Systems Evaluation Board (QSEB).



Governance



2021 Outlook

- Global Quality strategic Roadmap 2021-2023 has been established
- Global Audit Plan was executed
- Several QSEB (Escalation to Management) occurred within the year, few of them have triggered a local Health Authorities action
- ANSM Injunction Letter received on 23 March 2021:
 - Since beginning of the year a huge cross-functionally and cross-countries effort has been made to solve the deficiencies mentioned
 - Organizational Adjustments have been done to ensure sustainability
 - A new inspection took place in November 2021: all of the attention points were reviewed and are considered closed by the ANSM to date: no systemic issue was observed.

Objectives & Results

| KPI | 2021 | 2020 | 2019 |
|--|-------|-------|-------|
| Batch Acceptance level (%) | 99.8% | 99.7% | 99.5% |
| First Time Quality deviation (%) | 95.8% | 95.1% | 94.6% |
| Rate of on-time Corrective Action Corrective Prevention (CAPA) closure (%) | 95.0% | 95.3% | 92.0% |

4.2.2 Ensuring product and patient safety

Definition of the risk

Ipsen products portfolio is focused on transformative medicines in: Oncology, Rare Disease, Neuroscience and Consumer healthcare. All products' lifecycle activities including development, manufacturing and commercialization activities conducted by Ipsen have to comply with appropriate legal and regulatory framework.

Mission

The mission of Ipsen Global Patient Safety is to provide patients and healthcare providers with the means to safely and effectively utilize Ipsen's products.

In this context, Ipsen is operating a pharmacovigilance system, developed to protect patients against the inherent risks to the biologic action of medicinal products and ensuring a positive benefit/risk balance for all products. This pharmacovigilance system ensures the collection, detection, assessment, understanding and prevention of adverse effects or any other medicine-related problems.

Ipsen is committed to continuously develop and improve its pharmacovigilance system to guarantee that patients are protected and that Ipsen products can be used safely and effectively under changing circumstances, which includes changes in the legislation, changes in the product portfolio and changes in the structure and size of the Company.

Governance

The Head of Ipsen Global Patient Safety (GPS), the Qualified Person for Pharmacovigilance (QPPV), its deputies and local representatives are responsible for the maintenance and compliance of the Ipsen pharmacovigilance system and, as importantly, the quality of all signal detection and management activities for Ipsen products around the world. The QPPV with the deputies and the local pharmacovigilance representatives ensure that global and local applicable regulations are efficiently followed.

The Head of Global Patient Safety reports directly to the Chief Medical Officer, who reports directly to Ipsen Chief Executive Officer (CEO) ensuring a clear escalation path to manage any urgent and important safety risk.

Ipsen Chief Medical Officer co-chairs with the Head of Research & Development a cross-functional safety committee constituted by Ipsen senior and executive leaders including the QPPV, the Benefit-Risk Decision Board. This committee is accountable for making patient safety decisions for the entire Ipsen products whatever they development phase is. The Benefit-Risk Decision Board ensures the execution of actions made and monitor the preparation and implementation of the Action Plan for Emerging Safety Issues.

The key principle of pharmacovigilance (Global Patient Safety) within Ipsen is the empowerment of the dedicated pharmacovigilance representatives and cross functional teams for the collection, analysis of data and safety information with the goal to maximize the safety data acquisition & its level of quality.

The global patient safety department includes safety scientists and physicians dedicated to each therapeutic area to define product specific safety strategies, review and analyze all safety data and perform product signal detection and validation with the unique objective to minimize identified risks for the patient and monitor rigorously the benefit-risk profile of each product.

In addition to these patients safety expert teams, each product benefits from a dedicated cross-functional team ensuring the defined Benefit-Risk assessment is effectively communicated internally, to ensure safety measures implementation, and externally, to prescribers and patients. These cross-functional teams can raise topics to the attention of the Benefit-Risk Decision Board for recommendation, guidance, and escalation.

This 3-tiered governance structure and the escalation process uphold the quality of signal management process and ensure an accurate and up to date benefit-risk profile for Ipsen products.

Ipsen is dedicated to continuously develop, improve and adapt its pharmacovigilance system to ensure compliance with evolving regulation, legislation at global and local level to ensure patient safety. Ipsen therefore adheres to international standards developed by the International Conference for harmonization (ICH) as well as the Council for International Organizations of Medical Sciences (CIOMS) and the pharmacovigilance regulations and all regulations of countries where Ipsen products are being developed or registered and marketed. These activities and the maintenance of an acute knowledge and expertise in the field rely on a strong internal network of local Pharmacovigilance, regulatory and quality experts in constant interaction with global teams, as well as Ipsen's involvement in focused groups, consortium, and global pharmacovigilance responsible initiatives in collaboration with regulators.

Ipsen Global Patient Safety operates over the entire life of a medicinal product, starting at the non-clinical development stage, accompanying the clinical development in humans through all stages to build a robust safety dossier and benefit/risk assessment for regulatory filings and surveying the product on the market by collecting safety data from any interaction with healthcare providers or patients, in sporadic contacts or systematic data collection programs. In this context, Ipsen is dedicated to continuously train and maintain the pharmacovigilance knowledge of all stakeholders involved in any step of product life cycle in accordance with their role and expertise.



Ipsen's product safety management relies on a pharmacovigilance system encompassing all required safety processes operating in a pharmaceutical product lifecycle. The operation of the pharmacovigilance system ensures collection, analysis and reporting of safety data from all sources throughout the lifecycle of all products and involves close collaboration of many Ipsen functions, such as Regulatory Affairs, Clinical Operations, Medical Affairs, Quality, Marketing and business operations, and Legal. The robustness of these processes is based on a strong training plan and program for each Ipsen employee. Each Ipsen employee is annually trained on Pharmacovigilance main requirements and activities.

For product for which development and marketing responsibilities are shared with external parties (e.g. other pharmaceutical companies or academic partners) a dedicated governance structure is developed to ensure the collaboration across functional or organizational boundaries operates effectively. Ipsen Global Patient Safety team secures the flawless execution of the operational product data activities to support product reporting, product safety strategy development, appropriate maintenance risk management plan and related risk minimization measures to be shared with patients and healthcare providers.

As part of its continuous journey of improvement, Ipsen pharmacovigilance is prioritizing:

- The continuous development of local/global synergies through its regional cluster of excellence to maintain acute knowledge and implementation of regulatory requirements.

- Cross-functional collaboration consolidation for each product with a dedicated expert's team to facilitate and potentialize development strategies and cross fertilization.
- The development of a cross-functional Pharmacovigilance training strategy and its maintenance.

Results

Monitoring the safety profile of Ipsen products under development and marketed is the main mission of Ipsen pharmacovigilance function to proactively update the benefit-risk balance and inform patients and healthcare professional of any new risk.

Therefore, Ipsen pharmacovigilance system efficiency can be demonstrated by its ability to efficiently detect, analyze and assess safety signal to define appropriate action such as labelling update. Number of safety signals analyzed over a period is generally linked to the maturity of the portfolio and market expansion; increasing the knowledge on a product tends to decrease the number of the safety signals to analyze. Among all safety signal analyzed, we expect to have very few safety signal confirmed.

The compliance indicators presented below relate to Individual Case Safety Reports (ICSR) submitted under 15 days and 90 days directly by global Ipsen pharmacovigilance to the following Health Authorities: EMA, FDA, TGA & Health Canada, MHRA in the UK (post-Brexit), Russia and Commonwealth of Independent States (CIS) countries. Submissions to other Health Authorities are managed locally by each country depending on local regulatory requirements and reported regularly to global functions.

| For the entire Ipsen portfolio (under development and marketed products) | 2021 | 2020 | 2019 |
|---|-----------|-------|-------|
| On time ICSRs (**), submissions to Health Authorities managed at global level | > 97% (*) | > 98% | > 96% |
| Analyzed safety signals | 10 | 17 | 18 |
| Confirmed safety signals | 1 | 6 | 8 |

(*) Submission to MHRA in the UK since Jan 2021 and CIS countries HA submission since Sept 2021

(**) Individual Case Safety Reports

Audits and inspection KPIs

Being inspected by Health Authorities is part of the specific surveillance done by Health Authorities to guarantee that the maintenance of the licenses including the monitoring of the benefit-risk balance is performed by the pharmaceutical company in full compliance with the applicable regulations.

For pharmacovigilance system inspection, Health Authorities follow a specific calendar (i.e. inspection every 3 to 4 years if inspection outcome is favorable). The PV System of a pharmaceutical company can be inspected by each Health Authorities where active licenses are registered.

PV inspections conducted at global and local levels:

| PV inspections | 2021** | 2020* | 2019 |
|----------------|----------|----------|----------|
| Global | 1 | 2 | 0 |
| Local | 1 | 1 | 0 |
| Total | 2 | 3 | 0 |

(*) MHRA (UK) & ANSM (France) on behalf of EMA, URPL (Poland)

(**) ANSM on behalf of EMA

In addition to Health Authorities inspection, it is mandatory for each pharmaceutical company to conduct regularly audit to assess the compliance of the PV System internally (global & local) and externally (business partners). Audits are part of

continuous improvement and risk management. Conducting internal audit and being audited by partners participates to the maintenance of a robust PV System.

Audits of PV system including internally initiated audits and partner audits.

| PV Audits | 2021 | 2020 | 2019 |
|--------------|-----------|----------|----------|
| Global | 4 | 3 | 4 |
| Local | 16 | 6 | 5 |
| Total | 20 | 9 | 9 |

4.2.3 Animal welfare

Animal welfare is a sensitive issue for the community and Ipsen. Animal testing is required scientifically in order to ensure the safety of the pharmaceuticals produced and the health of the people who consume them. At Ipsen, meeting the highest standards of animal welfare is a top priority.

EU Directive 2010/63 on the protection of animals used for scientific purposes is one the most rigorous animal welfare standards in the world. The Directive calls for high-quality treatment and care for animal test subjects. Additionally, it mandates regular inspections and transparent communication on these assessments. At Ipsen, we comply with these EU guidelines regardless of where animal studies are conducted. Our culture of care goes beyond legal requirements to ensure the safest and most ethical research and testing methods worldwide.

We are signatories of Gircor's (*Groupe Interprofessionnel de Réflexion et de Communication sur la Recherche*) "French transparency charter on the use of animals for scientific and regulatory purposes." Gircor unites French biological and medical research organizations on the topic of animal research ethics. As members of Gircor, we share their dedication to staying informed on the latest research on developments in the world of animal research that enable us to adhere to the best practices.

While it is currently impossible to phase out the use of animals for scientific reasons, Ipsen commits to these guiding principles for the reduction (Reducing the number of animals used per experiment), refinement (Refining experiments to minimize animal suffering and improve welfare) and eventual replacement (Replacing animal experiments wherever/ whenever possible with alternatives) of animal experimentation whenever possible.

Examples of the Company's commitment towards the improvement of animal welfare can be found in the fact that:

- Ipsen encourages the development of *in vitro* alternatives with a level of precision comparable to animal experimentation whenever / wherever possible, while ensuring patients' safety and medicinal products' efficacy.
- Ipsen's collaborators conduct animal ethics evaluations during internal quality assessments and with all contract research organizations (CROs)
- Ipsen's Cell Based Assay ("CBA") was approved by the European and U.S. competent authorities, amongst others across the globe, to establish the potency of each batch of Ipsen's toxin and developed to replace the *in-vivo* "LD50" test. This achievement means the radical reduction of animal-based testing.



4.2.4 Committed to ensure supply continuity

Definition of the risk

Despite a strong end-to-end supply chain organization, the marketing of certain products by the Group has been and could be affected by supply shortages and other disruptions. Such difficulties may be:

- a) regulatory (e.g. the need to correct certain technical problems in order to bring production sites into compliance with applicable regulations); or
- b) technical (e.g. difficulties obtaining supplies of satisfactory quality, equipment failures, difficulties manufacturing active ingredients, or drugs complying with their technical specifications on a sufficiently reliable and uniform basis at the required volume); or
- c) natural (e.g. natural disasters...).

Mission

Our mission is to ensure supply continuity of our medicines to patients.

Governance

Several teams are fully dedicated to cover this end-to-end supply chain risk, from raw material suppliers to distributors in the different countries.

The risk mitigation and action plans are defined by different leadership teams from Global Supply Chain, Global Procurement, Global Manufacturing and External Manufacturing. All these functions are represented within the Technical Operations leadership team that endorses strategic

decisions, validates associated capital expenditures, and monitors key achievements.

Policies

All these functions have defined, and regularly update policies and Standard Operating Procedures to anticipate and appropriately manage all potential supply risks.

Actions

Major actions are:

- a) risk identification: supply chain risk mapping exercise conducted every year
- b) risk response: robustness and continuous improvement of manufacturing processes, critical suppliers risk management, insurance prevention actions, capital investments, security stocks and business continuity plans.

Objectives & results

We leverage our high-quality manufacturing network and end-to-end supply chain to deliver our medicines to patients in a safe and reliable manner:

- a) No product shortage;
- b) New product available upon market authorization.

| KPI | 2021 | 2020 |
|-------------------------|-----------|-------|
| OTIF (on-time, in-full) | 99.8% YTD | 99.8% |

4.2.5 Committed to fight against counterfeit products

Definition of the risk

Along with other manufacturers of pharmaceutical products, Ipsen and the patients are exposed to serious potential health risks presented by illegal, falsified and counterfeit versions of the products. A falsified medicine is any medicine that passes itself off as a real, authorized medicine. In the case of counterfeit medicines, the illegal products also infringe the Trademark rights of Ipsen.

The health risk for patients from taking falsified and / or counterfeit medicines includes:

- lack of effect, resulting in the underlying illness being untreated;
- infection / serious side effects from impurities and contaminants resulting from the frequently insanitary and unsafe conditions in which these products are produced, stored and distributed;
- in the most serious cases, falsified and counterfeit medicines have caused the death of patients.

To the extent that falsified medicines or counterfeit products are sold as being those of Ipsen, both the patients' confidence and the Healthcare practitioners' trust in Ipsen's products could be undermined and Ipsen's reputation could be affected.

Mission

Fighting against falsified medicines to contribute to secure patient safety worldwide

Ipsen is completely committed to taking the necessary proactive steps to always allow the patients to access to the highest health standards. Ipsen collaborates with other national and international stakeholders to protect the patients, partners and business from the risks of falsified and counterfeit medicines.

Governance

Ipsen has implemented an anti-counterfeiting organization involving various stakeholders. The governance is as follows:

- The Risk Committee (which is the most senior level of management involved in the oversight of the risks) is responsible for the oversight of the issue of falsified and counterfeit medicines.
- The Anti-counterfeiting Core Team (ACF Core Team) reports to the Risk Committee and is responsible for establishing, implementing and managing the anti-counterfeiting program. It is composed of experts from the Trademark, Risk Management, Global Security, Supply Chain, Quality, Regulatory, Commercial Operations (Specialty care and Consumer Health Care), Communication and Business Ethics departments.

Policies & action plans

Policies

The Global Policy

This Global Policy establishes the framework under which Ipsen anti-counterfeiting strategy is defined and managed to prevent suspicious counterfeit / falsified products from entering the legal supply chain. It ensures individual cases will be appropriately managed and documented, when detected, to ensure regulatory compliance, secure the supply chain and protect patients.

This policy sets out the key strategic and operational requirements to ensure that Ipsen anti-counterfeiting strategy is defined, implemented and maintained. This policy applies to all Ipsen Corporate functions, sites, entities and personnel managing or involved in the above listed activities related to suspicious counterfeit / falsified products.

The Standard Operating Procedure

The purpose of this procedure is to define the principles and practices for the management of any suspicious counterfeit/ falsified product case for an Ipsen product.

Main actions

1. Detecting and finding

Ipsen uses a variety of approaches to detect suspect falsified / counterfeit medicines. In the physical world, such reports may come from, *inter alia*, healthcare practitioners, patients, employees, healthcare and medicine regulatory agencies, they may also result from border measures (customs applications). In the digital world, the Company mainly relies on Internet online monitoring. Depending on regulations and circumstances Ipsen informs the local medicines regulatory agency where confirmed falsified and counterfeit medicines are found and may also support the regulatory agency investigation.

2. Improving supply chain

Today Ipsen's anti-counterfeiting strategy relies on 3 pillars:

- The serialization in order to ensure product traceability: which consists in the implementation of a unique number assigned to a single unit in a batch.
- The tamper evidence in order to ensure packaging integrity: it guarantees the integrity of the original manufacturer's pack and allows to detect if a box has been open.
- The safety features to facilitate counterfeit identification: they are hidden printings specificity onto packaging elements to maximize product identification versus counterfeits.

3. Cooperating with national and international organizations

Ipsen participates in local and international organizations.

Ipsen cooperates with law enforcement authorities, health authorities and other pharmaceutical companies notably in efforts to shut down illegal websites that sell falsified medicines or collect information to be used by law enforcement authorities to pursue criminal network selling falsified medicines.

Moreover, Ipsen collaborates with: *Union des fabricants* (Unifab), National federations such as LEEM (the French pharmaceutical companies association), Professional federations, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Security Institute (PSI).

Objectives & Results

Ipsen's objectives are:

- to protect Patients' safety by securing its supply chain and preventing counterfeit / falsified products from entering it;
- to encourage reporting of suspect falsified and counterfeit medicines wherever they are found in the physical or online environment;
- to provide an appropriate response to suspect falsified and counterfeit medicine cases (investigation, data collection, regulatory compliance).

| KPI | 2021 | 2020 | 2019 |
|--|------|------|------|
| Number of counterfeiting cases identified and reported to National Drug Safety Agency (ANSM) | 16 | 6 | 11 |

The increase of counterfeiting cases in 2021 derives from an improvement of our detection capabilities. Data indicate that the dominant factor is Turkey either in cases reported there, or elsewhere but with counterfeit Turkish product.

4.2.6 Promoting products responsibly

Definition of the risk

Companies are responsible for conducting promotion of their products without misleading or disguising it or engaging into off-label use related activities. The below general requirements are the basis of ethics and compliance programs which aim at mitigating relevant risks:

- **Fairness**

Promotion must be accurate, balanced, fair, objective and sufficiently complete to enable the recipient to form their opinion of the therapeutic value of the medicinal product concerned. It must not mislead by distortion, exaggeration, undue emphasis, omission or in any other way.



Any comparison made between different products must be based on relevant and comparable aspects of the products. Comparative advertising must not be misleading or disparaging.

• Objectivity

Promotion must encourage the rational use of medicinal products by presenting them objectively and without exaggerating their properties.

The promotion of food supplements must use different characteristics than for the promotion of drugs in order to not mislead the consumer on the nature of the product.

• Transparency

The Group must transparently state if materials or activities aim at the promotion of its medicines including but not limited to materials sponsored by a company and promotional articles in journals.

• Approvals

The promotion of use of unapproved medicines or unapproved indications or unapproved dosage or form of administration as defined in the market authorization.

Inappropriate promotion may have serious consequences related to the efficacy and safety of a product or may lead to wrong decisions impacting the health of patients.

Companies may face fines and penalties, expulsion from industry associations and reputational damage while depending on the seriousness of the cases, discredit of the entire industry may occur.

Governance

The Business Ethics Department supports the team managing products promotion to ensure the laws, regulations, Codes of practices and Ipsen policies and procedures are complied with.

Policies

Code of Conduct & Applicable Requirements

Ipsen through its Code of Conduct commits to promote its products, prescription-only, over-the-counter, medical devices or food supplements in accordance with the applicable laws, regulations and industry codes. Annual certification on the Code of Conduct is mandatory for all Ipsen employees.

Furthermore, Ipsen is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), European Federation of Pharmaceutical Industries and Associations (EFPIA) and other country industry associations such as Pharmaceutical Research and Manufacturers of America (PhRMA) in the United States and R&D-based Pharmaceutical Association Committee (RDPAC) in China and fully abides by their Codes including the articles dedicated to the promotion of products.

Procedures

In line with the the Code of Conduct, Ipsen has in place a Global Policy on Promotional Materials setting forth the general principles and requirements for the promotion of its medicines. In addition, since 2015, a global SOP has introduced a standard process for the review and approval of globally developed promotional materials. Employees of global functions are trained through mandatory e-learning training which new comers have to complete as part of their onboarding process.

Country procedures are applicable concerning the review, approval and storage of promotional materials.

The process has been automated using an electronic tool (*CoManDo*) which has been implemented for use by all global functions and countries.

Other policies and procedures such as the Global Directive on Digital Activities, the Global Directive on Interactions with Healthcare Professionals & Healthcare Organizations (Revised in 2021) or Review and Validation Process of Promotional materials for Food Supplements are in place to provide guidance and direction to Ipsen's employees on how promotional activities must be conducted to ensure promotion is conducted in a fully appropriate and responsible manner and in full compliance with applicable requirements.

Objectives & Results

The Code of Conduct is the most recent document that measures the commitment and knowledge of employees in this area.

PROMOTE OUR PRODUCTS RESPONSIBLY

Ipsen promotes its products responsibly, in compliance with the highest legal and regulatory standards.

- **We promote** our prescription-only medicines only for uses that have been approved by the relevant authorities.
- **We promote** our prescription-only medicines to HCPs. We also promote to the general public, but only in countries where direct-to-consumers advertising is allowed, and in compliance with the applicable laws, regulations and industry codes.
- **We promote** our over-the-counter and non-medicinal products to the general public and to HCPs in compliance with applicable laws, regulations and industry codes.
- **We communicate** product information which is fair, balanced, objective, complete, accurate, substantiated and up-to-date.
- **We promote** promotional materials prior to their use following the applicable Company processes.
- **We train** all employees involved in the promotion of our products, on approved uses, product-related data, applicable requirements and on the company's promotional rules.

FOR MORE INFORMATION

We can refer to the Ipsen Global and Country SOPs on Promotional Materials.
If we have questions or concerns, we speak to our manager or Business Ethics.
For reporting any concerns, we can use the Whispli designated Alert Platform (<https://app.whispli.com/IpsenAlerts>) or the email address Ipsen.Ethics.Hotline@ipsen.com

Mission

Code of Conduct: "Ipsen promotes its products responsibly, in compliance with the highest legal and regulatory standards"

| KPI | 2021 | 2020 | 2019 |
|---|------|------|------|
| Completion rate of trainings on the Code of Conduct (%) | 97,5 | 94 | 90 |

4.2.7 Enlarging access to health

Definition of the risk

The materiality analysis highlighted access to medicines as one of the main items expected by Ipsen stakeholders. Ipsen is looking for ways to develop differentiated approaches to improving healthcare in countries and for communities where access to medicines is difficult and diseases are difficult to treat. This is an important challenge for Ipsen given its size and the geographical areas in which it is located.

Policies & action plans

Ipsen contributes to enlarging access to health through different actions.

Humanitarian relief efforts⁽⁷⁾

At the beginning of the Ukraine invasion, Ipsen convened a crisis committee with two priority objectives: ensuring the safety of all our employees in the region and providing essential support and access to all our medicines to patients. At the time of this publication, all of our team members and their families in Ukraine are safe. Together with our partners, we are doing our very best to limit any impact to the supply of our medicines and maintain access to clinical trials – a lifeline to many patients across the region.

Beyond these two key priorities, Ipsen has decided to provide humanitarian relief to the people of Ukraine via a donation of €1.5 million, split between two humanitarian organizations.

- Tulipe, which collects donations from health companies to respond to the emergency needs of populations in distress during acute health crises, natural disasters and conflicts via its partners in the field.
- The Red Cross in France, an independent charity working alongside governments and public authorities, which undertakes neutral and impartial.

Patients support programs

In different countries, Ipsen has developed programs to support patients accessing its treatments. Two examples are developed in this section.

Ipsen ZAD is a Patient Support Program (PSP) which aims to offer patients access to affordable and adherence solutions to make their treatment journey smoother and easier.

ZAD is an Arabic word that means: All the supplies and necessities that a traveler will need during their journey to make it smoother. Similarly, Ipsen ZAD PSP is designed to equip the patient, during the treatment journey, with the needed services to make it a better & a smoother experience.

ZAD was launched in 2020 and is currently implemented in Saudi Arabia, United Arab Emirates, Jordan and Lebanon, and Ipsen is planning to extend the program soon in Egypt, Kuwait and Irak. ZAD can only serve patients who have a valid prescription for a locally registered indication for Cabometyx, Somatuline and Decapeptyl. This prescription should be validated with Healthcare professionals on regular basis.

Ipsen designed ZAD program in the region in response to the healthcare practitioners (HCP's) and to the urgent community

demands to all pharma companies to provide effective solutions to patients who are facing affordability issues; patients who cannot pay for their treatment specially for high-cost treatments. Being patient centric, Ipsen designed and provided solution packages to patients and included other services beside affordability aiming to offer a comprehensive 360 program; ZAD is designed to provide adherence solutions with an intention to help the chronic patients living with cancer to be able to adhere and comply with the prescribed treatments. Ipsen truly believes in serving the patient throughout the whole treatment journey and not to miss any gap that can affect the patient life.

The main foundations of ZAD program are: Affordability & Adherence.

1. Affordability: the program is designed customized solutions for patients who don't have access to medical insurance and those who are partially insured. For uninsured patients, ZAD provides patients with Free of charge packs while provides co-payment solution for those who are partially insured.
2. Adherence: the program is designed to provide sustainable solutions for the patients' treatment journey. It provides the patients with additional services such as:
 - a) Dedicated call centers: to answer any queries related to the disease, treatment, physicians, hospitals;
 - b) Home Nursing/ Home delivery services in order to provide patients with means to make the treatment access easier and the treatment admission smoother.

Ipsen partnered with Axios, "a specialized 3rd party" to implement ZAD in the region, Axios International has been providing healthcare access and pioneering solutions to address the changing needs of patients, across the globe, for the past 20 years. Axios International is licensed by the Local authority and is well recognized both locally and internationally, also they passed many external audits with satisfactory results from different clients and regulators which is an essential point to ensure that any interactions with patients or HCPs are done through ethical and compliant manners.

Ipsen is always concerned about the patient safety and the Company's reputation and so, the management & the implementation of ZAD is followed through a very strict and assertive process. For this reason, Ipsen was keen to isolate the communication channel related to the program from any commercial sales activities. This way, Ipsen will ensure that there is a firewall between promoting the products (done through Ipsen commercial teams) and notifying the HCPs about ZAD (done solely through Axios dedicated team). Ipsen is doing this to abide with Ipsen standard operating procedures and to follow the local Ministries of Health rules & regulations.

Ipsen's intention was to build a strong and sustainable program. Ipsen believed that the only solution to reach this goal was through partnering with the community. The program was designed to consider the local charities in each

⁽⁷⁾ This information has been added after the Board of Directors meeting of February 10th, 2022.



COMPANY SOCIAL RESPONSIBILITY

IMPROVING PATIENTS' LIVES BY OFFERING INNOVATIVE AND SAFE MEDICINES

country, as per the program mechanics; after finalizing the step related to referring the patient from the HCP to Axios, and Axios to validate the documents and to assess the patient's eligibility to join the program, directly Axios reaches to the local charities sharing the patient file and asking the charities to contribute to the patient's treatment. This step is extremely important, this step exemplifies the role of the effective partnership between Ipsen and the community, where the local charities help in the support needed to the patients in collaboration with Ipsen; by this, the patient's needs will be shared between Ipsen through the free of charge packs and the charities through purchased packs. This financial contribution from the charities will assist in sustaining the program from a financial aspect (through the purchased commercial packs) which will allow the program to support more number of patients for longer time as long as the patient is benefiting.

ZAD reached around 50 patients from Saudi Arabia, United Arab Emirates, Jordan and Lebanon benefiting from both services Affordability and Adherence in 2021 with a plan to add around 70 to 90 patients each year. Ipsen will spare no efforts to make sure that these patients are well served by the needed services aiming to make their treatment journey more smooth and easier.

Through the Ipsen iAccess Asean program, Ipsen has entered into a similar partnership with Axios International in September 2020.

Two products, Cabometyx and Somatuline, are part of the program for Malaysia and Thailand.

At the end of 2021, 27 patients are part of the program and the ambition is to reach 90 patients in one year.

Access Accelerated initiative

Ipsen joined in 2019 the Access Accelerated program, the largest collective industry effort to address the growing Non-Communicable Diseases (NCD) health challenge.

There is an urgent need to prevent and treat these diseases that affect many people around the world.

Global coalition of more than 25 biopharmaceutical companies, Access Accelerated is a concrete way for Ipsen to implement the "Together" and "For patients & society" pillars of our Group strategy ("Focus. Together. For patients & society").

The program develops, measures and replicates scalable and sustainable NCD solutions in low -and middle- income countries (LMIC) by helping the public and private sectors work better together.

Its commitment is to achieve the United Nations Development Goal 3.4: "By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being."

Using a multi-sectoral approach, Access Accelerated partners with worldwide networks dedicated to improving NCDs prevention, treatment and care (NCD Alliance, PATH) and organizations specializing in major non-communicable diseases (C/CAN for cancer, World Heart Federation for cardio-vascular diseases).

Access Accelerated also builds a strong partnership with the World Bank Group. Working closely with donors, development partners, governments and the private sector, the World Bank Group brings financial and technical assistance to developing countries to support them in achieving Universal Health Coverage (UHC) by 2030.

Over the last years, Access Accelerated has acted in 4 main domains:

- Supporting people living with NCDs, to be agents of change, through initiatives such as Patients groups in Kenya to share personal experience and information about disease and treatments or a worldwide social media campaign with #ActOnNCDs.
- Reinforcing Supply Chain, whose reliability is vital to ensure that treatments can reach the people who need them (roadmaps to strengthen NCD supply security in Ghana and Kenya, supply chain assessment in Vietnam, demand forecasting tool in Kenya, etc.).
- Developing Digital Health, a promising tool at global, national and local level to improve Healthcare delivery. One can mention the continued uptake of the NCD Navigator (dynamic mapping of NCD programs currently active in a country) or a digital app in Vietnam providing information, reminding people to get health checkups and allowing self-assessment for personal NCD risk factor.
- Integrate Primary Healthcare, which is for most people their first contact with the healthcare system (doctor's surgery, community clinic or a dispensary). Access Accelerated continues its multi-year partnership with World Bank Group in 20 countries, aiming at integrating NCD services at the primary care and community level to increase early detection of NCDs and improve patients outcomes (gather and spread best practices, training and mentoring sessions, creation of health education resources, National Guidelines implementation, etc.).

Meaningful results have been achieved, through the collective contribution of member companies and partnership with the World Bank and other key actors. The Access Accelerated initiative:

- reached a beneficiary population of 217 million people,
- unlocked U.S.\$ 355 million in new LMIC investments to combat NCDs,
- leveraged an additional U.S.\$ 2 billion World Bank investment in NCDs,
- catalysed innovative multicompany collaborations in Colombia, Kenya, Ghana, Vietnam,
- improved biopharmaceutical industry perception: WHO, UN, and civil society,
- generated 1.4 million global impressions from Access Accelerated - BBC - NCD Alliance documentary initiative.

The collaboration between the World Bank and Access Accelerated covers 36 LMICs across five continents, and by the end of 2020 the evidence generated from programs in Vietnam, Colombia, Kenya, Ghana, El Salvador and China has helped to secure \$355million in new investments in NCDs, supporting national policy change in 14 countries.

Supporting International Health Partners

Since 2019 and for the first time in its history, Ipsen has introduced in the revolving credit facility of the Company, three environmental, social and governance criteria (gender balance at Global Leadership Team, participation of Ipsen employees at the Community Day and reduction of our greenhouse gas emissions (Scopes 1 & 2)), thus reflecting Ipsen Group CSR commitment.

The mechanism implemented was innovative at the time it was set up, and structured to allow the payment of both sustainability discount or premium, if any, to a charity.

International Health Partners (IHP) has been selected as a beneficiary of the payments as it is in our area of expertise as biopharmaceutical company and provides health care services. Moreover, we wanted to join our forces to other pharmaceutical companies, as with Access Accelerated initiative, reinforcing and evidencing once again our strategy "Focus. Together. For Patients & society".

IHP is a non-profit organization founded in 2004 and the largest coordinator of donated medical products in Europe. It supports people in disaster-hit and vulnerable communities to get the medicines and health supplies they need.

IHP works with a strong network of Healthcare companies, Non-Governmental Organizations (NGO), Logistics partners and local alliances to source medicines and high-quality medical supplies that are appropriate for use in resource-poor contexts and send them around the world. It can respond rapidly to humanitarian disasters, supports long-term healthcare development projects and equips medics to carry out their work.

Over the last two years, the over-achievement of CSR criteria enabled our Group to donate to IHP over €220 000, helping sending 156,500 treatments to support 52,167 people in need. Ipsen's support has been applied to shipments reaching the poorest nations – specifically Ethiopia, Sierra Leone, Somaliland, South Sudan, Venezuela and Guatemala.

Fondation Ipsen

Fondation Ipsen functions independently to Ipsen Pharma is overseen by *Fondation de France* and an external scientific board.

Established in 1983, under the aegis of the *Fondation de France*, *Fondation Ipsen* focusses on improving public awareness of rare disease detection, with a vision to ensure that all people living with a rare disease are respected and receive an accurate and timely diagnosis.

To understand the needs of patients with rare diseases, *Fondation Ipsen* worked directly with 146 organizations on an outcome based, research-grade publishable needs assessment. The goal was to identify gaps and opportunities to accelerate rare diseases detection and diagnosis. To reach that goal: patients must be accurately informed about the science and its limitations; patients must be assisted by health workers informed of the latest advances; scientific laboratories must have capacity to identify relevant genes (technically and sufficiently funded) and there needs to be accurate communication of science to patients, health care providers and the public. *Fondation Ipsen* interacted with patient organizations, healthcare entities and scientific institutions in France, Belgium, the USA, Canada, South Africa and New Zealand. The Needs Assessment facilitates the detection of rare disease by means of improved

awareness through communication with the public, patients, patient organizations and the health and scientific communities.

The accurate transmission of science to the public is complex because scientific information is often technical and there is much inaccurate information. The *Fondation Ipsen* publishing arm, BookLab, addresses this need by offering, free of charge, educational high-quality books on sciences and health, with a focus on rare diseases and disabilities. To raise general interest in these issues and to fight against stigma that patients endure, *Fondation Ipsen* BookLab publications, with original and attractive formats, are intended for the public, patients and families of all ages and across cultures.

Fondation Ipsen's quarterly magazine for young children, Little Issue, offers complete educational content (sciences, languages, reading, general culture). Initially distributed to schools in South African townships, Little Issue is now sold at low price in South African supermarkets (SPAR). The quality of the content has aroused interest at an international level. Just two years after its creation, Little Issue is published in three versions (English + South African languages / French + English / Spanish + English) and distributed in schools in Asia (Nepal + Vietnam), in French-speaking Africa (Ivory Coast, Gambia, Madagascar, Niger, Togo), in France, and to sick children in hospitals in Mexico.

Books intended for children from 3 years old, the "Children of Genetics" break down the barriers between families living with a rare disease and the rest of the world. By taking the form of illustrated tales, these books bring the specific issues faced by these families and patients into everyone's daily life. The books inform the public, for a better detection of rare diseases and invite, from the youngest age, an acceptance of interindividual differences. The books are intended for distribution as eBooks, in different languages (French, English, Spanish, Chinese), via the main e-platforms (Amazon, Kobo, FNAC, etc.). The printed French versions (3,000 copies per title) are distributed to local communities (schools, libraries) and to patients/families, patient associations, via the Dijon University Hospital and the ARGAD Association (*Association de Recherche en Génétique et d'Accompagnement des familles et professionnels de Dijon-Bourgogne*).

My Life Beyond book series with Mayo Clinic. Pediatric patients' voices are rarely heard amid the complexity of modern medicine. That's why every story in the "My Life Beyond series" stems from the imagination and experience of a Mayo Clinic patient. The books were developed through collaboration between these patients, Mayo Clinic physicians and author-illustrator Hey Gee. Through this unique lens of inspiring experiences, the series, intended for 5-9 years old, explores how children view illness, challenges, and recovery. The printed books are distributed within the U.S., in book shops by Simon and Schuster and in France to collectivities (schools, libraries) and partner associations.



Fondation Ipsen's podcast program is composed of three channels, each having a different focus. The Science Corner, designed for children, addresses the subject of difference and tolerance in rare diseases, through the tales of Jonas, a 10-year-old schoolboy who finds himself trapped in the "DNA Vortex". Our Health, designed for the public and the scientific community, addresses health and well-being issues, and consists in interviews with prominent scientists and personalities. Science (Hi)Stories, designed for the public, offers a journey through time, making it possible to understand scientific issues through a historical perspective. On November 8th, 2021, the three channels had combined 81,233 downloads. The podcasts are available for free on all popular Podcast platforms like Apple Podcasts, Spotify, Deezer, Ausha, Podcast Addict and more. They are promoted on *Fondation Ipsen's* social networks (Facebook, LinkedIn, Instagram), as well as on its website.

Overall, *Fondation Ipsen* website <http://www.fondation-ipsen.org> is promoted to the general public in several ways. First, the Google Ads tool allows it to be promoted in English and French. In addition, *Ipsen Foundation* is active on social networks, especially on Facebook and Instagram. Finally, *Fondation Ipsen* is also well positioned on Google and related search engines using an optimized SEO approach.

Fondation Ipsen established an education platform directly to support rare disease patients and families <https://www.rarediseaseeducation.net/>.

With UNESCO, *Fondation Ipsen* produced the UNESCO Science Report: The Race Against Time for Smarter Development (2021) which was made available in more than 190 countries in 5 languages.

In 2021 *Fondation Ipsen* interacted with 22 million people.

4.3 ENHANCING INTEGRITY TO MAINTAIN A TRUSTED RELATIONSHIP WITH OUR STAKEHOLDERS

4.3.1 Committed to protect personal data

Definition of the risk

The major risk regarding processing of personal data is a breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure of, or access to, personal data transmitted, stored or otherwise processed.

This risk is important to manage considering current developments in information and communication technologies and because of its potential impact and consequences it can have on personal aspect.

Ipsen commits to protect the personal data of Ipsen employees, patients, healthcare professionals and other partners Ipsen interacts with. The Company protects patients and healthcare professionals' data and is transparent about use of their data in Ipsen activities such as Research, but also employees' data by accompanying and training Ipsen employees on processing and protection of personal data.

Mission

Our mission is to protect fundamental rights and freedoms of people and in particular their right to the protection of personal data by preserving integrity, confidentiality and availability of data

In order to perform its mission, Ipsen approaches Data Privacy on several parts such as a business approach by using prevention, measure of risks and conducting assessment, analysis and a legal approach to secure every project by protecting individual's rights within legal frameworks such as contract, privacy notice and consent forms.

One of the main aspect of Data Privacy is the IT security approach. Ipsen aims at securing its assets by always prioritizing defenses to protect. In order to achieve that goal, Ipsen developed a 'Risk Informed' strategy by understanding the threats, vulnerabilities and impacts to be able to take the right decision but also create a long-term Security Culture within the Group to protect people, processes and technologies.

Governance

Since 2016, the Data Protection Officer (DPO) is responsible for ensuring the implementation of a Data Privacy and Protection program within the Group. The role of the DPO is to advise, inform and monitor compliance with Data Privacy regulations.

The DPO reports to the General Counsel and Executive leadership team member.

The DPO has set up an international and corporate Privacy Champion Network in charge of the awareness and the support of each affiliate and corporate team. Members of the network are employees representing all functions and business.

The DPO also relies on the Data Privacy Board that ensure collaboration within Ipsen’s corporate department and affiliates regarding cross-functional projects and implementation of harmonized processes.

Policies & action plans

Ipsen’s activities involve different personal data processing for different groups of individuals such as employees, patients, healthcare professionals, contractors, scientists...

To protect the privacy of the individuals, Ipsen has created a Group’s Global Privacy policy that defines the main principles of Data protection. This global policy applies to all Ipsen employees processing personal data in compliance with European requirements and local regulations for each Ipsen Affiliate.

Main Data Privacy Principles at Ipsen



Actions

Development of employee awareness and trainings

In 2021, Ipsen has enhanced its mandatory annual training modules for all employees through online trainings, face-to-face tools adapted to the different functions so that employees are part of the data protection compliance pathway.

Training modules are updated regularly, awareness modules are available for every new comer and trainings are organized in every affiliate according to countries specific requirements.

Documentation for employees to process personal data are available on Ipsen intranet such as templates of contract, Privacy Notice, Consent form, checklists for compliance to General Data Protection Regulation (GDPR), policies and general documentation about Data Privacy.

Ipsen has implemented OneTrust, a data privacy management tool to assess the compliance of projects involving data processings with respect to the regulations, to define corrective actions to be implemented and maintaining our register of data processing.

In 2021 Ipsen also deployed the management of security incident involving personal data, the management of requests from individuals and the compliance of websites involving the use of cookies.

The Privacy Champion network is also a key asset in the awareness of employees in their role of identification of risky projects and Data Protection Impact Assessment needs.

Description of clinical trials data protection

Patients’ personal data may be collected for clinical trials. When it is the case, an Inform Consent form is required. That Consent form triggers a voluntary participation to a study and an information about the use of the data and the right to privacy depending on the applicable regulation, but also an information about the pharmacovigilance processing.

Healthcare professionals’ personal data may also be collected during a study: a privacy notice is then required to inform them about the processing of the data and the right to privacy depending on the applicable regulation, but also an information about the pharmacovigilance processing.

Objectives & Results

The main objective of Ipsen is to reach the highest level of data privacy compliance and awareness for Ipsen activities.

Ipsen number of cyberattacks for 2021 remains stable with 2 data breaches reported to the authority. As a result, Ipsen enhanced its awareness programs and procedures related to cyberattacks prevention and data breach notification by developing new policies and trainings.

Ipsen has implemented a catalog of modules concerning each step of compliance to data privacy regulation and keep updating trainings and adapting its roadmap in order to demonstrate its best compliance in terms of Data Privacy.

| KPI | 2021 | 2020 | 2019 |
|--|------|------|------|
| Number of cyberattacks cases reported to the authorities | 2 | 2 | 2 |



4.3.2 Fighting corruption

Definition of the risk

Corruption is the act of offering, promising, making, authorizing, requesting, agreeing to receive or accepting, directly or indirectly through third-parties or intermediaries, any transfer of value to any person or organization, for the purpose of obtaining or retaining any undue advantage.

Corruption in its broader definition may also include influence peddling, tax evasion, money laundering and fraud.

Corruption negatively impacts society in multiple ways.

It hinders economic and social development and creates poverty. Public money is misused instead of being used for the right priorities such as healthcare, education, pensions, investments and transport infrastructure. In the healthcare, decisions can be made for the benefit of individuals other than patients, patients may be prescribed the wrong treatment and citizens can suffer from distorted prices of medicines, medical devices or medical services.

It distorts fair trade and it may feed criminal networks and terrorist activities.

Corruption negatively impacts both companies and individuals.

The impact may range from damage of trust of consumers, candidates or other stakeholders, unquantifiable damage of reputation, impact on shares, fines and penalties, exclusion from public tenders, loss of talents up to discredit of an entire industry.

Mission

Ipsen rejects unequivocally any form of corruption and commits to act with the highest standards of ethics, integrity and transparency.

FIGHT CORRUPTION

Ipsen strongly rejects all forms of corruption as these distort fair trade, hinder economic development and impose multiple costs on society at large. Ipsen prohibits employees and contractors from accepting, offering or giving, directly or indirectly through third-parties, anything of value to any person or organization, whether public officials or not, to obtain or retain any undue advantage.

Ipsen complies with all applicable international and national laws, regulations and codes that prohibit any form of corruption. Non-compliance with applicable anti-corruption laws can have severe consequences for Ipsen and the employees concerned.

- We **interact** with all our stakeholders with the highest level of integrity based on the merits and the science behind our assets.
- We **do not** give any stakeholder anything of value to obtain or retain any undue advantage.
- We **do not** offer HCPs and/or other stakeholders any gifts, congress sponsorships, grants, donations, hospitality, or anything of value in return for an increase in prescriptions or to obtain other undue advantage for Ipsen.
- We **do not** contract with HCPs and/or other stakeholders for speaking services, advisory boards, scientific research or any other service in return for an increase in prescriptions or any other preferential treatment for Ipsen or its products.
- We **maintain** accurate books and records to reflect all financial transactions made and received.

FOR MORE INFORMATION

We refer to the Ipsen "Global Anti-Corruption Policy" (GLB-POL-004). If we have questions or concerns, we speak to our manager or Business Ethics or, for reporting any concerns, we can use the Whispli designated Alert Platform (<https://app.whispli.com/IpsenAlerts>) or the email address Ipsen.Ethics.Hotline@ipsen.com.



Governance

Business Ethics Infrastructure & Governance

Ipsen has established over the last years infrastructure and governance at global and country level to identify and mitigate compliance and ethics related risks.

Business Ethics Program & Ethical Culture

Ipsen Business Ethics Program is continuously enhanced with new elements, revisions and other improvements in areas such as policies and procedures, education, monitoring. In addition, existing and new initiatives intend to continuously shape Ipsen's culture with focus on ownership, accountability and decision making and conduct of activities. Ipsen routinely measures its ethical culture through specific questions in employee surveys. In the 2021 survey, to the question "I think of compliance or ethical considerations myself when taking a decision or implementing it", 90% of the responses were positive.

Governance & Resources

All entities including commercial operations, R&D and manufacturing sites as well as global functions are overseen by appointed Business Ethics Officers, members of the Ipsen's Ethics & Social Responsibility department.

Business Ethics Committees co-chaired by the Business Ethics Officers and the Country Managers oversee the evolution of the compliance programs and the external developments in the countries while the Business Ethics committee of the Executive Leadership Team is informed on important updates and endorses priorities twice a year.

The Ethics & Governance Committee of the Board oversees the evolution of the Business Ethics Program and significant matters that may have a major impact on its effectiveness.

Continuous Enhancement of Ipsen's Anti-Corruption Program

Further to its Anti-corruption Policy and the other elements described below, Ipsen strives to continuously assess and reinforce its Anti-corruption infrastructure in accordance with any applicable new requirements deriving from new country or extraterritorial laws, regulations or international standards.

In 2020, Ipsen has launched a new initiative with the aim to ensure that its Anti-corruption infrastructure in all relevant areas beyond policies and procedures can effectively address the risk and respond to the expectations of the identified interested parties. The dedicated Anti-corruption system has obtained in November 2021 the ISO 37001 certification, awarded by EuroCompliance following an audit carried out between May and November 2021 in different sites in France, Europe and United States, confirming its commitment to fight corruption.

Ipsen has also led other efforts towards this aim such as the revision of the Employees Conflict of Interest Policy and SOP, supported by an annual and mandatory e-learning assigned to all employees, launched in 2021.

Policies & action plans

Code of Conduct

Through its new Code of Conduct which was launched in 2019, and revised in June 2021, Ipsen and its Leadership reject unequivocally any form of corruption and commits to act with the highest standards of ethics, integrity and transparency.

The Code of Conduct and its training are available in 20 languages. The training on the Code of Conduct is mandatory for all new hires and mandatory annual certification by all Ipsen employees is required.

As part of the annual assignment, Ipsen employees were assigned with the Code of Conduct Training in 2021 and each individual has to certify the pledge to the Code.

Global Anti-Corruption Policy

The Global Policy has become effective since March 2019 and it comes to reaffirm Ipsen's position towards corrupt practices and to set global standards for its employees, its third parties and contractors.

Ipsen complies with all applicable laws, regulations and codes that prohibit any form of corruption, including, but not limited to, French Law 2016-1691 (Sapin II), Articles 432 and 433 of the French Criminal Code, the U.S. Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act when applicable, as well as applicable international conventions, including, but not limited to, the OECD Anti-Bribery Convention and the UN Convention against Corruption. Ipsen has joined the United Nations "Global Compact" program since 2012.

In accordance with this Policy, corruption in any form is strictly prohibited. Influence Peddling is also forbidden.

The Code of Conduct and Global Anti-corruption Policy constitute the cornerstone of the Ipsen's commitment against corruption and the anchor of its Anti-corruption Program. Consequently, any breach of the Code of Conduct, the Anti-corruption Policy or of the related laws, regulations and codes may result in disciplinary measures, up to termination, in compliance with the applicable employment legislation.

Training available in 20 languages on the Anti-corruption Policy is annually assigned to Ipsen employees since 2020. The training content is customized to ensure relevant cases are examined depending on the function/role of the individuals.

SPEAK UP

Ipsen strongly encourages a culture where employees can speak up and report behaviors that are suspected not to comply with our Code of Conduct, our policies and procedures and Ipsen's legal and ethical obligations.

When we speak up, we do the right thing. By raising compliance concerns, we help to protect ourselves, our colleagues and Ipsen's image and reputation:

- **We report** any suspected violation of Ipsen's Code of Conduct, policies and procedures and legal and ethical obligations.
- **We can speak** with our manager, with Human Resources or Business Ethics. Additionally, if we prefer, we can use the Whispli designated Alert Platform (<https://app.whispli.com/IpsenAlerts>) or the email address Ipsen.Ethics.Hotline@ipsen.com. The information submitted through the Alert Platform and the email address will only be received by the specific individuals in the Global Business Ethics department entrusted with the management of alerts.
- **We provide a safe environment** for raising concerns:
 - Confidentiality is ensured at all stages of processing any alert, to the extent permitted by applicable laws.
 - The protection of the individual making the alert is of paramount importance. Any information that may assist in identifying the individual making the alert will not be disclosed to any person other than those directly involved in the treatment of the alert.
 - Reports may be made anonymously, if the individual feels uncomfortable disclosing their identity.
 - Ipsen is committed to a strict non-retaliation policy. No retaliatory action will be taken against any individual making an alert in good faith.
 - Ipsen is responsible for the handling of any alert and takes all necessary precautions to ensure the protection of data.
 - Only personal data that is relevant, adequate and considered absolutely essential, will be collected.
 - Alerts must be based on facts and made in good faith. Abusive, malicious or frivolous reports may lead to disciplinary sanctions.

CONTACT US AT ETHICS & SOCIAL RESPONSIBILITY
Ipsen.Ethics.Hotline@ipsen.com
<https://app.whispli.com/IpsenAlerts>

OR

SCAN THE QR CODE or Go to the link to access the new Speak-up tool

IPSEN **WHISPLI**

20 WE CARE FOR OUR EMPLOYEES

Global Whistleblowing Policy

The enhancement of the speak-up culture is a priority for the Company, and this has been reflected in the 2019 Ipsen's Global Objectives. Its evolution is monitored every two years through the Employee Engagement Survey.

Ipsen has implemented the Global Whistleblowing Policy since September 2018 and across 2019 in various waves with the aim to encourage employees and contractors to report any concern for potential non-compliant or unethical behaviors. The Global Policy sets the principles and requirements on how these reports must be treated including confidentiality, respect of anonymity, personal data protection and non-retaliation.

The Global Policy's launch has been accompanied by the Global Investigations SOP to formalize the process of investigations from initiation up to its closure and remedial and/or disciplinary actions.

Over 140 Senior Leaders such as General Managers, Heads of Technical Operations and R&D Sites, Human Resources, Legal and Business Ethics have been trained until now.

Employees can report any concerns to their manager, HR, or Business Ethics Officer directly or use a central email address or a new platform which has become available to expand the channels of reporting. Both the Policy and the Platform are made available in 20 languages.

It is noted that most of the concerns are reported directly to the responsible function or country Business Ethics Officers.

Third-Party Business Ethics Management Program

The Third-Party Business Ethics Management Program has been initiated in 2017. It has been designed and is continuously improved to avoid any transactions with a Third-

Party subject to economic or trade sanctions, and to mitigate the risk related to corruption among other compliance related risks, to mitigate the risks related to CSR (e.g., Human rights) and to comply with all applicable anti-corruption and anti-bribery laws including the new French anti-corruption Law Sapin II.

The program has been revised in 2021 so the resources and attention are devoted throughout the whole business life of contract with the third party, with ongoing relationship management controls, with an objective of having the compliance responsibilities owned by Business owners, with more bridges between Operations and Business Ethics, for a more efficient risk management. The Code of Conduct for Business partners was also revised to reflect the vision of the Ipsen Third-Party Business Ethics Management.

Several thousands of suppliers have been assessed since its launch. The due diligence performed is also complemented by trainings and monitoring activities consistent with main anti-corruption laws and guidance documents (e.g., FCPA, UK Anti-Bribery Act and French Law Sapin II).

Objectives & results

| KPI | 2021 | 2020 | 2019 |
|--|----------|-------|------|
| Completion rate of trainings on the Code of Conduct (%) | 97,5 | 94 | 90 |
| Completion rate of trainings on Anti-Corruption (%) | 97.1 | 98 | 91 |
| Completion rate of trainings on conflict of Interest (%) | 97,5 (*) | - | - |
| Total number of Due diligence conducted | 1,159 | 1,146 | 458 |

(*) Training deployed in 2020 and first year of data collection in 2021

4.3.3 Promoting and defending Human Rights

Definition of the risk

As a Company present in several countries with many stakeholders, Ipsen must ensure that Human Rights are respected in all its activities and its supply chain. Human Rights refer to the fundamental rights of the United Nations (UN Global Compact, Universal Declaration of Human Rights) and the International Labor Organization (ILO).

Ipsen must comply with regulatory human rights obligations, including international standards such as the United Nations Guidelines on Business and Human Rights and national regulations and must identify the nature and extent of potential human rights violations in each country where the Company, its suppliers and direct sub-contractors operate.

Ipsen's organization, policies, action plans and individual approach to human rights are presented below.

Mission

Code of Conduct: "We respect human rights and carry out our human rights duties through exemplary behavior in our business conduct"

Governance

Human Rights are managed by the Procurement Department and the Business Ethics Department to ensure they are respected all along the value chain, from the supplier to the patients.

Policies & action plans

Policies

- Ipsen encourages its employees to be exemplary corporate citizens, committed to serving the communities in which the Company operates.
- These actions are made to respect people, protect the planet and integrate human rights and environmental considerations into all aspects of activities, from research and product development to the supply chain and manufacturing operations to patients. A specific section is dedicated to Human Rights in the Ipsen Code of Conduct, (as mentioned earlier, all Ipsen employees must complete an annual and mandatory e-learning).
- Ipsen has committed to the principles of the United Nations (UN) Global Compact since 2012 and support the 10 principles set out in the UN Declaration of Human Rights and the International Labor Organization's standards.
- Ipsen invests in communities and focus efforts on patient associations and charitable work. Ipsen's commitment reflects its Company Social Responsibility effort.

RESPECT HUMAN RIGHTS

Ipsen respects human rights and carries out its human rights duties through exemplary behavior in its business conduct.

- **We respect** and promote human rights.
- **We adhere** to the principles of the United Nations (UN) Global Compact; we support the principles set out in the UN Declaration of Human Rights and the International Labor Organization's standards regarding child labor and minimum wage.
- **We invest** in communities and focus our efforts on patient associations and charitable work. Our commitment reflects our Company Social Responsibility effort and Ipsen's employees are our ambassadors.
- **We select** sustainable suppliers that adhere to the principles of the UN Global Compact.

FOR MORE INFORMATION

We can refer to Ipsen's Annual Report, available on Ipsen's website, and to www.unglobalcompact.org. If we have questions or concerns, we speak to our manager or Business Ethics or for reporting any concerns, we can use the Whispli designated Alert Platform (<https://app.whispli.com/ipsenAlerts>) or the email address Ipsen.Ethics.Hotline@ipsen.com.

Main realizations

- Supplier Risk Management (SRM)

Ipsen wishes to only work with individuals and organizations who share Ipsen's commitment to ethical business practices and operate in a socially and environmentally responsible manner.

The Business Partner Code of Conduct clearly outlines the principles and expectations on suppliers who wish to establish and maintain a relationship with Ipsen. This includes Ipsen's requirements around human & labor rights, health & safety, protection of the environment and ethical business practices.

In 2021, the Ipsen procurement team initiated a Group SRM project to further improve our supplier risk management processes. Bringing together internal experts from procurement, business ethics, EHS, Data Privacy, cybersecurity and risk to develop a world-class SRM solution that protects the business and delivers on the objectives of the Code of Conduct. Ipsen continues to use the EcoVadis platform to monitor and develop suppliers that operate in higher risk markets or industries for EHS.⁽⁶⁾

Supplier risk evaluations will be updated routinely to ensure that their performance continues to operate at a high level.

- Third Party Business Ethics management program

The Ipsen Business Ethics Third Party program, aiming at fighting against corruption and bribery, assesses several hundreds of Ipsen partner's each year.

In 2020, the Business Ethics Third party management program has been reviewed to include more questions to the third parties assessed on human rights, in a dedicated section on Company Social Responsibility. The revised procedure describing the full program has been globally launched in 2021.

⁽⁶⁾ Number of suppliers evaluated by Ecovadis indicator removed since 2020 disclosure.

In 2021, 521 new Third Parties covered by the Business Ethics party management program have been evaluated, compared to 936 in 2020, year of the implementation of the digital platform supporting the Business Ethics assessment process (with inclusion of 2-year historical data).

- Ipsen Code of Conduct 2021



The Ipsen Code of Conduct, revised in 2021, is accompanied by an annual mandatory e-learning training for all employees.

Objectives & Results

Each year, the Ipsen Code of Conduct is reviewed, and revised if needed. Additional elements including Human Rights might be included, and the case studies to assess Ipsen employees understanding of the Code are being updated.

| KPI | 2021 | 2020 | 2019 |
|---|------|------|------|
| Number of new third parties assessed through the Business Ethics Management program | 521 | 936 | 365 |
| Completion rate of trainings on the Code of Conduct (%) | 97,5 | 94 | 90 |

4.4 DRIVING OUR EMPLOYEES’ EXCELLENCE AND ENGAGEMENT

4.4.1 Attracting the best talents

Definition of the risk

Ipsen continued expansion requires specific expertise and resources, such as marketing, clinical trials, and regulatory licenses and relies heavily on recruiting and retaining the best executive management and scientists.

Some examples of the specific challenges are:

- the strategic importance of Ipsen presence in the United States of America, while being still a relatively new and small player,
- a large geographical footprint with small-sized locations,
- the evolution of the portfolio *via* external acquisitions that may require to anticipate or adapt quickly to new assets.

In addition, the current “Great Resignation” environment creates a further challenge, in particular in the U.S., UK and Ireland.

Mission

To address these various challenges, the mission defined is as follows:

To apply a strategic approach to identify, attract, hire talented individuals to Ipsen, to efficiently and effectively meet our growing and dynamic business needs

Governance

Within Human Resources (HR), three types of HR professionals are working closely together to ensure Ipsen attracts the best talents: the Talent Acquisition Center of Excellence, the Strategic Business Partners and the HR Operations.

Their respective role is summarized below:



| Talent Acquisition | |
|--------------------|--|
| CoEs | <p>Talent Acquisition Center of Excellence: Global experts that define the Talent Acquisition roadmap and policies and own global Talent Acquisition tools. They are accountable for rolling out and ensuring consistency in the application of tools and policies. They review operational KPIs and identify action plans when needed.</p> |
| Division | <p>Strategic Business Partners: Senior level HR leaders who are responsible to maintain and feed the talent pipeline for their scope of responsibility.</p> |
| Operations | <p>HR Operations and Shared Service Center: Key resources for transactional HR interactions within a specific geographic zone (countries, regions, locations...) including on-boarding of new talents.</p> |

Policies & action plans

Existing policies

Ipsen Employment Value Proposition relies on 4 hallmarks: ideal size, constant transformation and growth, our unique mission in Specialty Care, and people-centered organization. Talents find the best of the two worlds: Pharma and Biotech. This value proposition will be refreshed by 2022 although the main hallmarks remain all the more valid in a post-COVID world. An Hybrid Work policy has also been implemented to answer flexibility.

The Talent Acquisition principles - that are part of a global document called "Ipsen HR Principles" - cover the following aspects: data-informed planning and strategy, link to internal succession plans, employer branding, candidate relationship management, candidate assessment, candidate care and feedback.

Ipsen also reviewed a **list of preferred executive search firms** to increase quality requirements and global footprint on the most critical profiles.

Recruitment resources are staffed and structured in our 3 hubs: North America, UK & Ireland and France.

Finally, Ipsen defined a **standard onboarding journey**, applicable to any newcomer to Ipsen.

Main recent achievements

2021 has been a very active year with significantly more recruitments than in 2020 but less than in 2019.

In order to better anticipate hiring needs, several functions have performed or initiated a Strategic Capabilities planning exercise: Supply Chain, CHC Marketing, Engineering, Procurement and IT. These exercises enable to clarify expected skills for each role and to anticipate the future evolutions in roles and skills. A project to establish a Strategic Workforce Planning process is being initiated.

• Reinforcement of Talent Acquisition operating model:

The Talent Acquisition Center of Excellence developed and deployed a range of KPIs to monitor Talent Acquisition activity and gain efficiencies and promotes the harmonization of processes.

The COE also developed a more systematic approach to gather external feedback provided via social media and targeted satisfaction questionnaires to create improvement plans.

Objectives & Results

Objective is to deliver strategic services that create a competitive position for Ipsen by sourcing, attracting and hiring high-caliber talent leveraging technology for engagement throughout the talent process for an exceptional candidate experience:

- create an exceptional experience for every candidate,
- elevate Ipsen's brand to be recognized as a leading biopharma company,
- operate as a nimble organization aligned to the business,
- upgrade capabilities to drive operational & execution excellence.

Description of key performance indicators:

| KPI | 2021 | 2020 | 2019 |
|------------------------|-------|------|-------|
| Number of recruitments | 1,232 | 936 | 1,386 |



4.4.2 Enhancing employees' engagement

Definition of the risk

The Group's success largely depends on the motivation of its employees. Negative impacts on employee motivation or on the quality of social relations could jeopardize the achievement of some Group targets related to research, production, or marketing activities and lead to a corresponding impact on the Group's results or financial position.

Also, the Group's success depends for a large part on certain essential managing executives and scientists. The departure of these senior employees could damage the Group's competitiveness and compromise its ability to achieve its objectives.

That is why, investing in employee's engagement and development is a key objective of the HR Policy.

Mission

Employees' engagement is at the center of the HR vision, that is outlined as follows:

Ipsen ambitious growth and innovation is driven by optimal organization capabilities and fully-engaged teams.
Each employee's engagement is the outcome of a carefully-built approach, based on the three "C's", capabilities, contributions, and commitment: build strong capabilities, ensure contributions are fully recognized and maintain an unflinching commitment from everyone.

Governance

The governance around the employees' engagement is to be considered at different levels:

HR Talent Management

At Ipsen, most topics directly related to employees' engagement (Learning and Development, Diversity and Inclusion, Engagement) are gathered under the "Talent" umbrella, that encompasses both Talent Management and Talent Acquisition and thus enables positive synergies that encompasses both Talent Management and Talent Acquisition and thus enables positive synergies.

The Talent governance involves 3 different types of actors within the HR function, with specific roles as described in the following chart:

| Talent Management | |
|-------------------|---|
| CoEs | <p>Talent Management Center of Excellence: Global experts that define the Talent Management roadmap and policies and own global Talent Management tools. They are accountable for rolling out global programs, for coordinating annual development and talent assessment campaigns and for ensuring global consistency in the application of tools and policies. They review operational KPIs and identify action plans when needed.</p> |
| Division | <p>Strategic Business Partners: Senior level HR leaders who are responsible to maintain and feed the talent pipeline for their scope of responsibility.</p> |
| Operations | <p>HR Operations and Shared Service Center: Key resources for more transactional HR interactions within a specific geographic zone (countries, regions, locations...). They are accountable for the local roll-out of annual campaigns, global policies, programs and tools.</p> |

HR Functions

In addition, and even if the Talent Management activities are critical in ensuring the engagement of all employees, all other HR Functions (such as Compensation & Benefits, International Mobility, HR Information Systems) also contribute to that objective.

CSR Department and the "Employees" pillar

On top of the HR functions, the Company Social Responsibility Department works closely with the HR Department to define the overall strategic goals of the "Employees" pillar of the CSR Policy: the CHRO (Corporate HR Officer) is a member of the CSR Strategic Committee and many local CSR ambassadors are also HR representatives.

Diversity & Inclusion Groups

Two types of D&I groups were set up in 2021, to help drive diversity & inclusion across Ipsen:

- Global D&I Council: core team of business leaders who help sponsor and drive D&I globally; the council is sponsored by two members of the ELT.
- Local Inclusion Groups: core team of employees who drive D&I in their own region. Ipsen now has Inclusion Groups in France, the U.S., the UK, & the DACH region.

The topic of D&I is regularly presented and reviewed by the Board of Directors.

Local level and well-being at work

Finally, as regards the specific topic of improving well-being at work, many concrete improvements are undertaken directly at local level. Ipsen decided that each site or country would be accountable to apply for external site certifications and to decide which certification is most appropriate. An increasing number of sites or countries decide to do so.

Policies & action plans

Policies and Tools

To sustain the three-C's approach to engagement, policies have been developed to cover each aspect:

- On the "Capabilities" side, the iPerform philosophy, aims at accelerating the development of all Ipsen employees with the support of the new iPeople system while the "iDevelop philosophy" ensures every single employee is a talent and deserves a development plan.
- To ensure contributions are fully recognized wherever in the Group. A project was launched in 2021 to survey Ipsen workforce about a potential evolution of the way Ipsen employees' contribution is recognized.

The *Compensation & Benefits principles* have been documented in 2019. These principles cover the following aspects: compensation, incentive plans, benefits and recognition plan and awards.

- To encourage the commitment of all employees, Ipsen's CSR strategy is being developed so that the "Employees" pillar is in synergy with the objectives of Ipsen's CSR pillars: Communities and Environment. Criteria have been defined to provide guidance to local teams in supporting the appropriate initiatives.

The Ipsen Code of Conduct states Ipsen principles in terms of inclusion and non-harassment, thus acknowledging that Inclusion is an important element of commitment.

Finally, Ipsen encourages its affiliates – while leaving it to their initiative – to seek external recognition awards such as "Great/Best Place to Work" to encourage their efforts to improve well-being at work. In 2021, some local HR professionals set up a specific workforce to provide advice and support to their colleagues in other countries that are willing to start the journey to obtain such an external recognition.

Engagement level is measured worldwide every other year by an independent provider, with action plans being followed wherever necessary.

Recent achievements

In 2020, in view of the COVID-19 environment, efforts were made both to reinforce existing processes and to find ways to manage the employee engagement.

• Everyone is a talent:

Since the culture of the annual development plan is now really embedded in the Company, a specific effort was made in 2020 to improve the quality of the development plans by pushing the "on-the-job" and "through others" development actions. Local and Divisional career weeks events are organized to value Ipsen development offer internally.

The assessment of our associate's potential helps our HR Business Partners to identify targeted development actions for our talents (or emerging talents) either through mobility or through specific leadership programs.

• Every day is a learning experience:

Content particularly suited for remote-working employees and content focused on well-being has been pushed

through the platform. In 2021, on-line learning has been enriched through a partnership with LinkedIn.

• Ipsen's goal is to provide opportunities to grow via first-class leadership programs:

Ipsen leadership programs are structured around the Ipsen Leadership Pathway. This Pathway is designed so that any employee, whatever their profile (individual contributors, leaders, senior leaders, executives, future leadership team members, high potentials) are offered a real opportunity to develop their leadership skills.


These programs range from simple, e-learning-based, soft-skills videos to highly-customized programs including a mix of learning activities.

All programs included in the pathway are designed to match demanding requirements. For example, two major global leadership development programs: one program for executives and "Leading the Ipsen Way" for middle management are based on a blended approach mixing webinars, face-to-face sessions and applied learnings. In 2022, the Executive program will be revamped and extended to the whole Global Leadership Team.

A specific focus was made in 2021 on the Mentoring as the tool is particularly powerful in the periods of lockdown and work-from-home as well as on a program called "FastTracking Talents" to help emerging Talents in the organization.

As the lockdowns are progressively lifted, management meetings, in particular of the Global Leadership Team (top 170) annual gathering, have been organized to support our managers.

In the most senior programs, the Executive Leadership Team members are directly participating.



• Develop career mobility:

Career Pathways have been developed for pivotal job and in areas of the Company where retention is a particularly acute issue.

Speed networking sessions between High Potential employees and Executive Leadership Team members when visiting the Ipsen sites.



• Establish a new Hybrid Model

As the local lockdowns are progressively being lifted, thus enabling the workforce to come back to the office, specific events, under the umbrella #Reconnect have been organized in Ipsen office places to encourage employees to come back to the office.

A guidance was provided to all countries as regards the number of days allowed to work from home. Employees were surveyed on this topic as part of the 2021 Engagement Survey. Existing and new workplaces will be progressively adapted to foster this new collaboration methods.

Specific training sessions have been held for employees and managers to support them through this significant change.

New buildings in Warsaw and Toronto were inaugurated in accordance with this new Hybrid Model.

Understand and promote Diversity and Inclusion

Under the responsibility of a newly-appointed Diversity and Inclusion Director, many actions were undertaken at Ipsen in 2021:

- Definition & sharing of a narrative to support leaders in their understanding of why D&I matters at Ipsen;
- Definition of a D&I strategy articulated around 3 pillars:
 - A workforce engaged around diversity,
 - A fair and impartial workplace,
 - A reputation for D&I.
- **D&I Survey:** In order to better understand the challenges of inclusion at Ipsen, a company-wide survey was rolled-out mid-2021 (with the exception of North America where a D&I survey had already been conducted earlier in the year). The results were shared with the Executive Leadership Team, HR Teams, and with the Global D&I Council, and lead to a set of recommendations from the Global D&I Council.
- **Awareness sessions:** various awareness sessions were proposed on topics such as LGBTQ+ (HR Community), D&I and my career (TechOps), Handicap (France: SEEPH), and world cafes engaging employees widely on D&I discussions. In addition, e-learning have been available since March 2021 to all employees, to deepen their understanding of Microaggressions, Bias, and 'In-groups'.
- Recruitment process enhancement to include engaging hiring managers in reflections on diversity for their teams; this was accompanied by online training for hiring managers and TA specialists.
- Parental leave enhancement.
- Headhunter specialized in diversity.
- Definition and roll-out of a methodology for the Compensation & Benefit teams to be able to analyze gender pay equity on their scope.
- Detailed action plan to reach the target of number of women at GLT (Global Leadership Team).

Anchor and evolve our Ipsen Way of Being

In 2021, a new version of the Ipsen Way of Being, that represent the backbone of Ipsen culture and values, was introduced to all Ipsen employees *via* dedicated workshops. This version, while being in the continuity of the previous one, put the emphasis on developing some specific aspects such as the ability to focus or the importance of being data-driven.

HR also globally supported some specific aspects of the transformation of Ipsen:

- The new "Asset Centric Model" for which HR developed a specific program to help Asset Teams work effectively together.
- Also, "a Digital Pathway" has been developed with an expert provider to provide high-quality e-learning modules on all digital aspects and from a "literacy" to an "expert" level. The "literacy" level was completed by more than 1,000 employees.
- Adapt the Ipsen assessment tools according to this new Ipsen Way of Being.

Listen actively to our employees

Ipsen also decided to make a specific effort in better listening to the employees. The implementation of a specific tool (Glint) along with a willingness to implement shorter, more frequent "pulse surveys", support this approach. In 2021, the Engagement Survey was run using this new tool that gives every manager a precise view of their team's results and encourage them to develop their own action plan.

The results of the 2021 global engagement survey were published in November and showed a slight regression versus the previous one (75 vs 78) but a result at benchmark. It should be noted that, as a consequence of the change in tool and provider, the basis of the index and the benchmark was similar but not identical to the previous one.

An Employee Assistance Program (EAP) was rolled-out to our main countries that provides assistance to all employees and their family members.

Finally, some HR resources have been specifically dedicated to supporting Ipsen efforts to sustain engagement in its workforce.

Along with developing employees, fostering their engagement for the benefit of Patients and of the community has also been a strong line of action:

• Combine Health with Patients support:

Ipsen in Motion is our global internal program promoting the health and well-being of our employees while allowing us to support patients associations and environmental causes in various countries where Ipsen has a presence. It consists in a series of sporting challenges proposed to all Ipsen employees around the world through a digital platform (United Heroes).

Five challenges are being proposed every year: one Global engagement challenge taking place over the whole year and four Local challenges, each of 1 month duration, scheduled over the year.

The associations for which we raise funds thanks to these challenges are chosen each year and we try to make our contribution to as many associations as possible working in our therapeutic areas.



Since its launch in 2018, Ipsen in Motion has gathered more and more active participants every year. In 2021, we were aiming to reach the ratio of 1 employee out of 5 participating and this ambitious target has been overachieved.

A total amount of €50 000 were donated in 2021 and shared between the 5 associations.

This year, we decided to broaden our support to environmental associations. Therefore the Global engagement challenge was in favor of The GoodPlanet Foundation, created and chaired by Yann Arthus-Bertrand, renowned photojournalist, with the aim of raising public awareness on environmental issues and environmental protection. As a partner, Ipsen supported more specifically the GoodPlanet Foundation on the Women and Shells project in Senegal.

This project was chosen because it brings together causes and values that we defend: the environment and biodiversity but also support to women and entrepreneurship.

It aimed to preserve the wetlands of the Saloum Delta, located in the Fatick region in Senegal. Shellfish harvesting has always been a staple diet and the basis of economy in coastal villages, mainly supported by women. But the natural environment being nowadays overexploited and impacted by climate changes, women have to take ever greater risks due to the scarcity of shellfish resources and are forced to venture far from the shores to meet the needs of their families. The project will allow to support women entrepreneurship and to develop a sustainable shellfish farming activity, increasing the women income by gradually replacing the collection of wild shellfish by shellfish culture and by improving the working and safety conditions.

The four Local challenges were chronologically initiated by DACH, France, North Africa and Mexico teams. All objectives have been exceeded, allowing to support local patients associations:

- German, Austrian and Swiss Dystonia Societies, whose purpose is to improve lives of people living with dystonia and stimulate research for more effective treatment,
- ISPC (*Institut de Santé Parasport Connecté*), the first institute in the world exclusively dedicated to parasport-health, which will be inaugurated at the time of 2024 Paris Paralympic Games,
- El Amel Association, created by the Pierre & Marie Curie oncology center. Its project "For Women" provides financial and material support to better detect breast cancer and help women after mastectomy,
- the Pequeño Leòn association supports patients with FOP (fibrodysplasia ossificans progressiva), by spreading information and awareness about FOP diagnosis.

Above the support to remarkable actions and the improvement of employees wellness, Ipsen in Motion creates a real link between Ipsen employees at local and global level. Supporting and encouraging each other is indeed a very concrete way to reinforce engagement and motivation.

• Spontaneous local communities support

In recent years, Ipsen implemented programs and initiatives to encourage employees engagement with patients associations and environmental organizations.

Beyond these organized and planned actions, local teams also respond to the call of their communities, when a crisis situation arises for example:

- Vietnam CHC team donated 2,000 boxes of Smecta Go when the country was hit by three major storms, resulting in massive flooding, to help treating diarrhea due to dirty water and contaminated food,
- Boulogne (France) EHS and facility management team initiated and closely worked with the site restaurant service provider and the City Hall during the COVID-19 pandemic to supply 500 full meals per month for city students who have been hit hard during that time,
- After a tornado passed through South Moravia in the Czech Republic in June, CEA (Central Europe & Adriatics) Cluster teams decided to help the affected local communities and participated in various projects such as cleaning, gardening, rebuilding, etc.,
- Greece having faced very violent forest fires this summer, Ipsen Greece's teams mobilized to provide firefighters with medical equipments and meals.

These spontaneous actions demonstrated the reactivity and generosity of employees as well as their true anchoring in their respective communities, which is a major indicator of shared values within the Group.

• Enable and encourage employees to take part in the "Ipsen Community Day":

As part of the second pillar of our CSR strategy (Communities) we launched in 2019 the Ipsen Community Day. Around the world, local affiliates organize a wide range of events to support patients, healthcare communities, caregivers and environmental associations.

Fully aligned with our Group strategy - Focus. Together. For patients and society. - the Community Day is one of the Group's key initiatives to be active members of our local communities and to act for our environment.

After a year in 2020 when the organization of these days was very complicated and some actions had to be converted into remote, 2021 was an exceptional year in terms of employees' engagement.





Despite successive waves of COVID and for some countries, lockdowns, the 28% participation target that we set was exceeded. More than 1,800 participants in more than 38 geographies dedicated time to these causes, representing a record-breaking participation rate of 32% and a 30% growth compared to 2019 participation rate.

Some of the actions which took place this year includes:

- Collection and donation of clothes, hygiene kits, water purification system, medicines, materials, etc. (France, Algeria, China, Italy, Mexico).
- Volunteering in foodbank, hospitals, etc. (UK, France, USA, Singapore, Spain).
- Renovation in hospitals, kindergarten, etc. (Slovakia, Czech Republic, Romania, France).
- Tree planting (Germany, France, Hungary, USA, Spain).
- Clean up, plogging, etc. (NOBA, Russia, Ireland, USA, Czech Republic, Ukraine, France).
- Christmas decoration (France, Greece).

Translate commitment financially:

To show its commitment to the CSR objectives, Ipsen has been willing to subject some financial obligations to its fulfilling of certain CSR criteria: this has been the case of the revolving credit facility negotiated in 2019, as well as of the French profit-sharing agreement.

Ipsen also wishes that each employee has a share in its success. Between February 2019 and December 2020, Ipsen implemented a program called "5 Shares for All" enabling more than 5,000 employees in 35 countries to become Ipsen shareholders. This operation is a strong recognition of the contribution of every and each employee in reaching more than two billion sales in 2018.

A key pillar of Ipsen Way of Being is sharing and celebrating our successes. In recognition of their valued commitment in 2021, all employees received an award of €500 gross (or equivalent) on an exceptional basis at the end of December provided they have been employed by Ipsen continuously since 30 June 2021 and are not in the highest level of responsibilities in the Company.

Objectives & Results

The objective is to provide an environment where employees can fulfill themselves and grow.

The main KPIs considered are the ones that:

- reflect the stability of workforce (turnover, % of permanent positions, absenteeism),
- the means to ensure their development (number of training hours per employee, % of employees with a formalized development plan),
- and the level of engagement (engagement index, number of certified sites).

| KPI | 2021 | 2020 | 2019 |
|--|------|------|---------------|
| Number of countries which are certified "Great / Best Place to Work" | 19 | 13 | 7 |
| Number of training hours per employee (h) | 29,8 | 25.8 | 26.8 |
| Employees with a formalized development plan (%) | 98 | 97 | 95 |
| Employees having taken part in the Ipsen Community Day (%) | 32 | 26 | 28.2 (France) |
| Turnover (%) ⁽¹⁾ | 13,3 | 11 | 11.7 |
| Percentage of permanent jobs in the Group (%) ⁽²⁾ | 96 | 95.6 | 85 |
| Absenteeism rate (%) | 2,8 | 2.8 | 2.5 |
| Gender Equality Index (France) | 88 | 83 | 83 |

(1) Voluntary turnover for permanent positions.

(2) The 2020 increase is driven by a technical reclassification of most Chinese employees from fixed-term to permanent job

| KPI | 2021-2022 | 2019-2020 | 2017-2018 |
|----------------------|-----------|-----------|-----------|
| Engagement index (%) | 76 | 78 | 79 |

Engagement Survey is run every other year.

4.4.3 Providing a healthy and safe workplace

Definition of the risk

The risks associated with employee motivation have been outlined above. Providing a safe and healthy workplace is an essential aspect of this and in preventing the loss of employee trust associated with employee injury or illness.

The supply of products to patients could be disrupted by a significant incident or regulator action that restricts or stops operations. Fines, penalties and business recovery will have financial impacts.

Health & Safety performance and management system effectiveness are also common supplier assessment criteria to establish and maintain customer commercial relationships.

Changes in regulatory requirements affect Ipsen operations and those across the supply chain.

All these risks can impact operations, costs and ability to compete in the biotech business sector.

Mission

Ipsen's Code of Conduct outlines Ipsen's commitment to "Provide a safe work environment".

Protecting our people and improving their well-being to ensure provision of Ipsen drugs for patients

Governance

Occupational health & safety compliance and risk Improvement is managed by the Environment Health and Safety (EHS) governance bodies at every level of the organization:



Group level: The Group EHS Council defines the vision of the Group, set up the strategy and objectives.

Division level: The Global Leadership teams drive the EHS performance for the Regional, Divisional and Functional Teams and are in charge of implementing EHS strategies and objectives.

Site level: the EHS Operational Teams drive the EHS performance at the **site level**.

Policies & action plans

Policies

Ipsen EHS policy drives the following principles for occupational Health & Safety:

- Provide a safe, injury-free workplace.
- Prevent illness and enhance well-being.
- Communicate plans, goals and results.
- Continually improve systems and approaches.

Ipsen's EHS Management System drives the management and operational standards necessary to protect employee, contractor and visitor Health & Safety.

Management system effectiveness is independently verified through the Ipsen Group certification to the international standard *ISO45001:2018 – Occupational health and safety management*.

FOCUS The People Based Safety program

- Ipsen's Behavioral safety approach structured around the S3 Code; Step Up, Speak Out, Stay Safe
 - Raises awareness to the fact that all accidents are preventable and everyone has a role to play
 - Fosters regular structured dialog and individual feedback around safety improvement; Peer to peer and management to team
 - Identifies and corrects unsafe conditions and unsafe behaviors
- Formal S3 visits and managerial safety visits are required at all R&D and manufacturing sites, supported by site specific targets

2021 Health and Safety Program Achievements

Group ISO 45001-2018 certification maintained; no material findings from independent audits.

Two additional R&D facilities added to Group ISO 45001-2018 certification; Les Ulis and Milton Park.

Internal EHS audits are conducted, on behalf of Ipsen corporate EHS, by a competent EHS audit partner. 2021 audit sampling included two manufacturing locations and six affiliate offices. Remote auditing was still a key means of assuring compliance to corporate requirements but with the lifting of local COVID-19 restrictions, most audits of facilities were conducted with the auditor on site.

Over 1,788 S3 visits were completed in 2021. Each an opportunity for teams to speak up about safety concerns and to make our facilities safer.

Continued development of affiliate EHS Champion capabilities with quarterly EHS skills webinars. Each session focuses on a relevant topic (e.g. Ergonomics, driver safety, etc.), increasing understanding of the topic and sharing best practice tools.



Objectives & Results

Ipsen is committed to delivering world-class safety performance. The business has set a target to achieve zero medicalized incidents by 2025 and to maintain this into the future.

In 2021, the Ipsen Group medicalized incident rate per 1 million hours worked (FR2) was 0.4. This is an increase of a single incident on 2020 but a 44% improvement since the 2019 base year. 2021 incident categories included cut injuries, fall at same level, struck by falling object and dilute chemical splash.

One of the medicalized incidents involved a broken foot from a voluntary team building activity. The incident is included in the disclosure as the recreation event was linked to business meetings at the same 3rd party venue and therefore is considered work-related in line with best practice OSHA (Occupational Safety and Health Administration, USA) guidance.

Occupational Illness incidences disclosed are all musculoskeletal in nature. The Ipsen Ergonomics program drives improvement in this area.

All incidents and illnesses are investigated to root cause and improvement actions are tracked to close within the Ipsen Group EHS information Platform; EHSphere.

All 2021 medicalized incidents occurred in Europe and the injured person gender profile is 1:1 male vs Female.

| KPI | 2021 | 2020 | 2019 |
|--|------|------|------|
| Ipsen Medicalized Accidents Frequency Rate (FR2) | 0.40 | 0.31 | 0.71 |

Collective agreement contribution to performance and employee well-being

Ipsen has put in place a strong social dialogue with its employee representatives:

- The Ipsen group EHS management system requires each location to establish and maintain employee consultation processes or forums such as safety committees.
- Employees are represented in each Ipsen legal entity in accordance with the applicable local legislation, *i.e.* by the Joint Consultation Group in the United Kingdom, by the *Rappresentanza Sindacale Unitaria* in Italy, by the *Comité de Empresa* in Spain. In France, employee representation is ensured at the local level (7 companies) and at the central level within the framework of an Economic and Social entity (*Unité Économique et Sociale*), with a single Central Works Council for all employees in France and a Central Negotiation Body (*Instance Centrale de Négociation*) which brings together trade unions representatives of the Economic and Social entity.

- The frequency of meetings between management and employee representatives depends on the applicable local legislation.
- The Group ensures that the rights and freedom of employee representatives are strictly observed and that they enjoy the same promotion and training opportunities as other employees.

A European Works Council, composed of 8 members representing European countries, was launched in 2014. The members of the European Works Council work together, taking a concerted approach, and in compliance with the legal and regulatory practices as well as the cultural and social characteristics of the various countries. Ordinary meetings are held annually in order to present the progress in Ipsen's business and its strategic directions.

A European employee representation body for information and consultation on so-called "transnational" issues which is responsible for sharing information and exchanging viewpoints, fostering experience-sharing and building coordination between European countries.

In 2017, Ipsen signed a 4-year agreement aimed at fostering well-being at work as well as gender equality. This agreement is structured around four pillars:

- work-life balance,
- support of accountability and empowerment,
- promotion of health and well-being at work,
- monitoring of risky situations and psychological support.

As this agreement was being rolled-out in 2018, all Ipsen French sites have reinforced their specific actions for well-being at work, such as sports activities, concierge service, corporate co-financed day-nursery and prevention of psychosocial risks.

The agreement has been renewed in November 2021 for another 4 years (2022-2025).

In 2018, Ipsen signed the charter of the *Institut National contre le Cancer* and thus committed itself to a set of 11 measures meant to improve the "patient/employee" life during and after medical leave.

In 2019, the trade union rights agreement to implement the new "Social and Economic Committee" within the seven former legal structures (EC, DP and CHSCT) was completely renegotiated.

Finally, the three-year profit-sharing agreement signed for 2019-2021 set up three criteria related to CSR: one related to environment (reduction of carbon emissions, implementation of eco-responsible solutions for the French sites), a second to security at work and a third to the French Community Day (Ipsen Patient Day) event, which offers employees the opportunity to volunteer their time in associations.

4.5 MINIMIZING OUR ENVIRONMENTAL IMPACT

4.5.1 Protecting the Environment

Definition of the risk

Water, waste and air emissions due to Ipsen's activity, which could cause significant damage to sensitive areas, ecosystems and to general public health.

The supply of products to patients can be disrupted by a significant incident or regulator action that restricts or stops operations. Any associate fines, penalties and business recovery will also have a financial impact.

Environmental performance and management system effectiveness are increasingly common supplier assessment criteria to establish and maintain customer commercial relationships.

Changes in regulatory requirements affect Ipsen operations and those across the supply chain. With the evolution of the EU taxonomy regulation, financial institutions are also focusing more on environmental criteria within investment risk evaluations.

Talent recruitment & retention is an emerging risk in relation to environmental performance and ambition. Top talent has greater sustainability expectations. Numerous studies have highlighted that approximately 60% of early career candidates see sustainability as one of their top considerations when choosing an employer.

All these risks can impact operations, costs and ability to compete in the biotech business sectors:

Mission

Ipsen's Code of Conduct outlines Ipsen's commitment to

Protect the environment throughout
the entire product lifecycle

Governance

Environmental issues are managed by the Environment Health and Safety (EHS) governance bodies at every level of the organization. For more details, please refer to 4.4.3 above.

Policies & Action Plans

The Ipsen Group EHS policy includes fundamental principles for protecting and enhancing the environment:

- comply with all applicable regulatory requirements,
- maximize water & energy efficiency,
- minimize waste,
- prevent environmental incidents,
- transparency in plans, goals and results,
- continually improve systems, controls and performance.

Ipsen's EHS Management System drives the management and operational standards necessary to protect the environment.

Management system effectiveness is independently verified through the Ipsen Group certification to the international

standard ISO14001:2015 – Environmental management systems.

The waste, water and air emissions management program focuses on eliminating or reducing adverse emissions from Ipsen operations.

We comply with all applicable regulatory requirements and Ipsen Environment, Health & Safety (EHS) policies, standards and requirements wherever we operate.

We invest in energy and water conservation through focused efforts to identify where conservation opportunities exist and will continue to do so.

We work to reduce our carbon emissions over time which will reduce our impact on climate change.

We design and manufacture products that strive to minimize impact on the environment.

We promote biodiversity wherever we can at our sites across the globe.

Objectives & Results

Ipsen protects the Environment around our facilities by effectively managing risk, complying with regulations/permits and continuously improving environmental performance. This is facilitated by establishing and maintaining Group certification to the ISO 14001-2015 Environmental Management system standard.

In 2021, independent management system surveillance audits identified no material findings. Two additional R&D facilities were also added to Group ISO 14001-2015 certification: Les Ulis and Milton Park.

Regulatory agencies also audit our facilities to ensure we are in compliance with obligations. Ipsen received Zero Notices of Violation in 2021.

Process efficiency improvements are also reducing environmental impact with significant reductions in air and waste-water emissions; Volatile organic compound (VOC) emissions to air are 15% lower vs 2019 base year. Biological Oxygen Demand (BOD) and suspended solids in wastewater are 35% and 43% lower respectively vs 2019 base year.

Ipsen protects the Environment across the rest of the value chain through

- The Code of Conduct and the Supplier Risk Management (SRM) program (see 4.3.3).
- Product Environmental Risk Assessment.
- The Pharmaceuticals in the Environment (PIE) program. In 2021, the PIE project team developed improved analytical methods to better detect and quantify PIE.

Ipsen enhances the environment and local ecosystems with a group wide Biodiversity program.



In 2021, the project team developed a Biodiversity Strategy Plan and proposed performance indicators to increase biodiversity at Ipsen-owned sites. Biodiversity surveys were extended to the Wrexham and Dublin manufacturing sites. Species data from these and previous surveys is monitored in a new database containing all wild fauna and flora recorded.

The UN International Day for Biological Diversity in May was celebrated across Ipsen with a range of activities including local habitat creation and enhancement (nest boxes, 'bug hotels', tree planting, wildflower planting), employee community day activities such as partnerships with external conservation organizations and litter picking. Employee awareness was also enhanced through employee engagement activities (children drawing competitions,

involvement in habitat creation on site, pledges and commitments). The Milton Park facility hosted, regenerative farmer, wildlife photographer and inspirational speaker, Rebecca Hosking, who was invited to speak on site, and on-line across the Group, about the criticality of biodiversity, its decline and what every individual can do to protect it.

In its third year, the most mature program for biodiversity is the partnership between Ipsen L'Isle-sur-la-Sorgue and the 'Ligue de Protection des Oiseaux' (LPO), which continued with a survey and additional habitat creation for reptiles.

Ipsen is also a Member of CSR-Europe Biodiversity & Industry Platform.

4.5.2 Climate Action

Definition of the risk

In addition to the Risks included above in 4.5.1. Climate change is a significant business risk associated with:

- Increased compliance obligations such as the EU green Deal
- Flooding, drought and other natural disasters which impact operations and supply chain
- Climate adaptation cost
- Investor confidence based on non-financial/EGS performance criteria
- Carbon taxation and Energy Pricing
- Mandatory mitigation standards, emission limits, and design standards
- Availability of natural resources as process inputs
- Reputational commercial impact from Environment, Social, Governance performance criteria.

Mission

Minimize Ipsen's contribution to global warming with science based climate action

Policies & action plans

Ipsen is committed to science-based reductions in our greenhouse gas (GHG) emissions, sufficiently ambitious to help keep global warming to 1.5°C as called for in the Paris climate agreement.

By joining the Business Ambition for 1.5°C campaign in 2021, Ipsen has also committed to reach net-zero value chain GHG emissions by 2050.

2021 Achievements

Ipsen now uses 100% 'Green' Electricity for all operations in the UK, Ireland and France. This has increased Ipsen's Group wide use of electricity from renewable sources to 88%, since April 2021.

Three manufacturing sites in France are now certified to ISO 50001, the international Energy Management System.

After the successful Phase 1 installation of the Dreux site chiller system heat recovery project in 2020, the Phase 2 project commenced this year. These projects are projected to reduce site CO₂e emissions (Scope 1 + Scope 2) by over 50% compared to the 2019 base year. The project also replaces the refrigerant gases used in the chillers with a much lower 'Global Warming potential' material (GWP of 6 vs 1430).

HVAC (Heating, ventilation, and air conditioning) is the most significant energy user at manufacturing sites. Projects are already in progress at all sites to reduce HVAC emissions across non-GMP areas. Ipsen is working with industry leading experts to develop projects and validation protocols, to optimize HVAC carbon intensity for GMP areas.

The Tianjin facility has seen an 55% reduction in Scope 1 emissions, vs 2020, driven by boiler efficiency projects and zero refrigerant gas emissions reported in 2021.

The Group 'Fleet for Future' project was launched in 2021. This project will significantly reduce the fleet energy intensity and define Ipsen's fleet energy mix transition to low carbon alternatives. Ipsen has identified the opportunity to have 30% of the Group fleet transitioned to electric vehicles by 2025. Ipsen leadership has also agreed to a global emissions cap of 150 gCO₂/km for any fossil fuel vehicles that remain.

COVID restrictions in 2020 saw a near 93% reduction in business travel emissions vs 2019. Internal travel restrictions remained in place for much of 2021 but as business travel restrictions are lifted, budgetary mechanisms and staff engagement campaigns are being utilized to limit emission rebound to no more than 30% of 2019 business travel emissions in 2022.



Ipsen's Executive Leadership Team and Board has approved significant changes to the group carbon action program from 2022, this includes;

- Transition the group climate action target from a carbon intensity-based metric to one based on absolute emissions to atmosphere
- Use 'market based' emission factors to calculate Scope 2 emissions. This allows for a better reflection of Ipsen's climate impact and supports the UN Sustainable Development Goal 13 on climate action to "Take urgent action to combat climate change and its impacts by regulating emissions and promoting developments in renewable energy"
- Commitment to set a science-based target through the Science Based Targets initiative, in 2022, including a 1.5°C aligned 50% reduction in Facility and fleet emissions (i.e. Scope 1 and Scope 2) by 2030 vs the 2019 base year

- Commitment to working with up and downstream value-chain partners to deliver science-based Scope 3 emissions reductions by 2030 (vs 2019)
- As a transition step on the pathway to net zero, Ipsen is also committing to climate-compensation measures from 2030 for the emissions not yet removed from its value chain. Even though such offsets will never be a substitute for science-based emissions reductions, they still have an important role in preserving or enhancing existing carbon stocks and thus limit the worst impacts of climate change.

Objectives & Results

The 2021 goal was to reduce facility (Scope 1 & Scope 2) GHG emission intensity, per Sq. meter, by 7% vs 2019 base year.

In 2021, Ipsen has reduced its facility carbon intensity by 18% vs 2019.

| KPI | 2021 | 2020 | 2019 |
|--|-------|-------|-------|
| Ipsen Facility* GHG Scopes 1 & 2 Location-Based Emissions Normalized to Occupied Area (TCO ₂ e/m ²) | 0.105 | 0.112 | 0.127 |

* Without direct emissions from 'mobile sources with combustion engines'.



4.5.3 Responsible Consumption and Production

Definition of the risk

Wasteful over consumption of water can lead to water shortages, an important material input to Ipsen operations. The depletion, by Ipsen, of water stocks for local communities is also a reputational risk.

This may also prompt regulatory action or price changes driven by scarcity.

Water risk associated with Climate change are addressed in 4.5.2. above. Water Quality risks are included in pollution prevention and regulatory compliance aspects of 4.5.1 above.

The generation and disposing of waste has significant environmental impacts and contributes to Ipsen's Scope 3 GHG emissions. The financial cost of raw materials, energy inputs and treatment inherent in the waste, can be significant.

The increased use of renewable energy will challenge energy providers as peak demand and supply may not always coincide. The building of infrastructure to meet increasing demand may also require high GHG processes (concrete, etc.); Even when purchasing green energy, reducing consumption is key to reducing environmental impact and costs.

See also risks included above in 4.5.1.

Mission

Minimize our consumption of natural resources

2021 Achievements

The Ipsen Natural Resource preservation project is designed to engage all manufacturing, R&D and significant office locations in reducing energy, waste and water intensity.

Ipsen also completed a water risk analysis of all site locations in 2021. Each site was mapped to their water basin to understand their future water risk; *i.e.* projecting availability vs demand pressures in 2040 assuming a trajectory aligned to a 2° rise in average global temperatures by 2100. The outcome highlights that over 85% of Ipsen's water consumption is from low water risk basins.

The Dublin site has delivered improvements to the purification process that has seen a >50% reduction in acetonitrile used in this process step and supported a >30% reduction in hazardous waste produced on site vs 2019. This makes the process more efficient, safer for our people and safer for the environment. This will also impact our scope 3 carbon emissions from purchased goods and waste treatment.

Ipsen is already leveraging our strengths in innovation to advance the science of Green Chemistry and develop processes that are more environmentally sustainable; see Katarzyna Wegner, Danielle Barnes, Kim Manzor, Agnieszka Jardine & Declan Moran (2021) Evaluation of greener solvents for solid-phase peptide synthesis, Green Chemistry Letters and Reviews, 14:1, 153-164, DOI: 10.1080/17518253.2021.1877363.

Objectives & Results

The 2021 Objectives were to:

- Reduce facility Energy intensity, per Sq. meter, by 7% vs 2019 base year.
- Reduce water intensity, per Sq. meter, by 5% vs 2019 base year.
- Reduce waste intensity, per Sq. meter, by 5% vs 2019 base year.

In 2021, Ipsen reduced facility energy intensity by 7%. vs 2019.

Water intensity performance remains well ahead of target. The L'Isle-sur-la-Sorgue (ISS) site accounts for approximately 70% of the total water consumed by Ipsen. While the site continues to improve water efficiency within the process, COVID related reductions in demand have also contributed significantly to reduced water consumption vs 2019 base year. As production volumes recover at ISS, water intensity has also rebounded.

Ipsen has also far exceeded the waste intensity target driven by an average 17% year on year reduction in absolute waste generated since 2019.

| KPI | 2021 | 2020 | 2019 |
|--|-------|-------|-------|
| Ipsen Total Facility* Energy Use Normalized to Occupied Area (MWh/m ²) | 0.563 | 0.57 | 0.605 |
| Ipsen Total Water consumption Normalized to Occupied Area (kWh/m ²)** | 2.48 | 2.31 | 3.72 |
| Ipsen Total Waste Intensity Normalized to Occupied Area (kg/m ²)*** | 27.93 | 37.32 | 44.24 |

* The facility area and energy use includes all facilities with more than 10 employees at sites.

** The facility area and water use includes the facilities that are Manufacturing and R&D (laboratory) facilities and where water use is metered.

*** The facility area and waste generation includes all the facilities that are Manufacturing and R&D (laboratory) facilities.



4.6 ANNEX I: SCOPE OF RISKS COVERED

| Law | Mandatory issue | How the risk is tackled |
|--|---|---|
| Decree implementing the European Directive (n° 2017-1265) | Consequences on climate change from the activity and the use of the Company's products and services | 4.5 Minimizing our environmental impact |
| | Circular economy | 4.5 Minimizing our environmental impact |
| | Fight against food waste | Considering Ipsen's business and activities, this issue was considered as non material for the Company |
| | Collective agreements | 4.4.3 Providing a safe and healthy workplace |
| | Actions against discrimination and in favor of diversity and the inclusion of disabled people | 4.2.7 and 4.4.2 |
| | Societal engagements in favor of sustainable development | 4.1.1 and 4.2.7 |
| Law on the fight against fraud – 23 October 2018 | Fight against tax evasion | 2.2.1 |
| Law on sustainable food – 30 October 2018 | Fight against food poverty, respect of animal well-being, responsible, equitable and sustainable food | 4.2.3 for animal well-being Considering Ipsen's business and activities, other issues are considered as non material for the Company |



4.7 ANNEX II: CORRESPONDENCE TABLE WITH GRI STANDARDS

Global Reporting Initiative (GRI) G4 table correspondence

| GRI category and requirement | Reference |
|--|---|
| General standard disclosure | |
| Strategy and Analysis | |
| G4-1: CEO statement. | 4.1.1 Presentation and governance of Ipsen's Company Social Responsibility |
| G4-2: Description of Key Impacts, Risks and Opportunities. | 4.1.2 The Group's key CSR Risks and opportunities 1.1.2.3 Ipsen's Business Model |
| Organization profile | |
| G4-12: Organization's supply chain. | 4.2.1 Bringing high quality product to patients 4.2.5 Committed to fight against counterfeit products 4.3.3 Promoting and defending Human Rights 4.4.3 Providing a healthy and safe workplace 4.5 Minimizing our environmental impact |
| G4-15: Economic, environmental and social charters, principles, or other initiatives to which the organization subscribes or which it endorses. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy – UN Global Compact 4.5.2 Climate action |
| G4-16: Membership of associations and organizations. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy – UN Global Compact 4.2.7 Enlarging access to health – Access Accelerated initiative 4.2.6 Promoting products responsibly – IFPMA, EFPIA and other country industry associations in pharmaceutical industry |
| Stakeholder Engagement | |
| G4-24: List of stakeholder groups engaged by the organization. | 4.1.2 The Group's key CSR Risks and opportunities |
| G4-26: Organization's approach to stakeholder engagement. | 4.3 Enhancing integrity to maintain a trusted relationship with our stakeholders |
| Governance | |
| G4-35: Process for delegating authority for economic, environmental and social topics from the highest governance body to senior executives and other employees. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |
| G4-36: Executive-level position or positions with responsibility for economic, environmental and social topics, and whether post holders report directly to the highest governance body. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |
| G4-37: Processes for consultation between stakeholders and the highest governance body on economic, environmental and social topics. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |
| G4-43: Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |
| G4-44: Expertise of the governance bodies in sustainability topics. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |
| G4-45: Highest governance body's role in the identification and management of sustainability impacts, risks, and opportunities. Include the highest governance body's role in the implementation of due diligence processes. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |
| G4-46: Highest governance body's role in reviewing the effectiveness of the organization's risk management processes for sustainability topics. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |
| G4-48: Highest committee or position that formally reviews and approves the organization's sustainability report and ensures that all material aspects are covered. | 4.1 Ipsen Company Social Responsibility's Vision and Strategy |

| GRI category and requirement | Reference |
|--|---|
| Ethics and Integrity | |
| G4-56: Organization's values, principles, standards and norms of behavior such as codes of conduct and codes of ethics. | 4.2.6 Promoting products responsibly 4.3.2 Fighting corruption 4.3.3 Promoting and defending Human Rights |
| G4-57: Internal and external mechanisms for seeking advice on ethical and lawful behavior, and matters related to organizational integrity, such as helplines or advice lines. | 4.3.2 Fighting corruption 4.3.3 Promoting and defending Human Rights |
| G4-58: Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity. | 4.3.2 Fighting corruption 4.3.3 Promoting and defending Human Rights |
| SPECIFIC STANDARDS DISCLOSURES | |
| Environmental – energy | |
| G4-EN3: Energy/fuel consumption within the organization. | 4.5.3 Responsible Consumption and Production |
| G4-EN6: Energy saved due to conservation and efficiency initiatives. | 4.5.3 Responsible Consumption and Production |
| G4-EN7: Reductions in energy requirements of products and services. | 4.5.3 Responsible Consumption and Production |
| Environmental – water | |
| G4-EN8: Total water withdrawal by source. | 4.5.3 Responsible Consumption and Production |
| Environmental – biodiversity | |
| G4-EN11: Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas. | 4.5.1 Protecting the Environment |
| G4-EN13: Habitats protected or restored. | 4.5.1 Protecting the Environment |
| Environmental – Emissions | |
| G4-EN15: Direct Greenhouse Gas (GHG) emissions (Scope 1) – Metric Tons of CO ₂ . | 4.5.2 Climate Action |
| G4-EN16: Energy indirect Greenhouse Gas (GHG) emissions (Scope 2) – Metric Tons of CO ₂ . | 4.5.2 Climate Action |
| Environmental – Effluents and Waste | |
| G4-EN23: Total weight of waste by type and disposal method. | 4.5.1 Protecting the Environment |
| Social – Labor Practices and Decent work | |
| G4-LA1: Total number and rates of new employee hires and turnover by age group, gender and region. | 4.4.2 Enhancing employees' engagement |
| G4-LA10: Programs for skills management and lifelong learning that support the continued employability of employees and assist them in managing career endings. | 4.4.2 Enhancing employees' engagement |
| G4-LA11: Percentage of employees receiving regular performance and career development reviews, by gender and by employee category. | 4.4.2 Enhancing employees' engagement |
| Social – Labor Practices and Decent work – Occupational, Health and Safety | |
| G4-LA5: Workers representation in formal joint management-worker health and safety committees | 4.4.3 Providing a healthy and safe workplace |
| G4-LA6: Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and number of work-related fatalities | 4.8 Annex III: Summary of our Key Performance Indicators (KPIs) |
| G4-LA8: Health and safety topics covered in formal agreements with trade unions. | 4.4.3 Providing a healthy and safe workplace |
| Social – Human Rights – Investment | |
| G4-HR2: Total hours of employee training on policies and procedures concerning aspects of human rights that are relevant to operations, including the percentage of employees trained. | 4.3.3 Promoting and defending Human Rights |



| GRI category and requirement | Reference |
|--|--|
| Social – Human Rights – Non-discrimination | |
| G4-HR4: Operations and suppliers identified in which the right to exercise freedom of association and collective bargaining may be violated or at significant risk, and actions taken to support these rights. | 4.4.3 Providing a healthy and safe workplace |
| Social – Human Rights – Security practices | |
| G4-HR7: Percentage of security personnel trained in the organization's policies and procedures concerning aspects of human rights that are relevant to operations. | 4.4.3 Providing a healthy and safe workplace |
| Social – Society – Anti-corruption | |
| G4-SO4: Communication and training on anti-corruption policies and procedures. (GRI G3 involved only employees' training). | 4.3.2 Fighting corruption |

4.8 ANNEX III: SUMMARY OF OUR KEY PERFORMANCE INDICATORS (KPIs)

| Description of the indicator | KPI 2021 | KPI 2020 | KPI 2019 |
|--|---------------------|----------|----------|
| Product quality | | | |
| Batch Acceptance level (%) | 99.8 | 99.7 | 99.5 |
| First Time Quality Deviation (%) | 95.8 | 95.1 | 94.6 |
| Rate of on-time CAPA closure (%) (Corrective Action Corrective Prevention) | 95.0 | 95.3 | 92.0 |
| Product and patient safety | | | |
| On time ICSRs ⁽⁷⁾ , submissions to Health Authorities managed at global level (%) | >97 ⁽⁸⁾ | >98 | >96 |
| Analyzed safety signals | 10 | 17 | 18 |
| Confirmed safety signals | 1 | 6 | 8 |
| Supply continuity | | | |
| OTIF (on-time, in-full) (%) | 99.8 | 99.8 | - |
| Counterfeit drugs | | | |
| Number of counterfeiting cases identified and reported to ANSM (National Drug Safety Agency) | 16 | 6 | 11 |
| Responsible product promotion | | | |
| Completion rate of trainings on the Code of Conduct (%) | 97.5 | 94 | 90 |
| Data privacy | | | |
| Number of cyberattacks cases reported to the authorities | 2 | 2 | 2 |
| Anti-Corruption | | | |
| Completion rate of trainings on the Code of Conduct (%) | 97.5 | 94 | 90 |
| Completion rate of trainings on Anti-Corruption (%) | 97.1 | 98 | 91 |
| Completion rate of trainings on Conflict of Interest (%) | 97.5 ⁽⁹⁾ | - | - |
| Total number of Due diligences conducted | 1,159 | 1,146 | 458 |
| Human Rights | | | |
| Number of third parties assessed through the Business Ethics Management program | 521 | 936 | 365 |
| Completion rate of trainings on the Code of Conduct (%) | 97.5 | 94 | 90 |
| Talent attraction | | | |
| Number of recruitments | 1,232 | 936 | 1,386 |

| Description of the indicator | KPI 2021 | KPI 2020 | KPI 2019 |
|--|-------------|--------------------------|---------------|
| Employee engagement | | | |
| Number of countries which are certified "Great/Best Place to Work" | 19 | 13 | 7 |
| Number of training hours per employee (h) | 29.8 | 25.8 | 26.8 |
| Employees with a formalized development plan (%) | 98 | 97 | 95 |
| Employees having taken part in the Ipsen Community Day (%) | 32 | 26 | 28.2 (France) |
| Turnover (%) ⁽¹⁰⁾ | 13.3 | 11.0 | 11.7 |
| Percentage of permanent jobs in the Group (%) | 96 | 95.6 ⁽²⁾ | 85 |
| Absenteeism rate (%) | 2.8 | 2.8 | 2.5 |
| Gender Equality Index (France) | 88 | 83 | 83 |
| Engagement index (%) | 76 | 78 (2019-2020 - 2 years) | |
| Headcount | 5,744 | 5,703 | 5,824 |
| Share of women in the Global Leadership Team (%) | 42.3 | 41.8 | 36 |
| Health and Safety | | | |
| Medicalized accident frequency rate (FR2) | 0,40 | 0.31 | 0,71 |
| Energy reduction and Climate change | | | |
| Ipsen Total Energy Normalized to Occupied Area (MWh/m ²) | 0.563 | 0.570 | 0.605 |
| Ipsen GHG Scope 1 & 2 Emissions Normalized to Occupied Area (tCO ₂ E/m ²) Location based ⁽³⁾ | 0.105 | 0.112 | 0.127 |
| Ipsen GHG Scope 1 & 2 Emissions Normalized to Occupied Area (tCO ₂ E/m ²) Market based ⁽³⁾ | 0.075 | 0.087 | 0.095 |
| Management of water | | | |
| Ipsen Total Water Consumption Normalized to Occupied Area (m ³ /m ²) | 2.48 | 2.31 | 3.72 |
| Safety and Health Management | | | |
| Ipsen Fatalities | 0 | 0 | 0 |
| Ipsen Medicalized Accidents with Lost Days (Frequency Rate 1 FR1) | 0.30 | 0.20 | 0.20 |
| Ipsen Medicalized Accidents with and without Lost Days (Frequency Rate 2 FR2) | 0.40 | 0.31 | 0.71 |
| Ipsen Severity Rate | 0.057 | 0.028 | 0.002 |
| Ipsen Manufacturing and R&D Medicalized Accidents with Lost Days (Frequency Rate 1 FR1) | 0.65 | 0.31 | 0.59 |
| Ipsen Manufacturing and R&D Medicalized Accidents with and without Lost Days (Frequency Rate 2 FR2) | 0.98 | 0.61 | 0.89 |
| Ipsen Occupational Illness | 2 | 4 | 6 |
| Contractor Fatalities | 0 | 0 | 0 |
| Contractor Medicalized Accidents with and without Lost Days | 1 | 3 | 16 |
| Waste Management | | | |
| Total Waste (tons) | 4,274 | 5,289 | 6,125 |
| Recycled Waste (tons) | 1,770 | 2,443 | 2,458 |
| Recovery (tons) | 1,588 | 1,992 | 1,368 |
| Disposed Waste (tons) | 916 | 853 | 2,299 |
| Hazardous Waste (tons) | 2,413 | 2,385 | 3,483 |
| Energy Management | | | |
| Total Energy (kWh) Ipsen | 116,159,104 | 112,325,177 | 114,506,810 |
| Electrical Energy (kWh) | 62,872,040 | 61,239,648 | 65,109,956 |
| Renewable Electricity (kWh) ⁽⁴⁾ | 46,719,376 | 22,756,558 | 26,704,472 |
| Fossil Fuel Derived Energy (kWh - HCV) | 53,284,856 | 51,083,429 | 49,927,686 |
| Other Energy (kWh) | 2,209 | 2,100 | 44,561 |



COMPANY SOCIAL RESPONSIBILITY
ANNEX III: SUMMARY OF OUR KEY PERFORMANCE INDICATORS (KPIs)

| Description of the indicator | KPI 2021 | KPI 2020 | KPI 2019 |
|--|----------------|----------------|----------------|
| Carbon Management | | | |
| Carbon Scope 1 Total Emissions (tCO ₂ E) | 15,408 | 14,916 | 18,553 |
| Carbon Scope 1 Building Energy Emissions (tCO ₂ E) | 10,943 | 10,570 | 10,205 |
| Carbon Scope 1 Refrigerant Gas Emissions (tCO ₂ E) | 766 | 1,323 | 1,086 |
| Carbon Scope 1 Car fleet Emissions (tCO ₂ E) ^{(5) (6)} | 3,698 | 3,022 | 7,262 |
| Carbon Scope 2 Total Emissions (tCO ₂ E) Location-based methodology | 9,907 | 10,421 | 12,079 |
| Carbon Scope 2 Total Emissions (tCO ₂ E) Market-based methodology | 3,826 | 5,377 | 6,217 |
| Carbon Scope 3 Total Emissions (tCO ₂ E) | 32,412 | 32,507 | 57,146 |
| Carbon Scope 3 Fuel and Energy-related Activities (tCO ₂ E) | 5,964 | 5,730 | 6,941 |
| Carbon Scope 3 Purchased Goods and Services (tCO ₂ E) | 11,853 | 12,363 | 13,186 |
| Carbon Scope 3 Capital Goods (tCO ₂ E) | 2,288 | 1,962 | 2,221 |
| Carbon Scope 3 Upstream Transportation and Distribution (tCO ₂ E) | 4,258 | 4,003 | 5,043 |
| Carbon Scope 3 Waste Generated in Operations (tCO ₂ E) | 1,030 | 2,290 | 2,607 |
| Carbon Scope 3 Other indirect emissions upstream | 460 | — | 1,736 |
| Carbon Scope 3 Business Travel (tCO ₂ E) | 1,426 | 1,017 | 14,714 |
| Carbon Scope 3 Downstream Transportation and Distribution (tCO ₂ E) | 2,751 | 3,874 | 5,807 |
| Carbon Scope 3 End of life Treatment of sold products (tCO ₂ E) | 761 | 728 | 871 |
| Carbon Scope 3 Employee Commuting (tCO ₂ E) | 1,620 | 1,622 | 4,020 |
| Water Management | | | |
| Total Water Consumption (m ³) | 368,861 | 326,772 | 492,332 |
| Supply from Well Water and Surface Water Origin (%) | 65 | 64 | 74 |
| Total Water Recycled (m ³) | 21,100 | 15,000 | 23,200 |
| Hazardous Materials Management | | | |
| Solvent Consumption (tons) | 742 | 717 | 925 |
| Compliance Management | | | |
| Notices of Violation Received | 0 | 0 | 0 |
| Fines and Penalties Paid | 0 | 0 | 0 |
| Air Emissions Management | | | |
| VOC Emissions (tons) | 1.70 | 2.44 | 1.99 |
| NOx Emissions (tNO ₂) | 0.78 | 3.82 | 0 |
| SOx Emissions (tSO ₂) | 4.44 | 0.69 | 0 |
| Waste Water Management | | | |
| Waste Water Treated (m ³) | 294,212 | 271,314 | 459,282 |
| COD Loading (tons) | 8.81 | 8.92 | 11.01 |
| BOD Loading (tons) | 3.97 | 4.23 | 6.18 |
| Total Suspended Solids (tons) | 4.93 | 6.31 | 8.73 |
| Sales (eM) | 2,869 | 2,592 | 2,576 |
| Total Facility Area (m²) | 206,994 | 201,592 | 194,209 |

- (1) Voluntary turnover on permanent positions.
- (2) 2020 increase driven by a technical reclassification of most Chinese employees from fixed-term to permanent job.
- (3) Without direct emissions from mobile sources with combustion engines.
- (4) Renewable electricity data for 2021 is based on guarantees of origin or similar assurance structures built into Power Purchase Agreements (PPA). Previous years quantities were calculated according to supplier electricity mix information provided on invoices, regardless of contract terms.
- (5) Car fleet data is split into business use (included in Scope 1) and non-business use of Company provided vehicle (included in Scope 3) in 2019 and 2021. Where primary use cannot be determined or quantified, emission are reported under Scope 1.
- (6) China is excluded from car fleet data, but is estimated to represent 0.3% of Group Scope 1 emissions.
- (7) Individual Case Safety Reports.
- (8) Submission to MHRA in the UK since Jan 2021 and CIS countries HA submission since Sept 2021.
- (9) Training deployed in 2020 and first year of data collection in 2021.
- (10) Voluntary turnover for permanent positions.

4.9 ANNEX IV: COMPLYING WITH THE EUROPEAN TAXONOMY

The European Union Taxonomy Regulation (Regulation EU 2020/852 entered into force on 12 July 2020) and the two delegated acts applicable as of January 1, 2022 supplementing this regulation, namely:

1. the delegated act concerning the technical screening criteria for economic activities with significant contribution to climate change mitigation and adaptation (the 'Climate Delegated Act');
2. the delegated act specifying the key performance indicators ("KPIs") related to turnover, capital expenditure ("Capex") and operational expenditure ("Opex") that non-financial companies must disclose under article 8 of the Taxonomy regulation.

The Taxonomy regulation will cover six environmental objectives (climate change mitigation, climate change mitigation adaptation, sustainable use and protection of water and marine resources, transition to a circular economy, pollution prevention and control, and the protection and restoration of biodiversity and ecosystems) when all the delegated acts will be published. However, only the two climate objectives are to be taken into account when calculating the indicators for the financial year 2021.

Regarding the specific disclosures on proportion of turnover derived from a product associated with eligible environmentally sustainable activities, by their nature, activities of the pharmaceutical industry have not been listed as activities contributing substantially to climate change mitigation or climate change adaptation. For this reason, the proportion of eligible turnover as of December 31 2021, is equal to zero⁽⁹⁾. However, it is anticipated that future disclosures will include alignment for one or more of the remaining objectives

Ipsen is committed to science-based reductions in Greenhouse gas (GHG) emissions and to deliver net zero emissions no later than 2050. Climate mitigation activities at our sites in 2021 reduced absolute Scope 1 + Scope 2 (Market Based) GHG emissions from our facilities by 10%. This was made possible through investments, some of which being taxonomy eligible CAPEX related to individual climate mitigation measures, such as:

Taxonomy Eligible Activities 2021¹⁰

| Taxonomy code | Activity related to capital expenditure (CAPEX) |
|---------------|---|
| 4.16 | Installation and operation of Electric heat pumps |
| 4.25 | Installation producing heat/cool using wasted heat |
| 6.5 | Transport by motorbikes, passenger cars and light commercial vehicles |
| 7.2 | Renovation of existing buildings |
| 7.3 | Energy efficiency equipment |
| 7.4 | Charging stations for electric vehicles |
| 7.5 | Energy performance of buildings |
| 7.7 | Acquisition and ownership of buildings |
| 8.2 | Data-driven solutions for GHG emissions reductions |

Climate Adaptation is considered within Ipsen's global risk management process. No climate adaptation CAPEX was identified for financial year 2021.

As of December 31, 2021, the proportion of eligible CapEx amounts to 9% of the total Capex⁽¹¹⁾. The low level of eligible capex is explained by the high proportion of capex related to intangible assets at December 31, 2021

The operational expenditures (OpEx) related to the activities listed above are eligible according to the Taxonomy regulation. However, these Opex have been deemed non-material in comparison to the Opex to be included in the denominator of the Opex ratio. The proportion of eligible operational expenditures as of December 31 2021, is therefore considered zero⁽¹²⁾

⁽⁹⁾ Total Sales 2021 IFRS: see section 3.2.1 Consolidated income statement.

⁽¹⁰⁾ Disclosed data is based on location reporting of eligible individual Capex and investments as of December 31, 2021. No allocation of investments between eligible and non-eligible capex has been necessary as Capex are already reported project by project in the financial consolidation system. Acquisition and ownership of buildings relate to leased office buildings. The transport by motorbikes, passenger cars and light commercial vehicles relate to the fleet of leased cars.

⁽¹¹⁾ Total Capex 2021: €427.7 million (see lines "Acquisitions/ Increases" of the Note 11 Other intangible assets (€331.7 million) and Note 12.1 Movements of Property, plant & equipment (€96.0 million) in Chapter 3.2 Consolidated Financial Statements 2021 (3.2.5. Notes).

⁽¹²⁾ Total Opex "Denominator" 2021 as per of Annex I of Reg UE 2021/2178: €446 million (OPEX R&D + maintenance & repairs + short-term leases). Maximum possible eligibility is 1.7%.



4.10 ANNEX V: REPORTING METHODOLOGY AND AUDIT REPORT

Human Resources

• Headcount

Headcount indicators reported in the universal registration document are based on Ipsen's global Human Resources Information Systems deployed in all countries. Primary, transactional, data is being kept up-to-date by the local HR and used for the global report.

The headcount includes any employee with a current work contract with Ipsen. Notably, external resources (temporary workers, trainees...) are excluded from headcount.

• Recruitments

Recruitments take into consideration employees coming from acquisitions (note there was no acquisition with personnel impact in 2021).

Regarding Joint Ventures, it must be noted that the Group HR policy does not apply to these entities and that no HR reporting is being requested from them. Therefore, all HR indicators mentioned in the universal registration document are shown without the Joint Ventures.

• Absenteeism

Absenteeism data are collected separately:

- For France, they are retrieved from the French payroll system,
- For other countries, they are collected from the HR manager.

At the end of 2021, this scope accounts for 90% of Ipsen's headcount.

• Training

Training activity is recorded in Ipsen Learning Platform by the owner of the training (Training Manager, HR...).

The evidence of the training duration is provided on this platform and/or by paper attendance signed sheets.

The training report is extracted at corporate level and all the collected data is consolidated into a common Excel file.

• Gender Equality Index (France)

The French "*Index de l'égalité professionnelle femmes-hommes*" measures gender pay gap with the following criteria:

- Gender pay gap,
- Distribution gap in individual increases,
- Distribution gap for promotions,
- Number of female employees increased on their return from maternity leave,
- Parity among the top 10 salaries.

• Engagement

Engagement rate is measured by running Company-wide surveys led every 2 years. In 2021, the provider was changed

and the questions asked were marginally amended to comply with the provider's and be able to benchmark. This change might have slightly impacted the overall results versus the previous campaign but there is no way to measure this impact.

• Human Rights

The assessment of the Third Parties was made through the Third Parties Due Diligence Platform live as of June 2019.

• Environment, Health and Safety (EHS)

Manufacturing and R&D sites include 7 manufacturing or production sites: Dreux (France), Dublin (Ireland), L'Isle-sur-la-Sorgue (France), Signes (France), Tianjin (China), Cambridge (USA) and Wrexham (United Kingdom), as well as 3 research and development (R&D) sites: Les Ulis (France), Cambridge (United States) and Oxford-Milton Park (United Kingdom).

Global Ipsen encompasses tertiary sites with a Human Resource representative, namely: Algeria, Germany, Switzerland, Austria, Australia, Czech Republic, Greece, Hungary, Poland, Romania, Mexico, the United States (Basking Ridge and Cambridge), France (Boulogne-Billancourt), Brazil, China, Korea, Taipei, Spain, Italy, Russia, Sweden and Nordics, Ukraine, Lithuania, Netherlands, Belgium, and Canada, the United Kingdom (Slough) and Vietnam.

Data collection is performed using an information system. The data is controlled and extracted from this central system, which possesses, means of control and alert (absurd data, problems of units...). This central system is a core training item for persons in charge of EHS on site in order to minimize the sources of errors.

The system has led to more accurate reporting. However, some parameters and KPI results have changed due to the improvement in data collection. It is nevertheless advisable to note that the extra-financial reporting does not benefit from the same maturity as the financial reporting. The practical modalities of data collection are still to be perfected, considering the diversity of Ipsen.

Further explanations are to be taken into account for the following indicators:

- Emission factors used to calculate Greenhouse Gas emissions are those of the Base Carbone ADEME and those provided by the IEA emission factors related to international electricity consumption.
- Renewable electricity data for 2021 is based on guarantees of origin or similar assurance structures built into Power Purchase Agreements (PPA). Previous years quantities were calculated according to supplier electricity mix information provided on invoices, regardless of contract terms.
- Car fleet data is split into business use (included in Scope 1) and non-business use of Company provided vehicle (included in Scope 3) in 2019 and 2021. Where available, the allocation of emissions is based on fuel payment data or mileage based compensation processes. Otherwise, the

split is determined based on primary use determination for each vehicle issued, e.g. Business need for sales force teams vs benefit vehicle primarily for personal use or commuting. Where primary use cannot be determined or quantified, emission are reported under scope 1.

- China is excluded from car fleet data. Ipsen does not have owned or leased fleet vehicles in China. Ipsen does not fund fuel payments nor does Ipsen offer mileage based compensation in China. A study has identified employees that may have a need to use personal vehicles in the course of their duties. These emissions are the estimated to be approximately 0.3% of Group Scope 1 emissions.
- Scope 3.1: Purchased Goods and Services emission factors are modeled based on product life cycle insights from studies, conducted in 2021, using 2019 production and sales data.
- Scope 3.7: Employee Commuting 2020 data are based on an internal estimation of the impact of the SARS-COV-2 health crisis on home-to-work travel: -50% for R&D and Manufacturing and -50% for office sites.

Health and safety indicators in particular for determining the accident frequency and severity rates include the following calculations:

- The frequency rate 1 (FR1) is the number of work related injuries that required an external medicalized treatment beyond first aid, with work lost time exceeding one day which have occurred over a period of 12 months per million hours worked (frequency rate 1 = number of medicalized injuries due to the work with lost time x 1,000,000 / number of hours worked).
- The frequency rate 2 (FR2) is the number of work related injuries requiring external medicalized treatment, beyond first aid, with work lost time exceeding one day and without work lost time which have occurred over a period of 12 months per million hours worked (frequency rate 2 = number of medicalized injuries due to the work with and without lost time x 1,000,000 / number of hours worked).
- The severity rate is the number of worker-days lost as a result of work related injury per thousand hours worked (severity rate = number of worker-days lost x 1,000 / number of hours worked).

The following table represents the approaches used to derive carbon emissions for Scopes 1, 2 and 3 included in the fight to prevent climate change section of the document.

| Scope | Categories | Description | Data sources | Emissions Factor sources |
|-------|---|--|--|---|
| 1 | Direct emissions from stationary combustion sources | Natural gas and fuel combustion (kWh) | R&D manufacturing and affiliates reporting | Base Carbone® |
| 1 | Direct emissions from mobile sources with combustion engine | Diesel, gasoline for business-related use | R&D manufacturing and affiliates reporting | Base Carbone® |
| 1 | Direct fugitive emissions | Refrigerant gas losses (tons) | R&D manufacturing reporting | Base Carbone® |
| 2 | Indirect emission from electricity consumption | Electricity consumption (kWh) | R&D manufacturing and affiliates reporting | IAE Highlights CO ₂ fossil fuels and Base Carbone for French sites |
| 2 | Indirect emission from steam, heat and cooling consumption | Steam and cooling consumption (kWh). Only one site is concerned | R&D manufacturing and affiliates reporting | Base Carbone® |
| 3 | Emissions due to fuels and energy (not covered by Scopes 1 and 2) | Upstream emissions from energy extraction and transportation (kWh), non-business use car fleet | R&D manufacturing and affiliates reporting | Base Carbone® |
| 3 | Purchased goods or services | Extraction and Manufacturing of raw materials such as paper, aluminum and excluding transportation | R&D manufacturing: Weight of every component of primary, secondary and tertiary packaging (tons) and modeled using an assessment conducted in 2021 together with 2019 production | Base Carbone® and CarbonEM methodology |
| 3 | Capital goods | As per ISO14064 & ISO/TR14069 For capital goods, such as IT equipment, the depreciation period is as per replacement period GHG Emissions due to the construction of buildings (industrial and offices) depreciation based on 50 years | R&D manufacturing and affiliates reporting Buildings (sqm) | Base Carbone® |



| Scope | Categories | Description | Data sources | Emissions Factor sources |
|-------|---|---|---|--------------------------|
| 3 | Upstream and downstream transportation and distribution | Road, Air, sea transportation of raw materials and final products from production site to first delivery local sites. Emissions are calculated on a well-to-wheel approach | Upstream: tons km from each site reporting Downstream: tons km from deliveries extraction | Base Carbone® |
| 3 | End of life treatment of waste generated from site operations | GHG Emissions due to the treatment of production waste (incineration, landfill, recycling) | R&D manufacturing Reporting (tons) | Base Carbone® |
| 3 | Business travels | GHG Emissions due to the car fleet consumption and plane travel; train travel and travel by taxi is not included but a first estimation concluded an insignificant contribution to Scope 3 emissions compared to other business travel modes covered in this report. Fugitive emissions (condensation trails) are not taken into account in the emissions factors of plane travel | Travel agency (km) and reporting on gasoline consumption (liters) | GHG Protocol |
| 3 | Employee commuting | GHG Emissions due to travels between working sites and employee's home excluding employee commuting using car fleet | Distances (km) estimated from average (French national survey (ENTD INSEE)). Employee Commuting 2020 data are based on an internal estimation of the impact of the SARS-COV-2 health crisis on home-to-work travel: -50% for R&D and Manufacturing and -75% for office sites | Base Carbone® |
| 3 | End-of-life treatment of sold products | GHG Emissions due to the treatment of packaging waste (including paper, aluminum, and plastic) after use of sold products (incineration, landfill, recycling) | Deliveries database (tons) and average waste treatment | Base Carbone® |

This is a free English translation of the report by one of the Statutory Auditors issued in French and is provided solely for the convenience of English-speaking readers. This report should be read in conjunction with, and construed in accordance with, French law and professional standards applicable in France.

Ipsen

Société anonyme:
65, Quai Georges Gorse –
92100 Boulogne-Billancourt

Report of one of the Statutory Auditors, appointed as independent third party, on the verification of the consolidated non-financial performance statement

Year ended December 31, 2021

To the Shareholders' Meeting,

In our capacity as Statutory Auditor of Ipsen (hereinafter the "Company"), appointed as independent third party ("third party") accredited by the French Accreditation Committee, COFRAC, under number 3-1048 (Cofrac Inspection Accreditation, no. 3-1048, scope available at www.cofrac.fr), and currently adapting our management system in the context of the evolution of the modalities of our accreditation required by the COFRAC (transition from ISO 17020 to ISO 17029), we have conducted procedures to express a limited assurance conclusion on the historical information (observed or extrapolated) in the consolidated non-financial performance statement, prepared in accordance with the Company's procedures (hereinafter the "Guidelines"), for the year ended December 31, 2021 (hereinafter the "Information" and the "Statement", respectively), presented in the Group management report pursuant to the legal and regulatory provisions of Articles L. 225-102-1, R. 225-105 and R. 225-105-1 of the French Commercial Code (*Code de commerce*).

Further to your request and beyond the scope of our accreditation by COFRAC, we also have conducted procedures to express a reasonable assurance conclusion on the fact that certain information, selected by the Company, has been prepared, in all material aspects, with the Guidelines.

Limited assurance conclusion on the Statement pursuant to article L. 225 102-1 of the French Commercial Code (*Code de commerce*)

Based on our procedures as described in the section "Nature and scope of procedures" and the evidence we have obtained, no material misstatements have come to our attention that cause us to believe that the non-financial performance statement does not comply with the applicable regulatory provisions and that the Information, taken as a whole, is not fairly presented in accordance with the Guidelines.



Reasonable assurance conclusion on selected information included in the Statement

In our opinion, the following information, selected by the Company, has been prepared, in all material aspects, in accordance with the Guidelines:

- Ipsen Manufacturing and R&D Medicalized Accidents with Lost Days (Frequency Rate 1 FR1)
- Ipsen Total Energy Normalized to Occupied Area (kWh/m²)
- Ipsen GHG Scopes 1 & 2 Emissions Normalized to Occupied Area (tCO₂E/m²)
- Ipsen Total Water Consumption Normalized to Occupied Area (m³/m²)

Preparation of the non-financial performance statement

The absence of a generally accepted and commonly used reference framework or established practices on which to base the assessment and measurement of the Information enables the use of different but acceptable measurement techniques that may impact comparability between entities and over time.

Accordingly, the Information must be read and interpreted with reference to the Guidelines, summarized in the Statement and available on the Company's website or on request from its headquarters.

Limits inherent in the preparation of the information relating to the Statement

The Information may be subject to uncertainty inherent to the state of scientific and economic knowledge and the quality of external data used. Some information is sensitive to the choice of methodology and the assumptions and/or estimates used for its preparation and presented in the Statement.

Responsibility of the Company

The Board of Directors is responsible for:

- selecting or determining the appropriate criteria for the preparation of the Information;
- preparing a Statement pursuant to legal and regulatory provisions, including a presentation of the business model, a description of the main non-financial risks, a presentation of the policies implemented with respect to these risks as well as the outcomes of these policies, including key performance indicators and the information set-out in Article 8 of Regulation (EU) 2020/852 (Green taxonomy);
- implementing such internal control as it determines is necessary to enable the preparation of Information that is free from material misstatement, whether due to fraud or error.

The Statement has been prepared by applying the Company's Guidelines as referred to above.

Responsibility of the Statutory Auditor appointed as independent third party

Based on our work, our responsibility is to express a limited assurance conclusion on:

- the compliance of the Statement with the requirements of Article R. 225-105 of the French Commercial Code;
- the fairness of the information provided pursuant to part 3 of sections I and II of Article R. 225-105 of the French Commercial Code, *i.e.* the outcomes of policies, including key performance indicators, and measures relating to the main risks, hereinafter the “Information.”

As it is our responsibility to issue an independent conclusion on the information prepared by management, we are not authorized to participate in the preparation of the Information, as this could compromise our independence.

It is not our responsibility to provide a conclusion on:

- the Company’s compliance with other applicable legal and regulatory provisions (particularly with regard to the information set-out in Article 8 of Regulation (EU) 2020/852 (Green taxonomy), the duty of vigilance and the fight against corruption and tax evasion);
- the fairness of information set-out in Article 8 of Regulation (EU) 2020/852 (Green taxonomy);
- the compliance of products and services with the applicable regulations.

Applicable regulatory provisions and professional guidance

We performed the work described below in accordance with Articles A. 225-1 *et seq.* of the French Commercial Code, the professional guidance issued by the French Institute of Statutory Auditors (*Compagnie nationale des commissaires aux comptes*) relating to this engagement and acting as the verification program and with ISAE 3000 (revised).

Independence and quality control

Our independence is defined by Article L. 822-11-3 of the French Commercial Code and French Code of Ethics for Statutory Auditors (*Code de déontologie*). In addition, we have implemented a system of quality control including documented policies and procedures aimed at ensuring compliance with applicable legal and regulatory requirements, ethical requirements and the professional guidance issued by the French Institute of Statutory Auditors (*Compagnie nationale des commissaires aux comptes*) relating to this engagement.

Means and resources

Our work engaged the skills of six people between December 2021 and February 2022 and took a total of ten weeks.

To assist us in conducting our work, we referred to our corporate social responsibility and sustainable development experts. We conducted around ten interviews with people responsible for preparing the Statement.

Nature and scope of procedures

We planned and performed our work taking account of the risk of material misstatement of the Information.

We consider that the procedures conducted in exercising our professional judgment enable us to express a limited assurance conclusion:

- We familiarized ourselves with the activities of all companies in the consolidation scope and the description of the principal risks;
- We assessed the suitability of the Guidelines with respect to their relevance, completeness, reliability, neutrality and clarity, taking into account, where appropriate, best practices within the sector;
- We verified that the Statement covers each category of information stipulated in section III of Article L. 225-102-1 governing social and environmental affairs;
- We verified that the Statement provides the information required under Article R.225-105 II of the French Commercial Code where relevant with respect to the principal risks, and includes, where applicable, an explanation for the absence of the information required under Article L.225-102-1 III, paragraph 2 of the French Commercial Code;
- We verified that the Statement presents the business model and a description of the principal risks associated with the activities of all the consolidated entities, including where relevant and proportionate, the risks associated with their business relationships, their products or services, as well as their policies, measures and the outcomes thereof, including key performance indicators associated to the principal risks;
- We referred to documentary sources and conducted interviews to:
 - assess the process used to identify and confirm the principal risks as well as the consistency of the outcomes, including the key performance indicators used, with respect to the principal risks and the policies presented, and
 - corroborate the qualitative information (measures and outcomes) that we considered to be the most important⁽¹⁾; for certain risks (Access to medicine), our work was carried out on the consolidating entity, while for other risks, our work was carried out on the consolidating entity and on a selection of entities;
- We verified that the Statement covers the consolidated scope, *i.e.* all companies within the consolidation scope in accordance with Article L. 233-16, with the limits specified in the Statement;
- We obtained an understanding of internal control and risk management procedures implemented by the Company and assessed the data collection process aimed at ensuring the completeness and fairness of the Information;
- For the key performance indicators and other quantitative outcomes⁽²⁾ that we considered to be the most important, we implemented:

(1) Access Accelerated initiative, introduction of CSR criteria in the Revolving Credit Facility.

(2) **HR and Health & Safety information:** Headcount, Share of women in the Global Leadership Team, Absenteeism rate (%), Number of recruitments, Turnover (%), Ipsen Manufacturing and R&D Severity Rate.

Environmental information: Carbon Scope 3 Total Emissions, Total Waste, Solvent Consumption.

Other non-financial information: % of employees having taken part in the Ipsen Community Day, Engagement index (%), Number of counterfeiting cases identified and reported to ANSM, Cases submitted in compliance with regulatory timelines (%), Completion rate of trainings on anti-corruption (%), Completion rate of trainings on the Code of Conduct (%), Anti-corruption: total number of due diligences conducted, Human Rights: Number of third parties assessed through the Business Ethics management program, First-time quality deviation (%), Batch Acceptance level (%), Rate of on-time CAPA closure (%).

- analytical procedures that consisted in verifying the correct consolidation of collected data as well as the consistency of changes thereto,
 - substantive tests, on a sample basis and using other selection methods, that consisted in verifying the proper application of definitions and procedures and reconciling data with supporting documents. These procedures were conducted for a selection of contributing entities⁽³⁾ and covered between 48% and 91% of the consolidated data selected for these tests;
- We assessed the overall consistency of the Statement in relation to our knowledge of the entire Company.

The procedures conducted in a limited assurance review are substantially less in scope than those required to issue a reasonable assurance opinion in accordance with the professional guidelines of the French National Institute of Statutory Auditors (*Compagnie Nationale des Commissaires aux Comptes, CNCC*); a higher level of assurance would have required us to carry out more extensive procedures.

Pursuant to your request, we have carried out additional procedures to express a reasonable assurance on the following information:

- Ipsen Manufacturing and R&D Medicalized Accidents with Lost Days (Frequency Rate 1 FR1)
- Ipsen Total Energy Normalized to Occupied Area (kWh/m²)
- Ipsen GHG Scope 1 & 2 Emissions Normalized to Occupied Area (tCO₂E/m²)
- Ipsen Total Water Consumption Normalized to Occupied Area (m³/m²)

We conducted work of the same nature as the work described above but in further detail, in particular:

- analytical procedures consisting in verifying the correct consolidation of the data collected as well as the consistency of their variation;
- detailed tests carried out on the basis of sample testing, consisting in verifying the correct application of definitions and procedures and reconciling the data with supporting documents.

The selected sample represents between 48% and 90% of the published data.

Paris-La Défense, February 16, 2022
One of the Statutory Auditors,

Deloitte & Associés

Frédéric Souliard
Partner, Audit

(3) Dreux, Dublin, Wrexham, L'Isle-sur-la-Sorgue.

[This page is intentionally left blank]

5

CORPORATE GOVERNANCE AND LEGAL INFORMATION

| | |
|---|------------|
| 5.1 FRAMEWORK FOR THE IMPLEMENTATION OF CORPORATE GOVERNANCE PRINCIPLES | 198 |
| 5.1.1 The AFEP-MEDEF Corporate Governance Code as a reference code | 198 |
| 5.1.2 Summary table of the AFEP-MEDEF Code recommendations which have not been applied | 198 |
| 5.1.3 Ethics of the Board of Directors and Executive Management | 199 |
| 5.2 GOVERNANCE STRUCTURE | 201 |
| 5.2.1 Guiding principles | 201 |
| 5.2.2 The Board of Directors | 205 |
| 5.3 EXECUTIVE MANAGEMENT | 234 |
| 5.3.1 Organization and modus operandi of the Executive Management | 234 |
| 5.3.2 Executive Management | 235 |
| 5.4 COMPENSATION OF CORPORATE OFFICERS | 238 |
| 5.4.1 Compensation policy of Corporate Officers | 238 |
| 5.4.2 Compensation of Corporate Officers (Articles L.22-10-34 I and L.22-10-9 I of the French Commercial Code) | 244 |
| 5.4.3 Comparative table of compensation of the Chairman and Chief Executive Officer with respect to other employees and put into perspective with the Company's performance | 255 |
| 5.4.4 Compensation paid or awarded in 2021 (Article L.22-10-34 II of the French Commercial Code) | 257 |
| 5.5 AUDITORS' SPECIAL REPORT ON REGULATED AGREEMENTS | 259 |
| 5.6 SHARE CAPITAL AND SHAREHOLDING | 260 |
| 5.6.1 Share capital | 260 |
| 5.6.2 Shareholding | 264 |
| 5.6.3 Main provisions of the Articles of association | 270 |



This section presents Ipsen S.A.'s Corporate governance and legal information and includes in particular the Board of Directors' Report on corporate governance. It will be presented to the Combined Shareholders' Meeting to be convened in 2022 to review and approve the financial statements for the financial year ended on 31 December 2021, in accordance with the provisions of Article L.22-10-10 4° of the French Commercial Code. It has been prepared with the assistance of the Executive Management, the Human Resources, Finance departments and the Company Secretary.

The Company is governed by a Board of Directors. It determines the Company's strategy and oversees its implementation in accordance with its corporate interest, taking into consideration the social and environmental issues of its activity. Subject to the powers expressly granted to Shareholders' Meetings and within the limits of the Company's corporate purpose, the Board of Directors considers all issues related to the efficient operation of the Company and, through its deliberations, settles all matters that may arise.

The Executive Management of the Company is provided by a Chief Executive Officer.

5.1 FRAMEWORK FOR THE IMPLEMENTATION OF CORPORATE GOVERNANCE PRINCIPLES

5.1.1 The AFEP-MEDEF Corporate Governance Code as a reference code

The Company refers to the AFEP-MEDEF Corporate Governance Code, revised on January 2020, available on the website www.afep.com. In accordance with the provisions of Article L.225-37-4 of the French Commercial Code, the Company specifies the recommendations of the Code which have not been applied and the reasons why.

5.1.2 Summary table of the AFEP-MEDEF Code recommendations which have not been applied

The Company presents a summary table of the recommendations of the AFEP-MEDEF Code that have not been adopted.

| AFEP-MEDEF recommendations not applied | Ipsen's practices and reasons why |
|--|--|
| Article 17.1 The Nomination Committee should have a majority of independent directors. | This provision is not being applied as the Company is controlled. Moreover, there are structural elements related to the Company's governance (number of independent directors (4), all of foreign nationalities and living outside of France, the number of specialized Committees (6), separation of the Compensation and Nomination Committees) to be taken into account. There is nevertheless ongoing high quality of work within each Committee (including the Nomination Committee) whilst maintaining a balanced composition of the Committees without having a majority of independent directors. Furthermore, the Board believes that both the quality and experience of independent members ensure open debate and that the current composition does not undermine the proper functioning of the Committee. |
| Article 18.1 The Compensation Committee should be chaired by an independent director and have a majority of independent directors. | This provision is not being applied as the Company is controlled. Moreover, two out of five members of the Compensation Committee are independent and one member representing the employees, so that the independence required to ensure its proper functioning is assured. Furthermore, it is specified that no executive officer is a member of this Committee. The Compensation Committee is chaired by Mr. Antoine Flochel, given his deep knowledge of the Group's operation, the pharmaceutical industry and his experience in matters of compensation. |

5.1.3 Ethics of the Board of Directors and Executive Management

In accordance with the provisions of European Commission delegated regulation No. 2019/980 supplementing Regulation (EU) 2017/1129 Delegated Regulation (EU) 2019/980 of 14 March 2019, in its current consolidated version of 17 September 2020, the Directors declared that they were subject to the obligations relating to their functions. In order to comply, the Company has put in place procedures applicable

to the Board members and Executive Management, some of which being set out below in this document.

■ 5.1.3.1 Prevention of conflicts of interest

The Internal Rules of the Board of Directors provide some procedures to prevent any conflict of interest situations as detailed herein below and in the present document.

Extract from the Internal Rules of the Board of Directors, as of 6 October 2021, relating to the prevention of conflicts of interest

"3.6.2 Conflicts of interest

Directors must act in all circumstances in the Company's interest.

Directors must inform the Board of any conflict of interest situation, including a potential conflict of interest, between themselves and the Company or the Group and shall abstain from attending the debate and taking part in any discussions and vote by the Board on the corresponding deliberations.

As part of its missions mentioned under paragraph 6.7.1, the Ethics and Governance Committee regularly reviews with the Board of Directors the issue of conflict of interest."

"6.4.4 Missions of the Audit Committee:

[...]

• examines and checks the rules and procedures applicable to conflicts of interest, expenses incurred by members of the management and the identification and measurement of the main financial risks, as well as their application and submits its

"6.7.1 The role of the Ethics and Governance Committee is to:

[...]

• examine situations of potential conflicts of interest of members of the Company's Board of Directors and communicate the results of its findings in accordance with an internal procedure which protects confidentiality;

• give a technical opinion - with regard to the rules of ethics and governance applied by the Group - on the mandates and functions performed outside the Group by the members of the Board of Directors, the Chief Executive Officer and, as the case may be, the Deputy Chief Executive Officers, at the time of their appointment and annually as part of the review of the information mentioned in the Report of Corporate Governance;

[...]

• give an opinion, in liaison with the Chairperson of the Board, on the list of independent directors of the Board of Directors when appointing a director and annually for all directors."

During 2021, in accordance with its missions, the Ethics and Governance Committee reviewed the proposals which had been made regarding the taking up of new offices by Piet Wigerinck and Marc de Garidel within companies outside of the Group and concluded that there was no conflict of interest.

In addition, as part of the annual review of conflicts of interest, members of the Board of Directors receive a questionnaire to be completed and returned to the Company for this purpose. After review by the Committee, no conflict of interest situations were identified within the Board.

■ 5.1.3.2 Insider Trading Policy

The Company has revised its Insider Trading Policy, in accordance with the European Market Abuse Regulation (EU Regulation No. 596/2014), in its current consolidated version of 1 January 2021 and the position-recommendation of the *Autorité des marchés financiers* (AMF) No. 2016-08 of 26 October 2016, modified on 29 April 2021, aimed at preventing insider trading and insider misconduct. More detailed information is provided in section 5.6.2.2 of this Document.

■ 5.1.3.3 Code of Conduct

The last version of the Ipsen Group's Code of Conduct has been updated in January 2021.

More detailed information about Ipsen Group's Code of Conduct, also adopted by the employees, can be found in Chapter 4 of this Document.

■ 5.1.3.4 Statement concerning the members of the Board of Directors and the Executive Management

Conflicts of interest involving governance and Executive Management bodies

To the best of the Company's knowledge and as of the date of publication of this Document:

- there is no conflict of interest between the duties of the members of the Board of Directors, Executive Management, and Company Officers vis-à-vis the Company and their personal interests and other duties;



- there is no undertaking or agreement with the main shareholders, clients, suppliers, or other parties pursuant to which one of the members of the Ipsen's Board of Directors and of the Executive Management of the Company has been appointed as Director;
- no Director or members of the Executive Management have entered into any agreement restricting the sale of their shareholding in the Company, at the exception, for the Company Officers, of the minimum portion of shares that must be held until his term of office.

The Executive Officers have signed a non-compete commitment to prevent certain situations of conflicts of interest arising when they leave the Group.

Absence of condemnation of the members of the Board of Directors and the Executive Management

To the Company's best knowledge, and as at the date of this Document, none of the members of the Board of Directors nor the Executive Management of the Company, have been over the last past five years:

- convicted of fraud, charged with any other offence or had any official public disciplinary action taken against them by statutory or regulatory authorities (including designated professional organizations);
- implicated in a bankruptcy, receivership or liquidation, placement under judicial administration while having served as a member of an administrative, management or supervisory body;
- disqualified from acting as a board member, senior executive or supervisory board member or from participating in the management or conduct of business of a listed company.

Service contracts with members of the Company's governing bodies

To the Company's best knowledge, there is no benefit provided under service contracts, involving directors or any member of the Board or of the Management and the issuing company or its subsidiaries.

Loans and guarantees granted to members of the Board

No loan or guarantee has been granted by the Company to any member of its Board of Directors or its Executive Management.

Specific terms for participating in Shareholders' Meetings

The specific terms for the participation of shareholders in the Annual Shareholders' Meeting are found in section 5.6.3.4 of this Document.

Factors likely to have an impact in the event of a public offer

The factors likely to have an impact in the event of a public offer are found in section 5.6.2.6 of this Document.

Delegations currently valid granted by the Shareholders' Meeting on capital increases

The delegations currently valid and having been granted by the Shareholders' Meeting regarding capital increases are found in section 5.6.1.4 of this Document.

5.2 GOVERNANCE STRUCTURE

5.2.1 Guiding principles

■ 5.2.1.1 Balanced governance structure

Ipsen is a French *société anonyme* with a Board of Directors, where the positions of Chairman and Chief Executive Officer are separated since 18 July 2016.

The separation of functions allows the Chief Executive Officer to focus on the Group's operations and the continuation of its transformation, while the Chairman of the Board of Directors can give his full attention to leading and managing the Board of Directors.

Chair of the Board of Directors

Marc de Garidel, Chairman and Chief Executive Officer until 18 July 2016, and Chairman of the Board of Directors from this date, was reappointed as Director by the Annual General Meeting of 28 May 2019, and as Chairman of the Board during the following Board meeting, which took place on the same day.

Executive Management

The Board of Directors of 28 May 2020, appointed David Loew as Chief Executive Office from 1 July 2020. David Loew was also coopted Director by the Board of Directors on 28 May 2020. The Shareholders' Meeting of 27 May 2021 ratified this temporary appointment and renewed his term of office as Director for a four-year term.

In accordance with the provisions of the Articles of association, if he wishes to do so, the Chief Executive Officer may propose to the Board of Directors to appoint one or several Deputy Chief Executive Officers in order to assist him.

■ 5.2.1.2 Diversity policy of the Board of Directors for its composition

The Nomination Committee and the Ethics and Governance Committee ensure the monitoring of a balanced composition of the Board of Directors and report on it. The objectives of the Board of Directors are to ensure the presence of independent members, in accordance with the AFEP-MEDEF Code recommendations, of the contribution of skills with regard to the Company's activity (particularly in management, strategy, science, finance and legal affairs), international experience, a balanced representation of women and men and a diversity of nationalities.

These two Committees consider each of these criteria when searching for future candidates and for every mandate renewal. During the 2021 financial year, this policy was implemented in connection with the succession of a director and the appointment of Karen Witts as a new independent director in January 2022.

In line with the Board of Directors' objectives regarding the desired balance, particularly in terms of diversity, the Board of Directors proposed the renewal and ratification of directors' appointments at the Shareholders' Meeting of 27 May 2021. For each expiring office term, the Board shall ensure the future balance of its composition.

The Board of Directors is as at the date of this document comprised of fourteen members, including six female (Anne Beaufour, permanent representative of Highrock S.à.r.l., Margaret Liu, Michèle Ollier, Karen Witts, Carol Xueref and Laetitia Ducroquet (Director representing the employees)⁽¹³⁾, and seven non-French nationals (Carol Xueref and Karen Witts, UK nationals, Margaret Liu and Paul Sekhri, U.S. nationals, Piet Wigerinck a Belgian national, Michèle Ollier, of French and Swiss nationality and David Loew, of Swiss nationality). The Board of Directors is comprised of four independent Directors and two directors representing the employees.

The competencies of the directors, as well as their biographies, showing the diversity of gender, experience and qualifications are listed in section 5.2.2.3 of this document.

⁽¹³⁾ Representing more than 40%, the Directors representing the employees not being taken into account in this calculation, pursuant to article L.225-18-1 of the French Commercial Code.

■ 5.2.1.3 Independence of the Board members

Extract from the Internal Rules of the Board of Directors, as of 6 October 2021, relating to the independence of the Board Members

"3.3 Independence of Directors

A Director is independent when he/she has no relationship of any kind whatsoever with the Company, its Group or the management that may interfere with his/her freedom of judgement. Accordingly, an independent Director is understood to be any non-executive Director of the Company or the Group who has no particular bonds of interest (significant shareholder, employee, other) with them.

Independent Directors should account for at least a third of Board members. Directors representing the employee shareholders and Directors representing employees are not taken into account when determining the percentage of independent Directors within the Board and the Committees.

The Board shall examine, upon recommendation of the Ethics and Governance Committee, at least once a year which Directors meet these independence criteria and shall report the conclusions of this review to shareholders (i) every year during the Shareholders' Meeting convened to approve the financial statements for the previous financial year and (ii) during Shareholders' Meetings convened to elect new Directors or ratify Directors co-opted by the Board.

Qualification as an independent Director should be discussed in the light of the AFEP-MEDEF Code criteria as follows:

- not to be and not to have been during the course of the previous five years:
 - an employee or executive Officer of the Company;
 - an employee, executive Officer of a company or a director of a company consolidated within the Company;
 - an employee, executive Officer or a director of the Company's parent company or a company consolidated within this parent;
- not to be an executive Officer of a company in which the Company holds a directorship, directly or indirectly, or in which an employee appointed as such or an executive Officer of the Company (currently in office or having held such office during the last five years) is a director;
- not to be a customer, supplier, commercial banker or investment banker or consultant (or be linked directly or indirectly to these persons):
 - that is material to the Company or its Group;
 - or for a significant part of whose business the Company or its Group accounts.

The evaluation of the significant or non-significant relationship with the Company or its Group must be debated by the Board and the quantitative criteria that lead to the evaluation (continuity, economic dependence, exclusivity, etc.) must be explicitly stated in the corporate governance report;

- not to be related by close family ties to a company Officer;
- not to have been an auditor of the Company within the previous five years;
- not to have been a director of the Company for more than twelve years. Loss of the status of independent director occurs on the date at which this period of twelve years is reached.

A non-executive Officer cannot be considered independent if he/she receives variable compensation in cash or in the form of shares or any compensation linked to the performance of the Company or Group or receives compensation of any kind from shareholders involved in the control of the company, or their holdings companies.

Directors representing major shareholders of the Company or their holding companies may be considered independent if such shareholders do not participate in the control of the Company. Above the threshold of 5% of the share capital or voting rights, these directors are presumed to be non-independent unless the Board of Directors decides otherwise upon recommendation of the Ethics and Governance Committee. Below this threshold (and excluding any holding obligation imposed on Directors by the Internal Board Rules), the Board, upon a report from the Ethics and Governance Committee, systematically reviews the qualification of independence, taking into account the composition of the Company's share capital and the existence of a potential conflict of interest."

At its meeting of 10 February 2022, the Board of Directors, upon an Ethics and Governance Committee proposal, deemed that:

- Margaret Liu, Karen Witts, Paul Sekhri and Piet Wigerinck are independent directors as defined by the AFEP-MEDEF Code and the Internal Rules of the Board of Directors described above. The other members of the Board of Directors are related to a shareholder of the Company or

hold management or employee positions in the Company. Anne Beaufour and Henri Beaufour are also brother and sister. There are no other family ties between the other members of the Board of Directors and/or the General Management of the Company;

- there is no business relationship between the members of the Board of Directors and the Company.

The detail of the current independence criteria evaluation is as follows:

| Independence criteria (*) | Not to be and not to have been during the course of the previous five years an employee or executive Officer of the Company; an employee, executive Officer of a company or a director of a company consolidated within the Company; an employee, executive Officer or a director of the Company's parent company or a company consolidated within this parent | Not to be an executive Officer of a company in which the Company holds a directorship, directly or indirectly, or in which an employee appointed as such or an executive Officer of the Company (currently in office or having held such office during the last five years) is a director | Not to be a customer, supplier, commercial banker or investment banker or consultant (or be linked directly or indirectly to these persons) | Not to be related by close family ties to a company Officer | Not to have been an auditor of the Company within the previous five years | Not to have been a director of the Company for more than twelve years |
|--|--|---|---|---|---|---|
| Directors | | | | | | |
| Marc de Garidel | Marc de Garidel has been Chairman and Chief Executive Officer until 18 July 2016. He is Chairman of the Board of Directors since this date. | – | – | – | – | – |
| Antoine Flochel | Antoine Flochel is Vice Chairman of the Ipsen S.A. Board, Chairman and Managing Director of Beech Tree S.A. and Managing Partner of MR BMH, direct shareholders of Ipsen S.A. | – | – | – | – | – |
| Highrock S.à.r.l. (represented by Anne Beaufour) | Highrock S.à.r.l. is a direct shareholder of Ipsen S.A. | – | – | Anne Beaufour is the permanent representative of Highrock S.à.r.l., member of the Board of Ipsen S.A. Anne and Henri Beaufour are brother and sister. | – | – |
| Henri Beaufour | Henri Beaufour is the sole shareholder of Beech Tree S.A., member of the Board of Directors of Ipsen S.A. and direct shareholder of Ipsen S.A. | – | – | Henri and Anne Beaufour are brother and sister. | – | – |
| Beech Tree S.A. (represented by Philippe Bonhomme) | Beech Tree S.A. is a direct and indirect shareholder of Ipsen S.A. | – | – | – | – | – |
| Laetitia Ducroquet | Laetitia Ducroquet is an employee of Ipsen Pharma S.A.S., a subsidiary wholly owned by Ipsen S.A., as Vice President Business Ethics Global Internal & Third Parties programs. | – | – | – | – | – |
| Margaret Liu | – | – | – | – | – | – |
| David Loew | David Loew is CEO of the Company since 1 July 2020. | – | – | – | – | – |
| Michèle Ollier | Michèle Ollier is closely linked to Highrock S.à.r.l., direct shareholder of Ipsen S.A. | – | – | – | – | – |
| Jean-Marc Parant | Jean-Marc Parant is an employee of Ipsen Pharma S.A.S., a subsidiary wholly owned by Ipsen S.A., as Head of Digital Learning Solutions. | – | – | – | – | – |
| Paul Sekhri | – | – | – | – | – | – |
| Piet Wigerinck | – | – | – | – | – | – |
| Karen Witts | – | – | – | – | – | – |
| Carol Xueref | Carol Xueref is closely linked to Highrock S.à.r.l., direct shareholder of Ipsen S.A. | – | – | – | – | – |

(*) The criterion of non-executive officer cannot receive a variable compensation and/or a compensation linked to the performance of the Company or Group is not presented in the table as only the executive officers receive such compensation. The significant shareholder criterion is also not presented in the table as the links with the major shareholders are mentioned above and as there is no representative of any other significant shareholder at the Board of Directors. For more information on share ownership, please refer to section 5.6.2 of the present Document.

■ 5.2.1.4 Employee representation at the Board of Directors

Extract from the Internal Rules of the Board of Directors relating to the employee representation at the Board of Directors

“ 3.7 Employee representation on the Board of Directors

The Board of Directors includes one or two Directors representing the employees.

Pursuant to Article 12 of the Articles of Association of the Company:

- *If the Ipsen S.A. Board of Directors is comprised of eight (8) members or fewer, the designation of a single employee representative is required.*

The Director representing the employees will be appointed by the Works Council of the existing economic and social unit within the Ipsen Group.

- *If the Board of Directors is comprised of more than eight (8) members, the designation of a second employee representative is required.*

The second Director representing the employees will be appointed by the European Works Council.

The office of Director representing the employees shall be incompatible with any office of trade union representative or with any office in one of the employee representative institutions listed in Article L.225-30 of the French Commercial Code.

Subject to the specific legal provisions applicable to them, the Directors representing the employees have the same rights, shall be bound by the same rules, especially with respect to confidentiality, and shall incur the same liability as other Board members.

They are bound by all the provisions of the Internal Rules of the Board of Directors, with the exception of those relating to the obligation to own any share in the Company. The Directors representing the employees will not be paid as part of their mandate.

The time dedicated to his/her mandate by the Director representing the employees is considered as effective working time and is remunerated by the compensation paid for his/her employment contract with the Company. He/she shall dedicate the time and attention required to fulfill the duties of his/her mandate, up to a maximum of 30% of his/her time paid by the Company.

In order to develop his/her skills and knowledge, the director representing the employees also receives, at his/her request, training suited to the exercise of his/her office of 40 hours of training a year.”

Jean-Marc Parant has been designated as director representing the employees by decision of the Central Works Council on 27 November 2018, noted by the Board of Directors on 13 December 2018. He is member of the Ethics and Governance Committee from 28 May 2019.

In accordance with the French Legislation n° 2019-486 of 22 May 2019 (PACTE Law), the Shareholders' Meeting of 29 May 2020 proceeded to the modification of the Articles of association regarding the threshold giving the obligation to appoint a second director representing the employees at the Board of Directors, threshold modified by the law from twelve members of the Board to eight. It was therefore

planned that a second director representing the employees will be designated by the European Works Council within 6 months from the modification of the Articles of association.

In this context, the European Works Council appointed Laetitia Ducroquet as second director representing the employees on 6 November 2020. The Board of Directors held on 19 November 2020 took note of this appointment. The Board of Directors also appointed her as member of the Compensation Committee on 27 May 2021, upon proposal of the Nomination Committee.

See the biographies below under section 5.2.2.3 hereafter.

5.2.2 The Board of Directors

■ 5.2.2.1 Chairman of the Board of Directors

Extract from the Internal Rules of the Board of Directors, as of 6 October 2021, relating to the Chairman of the Board

“Article 2.1 The Chairperson of the Board of Directors

The Chairperson organizes and directs the work of the Board and ensures the effective functioning of the corporate bodies in compliance with good governance principles. He/she coordinates the work of the Board with that of the Committees.

He/she ensures that the Directors are able to fulfill their mission and shall particularly ensure that they have all of the information they require to fulfill their mission.

The Secretary of the Board reports to the Chairperson. He assists the Chairperson in organizing the meetings of the Board, and fulfilling any other assignments linked to the corporate governance rules applicable to the Company.

The Chairperson reports each year the work of the Board of Directors to the Shareholders’ Meeting on the basis of the annual Corporate Governance Report approved by the Board.

The Chairperson may be in contact with the Statutory Auditors to prepare the work of the Board.

The Chairperson fulfills the following specific missions:

- *he/she may represent the Company, in cooperation with the Chief Executive Officer and at the request solely of the latter, in its high-level relations, on a national and international level, especially with the public authorities, the Group’s main partners and other strategic stakeholders of the Company;*
- *he/she may, without prejudice to the prerogatives of the Board of Directors and its Committees, be consulted by the Chief Executive Officer regarding any significant events related to the Company’s strategy and major growth projects.*

The Chairperson may attend all of the meetings of the Committees of which he is not a member in an advisory capacity and may consult them on any issue within their area of competence.

In all of these specific missions, the Chairperson acts in close coordination with the Chief Executive Officer and at the request of the latter who will solely be in charge of the leadership and operational management of the Group (subject to limitations of powers expressly decided by the Board of Directors).”

During the 2021 financial year, the Chairman of the Board of Directors organized and managed the work of thirteen Board meetings, assisted by the Vice Chairman in compliance with the Internal Rules of the Board of Directors. Before each meeting of the Board, the Chairman discussed with each Director the documents previously sent. He ensured the follow-up of the decisions taken, in connection with the management and informed absent director, as the case may be.

The Chairman of the Board is also the Chairman of the Innovation and Development Committee – Specialty Care and of the Innovation and Development Committee Consumer HealthCare, the two Committees in charge of the strategy and the two main activities of the Group. In this capacity, he prepared and led the five meetings of the Innovation and Development Committee – Specialty Care and the ten meetings of the Innovation and Development Committee – Consumer HealthCare. He coordinated the work of these Committees with that of the Board.

The Chairman of the Board also participated with the Nomination Committee in the choice of Karen Witts, independent director, co-opted by the Board of Directors on 20 January 2022. In addition, during the Shareholders’

Meeting of 27 May 2021, he presented the composition, organization and functioning of the Board of Directors, the activity of the Board and the Committees during financial year 2020, as well as the Directors whose appointment has been ratified and the renewal proposed.

■ 5.2.2.2 Members of the Board of Directors

Directors are appointed for a four-year term. Exceptionally and exclusively in order to enable the staggering of Directors’ terms of office to be implemented and maintained, the Ordinary Shareholders’ Meeting may appoint one or several directors for one year, two years or three years.

The number of Directors more than 70 years old cannot be higher than one-third of the Directors in office. When this age limit is exceeded, the oldest Director is automatically deemed to have resigned at the end of the following Ordinary Shareholders’ Meeting.

Duties of Directors come to an end upon the conclusion of the Ordinary Shareholders’ Meeting called to approve the financial statements for the previous financial year which is held in the year in which the term of office of the said Director expires. Incumbent Directors may always be re-elected.

Extracts from the Internal Rules of the Board of Directors, as of 6 October 2021, relating to the Directors**“3.1 Attendance**

Every Director shall dedicate the time and attention required to discharge the duties of his/her mandate and attend the meetings of the Board and the Committee(s) of which they are a member. The corporate governance report lists the mandates held by members of the Board of Directors and records their individual attendance at Board and Committee meetings.”

“3.2 Skills

3.2.1 The Board shall be comprised of Directors chosen because of their competence and their experience with respect to the Company and the Group’s operations.

3.2.2 Board members may attend training sessions on specific areas of the Company, its business line(s) and industrial sector and the consequences of its social and environmental risks that are to be arranged on the Company’s own initiative or at the request of the Board.”

“3.6.1 Knowledge of rights and obligations / Responsibilities

Before accepting office, each Director should ensure he/she is familiar with any general or specific obligations relating to his/her position. In particular, they ought to acquaint themselves thoroughly with the legal provisions governing the Company, its Articles of Association, and provisions of the Internal Rules of the Board which apply to them.

3.6.2 Conflicts of interest

Directors must act in all circumstances in the Company’s interest.

Directors must inform the Board of any conflict of interest situation, including a potential conflict of interest, between themselves and the Company or the Group and shall abstain from attending the debate and taking part in any discussions and vote by the Board on the corresponding deliberations.

As part of its missions mentioned under paragraph 6.7.1, the Ethics and Governance Committee regularly reviews with the Board of Directors the issue of conflict of interest.

Each Director must report his/her activities to the Ethics and Governance Committee on an annual basis for review and recommendation to the Board of Directors.

3.6.3 Vigilance

Directors are required to contribute to the determination of the orientations of the business of the Company and the Group and to supervise their implementation. They must exercise an effective and vigilant oversight of the Company’s and Group’s management.

3.6.4 Confidentiality

Directors have a general duty of discretion and confidentiality as regards the deliberations of the Board and its Committees. The same applies to all non-public information and documents provided to them at meetings or otherwise in connection with their functions as Board or Committee members or their participation in their deliberations. This duty of discretion and confidentiality shall continue to apply even after the end of the term of office.”

“3.6.7 Number of Directorships of Company officers and Directors

[...] With respect to corporate offices in listed companies, and without prejudice to the general legal rules applicable to the total number of corporate offices, an Executive officer of the Company should not hold more than two other directorships in listed companies, including foreign companies, not affiliated with his/her group. He/she must also seek the prior approval of the Board, after examination by the Ethics and Governance Committee, before accepting a new directorship.

A Director should not hold more than four other directorships in non-Group listed companies, including foreign companies. The Director must keep the Board informed of the offices and positions held in other companies.

The non-executive Chairman must also obtain the opinion of the Board, after examination by the Ethics and Governance Committee, before accepting a new corporate office.”

Board members in office as of the filing of this document

| Name | Function | Nationality | Gender | Age | Date of first appointment | Date of last renewal | End of term of office | Independence | Committee membership |
|---------------------------|---|--------------|--------|-----|-----------------------------------|----------------------|----------------------------|--------------|--|
| Marc de Garidel | Chairman of the Board of Directors | French | M | 64 | 11/10/2010 with effect 22/11/2010 | 28/05/2019 | ASM 2023 | No | <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Chairman) Innovation and Development Committee – Consumer HealthCare (Chairman) |
| Antoine Flochel | Vice Chairman ⁽¹⁾ and Director | French | M | 57 | 30/08/2005 | 27/05/2021 | ASM 2025 | No | <ul style="list-style-type: none"> Compensation Committee (Chairman) Innovation and Development Committee – Specialty Care |
| Highrock S.à.r.l. | Director | Luxembourg | – | – | 06/01/2020 | N/A | ASM 2022 ⁽²⁾ | No | <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (Permanent guest) |
| Anne Beaufour | Permanent representative of Highrock S.à.r.l. | French | F | 58 | 06/01/2020 | N/A | ASM 2022 | – | See Highrock S.à.r.l. above |
| Henri Beaufour | Director | French | M | 57 | 30/08/2005 | 28/05/2019 | ASM 2023 | No | <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (Permanent guest) |
| Beech Tree S.A. | Director | Luxembourg | – | – | 06/01/2020 | N/A | ASM 2024 | No | <ul style="list-style-type: none"> Audit Committee Nomination Committee Ethics and Governance Committee Innovation and Development Committee – Consumer HealthCare |
| Philippe Bonhomme | Permanent representative of Beech Tree S.A. | French | M | 52 | 06/01/2020 | N/A | ASM 2024 | – | See Beech Tree S.A. above |
| Laetitia Ducroquet | Director representing the employees | French | F | 42 | 06/11/2020 | N/A | ASM 2024 ⁽³⁾ | No | <ul style="list-style-type: none"> Compensation Committee |
| Margaret Liu | Independent Director | American | F | 65 | 07/06/2017 | 27/05/2021 | ASM 2025 | Yes | <ul style="list-style-type: none"> Ethics and Governance Committee (Chairperson) Innovation and Development Committee – Specialty Care Innovation and Development Committee – Consumer HealthCare |
| David Loew ⁽⁴⁾ | Chief Executive Officer and Director | Swiss | M | 55 | 28/05/2020 | 27/05/2021 | ASM 2025 | No | <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (Permanent guest) |
| Michèle Ollier | Director | French-Swiss | F | 63 | 27/05/2015 | 28/05/2019 | ASM 2023 | No | <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care |
| Jean-Marc Parant | Director representing the employees | French | M | 62 | 27/11/2018 | N/A | ASM 2022 ⁽³⁾⁽⁵⁾ | No | <ul style="list-style-type: none"> Ethics and Governance Committee |
| Paul Sekhri | Independent Director | American | M | 63 | 30/05/2018 | N/A | ASM 2022 ⁽²⁾ | Yes | <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care Audit Committee Nomination Committee |
| Piet Wigerinck | Independent Director | Belgian | M | 57 | 30/05/2018 | N/A | ASM 2022 ⁽²⁾ | Yes | <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care Compensation Committee |
| Karen Witts | Independent Director | British | F | 58 | 20/01/2022 ⁽⁶⁾ | N/A | ASM 2025 | Yes | <ul style="list-style-type: none"> Audit Committee (Chairperson) Compensation Committee |
| Carol Xueref | Director | British | F | 66 | 01/06/2012 | 29/05/2020 | ASM 2024 | No | <ul style="list-style-type: none"> Nomination Committee (Chairperson) Compensation Committee Innovation and Development Committee – Consumer HealthCare Ethics and Governance Committee |

- (1) The Vice-Chairman of the Board did mainly participate in the preparation of the 13 Board meetings. He also reviewed the documents and information made available to Directors before the Board's convening.
- (2) The renewal of the office will be submitted to the 2022 Shareholders' Meeting.
- (3) In accordance with the provisions of Article 12 of the Articles of association, directors representing the employees are appointed for a term of four years expiring at the end of the Shareholders' Meeting called to approve the financial statements for the previous financial year and held in the year during which the term of office expires.
- (4) The ratification of his cooptation and the renewal of the office as director were approved by the Shareholders' Meeting of 27 May 2021.
- (5) The office of the Director representing the employees expires at the end of the 2022 Shareholders' Meeting. A nomination process will be conducted by the Central Social and Economic Committee prior to this meeting.
- (6) Karen Witts, independent director, was appointed by the Board of Directors on 20 January 2022, to replace Carol Stuckley, who resigned. A proposal will be made to the Shareholders' Meeting to be held in 2022 to ratify this appointment for the remaining term of office of her predecessor, which will expire at the 2025 Shareholders' Meeting.

The offices of one director has been ratified and four offices renewed as part of the Shareholders' Meeting of 27 May 2021:

- David Loew was ratified and renewed as a director by the Shareholders' Meeting of 27 May 2021, *i.e.* until the end of the Shareholders' Meeting to be held in 2025 called to approve the accounts for the past financial year.
- Antoine Flochel, Margaret Liu and Carol Stuckley were renewed as directors by the Shareholders' Meeting of 27 May 2021 for a duration of four years, *i.e.* until the Shareholders' Meeting to be held in 2025 to approve the financial statements for the past financial year.

Evolution of the Board composition


| | Nature of the change |
|---|---|
| Combined Shareholders' Meeting of 27 May 2021 | Ratification of the temporary appointment of David Loew as Director, in replacement of David Meek further to his resignation, and renewal of his term of office as Director. Renewal of the term of office of Antoine Flochel, Margaret Liu and Carol Stuckley as Directors. |
| Board of Directors of 27 May 2021 | Appointment of Laetitia Ducroquet as member of the Compensation Committee. |
| Board of Directors of 28 July 2021 | Appointment by anticipation of Paul Sekhri as Chairman of the Audit Committee, replacing Carol Stuckley, in the context of her resignation effective August 2021. |
| Board of Directors of 31 August 2021 | Appointment of Margaret Liu as a member of the Innovation and Development Committee - Consumer HealthCare. |
| Board of Directors of 20 January 2022 | Appointment of Karen Witts as director, replacing Carol Stuckley, for the remaining term of her office. |
| Board of Directors of 10 February 2022 | Appointment of Karen Witts as Chairperson of the Audit Committee and as member of the Compensation Committee. |

There are currently fourteen Board members, four of whom are independent, and two are Directors representing the employees. Of the fourteen members, six are female, eight are male ; seven are of French nationality and seven are foreign directors.

■ 5.2.2.3 Experienced, qualified and committed Board members

The skills of the Directors are varied and complementary with respect to the Company's business, particularly in the areas of management and strategy, science, pharmaceuticals, legal, regulation, corporate social responsibility, digital and technology.

Competencies and experiences of the Board of Directors of Ipsen S.A.



Experiences and qualifications of the Board members in office on the date of this document

| | | |
|--|--|--|
| Marc de Garidel Chairman of the Board of Directors | Nationality: French | Shares owned: 138,501 Voting rights: 277,002 |
| Committees: <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Chairman) Innovation and Development Committee – Consumer HealthCare (Chairman) Date of birth: 16 March 1958 | Biography and experience | |
| Date of 1st appointment: 22 November 2010 | <p>Marc de Garidel joined Ipsen as Chairman and Chief Executive Officer in November 2010. He has been the Ipsen Chairman of the Board of Directors since July 2016. Marc de Garidel is Chief Executive Officer and Director of CinCor Pharma Inc. since July 2021. He was previously Chief Executive Officer and Director of AZTherapies between 1 October 2020 and 6 May 2021. He was before that Chief Executive Officer and Director of Corvidia Therapeutics, Inc. which was sold to Novo Nordisk in July 2020. Marc de Garidel started his career with the group Eli Lilly and pursued at Amgen, from 1995 to 2010, with increasing responsibility positions in the U.S. and Europe. Marc de Garidel is Director of Claris Biotherapeutics since July 2020. Previously, he was Director of several biotechnology companies, including Vice Chairman of the Board of Directors of Vifor Pharma (Switzerland) between May 2017 and 2018 (formerly Galenica), of which he was member of the Board since 2015. Marc de Garidel is a graduate from the French Engineering School ESTP and has an Executive MBA from Harvard Business School.</p> | |
| Last renewal date: 28 May 2019 | Positions and functions currently held | |
| Term of office: 2023 Shareholders' Meeting | Within the Ipsen Group or its main shareholders: <p>Listed company:</p> <ul style="list-style-type: none"> Ipsen S.A. (France), Chairman of the Board of Directors <p>Non listed company:</p> <ul style="list-style-type: none"> Highrock S.à.r.l. (Luxembourg), advisor Beech Tree S.A. (Luxembourg), advisor | Outside the Ipsen Group or its main shareholders: <p>Listed company:</p> <p>None</p> <p>Non listed company:</p> <ul style="list-style-type: none"> CinCor Pharma, Inc. (USA), Chief Executive Officer and Director Claris Biotherapeutics, Inc. (USA), Director |
| Positions previously held that expired during the last five years | | |
| <ul style="list-style-type: none"> Vifor Pharma GmbH (formerly Galenica) (Switzerland), Director and Vice President of the Board of Directors Vifor (formerly Galenica) (France), Director G5 Santé (France), Chairman and spokesperson Filière des Industries et Technologies de Santé (France), Vice President of the Strategic Committee Vectorlab GmbH (Switzerland), Chairman Ipsen SA (France), Chairman and Chief Executive Officer until 18 July 2016 Ipsen Pharma SAS (France), Chairman Suraypharm SAS (France), Chairman Mayroy SA (Luxembourg), advisor Corvidia Therapeutics, Inc. (USA), Chief Executive Officer and director AZTherapies, Inc. (USA), Chief Executive Officer and director | | |



| | | | |
|--|---|--|--|
| Antoine Flochel Vice Chairman of the Board of Directors | | Nationality: French | Shares owned: 5,000 * Voting rights: 10,000 * |
| Committees: <ul style="list-style-type: none"> • Compensation Committee (Chairman) • Innovation and Development Committee – Specialty Care Date of birth: 23 January 1965 | Biography and experience | | |
| | Antoine Flochel is currently the Managing Partner of Financière de Catalogne (Luxembourg) and Vice-Chairman of Ipsen S.A.'s Board of Directors. He is Chairman of the Board of Directors and Managing Director for day-to-day management of Beech Tree S.A., and Managing Director of MR BMH. | | |
| | Date of 1st appointment: 30 August 2005 | | |
| | Last renewal date: 27 May 2021 | | |
| Term of office: 2025 Shareholders' Meeting | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: | Outside the Ipsen Group or its main shareholders: | |
| | Listed company: <ul style="list-style-type: none"> • Ipsen S.A. (France), Vice Chairman of the Board of Directors | Listed company: None | |
| | Non listed company: <ul style="list-style-type: none"> • Beech Tree S.A. (Luxembourg), Chairman of the Board of Directors and Managing Director for day-to-day management • MR BMH (Luxembourg), Managing Partner | Non listed company: <ul style="list-style-type: none"> • Financière de Catalogne SPRL (Luxembourg), Managing Partner • Bluehill Participations S.à.r.l. (Luxembourg), Managing Partner • KF Finanz AG (Switzerland), Director • Financière CLED SPRL (Belgium), Managing Partner • Meet Me Out (France), Director • Massa Management (Luxembourg), Managing Partner | |
| Positions previously held that expired during the last five years | | | |
| <ul style="list-style-type: none"> • Alma Capital Europe SA (Luxembourg), Director* • Alma Capital Investment Funds SICAV (Luxembourg), Director* • Alma Capital Investment Managers (Luxembourg), Director* • Lepe Capital (UK), Member of the Investment Advisory Committee* • Mayroy SA (Luxembourg), Managing Director and Chairman of the Board • MR HB (Luxembourg), Managing Partner • Institut Français des Administrateurs, IFA (France), Director • VicJen Finance SA (France), Chairman | | | |

* Antoine Flochel is Managing Partner of Financière CLED SPRL which held 2,000 shares of the Company and 4,000 voting rights as of 31 December 2021, following the merger of VicJen Finance SA. He is also Managing Partner of Financière de Catalogne, which held 3,000 shares of the Company and 6,000 voting rights at the same date.

| | | |
|--|---|--|
| Highrock S.à.r.l. Director | Nationality: Luxembourg | Shares owned: 21,816,679 * Voting rights: 43,633,357 * |
| Committees: <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (Permanent guest) Date of 1st appointment: 6 January 2020 Term of office: 2022 Shareholders' Meeting ** | Biography and experience | |
| | <p>Highrock S.à.r.l. is a limited liability company under Luxembourg law incorporated on 25 May 2009. Since 19 December 2019, Highrock S.à.r.l. has been a shareholder of Ipsen S.A. Registered office: 9B, boulevard Prince Henri – L-1724 Luxembourg. RCS Luxembourg B146822.</p> <p>As of 31 December 2021, it held 21,816,679 shares, <i>i.e.</i> 26.03% of the share capital, and 43,633,357 voting rights, <i>i.e.</i> 33.36% of the actual voting rights. Anne Beaufour is the permanent representative of Highrock S.à.r.l.</p> | |
| Anne Beaufour Permanent representative of Highrock S.à.r.l. | Nationality: French | Shares owned: 1 * Voting rights: 2 * |
| Committees: <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (Permanent guest) Date of birth: 8 August 1963 | Biography and experience | |
| | <p>Anne Beaufour holds a Bachelor's degree in geology (University of Paris Orsay). Anne Beaufour is the shareholder of several companies, as described in section 5.6.2.1, which directly and/or indirectly hold shares of the Company.</p> | |
| | Positions and functions currently held | |
| | Within the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> Ipsen S.A. (France), Permanent representative of Highrock S.à.r.l. (Luxembourg) on the Board of Directors Non listed company: <ul style="list-style-type: none"> Highrock S.à.r.l. (Luxembourg), Manager | Outside the Ipsen Group or its main shareholders: Listed company: None Non listed company: <ul style="list-style-type: none"> South End Consulting Limited (SEC Ltd) (UK), Director CBA Estates Ltd (UK), Director |
| Positions previously held that expired during the last five years | | |
| <ul style="list-style-type: none"> FinHestia S.à.r.l. (Luxembourg), Legal Manager Mayroy SA (Luxembourg), Vice Chairperson of the Board of Directors and Managing Director Beech Tree S.A. (Luxembourg), Director and Chairperson of the Board of Directors Bluehill Participations S.à.r.l. (Luxembourg), Manager | | |

* The shareholding is described in section 5.6.2.1.

** The renewal of the office will be submitted to a vote at the next 2022 Shareholders' Meeting.



| | | | |
|--|--|--|---|
| Henri Beaufour Director | | Nationality: French | Shares owned: 1 * Voting rights: 2 * |
| Committees: <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (Permanent guest) Date of birth: 6 January 1965 Date of 1st appointment: 30 August 2005 Last renewal date: 28 May 2019 Term of office: 2023 Shareholders' Meeting | Biography and experience | | |
| | Henri Beaufour holds a Bachelor of Arts degree (Georgetown University, Washington DC, USA). Henri Beaufour is the shareholder of several companies which directly and/or indirectly hold shares of the Company (see the section 5.6.2.1). Henri Beaufour is also involved in philanthropic activities, in particular children's support associations helping young persons to have access to appropriate education, such as the Alasol Foundation. | | |
| | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> Ipsen S.A. (France), Director Non listed company: <ul style="list-style-type: none"> Beech Tree S.A. (Luxembourg), Director | Outside the Ipsen Group or its main shareholders: Listed company: None Non listed company: <ul style="list-style-type: none"> Massa Management SARL (Luxembourg), Partner and Legal Manager Massa Art SAS (France), Chairman Massa Management SwissCo Sarl (Switzerland), Partner, Legal Manager and Chairman | |
| Positions previously held that expired during the last five years | | | |
| <ul style="list-style-type: none"> Mayroy SA (Luxembourg), Director | | | |

* The indirect shareholding is described in section 5.6.2.1.

| | | |
|--|---|--|
| Beech Tree S.A. Director | Nationality: Luxembourg | Shares owned: 21,816,679 * Voting rights: 43,633,357 * |
| Committees: <ul style="list-style-type: none"> • Audit Committee • Nomination Committee • Ethics and Governance Committee • Innovation and Development Committee – Consumer HealthCare | Biography and experience | |
| Date of 1st appointment: 6 January 2020 | Beech Tree S.A. is a limited company under Luxembourg law, incorporated in 2001. Beech Tree S.A. is a direct and indirect shareholder of Ipsen S.A. Registered office: 11, Boulevard Royal – L-2449 Luxembourg. RCS Luxembourg B85327. As of 31 December 2020, it held directly 8,310,253 shares and 16,620,505 voting rights, and indirectly 13,506,426 shares and 27,012,852 voting rights through its subsidiary MR BMH, that it controls, <i>i.e.</i> 26.03% of the share capital and 33.36% of the net voting rights. Philippe Bonhomme is the permanent representative of Beech Tree S.A. | |
| Term of office: 2024 Shareholders' Meeting | | |
| Philippe Bonhomme Permanent representative of Beech Tree SA | Nationality: French | Shares owned: 500 Voting rights: 1,000 |
| Committees: <ul style="list-style-type: none"> • Audit Committee • Nomination Committee • Ethics and Governance Committee • Innovation and Development Committee – Consumer HealthCare | Biography and experience | |
| Date of birth: 5 November 1969 | Since 2005, Philippe Bonhomme has been Partner, Director and a member of the management committee of Hottinguer Corporate Finance, which is the investment banking arm of Hottinguer bank. He has been advising in France and abroad on numerous transactions in the pharma and healthcare sectors as well as on private equity-backed transactions. From 1993 to 2005, Philippe Bonhomme was first an auditor and then, a Corporate Finance consultant within Coopers & Lybrand (renamed into PricewaterhouseCoopers). From 2012 to 2018, Philippe Bonhomme was the permanent representative of the Company Mayroy SA, Director of Ipsen S.A. Since 30 May 2018, Philippe Bonhomme was a member of the Board of Directors of Ipsen S.A. On 6 January 2020, the Board of Directors acknowledged his resignation and co-opted Beech Tree S.A., in replacement, represented by Philippe Bonhomme. Philippe Bonhomme is a graduate of École des Hautes Études Commerciales (HEC, Paris) and a French Certified Public Accountant (CPA). | |
| | Positions and functions currently held | |
| | Within the Ipsen Group or its main shareholders: | Outside the Ipsen Group or its main shareholders: |
| | Listed company: <ul style="list-style-type: none"> • Ipsen S.A. (France), Permanent representative of Beech Tree on the Board of Directors | Listed company: None |
| | Non listed company: <ul style="list-style-type: none"> • Beech Tree S.A. (Luxembourg), Director | Non listed company: <ul style="list-style-type: none"> • Hottinguer Corporate Finance SA (France), Partner, Director and Member of the Management Committee • PBandCo SAS (France), Chairman |
| | Positions previously held that expired during the last five years | |
| | <ul style="list-style-type: none"> • Permanent representative of Mayroy at Ipsen's Board of Directors • Mayroy SA (Luxembourg), Director • MR HB S.à.r.l. (Luxembourg), Co-managing Director | |

* The indirect shareholding is described in section 5.6.2.1.



| | | | |
|--|---|--|---|
| Laetitia Ducroquet Director representing the employees | | Nationality: French | Shares owned: 180 * Voting rights: 180 * |
| Committees: <ul style="list-style-type: none"> • Compensation Committee ** Date of birth: 19 July 1979 Date of 1st appointment: 6 November 2020 Term of office: 2024 Shareholders' Meeting | Biography and experience Laetitia Ducroquet has been designated Director representing the employees by the European Works Council on 6 November 2020. Employee of the Ipsen Group since May 2015, Laetitia Ducroquet is currently Vice President Global Business Ethics, after various roles in the Ethics & Social Responsibility department. She is overseeing the execution and the continuous improvement of both internal and Third Party Business programs at Ipsen, partners with business teams to promote a culture of ethics and business accountability for the interests of patients, employees and other Ipsen stakeholders, in alignment with the Ethics & Social Responsibility's vision and mission. Laetitia is a pharmacist graduated from Paris V university, and a graduate of the EM Lyon Business School. | | |
| | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: | Outside the Ipsen Group or its main shareholders: | |
| | Listed company: <ul style="list-style-type: none"> • Ipsen S.A. (France), Director representing the employees | Listed company: None | |
| | Non listed company: <ul style="list-style-type: none"> • Ipsen Pharma SAS (France), Vice President Global Business Ethics | Non listed company: None | |
| Positions previously held that expired during the last five years None | | | |

* Shares held under free or performance share plans approved by the Board of Directors to the benefit of all the eligible employees or some of the Group employees. In capacity as director representing the employees, and in compliance with the Company's Articles of association, the director representing the employees is not required to hold a minimum number of shares.

** Laetitia Ducroquet is a member of the Compensation Committee since 27 May 2021.



| | | | |
|--|--|--|---|
| Margaret Liu Independent Director | | Nationality: American | Shares owned: 689 Voting rights: 1,378 |
| Committees: <ul style="list-style-type: none"> Ethics and Governance Committee (Chairperson) Innovation and Development Committee – Specialty Care Innovation and Development Committee – Consumer HealthCare Date of birth: 11 June 1956 Date of 1st appointment: 7 June 2017 Last renewal date: 27 May 2021 Term of office: 2025 Shareholders' Meeting | Biography and experience | | |
| | <p>Margaret Liu is currently a Global Health, Vaccines and Immunotherapy Consultant for pharma/biotech and investment companies, universities, and governmental scientific research councils. She has served on the faculty at the Karolinska Institute in Stockholm, Sweden beginning in 2003, first as Visiting Professor, then as Foreign Adjunct Professor and now as <i>Hedersdoktor</i>, (Honorary Doctor) with Scientific Affiliation. She is also Adjunct Full Professor at the University of California in San Francisco, CA since 2013.</p> <p>Before that, she occupied various functions in the private and public sector parallel to her academic career. From 1984 to 1988 she was Visiting Scientist at the Massachusetts Institute of Technology. From 1987 to 1989 she was Instructor of Medicine at Harvard University. From 1989 to 1995, she was Adjunct Assistant Professor of Medicine at the University of Pennsylvania in Philadelphia, PA. From 1990 to 1997, she served as Director, then Senior Director for Virus and Cell Biology at Merck Research Laboratories. From 1997 to 2000, she served as a Vice President of Vaccines Research and then Vice President of Vaccines and Gene Therapy at Chiron Corporation in Emeryville, CA. From 2000 to 2002, she was Senior Advisor in Vaccinology for the Bill & Melinda Gates Foundation. From 2000 to 2006, she was Vice Chairman of Transgène in Strasbourg, France. From 2005 to 2009, she served as a Director of Sangamo Biosciences Inc. She was President of the International Society for Vaccines from 2016 until the end of 2017.</p> <p>She is an accomplished leader in the research and development of vaccine and immunization programs for infectious diseases, particularly HIV and in the field of gene-based therapies. She earned her B.A. in Chemistry, <i>summa cum laude</i>, from Colorado College and an M.D. from Harvard Medical School. She was awarded an honorary Doctorate of Science (D.Sc.) from Colorado College and received the Karolinska Institute's highest distinction in May 2017, Medicine Doctor honoris causa-MDhc.</p> | | |
| | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> Ipsen S.A. (France), Independent Director Non listed company: None | Outside the Ipsen Group or its main shareholders: Listed company: None Non listed company: <ul style="list-style-type: none"> ProTherImmune (USA), Global Health, Vaccines and Immunotherapy Consultant International Society for Vaccines, Chairman of the Board Jenner Institute, University of Oxford (UK), Scientific Advisory Board PAX Therapeutics (USA), CEO | |
| Positions previously held that expired during the last five years | | | |
| <ul style="list-style-type: none"> International Society for Vaccines, President Simprints (UK, non-profit), Advisory Board member Adjuvance Technologies (USA), Director | | | |



| | | |
|---|--|--|
| David Loew Director and Chief Executive Officer | Nationality: Swiss | Shares owned: 500 Voting rights: 500 |
| Committees: <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (permanent guest) Date of birth: 20 March 1967 Date of 1st appointment: Chief Executive Officer: 1 July 2020 (unlimited period) Director: 28 May 2020 Ratification date and last renewal date: 27 May 2021 Term of office: 2025 Shareholders' Meeting | Biography and experience | |
| | <p>David Loew was coopted as Director of Ipsen S.A., by the Board on May 28, 2020, from this date, and appointed Chief Executive Officer from 1 July 2020. Prior to joining Ipsen, David was CEO of Sanofi Pasteur Vaccines. During his tenure, he piloted a successful worldwide growth strategy via acquisitions and licensing deals. David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region. David has served on the Board of the Global Alliance for Vaccines and Immunization (GAVI), chaired the Steering Committee of IFPMA and has strong connections with global organizations, including the WHO, UNICEF, the Bill & Melinda Gates Foundation, as well as American health agencies, including BARDA and the NIH. David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.</p> | |
| | Positions and functions currently held | |
| | Within the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> Ipsen S.A. (France), Director and Chief Executive Officer Non listed company: <ul style="list-style-type: none"> Ipsen Pharma SAS (France), Chairman | Outside the Ipsen Group or its main shareholders: Listed company: None Non listed company: None |
| Positions previously held that expired during the last five years | | |
| <ul style="list-style-type: none"> Sanofi Pasteur, Executive Vice President Global Alliance for Vaccines and Immunization (GAVI), Member of the Board of Directors International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Chairman of the vaccine Steering Committee | | |

| | | |
|---|--|--|
| Michèle Ollier Director | Nationality: French-Swiss | Shares owned: 500 Voting rights: 1 000 |
| Committees: | Biography and experience | |
| <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care | <p>Since 1 February 2016, Michèle Ollier is one of the partner and founder of Medicxi, a capital venture company located in Geneva and London. Medicxi is the spin-off of the life science section of Index Ventures.</p> | |
| Date of birth: | <p>From February 2006 to February 2016, Michèle Ollier was Partner in the life science investment team of Index Ventures.</p> | |
| 2 June 1958 | <p>From 2003 to 2006, she was the investment’s manager at Edmond de Rothschild Investment Partner in Paris. From 2000 to 2002, she was the corporate’s vice manager at Serono International. From 1994 to 2000, she occupied various posts at Rhône-Poulenc Rorer in particular in oncology and in the division “gene therapy”, RPR Gencell. Before, Michèle Ollier occupied various functions in strategy, development, and commercialization in the pharmaceutical companies Sanofi International and Bristol-Myers Squibb France.</p> | |
| Date of 1st appointment: | <p>Michèle Ollier is a graduate of the medicine faculty of Paris-Ouest.</p> | |
| 27 May 2015 | | |
| Last renewal date: | | |
| 28 May 2019 | | |
| Term of office: | Positions and functions currently held | |
| 2023 Shareholders’ Meeting | Within the Ipsen Group or its main shareholders: | Outside the Ipsen Group or its main shareholders: |
| | Listed company: | Listed company: |
| | <ul style="list-style-type: none"> Ipsen S.A. (France), Director | None |
| | Non listed company: | Non listed company: |
| | None | <ul style="list-style-type: none"> Medicxi (Switzerland and UK), Partner Epsilon 3 Bio Limited (UK) LinguaFlex Inc. (USA) Human Antibody Factory (UK) Kaerus France SAS (France), Kaerus Bioscience Limited (UK) and Kaerus Bioscience Inc., (USA) Mavalon Therapeutics Limited (UK) Villarix Therapeutics (USA) Yukin Therapeutics (France) Alderaan (France) NIRA Bioscience (USA) DepthCharge (Ireland) Aldena Therapeutics Inc. (USA), Aldena Therapeutics Limited (UK) and Aldena Therapeutics SA (Switzerland) Vimela Therapeutics Limited (UK) |
| | Positions previously held that expired during the last five years | |
| | <ul style="list-style-type: none"> Diasome Pharmaceuticals, Inc. (USA) STX pharma Limited (UK) Minerva Neuroscience, Inc.(USA) Purple Therapeutics Limited (UK) Encare Biotech BV (The Netherlands) AbTco BV (The Netherlands) Cyrenaic Pharma Inc. (USA) Profibrix (The Netherlands) Palladio Biosciences Inc. (USA) Kymo Therapeutics Limited (UK) Gadeta BV (The Netherlands) Vitavest NL Coop (The Netherlands) Pega-One (France) Pearl River Bio (Germany) Kymo Therapeutics France (France) Mavalon Therapeutics France (France) STX Pharma Limited (UK) Oncoethix SA (Switzerland) Sonkei Pharmaceuticals (USA) Funxional Therapeutics Limited (UK) | |



| | | | |
|---|--|-------------------------------|--|
| Jean-Marc Parant Director representing the employees | | Nationality: French | Shares owned: 35 * Voting rights: 65 * |
| Committee: <ul style="list-style-type: none"> Ethics and Governance Committee Date of birth: 28 September 1959 Date of 1st appointment: 27 November 2018 Term of office: 2022 Shareholders' Meeting | Biography and experience Jean-Marc Parant has been designated Director representing the employees by the Central Works Council on 27 November 2018. Employee of the Ipsen Group since January 1989, he is currently Head of Digital Learning Solutions and was previously Training Director. He thus contributed to the implementation of the training management system within the Ipsen Group, notably through dedicated digital platforms. Jean-Marc Parant is graduated from the Bordeaux School of Medicine, specialized in the field of medical informatics (artificial intelligence and data bases) and graduated in statistics. He is also an expert in Training and Digital learning. | | |
| | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: | | Outside the Ipsen Group or its main shareholders: |
| | Listed company: <ul style="list-style-type: none"> Ipsen S.A. (France), Director representing the employees | | Listed company: None |
| | Non listed company: <ul style="list-style-type: none"> Ipsen Pharma SAS, Head of Digital Learning Solutions | | Non listed company: None |
| Positions previously held that expired during the last five years None | | | |

* Shares held under free or performance share plans approved by the Board of Directors to the benefit of all the eligible employees or some of the Group employees. In capacity as director representing the employees, and in compliance with the Company's Articles of association, the director representing the employees is not required to hold a minimum number of shares.

| | | |
|---|---|---|
| Paul Sekhri Independent Director | Nationality: American | Shares owned: 500 Voting rights: 500 |
| Committees: <ul style="list-style-type: none"> • Audit Committee • Nomination Committee • Innovation and Development Committee – Specialty Care Date of birth: 26 April 1958 Date of 1st appointment: 30 May 2018 Term of office: 2022 Shareholders' Meeting * | Biography and experience | |
| | <p>Paul Sekhri has been President and Chief Executive Officer of e-Genesis, a company specialized in gene editing technology to deliver safe and effective human transplantable cells, tissues and organs, since 17 January 2019.</p> <p>Prior to this, Paul Sekhri was President and Chief Executive Officer of Lycera Corp., a U.S. biopharma company focused on treatments for cancer and autoimmune diseases from February 2015 until January 2019. He served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd. Before joining Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004 to 2009, Paul Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, he was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.</p> <p>Between 1999 and 2003, Paul Sekhri spent four years as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG and also developed the Disease Area Strategy. His first role was as Global Head, Early Commercial Development – a department he established to ensure the differential competitive advantage of Novartis' pipeline.</p> <p>Paul Sekhri is currently a member of the Board of Directors of Compugen Ltd., Pharming Group NV, Veeva Systems, Inc. and Longboard Pharmaceuticals.</p> <p>Additionally, he serves on non-profit boards such as the Knights and the Metropolitan Opera. Paul Sekhri received his BS in Zoology from the University of Maryland, College Park and completed graduate work in Neuroscience at the University of Maryland School of Medicine.</p> | |
| | Positions and functions currently held | |
| Within the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> • Ipsen S.A. (France), Independent Director Non listed company: None | Outside the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> • Compugen, Ltd. (Israel), Chairman of the Board • Pharming Group NV (The Netherlands), Chairman of the Board • Veeva Systems, Inc. (USA), Independent Director • Longboard Pharmaceuticals (USA), Chairman of the Board Non listed company: <ul style="list-style-type: none"> • e-Genesis (USA), President and Chief Executive Officer • Spring Discovery (USA), Director | |
| Positions previously held that expired during the last five years | | |
| <ul style="list-style-type: none"> • Enumeral Biomedical, Inc. (USA), Director • Nivalis Therapeutics, Inc. (USA) Director • Lycera Corp. (USA), President and Chief Executive Officer • Topas Therapeutics GmbH (Germany), Chairman of the Board of Supervisory Directors • Petra Pharma Corp. (USA), Chairman of the Board • Alpine Immune Sciences, Inc. (USA), Independent Director • BiomX, Inc. (Israel), Director | | |

* The renewal of the office will be submitted to a vote at the next 2022 Shareholders' Meeting.



| | | | |
|--|---|--|---|
| Piet Wigerinck Independent Director | | Nationality: Belgian | Shares owned: 680 Voting rights: 680 |
| Committees: <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care Compensation Committee Date of birth: 22 December 1964 | Biography and experience | | |
| | <p>Piet Wigerinck is a pharmacist and holds a Ph.D. in medicinal chemistry from the KU Leuven. He has over 30 years of R&D experience in the pharmaceutical industry and biotechnology. He has been a key driver of the research and development programs of 4 approved medicines: Prezista™, Olysio™, Jyseleca™ and Rekambys™.</p> <p>He started his career in industry at the Janssen Research labs in Beerse (1988-1998), next moved to Tibotec-Virco, where he was Vice President, Drug Discovery, Early Development and CM&C (1998-2008) and most recently was Chief Scientific Officer at Galapagos (2008-2021). Under his leadership, Galapagos built out a pipeline of first-in-class medicines that drove the growth of the company to a top European biotech player. He has been responsible for all aspects of drug discovery, preclinical research, CM&C and phase 1 and phase 2 clinical trials. He act as a consultant in the fields of anti-infective, autoimmune and anti-fibrotic diseases.</p> <p>Dr. Wigerinck is an independent board member of Ipsen S.A., France, miDiagnostics in Belgium, Atriva Therapeutics in Germany and is chair of the SAB of Ermium Therapeutics SA, France.</p> | | |
| | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: | Outside the Ipsen Group or its main shareholders: | |
| Listed company: <ul style="list-style-type: none"> Ipsen S.A. (France), Independent Director | Listed company: None | | |
| Non listed company: None | Non listed company: <ul style="list-style-type: none"> miDiagnostics (Belgium), Director and Chair of the R&D sub-committee Atriva Therapeutics GmbH (Germany), Director Ermium Therapeutics S.A. (France), Chairman of the Scientific Advisor Board UZA Foundation (Belgium, non-profit), Board member | | |
| Positions previously held that expired during the last five years | | | |
| <ul style="list-style-type: none"> Galapagos NV (Belgium), Chief Scientific Officer | | | |

* The renewal of the office will be submitted to a vote at the next 2022 Shareholders' Meeting.

| | | | |
|--|--|--|---|
| Karen Witts * Independent Director | | Nationality: American | Shares owned: 0 Voting rights: 0 |
| Committees: <ul style="list-style-type: none"> Audit Committee (Chairperson) Compensation Committee Date of birth: 28 May 1963 Date of 1st appointment: 20 January 2022 Term of office: 2025 Shareholders' Meeting | Biography and experience | | |
| | <p>Karen Witts was Group CFO at Compass Group Plc until October 2021. Compass is the world's leading food service company, operating in 43 countries and employing more than 500k people. She was responsible for corporate strategy and planning, business performance management and reporting, financial reporting and control, tax and treasury activities, M&A, internal audit and enterprise risk management, investor relations, and led the digital and technology function.</p> <p>Prior to this, Karen was Group CFO at Kingfisher Plc, the international home improvement company. She has also held various senior strategic finance positions at companies including Vodafone Group Services Ltd, and BT Plc.</p> <p>She brings expertise in transformation, investment, and risk management. Karen is an experienced Non-Executive Director and Chair of Audit.</p> <p>She is a fellow of the Institute of Chartered Accountants in England and Wales, and holds an MA from the University of Edinburgh.</p> | | |
| | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> Ipsen S.A. (France), Independent Director Non listed company: None | Outside the Ipsen Group or its main shareholders: Listed company: None Non listed company: None | |
| Positions previously held that expired during the last five years | | | |
| <ul style="list-style-type: none"> Compass Group Plc, Group Chief Financial Officer Kingfisher Plc, Group Chief Financial Officer | | | |

* Karen Witts was co-opted as an independent director on January 20, 2022. She has been a member and Chairman of the Audit Committee and a member of the Compensation Committee since February 10, 2022. The Shareholders' Meeting to be held in 2022 will be asked to ratify this decision for a term of office expiring at the 2025 Shareholders' Meeting.



| | | | |
|---|--|---|---|
| Carol Xueref Director | | Nationality: British | Shares owned: 500 Voting rights: 1,000 |
| Committees: <ul style="list-style-type: none"> • Nomination Committee (Chairperson) • Ethics and Governance Committee • Compensation Committee • Innovation and Development Committee – Consumer HealthCare Date of birth: 9 December 1955 Date of 1st appointment: 1 June 2012 Date of last renewal: 29 May 2020 Term of office: 2024 Shareholders' Meeting | Biography and experience | | |
| | <p>Carol Xueref is Chairperson of Floem SAS, a consultancy firm. She was Secretary General and a member of Essilor International's Executive Leadership Team until 30 June 2016. From 1982 to 1986, Carol Xueref was Deputy to the Attaché for Commercial Affairs at the British Embassy in Paris. From 1986 to 1990, she was Head of Division at the International Chamber of Commerce (Paris). In 1990, she became Director for Legal and Tax Affairs at the Banque Populaire de la Région Ouest de Paris. From 1993 to 1996, she was Head of a legal department within Crédit Lyonnais and subsequently Director for Legal Affairs of OIG (Crédit Lyonnais' defeasance entity). From 1996 to 2014, Carol Xueref was Director for Legal Affairs and Group Development and from 2014 to 2016 Secretary General; she was a member of Essilor International's Executive Leadership Team. She was a member of the <i>Autorité de la Concurrence</i> (French Competition Authority) from July 2006 to March 2019, and chaired its "Compliance" working group. She is a member of the Medef's Corporate Governance Committee.</p> <p>Carol Xueref is a founder member and a past-President of the Cercle Montesquieu (Association of French Legal Directors (1998-2002)) and chaired its "Ethics of in-house lawyers" working group. She is member of the "Association Française des Femmes Juristes" and Director of the Franco-British Lawyers Society.</p> <p>Carol Xueref holds a Masters Degree in Law and a Post Graduate Degree in International Commercial Law (DESS) from the University of Paris II (Assas).</p> | | |
| | Positions and functions currently held | | |
| | Within the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> • Ipsen S.A. (France), Director Non listed company: None | Outside the Ipsen Group or its main shareholders: Listed company: <ul style="list-style-type: none"> • Eiffage (France), Director and Chairperson of the Compensation and Appointments Committee and member of the Strategic Committee Non listed company: <ul style="list-style-type: none"> • Floem SAS (France), Chairperson | |
| | Positions previously held that expired during the last five years | | |
| None | | | |

Carol Stuckley was also a Director from 7 June 2017 to 6 August 2021. She was Chairperson and member of the Audit Committee and member of the Compensation Committee (see her biography in the 2020 Universal Registration Document). Her attendance rate is presented on the next page and her compensation for the 2021 financial year is disclosed in section 5.4.2.1

For the purposes of their office, Directors are domiciled at the Company's registered office.

Attendance rate of Directors at Board and Committees meetings

| Directors as of 31 December 2021 ⁽¹⁾ | Board of Directors | Innovation and Development Committee – Specialty Care | Audit Committee | Nomination Committee | Compensation Committee | Ethics and Governance Committee | Innovation and Development Committee – Consumer HealthCare |
|--|------------------------------|---|----------------------------|----------------------------|--|---------------------------------|--|
| Marc de Garidel | 13 meetings out of 13 (100%) | 5 meetings out of 5 (100%) | – | – | – | – | 10 meetings out of 10 (100%) |
| Antoine Flochel | 13 meetings out of 13 (100%) | 5 meetings out of 5 (100%) | – | – | 3 meetings out of 3 (100%) | – | – |
| Highrock S.à.r.l. (represented by Anne Beaufour) | 12 meetings out of 13 (92%) | – | – | – | – | – | – |
| Henri Beaufour | 13 meetings out of 13 (100%) | – | – | – | – | – | – |
| Beechtree SA (represented by Philippe Bonhomme) | 13 meetings out of 13 (100%) | – | 8 meetings out of 8 (100%) | 9 meetings out of 9 (100%) | – | 5 meetings out of 5 (100%) | 10 meetings out of 10 (100%) |
| Laetitia Ducroquet | 13 meetings out of 13 (100%) | – | – | – | 1 meeting out of 1 (100%) ⁽²⁾ | – | – |
| Margaret Liu | 13 meetings out of 13 (100%) | 5 meetings out of 5 (100%) | – | – | – | 5 meetings out of 5 (100%) | 3 meetings out of 3 (100%) ⁽²⁾ |
| David Loew | 13 meetings out of 13 (100%) | – | – | – | – | – | – |
| Michèle Ollier | 13 meetings out of 13 (100%) | 5 meetings out of 5 (100%) | – | – | – | – | – |
| Jean-Marc Parant | 13 meetings out of 13 (100%) | – | – | – | – | 5 meetings out of 5 (100%) | – |
| Paul Sekhri | 13 meetings out of 13 (100%) | 5 meetings out of 5 (100%) | 8 meetings out of 8 (100%) | 9 meetings out of 9 (100%) | – | – | – |
| Piet Wigerinck | 11 meetings out of 13 (85%) | 5 meetings out of 5 (100%) | – | – | 3 meetings out of 3 (100%) | – | – |
| Carol Xueref | 13 meetings out of 13 (100%) | – | – | 9 meetings out of 9 (100%) | 3 meetings out of 3 (100%) | 5 meetings out of 5 (100%) | 10 meetings out of 10 (100%) |

(1) Karen Witts was co-opted as a independent director on 20 January 2022. Carol Stuckley was an Independent Director until 6 August 2021. Her attendance rate at Board and Committee meetings was 100% for the period from 1 January 2021 to 6 August 2021 (i.e. 6 Board meetings, 4 Audit Committee meetings and 2 Compensation Committee meetings).

(2) Director who joined the committee during the 2021 financial year. For more details, please refer to the table "Changes in the Board of Directors and its Committees" in section 5.2.2.2 above.

■ 5.2.2.4 Activity of the Board of Directors in 2021

Extract from the Ipsen S.A. Articles of association as of 29 May 2020

"17.1 Powers of the Board of Directors

The Board of Directors defines guidelines for the Company's business operations and monitors their implementation.

Subject to the powers expressly conferred to Shareholders' Meetings and within the limits of the Company's corporate purpose, the Board of Directors is competent to consider any matters affecting the proper running of the Company, and can take decisions governing any matters concerning it.

With respect to third parties, the Company is bound by the Board of Directors' acts even when they run counter to the Company's corporate object, unless the Company can prove that the third party knew the act was ultra vires or could not fail to have known this given the circumstances, on the understanding that the mere publication of the Company's Articles of Association is not sufficient to constitute such proof.

The Board of Directors shall carry out such controls and verifications as it deems fit. [...]"

Extracts from the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the activity of the Board

"Article 1 - Role of the Board

In charge of managing the Company, in accordance with its legal obligations and the Articles of Association, the Board:

- *endeavours to promote long-term value creation by the Company by considering the social and environmental aspects of its activities. If applicable, it proposes any statutory change that it considers appropriate;*
- *in collaboration with the Chief Executive Officer, defines the strategic orientation, examines and decides on important operations, reviews the strategic orientations of the Company and the Group, which is made up of the Company and the business units it consolidates in its financial statements (hereafter "the Group"), its investment, disinvestment, or internal restructuring projects, the Group's overall policy with regard to human resources, in particular its policy on compensation, profit-sharing, and performance-based incentives. It appraises the performance of the Company's management on an annual basis and is consulted on new executive managers' recruitments;*
- *approves the annual budget presented by the Chief Executive Officer, and all its amendments when exceeding an amount of €10 million;*
- *approves, on a proposal of the relevant Innovation and Development Committee and before any decision is made, acquisitions or divestments of equity interests or assets, partnerships, alliances, or cooperation agreements relating to research, development, industry, and business as well as, generally speaking, any transaction or any commitment that might significantly affect the Group's financial or operating situation or its strategic guidelines;*
- *is regularly informed via the Audit Committee about the financial situation, the Company's cash position, and all the significant events affecting the Company; it is kept informed by its Chairperson and by its Committees of all significant events related to the conduct of business for the Company and the Group;*
- *ensures that shareholders and the public are well informed of the strategy, development model, major non-financial matters of the Company, issues as well as its long-term outlook, in particular via the control it exercises on the information given by the Company; and in this respect, it defines the Company's communication policy, in particular regarding the frequency with which financial and non-financial information relating to the Group is released;*
- *checks that the Company has reliable procedures in place to identify, assess, and monitor its commitments and risks, including off-balance sheet risks, as well as an appropriate internal control system;*
- *is informed about market developments, the competitive environment and the most important aspects facing the Company, including in the area of social and environmental responsibility;*
- *regularly reviews, in relation to the strategy it has defined, the opportunities and risks, such as financial, legal, operational, social and environmental risks, as well as the measures taken accordingly. To this end, the Board of Directors receives all of the information needed to carry out its task, notably from the executive officers;*
- *if applicable, ensures the implementation of a mechanism to prevent and detect corruption and influence peddling. It receives all of the information needed for this purpose;*
- *also ensures that the executive officers implement a policy of non-discrimination and diversity, notably with regard to the balanced representation of women and men on the governing bodies.*

More generally, the Board exercises the functions assigned to it by the law to act at all times in the Company's corporate interest, and takes particular care to prevent any conflicts of interest and to take all interests into account."

"Article 4.4 Evaluation

[...] Furthermore, the non-executive Directors also carry out, once a year, an evaluation of the Chairperson of the Board, the Chief Executive Officer and, as the case may be, the Deputy Chief Executive Officer(s), outside their presence. The results of this evaluation are communicated by the Chairperson of the Board of Directors to the Chief Executive Officer."

The Board of Directors met 13 times during the 2021 financial year. The average attendance rate at Board meetings was 98%.

The Company's Statutory Auditors were called to Board meetings held to approve the annual and half-year financial statements.

The following matters were reviewed and discussed by the Board of Directors in 2021:

- Financial statements and financial position: review and approval of the 2020 annual and consolidated financial statements, the 2021 half-year financial statements, the 2021 guidance, revised upwards in July and October 2021, the draft of 2022 budget;
- Strategy: review of the 5 years Group strategic plan and review of the Group's climate change objectives (see Chapter 4);
- Business development: review and follow-up of acquisition, partnership and Group development projects, and Group strategic review;
- Compensation policy: review of the respective compensation elements of the Chairman of the Board and of the Chief Executive Officer, preparation of the report on corporate governance including the Corporate Officers' compensation policy and grant of free shares (subject to performance conditions for executive officers and certain executives and without performance conditions for certain Group managers);
- Evaluation of the performance: an evaluation on the performance of the Chief Executive Officer has been conducted by the Board of Directors during 2021 without his presence. The conclusions have been presented to him;
- Succession plan: implementation of the succession plan of the directors with the cooptation of Karen Witts as an independent director in January 2022;
- Organization and functioning of the Board of Directors: proposals to the Shareholders' Meeting to ratify a provisional appointment, and to renew the appointments of Directors, report on the independence of the Directors, review of the Internal Rules of the Board of Directors;
- Shareholders' Meeting: review and approval of the report on corporate governance, the convening notice to the Shareholders' Meeting of 27 May 2021, the approval of the Shareholders' Meeting Agenda, the draft resolutions and the report of the Board of Directors to the Shareholders' Meeting and regulations follow-up allowing the holding of a shareholders' meeting behind closed doors given the exceptional health circumstances; and
- the monitoring of the selection process for the Statutory Auditors in preparation for the 2022 Shareholders' Meeting.

In addition, the Board of Directors met during the 2021 financial year in the absence of the Chief Executive Officer and members of management, in restricted sessions. All directors, excluding the Chief Executive Officer, were present at the session dedicated to the evaluation of the Chief Executive Officer's performance.

■ 5.2.2.5 Evaluation of the functioning of the Board and the Committees

Extract from the Internal Rules of the Board, as of 6 October 2021, regarding the evaluation of the Board of Directors

"Article 4 Functioning

[...] 4.4 Evaluation

At least, once a year, the Board discusses its operation, membership, and organization in an "executive session", without the Chairperson of the Board if appropriate, and without the presence of the Chief Executive Officer and management team members.

This "executive session" is prepared by the Ethics and Governance Committee in conjunction with the Vice Chairperson of the Board or a Director who is specially appointed for this purpose.

The Board also performs a formal evaluation at least once every three years.

The Board may call in an external consultant to conduct an evaluation [...]."

Evaluation of the Board of Directors

An evaluation of the functioning and the organization of the Board of Directors was prepared by the Ethics and Governance Committee at the end of the year and included in the Board meeting agenda of 10 February 2022.

As per the Internal Rules of the Board, an executive session was prepared by the Ethics and Governance Committee in conjunction with the Vice Chairman of the Board, and was held without the Chairman of the Board. The conclusions of the session were that this was an extremely busy year for the Board with a high number of committee meetings. Efforts will be made to ensure that optimal efficiency of the scheduling of committee meetings is performed, while noting that the high attendance rate of directors for Board and Committee meetings reflects the significant commitment of the directors to their responsibilities.

The activity of the Board is outlined in the section above "Activity of the Board of Directors in 2021".

Finally, a self-assessment will be formalized for the year 2022. As per the schedule, this will be a formal evaluation performed at least once every three years, with the assistance of an independent consulting firm. It will be initiated in the second half of 2022 and anticipated to include a documentary analysis (Articles of association, Internal Rules of the Board, Directors' Code of conduct, Board and Committees files and minutes) followed by individual interviews with each Director and selected members of the Executive Leadership Team.

■ 5.2.2.6 Committees of the Board of Directors

Extracts from the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the Committees of the Board

“5.1 Expertise provided by Committees

The Board of Directors may set up temporary or permanent specialized Committees comprising at least three (3) and no more than six (6) Directors, of its choosing, and appoints the Chairpersons of said Committees.

These Committees submit their opinions and proposals to the Board and report to the Board on their work.”

“Article 6 – Permanent Committees

By adopting these internal rules, the Board establishes six (6) permanent Committees:

- *an Innovation and Development Committee – Specialty Care,*
- *an Innovation and Development Committee – Consumer HealthCare,*
- *an Audit Committee,*
- *a Nomination Committee,*
- *a Compensation Committee,*
- *an Ethics and Governance Committee.*

6.1 Common rules applicable to all permanent Committees

6.1.1 Committee members are appointed according to their skills (in a personal capacity or as permanent representative) for the duration of their term of office as a Director. They can delegate another member of the same Committee to represent them for any meeting of the Committee. They can be replaced or dismissed at any time by the Board. Their terms of office are renewable. A single Director can be a member of several Committees.

6.1.2 The Chairperson of each Committee is appointed from among its members by the Board. He/she shall prepare the agenda and the necessary documentation with, if necessary, the assistance of the Secretary of the Board.

6.1.3 Subject to the specific rules applicable to them, each Committee determines the frequency of its meetings. Said meetings are held at the head office or any other location, or virtually, decided by its Chairperson when he/she convenes it and sets the meeting's agenda.

A Committee can only meet if at least half of its members are present, in one of the ways allowed by the law or the Articles of Association with respect to Directors attending Board meetings.

The Chairperson of a Committee may invite all Board members to one or several of its meetings, as well as any other person, to take part in discussions.

6.1.4 When minutes of the Committee meeting are drawn up, they are written by the Secretary of the Board under the authority of the Chairperson of the Committee, or by the Chairperson of the Committee. The minutes are then sent to all members of the Committee. The Chairpersons of Committees report to the Board on the work carried out by their Committees under the conditions set by the Board.

6.1.5 Within its own area of competence, each Committee issues proposals, recommendations, or opinions.

To this end, each Committee may carry out or have carried out, at the Company's expense, all external studies likely to enlighten the Board's deliberations.

Each Committee reports to the Board on its work at each one of the Board's meetings. A summary of the activity of each Committee is included in the annual Report on the corporate governance.

6.1.6 Each Committee may decide, if need be, on its other operating procedures. It conducts periodically a self-assessment of its activities to ensure that its rules and operating procedures enable it to assist the Board in deliberating validly on the issues within its remit and can propose to the Board a change in its Internal rules.”

The Nomination Committee

Extract from the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the Nomination Committee

“6.5 Nomination Committee

6.5.1 *The role of the Nomination Committee is :*

- *in conjunction with the Ethics and Governance Committee (for aspects relating to conflicts of interest) and the Chairperson of the Board, to make proposals to the Board of Directors concerning the re-election, replacement or appointment of new Directors, ensuring the balance and complementarity of the skills of the directors and the diversity of their profiles (succession planning);*
- *to organize a procedure to select future independent directors;*
- *recommend candidates to the Board of Directors when:*
 - *appointing or reappointing the Chairperson of the Board, the Vice Chairperson, the Chief Executive Officer or Deputy Chief Executive Officers, as relevant;*
 - *appointing or reappointing Board members at a Shareholders' Meeting; and*
 - *for the composition of the Board specialized committees.*

The members of the Committee must also be consulted about the appointment of Executive Leadership Team members. The Chief Executive Officer must ask the Committee to give its opinion prior to such recruitments;

- *design, if applicable, in conjunction with the Chairperson of the Board, a plan for replacement of Company Officers, so as to be able to propose replacement solutions to the Board in the event of an unforeseen vacancy (succession planning);*
- *regularly review directors training plans and the process for welcoming and integrating new directors.*

6.5.2 *The Nomination Committee comprises a minimum of three (3) directors and a maximum of six (6) directors, including at least one-third of independent directors who meet the criteria set out in 3.3 above, chosen from among Directors who are not executive officers. The Board appoints the Chairperson of the Committee from among its members.*

6.5.3 *The Nomination Committee meets at least twice (2) a year, when convened by its Chairperson or at the request of the Chairperson of the Board.”*

The Nomination Committee is currently comprised of three members, one of whom is independent.

Its members are:

- Carol Xueref (Chairperson),
- Beech Tree S.A. (represented by Philippe Bonhomme); and
- Paul Sekhri (Independent member).

The Chairman and the Chief Executive Officer may attend meetings of the Nomination Committee and give their opinion when the agenda is about the appointment of Executive Leadership Team members or managers of the Group or any other topic requiring their opinion.

Activity of the Nomination Committee

The Nomination Committee met 9 times in 2021 with an attendance rate of 100%.

The Committee's activity focused mainly on:

- the establishment of the skills matrix for Board members;
- the review of the succession plan or renewal of Board members and the selection of the future Directors (see below);
- monitoring the succession plans of corporate officers (see below), of members of the Executive Leadership Team and of the Global Leadership Team, as well as the Group's talent development programs;
- the review of the participation of some Directors in Committees, in particular in the context of the appointment of the second director representing the employees at the Compensation Committee, the chairmanship of the Audit Committee by Paul Sekhri in the context of Carol Stuckley's

departure, and the appointment of Margaret Liu as member of the Innovation and Development Committees Consumer Healthcare;

- monitoring the balanced composition of the Board of Directors, in relation with the Ethics and Governance Committee;
- amending the internal rules in order to specify the role of the Nomination Committee in the Board members recruitment process.

The activity of the Committee has been reported and, when appropriate, a recommendation made to the Board, after each Committee meeting.

Succession plan for Corporate Officers

The Nomination Committee continued its work in 2021 on the succession plans for Corporate Officers (Chief Executive Officer and Chairman of the Board). The succession plan is based on several hypothesis: emergency succession (e.g. in case of legal incapacity, sudden resignation, illness or death), planned succession (e.g. in case of renewal of office, reaching a legal age limit, resignation given with lengthy prior notice (+/- 6 months), etc.) and accelerated succession (e.g. in case of a problem of availability, conflicts of interest, objectives not reached, strategic divergences, etc.).

Each hypothesis for either of the Chief Executive Officer or for the Chairman of the Board was studied by the Nomination Committee, in conjunction with them and the Group Human Resources Officer.

The Nomination Committee also prepared an identification process for CEO and Chairman successors including internal pre-identified candidates, setting out job descriptions

(predetermined criteria and profiles based on the Company's ongoing needs), and pre-prepared press releases for each event.

The Nomination Committee also evaluated Executive Leadership Team profiles and performance, as well as their ability to assume an interim or ongoing executive management position in whole or in part, immediately or over time.

The Nomination Committee also presented to the Board of Directors its progress after each of its meetings and discussed conclusions within the terms of pre-arranged confidentiality constraints.

The Nomination Committee has reviewed the various assumptions of the succession plan, also regularly reviewed by the Board of Directors.

Procedure for the renewal and appointment of directors

The Nomination Committee has formalized a procedure for the renewal and appointment of members of the Board of Directors.

This procedure identifies, according to the different categories of directors, the different hypotheses that may occur (new appointment, renewal, planned succession, emergency succession).

The procedure for the renewal and appointment of directors establishes the list of the internal and external stakeholders, members of the management or of the Board of Directors and Committees, in charge of each specific part of the process. It also oversees the exchange of information between the various stakeholders.

This procedure recalls the principles of balance of representation, diversity, and the balance of powers applicable to the members of the Board.

In application of this procedure, and after having conducted its own studies, the Nomination Committee recommended to the Board the cooptation of Karen Witts as a new independent director, replacing Carol Stuckley. This cooptation has been made on 20 January 2022 and will be submitted to the next Shareholders' Meeting.

The Ethics and Governance Committee

Extract from the Internal Rules of the Board, as of 6 October 2021, regarding the missions of the Ethics and Governance Committee

"6.7 Ethics and Governance Committee

6.7.1 The role of the Ethics and Governance Committee is to:

- review the definition of the Group's fundamental values and its ethics and compliance policy;
- submit recommendations on ethics and compliance to the Board of Directors; discuss all issues relating to ethics and compliance referred to it by the Board;
- ensure the dissemination throughout the Group of the Code of Ethics and general ethics policies defined by the Group and their updates;
- ensure the implementation, monitoring and efficiency of procedures for the communication and comprehension of the Code of Ethics and compliance with it and overall policies by employees of the Group;
- examine the Group's risks mapping from an ethics and compliance standpoint;
- review the Group's ethics and compliance activity report;
- examine the organization of the ethics and compliance function and make recommendations, when relevant;
- receive any information concerning possible breaches of the ethics and compliance policy and review action plans implemented to address these;
- examine the evolution of corporate governance rules, particularly those of the AFEP-MEDEF Code, and report its conclusions and recommendations to the Board; monitor the application of the rules of corporate governance defined by the Board of Directors and ensure that the information is given to shareholders on this subject; specify, where appropriate, the recommendations of the AFEP-MEDEF Code that are not applied and explain the reasons in an understandable, relevant and detailed manner;
- propose the referral of the High Committee monitoring the application of the AFEP-MEDEF Code on any question relating to a provision or the interpretation of said code;
- examine situations of potential conflicts of interest of members of the Company's Board of Directors and communicate the results of its findings in accordance with an internal procedure which protects confidentiality;
- give a technical opinion - with regard to the rules of ethics and governance applied by the Group - on the mandates and functions performed outside the Group by the members of the Board of Directors, the Chief Executive Officer and, as the case may be, the Deputy Chief Executive Officers, at the time of their appointment and annually as part of the review of the information mentioned in the Report of Corporate Governance;
- prepare, under the direction of the Chairperson of the Committee, in liaison with the Vice Chairperson of the Board or a specially appointed director, the annual "restricted session" of the Board of Directors on its operation, without the presence of the Chairperson of the Board, the Chief Executive Officer and the executive members;
- give an opinion, in liaison with the Chairperson of the Board, on the list of independent directors of the Board of Directors when appointing a director and annually for all directors;

- make proposals to the Board for the establishment and structuring of Board Committees;
 - carry out, under the direction of the Chairperson of the Committee, a formal evaluation of the structure, size and composition of the Board, periodically and at least every three years, and make recommendations to the Board regarding any changes;
 - propose to the Board the appointment of a Director in charge of the relations of the Board with the shareholders, in coordination with the Investor Relations Department of the Company and the Chief Executive Officer;
 - if applicable, ensure the implementation of a mechanism to prevent and detect corruption and influence peddling. It receives all of the information needed for this purpose;
 - also ensure that the executive officers implement a policy of non-discrimination and diversity, notably with regard to the balanced representation of women and men on the governing bodies.
- 6.7.2 The Ethics and Governance Committee comprises a minimum of three (3) directors and a maximum of six (6) directors, including at least one (1) independent director who meet the criteria set out in 3.3 above, chosen from among Directors who are not executive officers. The Board appoints the Chairperson of the Committee from among its independent members.
- 6.7.3 The Ethics and Governance Committee may, when it deems necessary, meet with the Executive Management or members of their teams, Internal Audit, the Ethics and Compliance Department or any other member of management. Said meetings may be held, when necessary, without the presence of members of Executive Management.
- 6.7.4 The Ethics and Governance Committee meets at least twice (2) a year when convened by the Chairperson of the Committee.”

The Ethics and Governance Committee is currently comprised of four members, one of whom is independent and one representing the employees.

Its members are:

- Margaret Liu (Chairperson and independent member),
- Carol Xuerf,
- Beech Tree S.A. (represented by Philippe Bonhomme), and
- Jean-Marc Parant (Director representing the employees).

Activity of the Ethics and Governance Committee

The Committee met 5 times in 2021 with an attendance rate of 100%.

The Committee's work focused mainly on:

- the establishment of 2021 objectives for the Compliance function, with a focus on CSR (Corporate Social and Environmental Responsibility),
- the establishment of a new proposal in the governance of the approval process of Business Development operations and the corresponding amendment of the internal rules of the Board;
- the review of Ipsen' organization and verification of its compliance, with the requirements of the Sapin 2 law in the fight against corruption;

- the review of the new version of the Ipsen Code of Conduct effective on 1 July 2021;
- the review of the training plan of the Business Ethics organization;
- the review of new offices of certain Directors with respect to potential conflict of interest situations;
- the annual review of the questionnaires on conflicts of interests and positions of Directors;
- the review of the independence of Directors;
- in connection with the appointment of Karen Witts as an independent director, the review of her conflict of interests questionnaire and the review of the independence criteria;
- the evaluation of the Board and its Committees (see section 5.2.2.5 of this Document);
- the monitoring of the balanced composition of the Board of Directors in conjunction with the Nomination Committee.

The activity of the Committee has been reported and, when appropriate, a recommendation made to the Board, after each Committee meeting.

The Compensation Committee

Extract from the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the Compensation Committee**“6.6 Compensation Committee**

6.6.1 *The role of the Compensation Committee is to:*

- *make proposals to the Board of Directors on all components of the compensation paid to the Group’s corporate officers, senior management and senior executives;*
- *be informed on all matters pertaining to the recruitment of the Group’s main senior managers, other than the Chief Executive Officer, as well as on decisions concerning the fixing or changing of any part of their compensation;*
- *issue a recommendation on the amount and allocation of compensations among Board members;*
- *make recommendations to the Board of Directors on Group compensation policies as well as employee savings plans, employee share ownership schemes, stock options and bonus shares, pension plans, or any other similar forms of compensation.*

6.6.2 *The Compensation Committee comprises a minimum of three (3) directors and a maximum of six (6) directors, including a half of independent directors who meet the criteria set out in 3.3 above, chosen from among Directors who are not executive officers. The Board appoints the Chairperson of the Committee from among its members.*

6.6.3 *If it deems it useful, the Compensation Committee may ask the Chairperson of the Board to assist in its deliberations and work, except when it is discussing the Chairperson’s compensation.*

6.6.4 *The Compensation Committee meets at least twice (2) a year, when convened by its Chairperson or at the request of the Chairperson of the Board of Directors.”*

The Compensation Committee is currently comprised of five members, two of whom are independent and one representing the employees.

Its members are:

- Antoine Flochel (Chairman),
- Laetitia Ducroquet (Director representing the employees);
- Piet Wigerinck (Independent member),
- Karen Witts (Independent member), and
- Carol Xuerf.

Karen Witts has been a member of the Compensation Committee since 10 February 2022. Carol Stuckley was a member of the Compensation Committee until 6 August 2021.

The Chief Executive Officer and the Chairman of the Board may attend meetings of the Compensation Committee and give their opinion mainly on the compensation of the senior managers of the Group, the incentives and the performance share plans.

Activity of the Compensation Committee

The Compensation Committee met 3 times in 2021 with an attendance rate of 100%.

The Committee’s work focused mainly on:

- the review of the fixed and variable compensation elements of the Chief Executive Officer, David Loew, and the Chairman of the Board of Directors;
- the compensation policy for executive corporate officers;
- the granting of 2021 performance shares to the Group’s executive officers and employees and the granting of free shares to eligible employees within the Group;
- the approval of the 2021 Group shareholding plan;
- the reflection on the harmonization and evolution of the compensation and the retention policy within the Group.

These elements are described under section 5.4 of this document.

The activity of the Committee has been reported and, when appropriate, a recommendation made to the Board, after each Committee meeting.

The Audit Committee

Extract from the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the Audit Committee

“6.4 Audit Committee

6.4.1 *The role of the Audit Committee is to:*

- ensure the relevance and permanence of the accounting policies used to prepare both the Company's and the consolidated financial statements, review and assess the consolidation scope as well as evaluate and verify the relevance of the accounting methods applied to the Group;
- examine, before they are presented to the Board, draft annual and interim financial statements, draft annual and half-yearly reports, draft forecasts and annual budgets, the 5 Year Strategic Plan, as well as any accounting and financial information relating to any significant project; to that end, the Audit Committee should be able to cooperate (by exchanging information and working jointly) with the relevant Innovation and Development Committee and the Executive Management before a summary of their work is presented to the Board;
- examine, before they are presented to the Board, press releases on financial results and guidance, as well as the related presentations;
- examine draft resolutions relating to the financial statements in order to make comments or suggestions, before they are presented to the Board;
- control the quality of procedures relating to the preparation and processing of financial and extra-financial accounting information compliance with them, and assess the information received from management, internal committees and internal and external audits;
- monitor the effectiveness of internal control and risk management systems;
- examine the risk exposure, including those of a social and environmental nature, and major off-balance sheet commitments of the Company as well as the accounting options chosen;
- manage the selection and reappointment of the Statutory Auditors, verify their independence, give an opinion on the amount of fees they request, and submit the results of its work to the Board;
- examine the details and appropriateness of the fees paid by the Company and the Group to the Statutory Auditors and ensure that said fees and corresponding services are unlikely to affect the auditors' independence;
- authorize services, other than statutory audit work, that the Statutory Auditors and members of their networks may be asked to perform in accordance with the applicable laws and regulations;
- conduct an annual review of the status of major disputes;

6.4.2 *The Audit Committee is comprised of a minimum of three (3) directors and a maximum of six (6) directors, including two-thirds of independent directors who meet the criteria set out in 3.3 above, chosen from among Directors who are not executive officers. All members of the Audit Committee must have financial or accounting expertise. The Board appoints the Chairperson of the Committee from among its members. The Chairperson of the Committee is also an independent director with respect to the Company's independence criteria.*

6.4.3 *The Audit Committee meets at least four (4) times a year when convened by its Chairperson.*

6.4.4 *In the performance of its duties, the Audit Committee:*

- submits to the Board its proposals regarding the appointment, compensation or replacement of the Company's Statutory Auditors;
- reviews, with the management and the Company's Statutory Auditors, the quarterly, interim and annual financial statements, the accounting principles and policies implemented, the Group's audit and internal control principles and methods, risk management procedures and the analyses and reports relating to financial reporting, accounting policy and communications between management and the Company's Statutory Auditors;
- examines and checks the rules and procedures applicable to conflicts of interest, expenses incurred by members of the management and the identification and measurement of the main financial risks, as well as their application and submits its assessment every year to the Board;
- examines, checks and assesses on an annual basis the independence, the control procedures and the problems encountered by the Company's Statutory Auditors, as well as the measures adopted to solve said problems, and monitors in the same manner the way in which internal audit operates;
- more generally, it examines, checks and assesses everything likely to affect the regularity and fairness of the financial statements.

6.4.5 *The Audit Committee ensures it is provided, and in sufficient time, with all necessary or useful information and hears any person whose audition is necessary or useful with regard to its work. It may in particular have recourse to external experts.”*



The Audit Committee is currently comprised of three members, two of whom are independent.

Its members are:

- Karen Witts (Chairperson and Independent member),
- Paul Sekhri (Independent member), and
- Beech Tree S.A. (represented by Philippe Bonhomme).

Karen Witts was appointed Chairperson and member of the Audit Committee on 10 February 2022, replacing Carol Stuckley, Chairperson and independent member of the Audit Committee until 6 August 2021. The interim period was covered by Paul Sekhri, who was appointed as Chairman of the Audit Committee by anticipation on 28 July 2021.

In accordance with the terms of Article L.823-19 of the French Commercial Code at least one member of the Audit Committee must be independent and have finance, accounting or statutory audit expertise. Karen Witts and Paul Sekhri fulfill the independence and financial, accounting or statutory audit criteria given their professional experience as described above. Philippe Bonhomme, Beech Tree S.A. representative, is also competent in the financial, accounting and statutory audit fields.

Activity of the Audit Committee

The Audit Committee met 8 times in 2021 with an attendance rate of 100%.

The Statutory Auditors were present at meetings regarding the review of annual and half-year financial statements and presented the main aspects of the outcomes of the statutory audit and of the chosen accounting methods. The Committee heard, in particular, the Statutory Auditors, the Executive Vice President, Chief Financial Officer, the Group Controller, the

Head of Internal Audit, the Head of Tax and the Head of Risk Management.

The Committee's activity focused in particular on the review of:

- the 2021 revised budget and its review with respect to the modifications of the guidance in July and October 2021;
- the 2020 annual and consolidated financial statements;
- the approval of Audit related services and other services;
- the 2021 Group risk map;
- the report of the internal audit for 2021, the 2021 and 2022 internal audit plan and the internal control processes within the Group;
- the 2021 half-year financial statements;
- the 2021 closing options;
- the review of the 5-year strategic plan;
- the new proposal in the governance of the approval process of Business Development operations and the corresponding amendment of the Internal Rules of the Board, in conjunction with the Ethics and Governance Committee;
- the 2022 draft budget review;
- the Committee also monitored the selection process for the Group's Statutory Auditors for the six-year period from 2022 to 2028 and made a recommendation to the Board of Directors for the 2022 Shareholders' Meeting.

The activity of the Committee has been reported and, when appropriate, a recommendation made to the Board, after each Committee meeting.

The Innovation and Development Committee – Specialty Care

Extract of the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the Innovation and Development Committee – Specialty Care

“6.2 Innovation and Development Committee – Specialty Care

6.2.1 The role of the Innovation and Development Committee – Specialty Care is to:

- review the proposals presented by Management on internal Research & Development programs, Business Development and Merger & Acquisitions and Divestitures;
- follow the update of the Business Development portfolio by therapeutic areas.

6.2.2 The Innovation and Development Committee – Specialty Care comprises the Chairperson of the Board, who chairs this Committee, and five (5) other permanent members of the Board of Directors. The Board may also decide the existence of permanent guests to the Innovation and Development Committee – Specialty Care.

6.2.3 The Innovation and Development Committee – Specialty Care meets at least four (4) times a year, when convened by its Chairperson, or by a majority of its members.

6.2.4 To carry out its work, the Innovation and Development Committee – Specialty Care may audition the Group's senior executives, whether corporate officers or not.”

The Innovation and Development Committee – Specialty Care is currently composed of six members, three of whom are independent.

Its members are:

- Marc de Garidel (Chairman);
- Antoine Flochel;
- Margaret Liu (Independent member);
- Michèle Ollier;
- Paul Sekhri (Independent member); and
- Piet Wigerinck (Independent member).

Anne Beaufour, permanent representative of Highrock S.à.r.l., Henri Beaufour and David Loew are permanent guests of the Innovation and Development Committee – Specialty Care.

Activity of the Innovation and Development Committee – Specialty Care

The Innovation and Development Committee – Specialty Care met 5 times in 2021 with an attendance rate of 100%.

The Innovation and Development Committee – Specialty Care mainly worked during the year on:

- the review of the Group's R&D strategy and pipeline;
- the review of the approval process for external innovation operations;
- the review and exam of acquisitions projects;
- the review and evolution of the main partnerships of the Group;
- the review of the Business Development strategy as part of the 5 year strategic plan.

The activity of the Committee has been reported and, when appropriate, a recommendation made to the Board, after each Committee meeting.

The Innovation and Development Committee – Consumer HealthCare

Extract from the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the Innovation and Development Committee – Consumer HealthCare

“6.3 Innovation and Development Committee – Consumer HealthCare

6.3.1 *The role of the Innovation and Development Committee – Consumer HealthCare is to:*

- *review the proposals presented by Management on Business Development and Merger & Acquisitions and divestitures, relating to Consumer HealthCare;*
- *follow the update of the Consumer HealthCare portfolio.*

6.3.2 *The Innovation and Development Committee – Consumer HealthCare comprises the Chairperson, who chairs this Committee, of the Board and three (3) other permanent members of the Board of Directors. The Board may also decide the existence of permanent guests to the Innovation and Development Committee – Consumer HealthCare.*

6.3.3 *The Innovation and Development Committee – Consumer HealthCare meets at least twice (2) a year, when convened by its Chairperson, or by a majority of its members.*

6.3.4 *To carry out its work, the Innovation and Development Committee – Consumer HealthCare may audition the Group's senior executives, whether corporate officers or not.”*

The Innovation and Development Committee – Consumer HealthCare is currently composed of four members, including one independent.

Its members are:

- Marc de Garidel (Chairman);
- Beech Tree S.A. (represented by Philippe Bonhomme);
- Margaret Liu (Independent member); and
- Carol Xueref.

Anne Beaufour, permanent representative of Highrock S.à.r.l., Henri Beaufour and David Loew are permanent guests of the Innovation and Development Committee – Consumer HealthCare.

Activity of the Innovation and Development Committee – Consumer HealthCare

The Innovation and Development Committee – Consumer HealthCare met 10 times in 2021 with an attendance rate of 100%.

During the year, the Innovation and Development Committee – Consumer HealthCare mainly worked on the review and monitoring of the Consumer HealthCare activity, as well as the strategic review of this activity.

The activity of the Committee has been reported and, when appropriate, a recommendation made to the Board, after each Committee meeting.



5.3 EXECUTIVE MANAGEMENT

5.3.1 Organization and modus operandi of the Executive Management

In accordance with legal provisions, the Executive Management of the Company is assumed, under his responsibility, either by the Chairman of the Board of Directors, then qualified as Chairman and Chief Executive Officer, or by another individual appointed by the Board of Directors and bearing the title of Chief Executive Officer. The choice between these two methods of exercising Executive Management is made by the Board of Directors for a period of not less than one year.

At its meeting of 15 February 2016, the Board of Directors changed the Company's mode of governance by separating the functions of Chairman of the Board of Directors and of Chief Executive Officer. The separation of functions has been effective since 18 July 2016, date on which Marc de Garidel became Chairman of the Board of Directors.

The Board of Directors of 28 May 2020 appointed David Loew Chief Executive Officer effective 1 July 2020.

5.3.2 Executive Management

■ 5.3.2.1 Chief Executive Officer

Extract from the Ipsen S.A. Articles of association as of 29 May 2020

“17.2 Prior approval by the Board of Directors

The Chief Executive Officer is required to obtain the Board of Directors' prior approval for the following matters:

(i) Any decision relating to any investment, acquisition, divestment, disposal, sale or transfer (in any way whatsoever) of assets, branch or equity interests for a unit amount exceeding (i) thirty-five percent (35%) of the Core Operating Income (“COI”) as published in the last available yearly financial statements or (ii) 5 % of the market capitalization of the Company as at the date of the contemplated transaction;

(ii) Any decision on the Company's financial indebtedness resulting in (x) the consolidated net debt / consolidated EBITDA ratio being greater than 2 (using the EBITDA provided in the budget approved by the Board of Directors for the relevant period of time) or (y) a material off balance sheet commitment exceeding on of the thresholds mentioned in paragraph (i) immediately above; and

(iii) Any other decision for which the Chief Executive Officer is required to obtain the Board of Directors' prior approval pursuant to the Internal Rules of the Board of Directors.”

Extract of the Internal Rules of the Board of Directors, as of 6 October 2021, regarding the Chief Executive Officer

“Article 2.2 The Chief Executive Officer

The Chief Executive Officer is responsible for:

- The general management of the Company;
- The chair of the Executive Leadership Team (ELT);
- Directing the Company and managing its operations.;
- Acting with the broadest powers in the name of the Company in all circumstances, subject to powers attributed by law to the Board of Directors or to the Shareholders' General Meeting.

Notwithstanding the above, the Chief Executive Officer is required to obtain Board of Directors prior approval for the following matters:

- Acquisition, licensing, sale of assets or equity investments or off-balance sheet commitment within an approved strategy exceeding a unit amount of €50 million commitment. Conditions of approval exceeding this amount are described in a detailed procedure established by the Company;
- Transfers of assets and/or equity interests, partnerships or joint ventures, financial investments exceeding a unit amount of €20 million;
- Any transaction or off-balance sheet commitment that is outside the Company's approved strategic framework with a financial impact exceeding €10 million;
- Capital expenditures (Capex) or divestures exceeding a unit amount of €20 million;
- Strategic internal restructuring operations (including significant reorganization and/or locations of major industrial and commercial sites) and having a financial impact exceeding €20 million;
- Financing transactions (including lease agreement) likely to modify the financial structure of the Company with a financial value exceeding €20 million;
- Any new mid or long-term debt financing of the Company and its subsidiaries, with a financial value exceeding €50 million; or any financing draw of the Company and its subsidiaries that would result in increasing above two (2) times the ratio of (i) consolidated net debt to (ii) consolidated EBITDA as set in the latest budget approved by the Board of Directors for the period;
- Creation, acquisition or transfer of legal entities when the total related investment exceeds €20 million;
- Litigations, penalties, fines, settlements, compromises, exceeding €10 million.

In each of the aforementioned situations, the amounts referred to must, for the same project, be assessed by aggregating all the actions and decisions relating to the same purpose or pursuing the same goal (whether the investment, divestiture, acquisition, transfer, indebtedness or contract in question is carried out in one or several installments by the Company or one or more of its subsidiaries over multiple years).

The Chief Executive Officer informs the Directors, or ensures that they are informed of inspections, verifications or injunctions of authorities, and keeps the Directors informed of relevant follow-ups in a timely fashion.

The Chief Executive Officer may attend all of the meetings of the Committees of which he is not a member in an advisory capacity and may consult them on any issue within their area of competence.”

Appointment and dismissal

When the Board of Directors chooses to separate the functions of Chairman of the Board of Directors and Chief Executive Officer, it shall appoint the Chief Executive Officer, set the term of his office and, where applicable, determine the limits to his powers.

The Chief Executive Officer may be dismissed at any time by the Board of Directors. When the Chief Executive Officer does not assume the duties of Chairman of the Board of Directors, his dismissal may give rise to damages if it is decided without just cause.

The Chief Executive Officer is subject to the provisions of Article L.225-94-1 of the French Commercial Code relating to the simultaneous holding of offices as Chief Executive Officer, member of the Management Board, sole Chief Executive Officer, Director or member of the Supervisory Board of public limited companies having their registered office on French territory.

When the General Management is assumed by the Chairman of the Board of Directors, the provisions relating to the Chief Executive Officer apply to him.

Powers

The Chief Executive Officer is vested by the Articles of association with the broadest powers to act in all circumstances in the name and on behalf of the Company.

He exercises these powers within the limits of the corporate purpose and subject to those powers expressly granted by law to the Shareholders' Meetings and the Board of Directors, and in accordance with the provisions of Article 17.2 of the Articles of association and those of article 2.2. of the Internal Rules of the Board above.

The Chief Executive Officer represents the Company in its dealings with third parties. The Company shall be bound even by acts of the Chief Executive Officer that are not in the Company's interest, unless it proves that the third party knew that the act exceeded this interest or that it could not have been unaware of this fact in the circumstances, it being specified that the mere publication of the Articles of association is not sufficient to constitute such proof.

However, for certain Business Development transactions, the Board of Directors has determined thresholds, specific and distinct from those listed in the Internal Rules of the Board, for which the authorization of the Board, upon recommendation of the relevant Innovation and Development Committee, will be required.

Executive Management

David Loew has been appointed Chief Executive Officer by the Board of Directors of 28 May 2020, effective from 1 July 2020.

| | | |
|---|--|--|
| David Loew Director and Chief Executive Officer | Nationality: Swiss | Shares owned: 500 Voting rights: 500 |
| Committees: | Biography and experience | |
| <ul style="list-style-type: none"> Innovation and Development Committee – Specialty Care (Permanent guest) Innovation and Development Committee – Consumer HealthCare (permanent guest) | <p>David Loew was coopted as Director of Ipsen S.A., by the Board on 28 May 2020, from this date, and appointed Chief Executive Officer from 1 July 2020.</p> <p>Prior to joining Ipsen, David was CEO of Sanofi Pasteur Vaccines. During his tenure, he piloted a successful worldwide growth strategy <i>via</i> acquisitions and licensing deals.</p> <p>David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region.</p> <p>David has served on the Board of the Global Alliance for Vaccines and Immunization (GAVI), chaired the Steering Committee of IFPMA and has strong connections with global organizations, including the WHO, UNICEF, the Bill & Melinda Gates Foundation, as well as American health agencies, including BARDA and the NIH.</p> <p>David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.</p> | |
| Date of birth: 20 March 1967 | | |
| Date of 1st appointment: Chief Executive Officer: 1 July 2020 (unlimited period) Director: 28 May 2020 | | |
| Ratification date and last renewal date: 27 May 2021 | | |
| Term of office: 2025 Shareholders' Meeting | | |
| | Positions and functions currently held | |
| | Within the Ipsen Group or its main shareholders: | Outside the Ipsen Group or its main shareholders: |
| | Listed company: • Ipsen S.A. (France), Director and Chief Executive Officer | Listed company: None |
| | Non listed company: • Ipsen Pharma SAS (France), Chairman | Non listed company: None |
| | Positions previously held that expired during the last five years | |
| | <ul style="list-style-type: none"> Sanofi Pasteur, Executive Vice President Global Alliance for Vaccines and Immunization (GAVI), Member of the Board of Directors International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Chairman of the vaccine Steering Committee | |

For the purposes of his duties, the Chief Executive Officer is domiciled at the Company's registered office.

During 2021 financial year, as part of their duties, the Chief Executive Officer, the Chief Financial Officer and the Investor Relations Department met regularly with the Company's investors, notably at the moment of the presentation of the Company's financial results. During these meetings, they answered investors' questions about the Company's business. They reported to the Board of Directors. They also participated to investors' days. The presentations are available on Ipsen's website www.ipsen.com.

■ 5.3.2.2 Executive Leadership Team

To allow the Chief Executive Officer to conduct its missions, an Executive Leadership Team ("ELT") that is responsible for managing the Company's day-to-day operations and for coordinating the Group's various scientific, legal, financial, commercial, and strategic actions has been set up. The ELT is also responsible for establishing consistent management policies throughout the Group and for assisting the Chairman of the Board of Directors in implementing the Board's decisions.

Composition of the Executive Leadership Team at the date of the Document

The members of the ELT are as follows:

| Name | Function | Date of entry in the ELT |
|-----------------------------|---|--------------------------|
| David Loew | Chief Executive Officer and Chairman of the Executive Leadership Team | 2020 |
| Catherine Abi-Habib | Executive Vice President, Strategy, Transformation & Digital | 2022 |
| Bartosz (Bartek) Bednarz | Executive Vice President, Head of Global Product and Portfolio Strategy | 2020 |
| Stewart Campbell | Executive Vice President, President of Ipsen North America | 2021 |
| François Garnier | Executive Vice President, General Counsel & Chief Business Ethics Officer | 2015 |
| Benoît Hennion | Executive Vice President, Consumer HealthCare | 2017 |
| Steven Hildemann, M.D., PHD | Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs | 2020 |
| Aymeric Le Chatelier | Executive Vice President, Chief Financial Officer | 2014 |
| Philippe Lopes-Fernandes | Executive Vice President and Chief Business Officer | 2020 |
| Howard Mayer, M.D. | Executive Vice President, Head of Research & Development | 2019 |
| Régis Mulot | Executive Vice President, Chief Human Resources Officer | 2018 |
| Aidan Murphy | Executive Vice President, Technical Operations | 2018 |
| Mari Scheiffele | Executive Vice President, Specialty Care International | 2021 |
| Gwenan White | Executive Vice President, Communication and Public Affairs | 2021 |

Biographies of ELT members can be found on the Company's website www.ipsen.com.

The members of the ELT, with the exception of David Loew, hold an employment contract with the Group. There are no other agreements or service contracts entered into between the Company or one of its subsidiaries and one of the members of the Company's ELT.

Policies of non-discrimination and diversity within the Group, and of management bodies diversity

A policy of non-discrimination and diversity has been implemented within the Group, presented to the Board of Directors in 2018 and reviewed during the 2019 financial year.

In addition, a policy on gender diversity within governing bodies was presented to the Ethics and Governance Committee on 9 February 2021.

More details regarding these policies can be found in Chapter 4 of this document.



5.4 COMPENSATION OF CORPORATE OFFICERS

5.4.1 Compensation policy of Corporate Officers

These elements of the compensation policy for Corporate Officers are in line, in terms of principles and structure, with the policy approved by the Shareholders' Meeting of 27 May 2021.

In accordance with Article L.22-10-8 I of the French Commercial Code, this compensation policy also applies to Directors of the Company. It was drawn up by the Board of Directors, upon the recommendation of the Compensation Committee.

The compensation policy with regard to Corporate officers and their individual compensation is decided by the Board of Directors upon recommendation of the Compensation Committee, outside the presence of the Executive Corporate Officers concerned.

In accordance with Article L.22-10-34 II of the French Commercial Code, compensation elements paid during the 2021 financial year or granted for the 2021 financial year to the Chairman of the Board of Directors and to the Chief Executive Officer shall be submitted to the vote of the shareholders at the Annual Combined Shareholders' Meeting to be held in 2022 to approve the financial statements for the financial year ended on 31 December 2021, following a specific resolution for each element.

■ 5.4.1.1 General principles

Ipsen is a dynamic and growing global specialty-driven biopharmaceutical group focused on innovation and Specialty Care that is improving people's lives through differentiated and innovative medicines in Oncology, Neuroscience and Rare Disease. The strong position in Specialty Care, combined with the presence in Consumer HealthCare, provides the Group with the scale, expertise and stability needed to make a sustainable difference for people in a quickly-evolving healthcare environment.

In this context, several elements are taken into consideration to determine the compensation policy: consistency, comparability with the Ipsen environment reference market, well balanced nature of its alignment with the Group strategy and compliance with the AFEP-MEDEF Code.

The compensation policy adopted by the Board of Directors contains incentive elements that reflects the Group Strategy, including the sustainable growth over the long term by acting in a responsible way, respecting the social interest.

To determine the compensation policy, the Board of Directors takes into account the principles of completeness, balance, comparability, consistency, clarity and proportionality as recommended by the AFEP-MEDEF Code of Corporate Governance.

The compensation policy reflects the level of responsibility of the Corporate Officers and Senior executives. It is adapted to the Group context, remains competitive and is an incentive to

promote the Group's performance over the medium to long-term, in compliance with the corporate interest and the interests of all the stakeholders, and contributes to the commercial strategy as well as the sustainability of the Company. The compensation policy ensures that trends in the compensation of Corporate Officers are taking into consideration trends in compensation for all Group employees, and those of the Company. For the decision-making process followed for determining and adjusting the compensation policy, the terms of compensation and employment of the Company's employees have been considered by the Compensation Committee and the Board of Directors, specifically the information covered in Article L.22-10-9 of the French Commercial Code.

The compensation policy covers all aspects of the fixed, variable and exceptional compensation and of the benefits of any kind, paid or granted by the Company. It is decided not only on the basis of the work carried out, the results obtained, and the responsibility assumed, but also on the basis of practices for comparable companies and the compensation of the Company's other senior executives.

The compensation of the Corporate Officers is structured as follows:

- fixed or base compensation;
- annual variable compensation (only for Executive Corporate Officers);
- if applicable, multi-annual variable compensation (only for Executive Corporate Officers);
- if applicable, exceptional compensations and/or financial indemnity (only for Executive Corporate Officers);
- eligibility for compensation paid or granted to Directors;
- allocation of stock options and performance shares under plans approved by the Board of Directors (only for Executive Corporate Officers);
- if applicable, other benefits;
- if applicable, payments, benefits and compensation granted to Executive Corporate Officers upon termination of their functions;
- if applicable, retirement schemes.

In the event that the Board of Directors decides to appoint one or more Deputy Chief Executive Officers, the compensation policy applicable to the Chief Executive Officer would be applicable to the Deputy Chief Executive Officers.

In the event that the Board of Directors decides to combine the functions of Chairman and Chief Executive Officer, the compensation policy applicable to the Chief Executive Officer would apply to the Chairman and Chief Executive Officer.

■ 5.4.1.2 Decision making process for setting, revising and implementing the compensation policy

The compensation policy for Corporate Officers is set by the Board of Directors upon proposal of the Compensation Committee. The Board of Directors refers to the AFEP-MEDEF Code for the determination of the compensation and benefits granted to the executive and non-executive Corporate Officers.

In accordance with the Board of Directors' Internal Rules, the main duties of the Compensation Committee are (i) to propose to the Board the various components of compensation paid to corporate officers, members of Executive Management and senior Group managers, (ii) to keep itself informed of the recruitment of key members of Group management other than the Chief Executive Officer and of the setting of and changes in the various components of their compensation, (iii) to issue recommendations on the amount and distribution of compensation paid to Board members and (iv) to make recommendations to the Board on the Group's compensation policy, employee savings plans, reserved issues of securities giving access to the capital and the granting of stock options or bonus shares, pension plans, or any other equivalent formulas. For more information concerning the Compensation Committee, see section 5.2.2.6 above.

The members of the Compensation Committee are chosen for their technical skills, as well as for their good understanding of the standards in force, emerging trends and practices of the Company.

To carry out their mission, the members of the Committee regularly invite the Executive Vice President, Chief Human Resources Officer, to attend some meetings in order to present the Group compensation policy and review the compensation policy to Corporate Officers.

In addition, the Chairman of the Committee, who is also the Vice Chairman of the Board of Directors, may exchange with the Chairperson of the Audit Committee to study in particular the financial performance of the Group, accounting and fiscal impacts of the Corporate Officers and with the Chairman of the Board to study the strategy of the Group.

The members of the Compensation Committee also invite the Chairman of the Board and the Chief Executive Officer to discuss their performance. An evaluation on the performance of the Chairman and of the Chief Executive Officer is conducted every year, without their presence. The conclusions of the evaluation are presented to them.

In addition, to avoid or manage any conflict of interest, the Chairman of the Board and the Chief Executive Officer, if a Director, do not participate and do not take part in the Board's deliberations on an element or commitment to their benefit.

The compensation policy is not subject to an annual review; however, certain terms and conditions for implementing the policy are defined by the Board of Directors on an annual basis, such as the performance criteria applicable to the annual variable compensation of the Chief Executive Officer.

After consulting the Compensation Committee and, where appropriate, the other Specialized Committees, the Board of Directors may temporarily waive the compensation policy of the Chief Executive Officer in the event of exceptional circumstances and in the event that changes are made in line with social interest and necessary to guarantee the sustainability or viability of the Company. The events which could give rise to the use of this possibility of derogation from the compensation policy could be, without being limited to, exceptional external growth operations or a major change in strategy or in the event of a major economical, political or sanitary crisis.

The elements of compensation to which derogations may be made are the fixed compensation and the annual variable, and the derogations may consist of an increase or a decrease in the compensation concerned and/or adjustment of associated criteria.

In addition, the comments of shareholders are considered by the Company and the Board of Directors in determining the compensation policy.

■ 5.4.1.3 Components of the compensation of corporate officers

(a) Compensation policy for Directors

The Board of Directors decided at its meeting of 10 November 2009, with effect from the 2010 financial year, and within the global limit of €1,200,000 approved by the Combined Shareholders' Meeting held on 7 June 2017 (until new decision), to allocate a compensation to the Board members as follows:

- each member of the Board of Directors receives an amount of €40,000 for a full year of service,
- the Vice Chairman of the Board of Directors receives an additional amount of €50,000 for a full year of service,
- the members of Committees of the Board receive an amount of €15,000 for a full year of service,
- the Chairpersons of the Audit Committee and of the Compensation Committee receive an additional amount of €35,000 for a full year of service,
- the Chairpersons of the Nomination Committee, the Innovation and Development Committee – Specialty Care, the Innovation and Development Committee – Consumer HealthCare and the Ethics and Governance Committee receive an additional amount of €20,000 for a full year of service,
- each Director who is a member of at least one Committee shall receive an additional amount of €5,000 for a full year of service.

The Board of Directors can decide to allow an additional amount of €5,000 for intercontinental travel to attend a meeting of the Board.

The Board of Directors has decided on 13 December 2017 to implement a variability system related to effective attendance based upon the number annual meetings of the Board and the Committees, attending by each member, breaking down as follows:

- payment of a fixed proportion (40%) after the end of 1st half-year;

- payment of the variable proportion (60%) after the end of 2nd half-year after taking into account the effective attendance at the Board and Committee meetings over the year.

Pursuant to the Company's Articles of association, the Board of Directors may award exceptional compensation to Directors for the missions or mandates entrusted to them; as appropriate, the Statutory Auditors are notified of such compensation, which is submitted for approval to the Ordinary Shareholders' Meeting.

Moreover, Directors representing the employees shall not receive any compensation in his/her capacity as Director. They have an open-ended employment contract with a subsidiary of the Company, including terms of advance notice and cancellation, in accordance with regulations.

In addition, the term of office of directors is mentioned in section 5.2.2.2 of this document.

(b) Chairman of the Board

a. Allocation of the various compensation components

The compensation policy is decided by the Board of Directors, upon recommendation of the Compensation Committee, outside the presence of the Chairman.

The Board of Directors, upon recommendation of the Compensation Committee, determines the relevant compensation components applicable to the Chairman of the Board, taking into consideration the Group environment, the scope of responsibilities, the Chairman' prior positioning and service within the Group if applicable, and any other factors that would be relevant in the context of the Group.

b. Base compensation

Base compensation takes into account the reference markets of Ipsen, in particular in the pharmaceutical industry, and companies with similar size and environment, both in France, Europe and the U.S. given the international footprint of Ipsen and its strategy to be a global biopharmaceutical company focusing on Innovation and Specialty Care. It is subject to be reviewed by the Board of Directors, typically at relatively long intervals, according to the Company's market position and taking account changing responsibilities.

c. Variable compensation

The Board of Directors has decided that no annual or multi-annual variable compensation shall be paid or granted to the non-executive Chairman of the Board of Directors.

d. Exceptional compensation and/or financial indemnity

The non-executive Chairman of the Board of Directors shall not receive any exceptional compensation and/or financial indemnity.

e. Compensation as a Director

The corporate officers who are members of the Board of Directors may, where appropriate, upon recommendation of the Compensation Committee, and by decision of the Board of Directors, receive a compensation granted on the basis of their positions as Directors according to the rules applicable to all of the Directors.

f. Stock options and performance shares

In accordance with the recommendations of the AFEP-MEDEF Code, the non-executive Chairman of the Board of

Directors shall not benefit from stock option or performance share plans.

g. Other benefits

The Chairman of the Board may also be awarded benefits in respect of his duties carried out within Ipsen, including: benefits in kind (Company car, temporary accommodation and school fees), assistance for the preparation and filing of personal income tax returns, global healthcare coverage (health coverage and death/disability insurance) under the Group's contract, reimbursement of travel expenses and expenses incurred with the exercise of their corporate duties, and D&O liability insurance.

h. Severance payment

The Chairman may benefit from a severance payment clause, granted in the event of termination of his duties, of which the terms have been decided by the Board of Directors in accordance with the recommendations of the AFEP-MEDEF Code:

- payment granted only in the event of a forced departure (*départ contraint*) within the meaning of the AFEP-MEDEF Code; this payment will be excluded if the Chairman leaves on his own initiative the Company;
- equal to 24 months of gross fixed compensation paid for his duties;
- the granting of which is subject to some performance cumulative conditions, which are (i) Group operating income for 2017 and 2018 at a rate of at least 15% and, as of 2019 and subsequent years, the maintenance of Group operating income at a rate of at least 20%, and (ii) free cash flow before operating investments during the three years prior to departure above a threshold of €300 million, in line with the Group's strategy;
- including, for a portion equal to 50% of its total, the amount payable in consideration for the non-compete clause of the Chairman of the Board of Directors;
- no non-compete benefit is paid once the Chairman of the Board claims his pension rights and in any event, no benefit can be paid over the age of 65.

It is specified that the Board of Directors can waive the application of the non-compete undertaking upon departure of the Chairman of the Board.

i. Non-compete payment

The Company has concluded a non-compete agreement with the Chairman of the Board in case of departure from the Group for a reason other than a change of control. This agreement shall be valid for a certain period following the date of his actual departure. The non-compete payment may not exceed a ceiling of two years of base compensation, including, if applicable, the amount owed as a severance payment, for up to 50%.

It is specified that the Board of Directors can waive the application of the non-compete undertaking upon departure of the Chairman of the Board. It is also specified that no non-compete benefit will be paid once the Chairman of the Board claims his pension rights and in any event, no benefit can be paid over the age of 65.

j. Retirement Schemes

Executive Corporate Officers may benefit from defined-contribution plans or defined-benefit retirement plans, which benefit the Company's executives more broadly, in accordance with the AFEP-MEDEF Code. These elements are taken into account for the determination of Executive Corporate Officers' global compensation.

Pursuant to the PACTE Law No. 2019-486 of 22 May 2019 and Ordinance No. 2019-697 of 3 July 2019 on supplementary pension plans, the defined-benefit pension plan described below can no longer grant a right to acquire supplementary conditional rights as from 1 July 2019. On that date, it was also closed to new members of the Company.

This collective retirement scheme was implemented unilaterally by the Company in 2005 and adopted in a set of regulations which specifies the rights and obligations of the relevant participants in the Company.

The establishment of non-vested rights is based on the level of liability accrued in the Company's books at 30 June 2019, *i.e.* the Projected Benefits Obligations, PBO.

Establishment of the rights involves freezing the calculation of the defined-benefits pension at the level of the PBO at the closing date. No further rights were granted after the scheme was closed. At the same time, an additional collective defined-contribution plan ("Article 83") was established as of 1 July 2019. Under this plan, fully funded by the Company, executives may build up a supplementary retirement pension with a certain contribution percentage of the total compensation in cash (annual base and variable compensation).

To manage several types of situations, a defined-contribution plan with individual rights was established ("Article 82"). Under this scheme, fully funded by the Company, a custom amount to be outsourced to an insurance company can be determined, on an individual basis. This grant is subject to one condition of presence and two cumulative performance conditions, namely, as from 2019, (i) maintaining the level of the operating margin of the Group's activities during the three years preceding the departure at a minimum threshold of 20% and (ii) maintaining free cash flow before capital expenditure (CAPEX) during the three financial years preceding the departure at a minimum threshold of €300 million, in line with the Group's strategy.

(c) Executive Corporate Officers, the Chief Executive Officer

a. Allocation of the various compensation components

The compensation policy is decided by the Board of Directors, upon recommendation of the Compensation Committee, outside the presence of the Chief Executive Officer.

The Board of Directors, upon recommendation of the Compensation Committee, determines the relevant

compensation components applicable to the Chief Executive Officer, taking into consideration the Group environment, the scope of responsibilities, the Chief Executive Officer's prior positioning and service within the Group, if applicable, and any other factors that would be relevant in the context of the Group.

b. Base compensation

Base compensation takes into account the reference markets of Ipsen, in particular in the pharmaceutical industry, and companies with similar size and environment, both in France, Europe and the U.S. given the international footprint of Ipsen and its strategy to be a global biopharmaceutical company focusing on Innovation and Specialty Care. It is subject to be reviewed by the Board of Directors, typically at relatively long intervals, according to the Company's market position and taking account changing responsibilities.

c. Annual variable compensation

Annual variable compensation is linked to the Group's overall performance and to the achievement of Executive Corporate Officers' personal targets. Every year, the Board of Directors defines and precisely predetermines qualitative and quantifiable criteria for determining the variable compensation and the target objectives. Quantifiable criteria are preponderant to the determination of total variable compensation and a limit is set on the qualitative part.

Annual variable compensation is set on the basis of a target variable compensation equal to 100% of the base compensation, within a range between 0 and 150%, in case of under or overperformance. It is specified that, in 2020, this range was between 0 and 200%, it has been decided to set the limit at 150% to reinforce the alignment with the program of short term incentives for all Ipsen employees. The annual variable compensation is based on the following quantifiable and qualitative performance criteria: two-thirds of this target bonus are based on quantifiable criteria of equal weighting, *i.e.* achievement of consolidated net sales levels, core operating income, earnings per share and cash flow; the remainder is based on qualitative criteria clearly defined, split into three categories: Strategy/Business, Management and Social Responsibility. The Strategy/Business category includes targets supporting the Company's long-term mission and goals; Management includes corporate management targets to support the annual execution of the strategy defined by the Board of Directors; and Social Responsibility includes objectives supporting the corporate social responsibility strategy as developed through three pillars: employees, patients and society, and environment, in line with the strategy and CSR policy of the Group.

The Board of Directors, upon recommendation of the Compensation Committee, determines the level of achievement of these performance criteria, with respect to the Company's financial position at 31 December of each year and some criteria pre-established each year.

| | Criteria | Weight | Potential variation of the portion |
|-------------------------|------------------------|--------|------------------------------------|
| Performance indicators | Consolidated net sales | 1/6 | 0% to 150% |
| | Core operating income | 1/6 | 0% to 150% |
| | Cash flows | 1/6 | 0% to 150% |
| | Earnings per share | 1/6 | 0% to 150% |
| Quantifiable objectives | | 2/3 | 0% to 150% |
| Qualitative objectives | | 1/3 | 0% to 150% |
| Total | | 100% | 0% to 150% |

The results achieved, the rate of achievement of each criterion and the amount of the annual variable compensation are determined by the Board of Directors, at the latest at the meeting dedicated to the consolidated financial statements for the year. Subject to approval by the shareholders' meeting, the Board of Directors would benefit from a discretionary power in the application of the compensation policy in order to ensure that the annual variable compensation of the Chief Executive Officer correctly reflects the performance of the Group. If the Board of Directors decides, on a proposal from the Compensation Committee and due to exceptional circumstances, to use this discretionary power, it should respect the principles set out in the compensation policy and provide shareholders with a clear, precise and complete explanation of his choice. This discretionary power would only apply to a limited part of the annual variable compensation and could increase or decrease the amount of the annual variable compensation theoretically reached, in application of performance criteria, for the year; without ever exceeding the overall ceiling provided for in the compensation policy. Thus, the Board of Directors could determine, on a proposal from the Compensation Committee, that the compensation policy - previously approved by the shareholders - would be taken into account of the occurrence during the financial year of new circumstances. - unpredictable when the Board was determining the compensation policy for the related financial year - significantly impacting, upward or downward, the rate of achievement of the performance criteria attached to annual variable compensation. In this case, the Board could decide to modify in a limited way the amount of the annual variable compensation so that it better reflects the actual performance of the Group.

d. Multi-annual variable compensation

The Board of Directors may decide to grant multi-annual variable compensation to the Chief Executive Officer and certain managing executives of the Group as part of plans approved by the Board of Directors upon recommendation of the Compensation Committee; it is determined on the basis of a percentage of base compensation.

These plans are subject to a presence condition and, precisely predetermined performance conditions, financial and non financial ones, which could belong to some kind of criteria of annual variable compensation, which must be fulfilled during an acquisition period set by the Board of Directors. Nevertheless, in the event of death, disability, retirement or exception granted by the Board of Directors before the end of the acquisition period, the beneficiary may retain his rights. The details of the external and internal criteria and the completion levels (expected and realized) of the external and internal criteria are not disclosed for confidentiality reasons.

e. Exceptional compensation and/or financial indemnity

The Board of Directors may decide, in case of specific circumstances or events, to grant exceptional compensation to the Chief Executive Officer. The grant of exceptional compensation will be calculated based on the total annual compensation.

It can decide to grant an exceptional compensation and/or an exceptional financial indemnity to the Chief Executive Officer while taking into account the specific circumstances in which he carries out his duties.

f. Special financial indemnity

The Board of Directors may grant a special financial indemnity to a new Executive Corporate Officer coming in from a company outside the Group, in order to offset the loss of the benefits they received previously. This indemnity may be paid in cash, in performance shares or in a mix of cash and performances shares. Any grant of performance shares as part of the Special financial indemnity shall be subject to the terms and conditions set forth in section h. (Stock options and performance shares) hereafter.

g. Compensation as a Director

The Corporate Officers who are members of the Board of Directors may, where appropriate, upon recommendation of the Compensation Committee, and by decision of the Board of Directors, receive a compensation granted on the basis of their positions as Directors according to the rules applicable to all of the Directors.

h. Stock options and performance shares

Executive Corporate Officers as well as certain managing executives of the Group may benefit from stock options and/or performance shares under plans approved and set each year by the Board of Directors upon recommendation of the Compensation Committee. In accordance with the AFEP-MEDEF Code recommendations (§25.2), non-executive officers shall not benefit from stock option and/or performance shares plans.

The definitive number of stock options that will be granted to Executive Corporate Officers, will depend upon the level of achievement of the performance conditions set by the Board of Directors, based on one or several internal criteria.

The definitive number of performance shares that will be vested will depend upon the level of achievement of the performance conditions set by the Board of Directors, which are based on one or several internal criteria (e.g., quantifiable financial ratio) and on one or several external criteria (e.g., share price compared to a benchmark of comparable companies). Each of these conditions shall be assessed by comparing the target threshold and the actual performance of the Company over the period used as reference for the applicable plan. Each of these conditions may generate a

payout varying within a range between zero to a certain percentage pre-established and determined by the Board of Directors at the implementation of the plan.

The Board of Directors decided that the Corporate Officers must retain, until the end of their term of office, a number of shares equivalent to 20% of the net capital gain that would be realized upon the sale of the shares resulting from the exercise of stock options and/or from the performance shares.

The total number of free shares allocated shall not exceed 3% of the share capital on the date of the Shareholders' Meeting that authorized the Board to proceed with the share grants, with the specification that the total number of shares to which the holders of options that may be granted by the Board of Directors are entitled shall be applied against that ceiling.

The total number of free shares that may be granted to Corporate Officers of the Company shall not exceed 20% of this budget, and vesting shall be subject to performance conditions set by the Board of Directors.

The shares granted to recipients shall be final at the end of a vesting period, for which the term shall be set by the Board of Directors at not less than two years, with the specification, however, that the vesting period for Executive Corporate Officers shall not be less than three years. The Board of Directors may stipulate a retention requirement at the end of the vesting period.

Nevertheless, in the event of death, disability, retirement or change of control granted by the Board of Directors before the end of the acquisition period, the beneficiary or, if applicable, its assignees, can keep their rights.

The Executive Corporate Officers who are beneficiaries of these stock options and/or performance shares undertook a formal commitment not to engage in hedging transactions either on their options or on shares issued following the exercise of options or on performance shares granted until the end of the holding period that has been decided by the Board of Directors.

The Board of Directors has established periods preceding the publication of half-yearly and annual financial statements and sales figures during which it is not permitted to carry out any transaction on Company shares and has established the following procedure:

- the dates of the blackout periods for each financial year are communicated at the beginning of each year and before each blackout period;
- outside blackout periods, an identified person must be consulted to ensure that no insider information is held.

i. Other benefits

The Chief Executive Officer may also be awarded benefits in respect of his duties carried out within Ipsen, including: benefits in kind (Company car and temporary accommodation, school fees), assistance for the preparation and filing of personal income tax returns, global healthcare coverage (mutual and life/disability schemes) under the Group's contracts, reimbursement of travel expenses and expenses incurred with the exercise of their corporate duties, D&O liability insurance.

Payments, benefits and compensation granted to Executive Corporate Officers upon termination of their functions

j. Severance payment

Executive Corporate Officers may benefit from a severance payment clause, granted in the event of termination of their duties, of which the terms have been decided by the Board of Directors in accordance with the recommendations of the AFEP-MEDEF Code:

- payment granted only in the event of a forced departure (*départ contraint*) within the meaning of the AFEP-MEDEF Code, it being specified that the payment is excluded if the Corporate Officer leaves the Company on a voluntary basis;
- equal to 24 months of gross fixed compensation paid for his duties (fixed and variable annual compensation) for the corporate office;
- the grant of which is subject to two cumulative performance conditions which are (i) Group operating income for 2017 and 2018 at a rate of at least 15% and, as of 2019 and subsequent years, the maintenance of Group operating income at a rate of at least 20%, and (ii) free cash flow before operating investments during the three years prior to departure above a threshold of €300 million, in line with the Group's strategy;
- including 50% of the amount due under the non-competition undertaking given by the Chief Executive Officer.

It is specified that the Board of Directors may waive the implementation of the non-competition indemnity upon the departure of the Chief Executive Officer by decision of the Board.

k. Non-compete payment

The Board of Directors has concluded a non-compete agreement with the Chief Executive Officer in case of departure from the Group for a reason other than a change of control. This agreement shall be valid for a certain period following the date of departure.

The non-compete payment may not exceed a ceiling of two years of compensation (base and annual variable), including, if applicable, the amount of a severance payment, up to 50%.

It is specified that no non-compete benefit will be paid once the Chief Executive Officer claims his pension rights and that no benefit can be paid in this respect if the Chief Executive Officer has reached the age of 65 on the effective date of departure.

It is also specified that the Board of Directors can waive the application of the non-compete undertaking upon departure of the Chief Executive Officer by decision of the Board.

l. Retirement Schemes

The Executive Corporate Officers may benefit from defined contribution plans or defined-benefit plan which more broadly benefits the Company's executives, in accordance with the AFEP-MEDEF Code. These elements are taken into account for the determination of Executive Corporate Officers' global compensation.

An additional collective Defined Contribution scheme (“Article 83”) was set up as of 1 July 2019. This scheme, fully funded by the Company, allows Executives to build a supplementary retirement pension with a certain percentage of contribution of total cash compensation (annual base compensation and variable).

To manage several types of situations, a defined contribution scheme with individual rights (“Article 82”) was set up. Under this scheme, fully funded by the Company, a custom amount to be outsourced to an insurance company can be determined, on an individual basis. It will be subject to several cumulative performance conditions, which are (i) maintenance of the recurring operating margin of the Group and (ii) maintenance of the Free Cash Flow before capital expenditure (CAPEX).

5.4.2 Compensation of Corporate Officers (Articles L.22-10-34 I and L.22-10-9 I of the French Commercial Code)

5.4.2.1 Compensation of the Board members

The Board of Directors decided at its meeting of 10 November 2009, with effect from the 2010 financial year, and within the global limit of €1,200,000 approved by the Combined Shareholders’ Meeting held on 7 June 2017 (until new decision), to allocate a compensation to the Board members as follows:

- each member of the Board of Directors receives an amount of €40,000 for a full year of service,
- the Vice Chairman of the Board of Directors receives an additional amount of €50,000 for a full year of service,
- the members of Committees of the Board receive an amount of €15,000 for a full year of service,
- the Chairpersons of the Audit Committee and of the Compensation Committee receive an additional amount of €35,000 for a full year of service,
- the Chairpersons of the Nomination Committee, the Innovation and Development Committee – Specialty Care and Innovation and Development Committee – Consumer HealthCare and the Ethics and Governance Committee receive an additional amount of €20,000 for a full year of service,

- each Director who is a member of at least one Committee shall receive an additional amount of €5,000 for a full year of service.

The Board of Directors can decide to allow an additional amount of €5,000 for intercontinental travel to attend a meeting of the Board.

The Board of Directors has decided on 13 December 2017 to implement a variability system related to effective attendance based upon the number of annual meetings of the Board and the Committees which they attended to, breaking down as follows:

- payment of a fixed proportion (40%) at the end of 1st half-year;
- payment of the variable proportion (60%) at the end of 2nd half-year after taking into account the effective attendance at the Board and Committee meetings over the year.

The following table shows the amounts paid during the 2020 and 2021 financial years and awarded for those same financial years.

Individual amount and other compensation paid or granted to Directors (gross amounts – rounded)
(Table 3 of AMF recommendations)

| Directors | Amounts granted for 2020 | Amounts paid ⁽¹⁾ in 2020 | Amounts granted for in 2021 | Amounts paid ⁽¹⁾ in 2021 |
|----------------------------------|--------------------------|-------------------------------------|-----------------------------|-------------------------------------|
| Marc de Garidel ⁽¹⁾ | | | | |
| – Compensation as Director | – | – | – | – |
| – Other compensation | see section 5.4.2.2 | see section 5.4.2.2 | see section 5.4.2.2 | see section 5.4.2.2 |
| Anne Beaufour ⁽²⁾ | | | | |
| – Compensation as Director | €658 | €27,583 | – | €395 |
| – Other compensation | – | – | – | – |
| Highrock S.à.r.l. ⁽³⁾ | | | | |
| – Compensation as Director | €36,699 | €15,737 | €38,080 | €36,962 |
| – Other compensation | – | – | – | – |
| Henri Beaufour | | | | |
| – Compensation as Director | €38,800 | €33,040 | €40,000 | €38,800 |
| – Other compensation | – | – | – | – |
| Philippe Bonhomme ⁽²⁾ | | | | |
| – Compensation as Director | €1,726 | €68,690 | – | €1,036 |
| – Other compensation | – | – | – | – |
| Beech Tree S.A. ⁽³⁾ | | | | |
| – Compensation as Director | €103,274 | €41,310 | €105,000 | €103,964 |
| – Other compensation | – | – | – | – |

| Directors | Amounts granted for 2020 | Amounts paid ^(*) in 2020 | Amounts granted for in 2021 | Amounts paid ^(*) in 2021 |
|-----------------------------------|--------------------------|-------------------------------------|--------------------------------|-------------------------------------|
| Laetitia Ducroquet ⁽⁴⁾ | | | | |
| – Compensation as Director | – | – | – | – |
| – Other compensation | – | – | – | – |
| Antoine Flochel | | | | |
| – Compensation as Director | €160,000 | €163,845 | €160,000 | €160,000 |
| – Other compensation | – | – | – | – |
| Margaret Liu | | | | |
| – Compensation as Director | €103,800 | €115,000 | €109,973 | €98,800 |
| – Other compensation | – | – | – | – |
| David Loew ⁽⁵⁾ | | | | |
| – Compensation as Director | – | – | – | – |
| – Other compensation | cf. section 5.4.2.3 | cf. section 5.4.2.3 | cf. section 5.4.2.3 | cf. section 5.4.2.3 |
| Michèle Ollier | | | | |
| – Compensation as Director | €60,000 | €62,360 | €60,000 | €60,000 |
| – Other compensation | – | – | – | – |
| Jean-Marc Parant ⁽⁶⁾ | | | | |
| – Compensation as Director | – | – | – | – |
| – Other compensation | – | – | – | – |
| Paul Sekhri | | | | |
| – Compensation as Director | €92,100 | €95,560 | €104,000 | €87,100 |
| – Other compensation | – | – | – | – |
| Carol Stuckley ⁽⁷⁾ | | | | |
| – Compensation as Director | €120,000 | €130,000 | €70,397 | €115,000 |
| – Other compensation | – | – | – | – |
| Piet Wigerinck | | | | |
| – Compensation as Director | €75,000 | €66,245 | €71,400 | €75,000 |
| – Other compensation | – | – | – | – |
| Carol Xueref | | | | |
| – Compensation as Director | €123,800 | €117,838 | €125,000 | €123,800 |
| – Other compensation | – | – | – | – |
| Total / Gross amount | | | | |
| – Compensation as Director | €915,857 | €937,208 | €883,850 ⁽⁸⁾ | €900,857 ⁽⁸⁾ |
| – Other compensation | – | – | – | – |

(*) Amounts paid on a half-year basis in arrears (within the month following each half-year closing), based *pro rata temporis* on the time spent in office during the half-year, if applicable. The variability system of the directors' compensation has been applicable since 1 January 2018.

(1) Marc de Garidel does not receive any compensation as Director. It is stated that the compensation elements of Marc de Garidel paid or granted as Chairman of the Board of Directors are presented at section 5.4.2.2 of this document.

(2) Director since 6 January 2020, the amount of director's fees have been calculated *pro rata temporis* on the time spent in office during the year.

(3) Director until 6 January 2020, the amount of director's fees have been calculated *pro rata temporis* on the time spent in office during the year.

(4) Laetitia Ducroquet has been designated Director representing the employees by the European Works Council on 6 November 2020 and doesn't receive any compensation relating to her mandate. It is stressed that she holds an employment contract within the Group and as such receives compensation that is unrelated to the exercise of her mandate. As a result, this compensation is not communicated.

(5) David Loew does not receive any compensation as Director. It is stated that the compensation elements of David Loew as Chief Executive Officer are presented at section 5.4.2.3 of this document.

(6) Jean-Marc Parant has been designated Director representing the employees by the Central Works Council on 27 November 2018 and doesn't receive any compensation relating to his mandate. It is stressed that he holds an employment contract within the Group and as such receives compensation that is unrelated to the exercise of his mandate. As a result, this compensation is not communicated.

(7) Director until August 2021, the amount of directors' compensation has been calculated on a *pro rata* basis for the duration of the functions during the year.

(8) The amounts shown are gross amounts. In 2021, individual directors received a net amount after deduction of 12.8% for foreign tax residents and 30% for French residents. Legal entity directors received a net amount after deduction of 26.5% for withholding tax.

The payment of directors' compensation was suspended between 6 August 2021 and 20 January 2022 following the resignation of Carol Stuckley and until parity on the Board is regularized (return to a minimum of 40% of directors of each gender). The payment was made after this regularization.



5.4.2.2 Compensation of the Chairman of the Board

The compensation elements of Marc de Garidel, Chairman of the Board of Directors, were determined by the Board of Directors, upon recommendation of the Compensation Committee, at its meeting held on 28 May 2019 further to the renewal of his office. These elements were unchanged for 2021.

In accordance with the Articles L.22-10-8 and L.22-10-34 of the French Commercial Code, the compensation elements paid during the financial year ended 31 December 2021 or granted to Marc de Garidel for the year ended 31 December 2021, in respect of his term of office as Chairman of the Board of Directors, comply with the compensation policy

approved by the Shareholders' Meeting held on 27 May 2021 in its eleventh ordinary resolution.

Furthermore, the compensation policy applicable to Marc de Garidel, in respect of his duties as Chairman of the Board, was determined by the Board of Directors, upon recommendation of the Compensation Committee, at its meeting held on 10 February 2022 and will be the subject of a resolution submitted to the approval of the next Shareholders' Meeting.

Furthermore, it is specified that the Chairman of the Board of Directors does not receive variable compensation nor multi-annual variable compensation, subscription or purchase options nor performance shares.

A. Summary tables of compensations, options and shares granted to Marc de Garidel, Chairman of the Board

a. Summary table of compensations, options and performance shares

Total amount of compensations, options and performance shares granted for 2021 (table 1 of the AMF recommendations)

| (gross rounded amount – in euros) | 2020 Financial Year | 2021 Financial Year |
|---|---------------------|---------------------|
| Marc de Garidel Chairman of the Board of Directors | | |
| Compensation due for the year (see details below) | €600,000 | €600,000 |
| Book value of multi-annual variable compensations granted during the year | – | – |
| Book value of the options granted during the year | – | – |
| Book value of the performance shares granted during the year | – | – |
| Book value of other long-term compensation plans | – | – |
| Total | €600,000 | €600,000 |

b. Summary table of compensations (Table 2 of the AMF recommendations)

Total amount of the compensations for 2021 financial year

| (gross rounded amount – in euros) | 2020 | | 2021 | |
|---|-------------------------|-------------------------|-----------------|-----------------|
| | Amounts granted | Amounts paid | Amounts granted | Amounts paid |
| Marc de Garidel Chairman of the Board of Directors | | | | |
| Base compensation | €600,000 ⁽¹⁾ | €600,000 ⁽¹⁾ | €600,000 | €600,000 |
| Annual variable compensation | – | – | – | – |
| Multi-annual variable compensation | – | – | – | – |
| Exceptional compensation | – | – | – | – |
| Directors' fees | – | – | – | – |
| Benefits in kind | – | – | – | – |
| Totaux | €600,000 | €600,000 | €600,000 | €600,000 |

(1) The Board of Directors at its meeting held on 28 May 2019, confirmed the base compensation of Marc de Garidel to an annual amount unchanged at €600,000, in accordance with what was decided by the Board of Directors at its meeting held on March 28, 2018.

B. Details of the compensation elements granted to Marc de Garidel, Chairman of the Board of Directors

The compensation of the Chairman is determined by the Board of Directors upon recommendation of the Compensation Committee.

The Board of Directors, upon recommendation of the Compensation Committee, fixed, at its meeting held on 28 May 2019, the compensation elements of Marc de Garidel in respect of his duties as Chairman of the Board of Directors. These elements were unchanged for 2021.

It is recalled that Marc de Garidel was Chairman and Chief Executive Officer until 18 July 2016.

Base compensation

Base compensation is subject to be reviewed by the Board of Directors according to the Company's market position and taking into account changing responsibilities.

In compliance with the compensation policy applicable to the Chairman of the Board of Directors of Ipsen approved by the Shareholders' Meeting of 27 May 2021 in its eleventh ordinary resolution, and in compliance with the AFEP-MEDEF Code, the Board of Directors, upon recommendation of the Compensation Committee, also confirmed the base compensation of Marc de Garidel to an annual amount unchanged at €600,000.

Annual variable compensation

The Board of Directors has decided that Marc de Garidel will not receive any variable compensation in respect of his duties as Chairman of the Board of Directors.

Multi-annual variable compensation

The Board of Directors has decided that Marc de Garidel will not receive any multi-annual variable compensation in respect of his duties as Chairman of the Board of Directors of the Company.

Compensation as a Director

The Board of Directors has decided that Marc de Garidel will not receive any compensation as a Director in respect of his office as Chairman of the Board of the Company.

Stock options and performance shares

The Board of Directors has decided that Marc de Garidel will not receive any stock options and/or performance shares in respect of his duties as Chairman of the Board.

Other benefits

Marc de Garidel receives benefits resulting from the conditions linked to the performance of his duties at Ipsen. The detail of those benefits is as follows:

- assistance for the preparation and filing of personal income tax returns, in relation to his Ipsen compensation in France;
- access to a car driver pool for travel in relation to his Ipsen functions;
- D&O liability insurance consistent with the D&O liability insurance of the Ipsen Group;
- reimbursement of professional expenses incurred in relation to the exercise of his duties at Ipsen;
- administrative support provided by the Ipsen executive assistants of the Company in relation to his duties at Ipsen.

Payments, benefits and compensation granted or to be granted to Marc de Garidel upon termination of his functions within the Group

In accordance with Ipsen policy and in accordance with the AFEP-MEDEF Code, the Board of Directors, at its meeting held on 8 July 2016, decided to grant Marc de Garidel:

- a severance payment,
- the benefit of a defined-benefit additional pension scheme existing within the Company,
- a compensation under a non-compete agreement.

These payments and benefits that may be owed to the Chairman in connection upon termination of his duties replace those previously granted in respect of his duties as Chairman and Chief Executive Officer by the Board of Directors of 11 October 2010.

The Board of Directors, on 17 December 2020, decided to modify the conditions of his severance payment which Marc de Garidel could benefit in compliance with the recommendations of the AFEP-MEDEF Code, which are the following:

- a payment granted only in the event of a forced departure (*départ contraint*) within the meaning of the AFEP-MEDEF Code; this payment will be excluded if the Chairman leaves on his own initiative the Company,
- equal to 24 months of gross fixed compensation paid for his duties,
- the granting of which is subject to two cumulative performance conditions: which are (i) maintenance of the recurring operating margin of the Group for 2017 and 2018 at a rate of at least 15%, and for 2019 and following years maintenance of the core operating margin of the Group at a rate of at least 20% and (ii) maintenance of the Free Cash Flow before capital expenditure (CAPEX) during the three years preceding departure at a minimum threshold of €300 million,
- including, for a portion equal to 50% of its total, the amount payable in consideration for the non-compete clause of the Chairman of the Board of Directors. It is specified that the Board of Directors can waive the application of the non-compete undertaking upon departure of the Chairman of the Board by decision of the Board,
- no non-compete benefit is paid once Marc de Garidel has reached the age of 65 and has the opportunity to claim his pension rights.

Details of these commitments are given below (see section D. below).

C. Subscription and/or purchase options and performance shares granted to Marc de Garidel, Chairman and Chief Executive Officer until 18 July 2016

Executive directors and other senior executives of the Group can be awarded stock options and/or performance shares in the scope of the plans approved and set every year by the Board of Directors upon recommendation of the Compensation Committee. The number of shares vested shall depend on whether applicable performance conditions are met.

In accordance with the AFEP-MEDEF Code (§25.2), no stock options and/or performance shares have been granted to Marc de Garidel, in respect of his office as Chairman of the Board, since 18 July 2016.

Summary of performance shares granted

Marc de Garidel did not benefit from performance shares during the 2021 financial year.

In accordance with the provisions of article L.225-197-1 of the French Commercial Code, the Board of Directors, at its meetings held on 30 June 2011, 30 March 2012, 28 March 2013, 27 March 2014, 1 April 2015 and 31 May 2016 established rules requiring the Chairman and Chief Executive Officer to retain a number of shares resulting from performance shares, until the end of his term of office, equivalent to 20% of the net capital gain that would be realized upon the sale of the shares resulting from performance shares.

Marc de Garidel, Chairman and Chief Executive Officer until 18 July 2016, undertook a formal commitment not to engage in hedging transactions either on his options or on shares issued following the exercise of options or on performance shares granted until the end of the holding period that has been decided by the Board of Directors.

Performance shares that have become available during the 2021 financial year (Table 7 of AMF recommendations)

| Corporate Officer | Date granted | Number of shares that became available |
|--|--------------|--|
| Marc de Garidel Chairman of the Board of Directors ⁽¹⁾ | N/A | N/A |

⁽¹⁾ Marc de Garidel was Chairman and Chief Executive Officer until 18 July 2016 and has become Chairman of the Board of Directors from this date.

D. Summary of commitments made to Marc de Garidel, Chairman of the Board of Directors (Table 11 of AMF recommendations)

| | Employment contract | | Additional pension scheme | | Payments or benefits granted or to be granted in connection with the termination or change of functions | | Compensation under a non-compete clause | |
|-----------------|---------------------|----|---------------------------|----|---|----|---|----|
| | Yes | No | Yes | No | Yes | No | Yes | No |
| Marc de Garidel | | X | X | | X | | | X |

Employment contract

Marc de Garidel, Chairman of the Board, does not have any employment contract.

Retirement scheme

It is specified that additional pension plans are taken into account in the determination of the total compensation.

Marc de Garidel, Chairman of the Board, may potentially benefit from the defined-benefit additional pension scheme of the Company pursuant to the decision of the Board of Directors held on 8 July 2016. This pension commitment more broadly benefits the Company’s executives.

The benefit of the pension commitment is subject to:

- a minimum 5-year service,
- claiming Social Security pension at a full rate,
- the termination of any professional activity with the Company at the date of the liquidation of basic and additional pensions.

However, the right is maintained in case of early retirement or dismissal after the age of 55 subject to non-resumption of professional activity or if classified as having a 2nd or 3rd category of disability.

Furthermore, in case of death of the beneficiary during retirement, the potential right to widow or widower’s pension is maintained.

In accordance with the regulations, the grant of this additional pension scheme shall be subject to a performance condition, since 2019, the level of the core operating margin of the Group during the three years preceding departure at a minimum threshold of 20% and, since 2020, a second performance condition has been introduced: maintenance of

the Free Cash Flow before capital expenditure (CAPEX) during the three years preceding departure at a minimum threshold of €300 million, in line with the Group’s strategy.

The pension is calculated at a rate of 0.6% per year of seniority to the part of the reference compensation below 8 times the Annual Social Security Ceiling (“PASS”) and at a rate of 1% for the part of the reference compensation in excess of 8 times the PASS.

The reference compensation is the average of the total gross compensation received for a full time position (bonus included) during the last 36 months preceding the end of the contract and/or corporate mandate. Severance payments, expense reimbursement, profit-sharing and incentives are excluded.

Seniority is limited to 40 years.

Terms governing survivor’s pension benefits are set forth in the plan.

The annual pension owed to the beneficiaries shall not exceed 45% of their base and variable compensation.

The potential rights are financed by non-individualized premiums paid to an insurance institution. These premiums are deductible from the corporate tax base and subject to the contribution set forth in article L.137-11, I, 2° a) of the Social Security Code at the rate of 24%.

It is reminded that the Company’s supplementary defined-benefit pension plan was closed as of 30 June 2019 and that conditional rights were crystallized as of that date for each eligible beneficiary.

For Marc de Garidel, the amount of the annual pension established, as of 31 December 2021, is estimated at €49,527, unchanged since 30 June 2019.

The closure of the Defined-Benefit scheme in 2019, induces for Marc de Garidel a decrease of his expected pension below the level calculated in 2016. This pension should progressively amount to a level comparable to the one preceding his appointment as Chairman, should he leave on 31 December of the year of his 62nd birthday (see 2015 Registration Document).

Therefore, it was proposed to set up an additional individual Defined Contribution plan ("Article 82") to fill the gap between the Defined Benefit pension after crystallization and the level calculated in 2016. This would be paid at time of retirement, and in no event before November 2020. The retirement is being qualified as (1) having vested full rights under the French social security system ("*retraite à taux plein*") and (2) not being a "*mandataire social*" (corporate officer) of Ipsen anymore.

The payment under this individual defined contribution plan will be subject to one condition of presence and two cumulative performance conditions.

The payment related to this scheme would require validation of the performance achievement by the Board of Directors and submitted to vote at the first possible General Shareholders' meeting following the date of retirement.

Payments or benefits granted or likely to be granted upon termination of his functions within the Group

At its meeting held on 8 July 2016, the Board of Directors decided to grant Marc de Garidel, Chairman of the Board, the right to a severance payment on the following terms, in accordance with the recommendations of the AFEP-MEDEF Code.

At its meeting held on 17 December 2020, the Board of Directors decided to change the conditions of the severance payment which Marc de Garidel, Chairman of the Board, could benefit, in accordance with the recommendations of the AFEP-MEDEF Code:

- payment granted only in the event of a forced departure (*départ contraint*) within the meaning of the AFEP-MEDEF Code, it being specified that the payment is excluded if the corporate officer leaves the Company on a voluntary basis,
- equal to 24 months of gross fixed compensation paid for his duties,
- the granting of which is subject to two cumulative performance conditions which are (i) maintenance of the recurring operating margin of the Group for 2017 and 2018, at a rate of at least 15%, and, as from 2019 and for subsequent years, maintenance of the operating margin for the Group's activities at a rate of at least 20% and (ii) maintenance of the Free Cash Flow before capital expenditure (CAPEX) during the three years preceding departure at a minimum threshold of €300 million,
- including, for a portion equal to 50% of its total, the amount payable in consideration for the non-compete clause of the Chairman of the Board of Directors,
- the payment of any termination benefits must be excluded if Marc de Garidel has reached the age of 65 and is entitled to benefit from his pension rights.

It is also specified that the Board of Directors can waive the application of the non-compete undertaking upon departure of the Chairman of the Board by a decision.

Non-compete payment

Marc de Garidel, Chairman of the Board, agreed, in the event of his departure from the Group, during a period of 24 months following the date of his effective departure, not to perform or participate from an operational standpoint (including as a consultant), within the territory of the European Economic Area (EEA) and/or North America, in any activity relating to the development and/or the marketing of products belonging to the same therapeutic category (source IMS-Health) as the top three products of the Group in terms of turnover on the date of his effective departure.

The indemnity owed by the Company in consideration of this non-compete undertaking will be included in the severance package described above if it were also granted, for a portion equal to 50%.

It is specified that no non-compete benefit will be paid once the Chairman of the Board claims his pension rights and in any event, no benefit can be paid over the age of 65.

It is also specified that the Board of Directors can waive the application of the non-compete undertaking upon departure of the Chairman of the Board by a decision.

The compensation of Marc de Garidel is fully aligned with the Company's compensation policy. His total compensation is composed of an annual base salary, no variable compensation, no eligibility to performance shares, this compensation is also based on the recommendation of the Compensation Committee.

5.4.2.3 Compensation of the CEO

At its meeting on 28 May 2020, the Board of Directors appointed David Loew as Chief Executive Officer with effect from 1 July 2020.

David Loew, Chief Executive Officer

For financial year 2021, the compensation elements of David Loew, Chief Executive Officer, were determined by the Board of Directors, upon recommendation of the Compensation Committee, at its meeting held on 10 February 2021.

In accordance with Articles L.22-10-8 and L.22-10-34 of the French Commercial Code, the compensation elements paid during the financial year ended 31 December 2021 or granted to David Loew, Chief Executive Officer, for the financial year ended on 31 December 2021, in respect of his term of office, comply with the compensation policy approved by the Shareholders' Meeting held on 27 May 2021 in its twelfth ordinary resolution.

It is specified that the payment of the variable compensation elements allocated for the 2021 financial year will depend on the approval by the next Shareholders' Meeting to be held in 2022 of the compensation elements paid during the previous year or allocated for the previous year.

In accordance with Articles L.22-10-8 and L.22-10-34 of the French Commercial Code, the compensation policy applicable to David Loew, in respect of his duties as Chief Executive Officer, was determined by the Board of Directors, upon recommendation of the Compensation Committee, at its meeting held on 10 February 2022 and will be subject to a

resolution submitted to the approval of the next Shareholders' Meeting.

A. Summary tables of compensations, options and shares granted to David Loew, Chief Executive Officer

Summary table of compensations, options and performance shares (Table 1 of AMF recommendations)

| (gross rounded amount – in euros) | 2020 Financial Year | 2021 Financial Year |
|---|--------------------------|--------------------------|
| David Loew | | |
| Chief Executive Officer from 1 July 2020 | | |
| Compensations due for the year (see details below) | 1,982,750 | 2,298,000 |
| Book value of multi-annual variable compensations granted during the year | – | – |
| Book value of the options granted during the year | – | – |
| Book value of the bonus shares granted during the year ⁽¹⁾ | 2,830,816 ⁽²⁾ | 2,536,350 ⁽³⁾ |
| Book value of other long-term compensation plans | – | – |
| Total | 4,813,566 | 4,834,350 |

(1) For further details, see section 5.4.2.3 paragraphs B and C above.

(2) It was decided by the Board of a grant of performance shares with a book value of €2,830,816 including the financial compensation indemnity for 6,579 shares.

(3) It was decided by the Board of a grant of performance shares with a book value of €2,536,350.

Summary table of compensations (Table 2 of the AMF recommendations)

| (gross rounded amount – in euros) | 2020 | | 2021 | |
|---|--------------------------|------------------------|--------------------------|------------------------|
| | Amounts granted | Amounts paid | Amounts granted | Amounts paid |
| David Loew | | | | |
| Chief Executive Officer | | | | |
| Base compensation | 475,000 ⁽¹⁾ | 475,000 ⁽¹⁾ | 950,000 | 950,000 |
| Annual variable compensation – Annual performance | 498,750 | – | 1,330,000 ⁽²⁾ | 498,750 |
| Multi-annual variable compensation | – | – | – | – |
| Exceptional compensation – Integration within the Group | – | – | – | – |
| Special financial indemnity | 1,000,000 ⁽³⁾ | – | – | 500,000 ⁽³⁾ |
| Compensation as a Director | – | – | – | – |
| Benefits in kind | 9,000 | 9,000 | 18,000 ⁽⁴⁾ | 18,000 |
| Total | 1,982,750 | 484,000 | 2,298,000 | 1,966,750 |

(1) The Board of Directors of 28 May 2020, upon recommendation of the Compensation Committee, decided to set the annual compensation of the Chief Executive Officer for 2020 at €950,000. This amount was paid on a *pro rata* basis in 2020, taking into account his assumption of office on 1 July 2020. The annual compensation has been unchanged for 2021.

(2) The Board of Directors, at its meeting held on 10 February 2021, upon recommendation of the Compensation Committee, decided to set the gross target annual variable compensation at €950,000 which may vary within a range between 0% and 150% (i.e. €0 up to €1,425,000). The Board of Directors, at its meeting held on 10 February 2022, upon recommendation of the Compensation Committee and in light of the achievement of the criteria it had established, fixed the amount of the annual variable compensation of the Chief Executive Officer for 2021 at €1,330,000. This variable compensation will be paid in 2022, subject to the Shareholders' Meeting approval of the compensation elements paid during the previous financial year or granted for the previous financial year to the Chief Executive Officer. The performance criteria are presented in paragraph B below.

(3) The Boards of Directors of 28 May and 29 July 2020, to compensate for the loss of his existing financial package at his current employer, decided to grant to David Loew:

- an indemnity of €1,000,000 in cash, paid half in the month of the first anniversary of the effective date of taking office as Chief Executive Officer and half in the month of the second anniversary of the effective date of taking office as Chief Executive Officer. These payments will be subject to a presence requirement of David Loew within the Company on the day on which they are made. He was present in July 2021 and received half of this indemnity;
- an allocation of 6,579 performance shares for an equivalent amount of €500,000, which will be granted no later than the month following the effective date of taking office as Chief Executive Officer. The acquisition of these shares will be subject to a presence requirement and performance conditions (see below, paragraph B "Special financial indemnity").

(4) Benefits in kind are defined in paragraph B hereunder "Other benefits".

B. Details of the compensation elements granted to David Loew, Chief Executive Officer

The compensation of the Chief Executive Officer is determined by the Board of Directors upon recommendation of the Compensation Committee.

Base compensation

Base compensation takes into account Ipsen's reference markets. It is subject to be reviewed by the Board of Directors, typically at relatively long intervals, according to the Company's market position and taking account changing responsibilities.

The Board of Directors, at its meeting held on 10 February 2021 and upon recommendation of the Compensation Committee, has confirmed David Loew's base compensation for 2021 at a gross annual amount of €950,000, unchanged since his nomination in 2020.

Annual variable compensation

The annual variable compensation is linked to the Group's global performance and to the realization of personal goals set for the Chief Executive Officer.

For the 2021 financial year, the Board of Directors decided to grant David Loew a target gross annual variable compensation of €950,000 (corresponding to 100% of the objectives achieved), which may vary within a range of 0 to 150% (i.e., from €0 to €1,425,000).

Two-thirds (2/3) of this bonus target amount is based on four quantifiable criteria of equal weighting, based on the levels achieved of consolidated net sales at constant exchange rate, core operating income before amortization of intangible assets and at current exchange rate, free cash flow before capital expenditure (CAPEX) and earnings per share fully diluted. The remaining part (1/3) depends on three qualitative criteria in terms of strategy, management and CSR. Details of these qualitative criteria and the expected level of achievement of the performance criteria are not made public for confidentiality reasons.

The weighting, the possible variation and the percentage of realization of the quantifiable and qualitative objectives decided by the Board of Directors are as follows:

| | Criteria | Weight | Potential variation of the portion | | |
|--------------------------------|---------------------------|-------------|------------------------------------|-------------|------------------|
| Performance indicators | Consolidated net sales | 1/6 | 0% to 150% | | |
| | Core operating income | 1/6 | 0% to 150% | | |
| | Cash flow from operations | 1/6 | 0% to 150% | | |
| | Earnings per share | 1/6 | 0% to 150% | | |
| Quantifiable objectives | | 2/3 | 0% to 150% | 150% | 950,000 |
| Qualitative objectives | | 1/3 | 0% to 150% | 120% | 380,000 |
| Total | | 100% | 0% to 150% | 140% | 1,330,000 |

(1) Percentages of achievement approved by the Board of Directors at its meeting of 10 February 2022.

At its meeting of 10 February 2022, upon recommendation of the Compensation Committee and given the realization of the criteria it had established, the Board of Directors set the amount of the Chief Executive Officer's variable annual compensation for 2021 financial year to €1,330,000, corresponding to 140% of the base compensation.

The payment of the variable compensation elements of David Loew is subject to the approval of the Annual Shareholders' Meeting to be held in 2022 to approve the financial statements for the year ended 31 December 2021, of the elements of compensation paid or granted in respect of the past year.

Multi-annual variable compensation

David Loew did not receive a multi-annual variable compensation.

Special financial indemnity

The Board of Directors, during its meeting of 28 May 2020, has granted David Loew with a special financial indemnity to compensate certain advantages David Loew had given up by leaving his previous employer. This special financial indemnity takes the form of:

- an indemnity of €1,000,000 in cash, paid half in the month of the first anniversary of the effective date of taking office as Chief Executive Officer and half in the month of the second anniversary of the effective date of taking office as Chief Executive Officer. These payments will be subject to a presence requirement of David Loew within the Company on the day on which they are made;
- an allocation of 6,579 performance shares for an amount of €500,000, granted on 29 July 2020, described in section 5.4.1.3. (c) h above. The acquisition of these shares is subject to a condition of presence within the Company and the number of performance shares that will be acquired will depend upon the level of achievement of the performance conditions set by the Board of Directors and assessed over a period of three years, i.e.:
 - 60% based on two internal performance conditions, based on (i) the Group Core Operating Income (Group COI) excluding Business Development for 40% and (ii) CSR criteria for 20%. For each of these conditions, the level of payout (0 – 200%) will be defined as per the payout grid enclosed in the applicable plan rules, and
 - 40% based on an external performance condition measuring the relative performance of Ipsen's stock price

compared to that of the other issuers which are part of the STOXX TMI 600 Health Care index. Based on its ranking, the level of payout (0 – 200%) will be defined as per the payout grid enclosed in the applicable plan rules.

Each of these conditions shall be measured by comparing the target threshold and the actual performance of the Company (or the Company's stock price). Each of these conditions may generate a payout varying within a range between 0 and 200%.

Performance shares

Executive Corporate Officers as well as certain senior executives of the Group may benefit from stock options and/or performance shares under plans approved and set each year by the Board of Directors upon recommendation of the Compensation Committee.

The Board of Directors, at its meeting held on 27 May 2021, on recommendation of the Compensation Committee, granted to David Loew 30,063 performance shares (equivalent to 100% at target). The number of performance shares granted was calculated on the basis of the average market value of the IPSEN share over the 20 trading days preceding a period of 10 business days before the grant date.

This grant represents 0.04% of the share capital on the day of the grant.

The acquisition of the performance shares is subject to a condition of presence within the Company at the end of the vesting period. The number of performance shares that will be acquired will depend upon the level of achievement of five equally weighted performance criteria (20% each) set by the Board of Directors and assessed over a period of three years, *i.e.*:

- the Group's operating income (Group COI), excluding Business Development transactions;
- the change in Ipsen's share price compared to that of other listed companies in the STOXX TMI 600 Health Care index;
- a Corporate Social Responsibility (CSR) criteria;
- the evolution of the pipeline of products under development and from external innovation operations;
- the Free Cash flow.

For each of these conditions, the level of compensation (0 - 150%) is defined according to the payment scale included in the applicable plan rules.

Details regarding this allocation are given below.

b. Performance shares granted to David Loew, Chief Executive Officer

Performance shares granted during the 2021 financial year (table 6 of AMF recommendations)

| | Plan date | Number of performance shares granted | Book value of the shares ⁽¹⁾ | Book value of the shares ⁽¹⁾ | Acquisition date | Date of availability | Performance conditions |
|---------------------------------------|------------|--------------------------------------|---|---|------------------|----------------------|------------------------|
| David Loew Chief Executive Officer | 27/05/2021 | 30,063 ⁽²⁾ | €85.78 | €2,536,350 | 27/05/2024 | 28/05/2024 | Yes |

(1) Share value at the date of grant. For additional information see Note 5 of the consolidated financial statements. The global amount of granted shares book value is listed in table 1 above.

(2) Allocation subject to performance conditions, representing 0,04% of the share capital as of 29 July 2021.

Other benefits

David Loew received benefits resulting from the conditions linked to the performance of his duties at Ipsen, in particular: a relocation package in France, an assistance with filing his personal income tax returns, the reimbursement of reasonable attorney fees and expenses incurred in connection with the finalization of the terms and conditions of his office a Company car and driver, the business travel and accommodation expenses incurred whilst exercising his duties, an healthcare coverage under a global healthcare policy, and death and disability coverage under the Group's policy or a specific policy, D&O liability insurance.

Payments, benefits and compensations likely to be granted to David Loew, Chief Executive Officer

Details regarding these commitments are given below (see section D).

C. Subscription and/or purchase options and performance shares granted to David Loew, Chief Executive Officer

Executive officers and other senior executives of the Group can be awarded stock options and/or performance shares in the scope of the plans approved and set every year by the Board of Directors upon recommendation of the Compensation Committee. The definitive number of stock option and/or performance shares to vest will depend on the applicable performance conditions.

a. Subscription and/or purchase options granted to David Loew, Chief Executive Officer with effect on July 1st, 2020

Subscription or purchase options granted during the 2021 financial year (table 4 of AMF recommendations)

No option was granted to the Chief Executive Officer, David Loew, during the 2021 financial year.

Synthesis of the subscription or purchase options granted (table 8 of AMF recommendations)

The Chief Executive Officer, David Loew, does not hold any Ipsen option.

No option was still valid on 31 December 2021. For more information about subscription or purchase options, see section 5.6.1.3.1.

Subscription or purchase options exercised during the 2021 financial year (table 5 of AMF recommendations)

No option was exercised by the Chief Executive Officer, David Loew, during the 2021 financial year.

The number of performance shares granted is calculated on the basis of the average market value of the Ipsen share over the 20 trading days preceding a period of 10 business days before the grant date.

The acquisition of the performance shares will be subject to a condition of presence within the Company at the end of the vesting period. The number of performance shares that will be acquired will depend upon the level of achievement of five equally weighted performance criteria (20% each) set by the Board of Directors and assessed over a period of three years, *i.e.*:

- the Group's operating income (Group COI), excluding Business Development transactions;
- the change in Ipsen's share price compared to that of other listed companies in the STOXX TMI 600 Health Care index;
- a Corporate Social Responsibility (CSR) criteria;

- the evolution of the pipeline of products under development and from external innovation operations;
- the Free cash flow.

For each of these conditions, the level of compensation (0 - 150%) is defined according to the payment scale included in the applicable plan rules.

Each of these conditions shall be measured by comparing the target threshold and the actual performance of the Company (or the Company's stock price). Each of these conditions may generate a payout varying within a range between 0 and 150%.

According to the compensation policy of the Chief Executive Officer approved by the Shareholders during the Shareholders' Meeting of 27 May 2021 the Board of Directors decided that the Chief Executive Officer would have to retain, until the end of his term of office, a number of shares equivalent to 20% of the net capital gain that would be realized upon the sale of the shares resulting from the performance shares.

D. Summary of commitments issued in favor of David Loew, Chief Executive Officer (Table 11 of AMF recommendations)

| | Employment contract | | Additional pension scheme | | Payments or benefits granted or to be granted in connection with the termination or change of functions | | Compensation under a non-compete clause | |
|---------------------------------------|---------------------|----|---------------------------|----|---|----|---|----|
| | Yes | No | Yes | No | Yes | No | Yes | No |
| David Loew Chief Executive Officer | | X | X | | X | | X | |

Employment contract

David Loew, Chief Executive Officer with effect on 1 July 2020, does not have an employment contract.

Additional pension plan

It is specified that additional pension plans are taken into account in the determination of the total compensation.

David Loew should benefit from the existing defined-contribution pension schemes ("*régimes de retraite complémentaire à cotisations définies*") of the Company (Article 83), including the one specific to executives.

The estimated pension level for these contributions would be €4,963 per year, if he retired at the age of 62.

Payments or benefits granted or likely to be granted upon termination of his functions within the Group

At its meeting held on 29 May 2020, the Board of Directors decided to grant David Loew, Chief Executive Officer, the benefit of a severance payment on the following terms, in accordance with the recommendations of the AFEP-MEDEF Code:

In case of forced departure ("*départ contraint*"), David Loew will benefit from a severance payment:

- equivalent (at maximum) to the compensation (fixed and variable) paid for his duties as Chief Executive Officer for the last two closed financial years (or, in the event there would not be two financial years closed at the time of the departure, 24 times the average monthly gross fixed and variable (STI scheme only, excluding any other variable compensation, exceptional compensation and long term incentives) compensation actually received since the start of the corporate office as Chief Executive Officer),

- this grant is subject to performance conditions in accordance with the 2020 compensation policy, and
- constituting a global lump-sum indemnity including, if applicable, up to 50% of the amount payable for the non-compete undertaking described below.

In the event of departure within the period of three years immediately following the appointment as Chief Executive Officer, the maximum amount to which David Loew will be eligible (*i.e.*, 24 months of fix and variable compensation) will be adjusted downwards *pro rata temporis* the number of months actually carried out as Chief Executive Officer (based on the ratio: number of months of presence / 36 months). In this case, assuming that the non-compete is not be waived by the Company and as an exception to the lump-sum principle above-mentioned, the related non-compete indemnity would come in addition to this prorated severance pay (provided that the total of these combined amounts does not exceed the threshold of 24 months of fixed and variable compensation).

Non-compete payment

The Board of Directors of 29 May 2020 decided to fix the non-compete payment for David Loew. In consideration for its non-compete undertaking, David Loew will receive an indemnity:

- at the end of each month for which he will have complied with the commitment (for a duration of 12 months);
- equivalent to 50% of the gross average monthly compensation – fix and variable compensation (short term incentive scheme only, excluding any other variable compensation, exceptional compensation and long term



incentives) – received during the 12 months prior to the departure from the Company;

- deemed to be included in the severance pay if it is due to the extent indicated above;
- it is specified that the Board of Directors reserves its right to waive the implementation of this non-compete undertaking. For confidentiality reasons, the content of this non-compete undertaking cannot be made public.

The Board of Directors may waive this obligation.

It is specified that the non-compete undertaking will not apply and no non-compete indemnity will be paid, if David Loew is leaving the Company to retire or have reached the age of 65 at the date of effective departure.

In any case, the cumulative amount paid (if applicable) for the severance package and the non-compete payment cannot exceed the threshold of 24 months of fixed and variable compensation (short term incentive scheme only, excluding any other variable compensation, exceptional compensation and long term incentives).

According to the Articles L.22-10-8 and L.22-10-34 from the French Commercial Code, the compensation policy applying to David Loew, as Chief Executive Officer, was determined by the Board of Directors, upon recommendation of the Compensation Committee on 10 February 2022. These elements will be subject to the approval of the next shareholder meeting in 2022.

Aymeric Le Chatelier – Interim Chief Executive Officer from 1 January 2020 to 30 June 2020

Aymeric Le Chatelier, Executive Vice President, Group Chief Financial Officer, was appointed Interim Chief Executive Officer as of 1 January 2020 by decision of the Board of Directors on 17 December 2019 and until 30 June 2020.

The elements of his compensation as Interim Chief Executive Officer were determined by the Board of Directors, upon recommendation of the Compensation Committee, at its meeting on 12 February 2020. These elements are detailed in the 2020 Universal Registration Document.

For the 2021 financial year, Aymeric Le Chatelier, Group Chief Financial Officer, did not hold any corporate office. As a consequence, he did not receive any base or variable compensation, retirement scheme or any other compensation element as a Chief Executive Officer ad interim in 2020.

At its meeting of 10 February 2021, on the proposal of the Compensation Committee and in the light of the achievement of the criteria it had pre-established, the Board of Directors set the gross variable compensation of the interim Chief Executive Officer for the 2020 financial year at €281,250. This amount was approved by the Shareholders meeting of 27 May 2021 and paid following its approval by the shareholders.

5.4.3 Comparative table of compensation of the Chairman and Chief Executive Officer with respect to other employees and put into perspective with the Company's performance

Under Article L.22-10-9 of the French Commercial Code, and pursuant to the recommendations of the AFEP-MEDEF Code, the changes in compensation of the Executive Corporate Officers with respect to other employees are shown below and put into perspective with the Company's performance over the past five years.

The figures shown were calculated across the Company scope, as well as across an expanded scope including all Ipsen employees in France, so as to consider a scope representative of Ipsen's operations in France.

The Ipsen performance criteria shown, and their changes in comparison to the changes in compensation, were determined in light of their relevance to the Company's strategy in terms of growth and profitability:

- Change in Ipsen sales (%) vs. prior year,
- Change in core operating income (%) vs. prior year.

| | Relationship between compensation of Executive Corporate Officers and that of employees (FTE), and changes, on average and median | Chairman of the Board of Directors | Chief Executive Officer |
|------------------|---|------------------------------------|-------------------------|
| 2017 | A average | 4 | 3 |
| | A median | 3 | 3 |
| | B average | 46 | 40 |
| | B median | 67 | 60 |
| 2018 | A average | 1 | 4 |
| | A median | 1 | 3 |
| | B average | 8 | 44 |
| | B median | 12 | 63 |
| Change 2017-2018 | annual change in compensation of Executive Corporate Officers | -82.0% | 7.3% |
| | annual change in average compensation of A and B employees | | -2.5% |
| | annual change in Company performance as a percentage of annual change in sales (at constant exchange rates) | | 20.1% |
| | annual change in Company performance as a percentage of annual change in core operating income | | 31.0% |
| 2019 | A average | 1 | 3 |
| | A median | 1 | 3 |
| | B average | 8 | 38 |
| | B median | 10 | 50 |
| Change 2018-2019 | annual change in compensation of Executive Corporate Officers | -8.3% | -13.6% |
| | annual change in average compensation of A and B employees | | 1.8% |
| | annual change in Company performance as a percentage of annual change in sales (at constant exchange rates) | | 14.8% |
| | annual change in Company performance as a percentage of annual change in core operating income | | 18.6% |
| 2020 | A average | 1 | 4 |
| | A median | 1 | 4 |
| | B average | 7 | 47 |
| | B median | 10 | 65 |



CORPORATE GOVERNANCE AND LEGAL INFORMATION
COMPENSATION OF CORPORATE OFFICERS

| | Relationship between compensation of Executive Corporate Officers and that of employees (FTE), and changes, on average and median | Chairman of the Board of Directors | Chief Executive Officer |
|------------------|---|------------------------------------|-------------------------|
| Change 2019-2020 | annual change in compensation of Executive Corporate Officers | 0% | 34.1% |
| | annual change in average compensation of A and B employees | | 6.9% |
| | annual change in Company performance as a percentage of annual change in sales (at constant exchange rates) | | 3.0% |
| | annual change in Company performance as a percentage of annual change in core operating income | | 6.0% |
| 2021 | A average | 1 | 4 |
| | A median | 1 | 4 |
| | B average | 7 | 48 |
| | B median | 10 | 67 |
| Change 2020-2021 | annual change in compensation of Executive Corporate Officers | 0% | -0.30% |
| | annual change in average compensation of A and B employees | | -2.60% |
| | annual change in Company performance as a percentage of annual change in sales (at constant exchange rates) | | 12.3% |
| | annual change in Company performance as a percentage of annual change in core operating income | | 21.9% |

- A = the Company.
- B = all Ipsen Group employees in France.

Notes per year of reference:

- 2016: Marc de Garidel in his role of Chairman & CEO until 18 July then in his role of Chairman until the end of the year, David Meek in his role of CEO from 18 July until the end of the year. All calculations are made on annualized value for their respective compensation components.
- 2017: Marc de Garidel in his role of Chairman full year (including payout for multi-year variable pay granted in 2015), David Meek in his role of CEO full year.
- 2018: Marc de Garidel in his role of Chairman full year, David Meek in his role of CEO full year.
- 2019: Marc de Garidel in his role of Chairman full year, David Meek in his role of CEO full year.
- 2020: Marc de Garidel in his role of Chairman full year, David Meek's annual variable compensation paid in 2020 for 2019, Aymeric Le Chatelier in his role of interim CEO from 1 January to 30 June, then David Loew in his role of CEO with effect on 1 July.
- 2021: Marc de Garidel in his role of Chairman full year, David Loew in his role of CEO full year.

Additional methodological notes:

- Elements of compensation: all the elements paid, granted or due during the reference year: Base pay, annual bonus, exceptional bonus, director's fees, LTIs (IFRS value), benefits in kind, profit sharing.
- Full time equivalents including all fixed-term and open-ended contracts present each year.

5.4.4 Compensation paid or awarded in 2021 (Article L.22-10-34 II of the French Commercial Code)

Marc de Garidel, Chairman of the Board of Directors

| Compensation components of Marc de Garidel, Chairman of the Board of Directors, subject to a vote | Amounts paid during the past financial year | Amounts granted for the past financial year, or book value | Presentation |
|---|---|--|--------------------------|
| 2021 Base compensation | €600,000 | €600,000 | Annual base compensation |
| Severance payment | – | – | |
| Retirement scheme | – | – | |
| Non-compete payment | – | – | |

David Loew, Chief Executive Officer

| Compensation components of David Loew, Chief Executive Officer, subject to a vote | Amounts paid during the past financial year | Amounts granted for the past financial year | Presentation |
|--|--|---|---|
| 2021 fixed compensation | €950,000 | €950,000 | Fixed annual compensation. |
| 2021 annual variable compensation | €498,750 (Amount paid after approval by the 2021 Shareholders' Meeting) | €1,330,000 (Amount to be paid after approval by the 2022 Shareholders' Meeting, subject to its yes vote) | <p>Amount allocated for the past financial year with:</p> <ul style="list-style-type: none"> Quantifiable criteria for two third and qualitative criteria for one third contributed to the determination of this variable compensation; Maximum percentage of fixed compensation that variable compensation may represent: 100%. <p>The Board of Directors, on the recommendation of the Compensation Committee on 10 February 2022, and in view of the realization of the pre-established criteria, set the amount of the annual variable compensation of the Chief Executive Officer for 2021 at €1,330,000. This amount will be paid following the Shareholders' Meeting held in May 2022 to approve the amounts of the compensation components to be paid or granted to David Loew for the previous year.</p> |
| Stock options, performance shares, or any other long-term benefit (warrants, etc.) | | €2,536,350 | <p>30,063 shares were granted representing 0,04% of the share capital.</p> <p>The acquisition of the performance shares is subject to a condition of presence within the Company at the end of the vesting period. The number of performance shares that will be acquired will depend upon the level of achievement of five equally weighted performance criteria (20% each) set by the Board of Directors and assessed over a period of three years, i.e.:</p> <ul style="list-style-type: none"> the Group's operating income (Group COI), excluding Business Development transactions; the change in Ipsen's share price compared to that of other listed companies in the STOXX TMI 600 Health Care index; a Corporate Social Responsibility (CSR) criteria; the evolution of the pipeline of products under development and from external innovation operations; the Free cash flow. <p>For each of these conditions, the level of compensation (0 - 150%) is defined according to the payment scale included in the applicable plan rules.</p> |



CORPORATE GOVERNANCE AND LEGAL INFORMATION
COMPENSATION OF CORPORATE OFFICERS

| Compensation components of David Loew, Chief Executive Officer, subject to a vote | Amounts paid during the past financial year | Amounts granted for the past financial year | Presentation |
|---|---|---|---|
| Special financial indemnity | €500,000 | €500,000 | At its meeting of 29 July 2020, and in consideration of the benefits that David Loew renounced by leaving his previous position, the Board of Directors decided to set up an indemnity of 1,000,000 in cash, half of which will be paid on the month of the first anniversary of the effective date of assumption of duties as Chief Executive Officer, i.e. in July 2021, and half of which will be paid on the month of the second anniversary of the effective date of assumption of duties as Chief Executive Officer, i.e. in July 2022, these payments being subject to David Loew's presence within the Company on the day on which they are made. |
| Benefits in kind | €18,000 | €18,000 | Payment of car allowance. |
| Severance payment | – | – | |
| Retirement scheme | – | – | |
| Non-compete payment | – | – | |

5.5 AUDITORS' SPECIAL REPORT ON REGULATED AGREEMENTS

Ipsen

Société Anonyme

65, Quai Georges Gorse – 92100 Boulogne-Billancourt

Auditors' Special Report on regulated agreements

Shareholders' Meeting to approve the financial statements for the year ended 31 December 2021

To the Meeting of the Shareholders of Ipsen S.A.:

As the auditors of your company, we hereby present to you our report on the regulated agreements.

It is our duty to communicate to you, on the basis of the information provided to us, the characteristics, main methods and reasons justifying the interest for the Company of the agreements of which we have been advised or discovered during our audit, without our having to make any claims as to their usefulness or validity, or to determine the existence of any other agreements. In accordance with article R.255-31 of the French Commercial Code, it is your duty to assess the interest in finalizing these agreements with a view to their approval.

Additionally, it is our duty to advise you of the information stipulated in article R.255-31 of the French Commercial Code concerning the implementation during the previous financial year of the agreements, if any, approved by the Shareholders' Meeting.

We have conducted the due diligence we believed necessary in light of the professional code of the *Compagnie nationale des commissaires aux comptes* (French association of auditors) with regard to this audit.

AGREEMENTS PRESENTED FOR THE APPROVAL OF THE SHAREHOLDERS' MEETING

Agreements authorized and signed during the past financial year

We inform you that we were not advised of any agreements authorized and signed during the past financial year to be presented for the approval of the Shareholders' Meeting in accordance with the provisions of article L.225-38 of the French Commercial Code.

AGREEMENTS ALREADY APPROVED BY THE SHAREHOLDERS' MEETING

Agreements approved in previous fiscal years

We advise you that we have not received notice of any agreements already approved by the Shareholders' Meeting for which the implementation would have continued in the past fiscal year.

Paris-La Défense, 18 March 2022

The Auditors

KPMG Audit
A department of KPMG S.A.

Catherine Porta

Deloitte & Associés

Frédéric Souliard



5.6 SHARE CAPITAL AND SHAREHOLDING

5.6.1 Share capital

■ 5.6.1.1 Amount of the share capital

As of 31 December 2021, the share capital of the Company amounted to €83,814,526 divided into 83,814,526 shares fully subscribed and paid-up of same class, each with a par value of €1. The share capital amount has not changed since that date.

All the shares are registered or bearer shares and are freely transferable. They are traded on Euronext Paris (Compartment A) (ISIN code FR 0010259150).

■ 5.6.1.2 Changes in share capital

The table below summarizes the evolution of the share capital over the past five financial years. The share capital has not been modified between 31 December 2020 and 31 December 2021.

| Date | Operation | Par value per share (in euros) | Number of shares | Nominal amount (in euros) | Share or contribution premium (in euros) | Cumulative share or contribution premiums (in euros) | Cumulated amount of share capital (in euros) | Cumulated number of outstanding shares |
|------------|-------------------|--------------------------------|------------------|---------------------------|--|--|--|--|
| 22/02/2017 | Options exercises | 1 | 22,630 | 22,630 | 796,433 | 733,738,419 | 83,580,494 | 83,580,494 |
| 07/06/2017 | Options exercises | 1 | 57,440 | 57,440 | 1,967,094 | 735,705,513 | 83,637,934 | 83,637,934 |
| 30/06/2017 | Options exercises | 1 | 2,600 | 2,600 | 92,664 | 735,798,177 | 83,640,534 | 83,640,534 |
| 26/07/2017 | Options exercises | 1 | 20,000 | 20,000 | 712,800 | 736,510,977 | 83,660,534 | 83,660,534 |
| 04/10/2017 | Options exercises | 1 | 32,289 | 32,289 | 1,150,780 | 737,661,757 | 83,692,823 | 83,692,823 |
| 13/12/2017 | Options exercises | 1 | 38,724 | 38,724 | 1,418,879 | 739,080,636 | 83,731,547 | 83,731,547 |
| 31/12/2017 | Options exercises | 1 | 510 | 510 | 18,176 | 739,098,812 | 83,732,057 | 83,732,057 |
| 14/02/2018 | Options exercises | 1 | 50,251 | 50,251 | 1,790,946 | 740,889,758 | 83,782,308 | 83,782,308 |
| 30/05/2018 | Options exercises | 1 | 11,820 | 11,820 | 421,265 | 741,311,022 | 83,794,128 | 83,794,128 |
| 31/12/2018 | Options exercises | 1 | 14,633 | 14,633 | 420,439 | 741,731,462 | 83,808,761 | 83,808,761 |
| 31/07/2019 | Options exercises | 1 | 5,765 | 5,765 | 138,418 | 741,869,880 | 83,814,526 | 83,814,526 |

■ 5.6.1.3 Potential share capital

As of 31 December 2021, there are no financial instruments in force that could result in the creation of new shares:

5.6.1.3.1 Stock purchase or subscription options plans

The last stock subscription or purchase option plan implemented by the Company being expired since 10 November 2019. No option was still valid on 31 December 2021.

5.6.1.3.2 Bonus Shares and Performance shares grants

Description

The final acquisition of the shares granted as part of the 2017 plans mentioned in the table below, is effective at the end of the acquisition period:

- of a two-year duration starting from the grant date for French tax resident beneficiaries with an effective delivery of the acquired shares at the term of the two-year acquisition period. Half of the shares are transferable as from their delivery to the French tax resident beneficiaries and half of the shares must be held during an additional period of two years following the final acquisition date;
- of a two-year duration starting from the grant date for U.S. tax resident beneficiaries with an effective delivery of half of the acquired shares at the term of the two-year acquisition

period and of half of the remaining acquired shares two years after the term of the acquisition period. The shares are transferable as from their delivery to the beneficiaries;

- of a four-year duration starting from the grant date for non-French and U.S. tax resident beneficiaries at the grant date. The shares are transferable as from their delivery to the beneficiaries.

The final acquisition of the shares granted as part of the 2018 plans mentioned in the table below is effective for all the beneficiaries at the end of the acquisition period:

- of a two-year duration starting from the grant date, with an effective delivery of 50% of the acquired shares at the term of the two-year acquisition period;
- of a three-year duration starting from the grant date, with an effective delivery of the remaining 50% of the acquired shares at the term of an acquisition period of three years;
- the shares granted are not subject to any holding periods.

The final acquisition of the shares granted as part of the 2019, 2020 and 2021 plans mentioned in the table below is effective for all the beneficiaries after an acquisition period of two years for half of the acquired shares and of three years for the remainder, with the exception of the Executive Leadership Team members, for whom the acquisition period is of three

years. The acquired shares are not subject to any holding period, with the exception of the limitations applicable to the corporate officers.

The final acquisition is then effective subject to a presence condition and, for certain plans, to the achievement of performance conditions, mainly for the Executive Leadership Team members, set out by the Board of Directors.

The Shareholders' Meeting held on 29 May 2020, acting as an Extraordinary Shareholders' Meeting, authorized the Board of Directors to carry out free grants of existing shares and/or to be issued to salaried staff members and/or certain corporate officers, on one or several occasions. This Shareholders' Meeting granted all the powers to the Board of Directors to implement such free grant of shares.

To celebrate the crossing of the 2-billion-euros sales mark for the first time in Ipsen's history, and to share Ipsen's success with Group employees, the Board of Directors of 13 February 2019 decided to grant 5 Ipsen shares to all the eligible employees of the Group (except Executive Leadership Team members). The allocation of the "5 Shares for all" shares is

effective after an acquisition period of two years, *i.e.* 13 February 2021, and the shares acquired are not subject to any holding period.

During the 2021 financial year, 142,071 shares were transferred to beneficiaries at the end of the definitive acquisition period for bonus shares granted under the 29 March 2017, 30 May 2018, 13 February 2019 and 28 May 2019 plans, under the form of existing shares.

As of 31 December 2021, with respect to all Ipsen plans, 967,901 rights to bonus shares that may be acquired by beneficiaries were still valid (after deduction of the number of shares acquired or of rights cancelled to take into account the departure of certain beneficiaries), under the form of existing shares. No increase of share capital is to be planned.

The following table (table 10 of AMF recommendations) presents, as of 31 December 2021, the description and terms of the Ipsen bonus shares and performance shares granted, subject to the completion of presence conditions and, for certain grants, of performance conditions set out by the Board of Directors:

| Date of the Shareholders' Meeting | Date of the Board of Directors | Grant date | Number of Bonus shares granted | | | | Nature of the Bonus shares granted | Date of final acquisition | Date of availability | Number of Bonus shares | | |
|-----------------------------------|--------------------------------|------------|--------------------------------|------------------------|-------------------------|-----------------|------------------------------------|---------------------------|----------------------|----------------------------|---|------------------------------|
| | | | Total number | | Of which number granted | | | | | Cancelled as at 31/12/2021 | Number of shares transferred or created | Outstanding as at 31/12/2021 |
| | | | Of beneficiaries | Of Bonus shares | To company officers | Of Bonus shares | | | | | | |
| 31/05/2016 | 29/03/2017 | 29/03/2017 | 113 | 30,428 ⁽¹⁾ | – | – | Existing shares | 30/03/2019 | 30/03/2021 | 7,734 | 22,694 ⁽²⁾ | – |
| 31/05/2016 | 29/03/2017 | 29/03/2017 | 1 | 6,682 ⁽¹⁾ | 1 | 6,682 | Existing shares | 30/03/2019 | 30/03/2021 | – | 7,236 ⁽²⁾ | – |
| 31/05/2016 | 29/03/2017 | 29/03/2017 | 68 | 35,790 ⁽¹⁾ | – | – | Existing shares | 30/03/2021 | 30/03/2021 | 17,610 | 18,180 ⁽³⁾ | – |
| 31/05/2016 | 29/03/2017 | 29/03/2017 | 18 | 20,912 ⁽¹⁾ | – | – | Existing shares | 29/03/2019 | 30/03/2021 | 8,487 | 12,425 ⁽²⁾⁽⁴⁾ | – |
| 30/05/2018 | 30/05/2018 | 30/05/2018 | 410 | 43,755 | – | – | Existing shares | 31/05/2021 | 31/05/2021 | 19,580 | 24,175 ⁽³⁾ | – |
| 30/05/2018 | 30/05/2018 | 30/05/2018 | 153 | 61,815 ⁽¹⁾ | 1 | 4,615 | Existing shares | 31/05/2021 | 31/05/2021 | 44,927 | 16,888 ⁽³⁾ | – |
| 30/05/2018 | 13/02/2019 | 13/02/2019 | 5,176 | 25,880 ⁽⁴⁾ | – | – | Existing shares | 13/02/2021 | 13/02/2021 | 8,945 | 16,935 | – |
| 30/05/2018 | 28/05/2019 | 28/05/2019 | 156 | 58,580 ⁽¹⁾ | – | – | Existing shares | 31/05/2021 | 31/05/2021 | 36,472 | 22,108 ⁽³⁾ | – |
| 30/05/2018 | 28/05/2019 | 28/05/2019 | 156 | 58,580 ⁽¹⁾ | – | – | Existing shares | 30/05/2022 | 30/05/2022 | 22,035 | – | 36,545 |
| 30/05/2018 | 28/05/2019 | 28/05/2019 | 644 | 64,100 | – | – | Existing shares | 31/05/2021 | 31/05/2021 | 19,825 | 44,275 ⁽³⁾ | – |
| 30/05/2018 | 28/05/2019 | 28/05/2019 | 644 | 64,100 | – | – | Existing shares | 30/05/2022 | 30/05/2022 | 26,205 | 150 | 37,745 |
| 30/05/2018 | 28/05/2019 | 28/05/2019 | 12 | 43,520 ⁽¹⁾ | 1 | 11,730 | Existing shares | 30/05/2022 | 30/05/2022 | 23,630 | – | 19,890 |
| 30/05/2018 | 12/02/2020 | 12/02/2020 | 64 | 71,650 | – | – | Existing shares | 13/02/2022 | 13/02/2022 | 31,250 | – | 40,400 |
| 29/05/2020 | 29/05/2020 | 29/05/2020 | 909 | 223,154 | – | – | Existing shares | 30/05/2022 | 30/05/2022 | 64,063 | 280 | 158,811 |
| 29/05/2020 | 29/05/2020 | 29/05/2020 | 743 | 120,243 | – | – | Existing shares | 30/05/2023 | 30/05/2023 | 35,382 | 280 | 84,581 |
| 29/05/2020 | 29/05/2020 | 29/05/2020 | 176 | 176,871 ⁽¹⁾ | 1 | 4,690 | Existing shares | 29/05/2023 | 29/05/2023 | 37,859 | – | 139,012 |
| 29/05/2020 | 29/07/2020 | 29/07/2020 | 1 | 37,829 ⁽¹⁾ | 1 | 37,829 | Existing shares | 31/07/2023 | 31/07/2023 | – | – | 37,829 |
| 29/05/2020 | 27/05/2021 | 27/05/2021 | 167 | 161,313 ⁽¹⁾ | 1 | 30,063 | Existing shares | 28/05/2024 | 28/05/2024 | 6,415 | – | 154,898 |
| 29/05/2020 | 27/05/2021 | 27/05/2021 | 740 | 172,930 | – | – | Existing shares | 28/05/2023 | 29/05/2023 | 17,930 | – | 155,000 |
| 29/05/2020 | 27/05/2021 | 27/05/2021 | 740 | 93,090 | – | – | Existing shares | 28/05/2024 | 28/05/2024 | 11,515 | – | 81,575 |
| 29/05/2020 | 27/05/2021 | 27/05/2021 | 32 | 24,400 | – | – | Existing shares | 28/05/2023 | 29/05/2023 | 2,785 | – | 21,615 |
| Total | | | | 1,595,622 | | | | | | 425,217 | 161,451 | 967,901 |

⁽¹⁾ Shares granted under performance conditions, see section 5.6.1.3.2.

⁽²⁾ The Board of Directors, at its meeting held on 29 March 2019, noted the achievement of performance conditions attached to these shares.

⁽³⁾ The Board of Directors, at its meeting held on 27 May 2021, noted the achievement of performance conditions attached to these shares.

⁽⁴⁾ Shares granted under the "5 Shares for all" plan.

⁽⁵⁾ The registration on the accounts will be made after a four-year period following the date of grant.



Grants of Ipsen performance Shares to the employees during financial year 2021

During the 2021 financial year, the top ten Group employees (excluding corporate officers) to whom have been granted the

highest number of performance shares, received a total number of 49,755 rights to performance shares.

5.6.1.4 Authorized and non-issued share capital

The Combined Shareholders' Meetings held on 29 May 2020 and 27 May 2021 authorized the delegation of authority to the

Board of Directors regarding shares capital increases as followed, being specified that below are mentioned only the ongoing delegations and authorizations as of 31 December 2021:

Issues reserved to shareholders

| | Ongoing authorizations | | |
|---|---|--------------------------|---|
| | Date of the Shareholders' Meeting (resolution number) | Duration (expiry) | Maximum nominal amount of the share capital increase authorized |
| Share capital increase by incorporating reserves, profits and/or premiums as bonus shares grant and/or increase share par value | 27 May 2021 (19 th) | 26 months (26 July 2023) | 20% of the share capital ^(1, 5, 9) |
| Share capital increase by issues of ordinary shares and/or securities with retention of preferential subscription rights for shareholders | 27 May 2021 (20 th) | 26 months (26 July 2023) | 20% of the share capital ^(1, 2, 5, 9) |

Issues without preferential subscription rights for shareholders

| | Ongoing authorizations | | |
|--|---|--------------------------|---|
| | Date of the Shareholders' Meeting (resolution number) | Duration (expiry) | Maximum nominal amount of the share capital increase authorized |
| Share capital increase by issues of ordinary shares or securities without preferential subscription rights for shareholders by offer to the public | 27 May 2021 (21 st) | 26 months (26 July 2023) | 10% of the share capital ^(1, 3, 4, 5, 9) |
| Share capital increase by issues of ordinary shares or securities without preferential subscription rights for shareholders by private placement | 27 May 2021 (22 nd) | 26 months (26 July 2023) | 10% of the share capital ^(1, 3, 4, 5, 9) |
| Share capital increase to compensate contributions in kind of shares or securities | 27 May 2021 (24 th) | 26 months (26 July 2023) | 10% of the share capital ^(1, 5, 9) |

Issues reserved to employees (and, if applicable, to company officers)

| | Ongoing authorizations | | |
|--|---|--------------------------|---|
| | Date of the Shareholders' Meeting (resolution number) | Duration (expiry) | Maximum nominal amount of the share capital increase authorized |
| Share capital increase reserved for members of a company savings plan | 27 May 2021 (25 th) | 26 months (26 July 2023) | 5% of the share capital ^(1, 5) |
| Stock subscription and purchase options granted to employees and company officers | 27 May 2021 (26 th) | 26 months (26 July 2023) | 3% of the share capital ^(1, 5, 6, 8) |
| Authorization to allocate free of charge existing shares and/or shares to be issued to waged staff members and/or certain company officers | 29 May 2020 (18 th) | 26 months (28 July 2022) | 3% of the share capital ^(6, 7, 8) |

(1) Based on a share capital of €83,814,526 as at the date of the combined Shareholders' Meeting held on 27 May 2021.

(2) Global common limit of 20% of the share capital as of the date of the 27 May 2021 combined Shareholders' Meeting.

(3) The issues decided under this delegation are deducted from the global common limit of 20% of the share capital.

(4) The issues decided under delegations by offer to the public or private placement are deducted respectively from limits of each delegation, in addition to the global limit of 20% of the share capital.

(5) Unused.

(6) Common limit of 3% of the share capital.

(7) On the basis of the share capital on the 29 May 2020 Combined Shareholders' Meeting. This authorization has been used in 2021 up to a target number of 451,733 shares (free and performance), i.e. 0.54% of the share capital.

(8) Sub-ceiling of 20% of the share capital within this envelop for allocation to company officers.

(9) Suspended in period of public offer.

■ 5.6.1.5 Number of shares held by the Company

Authorizations

Share repurchase program and cancellation of shares

| | Ongoing authorizations | | |
|------------------------|---|------------------------------|--|
| | Date of the Shareholders' Meeting (resolution number) | Duration (expiry) | Characteristics |
| Share repurchase | 27 May 2021 (17 th resolution) | 18 months (26 November 2022) | Maximum repurchase price per share: €200 Limit of 10% of the number of shares comprising the share capital ⁽¹⁾ |
| Cancellation of shares | 27 May 2021 (18 th resolution) | 24 months (26 May 2023) | 10% of the share capital as of the date of decision of cancellation |

(1) Suspended in period of public offer. This authorization has been used in 2021, mainly as part of a share buyback program in a total number of 500,000 shares of the Company, see section 3.3.2 note 1 and section 5.6.1.6 below.

Treasury shares (excluding liquidity agreement)

As of 31 December 2021, the Company held 1,317,531 of its own shares dedicated to the covering of its bonus shares and performance shares plans.

As of 28 February 2022, the Company held 1,263,149 of its own shares dedicated to the covering of its bonus shares and performance shares plans (see section 5.6.1.3.2).

■ 5.6.1.6 Share repurchase program

Since 26 February 2007, the Company had mandated Natexis Bleichroder, a subsidiary of Natixis, to implement a liquidity contract for a one-year period with tacit renewal. This contract is compliant with the market practice admitted by regulations. As per the liquidity contract, the following assets appeared on the liquidity account: 46,838 shares and €1,259,939.79.

The liquidity contract originally implemented with Natixis has been transferred to the company ODDO BHF with effect 18 July 2018. The operations carried out in this context are summarized in the table below.

The Combined Shareholders' Meeting held on 27 May 2021 conferred to the Board of Directors a new authorization to repurchase the Company's shares for a 18 month period and

terminated the prior authorization granted on 29 May 2020. Pursuant to this decision, the Board of Directors decided on 27 May 2021 to set up a new share repurchase program with a limit of 10% of the share capital.

On 2 June 2021, the Company announced having given a mandate to purchase 500,000 Ipsen. shares, or about 0.6% of the share capital, for a maximum period of 6 months. The shares purchased under this agreement will be mainly allocated to cover its free share-allocation plans and its new employee share-ownership plan implemented during the financial year 2021. This mandate, ended on 25 August 2021 due to the acquisition of the target number of shares for a total amount of €42.9 million.

142,071 treasury shares have been used in 2021 as part of final share grants to employees (see 5.6.1.3).

114,442 treasury shares have been used as part of the 2021 employee share purchase plan.

Review of the share buyback program

The following tables present the purchase and sale transactions carried out by the Company in respect of its own shares, between the opening and closing dates of the 2021 financial year:

| | |
|--|--|
| Number of shares purchased: | 800,895 |
| Average purchase price: | €84.29 |
| Number of shares sold: | 305,639 |
| Average sale price: | €82.64 |
| Total amount of dealing and brokerage expenses: | €121,598.58 |
| Number of shares used in 2021: | 142,071 shares for performance shares plans and 114,442 shares as part of the employee share purchase plan |
| Number of shares registered in the name of the Company at the end of the financial year: | 1,317,531 (of which mainly 34,053 shares within the liquidity contract and 500,000 within the repurchase mandate) |
| Estimated value at the average purchase price: | €111,054,687.99 |
| Nominal value: | 1,317,531 including: <ul style="list-style-type: none"> • 783,478 dedicated to the coverage of options and shares plans • 500,000 as part of the share buyback program • 34,053 within the liquidity contract for the purposes of the animation of shares price |

| Distribution of own shares | % of the share capital |
|---|------------------------|
| Animation of share price | 0.04% |
| Coverage of stock purchase options or other employee share ownership system | 0.93% |
| Securities giving right to shares | – |
| Acquisitions | – |
| Cancellation | – |

■ 5.6.1.7 Non-equity securities

As at 2 December 2015, the Company organized an emission plan of commercial papers (NEU CP – Negotiable European Commercial Paper) to satisfy the general needs for financing the Group.

The case of financial display about the emission plan of commercial papers and the outstanding discounted bills of emissions can be consulted on the *Banque de France* website (www.banque-france.fr).

5.6.2 Shareholding

■ 5.6.2.1 Share ownership and voting rights

As of 31 December 2021, the Company's share capital amounted to €83,814,526 divided into 83,814,526 shares, each with a par value of €1. The corresponding theoretical number of voting rights amounted to 132,125,842 and the number of net voting rights amounts to 130,808,311.

The difference between the number of shares and voting rights results from double voting rights.

The difference between the number of theoretical voting rights and the number of real voting rights corresponds to the number of treasury shares.

As of 31 December 2021, to the best knowledge of the Company, its main shareholders are:

| | Share capital | | Gross voting rights | | Net voting rights | |
|--|-------------------|--------------|---------------------|--------------|--------------------|--------------|
| | Number | Percentage | Number | Percentage | Number | Percentage |
| Beech Tree ⁽¹⁾ , incl.: | 21,816,679 | 26.03 | 43,633,357 | 33.03 | 43,633,357 | 33.36 |
| • Directly by Beech Tree SA ⁽²⁾ | 8,310,253 | 9.92 | 16,620,505 | 12.58 | 16,620,505 | 12.71 |
| • Indirectly through MR BMH | 13,506,426 | 16.11 | 27,012,852 | 20.45 | 27,012,852 | 20.65 |
| Highrock ⁽³⁾ | 21,816,679 | 26.03 | 43,633,357 | 33.03 | 43,633,357 | 33.36 |
| MR Schwabe ⁽⁴⁾ | 3,636,455 | 4.34 | 7,272,910 | 5.50 | 7,272,910 | 5.56 |
| Finvestan ⁽⁴⁾ | 187,923 | 0.22 | 375,846 | 0.28 | 375,846 | 0.29 |
| Beaufour-Schwabe concert⁽⁵⁾ | 47,457,736 | 56.62 | 94,915,470 | 71.84 | 94,915,470 | 72.56 |
| Free Float | 33,922,804 | 40.47 | 33,922,804 | 25.67 | 33,922,804 | 25.93 |
| Treasury shares ⁽⁶⁾ | 1,317,531 | 1.57 | 1,317,531 | 1.00 | 0 | 0 |
| Other registered shareholders (including free shares to employees ⁽⁷⁾) | 700,014 | 0.84 | 1,217,479 | 0.92 | 1,217,479 | 0.93 |
| Employee FCP ⁽⁸⁾ | 273,854 | 0.33 | 469,249 | 0.36 | 469,249 | 0.36 |
| Board of Directors ⁽⁹⁾ | 142,587 | 0.17 | 283,309 | 0.21 | 283,309 | 0.22 |
| Total | 83,814,526 | 100 | 132,125,842 | 100 | 130,808,311 | 100 |

(1) Beech Tree is a limited company under Luxembourg law whose capital is controlled, on the date of filing of this document, by Henri Beaufour. Beech Tree controls the limited liability company under Luxembourg law MR BMH, direct shareholders of Ipsen S.A.

(2) Since 8 August 2020, the date of the merger of MR HB by Beech Tree. This operation is detailed below.

(3) Highrock is a limited liability company under Luxembourg law, the capital of which is controlled, on the date of filing of this document, by Anne Beaufour.

(4) MR Schwabe is a limited liability company under Luxembourg law, the capital of which is indirectly controlled, on the date of this document by the Schwabe family. Finvestan is limited liability company under Luxembourg law controlled by the Schwabe family.

(5) The agreements establishing the concert between the Beaufour family and the Schwabe family and the sub-concerts were subject to a notice of the French Autorité des Marchés Financiers n° 219C2985 dated 31 December 2019, as supplemented by a notice n° 220C4199 dated 9 October 2020.

(6) Including the liquidity agreement.

(7) The FCP Ipsen Shares is the sole employee shareholding fund to the share capital of the company.

(8) The free shares granted mainly include the ones provided in accordance with article L.225-102 of the French Code of Commerce.

(9) Excluding Beech Tree and Highrock, directors since 6 January 2020.

In accordance with the provisions of the law and its bylaws providing the disclosing of any detention of more than 1% of the share capital or voting rights, the Company has been informed of the following thresholds during the last three financial years:

- the company Amundi declared to the Company that it crossed:
 - downwards, on 5 March 2019, the 2% share capital threshold;
 - downwards, on 9 December 2019, the 1% share capital threshold;

- downwards, on 22 June 2020, the 1% share capital threshold;
 - upwards, on 23 June 2020, the 1% share capital threshold;
 - downwards, on 24 June 2020, the 1% share capital threshold;
 - upwards, on 22 July 2020, the 1% share capital threshold;
 - downwards, on 26 November 2020, the 1% share capital threshold;
 - upwards, on 11 December 2020, the 1% share capital threshold;
 - the company Black Creek Investment Management Inc., acting on account of its affiliates, declared to the Company that it crossed:
 - upwards, on 4 January 2021, the 1% of the share capital threshold;
 - the company BlackRock, Inc., acting on its own account and the account of its affiliates, declared to the Company that it crossed:
 - upwards, on 23 September 2019, the 3% of the share capital threshold;
 - upwards, on 27 September 2019, the 3% of the share capital threshold;
 - downwards, on 17 January 2020, the 3% of the share capital threshold;
 - upwards, on 20 January 2020, the 3% of the share capital threshold;
 - downwards, on 21 January 2020, the 3% of the share capital threshold;
 - upwards, on 22 January 2020, the 3% of the share capital threshold;
 - downwards, on 24 January 2020, the 3% of the share capital threshold;
 - the company Sycomore Asset Management declared to the Company that it crossed:
 - upwards, on 18 June 2020, the 1% of the share capital threshold;
 - downwards, on 7 August 2020, the 1% of the share capital threshold;
 - upwards, on 13 August 2020, the 1% of the share capital threshold;
 - downwards, on 21 September 2020, the 1% of the share capital threshold;
 - the company T. Rowe Price, acting on the account of its affiliates, declared to the Company that it crossed:
 - downwards, on 27 January 2021, the 2% of the share capital threshold.
 - the company Parvus Asset Management Europe Limited, acting on the account of its affiliates, declared to the Company that it crossed:
 - upwards, on 8 April 2021, the 1% of the share capital threshold;
 - upwards, on 14 April 2021, the 1% of the voting rights and the 2% of the share capital threshold;
 - upwards, on 27 April 2021, the 2% of the voting rights and the 3% of the share capital threshold;
 - upwards, on 5 October 2021, the 4% of the share capital threshold;
 - upwards, on 29 November 2021, the 3% of the voting rights threshold;
 - upwards, on 21 December 2021, the 5% of the share capital threshold (AMF notice n.221C3621).
 - the company Norges Bank, declared to the Company that it crossed:
 - downwards, on 13 August 2021, the 1% of the share capital threshold,
 - upwards, on 22 March 2022, the 1% of the share capital threshold.
 - the company *Caisse des dépôts et consignations* (CDC), acting through CNP Assurances, declared to the Company that it crossed:
 - upwards, on 4 May 2021, the 1% of the share capital threshold;
 - upwards, on 13 May 2021, the 1% of the voting rights and the 2% of the share capital thresholds;
 - downwards, on 26 May 2021, the 1% of the voting rights and the 2% then 1% of the share capital thresholds;
 - upwards, on 16 July 2021, the 1% of the share capital threshold;
 - downwards, on 19 October 2021, the 1% of the share capital threshold;
 - upwards, on 29 October 2021, the 1% of the voting rights and of the share capital threshold;
 - downwards, on 21 December 2021, the 1% of the voting rights threshold;
 - upwards, on 28 December 2021, the 1% of the voting rights threshold;
 - downwards, on 14 February 2022, the 1% of the voting rights threshold.
- Further to the demerger of the company Mayroy and the internal reclassification of its shares, according to the terms described in the press releases published by Ipsen and Mayroy on 5 November and 19 December 2019, were declared the following threshold crossings (it being specified that the family shareholding controlling the Company remains unchanged following these operations):
- the limited liability company under Luxembourg law MR HB (11 boulevard Royal, L-2449 Luxembourg, Grand Duchy of Luxembourg) declared that it had individually crossed upward the thresholds of 5% of capital and voting rights and 10% voting rights of the Company;
 - the limited liability company under Luxembourg law MR BMH (11 boulevard Royal, L-2449 Luxembourg, Grand Duchy of Luxembourg) declared that it had individually crossed upward the thresholds of 5%, 10% and 15% of the capital and voting rights and 20% of the voting rights of the Company;
 - the limited company under Luxembourg law Altawin (3 rue Nicolas Adames L-1114 Luxembourg, Grand Duchy of Luxembourg) declared that it had individually crossed upward (by assimilation), the thresholds of 5%, 10% and 15% of the capital and voting rights and 20% of the voting rights of the Company;
 - Henri Beaufour declared that he had indirectly crossed upward the thresholds of 5%, 10%, 20% and 25% of the capital and voting rights through the intermediary of the companies MR HB and MR BMH which he controls and 30% of the voting rights of the Company;
 - the limited liability company under Luxembourg law Highrock (9B boulevard du Prince Henri, L-1724 Luxembourg, Grand Duchy of Luxembourg) declared to have crossed upward individually the thresholds of 5%, 10%, 20% and 25% capital and voting rights and 30% of the voting rights of the Company;
 - Anne Beaufour declared that she had indirectly crossed upward, through the company Highrock which she controls, the thresholds of 5%, 10%, 20% and 25% of the capital and voting rights and 30% of the voting rights of the Company;
 - the limited liability company under Luxembourg Law MR Schwabe (3 rue Nicolas Adames, L-1114 Luxembourg, Grand Duchy of Luxembourg) declared to have crossed upward individually the threshold of 5% of the voting rights of the Company;

- the companies MR HB, MR BMH, Altawin and MR Schwabe declared that they together crossed upward in concert the thresholds of 5%, 10%, 15%, 20%, 25%, 30%, 1/3, 50% of the capital and voting rights and 2/3 of the voting rights of the Company.

Overall, the Beaufour-Schwabe concert did not cross any threshold and was holding, on 31 December 2019, 47,269,813 Ipsen shares representing 94,539,624 voting rights, *i.e.* 56.40% of the capital and 71.65% of the voting rights of the Company.

On 8 August 2020, the Company MR HB was absorbed by the limited company under Luxembourg law Beech Tree, resulting in the universal transfer of the assets of the company MR HB in favor of the company Beech Tree. Following this transaction, the company Beech Tree directly holds 9.92% of the capital and 12.58% of the voting rights of the Company.

On 10 September 2020, the company Bee Master Holding BV was absorbed by its wholly owned subsidiary, MR BMH, resulting in the universal transfer of the assets of the company Bee Master Holding BV in favor of the company MR BMH.

On 2 October 2020, the shares of the Company held by the Luxembourg company Finvestan, controlled by the Schwabe family, were included in the Schwabe-Beaufour voting syndicate by amendment to the "Schwabe" shareholders' agreement, and are now taken into account in the holding of the Beaufour-Schwabe concert.

On this occasion, the concert composed of the Beaufour and Schwabe families did not cross any threshold and stated that it held, as of 2 October 2020, 47,457,736 IPSEN shares representing 94,915,470 voting rights, *i.e.* 56.62% of the capital and 71.83% of the voting rights of the Company.

To the Company's knowledge, on this declaratory basis, except to what is described above, no other shareholder owns, directly or indirectly, acting alone or in concert, more than 5% of the share capital or voting rights.

As at the setting-up date of this universal registration document, and to the Company's knowledge, there were no significant alterations of the share capital distribution, with regard to the one presented above on 31 December 2021.

5.6.2.2 Transactions on Company's Shares

Definition of blackout periods

The Company complies with the recommendation n° 2016-08 of the *Autorité des marchés financiers* of 26 October 2016, and the European Regulation (EU) No 596/2014 on market abuse. Accordingly, purchases and sales of Company securities or financial instruments are prohibited during the periods running from the date on which persons having managerial responsibilities, as well as any other person who has access to privileged information on a regular or occasional basis, have knowledge of information of a precise

Transactions on the Company's Securities carried out in 2021

Pursuant to Article 223-26 of the General Regulations of the *Autorité des marchés financiers*, the table below sets out transactions on Company's securities carried out in 2021, as such transactions were notified to the Company and the *Autorité des marchés financiers*:

| | Purchases | | | Sales | | | Other operations | | |
|---|-----------|--------|-----------------|-------|--------|-----------------|------------------|--------------------------|-----------------|
| | Date | Number | Price per unite | Date | Number | Price per unite | Date | Number | Price per unite |
| Highrock S.à.r.l., Director | - | - | - | - | - | - | 04/06/2021 | 1,363,180 ⁽¹⁾ | - |
| Antoine Flochel, Vice Chairman of the Board | - | - | - | - | - | - | 20/10/2021 | 2,000 ⁽²⁾ | - |

(1) Release of pledges.

(2) Intra-group cross-border merger.

nature, which has not been made public, relating, directly or indirectly, to one or more issuers or to one or more financial instruments, and which, if it were made public, would be likely to have a significant effect on the prices of those financial instruments or on the price of related derivative financial instruments. Furthermore, they are also prohibited during a period of:

- 30 calendar days prior to the publication of press release on the annual and half-year financial statements and the day of publication included, and
- 30 calendar days prior to the publication of quarterly information and the day of publication included.

At the beginning of every year, the Company draws up and releases, a timetable that defines the periods during which trading in Company securities is prohibited and stipulates that the indicated periods do not anticipate the existence of other blackout periods that result from knowledge of precise non public information that directly or indirectly concerns Ipsen, which, if it were disclosed, would be likely to have a significant affect on the price of the securities concerned.

In accordance with the recommendations of the AFEP-MEDEF Code (section 25.3.3), hedging of any kind on securities of the Company, with regard to options, to shares resulting from the exercise of options or to performance shares, is prohibited.

Marc de Garidel, Chairman of the Board of Directors, and David Loew, Chief Executive Officer, undertook a formal commitment not to engage in hedging transactions either on the options or on shares issued following the exercise of options or on performance shares granted until the end of the holding period that has been decided by the Board of Directors.

In addition, each director, with the exception of the directors representing the employees, must be a shareholder of the Company in a personal capacity and own, directly or indirectly, a relatively significant number of shares. The director, natural or legal person, permanent representative of a legal person to whom a compensation in this capacity has been paid, must hold, before the expiry of a two-year term after his first appointment, 500 Company shares.

Corporate Officers must retain, until the end of their term of office, a number of shares equivalent to 20% of the net capital gain that would be realized upon the sale of the shares resulting from the exercise of stock options and/or from the performance shares.

These shares must be held in the registered form.

The Company regularly communicates to the directors the calendar of the black-out periods as well as their new obligations.

■ 5.6.2.3 Evolution of share ownership and voting rights over the past three financial years (as of 31 December)

| | 2021 | | | | | |
|---|-------------------|--------------|-------------------------------|--------------|-----------------------------|--------------|
| | Number of shares | % | Number of gross voting rights | % | Number of net voting rights | % |
| Beech Tree, incl.: | 21,816,679 | 26.03 | 43,633,357 | 33.03 | 43,633,357 | 33.36 |
| • Directly by Beech Tree | 8,310,253 | 9.92 | 16,620,505 | 12.58 | 16,620,505 | 12.71 |
| • Indirectly through MR BMH | 13,506,426 | 16.11 | 27,012,852 | 20.45 | 27,012,852 | 20.65 |
| Highrock | 21,816,679 | 26.03 | 43,633,357 | 33.03 | 43,633,357 | 33.36 |
| MR Schwabe | 3,636,455 | 4.34 | 7,272,910 | 5.50 | 7,272,910 | 5.56 |
| Finvestan | 187,923 | 0.22 | 375,846 | 0.28 | 375,846 | 0.29 |
| Beaufour-Schwabe concert | 47,457,736 | 56.62 | 94,915,470 | 71.84 | 94,915,470 | 72.56 |
| Free Float | 33,922,804 | 40.47 | 33,922,804 | 25.67 | 33,922,804 | 25.93 |
| Treasury shares ⁽¹⁾ | 1,317,531 | 1.57 | 1,317,531 | 1.00 | 0 | 0 |
| Other registered shareholders (including shares granted to employees) | 700,014 | 0.84 | 1,217,479 | 0.92 | 1,217,479 | 0.93 |
| Employee FCP ⁽²⁾ | 273,854 | 0.33 | 469,249 | 0.36 | 469,249 | 0.36 |
| Board of Directors ⁽³⁾ | 142,587 | 0.17 | 283,309 | 0.21 | 283,309 | 0.22 |
| Total | 83,814,526 | 100 | 132,125,842 | 100 | 131,808,311 | 100 |

| | 2020 | | | | | | 2019 | | | | | | |
|---|-------------------|--------------|-------------------------------|--------------|-----------------------------|--------------|---|-------------------|-------------------------------|--------------------|-----------------------------|--------------------|--------------|
| | Number of shares | % | Number of gross voting rights | % | Number of net voting rights | % | Number of shares | % | Number of gross voting rights | % | Number of net voting rights | % | |
| Beech Tree, incl.: | 21,816,679 | 26.03 | 43,633,357 | 33.03 | 43,633,357 | 33.30 | Beech Tree, incl.: | 21,816,679 | 26.03 | 43,633,357 | 33.07 | 43,633,357 | 33.26 |
| • Directly by Beech Tree | 8,310,253 | 9.92 | 16,620,505 | 12.58 | 16,620,505 | 12.68 | • Directly by Beech Tree | 8,310,253 | 9.92 | 16,620,505 | 12.60 | 16,620,505 | 12.67 |
| • Indirectly through MR BMH | 13,506,426 | 16.11 | 27,012,852 | 20.45 | 27,012,852 | 20.62 | • Indirectly through MR BMH | 13,506,426 | 16.11 | 27,012,852 | 20.47 | 27,012,852 | 20.59 |
| Highrock | 21,816,679 | 26.03 | 43,633,357 | 33.03 | 43,633,357 | 33.30 | Highrock | 21,816,679 | 26.03 | 43,633,357 | 33.07 | 43,633,357 | 33.26 |
| MR Schwabe | 3,636,455 | 4.34 | 7,272,910 | 5.50 | 7,272,910 | 5.55 | MR Schwabe | 3,636,455 | 4.34 | 7,272,910 | 5.51 | 7,272,910 | 5.54 |
| Finvestan | 187,923 | 0.22 | 375,846 | 0.28 | 375,846 | 0.29 | | | | | | | |
| Beaufour-Schwabe concert | 47,457,736 | 56.62 | 94,915,470 | 71.84 | 94,915,470 | 72.44 | Beaufour-Schwabe concert | 47,269,813 | 56.40 | 94,539,624 | 71.65 | 94,539,624 | 72.07 |
| Free Float | 34,247,720 | 40.86 | 34,247,720 | 25.92 | 34,247,720 | 26.14 | Free Float | 34,588,599 | 41.27 | 34,588,599 | 26.21 | 34,588,599 | 26.37 |
| Other registered shareholders (including shares granted to employees) | 665,647 | 0.79 | 1,160,431 | 0.88 | 1,160,431 | 0.89 | Other registered shareholders (including shares granted to employees) | 803,543 | 0.96 | 1,366,775 | 1.04 | 1,366,775 | 1.03 |
| Treasury shares ⁽¹⁾ | 1,092,066 | 1.30 | 1,092,066 | 0.83 | 0 | 0 | Treasury shares ⁽¹⁾ | 777,182 | 0.93 | 777,182 | 0.59 | 0 | 0 |
| Employee FCP ⁽²⁾ | 208,405 | 0.25 | 416,810 | 0.32 | 416,810 | 0.32 | Employee FCP ⁽²⁾ | 218,276 | 0.26 | 387,243 | 0.29 | 387,243 | 0.30 |
| Board of Directors ⁽³⁾ | 142,952 | 0.17 | 283,526 | 0.21 | 283,526 | 0.22 | Board of Directors ⁽³⁾ | 157,113 | 0.18 | 288,935 | 0.22 | 288,935 | 0.21 |
| Total | 83,814,526 | 100 | 132,116,023 | 100 | 131,023,957 | 100 | Total | 83,814,526 | 100 | 131,948,358 | 100 | 131,171,176 | 100 |

⁽¹⁾ Including the liquidity agreement.

⁽²⁾ The FCP Ipsen Shares is the sole employee shareholding fund to the share capital of the Company.

⁽³⁾ Excluding shares held by the representatives of the above-mentioned Highrock S.à.r.l. and Beech Tree SA, directors since January 6, 2020. Includes the shares held by the directors representing the employees presented in section 5.2.1.4.

■ 5.6.2.4 Shareholders' agreements and parties acting in concert

Agreements between shareholders of the Company

By letter dated 23 and 26 December 2019, the French *Autorité des marchés financiers* and the Company were informed of the conclusion, on 19 December 2019, of the following three shareholder agreements (AMF notice 219C2985, as amended on 2 October 2020 (AMF notice 220C4199)):

- The "Ipsen" shareholders' agreement: the companies Highrock, Beech Tree and Altawin (controlled by B.I.O Trust) have concluded a shareholders' agreement constituting a concert between them vis-à-vis Ipsen.

This agreement is entered into for an initial period of four years, renewable by tacit agreement for 3-year periods.

In terms of governance, it provides for a concertation procedure between Highrock and Beech Tree in order to reach, as far as possible, a common position mainly on the strategic decisions about the Company and its subsidiaries, as well as rules for the composition of the Board of Directors of the Company.

In terms of securities transfers, this agreement provides for an inalienability period of two years for the securities held by the parties, followed by an undertaking of each party to hold a sufficient number of shares during the 12 months following the expiry of this inalienability period so that the shares held by the Beaufour concert represent at least 50.01% of the voting rights of the Company.

In addition, this pact provides in particular for mechanisms of right of first offer for the benefit of Highrock or Beech Tree in the event of transfer by Highrock, Beech Tree or Altawin except for free transfers or below a certain threshold, as well as a right of joint sale in favor of Beech Tree and Altawin in certain cases of acquisition of shares by Highrock.

- The "Beech Tree" governance agreement: Henri Beaufour and the company Altawin (controlled by B.I.O Trust), in presence of Beech Tree, have concluded, on 19 December 2019, a governance agreement.

This agreement is entered into for an initial period of five years, renewable by tacit agreement for 2-year periods.

The Beech Tree shareholders' agreement arranges the following particular rights to the benefit of Altawin as a result of the holding by this company of participatory notes issued by Beech Tree:

- A right of veto with regard to certain strategic decisions concerning in particular the transfer of the shares of the Company held by Beech Tree and MR BMH and the modification of the capital;
- A discretionary liquidity option;
- An enhanced information right.

The agreement also organizes the composition of the Board of Directors of Beech Tree and its representation at Ipsen's level.

- The "Schwabe" shareholders' agreement: the members of the Beaufour sub-concert on the one side and FinHestia, Finvestan and Finveska (controlled by the Schwabe family) on the other side, have concluded, on 19 December 2019,

a shareholders' agreement constitutive of a concert between the parties with respect to Ipsen.

The agreement is entered into for a duration of four years, renewable for 3-year periods. Except express renewal the agreement will end after ten years; this agreement will terminate early in respect of a party in the event of the transfer of all of its shares under the agreement.

This pact provides for a voting syndicate mechanism relating to 28% of Ipsen shares, for which voting at shareholders' meetings will be determined by a majority of 75% of the shares under the agreement.

In terms of transfer, any plan to transfer the shares subject to the agreement (except between the parties or to entities wholly owned by them) must be authorized by the parties to the Schwabe agreement ruling by a majority of 75% of the shares subject to the agreement.

- The French *Autorité des marchés financiers* has been informed of the intention of Anne Beaufour to set up 3 asset holdings in order to make donations of bare ownership of shares in the said holdings for the benefit of each of her children, Anne Beaufour and the said holdings (of which Anne Beaufour would retain the usufruct), owning 100% of the company Highrock. The *Autorité des marchés financiers* has also been informed of the intention of Anne Beaufour and her 3 children to conclude, once these donations have been made, an agreement organizing a concerted action between them vis-à-vis Ipsen providing for a consultation within a family meeting in order to exchange views and reach, as far as possible, a common position, in particular on the draft resolutions submitted to the vote of the shareholders of Ipsen. As of the date of this document, the donations have not been made and this shareholders' agreement has not yet been concluded.

Parties acting in concert

To the Company's knowledge, there is no other concerts than the Beaufour-Schwabe concert and its sub-concerts, formalized by the shareholders' agreements and governance agreement as mentioned above.

■ 5.6.2.5 Nature of control

The Company is controlled as described above. Measures taken to avoid any abusive control are, in particular, the following:

- separation of the functions of Chairman of the Board and Chief Executive Officer;
- presence of one independent Director of three members in the Nomination Committee;
- presence of one independent Director and one Director representing the employees of four members in the Ethics and Governance Committee, including the Chairperson of the Committee;
- presence of two independent Directors and one Director representing the employees of five members in the Compensation Committee;
- presence of two independent Directors of three members in the Audit Committee, including the Chairperson of the Committee;
- presence of four independent Directors of fourteen members in the Company's Board of Directors as described in section 5.2.1.3. of this universal registration document;

- presence of three independent Directors of six members in the Innovation and Development Committee – Specialty Care and one independent in the Innovation and Development Committee – Consumer HealthCare;
- presence of two directors representing the employees to the Board of Directors, designated on 27 November 2018 and 6 November 2020. In compliance with French law, it has been proposed to the next Shareholders' Meeting to deliberate on a modification of the Articles of association aiming at amending the Articles of association to lower from 12 to 8 the threshold for the mandatory representation to designate a second director representing the employees to the Board. This resolution had been approved during the Meeting held on 29 May 2020.

■ 5.6.2.6 Information or agreements likely to involve a change in control or to have an impact in the event of a takeover bid

Agreements likely to involve a change in control

None.

Information likely to have an impact in the event of a public offer

In accordance with provisions of Article L.22-10-11 of the French Commercial Code, the following information may have an impact in the event of a public offer:

- Ownership of the Company's share capital: see section 5.2.3 of the present document.
- Restrictions contained in the Articles of association on voting rights: none; except, in case of none-statement of crossing a statutory threshold, temporary suspension of voting rights which may be requested during a shareholders' meeting by one or more shareholders holding at least 1% of the share capital or voting rights (article 10.3 of the Articles of association, see section 5.6.3.5).
- Restrictions contained in the Articles of association on transfer of shares or agreements whose the Company has knowledge in accordance with the provisions of Article L.233-11 of the French Commercial Code: not applicable.

- Direct and indirect interests in the share capital known by the Company in accordance with the provisions of Articles L.233-7 and L.233-12 of the French Commercial Code: see section 5.2.3 of this document.
- Shareholders holding any share conferring specific control rights and description: there are no shares conferring specific control rights. However, a double voting right exists for any fully paid-up registered under the name of a same shareholder for at least 2 years as described in section 5.6.3.3 (Article 26 of the Articles of association).
- Control mechanisms provided for in an employee shareholding system if controlling rights are not exercised by said system: voting rights attached to the Ipsen shares held by employees through the FCP Ipsen Shares, the only mutual fund for employees, are exercised by a person empowered by the supervisory board of the mutual fund in order to be represented in shareholders' meeting (see section 5.2.3 of the present universal registration document).
- Agreements between shareholders of which the Company is aware that may cause restrictions to transfers of shares and exercises of voting rights: see section 5.6.2.4 of the present universal registration document.
- Provisions governing the election and replacement of Board Members: see section 5.2.1.2 of the present document.
- Provisions governing the amendment of the Company's Articles of association: legal rules.
- Powers of the Board of Directors, in particular concerning issuance or repurchases of shares: see section 5.2.2.4 of the present universal registration document.
- Agreements entered into by the Company that are amended or expire in the event of a change of control of the Company, unless this disclosure, except if required by law, may have a material negative impact on its interests: none.
- Agreements providing for compensations of members of the Board of Directors or employees in case of resignation or dismissal without cause or if their employment ends as a result of a public offer: see section 5.1.3 of the present universal registration document.

■ 5.6.2.7 Dividends

Dividends paid in the past three financial years

| For financial year | Incomes eligible for the deduction provided by article 158-3-2° of the French Tax Code | | Incomes not eligible for the deduction provided by article 158-3-2° of the French Tax Code |
|--------------------|--|------------------------|--|
| | Dividends | Other incomes paid out | |
| 2018 | €83,808,761.00 * i.e. €1.00 per share ** | – | – |
| 2019 | – | – | €83,814,526.00 * i.e. €1.00 per share *** |
| 2020 | €83,814,526.00 * i.e. €1.00 per share | – | – |

(*) Including the amount on the unpaid dividend or distribution corresponding to treasury shares and allocated to the account on which it has been withdrawn.

(**) Distribution of the entire balance of the retained earnings account and reserves in the amount of €40,763,761.64.

(***) Distribution made from the "share premium account" in the amount of €83,814,526.



Dividends and reserves distribution policy

The dividend payout policy is determined by the Company's Board of Directors after analysis, mainly, of the Company's financial results and position. The Company's objective for future years is to develop a payout policy consistent with its growth strategy.

Statute of limitations

Dividends which are not claimed within five years of their payment date shall lapse and become the property of the State.

5.6.2.8 Related-party transactions

The Company and the Schwabe group hold joint participations in certain companies, consolidated applying the equity method (see section 3.2, note 2.1).

Subject to, (i) the agreements entered into with the Schwabe group described in section 1.2.2.2 of the present document, (ii) information regarding related-party transactions described in section 3.2, note 2.1, (iii) the agreements and commitments described in the Special Report of the Statutory Auditors on regulated agreements presented in section 5.5 of the universal registration document, there are no other agreements between the Group and related parties.

In addition, in accordance with the PACTE law and article L. 225-39 of the French Commercial Code, an internal procedure to identify and assess agreements qualified as regulated prior to their conclusion or modification, as well as current conventions concluded at normal conditions, has been put in place to facilitate the monitoring of agreements entered into by the Company.

5.6.3 Main provisions of the Articles of association

5.6.3.1 Corporate purpose (Article 2 of the Articles of association)

The Company's corporate purpose is the following in France and any other country whether directly or indirectly:

- to invent, manufacture, process, and sell pharmaceutical products, para-pharmaceutical products, cosmetics or any other manufactured products in the fields of drugs and fine chemicals, and all products and materials used to manufacture, process and sell such products;
- to conduct all industrial and commercial activities directly or indirectly related to the foregoing purpose, including research and design, acquiring, owning, exploiting and selling patents, licenses, know-how and more generally all intellectual and industrial property rights; and
- more generally, to conduct all industrial, commercial, financial or property transactions which may directly or indirectly facilitate or further the achievement of the foregoing purposes and any similar purposes.

5.6.3.2 Governance of the Company

Board of Directors

The Company is governed by a Board of Directors. The Board of Directors is responsible for defining and implementing the Company's strategic objectives. Subject to the powers expressly reserved for the Shareholders' Meeting and within the limits of the Company's corporate purpose, the Board of Directors is competent to consider and settle all issues involving the proper functioning of the Company through the passing of its resolutions.

Executive Management

In accordance with the legal provisions, the Executive Management of the Company is the responsibility either of the Chairman of the Board of Directors, who then serves as Chairman and Chief Executive Officer, or of another person

appointed by the Board of Directors who then serves as Chief Executive Officer.

The Board of Directors is responsible for electing one of these two options for a period which may not be less than one year.

At its meeting on 15 February 2016, the Board of Directors decided to change the Company's form of governance by separating the duties of Chairman of the Board of Directors and Chief Executive Officer. The separation of said functions is effective since 18 July 2016 date. Within this change of governance, the appointment of Marc de Garidel as Chairman of the Board of Directors had been confirmed.

Further to David Meek's resignation from his position as Chief Executive Officer, and member of the Board of Directors, effective 31 December 2019, the Board of Directors decided to appoint Aymeric Le Chatelier, currently Chief Financial Officer, as Interim CEO as of 1 January 2020. David Loew was then appointed Chief Executive Officer by the Board of Directors of 28 May 2020, effective 1 July 2020, and directors from 28 May 2020. For further details, see section 5.1.

5.6.3.3 Rights and obligations attached to shares

Distribution of profits (Article 29 of the Articles of association)

In accordance with the terms and provisions of Article 29 of the Articles of association, after approval of the financial statements and recognition of a distributable profit within the meaning of the law, the Shareholders' Meeting may resolve to transfer the distributable profit to one or more discretionary reserve accounts, for which it fixes the allocation or use, or retained earnings or to distribute it as a dividend. After deduction of any prior year losses, at least 5% of each year's net profit is transferred to the statutory reserve as required by law. This provision ceases to apply once the statutory reserve has reached one tenth of the Company's share capital.

The Shareholders' Meeting may decide to distribute amounts from reserves to which the shareholders are entitled. In this case, the resolution must expressly indicate which reserve accounts are to be used. However, dividends must be drawn in priority from the year's distributable profit.

The Shareholders' Meeting may resolve to offer payment of all or part of the dividend or interim dividends in cash or in shares at the personal choice of each shareholder.

A shareholder's right to the profits and contribution to losses is proportional to the percentage of share capital owned.

Form of shares issued by the Company (Article 9 of the Articles of association)

The shares issued by the Company may be registered or bearer shares. Existence of the shares is evidenced by their registration on securities accounts held in the name of the holder under the terms and conditions set out by law either by the Company or its appointed custodian in the case of registered shares or by an authorized intermediary authorized of bearer shares.

Shareholders' voting rights (Articles 26.1 and 11.3 of the Articles of association)

In Ordinary and Extraordinary Shareholders' Meetings, each shareholder has a voting right equal to the number of shares he/she holds or represents without limit.

However, the Board of Directors held on 30 August 2005 decided that a double voting right is attached to any ordinary fully paid-up share which is owned under the registered form by the same shareholder for at least two years. The double voting rights shall automatically end with its conversion to the form of bearer share, as well as its transfer, except in cases provided for by law.

According to the provisions of article 11.3 of the Articles of association, the voting right attached to shares belongs to the usufruct holder in Ordinary Shareholders' Meetings and to the bare owner in Extraordinary Shareholders' Meetings.

Actions necessary to modify shareholder's rights

There are no specific existing rules regarding the modification of shareholders' rights which are made in accordance with the legal provisions.

■ 5.6.3.4 Shareholders' Meetings (Articles 21 to 26 of the Articles of association)

Participation in Shareholders' Meetings

Any shareholder has the right to attend Shareholders' Meetings and take part in the vote either in person or by proxy, regardless of the number of shares owned, by providing evidence of his/her status as shareholder.

In accordance with article R.225-85 of the French Commercial Code, the right to participate in Shareholders' Meetings is subject to the account registration of the shares being registered in an account in the name of the shareholder or of the financial intermediary acting on the shareholder's behalf, at midnight, Paris time, on the second business day preceding the date of the General Meeting, either in the registered share accounts kept by the Company or in the bearer share accounts kept by the authorized intermediary.

Ordinary Shareholders' Meeting

The Ordinary Shareholders' Meeting receives the Board of Directors' report and the Statutory Auditors' reports, approves the annual financial statements and votes on the distribution of profits. It appoints and dismisses the Directors and sets their compensation in accordance with the legal provisions and the Articles of association. It appoints the Company's Statutory Auditors.

The Ordinary Shareholders' Meeting may delegate authority to the Board of Directors at the Board's request to deal with all matters not specifically reserved for Extraordinary Shareholders' Meetings.

More generally, the Ordinary Shareholders' Meeting resolves on all matters that do not entail a direct or indirect modification of the Articles of association.

The Ordinary Shareholders' Meeting is held every year no later than six months after the end of the previous financial year-end, unless this time period is extended by court order.

Extraordinary Shareholders' Meeting

The Extraordinary Shareholders' Meeting may amend any and all of the provisions of the Articles of association of the Company. However, it may not increase the shareholders' liability, or change the nationality of the Company except under the terms and conditions set forth by law and international treaties.

Notice and Meeting of Shareholders' Meetings

General Shareholders' Meetings are called by the Board of Directors or, if applicable, by the Statutory Auditors or any other person duly empowered by law. The meetings take place at the registered office or any other place indicated in the notice of meeting.

The agenda is set by the person who convenes the meeting. However, one or several shareholders may request, under the terms and conditions set forth by legal and regulatory provisions in force, the inclusion of items or draft resolutions in the agenda. The works council may also require the inclusion of proposed resolutions in the agenda in accordance with the regulation in force. The Shareholders' Meeting may not resolve on items which are not on the agenda, in accordance with the current regulation. However, it may in any event remove one or more Directors from office and appoints new directors in replacement. The agenda may not be revised for an adjourned meeting.

Given the administrative measures implemented as a result of the COVID-19 epidemic prohibiting any meetings for health reasons in France, the organisation of the Shareholders' Meeting held on Friday, 29 May 2020, and the shareholders' participation have had to be changed. In accordance with Order No 2020-321 of 25 March 2020 (as ex-tended and amended by Order No. 2020-1497 of 2 December 2020) and Decree No. 2020-418 of 10 April 2020 (as extended and amended by Decrees No. 2020-1614 of 18 December 2020 and No. 2021-255 of 9 March 2021) the Combined Shareholders' Meeting of the Company of Thursday 27 May 2021, by decision of the Board of Directors, will exceptionally be held behind closed doors, without the shareholders and other persons entitled to attend being physically present. The shareholders had been able to vote or give a proxy either by using the voting form or electronically using a secure voting platform.

Quorum

The Ordinary Shareholders' Meeting validly deliberates, on first notice, if the shareholders present or represented, or voting by postal vote, represent at least one fifth of the shares with voting rights. No quorum is required for an adjourned meeting. It passes its resolution by a simple majority vote of the shareholders present or represented or voting by postal vote. The quorum is calculated on the basis of the shares comprising the share capital, less any shares deprived of voting rights in accordance with the law and provisions of the Company's Articles of association.

The Extraordinary Shareholders' Meeting validly deliberates if the shareholders present or represented, or voting by postal vote, represent, on first notice, one quarter of the shares with voting rights, and one fifth on second notice. In the event this quorum is not reached, the second Shareholders' Meeting may be postponed to a further date no later than two months from the original convening's date.

Shareholders attending the meeting by videoconferencing or other means of telecommunication allowing their identification and compliant with the legal and regulatory provisions are counted as present for the purpose of calculating the quorum.

■ 5.6.3.5 Crossing of thresholds (Article 10.3 of the Articles of association)

In addition to the legal disclosure requirements set out in Article L.233-7 of the French Commercial Code, any person or legal entity, acting either alone or in concert, who holds by any mean a number of shares representing one percent (1%) of the share capital or voting rights, or any multiple thereof, must no later than five (5) business days after the occurrence, advise the Company by fax of the total number and percentage of shares and voting rights held, with written confirmation sent the same day by recorded delivery mail.

Such persons are also required to advise the Company if their holding falls back below those thresholds, under the same terms and conditions.

In case of failure to comply with these requirements, the shares exceeding the part that should have been disclosed are deprived of the voting right for any Shareholders' Meeting that would be held in a two-year period following the date of regularization of the disclosure. Except in the case of crossing one of the thresholds provided for by Article L.233-7 of the French Commercial Code, the deprivation of the voting rights, which will be recorded in the minutes of the Shareholders' Meeting, may only occur if requested by one or more of the shareholders representing at least one percent (1%) of the share capital and voting rights of the Company.

■ 5.6.3.6 Identification of bearer shareholders (Article 10.2 of the Articles of association)

The Company may at any time, in accordance with the applicable legal and regulatory provisions and at its own expenses, request the relevant central depository for financial instruments, to provide it with the name, or the corporate name in case of a legal entity, nationality and address or as the case may be, the registered office, of holders of securities conferring the right to vote at its General Shareholders' Meetings either immediately or in the future, as well as the number of securities held by each of them and any restrictions attached thereto.

■ 5.6.3.7 Specific provisions governing changes in the share capital

The share capital and the rights attached to shares can only be modified in accordance with applicable legal provisions. The Articles of association of the Company do not provide for any specific provision in that respect.

■ 5.6.3.8 Financial year (Article 27 of the Articles of association)

Each financial year has a 12-month term beginning on 1 January and ending on 31 December.

■ 5.6.3.9 Provisions that could delay, defer or prevent a change in control

There is no specific provisions of the Articles of association that could delay, defer or prevent a change in the control of the Company.

6

ANNEXES

| | |
|---|------------|
| 6.1 PERSON RESPONSIBLE | 274 |
| 6.1.1 Person responsible for the universal registration document | 274 |
| 6.1.2 Attestation by the person responsible for the universal registration document including the Annual Financial Report | 274 |
| 6.1.3 Persons responsible for financial information | 274 |
| 6.1.4 Person responsible for account audit and fees | 274 |
| 6.2 THIRD PARTY INFORMATION, STATEMENTS BY EXPERTS AND DECLARATIONS OF INTERESTS | 275 |
| 6.3 CONSULTATION OF LEGAL DOCUMENTS | 275 |
| 6.4 CROSS-REFERENCE TABLES | 275 |
| 6.4.1 Universal registration document concordance table | 275 |
| 6.4.2 Annual Financial Report cross-reference table | 279 |
| 6.4.3 Cross-reference table of the Management Report and of the Board of Directors' Report on Corporate Governance | 279 |
| 6.4.4 Cross-reference table for the filing of the financial statements | 282 |



6.1 PERSON RESPONSIBLE

6.1.1 Person responsible for the universal registration document

David Loew

Chief Executive Officer

6.1.2 Attestation by the person responsible for the universal registration document including the Annual Financial Report

"I affirm that having taken all reasonable care to ensure that such is the case, the information contained in this universal registration document is, to the best of my knowledge, in accordance with the facts and contains no omission likely to affect its import.

I hereby declare that, to the best of my knowledge, the financial statements have been prepared in accordance with the applicable accounting standards and give a true and fair view of the assets, liabilities, financial position and results of the Company and all the other companies included in the scope of consolidation, and that the Management Report which different sections are mentioned in the concordance

table on Chapter 6 of this universal registration document gives a fair description of the business developments, results and financial position of the Company and all the other companies included in the scope of consolidation, as well as a description of the main risks and contingencies with which the Company may be confronted."

Boulogne-Billancourt,
12 April 2022
David Loew
Chief Executive Officer

6.1.3 Persons responsible for financial information

David Loew

Chief Executive Officer

Aymeric Le Chatelier

Chief Financial Officer

Craig Marks

Vice President, Investor Relations

Ipsen

65, quai Georges Gorse
92100 Boulogne-Billancourt
Phone: +33 (0)1 58 33 50 00
Fax: +33 (0)1 58 33 50 01
investor.relations@ipsen.com

www.ipsen.com

6.1.4 Person responsible for account audit and fees

■ 6.1.4.1 Statutory Auditors

Deloitte & Associés

Represented by Frédéric Souliard

6 place de la Pyramide

92908 Paris-La Défense Cedex – France

First appointed at the Annual Shareholders' Meeting held on 17 December 1998. Term of office renewed by the Annual Shareholders' Meeting held on 31 May 2016.

KPMG Audit

Department of KPMG S.A.

Represented by Catherine Porta

2, avenue Gambetta

CS 60055

92066 Paris-La Défense Cedex – France

First appointed at the Annual Shareholders' Meeting held on 18 June 2005. Term of office renewed by the Annual Shareholders' Meeting held on 7 June 2017.

■ 6.1.4.2 Alternate Statutory Auditors

B.E.A.S.

7-9, villa Houssay
92524 Neuilly-sur-Seine Cedex – France

First appointed at the Annual Shareholders' Meeting held on 10 April 2002. Term of office renewed by the Annual Shareholders' Meeting held on 31 May 2016.

■ 6.1.4.3 Auditors' fees

The auditors' fees can be found in section 3.2.5, note 27.

6.2 THIRD PARTY INFORMATION, STATEMENTS BY EXPERTS AND DECLARATIONS OF INTERESTS

None.

6.3 CONSULTATION OF LEGAL DOCUMENTS

During the validity period of the present universal registration document, the Articles of incorporation, the Statutory Auditors' reports, the annual financial statements of the past three years, as well as any reports, letters or other documents and historical financial information of the Company and its subsidiaries over the past three years and, valuations and statements made by experts, where such documents are provided for by law and any other document provided for by law may be consulted at the Company's registered office.

Copies of the present universal registration document are available free of charge at the Company's registered office (located at 65 quai Georges Gorse – 92100 Boulogne-Billancourt – France – Tel.: +33 (0)1 58 33 50 00) as well as on Ipsen's website (www.ipsen.com) and on the AMF's website (www.amf-france.org).

6.4 CROSS-REFERENCE TABLES

6.4.1 Universal registration document concordance table

To facilitate consultation of this universal registration document, the table below outlines the minimum information to be included in this registration document pursuant to Appendices I and II of EU Regulation 2019/980 of 14 March 2019.

| New URD references | Title | Previous registration document references | Paragraph | Pages |
|--------------------|---|---|---------------|-------|
| SECTION 1 | RESPONSIBLE PERSONS, INFORMATION FROM THIRD PARTIES, EXPERT REPORTS AND APPROVAL FROM THE RELEVANT AUTHORITY | 1. | | |
| Point 1.1 | Persons responsible for the registration document | 1.1 | 6.1.1 – 6.1.3 | 274 |
| Point 1.2 | Attestation from persons responsible for the document | 1.2 | 6.1.2 | 274 |
| Point 1.3 | Expert Statement | 23.1 | 6.2 | 275 |
| Point 1.4 | Other attestations in cases of information from third parties | 23.2 | NA | |
| Point 1.5 | Declaration regarding document approval | | Cover page | 1 |
| SECTION 2 | STATUTORY AUDITORS | 2. | | |
| Point 2.1 | Identities and addresses | 2.1 | 6.1.4 | 274 |
| Point 2.2 | Changes | 2.2 | NA | |



| New URD references | Title | Previous registration document references | Paragraph | Pages |
|--------------------|--|---|---------------------|-------------|
| SECTION 3 | RISK FACTORS | 4. | 2.1 | 34 |
| Point 3.1 | Description of key risks | | | |
| SECTION 4 | INFORMATION ABOUT THE ISSUER | 5. | | |
| Point 4.1 | Corporate name and trading name | 5.1.1 | 1.1.1.1 | 6 |
| Point 4.2 | Trade register no. and LEI | 5.1.2 | 1.1.1.1 | 6 |
| Point 4.3 | Date of incorporation and term | 5.1.3 | 1.1.1.1 | 6 |
| Point 4.4 | Headquarters – legal form – applicable law | 5.1.4 | 1.1.1.1 | 6 |
| SECTION 5 | BUSINESS OVERVIEW | 6. | | |
| Point 5.1 | Principal activities | 6.1 | | |
| <i>Point 5.1.1</i> | <i>Operations and principal activities</i> | 6.1.1 | 1.1.1.2 | 6 |
| <i>Point 5.1.2</i> | <i>New products and/or services</i> | 6.1.2 | 1.2.1 | 12 |
| Point 5.2 | Principal markets | 6.2 | 1.2.1 – 1.2.5 | 12 – 30 |
| Point 5.3 | Key events | 5.1.5 | 3.1.1 | 50 |
| Point 5.4 | Financial and non-financial(1) strategy and goals | | 1.1.2 – 4 | 9 – 143 |
| Point 5.5 | Extent to which the issuer is dependent | 6.4 | 2.1.2.5 | 36 |
| Point 5.6 | Competitive position | 6.5 | 1.2.5.2 | 30 |
| Point 5.7 | Investments | 5.2 | | |
| <i>Point 5.7.1</i> | <i>Key investments</i> | 5.2.1. | 3.1.3.1 | 57 |
| <i>Point 5.7.2</i> | <i>Ongoing key investments or firm commitments</i> | 5.2.2. 5.2.3 | 3.1.3.1 NA | 57 |
| <i>Point 5.7.3</i> | <i>Joint ventures and significant interests</i> | | 1.2.7 – 3.1.1 | 31 – 50 |
| <i>Point 5.7.4</i> | <i>Environmental impact of the use of the tangible assets</i> | 8.2 | 4.5 | 177 |
| SECTION 6 | ORGANIZATIONAL STRUCTURE | 7. | | |
| Point 6.1 | Brief description of the Group/Organization chart | 7.1 | 1.2.7.1 | 31 |
| Point 6.2 | List of significant subsidiaries | 7.2 | 3.2.5 note 26 | 113 |
| SECTION 7 | OPERATING AND FINANCIAL REVIEW | 9. | | |
| Point 7.1 | Financial condition | 9.1 | Introduction – 3 | 3 – 49 |
| <i>Point 7.1.1</i> | <i>Description of developments and profit/loss from operations</i> | | 3 | 49 |
| <i>Point 7.1.2</i> | <i>Future developments and research and development activity</i> | | 1.2.3 – 3.1.6 | 22 – 65 |
| Point 7.2 | Operating results | 9.2 | 3 | 49 |
| <i>Point 7.2.1</i> | <i>Significant factors</i> | 9.2.1 | 3 | 49 |
| <i>Point 7.2.2</i> | <i>Material changes in net sales or revenues</i> | 9.2.2 | 3 | 49 |
| SECTION 8 | CAPITAL RESOURCES | 10. | | |
| Point 8.1 | Capital resources (short and long term) | 10.1 | 3.1.3 | 57 |
| Point 8.2 | Cash flows | 10.2 | 3.1.3 | 57 |
| Point 8.3 | Financing requirements and funding structure | 10.3 | 3.1.3 | 57 |
| Point 8.4 | Restrictions on the use of capital resources | 10.4 | 3.1.3 | 57 |
| Point 8.5 | Anticipated sources of funds needed | 10.5 | NA | |
| SECTION 9 | REGULATORY ENVIRONMENT | | | |
| Point 9.1 | Description of the regulatory environment and external influencing factors | 9.2.3 | 1.1.2.1 – 1.2.6 – 3 | 9 – 31 – 49 |

| New URD references | Title | Previous registration document references | Paragraph | Pages |
|--------------------|---|---|-------------------------|-------------|
| SECTION 10 | TREND INFORMATIONS | 12. | | |
| Point 10.1 | a) Recent trends production | 12.1 | 1.1.2.1 – 1.2.6 – 3.1.6 | 9 – 31 – 65 |
| | b) Key changes to the financial performance of the Group since the end of the financial year | | 3.2.5 note 25 | 113 |
| Point 10.2 | Events that are reasonably likely to have a material effect on prospects | 12.2 | 1.2.6 | 31 |
| SECTION 11 | PROFIT FORECAST OR ESTIMATES | 13. | | |
| Point 11.1 | Ongoing profit forecast or estimation | 13.4 | 3.1.6 | 65 |
| Point 11.2 | Principal assumptions | 13.1 | 3.1.6 | 65 |
| Point 11.3 | Attestation on profit forecast or estimation | 13.3 | 3.1.6 | 65 |
| SECTION 12 | ADMINISTRATIVE, MANAGEMENT, AND SUPERVISORY BODIES | 14. | | |
| Point 12.1 | Name, business address, and functions of the corporate officers in the issuing company | 14.1 | 5.2 – 5.3 | 201 – 234 |
| Point 12.2 | Conflicts of interest | 14.2 | 5.1.3.1 | 199 |
| SECTION 13 | COMPENSATION AND BENEFITS | 15. | | |
| Point 13.1 | Remuneration and benefits paid or granted | 15.1 | 5.4 | 238 |
| Point 13.2 | Amounts set aside to provide pension, retirement or similar benefits | 15.2 | 5.4 | 238 |
| SECTION 14 | BOARD PRACTICES | 16. | | |
| Point 14.1 | Date of expiration of the current term of office | 16.1 | 5.2.2.2 | 205 |
| Point 14.2 | Service contracts | 16.2 | 5.1.3.4 | 199 |
| Point 14.3 | Committees | 16.3 | 5.2.2.6 | 226 |
| Point 14.4 | Compliance with principles of corporate governance | 16.4 | 5.1.1 | 198 |
| Point 14.5 | Significant potential events and future changes in governance | | NA | |
| SECTION 15 | EMPLOYEES | 17. | | |
| Point 15.1 | Breakdown of employees | 17.1 | 4.9 | 187 |
| Point 15.2 | Shareholding and stock options | 17.2 | 5.6.1 | 260 |
| Point 15.3 | Arrangements for involving the employees in the capital | 17.3 | NA | |
| SECTION 16 | MAJOR SHAREHOLDERS | 18. | | |
| Point 16.1 | Breakdown of capital [or appropriate declaration] | 18.1 | 5.6.2.1 | 264 |
| Point 16.2 | Various voting rights [or appropriate declaration] | 18.2 | 5.6.2.1 | 264 |
| Point 16.3 | Control of the issuer | 18.3 | 5.6.2.1 – 5.6.2.4 | 264 – 268 |
| Point 16.4 | Description of any arrangements | 18.4 | 5.6.2.4 – 5.6.2.5 | 268 – 268 |
| SECTION 17 | RELATED PARTY TRANSACTIONS | 19. | | |
| Point 17.1 | Detail of transactions | | 5.6.2.8 | 270 |
| SECTION 18 | FINANCIAL INFORMATION CONCERNING ASSETS AND LIABILITIES, THE FINANCIAL SITUATION AND RESULTS OF THE ISSUER | 20. | | |
| Point 18.1 | Historical financial information | 20.1 | Introduction – 3 | 3 – 49 |
| Point 18.1.1 | Historical financial information | 20.1 | Introduction – 3 | 3 – 49 |
| Point 18.1.2 | Change of date of the universal accounting registration | | NA | |
| Point 18.1.3 | Accounting standards | 20.1 | Introduction – 3 | 3 – 49 |
| Point 18.1.4 | Change in accounting standard | 20.1 | Introduction – 3 | 3 – 49 |
| Point 18.1.5 | Minimum content of audited financial information | 20.1 | Introduction – 3 | 3 – 49 |
| Point 18.1.6 | Consolidated financial statements | 20.3 | 3.2 | 66 |
| Point 18.1.7 | Age of latest financial information | 20.5 | 3.2.5 note 3 | 74 |



| New URD references | Title | Previous registration document references | Paragraph | Pages |
|---------------------|--|---|---------------------|-----------|
| Point 18.2 | Interim and other financial information | 20.6 | NA | |
| <i>Point 18.2.1</i> | <i>Quarterly or half-yearly financial information</i> | 20.6.1 | NA | |
| Point 18.3 | Auditing of historical annual financial information | 20.4 | | |
| <i>Point 18.3.1</i> | <i>Audit report</i> | 20.4.1 | 3.2.6 – 3.3.3 | 116 – 136 |
| <i>Point 18.3.2</i> | <i>Other audited information</i> | 20.4.2 | 5.5 | 259 |
| <i>Point 18.3.3</i> | <i>Non-audited financial information</i> | 20.4.3 | NA | |
| Point 18.4 | Pro forma financial information | 20.2 | NA | |
| <i>Point 18.4.1</i> | <i>Significant changes to gross values</i> | 20.2 | NA | |
| Point 18.5 | Dividend policy | 20.7 | | |
| <i>Point 18.5.1</i> | <i>Description</i> | 20.7 | 5.6.2.7 | 269 |
| <i>Point 18.5.2</i> | <i>Amount of dividend per share</i> | 20.7.1 | 3.2.5 note 18.3 | 103 |
| Point 18.6 | Legal and arbitration proceedings | 20.8 | 2.1.5.5 | 40 |
| <i>Point 18.6.1</i> | <i>Significant procedures</i> | 20.8 | 2.1.5 | 39 |
| Point 18.7 | Significant change in the issuer's financial or trading position | 20.9 | 3.2.5 notes 1 and 2 | 73 – 74 |
| <i>Point 18.7.1</i> | <i>Significant changes since end of financial year</i> | 20.9 | 3.2.5 notes 1 and 2 | 73 – 74 |
| SECTION 19 | ADDITIONAL INFORMATION | 21. | | |
| Point 19.1 | Share capital | 21.1 | 5.6.1 | 260 |
| <i>Point 19.1.1</i> | <i>Amount of capital issued</i> | 21.1.1 | 5.6.1 – 5.6.1.5 | 260 – 263 |
| <i>Point 19.1.2</i> | <i>Shares not representing the capital</i> | 21.1.2 | NA | |
| <i>Point 19.1.3</i> | <i>Treasury shares</i> | 21.1.3 | 5.6.1.5 | 263 |
| <i>Point 19.1.4</i> | <i>Securities</i> | 21.1.4 | 5.6.1.3 | 260 |
| <i>Point 19.1.5</i> | <i>Conditions of right to buy and/or any obligation</i> | 21.1.5 | NA | |
| <i>Point 19.1.6</i> | <i>Option or agreement</i> | 21.1.6 | NA | |
| <i>Point 19.1.7</i> | <i>History of share capital</i> | 21.1.7 | 5.6.1.2 | 260 |
| Point 19.2 | Memorandum and Articles of Association | 21.2 | | |
| <i>Point 19.2.1</i> | <i>Register entry and corporate purpose</i> | 21.2.1 | 5.6.3.1 | 270 |
| <i>Point 19.2.2</i> | <i>Categories of existing shares</i> | 21.2.3 | 5.6.3.3 | 270 |
| <i>Point 19.2.3</i> | <i>Provision affecting a change in control</i> | 21.2.6 | 5.6.2.5 | 268 |
| SECTION 20 | MATERIAL CONTRACTS | 22. | | |
| Point 20.1 | Summary of each contract | 22. | 1.2.2 | 19 |
| SECTION 21 | AVAILABLE DOCUMENTS | 24. | | |
| Point 21.1 | Declaration on available documents | 24. | 6.3 | 275 |

6.4.2 Annual Financial Report cross-reference table

| INFORMATION | Chapters | Pages |
|---|--|------------------------|
| Attestation by the person responsible | 6.1.1 | 274 |
| Annual financial statements | 3.3 | 120 |
| Consolidated financial statements | 3.2 | 66 |
| Statutory Auditors' Report on the annual financial statements | 3.3.3 | 136 |
| Statutory Auditors' Report on the consolidated financial statements | 3.2.6 | 116 |
| Statutory Auditors' fees | 3.2.5 note 27 | 115 |
| Management Report: | 6.4.3 | 279 |
| Information contained in Article L.225-100-1 of the French Commercial Code: | | |
| <ul style="list-style-type: none"> Analysis of changes in the business, results and financial position of the Company and the Group | 3.1.1, 3.1.2, 3.1.3, 3.2.5 notes 1 and 2 | 50 – 52 – 57 – 73 – 74 |
| <ul style="list-style-type: none"> Financial and non-financial key performance indicators of the Company and the Group | Introduction | 3 |
| <ul style="list-style-type: none"> Principal risks and uncertainties facing the Company and the Group | 2.1, 3.1, 3.2.5 notes 1 and 2 | 34 – 50 – 73 – 74 |
| <ul style="list-style-type: none"> Objective and hedging policy for transactions of the Company and the Group for which hedge accounting is used Exposure to price, credit, liquidity and cash flow risks of the Company and the Group Use of financial instruments by the Company and the Group | 2.1 – 2.2 – 3.2.5 notes 21 and 22 | 34 – 41 – 106 – 108 |
| Internal control and risk management procedures relating to the preparation and processing of accounting and financial information of the Company and the Group | 2.2 | 41 |
| Financial risks linked to the effects of climate change and low carbon strategy of the Company and the Group | 2.1.3.2 | 37 |
| Information regarding the buying back of shares (Article L.225-211 of the French Commercial Code) | 5.6.1.5 – 5.6.1.6 | 263 |

6.4.3 Cross-reference table of the Management Report and of the Board of Directors' Report on Corporate Governance

■ Management Report

| INFORMATION | Chapters | Pages |
|---|--|------------------------|
| Information regarding the activities of the Company and the Group | | |
| Position of the Company and the Group during the previous financial year, foreseeable changes and significant events after the reporting period (Articles L.232-1 and L.233-26 of the French Commercial Code) | 1.2, 3.1.1, 3.1.6 | 12 – 50 – 65 |
| Activities and results of the Company and the Group by business segment (Article L.233-6 of the French Commercial Code) | 3.1.2.4 | 56 |
| Objective and exhaustive analysis of developments in the business, results and financial position of the Company and the Group (Article L.225-100-1 of the French Commercial Code) | 3.1.1, 3.1.2, 3.1.3, 3.2.5 notes 1 and 2 | 50 – 52 – 57 – 73 – 74 |
| Financial and non-financial key performance indicators of the Company and the Group (Article L.225-100-1 of the French Commercial Code) | Introduction | 3 |
| Principal risks and uncertainties facing the Company and the Group (Article L.225-100-1 of the French Commercial Code) | 2.1, 3.1, 3.2.5 notes 1 and 2 | 34 – 50 – 73 – 74 |
| Internal control and risk management procedures relating to the preparation and processing of accounting and financial information of the Company and the Group | 2.2 | 41 |
| Objective and hedging policy of transactions for which hedge accounting is applied in the Company and the Group Exposure to price, credit, liquidity and cash flow risks of the Company and the Group Use of financial instruments by the Company and the Group (Article L.225-100-1 of the French Commercial Code) | 2.1.4, 3.2.5 notes 21 and 22 | 38 – 106 – 108 |



| INFORMATION | Chapters | Pages |
|--|-------------------|-----------|
| Financial risks linked to the effects of climate change and low carbon strategy of the Company and the Group | 2.1.3.2 | 37 |
| Research and Development activities of the Company and the Group (Articles L.232-1 and L.233-26 of the French Commercial Code) | 1.2.3 | 22 |
| Existing branches within the Company (Article L.232-1 of the French Commercial Code) | NA | |
| Business Model | 1.1.2.3 | 11 |
| Legal, financial and tax information of the Company | | |
| Breakdown and changes in share ownership (Article L.233-13 of the French Commercial Code) | 5.6.2.1– 5.6.2.3 | 264 – 267 |
| Names of controlled companies and portion of the Company's share capital they hold (Article L.233-13 of the French Commercial Code) | 1.2.7 | 31 |
| Significant holdings acquired during the financial year in companies whose headquarters are located in France (Article L.233-6 of the French Commercial Code) | NA | |
| Cross-shareholding (Article L.233-29 of the French Commercial Code) | NA | |
| Statement of employee profit-sharing (Article L.225-102 of the French Commercial Code) | 5.6.2.1 | 264 |
| Acquisition and disposal by the Company of its own shares (buyback of shares) (Article L.225-211 of the French Commercial Code) | 5.6.1.5 – 5.6.1.6 | 263 |
| Adjustments to securities giving access to the share capital in the event of financial transactions (Article R.228-91 of the French Commercial Code) | NA | |
| Adjustments to securities giving access to the share capital and the stock options in the event of the buyback of shares (Articles R.228-90 and R.225-138 of the French Commercial Code) | NA | |
| Dividends distributed for the three previous financial years (243 bis of the French General Tax Code) | 5.6.2.7 | 269 |
| Non-tax deductible expenses and charges (223 quater of the French General Tax Code) | 3.3.4.9 | 140 |
| Court orders or financial penalties imposed for anti-competitive practices (Article L.464-2 I paragraph 5 of the French Commercial Code) | NA | |
| Payment deadlines and breakdown of the accounts payable and accounts receivable balances (Article L.441-14 of the French Commercial Code) | 3.3.4.8 | 140 |
| Amount of the inter-company loans (Article L.511-6 3 bis of the French Monetary and Financial Code) | 3.3.2 note 3 | 125 |
| Information on the operation of a SEVESO site (Article L.515-8 of the French Environmental Code) (Article L.225-102-2 of the French Commercial Code) | NA | |
| Information regarding the corporate officers | | |
| Summary of securities transactions performed by persons with managerial responsibilities and closely affiliated persons (Article L.621-18-2 of the French Monetary and Financial Code) | 5.6.2.2 | 266 |
| CSR Information | | |
| Awareness of the social and environmental consequences of the activities, including the impact on climate change and the impact resulting from the use of the goods and services produced, as well as the societal commitments promoting sustainable development, the circular economy, the fight against food waste, the fight against discrimination and the promotion of diversity (Articles L.225-102-1; R.225-105; R.225-105-1 of the French Commercial Code) | 4.1 – 4.10 | 144 – 190 |
| Monitoring plan | NA | |

■ Appendices to the Management Report

| INFORMATION | Chapters | Pages |
|---|----------|-------|
| Report on payments to governments (Article L.225-102-3 of the French Commercial Code) | NA | |
| Table on the Company's results during each of the last five financial years (Article R.225-102 of the French Commercial Code) | 3.3.4.11 | 141 |

■ Corporate Governance Report

| INFORMATION | Chapters | Pages |
|--|---------------------------|-----------------|
| Compensation information | | |
| Information on the compensation policy of Corporate Officers (Articles L.22-10-8 and L.225-82-2 of the French Commercial Code) | 5.4.1 | 238 |
| Total compensation and benefits in kind paid during the fiscal year to each corporate officer of the Company, the companies it controls or the company that controls it (Article L.22-10-9 of the French Commercial Code) | 5.4.2 | 244 |
| Commitments of any type undertaken by the Company for the benefit of its corporate officers (Article L.22-10-9) | 5.4.1 | 238 |
| Option selected by the Board regarding the procedures for the retention of free shares and/or shares resulting from the exercise of stock options by the corporate officers (Articles L.225-197-1 and L.225-185 of the French Commercial Code) | 5.4.1 – 5.4.2.2 – 5.4.2.3 | 238 – 246 – 249 |
| Information regarding the composition, operation and powers of the Board | | |
| List of all offices and positions held by each of the corporate officers in or outside the company during the financial year (Article L. 225-37-4 1° of the French Commercial Code) | 5.2.2 | 205 |
| Agreements entered into directly or <i>via</i> an intermediary (i) between a corporate officer or shareholder holding a percentage of voting rights in excess of 10% and (ii) a company of which more than 50% of the share capital is held, directly or indirectly (with the exception of agreements involving ordinary transactions that are entered into under normal conditions) (Article L.225-37-4 2° of the French Commercial Code) | 5.5 | 259 |
| Summary of the delegations regarding capital increases (Article L.225-37-4 3° of the French Commercial Code) | 5.6.1.4 | 262 |
| Form of Executive Management (Article L.225-37-4 4° of the French Commercial Code) | 5.3.1 | 234 |
| Composition, conditions for the preparation and organization of the work of the Board | 5.2.2 | 205 |
| Application of the principle of balanced gender representation on the Board | 5.2.1.2 | 201 |
| Potential limitations that may be imposed on the powers of the Chief Executive Officer by the Board of Directors | 5.3.2.1 | 235 |
| Reference to a company government code and application of the “comply or explain” principal, together with the place in which this code can be consulted | 5.1.1 – 5.1.2 | 198 |
| Procedures for the participation of shareholders in the Annual General Meeting | 5.6.3.4 | 271 |
| Information regarding items likely to have a material impact in the event of a public offer | 5.6.2.6 | 269 |



6.4.4 Cross-reference table for the filing of the financial statements

| INFORMATION | Chapters | Pages |
|---|------------------|------------------|
| Annual financial statements | 3.3 | 120 |
| Consolidated financial statements | 3.2 | 66 |
| Management Report | 3.1 | 50 |
| Board of Directors' Report on Corporate Governance and conclusions of the Statutory Auditors | 5 – 3.3.3 | 197 – 136 |
| Activities of the Company and the Group/Other | 1.2 | 12 |
| Results of the last five financial years | 3.3.4.11 | 141 |

Contacts

Readers can address any comments and questions on this document to:



Ipsen
65, quai Georges Gorse
92100 Boulogne-Billancourt

Phone: +33 1 58 33 50 00
Fax: +33 1 58 33 50 01

www.ipсен.com

2021 Universal registration document

This universal registration document is also available on the Company's website at www.ipсен.com.

Designed & published by



+33 (0)1 40 55 16 66

* Innover pour mieux soigner.



www.ipsen.com